OA20225A - Baron containing PDE4 inhibitors. - Google Patents
Baron containing PDE4 inhibitors. Download PDFInfo
- Publication number
- OA20225A OA20225A OA1202100144 OA20225A OA 20225 A OA20225 A OA 20225A OA 1202100144 OA1202100144 OA 1202100144 OA 20225 A OA20225 A OA 20225A
- Authority
- OA
- OAPI
- Prior art keywords
- alkyl
- alkoxy
- hydroxy
- oxaborolan
- independently
- Prior art date
Links
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 title description 2
- 102100010735 RUBCN Human genes 0.000 title 1
- 101710029688 RUBCN Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 251
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims abstract description 54
- 229910052796 boron Inorganic materials 0.000 claims abstract description 54
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 33
- 201000010099 disease Diseases 0.000 claims abstract description 28
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 claims abstract description 17
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 claims abstract description 17
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 16
- 230000001668 ameliorated Effects 0.000 claims abstract description 4
- -1 (Ci-C6)alkyl-di-i3 Chemical group 0.000 claims description 612
- 125000000217 alkyl group Chemical group 0.000 claims description 592
- 125000003545 alkoxy group Chemical group 0.000 claims description 309
- 125000004414 alkyl thio group Chemical group 0.000 claims description 78
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 76
- 229910052736 halogen Inorganic materials 0.000 claims description 73
- 150000002367 halogens Chemical class 0.000 claims description 73
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 50
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 50
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 46
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 45
- 125000001072 heteroaryl group Chemical group 0.000 claims description 41
- 125000000623 heterocyclic group Chemical group 0.000 claims description 41
- 125000003118 aryl group Chemical group 0.000 claims description 39
- YZCKVEUIGOORGS-OUBTZVSYSA-N deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 36
- 229910052805 deuterium Inorganic materials 0.000 claims description 36
- 229910052717 sulfur Inorganic materials 0.000 claims description 33
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 26
- 125000006625 (C3-C8) cycloalkyloxy group Chemical group 0.000 claims description 23
- 229910052739 hydrogen Inorganic materials 0.000 claims description 22
- 239000001257 hydrogen Substances 0.000 claims description 22
- 229910052760 oxygen Inorganic materials 0.000 claims description 22
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 21
- 229910052757 nitrogen Inorganic materials 0.000 claims description 21
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 19
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 17
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 16
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 16
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 15
- 229910003827 NRaRb Inorganic materials 0.000 claims description 11
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 11
- 125000005842 heteroatoms Chemical group 0.000 claims description 11
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 10
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 10
- 125000005368 heteroarylthio group Chemical group 0.000 claims description 10
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 9
- 125000005110 aryl thio group Chemical group 0.000 claims description 9
- 125000004104 aryloxy group Chemical group 0.000 claims description 9
- 125000003302 alkenyloxy group Chemical group 0.000 claims description 8
- 125000005108 alkenylthio group Chemical group 0.000 claims description 8
- 125000005109 alkynylthio group Chemical group 0.000 claims description 8
- 125000005366 cycloalkylthio group Chemical group 0.000 claims description 8
- 229910052701 rubidium Inorganic materials 0.000 claims description 8
- 125000006766 (C2-C6) alkynyloxy group Chemical group 0.000 claims description 7
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 26
- 125000001475 halogen functional group Chemical group 0.000 claims 20
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 146
- 239000012071 phase Substances 0.000 description 142
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 130
- 125000005843 halogen group Chemical group 0.000 description 120
- 201000004624 dermatitis Diseases 0.000 description 119
- 201000004681 psoriasis Diseases 0.000 description 106
- 231100000406 dermatitis Toxicity 0.000 description 98
- 239000000203 mixture Substances 0.000 description 84
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 66
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 58
- 231100000080 dermatitis contact Toxicity 0.000 description 57
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 54
- 229910002092 carbon dioxide Inorganic materials 0.000 description 54
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 51
- 229910001868 water Inorganic materials 0.000 description 51
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 47
- 125000001424 substituent group Chemical group 0.000 description 42
- 206010020751 Hypersensitivity Diseases 0.000 description 40
- 206010037575 Pustular psoriasis Diseases 0.000 description 40
- 206010025135 Lupus erythematosus Diseases 0.000 description 39
- VHUUQVKOLVNVRT-UHFFFAOYSA-N ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 39
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 39
- CZPWVGJYEJSRLH-UHFFFAOYSA-N 289-95-2 Chemical group C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 38
- 208000010247 Contact Dermatitis Diseases 0.000 description 38
- 206010012442 Dermatitis contact Diseases 0.000 description 38
- 230000004054 inflammatory process Effects 0.000 description 38
- 206010061218 Inflammation Diseases 0.000 description 37
- 239000003814 drug Substances 0.000 description 37
- 206010072757 Chronic spontaneous urticaria Diseases 0.000 description 36
- 206010024380 Leukoderma Diseases 0.000 description 36
- 208000007256 Nevus Diseases 0.000 description 36
- 238000010828 elution Methods 0.000 description 36
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 35
- 229940079593 drugs Drugs 0.000 description 33
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 32
- 238000004519 manufacturing process Methods 0.000 description 29
- 238000002953 preparative HPLC Methods 0.000 description 29
- 239000000243 solution Substances 0.000 description 28
- 239000002904 solvent Substances 0.000 description 28
- 230000001684 chronic Effects 0.000 description 27
- 210000003491 Skin Anatomy 0.000 description 25
- 239000003795 chemical substances by application Substances 0.000 description 25
- 238000000034 method Methods 0.000 description 24
- 239000000126 substance Substances 0.000 description 24
- 206010037162 Psoriatic arthropathy Diseases 0.000 description 23
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 23
- 201000001263 psoriatic arthritis Diseases 0.000 description 23
- PBMFSQRYOILNGV-UHFFFAOYSA-N Pyridazine Chemical group C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 22
- 235000019439 ethyl acetate Nutrition 0.000 description 22
- KYQCOXFCLRTKLS-UHFFFAOYSA-N pyrazine Chemical group C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 22
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 22
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
- 206010003246 Arthritis Diseases 0.000 description 21
- 206010003645 Atopy Diseases 0.000 description 21
- 208000001640 Fibromyalgia Diseases 0.000 description 20
- 206010016654 Fibrosis Diseases 0.000 description 20
- 206010018797 Guttate psoriasis Diseases 0.000 description 20
- 206010028703 Nail psoriasis Diseases 0.000 description 20
- 210000000282 Nails Anatomy 0.000 description 20
- 241001303601 Rosacea Species 0.000 description 20
- 201000005794 allergic hypersensitivity disease Diseases 0.000 description 20
- 230000004761 fibrosis Effects 0.000 description 20
- 201000004700 rosacea Diseases 0.000 description 20
- 230000029663 wound healing Effects 0.000 description 20
- UGUHFDPGDQDVGX-UHFFFAOYSA-N 1,2,3-thiadiazole Chemical group C1=CSN=N1 UGUHFDPGDQDVGX-UHFFFAOYSA-N 0.000 description 19
- 206010000748 Acute febrile neutrophilic dermatosis Diseases 0.000 description 19
- 208000004631 Alopecia Areata Diseases 0.000 description 19
- 208000006673 Asthma Diseases 0.000 description 19
- 208000000594 Bullous Pemphigoid Diseases 0.000 description 19
- 208000004921 Cutaneous Lupus Erythematosus Diseases 0.000 description 19
- 208000005373 Dyshidrotic Eczema Diseases 0.000 description 19
- 206010014989 Epidermolysis bullosa Diseases 0.000 description 19
- 210000000744 Eyelids Anatomy 0.000 description 19
- 206010058898 Hand dermatitis Diseases 0.000 description 19
- 208000002557 Hidradenitis Diseases 0.000 description 19
- 208000001875 Irritant Dermatitis Diseases 0.000 description 19
- 206010066295 Keratosis pilaris Diseases 0.000 description 19
- 208000007820 Lichen Sclerosus et Atrophicus Diseases 0.000 description 19
- 206010034277 Pemphigoid Diseases 0.000 description 19
- 241000721454 Pemphigus Species 0.000 description 19
- 208000009675 Perioral Dermatitis Diseases 0.000 description 19
- 206010035111 Pityriasis alba Diseases 0.000 description 19
- 208000008742 Seborrheic Dermatitis Diseases 0.000 description 19
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 19
- 206010041955 Stasis dermatitis Diseases 0.000 description 19
- 208000010265 Sweet Syndrome Diseases 0.000 description 19
- 206010047642 Vitiligo Diseases 0.000 description 19
- 208000010484 Vulvovaginitis Diseases 0.000 description 19
- 239000000969 carrier Substances 0.000 description 19
- 201000001981 dermatomyositis Diseases 0.000 description 19
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 19
- 201000007162 hidradenitis suppurativa Diseases 0.000 description 19
- 201000011486 lichen planus Diseases 0.000 description 19
- 201000009053 neurodermatitis Diseases 0.000 description 19
- 201000010914 pustulosis of palm and sole Diseases 0.000 description 19
- WTKZEGDFNFYCGP-UHFFFAOYSA-N pyrazole Chemical group C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 19
- 230000000699 topical Effects 0.000 description 19
- 206010021972 Inflammatory bowel disease Diseases 0.000 description 18
- 206010027145 Melanocytic naevus Diseases 0.000 description 18
- 206010036229 Post inflammatory pigmentation change Diseases 0.000 description 18
- 206010046751 Urticaria physical Diseases 0.000 description 18
- 208000001445 Uveomeningoencephalitic Syndrome Diseases 0.000 description 18
- 201000003087 Vogt-Koyanagi-Harada disease Diseases 0.000 description 18
- 200000000018 inflammatory disease Diseases 0.000 description 18
- 201000002881 physical urticaria Diseases 0.000 description 18
- 238000005160 1H NMR spectroscopy Methods 0.000 description 17
- 206010011401 Crohn's disease Diseases 0.000 description 17
- 239000006071 cream Substances 0.000 description 17
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 17
- FZWLAAWBMGSTSO-UHFFFAOYSA-N thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 17
- 230000002757 inflammatory Effects 0.000 description 16
- 239000006210 lotion Substances 0.000 description 16
- 239000011780 sodium chloride Substances 0.000 description 16
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 16
- 206010009900 Colitis ulcerative Diseases 0.000 description 15
- 210000000003 Hoof Anatomy 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 15
- 239000000499 gel Substances 0.000 description 15
- 201000006704 ulcerative colitis Diseases 0.000 description 15
- 210000000078 Claw Anatomy 0.000 description 14
- 210000004209 Hair Anatomy 0.000 description 14
- 239000002674 ointment Substances 0.000 description 14
- 125000004434 sulfur atoms Chemical group 0.000 description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 13
- 239000003085 diluting agent Substances 0.000 description 13
- 125000006239 protecting group Chemical group 0.000 description 13
- 150000003839 salts Chemical class 0.000 description 13
- 238000004440 column chromatography Methods 0.000 description 12
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 11
- 102000004127 Cytokines Human genes 0.000 description 11
- 108090000695 Cytokines Proteins 0.000 description 11
- 239000000377 silicon dioxide Substances 0.000 description 11
- 238000003786 synthesis reaction Methods 0.000 description 11
- GQHTUMJGOHRCHB-UHFFFAOYSA-N DBU Substances C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 10
- SCVFZCLFOSHCOH-UHFFFAOYSA-M Potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- 235000011114 ammonium hydroxide Nutrition 0.000 description 10
- 125000004432 carbon atoms Chemical group C* 0.000 description 10
- 125000004122 cyclic group Chemical group 0.000 description 10
- 150000002148 esters Chemical class 0.000 description 10
- 239000003112 inhibitor Substances 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 125000004430 oxygen atoms Chemical group O* 0.000 description 10
- 239000000546 pharmaceutic aid Substances 0.000 description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- 229910052938 sodium sulfate Inorganic materials 0.000 description 10
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-Bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 9
- 101700046984 CDK20 Proteins 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 9
- 239000003623 enhancer Substances 0.000 description 9
- 230000002708 enhancing Effects 0.000 description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 238000004128 high performance liquid chromatography Methods 0.000 description 9
- 239000008177 pharmaceutical agent Substances 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 241001251200 Agelas Species 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 235000010290 biphenyl Nutrition 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
- WQDUMFSSJAZKTM-UHFFFAOYSA-N sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 8
- 239000004912 1,5-cyclooctadiene Substances 0.000 description 7
- 239000007832 Na2SO4 Substances 0.000 description 7
- 102100014526 TBC1D8 Human genes 0.000 description 7
- 101710035852 TBC1D8 Proteins 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- 229910052799 carbon Inorganic materials 0.000 description 7
- 239000003054 catalyst Substances 0.000 description 7
- HEDRZPFGACZZDS-MICDWDOJSA-N cdcl3 Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 7
- 239000003937 drug carrier Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000000543 intermediate Substances 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 239000002502 liposome Substances 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 239000003755 preservative agent Substances 0.000 description 7
- 238000000844 transformation Methods 0.000 description 7
- 230000001131 transforming Effects 0.000 description 7
- 241000124008 Mammalia Species 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Substances BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 6
- 229960004063 Propylene glycol Drugs 0.000 description 6
- 125000004429 atoms Chemical group 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000004305 biphenyl Substances 0.000 description 6
- 239000012267 brine Substances 0.000 description 6
- OKKJLVBELUTLKV-MZCSYVLQSA-N cd3od Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 6
- 210000004027 cells Anatomy 0.000 description 6
- 238000006880 cross-coupling reaction Methods 0.000 description 6
- 150000002430 hydrocarbons Chemical class 0.000 description 6
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 6
- 125000002524 organometallic group Chemical group 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 230000002335 preservative Effects 0.000 description 6
- 239000002464 receptor antagonist Substances 0.000 description 6
- YOQDYZUWIQVZSF-UHFFFAOYSA-N sodium borohydride Chemical compound [BH4-].[Na+] YOQDYZUWIQVZSF-UHFFFAOYSA-N 0.000 description 6
- 210000001519 tissues Anatomy 0.000 description 6
- 239000004215 Carbon black (E152) Substances 0.000 description 5
- BZLVMXJERCGZMT-UHFFFAOYSA-N MeOtBu Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 5
- 239000000908 ammonium hydroxide Substances 0.000 description 5
- 125000001246 bromo group Chemical group Br* 0.000 description 5
- IVOMOUWHDPKRLL-KQYNXXCUSA-N cAMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 5
- 238000002425 crystallisation Methods 0.000 description 5
- 230000005712 crystallization Effects 0.000 description 5
- 238000009792 diffusion process Methods 0.000 description 5
- 239000003995 emulsifying agent Substances 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 235000019253 formic acid Nutrition 0.000 description 5
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- BAVYZALUXZFZLV-UHFFFAOYSA-N methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 5
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 5
- 230000003000 nontoxic Effects 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 5
- 230000035699 permeability Effects 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- BDERNNFJNOPAEC-UHFFFAOYSA-N propanol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 239000000375 suspending agent Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000001993 wax Substances 0.000 description 5
- 239000000080 wetting agent Substances 0.000 description 5
- TZRAEHUUJAELIA-UHFFFAOYSA-N 2-hydroxyoxaborolane Chemical compound OB1CCCO1 TZRAEHUUJAELIA-UHFFFAOYSA-N 0.000 description 4
- GPAYUJZHTULNBE-UHFFFAOYSA-N Diphenylphosphine Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-N 0.000 description 4
- 241000276438 Gadus morhua Species 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 4
- 102000004311 Liver X Receptors Human genes 0.000 description 4
- 108090000865 Liver X Receptors Proteins 0.000 description 4
- NHQDETIJWKXCTC-UHFFFAOYSA-N Meta-Chloroperoxybenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 4
- ZADPBFCGQRWHPN-UHFFFAOYSA-N OBO Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 4
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 4
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 4
- VZJVWSHVAAUDKD-UHFFFAOYSA-N Potassium permanganate Chemical compound [K+].[O-][Mn](=O)(=O)=O VZJVWSHVAAUDKD-UHFFFAOYSA-N 0.000 description 4
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N Trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N Triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- CXNIUSPIQKWYAI-UHFFFAOYSA-N Xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
- 125000002015 acyclic group Chemical group 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 235000010443 alginic acid Nutrition 0.000 description 4
- 229920000615 alginic acid Polymers 0.000 description 4
- 150000008064 anhydrides Chemical class 0.000 description 4
- 230000000111 anti-oxidant Effects 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 125000001309 chloro group Chemical group Cl* 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 235000019516 cod Nutrition 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 238000005755 formation reaction Methods 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000002609 media Substances 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 150000002829 nitrogen Chemical group 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- 239000001184 potassium carbonate Substances 0.000 description 4
- 235000015320 potassium carbonate Nutrition 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 229940002612 prodrugs Drugs 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-M propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 4
- 230000001681 protective Effects 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 230000001225 therapeutic Effects 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- QFMZQPDHXULLKC-UHFFFAOYSA-N 1,2-Bis(diphenylphosphino)ethane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 QFMZQPDHXULLKC-UHFFFAOYSA-N 0.000 description 3
- VYXHVRARDIDEHS-UHFFFAOYSA-N 1,5-Cyclooctadiene Chemical compound C1CC=CCCC=C1 VYXHVRARDIDEHS-UHFFFAOYSA-N 0.000 description 3
- RKMGAJGJIURJSJ-UHFFFAOYSA-N 2,2,6,6-Tetramethylpiperidine Chemical compound CC1(C)CCCC(C)(C)N1 RKMGAJGJIURJSJ-UHFFFAOYSA-N 0.000 description 3
- BGLPECHZZQDNCD-UHFFFAOYSA-N 4-(cyclopropylamino)-2-[4-(4-ethylsulfonylpiperazin-1-yl)anilino]pyrimidine-5-carboxamide Chemical compound C1CN(S(=O)(=O)CC)CCN1C(C=C1)=CC=C1NC1=NC=C(C(N)=O)C(NC2CC2)=N1 BGLPECHZZQDNCD-UHFFFAOYSA-N 0.000 description 3
- YKIOKAURTKXMSB-UHFFFAOYSA-N Adams's catalyst Chemical group O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 241000416162 Astragalus gummifer Species 0.000 description 3
- IPWKHHSGDUIRAH-UHFFFAOYSA-N Bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 3
- 229960005069 Calcium Drugs 0.000 description 3
- ZDQWVKDDJDIVAL-UHFFFAOYSA-N Catecholborane Chemical compound C1=CC=C2O[B]OC2=C1 ZDQWVKDDJDIVAL-UHFFFAOYSA-N 0.000 description 3
- 229950006295 Cerdulatinib Drugs 0.000 description 3
- ZOOGRGPOEVQQDX-KHLHZJAASA-N Cyclic Guanosine Monophosphate Chemical compound C([C@H]1O2)O[P@](O)(=O)O[C@@H]1[C@H](O)[C@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-KHLHZJAASA-N 0.000 description 3
- 108010036949 Cyclosporine Proteins 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 230000005526 G1 to G0 transition Effects 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101700069907 IL31 Proteins 0.000 description 3
- 108010065805 Interleukin-12 Proteins 0.000 description 3
- 102000013691 Interleukin-17 Human genes 0.000 description 3
- 108050003558 Interleukin-17 family Proteins 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 108010065637 Interleukin-23 Proteins 0.000 description 3
- 108010067003 Interleukin-33 Proteins 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N P-Toluenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 3
- 238000006069 Suzuki reaction reaction Methods 0.000 description 3
- 229940116362 Tragacanth Drugs 0.000 description 3
- 229920001615 Tragacanth Polymers 0.000 description 3
- LWIHDJKSTIGBAC-UHFFFAOYSA-K Tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 3
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- 125000003158 alcohol group Chemical group 0.000 description 3
- 235000012216 bentonite Nutrition 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 230000036983 biotransformation Effects 0.000 description 3
- 239000006172 buffering agent Substances 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- OKKJLVBELUTLKV-MICDWDOJSA-N deuteriomethanol Chemical compound [2H]CO OKKJLVBELUTLKV-MICDWDOJSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 150000002009 diols Chemical class 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 125000002346 iodo group Chemical group I* 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Substances [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 150000002739 metals Chemical class 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N n-heptane Chemical class CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- 125000004433 nitrogen atoms Chemical group N* 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 239000002304 perfume Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 235000011056 potassium acetate Nutrition 0.000 description 3
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Inorganic materials [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000002633 protecting Effects 0.000 description 3
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 3
- 150000003230 pyrimidines Chemical class 0.000 description 3
- 239000001187 sodium carbonate Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 230000002194 synthesizing Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 3
- 235000010487 tragacanth Nutrition 0.000 description 3
- 239000000196 tragacanth Substances 0.000 description 3
- 230000037317 transdermal delivery Effects 0.000 description 3
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 3
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N (2E,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 2
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-Methyl-2,4-pentanediol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 2
- GFPPXZDRVCSVNR-UHFFFAOYSA-N 2-[2-methyl-1-[[4-methylsulfonyl-2-(trifluoromethyl)phenyl]methyl]pyrrolo[2,3-b]pyridin-3-yl]acetic acid Chemical compound CC1=C(CC(O)=O)C2=CC=CN=C2N1CC1=CC=C(S(C)(=O)=O)C=C1C(F)(F)F GFPPXZDRVCSVNR-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- DREIJXJRTLTGJC-JQCLMNFQSA-N 4-[[(1R,3S)-5-hydroxy-2-adamantyl]amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide Chemical compound C([C@H]1CC(O)(C2)C3)C2C[C@H]3C1NC1=C2C=CNC2=NC=C1C(=O)N DREIJXJRTLTGJC-JQCLMNFQSA-N 0.000 description 2
- XSMSNFMDVXXHGJ-UHFFFAOYSA-N 6-(1H-indazol-6-yl)-N-(4-morpholin-4-ylphenyl)imidazo[1,2-a]pyrazin-8-amine Chemical compound C1COCCN1C(C=C1)=CC=C1NC1=NC(C=2C=C3NN=CC3=CC=2)=CN2C1=NC=C2 XSMSNFMDVXXHGJ-UHFFFAOYSA-N 0.000 description 2
- SEJLPXCPMNSRAM-GOSISDBHSA-N 6-amino-9-[(3R)-1-but-2-ynoylpyrrolidin-3-yl]-7-(4-phenoxyphenyl)purin-8-one Chemical compound C1N(C(=O)C#CC)CC[C@H]1N1C(=O)N(C=2C=CC(OC=3C=CC=CC=3)=CC=2)C2=C(N)N=CN=C21 SEJLPXCPMNSRAM-GOSISDBHSA-N 0.000 description 2
- 108010007562 Adalimumab Proteins 0.000 description 2
- UDMBCSSLTHHNCD-KQYNXXCUSA-N Adenosine monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 2
- 229950006790 Adenosine phosphate Drugs 0.000 description 2
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K Aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- ATALOFNDEOCMKK-OITMNORJSA-N Aprepitant Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC1=NNC(=O)N1 ATALOFNDEOCMKK-OITMNORJSA-N 0.000 description 2
- 206010060945 Bacterial infection Diseases 0.000 description 2
- XUZMWHLSFXCVMG-UHFFFAOYSA-N Baricitinib Chemical compound C1N(S(=O)(=O)CC)CC1(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 XUZMWHLSFXCVMG-UHFFFAOYSA-N 0.000 description 2
- 229950000971 Baricitinib Drugs 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N Benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- WYQFJHHDOKWSHR-MNOVXSKESA-N CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1C1=CN=C2N1C(C=CN1)=C1N=C2 Chemical compound CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1C1=CN=C2N1C(C=CN1)=C1N=C2 WYQFJHHDOKWSHR-MNOVXSKESA-N 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L Caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- CSJLBAMHHLJAAS-UHFFFAOYSA-N Diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 2
- 229950003468 Dupilumab Drugs 0.000 description 2
- 208000005679 Eczema Diseases 0.000 description 2
- 229950004136 Entospletinib Drugs 0.000 description 2
- 210000002615 Epidermis Anatomy 0.000 description 2
- 108010008165 Etanercept Proteins 0.000 description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N Ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
- KTWOOEGAPBSYNW-UHFFFAOYSA-N Ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 2
- 229950003562 Fevipiprant Drugs 0.000 description 2
- 229950006663 Filgotinib Drugs 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 101700021558 GATA3 Proteins 0.000 description 2
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- 229940093915 Gynecological Organic acids Drugs 0.000 description 2
- VKYKSIONXSXAKP-UHFFFAOYSA-N Hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 2
- 102100016185 IRAK4 Human genes 0.000 description 2
- 101700044314 IRAK4 Proteins 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical group C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- 108010053490 Infliximab Proteins 0.000 description 2
- 108090000176 Interleukin-13 Proteins 0.000 description 2
- 102000003816 Interleukin-13 Human genes 0.000 description 2
- 108090000171 Interleukin-18 Proteins 0.000 description 2
- 102000003810 Interleukin-18 Human genes 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 102000004388 Interleukin-4 Human genes 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- JJWLVOIRVHMVIS-UHFFFAOYSA-N Isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 2
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 description 2
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 description 2
- YNESATAKKCNGOF-UHFFFAOYSA-N Lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 2
- ANYSGBYRTLOUPO-UHFFFAOYSA-N Lithium tetramethylpiperidide Chemical compound [Li]N1C(C)(C)CCCC1(C)C ANYSGBYRTLOUPO-UHFFFAOYSA-N 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N Methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- RIJLVEAXPNLDTC-UHFFFAOYSA-N N-[5-[4-[(1,1-dioxo-1,4-thiazinan-4-yl)methyl]phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide Chemical compound C1CC1C(=O)NC(=NN12)N=C1C=CC=C2C(C=C1)=CC=C1CN1CCS(=O)(=O)CC1 RIJLVEAXPNLDTC-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N Oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 102100007288 PTGDR2 Human genes 0.000 description 2
- 101710013017 PTGDR2 Proteins 0.000 description 2
- 229950005157 Peficitinib Drugs 0.000 description 2
- 229940067631 Phospholipids Drugs 0.000 description 2
- UHZYTMXLRWXGPK-UHFFFAOYSA-N Phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N Phosphoryl chloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- KASDHRXLYQOAKZ-XDSKOBMDSA-N Pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-XDSKOBMDSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 206010037888 Rash pustular Diseases 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N Silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 208000006641 Skin Disease Diseases 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- JNYAEWCLZODPBN-CTQIIAAMSA-N Sorbitan Chemical compound OCC(O)C1OCC(O)[C@@H]1O JNYAEWCLZODPBN-CTQIIAAMSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 108060008443 TPPP Proteins 0.000 description 2
- 229960001967 Tacrolimus Drugs 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M Tetra-n-butylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 210000003371 Toes Anatomy 0.000 description 2
- 239000004012 Tofacitinib Substances 0.000 description 2
- 229950011232 Tradipitant Drugs 0.000 description 2
- SHGAZHPCJJPHSC-NWVFGJFESA-N Tretinoin Chemical compound OC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NWVFGJFESA-N 0.000 description 2
- 229960001727 Tretinoin Drugs 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- HWKQNAWCHQMZHK-UHFFFAOYSA-N Trolnitrate Chemical compound [O-][N+](=O)OCCN(CCO[N+]([O-])=O)CCO[N+]([O-])=O HWKQNAWCHQMZHK-UHFFFAOYSA-N 0.000 description 2
- 206010047461 Viral infection Diseases 0.000 description 2
- 208000001756 Virus Disease Diseases 0.000 description 2
- CAVRKWRKTNINFF-UHFFFAOYSA-N [2-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-pyridin-4-yltriazol-4-yl]pyridin-3-yl]-(2-chlorophenyl)methanone Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(CN2C(=C(N=N2)C=2C(=CC=CN=2)C(=O)C=2C(=CC=CC=2)Cl)C=2C=CN=CC=2)=C1 CAVRKWRKTNINFF-UHFFFAOYSA-N 0.000 description 2
- LXNAVEXFUKBNMK-UHFFFAOYSA-N acetic acid;palladium Chemical compound [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 229960002964 adalimumab Drugs 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000240 adjuvant Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 229960001445 alitretinoin Drugs 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 230000003110 anti-inflammatory Effects 0.000 description 2
- 229960001372 aprepitant Drugs 0.000 description 2
- 238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- 150000001649 bromium compounds Chemical class 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N butylene glycol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 239000003601 chymase inhibitor Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 125000000000 cycloalkoxy group Chemical group 0.000 description 2
- SNRCKKQHDUIRIY-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloromethane;dichloropalladium;iron(2+) Chemical compound [Fe+2].ClCCl.Cl[Pd]Cl.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 SNRCKKQHDUIRIY-UHFFFAOYSA-L 0.000 description 2
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 2
- PMATZTZNYRCHOR-UHFFFAOYSA-N cyclosporine A Chemical compound CCC1NC(=O)C(C(O)C(C)CC=CC)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-UHFFFAOYSA-N 0.000 description 2
- 230000002354 daily Effects 0.000 description 2
- 230000003111 delayed Effects 0.000 description 2
- 239000002027 dichloromethane extract Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- PWEGVZDXTQLFLQ-UHFFFAOYSA-N dioxidoboron Chemical compound [O-][B][O-] PWEGVZDXTQLFLQ-UHFFFAOYSA-N 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 108091003598 dupilumab Proteins 0.000 description 2
- 231100001003 eczema Toxicity 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- 229960000403 etanercept Drugs 0.000 description 2
- 229940093471 ethyl oleate Drugs 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-M fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229940051250 hexylene glycol Drugs 0.000 description 2
- 238000006197 hydroboration reaction Methods 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 description 2
- 229960001507 ibrutinib Drugs 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 230000002584 immunomodulator Effects 0.000 description 2
- 229940121354 immunomodulators Drugs 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 229960000598 infliximab Drugs 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 108010074109 interleukin-22 Proteins 0.000 description 2
- 230000000968 intestinal Effects 0.000 description 2
- 150000004694 iodide salts Chemical class 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-M isethionate Chemical compound OCCS([O-])(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-M 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- BNHFWQQYLUPDOG-UHFFFAOYSA-N lithium;1,2,2,3-tetramethylpiperidine Chemical compound [Li].CC1CCCN(C)C1(C)C BNHFWQQYLUPDOG-UHFFFAOYSA-N 0.000 description 2
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 2
- 238000011068 load Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 230000000051 modifying Effects 0.000 description 2
- QDHHCQZDFGDHMP-UHFFFAOYSA-N monochloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 2
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229960005330 pimecrolimus Drugs 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- JQRYUMGHOUYJFW-UHFFFAOYSA-N pyridine;trihydrobromide Chemical compound [Br-].[Br-].[Br-].C1=CC=[NH+]C=C1.C1=CC=[NH+]C=C1.C1=CC=[NH+]C=C1 JQRYUMGHOUYJFW-UHFFFAOYSA-N 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 239000003340 retarding agent Substances 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 description 2
- 229960000215 ruxolitinib Drugs 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 231100000486 side effect Toxicity 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- ODGROJYWQXFQOZ-UHFFFAOYSA-N sodium;boron(1-) Chemical compound [B-].[Na+] ODGROJYWQXFQOZ-UHFFFAOYSA-N 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 230000002522 swelling Effects 0.000 description 2
- NWJQLQGQZSIBAF-MLAUYUEBSA-N tacrolimus hydrate Chemical compound O.C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 NWJQLQGQZSIBAF-MLAUYUEBSA-N 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- 229950009104 tirabrutinib Drugs 0.000 description 2
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 2
- 229960001350 tofacitinib Drugs 0.000 description 2
- 125000002306 tributylsilyl group Chemical group C(CCC)[Si](CCCC)(CCCC)* 0.000 description 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- 235000019798 tripotassium phosphate Nutrition 0.000 description 2
- 229950000088 upadacitinib Drugs 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (-)-propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- VJGFOYBQOIPQFY-XMMPIXPASA-N (2R)-1,1,1-trifluoro-4-(5-fluoro-2,3-dihydro-1-benzofuran-7-yl)-4-methyl-2-[[(2-methylquinolin-5-yl)amino]methyl]pentan-2-ol Chemical compound C([C@@](O)(CNC=1C2=CC=C(N=C2C=CC=1)C)C(F)(F)F)C(C)(C)C1=CC(F)=CC2=C1OCC2 VJGFOYBQOIPQFY-XMMPIXPASA-N 0.000 description 1
- ASUGUQWIHMTFJL-QGZVFWFLSA-N (2R)-2-methyl-2-[[2-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]amino]-N-(2,2,2-trifluoroethyl)butanamide Chemical compound FC(F)(F)CNC(=O)[C@@](C)(CC)NC1=CC=NC(C=2C3=CC=CN=C3NC=2)=N1 ASUGUQWIHMTFJL-QGZVFWFLSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17 Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- PGVBHBWAIOOUAA-UHFFFAOYSA-N (4-methoxy-3-propoxyphenyl)boronic acid Chemical compound CCCOC1=CC(B(O)O)=CC=C1OC PGVBHBWAIOOUAA-UHFFFAOYSA-N 0.000 description 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 1
- 229940095131 (R)- PROPYLENE GLYCOL Drugs 0.000 description 1
- 229960004463 (S)- propylene glycol Drugs 0.000 description 1
- OVAGJAAQMBYZDS-FXSDFHGDSA-N (Z)-but-2-enedioic acid;6-N-[(1S)-1-(4-fluorophenyl)ethyl]-4-(1-methylpyrazol-4-yl)-2-N-pyrazin-2-ylpyridine-2,6-diamine Chemical compound OC(=O)\C=C/C(O)=O.N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=CC(C2=CN(C)N=C2)=CC=1NC1=CN=CC=N1 OVAGJAAQMBYZDS-FXSDFHGDSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-dichloroethane Chemical group ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- IGERFAHWSHDDHX-UHFFFAOYSA-N 1,3-dioxanyl Chemical group [CH]1OCCCO1 IGERFAHWSHDDHX-UHFFFAOYSA-N 0.000 description 1
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
- ILWJAOPQHOZXAN-UHFFFAOYSA-N 1,3-dithianyl Chemical group [CH]1SCCCS1 ILWJAOPQHOZXAN-UHFFFAOYSA-N 0.000 description 1
- FLOJNXXFMHCMMR-UHFFFAOYSA-N 1,3-dithiolanyl Chemical group [CH]1SCCS1 FLOJNXXFMHCMMR-UHFFFAOYSA-N 0.000 description 1
- DLDJFQGPPSQZKI-UHFFFAOYSA-N 1,4-Butynediol Chemical compound OCC#CCO DLDJFQGPPSQZKI-UHFFFAOYSA-N 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-Chlorobutane Chemical class CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- VUQPJRPDRDVQMN-UHFFFAOYSA-N 1-chlorooctadecane Chemical class CCCCCCCCCCCCCCCCCCCl VUQPJRPDRDVQMN-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- FLDCGABOSKKJQE-UHFFFAOYSA-N 1-trimethylsilylethanesulfonamide Chemical compound C[Si](C)(C)C(C)S(N)(=O)=O FLDCGABOSKKJQE-UHFFFAOYSA-N 0.000 description 1
- 238000004293 19F NMR spectroscopy Methods 0.000 description 1
- 125000003287 1H-imidazol-4-ylmethyl group Chemical group [H]N1C([H])=NC(C([H])([H])[*])=C1[H] 0.000 description 1
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 1
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical class CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-Phenylethylbromide Chemical class BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
- KTBSXLIQKWEBRB-UHFFFAOYSA-N 2-[1-[1-[3-fluoro-2-(trifluoromethyl)pyridine-4-carbonyl]piperidin-4-yl]-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1=CN=C(C(F)(F)F)C(F)=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 KTBSXLIQKWEBRB-UHFFFAOYSA-N 0.000 description 1
- TXGKRVFSSHPBAJ-JKSUJKDBSA-N 2-[[(1R,2S)-2-aminocyclohexyl]amino]-4-[3-(triazol-2-yl)anilino]pyrimidine-5-carboxamide Chemical compound N[C@H]1CCCC[C@H]1NC1=NC=C(C(N)=O)C(NC=2C=C(C=CC=2)N2N=CC=N2)=N1 TXGKRVFSSHPBAJ-JKSUJKDBSA-N 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- FSTPMFASNVISBU-UHFFFAOYSA-N 2-methoxybenzonitrile Chemical compound COC1=CC=CC=C1C#N FSTPMFASNVISBU-UHFFFAOYSA-N 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- 125000006022 2-methyl-2-propenyl group Chemical group 0.000 description 1
- 125000006031 2-methyl-3-butenyl group Chemical group 0.000 description 1
- 125000006056 2-methyl-4-pentenyl group Chemical group 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N 2-stearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- YZYQQJHFYIVWPS-UHFFFAOYSA-N 3,4,5,6-tetradehydrothiopyran Chemical group [CH]1SC#CC#C1 YZYQQJHFYIVWPS-UHFFFAOYSA-N 0.000 description 1
- LOWWYYZBZNSPDT-ZBEGNZNMSA-N 3-[(3S,4R)-3-methyl-7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,7-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile Chemical compound C[C@H]1CN(C(=O)CC#N)[C@@]11CN(C=2C=3C=CNC=3N=CN=2)CC1 LOWWYYZBZNSPDT-ZBEGNZNMSA-N 0.000 description 1
- SQSZANZGUXWJEA-UHFFFAOYSA-N 3-[(4-chloro-2-fluorophenyl)methyl]-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholin-4-ylmethyl)imidazo[1,2-b]pyridazin-6-amine Chemical compound N1C(C)=CC(NC2=NN3C(CC=4C(=CC(Cl)=CC=4)F)=C(C)N=C3C(CN3CCOCC3)=C2)=N1 SQSZANZGUXWJEA-UHFFFAOYSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- JYZYBMYWPQSOCM-UHFFFAOYSA-N 4,4,5,5-tetramethyl-2-[1-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl]-1,3,2-dioxaborolane Chemical compound O1C(C)(C)C(C)(C)OB1C(C)B1OC(C)(C)C(C)(C)O1 JYZYBMYWPQSOCM-UHFFFAOYSA-N 0.000 description 1
- MRWWWZLJWNIEEJ-UHFFFAOYSA-N 4,4,5,5-tetramethyl-2-propan-2-yloxy-1,3,2-dioxaborolane Chemical group CC(C)OB1OC(C)(C)C(C)(C)O1 MRWWWZLJWNIEEJ-UHFFFAOYSA-N 0.000 description 1
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-Dimethylaminophenol Substances CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 1
- USZAGAREISWJDP-UHFFFAOYSA-N 4-[(1-hydroxy-3H-2,1-benzoxaborol-5-yl)oxy]benzonitrile Chemical compound C=1C=C2B(O)OCC2=CC=1OC1=CC=C(C#N)C=C1 USZAGAREISWJDP-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- ZISJNXNHJRQYJO-CMDGGOBGSA-N 5-[(E)-2-phenylethenyl]-2-propan-2-ylbenzene-1,3-diol Chemical compound C1=C(O)C(C(C)C)=C(O)C=C1\C=C\C1=CC=CC=C1 ZISJNXNHJRQYJO-CMDGGOBGSA-N 0.000 description 1
- YJISHJVIRFPGGN-UHFFFAOYSA-N 5-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxy-6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)O)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 YJISHJVIRFPGGN-UHFFFAOYSA-N 0.000 description 1
- PDOQBOJDRPLBQU-QMMMGPOBSA-N 5-chloro-2-N-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-4-N-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine Chemical compound N([C@@H](C)C=1N=CC(F)=CN=1)C(N=1)=NC=C(Cl)C=1NC=1C=C(C)NN=1 PDOQBOJDRPLBQU-QMMMGPOBSA-N 0.000 description 1
- 125000006043 5-hexenyl group Chemical group 0.000 description 1
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-DIMETHYL-1-[3-(2,4,5-TRICHLOROPHENOXY)PROPOXY]-1,6-DIHYDRO-1,3,5-TRIAZINE-2,4-DIAMINE Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- FJXOGVLKCZQRDN-PHCHRAKRSA-N Alclometasone Chemical compound C([C@H]1Cl)C2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O FJXOGVLKCZQRDN-PHCHRAKRSA-N 0.000 description 1
- VSCWAEJMTAWNJL-UHFFFAOYSA-K Aluminium chloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N Aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 1
- 206010001897 Alzheimer's disease Diseases 0.000 description 1
- 108010047814 Antigen-Antibody Complex Proteins 0.000 description 1
- 208000003017 Aortic Valve Stenosis Diseases 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 240000005781 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 102000003984 Aryl hydrocarbon receptors Human genes 0.000 description 1
- 108090000448 Aryl hydrocarbon receptors Proteins 0.000 description 1
- 229940009098 Aspartate Drugs 0.000 description 1
- JCINBYQJBYJGDM-UHFFFAOYSA-N BMS-911543 Chemical compound CCN1C(C(=O)N(C2CC2)C2CC2)=CC(C=2N(C)C=NC=22)=C1N=C2NC=1C=C(C)N(C)N=1 JCINBYQJBYJGDM-UHFFFAOYSA-N 0.000 description 1
- 229940050390 Benzoate Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N Betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 210000000988 Bone and Bones Anatomy 0.000 description 1
- 210000004958 Brain cells Anatomy 0.000 description 1
- 210000000481 Breast Anatomy 0.000 description 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 1
- 102100009787 CABIN1 Human genes 0.000 description 1
- 108010066057 CABIN1 Proteins 0.000 description 1
- 102100019487 CCL11 Human genes 0.000 description 1
- 101700074178 CCL11 Proteins 0.000 description 1
- 102100019485 CCL13 Human genes 0.000 description 1
- 101700034979 CCL13 Proteins 0.000 description 1
- 102100019493 CCL18 Human genes 0.000 description 1
- 101700059693 CCL18 Proteins 0.000 description 1
- 102100012032 CCL20 Human genes 0.000 description 1
- 101700018681 CCL20 Proteins 0.000 description 1
- 102100008431 CCL26 Human genes 0.000 description 1
- 101700040437 CCL26 Proteins 0.000 description 1
- 102100008433 CCL27 Human genes 0.000 description 1
- 101700020729 CCL27 Proteins 0.000 description 1
- 102100016449 CCL5 Human genes 0.000 description 1
- 101700063377 CCL5 Proteins 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-O CC[NH+](CC)CC Chemical compound CC[NH+](CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-O 0.000 description 1
- 102100003325 CDK20 Human genes 0.000 description 1
- ZVHNDZWQTBEVRY-UHFFFAOYSA-N CYT387 Chemical compound C1=CC(C(NCC#N)=O)=CC=C1C1=CC=NC(NC=2C=CC(=CC=2)N2CCOCC2)=N1 ZVHNDZWQTBEVRY-UHFFFAOYSA-N 0.000 description 1
- 229940046731 Calcineurin inhibitors Drugs 0.000 description 1
- LWQQLNNNIPYSNX-UROSTWAQSA-N Calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 description 1
- 229960003563 Calcium Carbonate Drugs 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- DSSYKIVIOFKYAU-UHFFFAOYSA-N Camphor Chemical compound C1CC2(C)C(=O)CC1C2(C)C DSSYKIVIOFKYAU-UHFFFAOYSA-N 0.000 description 1
- 210000001736 Capillaries Anatomy 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 210000000845 Cartilage Anatomy 0.000 description 1
- 229920002301 Cellulose acetate Polymers 0.000 description 1
- 108010070202 Certolizumab Pegol Proteins 0.000 description 1
- OSASVXMJTNOKOY-UHFFFAOYSA-N Chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 1
- 229960004926 Chlorobutanol Drugs 0.000 description 1
- 229940001468 Citrate Drugs 0.000 description 1
- 206010009887 Colitis Diseases 0.000 description 1
- 210000001072 Colon Anatomy 0.000 description 1
- 206010057254 Connective tissue inflammation Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- JYGXADMDTFJGBT-VWUMJDOOSA-N Cortisol Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 1
- 229950008199 Crisaborole Drugs 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 229940119017 Cyclosporine Drugs 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N DL-aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- 206010064769 Dactylitis Diseases 0.000 description 1
- 229950008830 Decernotinib Drugs 0.000 description 1
- 210000004207 Dermis Anatomy 0.000 description 1
- WBGKWQHBNHJJPZ-LECWWXJVSA-N Desonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O WBGKWQHBNHJJPZ-LECWWXJVSA-N 0.000 description 1
- 229960002593 Desoximetasone Drugs 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N Diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- XEHVFKKSDRMODV-UHFFFAOYSA-N Ethynyl radical Chemical group C#[C] XEHVFKKSDRMODV-UHFFFAOYSA-N 0.000 description 1
- 210000003414 Extremities Anatomy 0.000 description 1
- 206010016256 Fatigue Diseases 0.000 description 1
- 229950003487 Fedratinib Drugs 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 210000004905 Finger nails Anatomy 0.000 description 1
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 description 1
- IRXSLJNXXZKURP-UHFFFAOYSA-N Fluorenylmethyloxycarbonyl chloride Chemical compound C1=CC=C2C(COC(=O)Cl)C3=CC=CC=C3C2=C1 IRXSLJNXXZKURP-UHFFFAOYSA-N 0.000 description 1
- 210000002683 Foot Anatomy 0.000 description 1
- GKDRMWXFWHEQQT-UHFFFAOYSA-N Fostamatinib Chemical compound COC1=C(OC)C(OC)=CC(NC=2N=C(NC=3N=C4N(COP(O)(O)=O)C(=O)C(C)(C)OC4=CC=3)C(F)=CN=2)=C1 GKDRMWXFWHEQQT-UHFFFAOYSA-N 0.000 description 1
- 229950005309 Fostamatinib Drugs 0.000 description 1
- 229950008908 GANDOTINIB Drugs 0.000 description 1
- 210000004392 Genitalia Anatomy 0.000 description 1
- 210000004013 Groin Anatomy 0.000 description 1
- 230000036499 Half live Effects 0.000 description 1
- 210000003709 Heart Valves Anatomy 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 210000001624 Hip Anatomy 0.000 description 1
- 108010064750 Humanized Monoclonal Antibodies Proteins 0.000 description 1
- 102000015434 Humanized Monoclonal Antibodies Human genes 0.000 description 1
- 206010053317 Hydrophobia Diseases 0.000 description 1
- 206010020863 Hypertrichosis Diseases 0.000 description 1
- 206010020864 Hypertrichosis Diseases 0.000 description 1
- 208000003367 Hypopigmentation Diseases 0.000 description 1
- 102100015720 IFNB1 Human genes 0.000 description 1
- 101700011451 IFNB1 Proteins 0.000 description 1
- 102100016020 IFNG Human genes 0.000 description 1
- 101700086956 IFNG Proteins 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 102100001475 ITGB2 Human genes 0.000 description 1
- 108090001124 Immunoglobulin E Proteins 0.000 description 1
- 210000004969 Inflammatory Cells Anatomy 0.000 description 1
- 229940102223 Injectable Solution Drugs 0.000 description 1
- 229940102213 Injectable Suspension Drugs 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000004125 Interleukin-1alpha Human genes 0.000 description 1
- 108010082786 Interleukin-1alpha Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N Isothiazole Chemical group C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N Isoxazole Chemical group C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 210000001503 Joints Anatomy 0.000 description 1
- 210000003127 Knee Anatomy 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 229950002183 Lebrikizumab Drugs 0.000 description 1
- 229940067606 Lecithin Drugs 0.000 description 1
- UIARLYUEJFELEN-LROUJFHJSA-N Lestaurtinib Chemical compound C12=C3N4C5=CC=CC=C5C3=C3C(=O)NCC3=C2C2=CC=CC=C2N1[C@]1(C)[C@](CO)(O)C[C@H]4O1 UIARLYUEJFELEN-LROUJFHJSA-N 0.000 description 1
- 229950001845 Lestaurtinib Drugs 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 210000000265 Leukocytes Anatomy 0.000 description 1
- 229940040692 Lithium Hydroxide Monohydrate Drugs 0.000 description 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229950001567 Mapracorat Drugs 0.000 description 1
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 230000036650 Metabolic stability Effects 0.000 description 1
- 229960004011 Methenamine Drugs 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N Methyl acetate Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- KJTLQQUUPVSXIM-ZCFIWIBFSA-N Mevalonic acid Chemical compound OCC[C@](O)(C)CC(O)=O KJTLQQUUPVSXIM-ZCFIWIBFSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 229950008814 Momelotinib Drugs 0.000 description 1
- 229960001664 Mometasone Drugs 0.000 description 1
- 210000004400 Mucous Membrane Anatomy 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 208000010125 Myocardial Infarction Diseases 0.000 description 1
- 210000004165 Myocardium Anatomy 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N N,N-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N N-(p-Tolylsulfonyl)-N'-butylcarbamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- VODZWWMEJITOND-OWWNRXNESA-N N-Stearoylsphingosine Chemical compound CCCCCCCCCCCCCCCCCC(=O)NC(CO)C(O)\C=C\CCCCCCCCCCCCC VODZWWMEJITOND-OWWNRXNESA-N 0.000 description 1
- HJWLJNBZVZDLAQ-UHFFFAOYSA-N N-methyl-1-[4-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclohexyl]methanesulfonamide Chemical compound C1CC(CS(=O)(=O)NC)CCC1N(C)C1=NC=NC2=C1C=CN2 HJWLJNBZVZDLAQ-UHFFFAOYSA-N 0.000 description 1
- JOOXLOJCABQBSG-UHFFFAOYSA-N N-tert-butyl-3-[[5-methyl-2-[4-(2-pyrrolidin-1-ylethoxy)anilino]pyrimidin-4-yl]amino]benzenesulfonamide Chemical compound N1=C(NC=2C=C(C=CC=2)S(=O)(=O)NC(C)(C)C)C(C)=CN=C1NC(C=C1)=CC=C1OCCN1CCCC1 JOOXLOJCABQBSG-UHFFFAOYSA-N 0.000 description 1
- 229910017912 NH2OH Inorganic materials 0.000 description 1
- 229940097496 Nasal Spray Drugs 0.000 description 1
- 229950010012 Nemolizumab Drugs 0.000 description 1
- 239000006057 Non-nutritive feed additive Substances 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 108010029597 Omalizumab Proteins 0.000 description 1
- 229960000470 Omalizumab Drugs 0.000 description 1
- 208000006187 Onycholysis Diseases 0.000 description 1
- 229940041678 Oral Spray Drugs 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 102100003492 PDE4A Human genes 0.000 description 1
- 101700029476 PDE4A Proteins 0.000 description 1
- 102100018800 PDE4B Human genes 0.000 description 1
- 101700057678 PDE4B Proteins 0.000 description 1
- 102100018799 PDE4C Human genes 0.000 description 1
- 101700042596 PDE4C Proteins 0.000 description 1
- 102100018798 PDE4D Human genes 0.000 description 1
- 101700057277 PDE4D Proteins 0.000 description 1
- HWXVIOGONBBTBY-ONEGZZNKSA-N Pacritinib Chemical compound C=1C=C(C=2)NC(N=3)=NC=CC=3C(C=3)=CC=CC=3COC\C=C\COCC=2C=1OCCN1CCCC1 HWXVIOGONBBTBY-ONEGZZNKSA-N 0.000 description 1
- 229950011410 Pacritinib Drugs 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L Palladium(II) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N Pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 235000003177 Panax trifolius Nutrition 0.000 description 1
- 241001111421 Pannus Species 0.000 description 1
- 206010061536 Parkinson's disease Diseases 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229940066842 Petrolatum Drugs 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- RRRUXBQSQLKHEL-UHFFFAOYSA-N Piclamilast Chemical compound COC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OC1CCCC1 RRRUXBQSQLKHEL-UHFFFAOYSA-N 0.000 description 1
- 229950005184 Piclamilast Drugs 0.000 description 1
- IIMIOEBMYPRQGU-UHFFFAOYSA-L Picoplatin Chemical compound N.[Cl-].[Cl-].[Pt+2].CC1=CC=CC=N1 IIMIOEBMYPRQGU-UHFFFAOYSA-L 0.000 description 1
- IVDFJHOHABJVEH-UHFFFAOYSA-N Pinacol Chemical compound CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 1
- 229950010765 Pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N Pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 229910019020 PtO2 Inorganic materials 0.000 description 1
- 210000004915 Pus Anatomy 0.000 description 1
- 210000000664 Rectum Anatomy 0.000 description 1
- 229960002586 Roflumilast Drugs 0.000 description 1
- MNDBXUUTURYVHR-UHFFFAOYSA-N Roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 description 1
- 125000000066 S-methyl group Chemical group [H]C([H])([H])S* 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 210000004761 Scalp Anatomy 0.000 description 1
- 229960004540 Secukinumab Drugs 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 206010040925 Skin striae Diseases 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 240000001016 Solanum tuberosum Species 0.000 description 1
- 229940075582 Sorbic Acid Drugs 0.000 description 1
- 210000002784 Stomach Anatomy 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 210000004243 Sweat Anatomy 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 210000001258 Synovial Membrane Anatomy 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N THP Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- 101710040537 TNF Proteins 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 208000009056 Telangiectasis Diseases 0.000 description 1
- CBXCPBUEXACCNR-UHFFFAOYSA-N Tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N Tetrahydro-2-furanmethanol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N Tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 230000036335 Tissue distribution Effects 0.000 description 1
- XJDNKRIXUMDJCW-UHFFFAOYSA-J Titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
- 210000004906 Toe nails Anatomy 0.000 description 1
- 229950000835 Tralokinumab Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N Triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N Trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- WRECIMRULFAWHA-UHFFFAOYSA-N Trimethyl borate Chemical compound COB(OC)OC WRECIMRULFAWHA-UHFFFAOYSA-N 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 206010068760 Ulcers Diseases 0.000 description 1
- 108010077389 Ustekinumab Proteins 0.000 description 1
- 229940046008 Vitamin D Drugs 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N XPhos Chemical group CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 1
- 239000012391 XPhos Pd G2 Substances 0.000 description 1
- 241000209149 Zea Species 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- CWTUREABAILGIK-UHFFFAOYSA-L [Li+].[Cl-].[Cl-].CC(C)[Mg+] Chemical group [Li+].[Cl-].[Cl-].CC(C)[Mg+] CWTUREABAILGIK-UHFFFAOYSA-L 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000037374 absorbed through the skin Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229960000552 alclometasone Drugs 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 125000005133 alkynyloxy group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940027983 antiseptics and disinfectants Quaternary ammonium compounds Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000005620 boronic acid group Chemical group 0.000 description 1
- 238000006795 borylation reaction Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 239000012512 bulk drug substance Substances 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 108010044481 calcineurin phosphatase Proteins 0.000 description 1
- 229960004649 calcipotriene Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M caproate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 125000006244 carboxylic acid protecting group Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 230000003197 catalytic Effects 0.000 description 1
- 229960003115 certolizumab pegol Drugs 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 230000001889 chemoattractant Effects 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Substances ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229910052570 clay Inorganic materials 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 230000001010 compromised Effects 0.000 description 1
- 201000006233 congestive heart failure Diseases 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005824 corn Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004410 cyclooctyloxy group Chemical group C1(CCCCCCC1)O* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000002939 deleterious Effects 0.000 description 1
- 229950009684 delgocitinib Drugs 0.000 description 1
- 229960003662 desonide Drugs 0.000 description 1
- VWVSBHGCDBMOOT-IIEHVVJPSA-N desoximetasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@@H]2O VWVSBHGCDBMOOT-IIEHVVJPSA-N 0.000 description 1
- 150000008050 dialkyl sulfates Chemical class 0.000 description 1
- 201000008286 diarrhea Diseases 0.000 description 1
- 125000005959 diazepanyl group Chemical group 0.000 description 1
- VBXDEEVJTYBRJJ-UHFFFAOYSA-N diboronic acid Chemical compound OBOBO VBXDEEVJTYBRJJ-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- YLNKFQWRRIXZPJ-UHFFFAOYSA-N diethylamino(difluoro)sulfanium;tetrafluoroborate Chemical group F[B-](F)(F)F.CCN(CC)[S+](F)F YLNKFQWRRIXZPJ-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-O diethylazanium Chemical compound CC[NH2+]CC HPNMFZURTQLUMO-UHFFFAOYSA-O 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 125000005805 dimethoxy phenyl group Chemical group 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- ROSDSFDQCJNGOL-UHFFFAOYSA-O dimethylaminium Chemical compound C[NH2+]C ROSDSFDQCJNGOL-UHFFFAOYSA-O 0.000 description 1
- GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical class CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 108010010371 efalizumab Proteins 0.000 description 1
- 229960000284 efalizumab Drugs 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-M ethyl carbonate Chemical compound CCOC([O-])=O CQDGTJPVBWZJAZ-UHFFFAOYSA-M 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-O ethylaminium Chemical compound CC[NH3+] QUSNBJAOOMFDIB-UHFFFAOYSA-O 0.000 description 1
- 229940093476 ethylene glycol Drugs 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229950009618 fenebrutinib Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229960000785 fluocinonide Drugs 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N furane Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 108010086781 golimumab Proteins 0.000 description 1
- 229960001743 golimumab Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000002140 halogenating Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- 235000010299 hexamethylene tetramine Nutrition 0.000 description 1
- 239000004312 hexamethylene tetramine Substances 0.000 description 1
- 239000008079 hexane Substances 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000003301 hydrolyzing Effects 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxyl anion Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 230000003425 hypopigmentation Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 229940121454 ilginatinib Drugs 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001861 immunosuppresant Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002458 infectious Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052741 iridium Inorganic materials 0.000 description 1
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000005969 isothiazolinyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M isothiocyanate Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 125000003971 isoxazolinyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 229950001890 itacitinib Drugs 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 108010010776 lebrikizumab Proteins 0.000 description 1
- 230000004301 light adaptation Effects 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 238000003819 low-pressure liquid chromatography Methods 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-L maleate(2-) Chemical compound [O-]C(=O)\C=C/C([O-])=O VZCYOOQTPOCHFL-UPHRSURJSA-L 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000001404 mediated Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- MJHOMTRKVMKCNE-NWDGAFQWSA-N mivavotinib Chemical compound C1=NN(C)C=C1C1=NC(N[C@H]2[C@H](CCCC2)N)=C(F)C2=C1C(=O)NC2 MJHOMTRKVMKCNE-NWDGAFQWSA-N 0.000 description 1
- 229940121463 mivavotinib Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 108091007356 nemolizumab Proteins 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 229960004955 oclacitinib Drugs 0.000 description 1
- OIPZNTLJVJGRCI-UHFFFAOYSA-M octadecanoyloxyaluminum;dihydrate Chemical compound O.O.CCCCCCCCCCCCCCCCCC(=O)O[Al] OIPZNTLJVJGRCI-UHFFFAOYSA-M 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 230000003287 optical Effects 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 235000020825 overweight Nutrition 0.000 description 1
- OHENQANLQNOMAO-UHFFFAOYSA-N oxaborole Chemical group O1B=CC=C1 OHENQANLQNOMAO-UHFFFAOYSA-N 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical group C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- 125000005963 oxadiazolidinyl group Chemical group 0.000 description 1
- 125000005882 oxadiazolinyl group Chemical group 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N oxazole Chemical group C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000005968 oxazolinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N oxygen atom Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 101710031992 pRL90232 Proteins 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N palmityl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 230000000737 periodic Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-N phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000011528 polyamide (building material) Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- UFUASNAHBMBJIX-UHFFFAOYSA-N propan-1-one Chemical group CC[C]=O UFUASNAHBMBJIX-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000001823 pruritic Effects 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N pyrrole Chemical group C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 230000002285 radioactive Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 230000002829 reduced Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000002407 reforming Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 1
- 229950005741 rolipram Drugs 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 108010040425 secukinumab Proteins 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 231100000245 skin permeability Toxicity 0.000 description 1
- 238000010583 slow cooling Methods 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- WSWCOQWTEOXDQX-UHFFFAOYSA-N sorbic acid Chemical compound CC=CC=CC(O)=O WSWCOQWTEOXDQX-UHFFFAOYSA-N 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 201000002661 spondylitis Diseases 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000010922 spray-dried dispersion Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 238000004808 supercritical fluid chromatography Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 231100001005 telangiectasia Toxicity 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 125000005304 thiadiazolidinyl group Chemical group 0.000 description 1
- 125000005305 thiadiazolinyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 239000008009 topical excipient Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 108010037465 tralokinumab Proteins 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- BSUNTQCMCCQSQH-UHFFFAOYSA-N triazine Chemical group C1=CN=NN=C1.C1=CN=NN=C1 BSUNTQCMCCQSQH-UHFFFAOYSA-N 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 150000003852 triazoles Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 125000005034 trifluormethylthio group Chemical group FC(S*)(F)F 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-O trimethylammonium Chemical compound C[NH+](C)C GETQZCLCWQTVFV-UHFFFAOYSA-O 0.000 description 1
- 239000011778 trisodium citrate Substances 0.000 description 1
- 125000005455 trithianyl group Chemical group 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-M undecanoate Chemical compound CCCCCCCCCCC([O-])=O ZDPHROOEEOARMN-UHFFFAOYSA-M 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 229960003824 ustekinumab Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
Abstract
The present invention relates to boron containing compounds of Formula (I)
Description
BORON CONTAINING PDE4 INHIBITORS
FIELD OF THE INVENTION
The présent invention relates to pharmaceutically active boron containing compounds that inhibit phosphodiesterase 4 (PDE4), pharmaceutical compositions containing these compounds, and the use of these compounds for treating or preventing diseases, conditions, or disorders ameliorated by inhibition of PDE4.
BACKGROUND
Inflammation is a major component of numerous diseases and individuals with such diseases often exhibit high levels of inflammatory regulators that include, but are not limited to, the following cytokines IL-1a, IL-Ιβ, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-12, IL-13, IL-17, IL18, IL-23, IL-31, IL-33, TNF-α, IFN-a, IFN-β, and IFN-γ. A non-limiting list of disease States that are directly associated with inflammatory cytokines include: atopie dermatitis wherein inflammatory cytokines induce inflammation; psoriasis wherein inflammatory cytokines induce dermatitis; arthritis wherein inflammatory cytokines can lead to lésions in the synovial membrane and destruction of joint cartilage and bone; fibrosis wherein inflammatory cytokines can attack traumatized tissue; lupus wherein inflammatory cytokines can exacerbate the immune complex déposition and damage; allergy wherein inflammatory cytokines can induce inflammation, production of IgE, and congestion; fibromyalgia wherein inflammatory cytokines are elevated in patients; and surgical complications wherein inflammatory cytokines can avert healing.
Other diseases associated with chronic inflammation include: cancer; heart attack wherein chronic inflammation contributes to coronary atherosclerosis; Alzheimer's disease wherein chronic inflammation negatively effects brain cells; congestive heart failure wherein chronic inflammation causes heart muscle wasting; stroke wherein chronic inflammation promûtes thromboembolie events; and aortic valve stenosis wherein chronic inflammation damages heart valves. Arteriosclerosis, osteoporosis, Parkinson's disease, bacterial infection, viral infection, inflammatory bowel disease including Crohn's disease and ulcerative colitis, as well as multiple sclerosis (a typical autoimmune inflammatory-related disease) are also related to inflammation. Current methods available for the treatment of such inflammatory diseases can be unsatisfactory due to a lack of sufficient efficacy and/or drug related side effects associated therein. Therefore a need exists for new therapeutic methods that modulate inflammatory process involved in the diseases, conditions, and disorders, disclosed herein.
In particular, Atopie Dermatitis (AD) is an inflammatory skin disease that, typically, manifests during early childhood but can appear in adolescence or adulthood and follows either a chronic or a relapsing/remitting disease progression. AD patients display pruritic skin and show susceptibility to cutaneous secondary bacterial, viral and fungal infections. Patients with
AD can also demonstrate a compromised barrier function that leads to activation of kératinocytes and other immune cells. A number of inflammatory cytokines are involved in the symptoms characteristic of AD including, but not limited to, IL-1 IL-2, IL-3, IL-4, IL-5, IL-6, IL-12, IL-13, IL-17, IL-18, IL-22, IL-23, IL-31, IL-33, IL-36, and TNF-α. Inflammatory cytokines facilitate the production of various chemoattractants or chemokines which support the recruitment of leukocytes to the disease site. Chemokines that contribute to inflammation in AD patients include, but not limited to, CCL1, CCL2, CCL3, CCL4, CCL5, CCL11, CCL13, CCL17, CCL18, CCL20, CCL22, CCL26 and CCL27.
There are limited therapeutic options for the treatment of AD. The topical use of antiinflammatory steroids has been utilized in AD treatment particularly in the case of acute disease flares. The steroids suppress the activation and prolifération of inflammatory cells as well as kératinocytes and fibroblasts. However, steroids can cause adverse local side effects that include, but are not restricted to, skin atrophy, telangiectasia (abnormal dilation of capillary vessels), epidermal barrier disturbance, striae, rosacea, acné, hypertrichosis, hypopigmentation, delayed wound healing and alterations in skin elasticity. Emollients including petrolatum and over-the-counter moisturizers hâve been used to reduce the use of topical steroids. Topical application of mevalonic acid and nicotinamide has been used to improve the epidermal barrier permeability through the production of cholestérol and ceramide. Topical calcineurin inhibitors (TCI) such as tacrolimus and pimecrolimus hâve been used in the treatment of AD. Cyclosporine A (CyA) has been used as an immunosuppressant to inhibit calcineurin phosphatase thereby leading to réduction in levels of IL-2 and inhibition of T cell prolifération. Systemic treatment include humanized monoclonal antibodies such as Omalizumab, Efalizumab and Etanercept, Dupilumab that target sérum IgE, LFA-1, TNF-α, and IL-4r respectively [Rahman, Inf. & AH. 2011,10, 486], Additional eczema, skin and disease conditions include hand dermatitis, contact dermatitis, allergie contact dermatitis, irritant contact dermatitis, neurodermatitis, perioral dermatitis, stasis dermatitis, dyshidrotic eczema, xerotic dermatitis, nummalar dermatitis, seborrheic dermatitis, eyelid dermatitis, diaper dermatitis, dermatomyositis, lichen planus, lichen sclerosis, alopecia areata, vitiligo, rosacea, epidermolysis bullosa, keratosis pilaris, pityriasis alba, pemphigus, vulvovaginitis, acné, chronic spontaneous urticaria, chronic idiopathic urticaria, chronic physical urticaria, vogt-koyanagi-harada disease, sutton nevus/nevi, post inflammatory hypopigmentation, senile leukoderma, chemical/druginduced leukoderma, cutaneous lupus erythematosus, discoid lupus, palmoplantar pustulosis, pemphigoid, sweet's syndrome, and hidradenitis suppurativa [Eyerich and Eyerich, J. Eur. Ac. Derm. Ven., 32, 692 (2018)].
Psoriasis is an immune-mediated chronic skin disease that exists in several different forms including plaque psoriasis, pustular psoriasis, nail psoriasis, flexural psoriasis, guttate psoriasis, psoriatic arthritis, érythrodermie psoriasis, and inverse psoriasis. Plaque psoriasis (psoriasis vulgaris) is the most common form of psoriasis and typically appears as patches of b raised red skin covered by a flaky white buildup. Pustular psoriasis appears as raised bumps that are filled with non-infectious pus (pustules). The skin under and surrounding pustules is red and tender. Pustular psoriasis can be localized, commonly to the hands and feet, or generalized with widespread patches occurring on any part ofthe body. Nail psoriasis produces a variety of changes in the appearance of finger and toe nails. These changes include discoloring under the nail plate, pitting ofthe nails, lines going across the nails, thickening ofthe skin under the nail, and the loosening (onycholysis) and crumbling ofthe nail. Flexural psoriasis (inverse psoriasis) appears as smooth inflamed patches of skin. It occurs in skin folds, particularly around the genitals (between the thigh and groin), the armpits, under an overweight stomach (pannus), and under the breasts (inframammary fold). It is aggravated by friction and sweat, and is vulnérable to fungal infections. Guttate psoriasis is characterized by numerous small oval spots. These spots of psoriasis appear over large areas ofthe body, such as the trunk, limbs, and scalp. Psoriatic arthritis involves joint and connective tissue inflammation. Psoriatic arthritis can affect any joint but is most common in the joints of the fingers and toes. Psoriatic arthritis can resuit in swelling of the fingers and toes known as dactylitis. Psoriatic arthritis can also affect the hips, knees and spine (spondylitis). Erythrodermie psoriasis involves the widespread inflammation and exfoliation ofthe skin over most ofthe body surface. It may be accompanied by severe itching, swelling and pain. It is often the resuit of an exacerbation of unstable plaque psoriasis, particularly following the abrupt withdrawal of systemic treatment. Current thérapies available for treatment of psoriasis include topical treatment, phototherapy, and systemic applications. The treatments are either cosmetically undesirable, inconvénient for long-term use, or hâve limited effectiveness.
Inflammatory Bowel Disease (IBD) describes a group of intestinal disorders that involve inflammation of the digestive tract including ulcerative colitis and Crohn's disease. Ulcerative
Colitis (UC) causes periodic and chronic inflammation and ulcers in the lining of the large intestine (colon). Crohn's disease (CD) is characterized by inflammation ofthe lining ofthe gastrointestinal tract and can penetrate into related tissues. Patients with IBD can exhibit diarrhea, abdominal pain, fatigue, and weight loss, and these conditions can be severe and debilitating. As the symptoms vary depending on the level and duration of inflammation, an agent that modulâtes said inflammation would be useful in treating IBD.
Phosphodiesterases (PDEs) represent a family of enzymes that catalyze the hydrolysis of various cyclic nucleoside monophosphates including cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). PDEs regulate the level of cyclic nucléotides within cells and maintain cyclic nucléotide homeostasis by hydrolyzing such cyclic mononucleotides resulting in termination of their messenger rôle. PDE enzymes can be grouped into families according to their specificity toward hydrolysis of cAMP and/or cGMP, their sensitivity to régulation by calcium and calmodulin, and their sélective inhibition by various compounds.
The PDE4 enzyme sub-family consists of four genes which produce 4 isoforms ofthe
PDE4 enzyme designated PDE4A, PDE4B, PDE4C, and PDE4D [Wang étal., Biochem. Biophys. Res. Comm., 234, 320 (1997)]. In addition, various splice variants of each PDE4 isoform hâve been identified. PDE4 isoenzymes specifically inactivate cAMP by catalyzing its hydrolysis to adenosine 5'-monophosphate (AMP). Régulation of cAMP activity is important in many biological processes including inflammation.
The compounds ofthe présent invention inhibit phosphodiesterases, including PDE4, and modulate inflammatory cytokine levels and are, therefore, useful in treating inflammatory disorders such as atopie dermatitis, eczema, psoriasis, arthritis, asthma, fibrosis, lupus, allergy, fibromyalgia, wound healing, ulcerative colitis, Crohn’s disease, inflammatory bowel disease, and inflammation resulting from surgical complications.
SUMMARY OF THE INVENTION
The présent invention provides compounds of Formula (I) that inhibit PDE4 and are useful for treating or preventing disorders ameliorated by inhibition of PDE4 in humans,
X-Y-Z
Formula (I) or a pharmaceutically acceptable sait thereof, wherein
X is phenyl, pyridine, pyrimidine, pyrazine, pyridazine, ortriazine, wherein each is optionally substituted with 1,2, 3, 4, or 5 substituents that are independently deuterium, (C2-C6)alkenyl, (C2-C6)alkenyloxy, (C2-C6)alkenylthio, (Ci-Cejalkoxy, (Ci-C6)alkoxy-c/i-i3, (C-i-CejalkoxyfCi-CeJalkoxy, (Ci-C6)alkoxy(Ci-C6)alkyl, (Ci-C6)alkoxycarbonyl, (Ci-Ce)alkyl, (Ci-C6)alkyl-c/i-i3, (Ci-C6)alkylcarbonyl, (Ci-C6)alkylthio, (C2-C6)alkynyl, (C2-C6)alkynyloxy, (C2-C6)alkynylthio, aryl, aryl(Ci-C6)alkoxy, aryl(Ci-C6)alkyl, aryl(Ci-C6)alkylthio, aryloxy, arylthio, carboxy, carboxy(Ci-C6)alkoxy, carboxy(Ci-C6)alkyl, cyano, (C3-Ca)cycloalkyl, (C3-Cs)cycloalkyl(Ci-C6)alkoxy, (C3-C8)cycloalkyl(Ci-C6)alkyl, C3-C8)cycloalkyl(Ci-C6)alkylthio, (C3-C8)cycloalkyloxy, (C3-C8)cycloalkylthio, halogen, halo(Ci-C6)alkoxy, halo(Ci-C6)alkyl, halo(Ci-C6)aIkylthio, (5-6 membered)heteroaryl, (5-6 membered)heteroaryl(Ci-C6)alkoxy, (5-6 membered)heteroaryl(Ci-C6)alkyl, (5-6 membered)heteroaryl(Ci-C6)alkylthio, (5-6 membered)heteroaryloxy, (5-6 membered)heteroarylthio, (4-7 membered)heterocycle containing at least one heteroatom independently selected from the group consisting of O, N, and S, (4-7 membered)heterocycle(Ci-C6)alkoxy, (4-7 membered)heterocycle(Ci-C6)alkyl, (4-7 membered)heterocycle(Ci-C6)alkylthio, (4-7 membered)heterocycleoxy, (4-7 membered)heterocyclethio, hydroxy, hydroxy(Ci-C6)alkoxy, hydroxy(Ci-C6)alkyl· mercapto, nitro, thioiCrCsJalkyl, -NRARB, NRARB(Ci-C6)alkoxy, NRARB(Ci-C6)alkyl, or (NRARB)carbonyl; RA and Rb are independently hydrogen, (Ci-Ce)alkyl, or (Ci-Ce)alkylcarbonyl; Y is phenyl, pyridine, pyrimidine, pyrazine, pyridazine, triazine, furan, thiophene, pyrrole, oxazole, thiazole, imidazole, isoxazole, isothiazole, pyrazole, oxadiazole, thiadiazole, or triazole, wherein each is optionally substituted with 1, 2, or 3 substituents that are independently deuterium, (Ci-C6)alkoxy, (Ci-C6)alkoxy-di-i3, (Ci-C6)alkoxy(Ci-C6)alkoxy, (Ci-C6)alkoxy(Ci-C6)alkyl, (Ci-C6)alkoxycarbonyl, (Ci-C6)alkoxycarbonyl(Ci-C6)alkyl, (Ci-C3)alkyl, (Ci-C3)alkyl-c/i-7, (Ci-Ce)alkyl, (Ci-Ce)alkyl-c/i-i3, (Ci-Cejalkylcarbonyl, (Ci-Cejalkylthio, carboxy, carboxy(Ci-C6)alkoxy, carboxy(Ci-C6)alkyl, cyano, halogen, halo(Ci-Ce)alkoxy, halo(Ci-Ce)alkyl, hydroxy, hydroxy(Ci-C6)alkoxy, hydroxy(Ci-Cs)alkyl, mercapto, nitro, -NRcRd, NRcRD(Ci-C6)alkoxy, NRcRD(Ci-C6)alkyl, or (NRcRo)carbonyl; Rc and Rd are independently hydrogen, (Ci-C6)alkyl, or (Ci-C6)alkylcarbonyl; Z is
wherein B is boron; Rio at each occurrence is independently H, deuterium, (Ci-C6)alkoxy(Ci-C6)alkyl, (Ci-Ce)alkyl, (Ci-C6)alkyl-di-13, (Ci-C6)alkylthio(Ci-C6)alkyl, hydroxy(Ci-C6)alkyl, or thio(Ci-C6)alkyl; Ru at each occurrence is independently deuterium, (Ci-C3)alkyl, or (Ci-Cftalkyl-dw; R12 is independently H, (Ci-Cs)alkyl, or hydroxy(Ci-C6)alkyl; m is 0, 1, 2, or 3; n is 0, 1,2, 3, or 4; p is 0, 1, 2, 3, 4, or 5; q is 0, 1,2, 3, 4, 5, or 6; and r is 0, 1,2, 3, 4, 5, 6 or 7.
In another embodiment, the présent invention provides a pharmaceutical composition comprising a compound of Formula (I) and at least one pharmaceutically acceptable excipient, 10 diluent, or carrier.
In another embodiment, the présent invention provides a method for treating or preventing inflammatory diseases in a mammal, particularly a human, comprising administering to the mammal or human, in need of such treatment, a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable sait thereof.
in another embodiment, the présent invention provides a method for treating or preventing inflammatory diseases in a mammal, particularly a human, comprising topically administering to the mammal or human, in need of such treatment, a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable sait thereof.
In another aspect, the présent invention provides the use of compounds of Formula (I) in 20 the manufacture of a médicament for treating inflammatory diseases in a mammal, particularly a human.
BRIEF DESCRIPTION OF THE FIGURES
Figure 1 is an X-ray structure (ORTEP drawing) of crystalline (R)-4-(5-(3-ethoxy-425 methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol (Example 3).
Figure 2 is an X-ray structure (ORTEP drawing) of crystalline (R) 4-(5-(4-methoxy-3propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol (Example 4).
Figure 3 is an X-ray structure (ORTEP drawing) of crystalline (S)-4-(5-(4-methoxy-3propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol (Example 5).
Figure 4 is an X-ray structure (ORTEP drawing) of crystalline (R) 4-(5-(3-ethoxy-4methoxyphenyl)-6-methylpyridin-3-yl)-1,2-oxaborolan-2-ol (Example 19).
Figure 5 is a powder X-ray diffraction analysis of crystalline (R)-4-(5-(3-ethoxy-4methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol (Example 3).
Figure 6 is a powder X-ray diffraction analysis of crystalline (R)-4-(5-(4-methoxy-3propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol (Example 4).
Figure 7 is a powder X-ray diffraction analysis of crystalline (S)-4-(5-(4-methoxy-3propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol (Example 5).
Figure 8 is a powder X-ray diffraction analysis of crystalline (-) 4-(5-(2-(difluoromethyl)-3ethoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol (Example 10).
Figure 9 is a powder X-ray diffraction analysis of crystalline (R)-4-(5-(3-ethoxy-4methoxyphenyl)-6-methylpyridin-3-yl)-1,2-oxaborolan-2-ol (Example 19).
Figure 10 is a powder X-ray diffraction analysis of crystalline (4-methoxy-3propoxyphenyl)boronic acid.
Figure 11 is a powder X-ray diffraction analysis of crystalline 3-bromo-5-(4-methoxy-3propoxyphenyl)pyridine.
Figure 12 is a powder X-ray diffraction analysis of crystalline 3-(3-((tertbutyldimethylsilyl)oxy)prop-1-en-2-yl)-5-(4-methoxy-3-propoxyphenyl)pyridine.
DETAILED DESCRIPTION OF THE INVENTION In another embodiment, the présent invention provides compounds of Formula (I)
X-Y-Z
Formula (I) or a pharmaceutically acceptable sait thereof, wherein X is phenyl, pyridine, or pyrimidine, wherein each is optionally substituted with 1, 2, 3, 4, or 5 substituents that are independently deuterium, (C2-C6)alkenyl, (C2-C6)alkenyloxy, (C2-C6)alkenylthio, (Ci-C6)alkoxy, (Ci-C6)alkoxy-di-i3, (Ci-C6)alkoxy(Ci-C6)alkoxy, (Ci-C6)alkoxy(Ci-C6)alkyl, (Ci-C6)alkoxycarbonyl, (Ci-C6)alkyl, (Ci-C6)alkyl-di-i3, (Ci-C6)alkylcarbonyl, (Ci-C6)alkylthio, (C2C6)alkynyl, (C2-C6)alkynyloxy, (C2-C6)alkynylthio, aryl, aryl(Ci-C6)alkoxy, aryl(Ci-C6)alkyl, aryl(Ci-Cs)alkylthio, aryloxy, arylthio, carboxy, carboxy(Ci-C6)alkoxy, carboxy(Ci-C6)alkyl, cyano, (C3-C8)cycloalkyl, (C3-C8)cycloalkyl(Ci-C6)alkoxy, (C3-C8)cycloalkyl(Ci-C6)alkyl, C3-C8)cycloalkyl(Ci-C6)alkylthio, (C3-C8)cycloalkyloxy, (C3-C8)cycloalkylthio, halogen, halo(Ci-C6)alkoxy, halo(Ci-C6)alkyl, halo(Ci-Ce)alkylthio, (5-6 membered)heteroaryl, (5-6 membered)heteroaryl(Ci-C6)alkoxy, (5-6 membered)heteroaryl(Ci-C6)alkyl, (5-6 membered)heteroaryl(Ci-C6)alkylthio, (5-6 membered)heteroaryloxy, (5-6 membered)heteroarylthio, (4-7 membered)heterocycle containing at least one heteroatom independently selected from the group consisting of O, N, and S, (4-7 membered)heterocycle(Ci-C6)alkoxy, (4-7 membered)heterocycle(Ci-C6)alkyl, (4-7 membered)heterocycle(Ci-C6)alkylthio, (4-7 membered)heterocycleoxy, (4-7 membered)heterocyclethio, hydroxy, hydroxy(Ci-C6)alkoxy, hydroxy(Ci-C6)alkyl, mercapto, nitro, thio(Ci-C6)alkyl, -NRaRb, NRARsfCi-Cejalkoxy, NRARB(Ci-C6)alkyl, or (NRARejcarbonyl; Ra and Rb are independently hydrogen, (Ci-C6)alkyl, or (Ci-Cejalkylcarbonyl; Y is phenyl, pyridine, pyrimidine, pyrazine, pyridazine, thiazole, pyrazole, or thiadiazole, wherein each is optionally substituted with 1,2, or 3 substituents that are independently deuterium, (Ci-Cs)alkoxy, (Ci-C6)alkoxy-di-i3, (Ci-C6)alkoxy(Ci-C6)alkoxy, (Ci-Cs)alkoxy(Ci-C6)alkyl, (Ci-C6)alkoxycarbonyl, (Ci-C6)alkoxycarbonyl(Ci-C6)alkyl, (Ci-C3)alkyl, (Ci-C3)alkyl-c/i-7, (Ci-C6)alkyl, (Ci-C6)alkyl-c/i-i3, (Ci-C6)alkylcarbonyl, (Ci-C6)alkylthio, carboxy, carboxy(Ci-C6)alkoxy, carboxy(Ci-C6)alkyl, cyano, halogen, halo(Ci-C8)alkoxy, halo(Ci-C6)alkyl, hydroxy, hydroxy(Ci-C6)alkoxy, hydroxy(Ci-C6)alkyl, mercapto, nitro, -NRcRd, NRcRD(Ci-Cs)alkoxy, NRcRofCi-Cejalkyl, or (NRcRo)carbonyl; Rc and Rd are independently hydrogen, (Ci-Cejalkyl, or (Ci-Ce)alkylcarbonyl; Z is as defined in the Summary section herein; Rio at each occurrence is H, deuterium, (Ci-C6)alkyl, (Ci-C6)alkyl-c/i-i3, or hydroxy(Ci-C6)alkyl; Ru at each occurrence is deuterium, methyl, or methyl-d3; Ri2 is independently H, (Ci-C6)alkyl, or hydroxy(Ci-Cs)alkyl; m is 0, 1,2, or 3; n is 0 or 1 ; p is 0, 1, 2, 3, 4, or 5; q is 0, 1, 2, or 3; and r is 0, 1,2, 3, 4, 5, 6 or 7
In another embodiment, the présent invention provides compounds of Formula (I), or a pharmaceutically acceptable sait thereof, wherein X is phenyl, pyridine, or pyrimidine, wherein each is optionally substituted with 1, 2, or 3 substituents that are independently (Ci-C6)alkoxy, (Ci-Ce)alkyl, (Ci-C6)alkylthio, cyano, (C3-C8)cycloalkyloxy, halogen, halo(Ci-C6)alkoxy, halo(Ci-C6)alkyl, (4-7 membered)heterocycleoxy, or hydroxy(Ci-C6)alkoxy; Y is phenyl, pyridine, pyrimidine, pyrazine, pyridazine, thiazole, pyrazole, or thiadiazole, wherein each is optionally substituted with 1 substituent that is (Ci-C6)alkoxy, (Ci-C6)alkoxy(Ci-C6)alkyl, (Ci-C6)alkoxycarbonyl(Ci-C6)alkyl, (CrC3)alkyl, (Ci-C6)alkyl, carboxy(Ci-C6)alkyl, halogen, halo(Ci-C6)alkyl, hydroxy(Ci-C6)alkoxy, or hydroxy(Ci-C6)alkyl; Z is p
^(Rioip (Rlo)m , wherein B is boron;
Rw at each occurrence is H, methyl or hydroxymethyl; m is 1; and p is 1.
In another embodiment, the présent invention provides compounds of Formula (I), or a pharmaceutically acceptable sait thereof, wherein X is phenyl, pyridine, or pyrimidine, wherein each is optionally substituted with 1, 2, or 3 substituents that are independently (Ci-C6)alkoxy, (Ci-Cs)alkyl, (Ci-C6)alkylthio, cyano, (C3-C8)cycloalkyloxy, halogen, halo(Ci-C6)alkoxy, halo(Ci-C6)alkyl, (3-7membered)heterocycleoxy, or hydroxy(Ci-C6)alkoxy; Y is phenyl, pyridine, pyrimidine, pyrazine, pyridazine, thiazole, pyrazole, or thiadiazole, wherein each is optionally substituted with 1 substituent that is (O-Csjalkoxy, (Ci-C6)alkoxy(Ci-C6)alkyl, (Ci-C6)alkoxycarbonyl(Ci-C6)alkyl, (Ci-C3)alkyl, (Ci-Ce)alkyl, carboxy(Ci-C6)alkyl, halogen, halo(Ci-Cs)alkyl, hydroxy(Ci-C6)alkoxy, or hydroxy(Ci-C6)alkyl; Z is
OH wherein B is boron.
In another embodiment, the présent invention provides compounds of Formula (I), or a pharmaceutically acceptable sait thereof, wherein X is phenyl, pyridine, or pyrimidine, wherein each is optionally substituted with 1,2, or 3 substituents that are independently (Ci-C6)alkoxy, (Ci-Ce)alkyl, (Ci-Cejalkylthio, cyano, (C3-C8)cycloalkyloxy, halogen, halo(Ci-Cs)alkoxy, halo(Ci-Cs)alkyl, (4-7 membered)heterocycleoxy, or hydroxy(Ci-Cs)alkoxy; Y is phenyl, pyridine, pyrimidine, pyrazine, pyridazine, thiazole, pyrazole, or thiadiazole, wherein each is optionally substituted with 1 substituent that is (Ci-C6)alkoxy, (Ci-C6)alkoxy(Ci-C6)alkyl, (Ci-C6)alkoxycarbonyl(Ci-C6)alkyl, (Ci-C3)alkyl, (Ci-C6)alkyl, carboxy(Ci-C6)alkyl, halogen, halo(Ci-C6)alkyl, hydroxy(Ci-C6)alkoxy, or hydroxy(Ci-C6)alkyl; Z is OH / ^B \ X° wherein B is boron.
In another embodiment, the présent invention provides compounds of Formula (I), or a pharmaceutically acceptable sait thereof, wherein X is phenyl, pyridine, or pyrimidine, wherein each is optionally substituted with 1, 2, or 3 substituents that are independently (Ci-C6)alkoxy, (Ci-C6)alkyl, (Ci-Cejalkylthio, cyano, (C3-C8)cycloalkyloxy, halogen, halo(Ci-C6)alkoxy, halo(Ci-Ce)alkyl, (4-7 membered)heterocycleoxy, or hydroxy(Ci-C6)alkoxy; Y is phenyl, pyridine, pyrimidine, pyrazine, pyridazine, thiazole, pyrazole, or thiadiazole, wherein each is optionally substituted with 1 substituent that is (Ci-C6)alkoxy, (Ci-Cs)alkoxy(Ci-C6)alkyl, (Ci-C6)alkoxycarbonyl(Ci-C6)alkyl, (Ci-Csjalkyl, (Ci-Ce)alkyl, carboxy(Ci-C6)alkyl, halogen, halo(Ci-Cs)alkyl, hydroxy(Ci-C6)alkoxy, or hydroxy(Ci-C6)alkyl; Z is
OH / ^•B fTy° X wherein B is boron.
In another embodiment, the présent invention provides compounds of Formula (I), or a pharmaceutically acceptable sait thereof, wherein X is phenyl, pyridine, or pyrimidine, wherein each is optionally substituted with 1, 2, or 3 substituents that are independently (Ci-C6)alkoxy, (Ci-C6)alkyl, (Ci-Cejalkylthio, cyano, (C3-C8)cycloalkyloxy, halogen, halo(Ci-C8)alkoxy, halo(C-i-C6)alkyl, (4-7 membered)heterocycleoxy, or hydroxy(Ci-C6)alkoxy; Y is phenyl, pyridine, pyrimidine, pyrazine, pyridazine, thiazole, pyrazole, or thiadiazole, wherein each is optionally substituted with 1 substituent that is (Ci-Ce)alkoxy, (Ci-C6)alkoxy(Ci-C6)alkyl, (Ci-C6)alkoxycarbonyl(Ci-C6)alkyl, (Ci-C3)alkyl, (Ci-Ce)alkyl, carboxy(Ci-C6)alkyl, halogen, halo(Ci-C6)alkyl, hydroxy(Ci-Ce)alkoxy, or hydroxy(Ci-Ce)alkyl; Z is
Rio at each occurrence is H, methyl or hydroxymethyl; p is 1; and r is 1.
In another embodiment, the présent invention provides compounds of Formula (I), or a pharmaceutically acceptable sait thereof, wherein X is phenyl, pyridine, or pyrimidine, wherein each is optionally substituted with 1,2, or 3 substituents that are independently (Ci-C6)alkoxy, (Ci-C6)alkyl, (Ci-C6)alkylthio, cyano, (C3-C8)cycloalkyloxy, halogen, halo(Ci-C6)alkoxy, halo(Ci-C6)alkyl, (4-7 membered)heterocycleoxy, or hydroxy(Ci-C6)alkoxy; Y is phenyl, pyridine, pyrimidine, pyrazine, pyridazine, thiazole, pyrazole, or thiadiazole, wherein each is optionally substituted with 1 substituent that is (Ci-Ce)alkoxy, (Ci-C6)alkoxy(Ci-C6)alkyl, (Ci-C6)alkoxycarbonyl(Ci-C6)alkyl, (Ci-Csjalkyl, (Ci-Cs)alkyl, carboxy(Ci-C6)alkyl, halogen, halo(Ci-C6)alkyl, hydroxy(Ci-C6)alkoxy, or hydroxy(Ci-C6)alkyl; Z is
wherein B is boron; Rw at each occurrence is H, methyl or hydroxymethyl; R12 is at each occurrence independently H, (Ci-C6)alkyl, or hydroxy(Ci-Ce)alkyl.
In another embodiment, the présent invention provides compounds of Formula (I), or a pharmaceutically acceptable sait thereof, wherein X is phenyl, pyridine, or pyrimidine, wherein each is optionally substituted with 1, 2, or 3 substituents that are independently (Ci-Ce)alkoxy, (Ci-Ce)alkyl, (Ci-Cejalkylthio, cyano, (Ca-Csjcycloalkyloxy, halogen, halo(Ci-C6)alkoxy, halo(Ci-C6)alkyl, (4-7 membered)heterocycleoxy, or hydroxy(Ci-C6)alkoxy; Y is phenyl, pyridine, 20 pyrimidine, pyrazine, pyridazine, thiazole, pyrazole, or thiadiazole, wherein each is optionally substituted with 1 substituent that is (Ci-C6)alkoxy, (Ci-C6)alkoxy(Ci-C6)alkyl, (Ci-Cs)alkoxycarbonyl(Ci-C6)alkyl, (Ci-C3)alkyl, (Ci-C6)alkyl, carboxy(Ci-Cs)alkyl, halogen, halo(Ci-C6)alkyl, hydroxy(Ci-Ce)alkoxy, or hydroxy(Ci-C6)alkyl; Z is
ORi2 wherein B is boron; Ri2 is at each occurrence independently H, (Ci-C6)alkyl, or hydroxy(Ci-C6)alkyl.
In another embodiment, the présent invention provides compounds of Formula (I), or a pharmaceutically acceptable sait thereof, wherein X is phenyl, pyridine, or pyrimidine, wherein each is optionally substituted with 1, 2, or 3 substituents that are independently (Ci-C6)alkoxy, (Ci-Cejalkyl, (Ci-C8)alkylthio, cyano, (C3-C8)cycloalkyloxy, halogen, halo(Ci-C6)alkoxy, halo(Ci-C6)alkyl, (4-7 membered)heterocycleoxy, or hydroxy(Ci-C6)alkoxy; Y is phenyl, pyridine, pyrimidine, pyrazine, pyridazine, thiazole, pyrazole, or thiadiazole, wherein each is optionally substituted with 1 substituent that is (Ci-Cs)alkoxy, (Ci-C6)alkoxy(Ci-Cs)alkyl, (Ci-CejalkoxycarbonyKCi-Cejalkyl, (Ci-Cs)alkyl, (Ci-Ce)alkyl, carboxy(Ci-C6)alkyl, halogen, halo(Ci-C6)alkyl, hydroxy(Ci-Cs)alkoxy, or hydroxy(Ci-C6)alkyl; Z is
OR12 ' B-OR12 vL/OH wherein B is boron; Ri2 is at each occurance independently H, (Ci-C6)alkyl, or hydroxy(Ci-C6)alkyl.
In another embodiment, the présent invention provides compounds of Formula (I), or a pharmaceutically acceptable sait thereof, wherein X is phenyl, pyridine, or pyrimidine, wherein each is optionally substituted with 1,2, or 3 substituents that are independently (Ci-C6)alkoxy, (Ci-Cejalkyl, (Ci-C6)alkylthio, cyano, (C3-C8)cycloalkyloxy, halogen, halo(Ci-Cs)alkoxy, halo(Ci-C6)alkyl, (4-7 membered)heterocycleoxy, or hydroxy(Ci-C6)alkoxy; Y is phenyl, pyridine, pyrimidine, pyrazine, pyridazine, thiazole, pyrazole, or thiadiazole, wherein each is optionally substituted with 1 substituent that is (Ci-Ce)alkoxy, (Ci-C6)alkoxy(Ci-C6)alkyl, (Ci-C6)alkoxycarbonyl(Ci-C6)alkyl, (Ci-C3)alkyl, (Ci-C6)alkyl, carboxy(Ci-C6)alkyl, halogen, halo(Ci-C6)alkyl, hydroxy(Ci-C6)alkoxy, or hydroxy(Ci-C6)alkyl; Z is θ^12 wherein B is boron; and R12 is at each occurrence independently H, (Ci-Ce)alkyl, or hydroxy(Ci-C6)alkyl.
In another embodiment, the présent invention provides compounds of Formula (I), or a pharmaceutically acceptable sait thereof, wherein X is phenyl, pyridine, or pyrimidine, wherein each is optionally substituted with 1, 2, or 3 substituents that are independently (Ci-C6)alkoxy, (Ci-C6)alkyl, (Ci-C6)alkylthio, cyano, (C3-C8)cycloalkyloxy, halogen, halo(Ci-C6)alkoxy, halo(Ci-C6)alkyl, (4-7 membered)heterocycleoxy, or hydroxy(Ci-C6)alkoxy; Y is phenyl, pyridine, pyrimidine, pyrazine, pyridazine, thiazole, pyrazole, or thiadiazole, wherein each is optionally substituted with 1 substituent that is (Ci-C6)alkoxy, (Ci-C6)alkoxy(Ci-C6)alkyl, (Ci-C6)alkoxycarbonyl(Ci-C6)alkyl, (Ci-C3)alkyl, (Ci-C6)alkyl, carboxy(Ci-C6)alkyl, halogen, halo(Ci-C6)alkyl, hydroxy(Ci-C8)alkoxy, or hydroxy(Ci-C6)alkyl; Z is
boron; Rw at each occurrence is H, methyl or hydroxy methyl; Rn at each occurrence is independently (Ci-Csjalkyl; and n is 0, 1,2, 3, or 4.
In another embodiment, the présent invention provides compounds of Formula (I), or a pharmaceutically acceptable sait thereof, wherein X is phenyl, pyridine, or pyrimidine, wherein each is optionally substituted with 1, 2, or 3 substituents that are independently (Ci-C6)alkoxy, (Ci-C6)alkyl, (Ci-C6)alkylthio, cyano, (C3-Cs)cycloalkyloxy, halogen, halo(Ci-C8)alkoxy, halo(Ci-C6)alkyl, (4-7 membered)heterocycleoxy, or hydroxy(Ci-C6)alkoxy; Y is phenyl, pyridine, pyrimidine, pyrazine, pyridazine, thiazole, pyrazole, or thiadiazole, wherein each is optionally substituted with 1 substituent that is (Ci-Cejalkoxy, (Ci-C6)alkoxy(Ci-C6)alkyl, (Ci-C6)alkoxycarbonyl(Ci-C6)alkyl, (Ci-C3)alkyl, (Ci-C6)alkyl, carboxy(Ci-C6)alkyl, halogen, halo(Ci-C6)alkyl, hydroxy(Ci-C6)alkoxy, or hydroxy(Ci-C6)alkyl; Z is oO<
, wherein B is boron; Rn is methyl; and n is 0 or 1.
In another embodiment, the présent invention provides compounds of Formula (I), or a 15 pharmaceutically acceptable sait thereof, wherein X is phenyl, pyridine, or pyrimidine, wherein each is optionally substituted with 1, 2, or 3 substituents that are independently (Ci-Ce)alkoxy, (Ci-Cs)alkyl, (Ci-C6)alkylthio, cyano, (C3-C8)cycloalkyloxy, halogen, halo(Ci-C6)alkoxy, halo(Ci-Cs)alkyl, (4-7 membered)heterocycleoxy, or hydroxy(Ci-C8)alkoxy; Y is phenyl, pyridine, pyrimidine, pyrazine, pyridazine, thiazole, pyrazole, or thiadiazole, wherein each is optionally substituted with 1 substituent that is (Ci-C6)alkoxy, (Ci-C6)alkoxy(Ci-Cs)alkyl, (Ci-C6)alkoxycarbonyl(Ci-C6)alkyl, (Ci-C3)alkyl, (Ci-Ce)alkyl, carboxy(Ci-C6)alkyl, halogen, halo(Ci-C6)alkyl, hydroxy(Ci-C6)alkoxy, or hydroxy(C-i-Ce)alkyl; Z is /(R1l)n οχ I >
'' , wherein Β is boron; Rn is methyl; and n is 0 or 1.
In another embodiment, the présent invention provides compounds of Formula (I), or a 25 pharmaceutically acceptable sait thereof, wherein X is phenyl, pyridine, or pyrimidine, wherein each is optionally substituted with 1,2, or 3 substituents that are independently (Ci-C6)alkoxy, (Ci-Cs)alkyl, (Ci-C6)alkylthio, cyano, (C3-C8)cycloalkyloxy, halogen, halo(Ci-C6)alkoxy, halo(Ci-C6)alkyl, (4-7 membered)heterocycleoxy, or hydroxy(Ci-C6)alkoxy; Y is phenyl, pyridine, pyrimidine, pyrazine, pyridazine, thiazole, pyrazole, or thiadiazole, wherein each is optionally substituted with 1 substituent that is (Ci-C6)alkoxy, (Ci-C6)alkoxy(Ci-Cs)alkyl, (Ci-C6)alkoxycarbonyl(Ci-C6)alkyl, (Ci-Csjalkyl, (Ci-Ce)alkyl, carboxy(Ci-Ce)alkyl, halogen, halo(Ci-C6)alkyl, hydroxy(Ci-Ce)alkoxy, or hydroxy(Ci-C6)alkyl; Z is
, wherein B is boron; Rn is methyl; and n is 0 or 1.
In another embodiment, the présent invention provides compounds of Formula (I), or a pharmaceutically acceptable sait thereof, wherein X is phenyl, pyridine, or pyrimidine, wherein each is optionally substituted with 1, 2, or 3 substituents that are independently (Ci-Ce)alkoxy, (Ci-C6)alkyl, (Ci-C6)alkylthio, cyano, (C3-Cs)cycloalkyloxy, halogen, halo(Ci-C6)alkoxy, halo(Ci-Ce)alkyl, (4-7 membered)heterocycleoxy, or hydroxy(Ci-C6)alkoxy; Y is phenyl, pyridine, pyrimidine, pyrazine, pyridazine, thiazole, pyrazole, or thiadiazole, wherein each is optionally substituted with 1 substituent that is (Ci-C6)alkoxy, (Ci-C6)alkoxy(Ci-C6)alkyl, (Ci-C6)alkoxycarbonyl(Ci-C6)alkyl, (Ci-C3)alkyl, (Ci-C6)alkyl, carboxy(Ci-Ce)alkyl, halogen, halo(Ci-C6)alkyl, hydroxy(Ci-C6)alkoxy, or hydroxy(Ci-C6)alkyl; Z is
wherein B is boron; Rio at each occurrence is H, methyl or hydroxymethyl;
Rn at each occurrence is independently (Ci-C3)alkyl; and q is 0, 1, 2, 3, 4, 5, or 6.
In another embodiment, the présent invention provides compounds of Formula (I), or a pharmaceutically acceptable sait thereof, wherein X is phenyl, pyridine, or pyrimidine, wherein each is optionally substituted with 1, 2, or 3 substituents that are independently (Ci-C6)alkoxy, (Ci-C6)alkyl, (Ci-Cejalkylthio, cyano, (C3-C8)cycloalkyloxy, halogen, halo(Ci-C6)alkoxy, halo(Ci-C6)alkyl, (4-7 membered)heterocycleoxy, or hydroxy(Ci-C6)alkoxy; Y is phenyl, pyridine, 25 pyrimidine, pyrazine, pyridazine, thiazole, pyrazole, or thiadiazole, wherein each is optionally substituted with 1 substituent that is (Ci-C6)alkoxy, (Ci-C6)alkoxy(Ci-C6)alkyl, (Ci-C6)alkoxycarbonyl(Ci-C6)alkyl, (Ci-C3)alkyl, (Ci-C6)alkyl, carboxy(Ci-C6)alkyl, halogen, halo(Ci-Ce)alkyl, hydroxy(Ci-C6)alkoxy, or hydroxy(Ci-C6)alkyl; Z is
(Rn)q
Ο
OH wherein B is boron; Ru at each occurrence is methyl; and q is 0, 1,2, or 3.
In another embodiment, the présent invention provides compounds of Formula (I), or a pharmaceutically acceptable sait thereof, wherein X is phenyl, pyridine, or pyrimidine, wherein each is optionally substituted with 1,2, or 3 substituents that are independently (Ci-C6)alkoxy, (Ci-C6)alkyl, (Ci-C6)alkylthio, cyano, (C3-C8)cycloalkyloxy, halogen, halo(Ci-C6)alkoxy, halo(Ci-C6)alkyl, (4-7 membered)heterocycleoxy, or hydroxy(Ci-C6)alkoxy; Y is phenyl, pyridine, pyrimidine, pyrazine, pyridazine, thiazoie, pyrazole, or thiadiazole, wherein each is optionally substituted with 1 substituent that is (Ci-C6)alkoxy, (Ci-C6)alkoxy(Ci-C6)alkyl, (Ci-C6)alkoxycarbonyl(Ci-C6)alkyl, (Ci-C3)alkyl, (Ci-C6)alkyl, carboxy(Ci-C6)alkyl, halogen, halo(Ci-C8)alkyl, hydroxy(Ci-C6)alkoxy, or hydroxy(Ci-C6)alkyl; Z is (Rll)q
J r ''v wherein B is boron; Rn at each occurrence is methyl; and q is 0, 1,2, or 3.
In another embodiment, the présent invention provides compounds of Formula (I), or a pharmaceutically acceptable sait thereof, wherein X is phenyl, pyridine, or pyrimidine, wherein each is optionally substituted with 1,2, or 3 substituents that are independently (Ci-Cs)alkoxy, (Ci-C6)alkyl, (Ci-C6)alkylthio, cyano, (C3-C8)cycloalkyloxy, halogen, halo(Ci-C6)alkoxy, halo(Ci-C6)alkyl, (4-7 membered)heterocycleoxy, or hydroxy(Ci-C6)alkoxy; Y is phenyl, pyridine, pyrimidine, pyrazine, pyridazine, thiazoie, pyrazole, or thiadiazole, wherein each is optionally substituted with 1 substituent that is (Ci-Ce)alkoxy, (Ci-C6)alkoxy(Ci-C6)alkyl, (Ci-C6)alkoxycarbonyl(Ci-Cs)alkyl, (Ci-C3)alkyl, (Ci-C6)alkyl, carboxy(Ci-C6)alkyl, halogen, halo(Ci-C8)alkyl, hydroxy(Ci-Ce)alkoxy, or hydroxy(Ci-Cs)alkyl; Z is (Rn )q 0^1
O
OH wherein B is boron; Ru at each occurrence is methyl; and q is 0, 1,2, or 3.
In another embodiment, the présent invention provides compounds of Formula (I), or a pharmaceutically acceptable sait thereof, wherein X is
Ai and A2 are independently O or S; R^ R2, and R5 are independently H, deuterium, cyano, halogen, or halo(Ci-C6)alkyl; R3 and R4 are independently H, (Ci-Ce)alkyl, (Ci-C6)alkyl-di-i3, (C3-C8)cycloalkyl, halo(Ci-C6)alkyl, or hydroxy(Ci-C6)alkyl; Y is
0-N , N-0
S-N . N-S > N-N >
Re, R7, Rs, and R9 are independently H, deuterium, (Ci-C6)alkoxy, (Ci-C6)alkoxy-di-i3, (Ci-C6)alkoxy(Ci-C6)alkoxy, (Ci-C6)alkoxy(Ci-Ce)alkyl, (Ci-Ce)alkoxycarbonyl, (Ci-C6)alkoxycarbonyl(Ci-C6)alkyl, (Ci-C3)alkyl, (Ci-C3)alkyl-c/i.7, (Ci-Ce)alkyl, (Ci-C6)alkyl-c/i-i3, (Ci-C6)alkylcarbonyl, (Ci-C6)alkylthio, carboxy, carboxy(Ci-C6)alkoxy, carboxy(Ci-C6)alkyl, cyano, halogen, halo(Ci-C6)alkoxy, halo(Ci-C6)alkyl, hydroxy, hydroxy(Ci-C6)alkoxy, hydroxy(Ci-C6)alkyl, mercapto, nitro, -NRcRd, NRcRD(Ci-Cs)alkoxy, NRcRo(Ci-C6)alkyl, or (NRcRo)carbonyl; Rc and Rd are independently hydrogen, (Ci-Ce)alkyl, or (Ci-Cejalkylcarbonyl; Z is as defined in the Summary section herein; Rw at each occurrence is independently H, deuterium, (Ci-Cs)alkoxy(Ci-C6)alkyl, (Ci-C6)alkyl, (Ci-C6)alkyl-di-i3, (Ci-C6)alkylthio(Ci-C6)alkyl, hydroxy(Ci-C6)alkyl, or thio(Ci-C6)alkyl; Rn at each occurrence is independently (Ci-C3)alkyl or (C^Csjalkyl-di-y; R12 is independently H, (Ci-C6)alkyl, or hydroxy(Ci-C6)alkyl; m is 0, 1,2, or 3; n is 0, 1, 2, 3, or 4; p is 0, 1, 2, 3, 4, or 5; q is 0, 1, 2, 3, 4, 5, or 6; and r is 0, 1,2, 3, 4, 5, 6 or 7.
In another embodiment, the présent invention provides compounds of Formula (I), or a pharmaceutically acceptable sait thereof, wherein X is
Ri, R2, and R5 are independently H, cyano, halogen, or halo(Ci-Ce)alkyl; R3 and R4 are independently (Ci-Ce)alkyl, (Cs-Csjcycloalkyl, halo(Ci-C6)alkyl, or hydroxy(Ci-C6)alkyl; Y is R6 R6
Re, R7, Rs, and Rg are independently H, (Ci-C6)alkoxy, (Ci-C6)alkoxy(Ci-C6)alkyl, (Ci-Cs)alkoxycarbonyl(Ci-C6)alkyl, (Ci-C3)alkyl, (Ci-C6)alkyl, carboxy^-Ce^lkyl, halogen, halo(Ci-C6)alkyl, hydroxy(Ci-C6)alkoxy, or hydroxy(Ci-Ce)alkyl; Z is as defined in the Summary section herein; R10 at each occurrence is independently H, (Ci-C6)alkoxy(Ci-C6)alkyl, (Ci-C6)alkyl, (Ci-C6)alkylthio(Ci-C6)alkyl, hydroxy(Ci-C6)alkyl, or thio(Ci-C6)alkyl; Rn at each occurrence is independently (Ci-C3)alkyl; R12 is independently H, (Ci-C6)alkyl, or hydroxy(Ci-C6)alkyl; m is 0, 1,2, or 3; n is 0, 1, 2, 3, or 4; p is 0, 1, 2, 3, 4, or 5; q is 0, 1, 2, 3, 4, 5, or 6; and r is 0, 1,2, 3, 4, 5, 6 or 7.
In another embodiment, the présent invention provides compounds of Formula (I), or a pharmaceutically acceptable sait thereof, wherein X is
Ri, R2, and Rs are independently H, cyano, halogen, or halo(Ci-C6)alkyl; R3 and R4 are independently (Ci-C6)alkyl, (C3-C8)cycloalkyl, halo(Ci-C6)alkyl, or hydroxy(Ci-C6)alkyl; Y is
Re, R7, Rs, and R9 are independently H, (Ci-C6)alkoxy, (Ci-C6)alkoxy(Ci-C6)alkyl, (Ci-C6)alkoxycarbonyl(Ci-C6)alkyl, (Ci-C3)alkyl, (Ci-Ce)alkyl, carboxy(Ci-C6)alkyl, halogen, halofCi-CeJalkyl, hydroxy(Ci-C6)alkoxy, or hydroxy(Ci-C6)alkyl; Z is
OH
OH
OH
, wherein B is boron;
R10 at each occurrence is independently H, (Ci-C6)alkyl, or hydroxy(Ci-C6)alkyl; m is 0, 1,2, or 3; and p is 0, 1,2, 3, 4, or 5.
In another embodiment, the présent invention provides compounds of Formula (I), or a pharmaceutically acceptable sait thereof, wherein X is
Ri, R2, and R5 are independently H, cyano, halogen, or halo(Ci-C6)alkyl; R3 and R4 are independently (Ci-Ce)alkyl, (C3-C8)cycloalkyl, halo(Ci-C6)alkyl, or hydroxy(Ci-C8)alkyl; Y is
Re, Rz, Rs, and R9 are independently H, (Ci-C6)alkoxy, (Ci-C6)alkoxy(Ci-C6)alkyl, (Ci-C6)alkoxycarbonyl(Ci-C6)alkyl, (Ci-C3)alkyl, (Ci-Ce)alkyl, carboxy(Ci-C6)alkyl, halogen, halo(Ci-C6)alkyl, hydroxy(Ci-C8)alkoxy, or hydroxy(Ci-C8)alkyl; and Z is
OH /
wherein B is boron.
In another embodiment, the présent invention provides compounds of Formula (I), or a pharmaceutically acceptable sait thereof, wherein X is
Ri, R2, and R5 are independently H, cyano, halogen, or halo(Ci-C6)alkyl; R3 and R4 are independently (Ci-C6)alkyl, (C3-C8)cycloalkyl, halo(Ci-C6)alkyl, or hydroxy(Ci-C6)alkyl; Y is
Re, R?, Ra, and R9 are independently H, (Ci-C6)alkoxy, (Ci-C6)alkoxy(Ci-C6)alkyl, (Ci-C6)alkoxycarbonyl(Ci-C6)alkyl, (Ci-C3)alkyl, (Ci-C6)alkyl, carboxy(Ci-C6)alkyl, halogen, halo(Ci-C6)alkyl, hydroxy(C-i-C6)alkoxy, or hydroxy(Ci-C6)alkyl; and Z is
OH /
wherein B is boron.
In another embodiment, the présent invention provides compounds of Formula (I), or a pharmaceutically acceptable sait thereof, wherein X is
Ri, R2, and R5 are independently H, cyano, halogen, or halo(Ci-C6)alkyl; R3 and R4 are independently (Ci-C6)alkyl, (C3-C8)cycloalkyl, halo(Ci-C6)alkyl, or hydroxy(Ci-C6)alkyl; Y is
Re, R7, Ra, and R9 are independently H, (Ci-C6)alkoxy, (Ci-C6)alkoxy(Ci-C6)alkyl, (Ci-C6)alkoxycarbonyl(Ci-C6)alkyl, (Ci-C3)alkyl, (Ci-Ce)alkyl, carboxy(Ci-C6)alkyl, halogen, halo(Ci-C6)alkyl, hydroxy(Ci-C6)alkoxy, or hydroxyCCrCsjalkyl; and Z is
OH
wherein B is boron.
In another embodiment, the présent invention provides compounds of Formula (IA)
Formula (IA) or a pharmaceutically acceptable sait thereof, wherein B is boron; Ai and A2 are independently
O or S; Ri, R2, and R5 are independently H, deuterium, (C2-C6)alkenyl, (C2-C6)alkenyloxy, (C2-C6)alkenylthio, (Ci-Cs)alkoxy, (Ci-C6)alkoxy-di-i3, (Ci-C6)alkoxy(Ci-C6)alkoxy, (Ci-Cs)alkoxy(Ci-C6)alkyl, (Ci-C6)alkoxycarbonyl, (Ch-Cejalkyl, (Ci-C6)alkyl-di-i3, (Ci-Cejalkylcarbonyl, (Ci-Cejalkylthio, (C2-C6)alkynyl, (C2-C6)alkynyloxy, (C2-C6)alkynylthio, aryl, aryl(Ci-C6)alkoxy, aryl(Ci-C6)alkyl, aryl(Ci-C6)alkylthio, aryloxy, arylthio, carboxy, carboxy(Ci-Cs)alkoxy, carboxy(Ci-C6)alkyl, cyano, (C3-C8)cycloalkyl, (C3-C8)cycloalkyl(CiC6)alkoxy, (C3-C8)cycloalkyl(Ci-C6)alkyl, C3-C8)cycloalkyl(Ci-C6)alkylthio, (C3-C8)cycloalkyloxy, (C3-C8)cycloalkylthio, halogen, halo(Ci-Ce)alkoxy, halo(Ci-C6)alkyl, halo(Ci-C8)alkylthio, (5-6 membered)heteroaryl, (5-6 membered)heteroaryl(Ci-C6)alkoxy, (5-6 membered)heteroaryl(Ci-C6)alkyl, (5-6 membered)heteroaryl(Ci-C6)alkylthio, (5-6 membered)heteroaryloxy, (5-6 membered)heteroarylthio, (4-7 membered)heterocycle containing at least one heteroatom independently selected from the group consisting of O, N, and S, (4-7 membered)heterocycle(Ci-C6)alkoxy, (4-7 membered)heterocycle(Ci-C6)alkyl, (4-7 membered)heterocycle(Ci-C6)alkylthio, (4-7 membered)heterocycleoxy, (4-7 membered)heterocyclethio, hydroxy, hydroxy(Ci-C6)alkoxy, hydroxy(Ci-Ce)alkyl, mercapto, nitro, thio(Ci-C6)alkyl, -NRaRb, NRARB(Ci-C6)alkoxy, NRARB(Ci-C6)alkyl, or (NRARB)carbonyl; RA and Rb are independently hydrogen, (Ci-C6)alkyl, or (Ci-C6)alkylcarbonyl; R3 and R4 are independently H, deuterium, (Ci-C3)alkyl, (Ci-C3)alkyl-di-7, (Ci-C6)alkyl, (Ci-C6)alkyl-di-i3, (C3-C8)cycloalkyl, halo(Ci-C6)alkyl, or hydroxy(Ci-C6)alkyl; R6, R7, and R9 are independently, H, deuterium, (Ci-Cs)alkoxy, (Ci-C6)alkoxy-c/i-i3, (Ci-Ce)alkoxy(Ci-C6)alkoxy, (Ci-C6)alkoxy(Ci-C6)alkyl, (Ci-C6)alkoxycarbonyl, (Ci-C6)alkoxycarbonyl(Ci-C6)alkyl, (Ci-C3)alkyl, (Ci-C3)alkyl-di-7, (Ci-C6)alkyl, (Ci-C6)alkyl-di-i3, (Ci-Ce)alkylcarbonyl, (Ci-C6)alkylthio, carboxy, carboxy(Ci-C6)alkoxy, carboxy(Ci-C6)alkyl, cyano, halogen, halo(Ci-C6)alkoxy, halo(Ci-C6)alkyl, hydroxy, hydroxy(Ci-C6)alkoxy, hydroxy(Ci-C6)alkyl, mercapto, nitro, -NRcRd, NRcRD(Ci-C6)alkoxy, NRcRD(Ci-C6)alkyl, or (NRcRo)carbonyl; Rc and Rd are independently hydrogen, (Ci-Cs)alkyl, or (Ci-C6)alkylcarbonyl; Rw at each occurrence is independently deuterium, (Ci-C6)alkoxy(Ci-C6)alkyl, (Ci-C3)alkyl, (Ci-C3)alkyl-di-7, (Ci-Ce)alkyl, (Ci-C6)alkyl-di-i3, (Ci-C6)alkylthio(Ci-C6)alkyl, hydroxy(Ci-C6)alkyl, or thio(Ci-C6)alkyl; and p is 0, 1, 2, 3, 4, or 5.
In another embodiment, the présent invention provides compounds of Formula (IA), or a pharmaceutically acceptable sait thereof, wherein B is boron; Ai and A2 are O; Ri, R2, and R5 are independently H, cyano, halogen, or halo(Ci-C6)alkyl; R3 and R4 are independently (Ci-C6)alkyl, (C3-C8)cycloalkyl, halo(Ci-C6)alkyl, or hydroxy(Ci-C6)alkyl; R6, R7, and R9 are independently, H, (Ci-Ce)alkoxy, (Ci-C6)alkoxy(Ci-C6)alkyl, (Ci-C6)alkoxycarbonyl(Ci-C6)alkyl, (Ci-Ce)alkyl, carboxy(Ci-C6)alkyl, halogen, halo(Ci-C8)alkyl, hydroxy(Ci-C8)alkoxy, or hydroxy(Ci-C6)alkyl; R10 is (Ci-C3)alkyl, (Ci-Cs)alkyl or hydroxy(Ci-C6)alkyl; and p is 0 or 1.
In another embodiment, the présent invention provides compounds of Formula (IA), or a pharmaceutically acceptable sait thereof, wherein B is boron; Ai and A2 are O; Ri, R2, and R5 are H; R3 and R4 are independently (Ci-C6)alkyl, (C3-C8)cycloalkyl, halo(Ci-C6)alkyl, or hydroxy(Ci-C6)alkyl; R6, R?, and R9 are independently H or (C-i-C3)alkyl; Rio is methyl; and p is 0, 1, or 2.
In another embodiment, the présent invention provides compounds of Formula (IA), or a pharmaceutically acceptable sait thereof, wherein B is boron; Ai and A2 are O; Ri, R2, and R5 are H; R3 and R4 are independently (Ci-C6)alkyl, (C3-C8)cycloalkyl, halo(Ci-Cs)alkyl, or hydroxy(Ci-C8)alkyl; R6, R?, and Rg are independently H or (Ci-C3)alkyl; and p is 0.
In another embodiment, the présent invention provides compounds of Formula (IA), or a pharmaceutically acceptable sait thereof, wherein B is boron; Ai and A2 are O; Ri, R2, and R5 are H; R3 and R4 are independently (Ci-C3)alkyl; R8, R7, and R9 are independently H or (Ci-C3)alkyl; and p is 0.
In another embodiment, the présent invention provides compounds of Formula (IA), or a pharmaceutically acceptable sait thereof, wherein B is boron; Ai and A2 are O; Ri, R2, and R5 are H; R3 and R4 are independently (Ci-C3)alkyl; R6, R7, and R9 are H; and p is 0.
In another embodiment, the présent invention provides compounds of Formula (IB)
Formula (IB) or a pharmaceutically acceptable sait thereof, wherein B is boron; Ai and A2 are independently O or S; Ri, R2, and R5 are independently H, deuterium, (C2-C6)alkenyl, (C2-C6)alkenyloxy, (C2-C6)alkenylthio, (Ci-C6)alkoxy, (Ci-C6)alkoxy-di-i3, (Ci-C6)alkoxy(Ci-C6)alkoxy, (Ci-C6)alkoxy(Ci-C6)alkyl, (Ci-C6)alkoxycarbonyl, (Ci-C6)alkyl, (Ci-C6)alkyl-di.13, (Ci-Cs)alkylcarbonyl, (Ci-C8)alkylthio, (C2-C8)alkynyl, (C2-C8)alkynyloxy, (C2-C8)alkynylthio, aryl, aryl(Ci-C6)alkoxy, aryl(Ci-C6)alkyl, aryl(Ci-C6)alkylthio, aryloxy, arylthio, carboxy, carboxy(Ci-C6)alkoxy, carboxy(Ci-C6)alkyl, cyano, (C3-C8)cycloalkyl, (C3-C8)cycloalkyl(CiC8)alkoxy, (C3-C8)cycloalkyl(Ci-C8)alkyl, C3-C8)cycloalkyl(Ci-C6)alkylthio, (C3-C8)cycloalkyloxy, (C3-C8)cycloalkylthio, halogen, halo(Ci-C6)alkoxy, halo(Ci-C6)alkyl, halo(Ci-C6)alkylthio, (5-6 membered)heteroaryl, (5-6 membered)heteroaryl(Ci-C6)alkoxy, (5-6 membered)heteroaryl(Ci-C6)alkyl, (5-6 membered)heteroaryl(Ci-C6)alkylthio, (5-6 membered)heteroaryloxy, (5-6 membered)heteroarylthio, (4-7 membered)heterocycle containing at least one heteroatom independently selected from the group consisting of O, N, and S, (4-7 membered)heterocycle(Ci-C6)alkoxy, (4-7 membered)heterocycle(Ci-C6)alkyl, (4-7 membered)heterocycle(Ci-Cs)alkylthio, (4-7 membered)heterocycleoxy, (4-7 membered)heterocyclethio, hydroxy, hydroxy(Ci-C6)alkoxy, hydroxy(Ci-C6)alkyl, mercapto, nitro, thio(Ci-C6)alkyl, -NRaRb, NRARB(Ci-C6)alkoxy, NRARB(Ci-C6)alkyl, or (NRARB)carbonyl; RA and Rb are independently hydrogen, (Ci-C6)alkyl, or (Ci-C6)alkylcarbonyl; R3 and R4 are independently H, deuterium, (Ci-C3)alkyl, (Ci-C3)alkyl-di.7, (Ci-C6)alkyl, (Ci-Cs)alkyl-di-i3, (C3-C8)cycloalkyl, halo(Ci-C6)alkyl, or hydroxy(Ci-C6)alkyl; R6, R7, and R9 are independently, H, deuterium, (Ci-C6)alkoxy, (Ci-C6)alkoxy-di-i3, (Ci-C6)alkoxy(Ci-C6)alkoxy, (Ci-C6)alkoxy(Ci-C6)alkyl, (Ci-C6)alkoxycarbonyl, (Ci-C6)alkoxycarbonyl(Ci-Cs)alkyl, (Ci-C3)alkyl, (Ci-Ce)alkyl, (Ci-C6)alkylcarbonyl, (Ci-C8)alkylthio, carboxy, carboxy(Ci-C6)alkoxy, carboxy(Ci-Ce)alkyl, cyano, halogen, halo(Ci-C6)alkoxy, halo(Ci-C8)alkyl, hydroxy, hydroxy(Ci-C6)alkoxy, hydroxy(Ci-C6)alkyl, mercapto, nitro, -NRcRd, NRcRo(Ci-C8)alkoxy, NRcRD(Ci-C8)alkyl, or (NRcRo)carbonyl; Rc and RD are independently hydrogen, (Ci-Cs)alkyl, or (Ci-C6)alkylcarbonyl; Rw at each occurrence is independently deuterium, (Ci-C8)alkoxy(Ci-C6)alkyl, (Ci-C3)alkyl, (Ci-C3)alkyl-c/-i-7, (Ci-Ce)alkyl, (Ci-C8)alkyl-di-i3, (Ci-Cs)alkylthio(Ci-C6)alkyl, hydroxy(Ci-C6)alkyl, or thio(Ci-C6)alkyl; and p is 0, 1,2, 3, 4, or 5.
In another embodiment, the présent invention provides compounds of Formula (IB), or a pharmaceutically acceptable sait thereof, wherein B is boron; Ai and A2 are O; Ri, R2, and R5 are independently H, cyano, halogen, or halo(Ci-C6)alkyl; R3 and R4 are independently (Ci-Ce)alkyl, (C3-C8)cycloalkyl, halo(Ci-C6)alkyl, or hydroxy(Ci-C6)alkyl; Rs, R7, and R9 are independently, H, (Ci-C6)alkoxy, (Ci-C6)alkoxy(Ci-C6)alkyl, (Ci-C6)alkoxycarbonyl(Ci-C6)alkyl, (Ci-Cs)alkyl, carboxy(Ci-C8)alkyl, halogen, halo(Ci-C6)alkyl, hydroxy(Ci-C6)alkoxy, or hydroxy(Ci-C6)alkyl; R™ is (Ci-C3)alkyl, (Ci-C6)alkyl or hydroxy(Ci-C6)alkyl; and p is 0 or 1.
In another embodiment, the présent invention provides compounds of Formula (IB), or a pharmaceutically acceptable sait thereof, wherein B is boron; Ai and A2 are O; Rb R2, and R5 are H; R3 and R4 are independently (Ci-Ce)alkyl, (C3-C8)cycloalkyl, halo(Ci-C6)alkyl, or hydroxy(Ci-C6)alkyl; R6, R7, and R9 are independently H or (Ci-C3)alkyl; Rio is methyl; and p is 0, 1, or 2.
In another embodiment, the présent invention provides compounds of Formula (IB), or a pharmaceutically acceptable sait thereof, wherein B is boron; Ai and A2 are O; Ri, R2, and R5 are H; R3 and R4 are independently (Ci-C6)alkyl, (C3-C8)cycloalkyl, halo(Ci-C6)alkyl, or hydroxy(Ci-C6)alkyl; R6, R7, and R9 are independently H or (Ci-C3)alkyl; and p is 0.
In another embodiment, the présent invention provides compounds of Formula (IB), or a pharmaceutically acceptable sait thereof, wherein B is boron; Ai and A2 are O; Rb R2, and R5 are H; R3 and R4 are independently (Ci-C3)alkyl; R6, R7, and R9 are independently H or (Ci-C3)alkyl; and p is 0.
In another embodiment, the présent invention provides compounds of Formula (IB), or a pharmaceutically acceptable sait thereof, wherein B is boron; Ai and A2 are O; R^ R2, and R5 are H; R3 and R4 are independently (Ci-C3)alkyl; Rs, R7, and R9 are H; and p is 0.
In another embodiment, the présent invention provides compounds of Formula (IC)
Formula (IC) or a pharmaceutically acceptable sait thereof, wherein B is boron; Ai and A2 are independently O or S; Ri, R2, and R5 are independently H, deuterium, (C2-Cs)alkenyl, (C2-C6)alkenyloxy, (C2-C6)alkenylthio, (Ci-Cs)alkoxy, (Ci-C6)alkoxy-c/i-13, (Ci-C6)alkoxy(Ci-C6)alkoxy, (Ci-C6)alkoxy(CrC6)alkyl, (Ci-C6)alkoxycarbonyl, (Ci-Cejalkyl, (Ci-C6)alkyl-di-i3, (Ci-Cejalkylcarbonyl, (Ci-C6)alkylthio, (C2-C6)alkynyl, (C2-C6)alkynyloxy, (C2-C6)alkynylthio, aryl, aryl(Ci-C6)alkoxy, aryl(Ci-C6)alkyl, aryl(C-i-C6)alkylthio, aryloxy, arylthio, carboxy, carboxy(Ci-C6)alkoxy, carboxy(C-i-C6)alkyl, cyano, (C3-C8)cycloalkyl, (C3-C8)cycloalkyl(Ci10 C6)alkoxy, (C3-C8)cycloalkyl(Ci-C6)alkyl, C3-C8)cycloalkyl(Ci-C6)alkylthio, (C3-C8)cycloalkyloxy, (C3-C8)cycloalkylthio, halogen, halo(Ci-C6)alkoxy, halo(Ci-C6)alkyl, halo(Ci-C6)alkylthio, (5-6 membered)heteroaryl, (5-6 membered)heteroaryl(Ci-C6)alkoxy, (5-6 membered)heteroaryl(Ci-C6)alkyl, (5-6 membered)heteroaryl(Ci-C6)alkylthio, (5-6 membered)heteroaryloxy, (5-6 membered)heteroarylthio, (4-7 membered)heterocycle containing at least one heteroatom independently selected from the group consisting of O, N, and S, (4-7 membered)heterocycle(Ci-C6)alkoxy, (4-7 membered)heterocycle(Ci-C6)alkyl, (4-7 membered)heterocycle(Ci-C6)alkylthio, (4-7 membered)heterocycleoxy, (4-7 membered)heterocyclethio, hydroxy, hydroxy(Ci-Cs)alkoxy, hydroxy(Ci-C6)alkyl, mercapto, nitro, thio(Ci-C6)alkyl, -NRaRb, NRARB(Ci-C8)alkoxy, NRARB(Ci-C8)alkyl, or (NRARB)carbonyi; Ra and RB are independently hydrogen, (Ci-C6)alkyl, or (Ci-C6)alkylcarbonyl; R3 and R4 are independently H, deuterium, (Ci-C3)alkyl, (Ci-C3)alkyl-di-7, (Ci-C6)alkyl, (Ci-C6)alkyl-c/i-i3, (C3-C8)cycloalkyl, halo(Ci-Ce)alkyl, or hydroxy(Ci-C8)alkyl; R6, R7, and Rg are independently, H, deuterium, (Ci-C6)alkoxy, (Ci-C6)alkoxy-d1-13, (Ci-C6)alkoxy(Ci-C6)alkoxy, (Ci-Cs)alkoxy(Ci-C6)alkyl, (Ci-C6)alkoxycarbonyl, (Ci-C6)alkoxycarbonyl(Ci-C6)alkyl, (Ci-C3)alkyl, (Ci-C3)alkyl-di-7, (Ci-Cs)alkyl, (Ci-Ce)alkyl-c/i.i3, (Ci-Cejalkylcarbonyl, (Ci-C6)alkylthio, carboxy, carboxy(Ci-C6)alkoxy, carboxy(Ci-C6)alkyl, cyano, halogen, haloiCrCejalkoxy, halo(Ci-C6)alkyl, hydroxy, hydroxy(Ci-C6)alkoxy, hydroxy(Ci-C6)alkyl, mercapto, nitro, -NRcRd, NRcRD(Ci-C6)alkoxy, NRcRD(Ci-C6)alkyl, or (NRcRD)carbonyl; Rc and Rd are independently hydrogen, (Ci-Ce)alkyl, or (Ci-C6)alkylcarbonyl; Rw at each occurrence is independently deuterium, (Ci-C6)alkoxy(Ci-Cs)alkyl, (Ci-C3)alkyl, (C1-C3)alkyl-c/1.7, (Ci-Ce)alkyl, (Ci-C6)alkyl-di-i3, (Ci-C6)alkylthio(Ci-C6)alkyl, hydroxy(Ci-C6)alkyl, or thio(Ci-C6)alkyl; and p is 0, 1, 2, 3, 4, or 5.
In another embodiment, the présent invention provides compounds of Formula (IC), or a pharmaceutically acceptable sait thereof, wherein B is boron; Ai and A2 are O; Ri, R2, and R5 are independently H, cyano, halogen, or halo(Ci-C6)alkyl; R3 and R4 are independently (Ci-C6)alkyl, (C3-C8)cycloalkyl, halo(Ci-C8)alkyl, or hydroxy(Ci-C8)alkyl; R6, R7, and R9 are independently, H, (Ci-Ce)alkoxy, (Ci-C6)aIkoxy(Ci-C6)alkyl, (Ci-C6)alkoxycarbonyl(Ci-C6)alkyl, (Ci-C6)alkyl, carboxy(Ci-C6)alkyl, halogen, halo(Ci-C8)alkyl, hydroxy(Ci-C6)alkoxy, or hydroxy(Ci-Ce)alkyl; Rw is (Ci-C3)alkyl, (Ci-Ce)alkyl or hydroxy(Ci-C8)alkyl; and p is 0 or 1.
In another embodiment, the présent invention provides compounds of Formula (IC), or a pharmaceutically acceptable sait thereof, wherein B is boron; Ai and A2 are O; Ri, R2, and R5 are H; R3 and R4 are independently (Ci-C8)alkyl, (C3-C8)cycloalkyl, halo(Ci-C8)alkyl, or hydroxy(Ci-Ce)alkyl; R8, R7, and Rg are independently H or (Ci-C3)alkyl; Rw is methyl; and p is 0, 1, or 2.
In another embodiment, the présent invention provides compounds of Formula (IC), or a pharmaceutically acceptable sait thereof, wherein B is boron; Ai and A2 are O; Ri, R2, and R5 are H; R3 and R4 are independently (Ci-C6)alkyl, (C3-C8)cycloalkyl, halo(Ci-C6)alkyl, or hydroxy(Ci-C6)alkyl; R6, R7, and Rg are independently H or (Ci-C3)alkyl; and p is 0.
In another embodiment, the présent invention provides compounds of Formula (IC), or a pharmaceutically acceptable sait thereof, wherein B is boron; Ai and A2 are O; Ri, R2, and R5 are H; R3 and R4 are independently (Ci-C3)alkyl; R6, R7, and Rg are independently H or (Ci-C3)alkyl; and p is 0.
In another embodiment, the présent invention provides compounds of Formula (IC), or a pharmaceutically acceptable sait thereof, wherein B is boron; Ai and A2 are O; Ri, R2, and R5 are H; R3 and R4 are independently (Ci-C3)alkyl; R8, R7, and R9 are H; and p is 0.
In another embodiment, the présent invention provides the following compounds:
(R) 4-(5-(3,4-dimethoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; (S) 4-(5-(3,4dimethoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; (R) 4-(5-(3-ethoxy-4-methoxyphenyl)pyridin3-yl)-1,2-oxaborolan-2-ol; (S) 4-(5-(3-ethoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; (R) 4-(5-(3-isopropoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; (S) 4-(5-(3isopropoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; (R) 4-(5-(3-cyclopropoxy-4methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; (S) 4-(5-(3-cyclopropoxy-4methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; (R) 4-(5-(3-(2-hydroxyethoxy)-4methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; (S) 4-(5-(3-(2-hydroxyethoxy)-4methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; (R) 4-(5-(3-(3-hydroxypropoxy)-4methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; (S) 4-(5-(3-(3-hydroxypropoxy)-4methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; (R) 4-(5-(2-(difluoromethyl)-3-ethoxy-4methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; (S) 4-(5-(2-(difluoromethyl)-3-ethoxy-4methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; (R) 4-(5-(3-ethoxy-5-fluoro-4methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; (S) 4-(5-(3-ethoxy-5-fluoro-4methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; (R) 4-(5-(3-chloro-5-ethoxy-4methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; (S) 4-(5-(3-chloro-5-ethoxy-420225 p methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; (R) 4-(5-(5-ethoxy-2-fluoro-4methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; (S) 4-(5-(5-ethoxy-2-fluoro-4methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; (R) 4-(5-(2-chloro-5-ethoxy-4methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; (S) 4-(5-(2-chloro-5-ethoxy-45 methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; (R) 4-(3-fluoro-5-methoxy-6-propoxy-[2,3'bipyridin]-5'-yl)-1,2-oxaborolan-2-ol; (S) 4-(3-fluoro-5-methoxy-6-propoxy-[2,3'-bipyridin]-5'-yl)1,2-oxaborolan-2-ol; (R) 4-(5-(4-(difluoromethoxy)-3-propoxyphenyl)pyridin-3-yl)-1,2oxaborolan-2-ol; (S) 4-(5-(4-(difluoromethoxy)-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2ol; (R) 4-(6'-methoxy-5'-propoxy-[3,3'-bipyridin]-5-yl)-1,2-oxaborolan-2-ol; (S) 4-(6'-methoxy-5'10 propoxy-[3,3'-bipyridin]-5-yl)-1,2-oxaborolan-2-ol; (R) 4-(5-(3-ethoxy-4-methoxyphenyl)-6methylpyridin-3-yI)-1,2-oxaborolan-2-ol; (S) 4-(5-(3-ethoxy-4-methoxyphenyl)-6-methylpyridin-3yI)-1,2-oxaborolan-2-ol; (R) 4-(5-(3-ethoxy-4-methoxyphenyl)-4-methylpyridin-3-yl)-1,2oxaborolan-2-ol; (S) 4-(5-(3-ethoxy-4-methoxyphenyl)-4-methylpyridin-3-yl)-1,2-oxaborolan-2-ol; (R) 4-(2-(4-methoxy-3-propoxyphenyl)-6-methylpyrimidin-4-yl)-1,2-oxaborolan-2-ol; (S) 4-(2-(415 methoxy-3-propoxyphenyl)-6-methylpyrimidin-4-yl)-1,2-oxaborolan-2-ol; (R) 4-(2-(4-methoxy-3propoxyphenyl)-6-(trifluoromethyl)pyrimidin-4-yl)-1,2-oxaborolan-2-ol; (S) 4-(2-(4-methoxy-3propoxyphenyl)-6-(trifluoromethyl)pyrimidin-4-yl)-1,2-oxaborolan-2-ol; (R) 4-(6-(3-ethoxy-4methoxyphenyl)pyrazin-2-yl)-1,2-oxaborolan-2-ol; (S) 4-(6-(3-ethoxy-4-methoxyphenyl)pyrazin2-yl)-1,2-oxaborolan-2-ol; 4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborol-2(5H)-ol;
(R) 4-(6-(4-methoxy-3-propoxyphenyl)pyridin-2-yl)-1,2-oxaborinan-2-ol; (S) 4-(6-(4-methoxy-3propoxyphenyl)pyridin-2-yl)-1,2-oxaborinan-2-ol; (R) 4-(6-(4-methoxy-3-propoxyphenyl)pyridin2-yl)-3-methyl-1,2-oxaborolan-2-ol; (S) 4-(6-(4-methoxy-3-propoxyphenyl)pyridin-2-yl)-3-methyl1,2-oxaborolan-2-ol; 4-(6-(4-methoxy-3-propoxyphenyl)pyridin-2-yl)-3-methyl-1,2-oxaborol2(5H)-ol; (R) 4-(6-(4-methoxy-3-propoxyphenyl)pyridin-2-yl)-4-methyl-1,2-oxaborolan-2-ol; (S) 425 (6-(4-methoxy-3-propoxyphenyl)pyridin-2-yl)-4-methyl-1,2-oxaborolan-2-ol; (R) 4-(6-(4-methoxy3-propoxyphenyl)pyridazin-4-yl)-5-methyl-1,2-oxaborolan-2-ol; (S) 4-(6-(4-methoxy-3propoxyphenyl)pyridazin-4-yl)-5-methyl-1,2-oxaborolan-2-ol; (R) 4-(hydroxymethyl)-4-(5-(4methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; (S) 4-(hydroxymethyl)-4-(5-(4methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; (R) 4-(5-(3-(2-fluoroethoxy)-430 methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; (S) 4-(5-(3-(2-fluoroethoxy)-4methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; (R) 4-(3'-(3-fluoropropoxy)-4'-methoxy-[1,1'biphenyl]-3-yl)-1,2-oxaborolan-2-ol; (S) 4-(3'-(3-fluoropropoxy)-4'-methoxy-[1,1'-biphenyl]-3-yl)1,2-oxaborolan-2-ol; (R) 3'-(2-hydroxy-1,2-oxaborolan-4-yl)-4-methoxy-3-propoxy-[1,1'biphenyl]-2-carbonitrile; (S) 3'-(2-hydroxy-1,2-oxaborolan-4-yl)-4-methoxy-3-propoxy-[1,1'35 biphenyl]-2-carbonitrile; (R) 3'-(2-hydroxy-2,5-dihydro-1,2-oxaborol-4-yl)-4-methoxy-3-propoxy[1,1'-biphenyl]-2-carbonitrile; (S) 3'-(2-hydroxy-2,5-dihydro-1,2-oxaborol-4-yl)-4-methoxy-3propoxy-[1,1 '-biphenyl]-2-carbonitrile; (R) 4-(5-(2-fluoro-4-methoxy-5-propoxyphenyl)pyridin-3yl)-1,2-oxaboroIan-2-ol; (S) 4-(5-(2-fluoro-4-methoxy-5-propoxyphenyl)pyridin-3-yl)-1,220225
B oxaborolan-2-ol; (R) 4-(6-(hydroxymethyl)-2-(4-methoxy-3-propoxyphenyl)pyrimidin-4-yl)-1,2oxaborolan-2-ol; (S) 4-(6-(hydroxymethyl)-2-(4-methoxy-3-propoxyphenyl)pyrimidin-4-yl)-1,2oxaborolan-2-ol; (R) 4-(2-(3-ethoxy-4-methoxyphenyl)thiazol-4-yl)-1,2-oxaborolan-2-ol; (S) 4-(2(3-ethoxy-4-methoxyphenyl)thiazol-4-yl)-1,2-oxaborolan-2-ol; (2R)-2-(5-(4-methoxy-35 propoxyphenyl)pyridin-3-yl)-3-(4,4,6-trimethyl-1,3,2-dioxaborinan-2-yl)propan-1-ol; (2S)-2-(5-(4methoxy-3-propoxyphenyl)pyridin-3-yl)-3-(4,4,6-trimethyl-1,3,2-dioxaborinan-2-yl)propan-1-ol; (R) 4-(5-methoxy-6-propoxy-[2,3'-bipyridin]-5'-yl)-1,2-oxaborolan-2-ol: (S) 4-(5-methoxy-6propoxy-^.S'-bipyridinl-S'-yO-l ,2-oxaborolan-2-ol; (R) 4-(3'-(2-fluoroethoxy)-4'-methoxy-[1,1'biphenyl]-3-yl)-1,2-oxaborolan-2-ol; (S) 4-(3'-(2-fluoroethoxy)-4'-methoxy-[1,1 '-biphenyl]-3-yl)10 1,2-oxaborolan-2-ol; (R) 4-(4-(hydroxymethyl)-6-(4-methoxy-3-propoxyphenyl)pyridin-2-yl)-1,2oxaborolan-2-ol; (S) 4-(4-(hydroxymethyl)-6-(4-methoxy-3-propoxyphenyl)pyridin-2-yl)-1,2oxaborolan-2-ol; (R) 4-(6-(3-(cyclopentyloxy)-4-methoxyphenyl)pyridin-2-yl)-1,2-oxaborolan-2-ol; (S) 4-(6-(3-(cyclopentyloxy)-4-methoxyphenyl)pyridin-2-yl)-1,2-oxaborolan-2-ol; (R) 4-(5-(4methoxy-3-(thietan-3-yloxy)phenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; (S) 4-(5-(4-methoxy-315 (thietan-3-yloxy)phenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; (R) 4-(5-(5-ethoxy-4-methoxy-2methylphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; (S) 4-(5-(5-ethoxy-4-methoxy-2methylphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; (R) 4-(5-(3-ethoxy-4-methoxyphenyl)-1,2,4thiadiazol-3-yl)-1,2-oxaborolan-2-ol; (S) 4-(5-(3-ethoxy-4-methoxyphenyl)-1,2,4-thiadiazol-3-yl)1,2-oxaborolan-2-ol; (R) 4-(5-(3-ethoxy-2-fluoro-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan20 2-ol; (S) 4-(5-(3-ethoxy-2-fluoro-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; (R) 4-(3'isopropoxy-4'-methoxy-[1,1 '-biphenyl]-3-yI)-1,2-oxaborolan-2-ol; (S) 4-(3'-isopropoxy-4'methoxy-[1,1 '-biphenyl]-3-yl)-1,2-oxaborolan-2-ol; (R) 4-(3'-ethoxy-4'-methoxy-[1,1 ’-biphenyl]-3yl)-1,2-oxaborolan-2-ol; (S) 4-(3'-ethoxy-4'-methoxy-[1,1 '-biphenyl]-3-yl)-1,2-oxaborolan-2-ol; (R) 4-(5-(4-methoxy-3-((tetrahydrothiophen-3-yl)oxy)phenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; (S) 425 (5-(4-methoxy-3-((tetrahydrothiophen-3-yl)oxy)phenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; (R) 4-(5(2-fluoro-4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; (S) 4-(5-(2-fluoro-4methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; (R)-4-(6-((S)-1-hydroxyethyl)-2-(4methoxy-3-propoxyphenyl)pyrimidin-4-yl)-1,2-oxaborolan-2-ol; (R)-4-(6-((R)-1-hydroxyethyl)-2(4-methoxy-3-propoxyphenyl)pyrimidin-4-yl)-1,2-oxaborolan-2-ol; (S)-4-(6-((S)-1-hydroxyethyl)30 2-(4-methoxy-3-propoxyphenyl)pyrimidin-4-yl)-1,2-oxaborolan-2-ol; (S)-4-(6-((R)-1hydroxyethyl)-2-(4-methoxy-3-propoxyphenyl)pyrimidin-4-yl)-1,2-oxaborolan-2-ol (R) 4-(5-(4methoxy-3-propoxyphenyl)-4-methylpyridin-3-yl)-1,2-oxaborolan-2-ol; (S) 4-(5-(4-methoxy-3propoxyphenyl)-4-methylpyridin-3-yl)-1,2-oxaborolan-2-ol; (R) 6-(6-(2-hydroxy-1,2-oxaborolan-4yl)pyridin-2-yl)-3-methoxy-2-propoxybenzonitrile; (S) 6-(6-(2-hydroxy-1,2-oxaborolan-435 yl)pyridin-2-yl)-3-methoxy-2-propoxybenzonitrile; (R) 4-(4'-methoxy-3’-propoxy-[1,1'-biphenyl]-3yI)-1,2-oxaborolan-2-ol; (S) 4-(4'-methoxy-3'-propoxy-[1,1 '-biphenyl]-3-yl)-1,2-oxaborolan-2-ol; (R) 4-(2-(5-ethoxy-2-fluoro-4-methoxyphenyl)thiazol-4-yl)-1,2-oxaborolan-2-ol; (S) 4-(2-(5ethoxy-2-fluoro-4-methoxyphenyl)thiazol-4-yl)-1,2-oxaborolan-2-ol; (R) 4-(3-(4-(cyclopentyloxy)20225
P 5-methoxypyrimidin-2-yl)phenyl)-1,2-oxaborolan-2-ol; (S) 4-(3-(4-(cyclopentyloxy)-5methoxypyrimidin-2-yl)phenyl)-1,2-oxaborolan-2-ol; (R) 4-(5-(3-ethoxy-4-methoxy-2(trifluoromethyl)phenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; (S) 4-(5-(3-ethoxy-4-methoxy-2(trifluoromethyl)phenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; (R) 4-(5-(3,4-diethoxyphenyl)pyridin-35 yl)-1,2-oxaborolan-2-ol; (S) 4-(5-(3,4-diethoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; (R) 4-(5(3-(cyclopentyloxy)-4-(methylthio)phenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; (S) 4-(5-(3(cyclopentyloxy)-4-(methylthio)phenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; (R) 4-(2-(4-methoxy-3propoxyphenyl)-6-(methoxymethyl)pyrimidin-4-yl)-1,2-oxaborolan-2-ol; (S) 4-(2-(4-methoxy-3propoxyphenyl)-6-(methoxymethyl)pyrimidin-4-yl)-1,2-oxaborolan-2-ol; (R) 4-(5-(4-ethoxy-310 propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; (S) 4-(5-(4-ethoxy-3-propoxyphenyl)pyridin-3yl)-1,2-oxaborolan-2-ol; (R) 4-(5-(2-fluoro-3,4-dimethoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; (S) 4-(5-(2-fluoro-3,4-dimethoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; (R) 4-(4'-methoxy-3'(pentyloxy)-[1,1'-biphenyl]-3-yl)-1,2-oxaborolan-2-ol; (S) 4-(4'-methoxy-3'-(pentyloxy)-[1,1'biphenyl]-3-yl)-1,2-oxaborolan-2-ol; (R) 4-(5-(4-(methylthio)-3-propoxyphenyl)pyridin-3-yl)-1,215 oxaborolan-2-ol; (S) 4-(5-(4-(methylthio)-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; (R) 4-(6-(4-methoxy-3-propoxyphenyl)pyrazin-2-yl)-1,2-oxaborolan-2-ol; (S) 4-(6-(4-methoxy-3propoxyphenyl)pyrazin-2-yl)-1,2-oxaborolan-2-ol; (R) 4-(2'-fluoro-4'-methoxy-3'-propoxy-[1,1'biphenyl]-3-yl)-1,2-oxaborolan-2-ol; (S) 4-(2'-fluoro-4'-methoxy-3'-propoxy-[1,r-biphenyl]-3-yl)1,2-oxaborolan-2-ol; (R) 3'-(2-hydroxy-1,2-oxaborolan-4-yl)-4,5-dimethoxy-[1,1 '-biphenyl]-320 carbonitrile; (S) 3'-(2-hydroxy-1,2-oxaborolan-4-yl)-4,5-dimethoxy-[1,1'-biphenyl]-3-carbonitrile; (R) 3-ethoxy-5-(5-(2-hydroxy-1,2-oxaborolan-4-yl)pyridin-3-yl)-2-methoxybenzonitrile; (S) 3ethoxy-5-(5-(2-hydroxy-1,2-oxaborolan-4-yl)pyridin-3-yl)-2-methoxybenzonitrile; 4-(3-(6-ethoxy5-methoxypyridin-2-yl)phenyl)-1,2-oxaborol-2(5H)-ol; (R) 4-(3-(6-ethoxy-5-methoxypyridin-2yl)phenyl)-1,2-oxaborolan-2-ol; (S) 4-(3-(6-ethoxy-5-methoxypyridin-2-yl)phenyl)-1,225 oxaborolan-2-ol; (R) 4-(3-(4,5-dimethoxypyrimidin-2-yl)phenyl)-1,2-oxaborolan-2-ol; (S) 4-(3(4,5-dimethoxypyrimidin-2-yl)phenyl)-1,2-oxaborolan-2-ol; (R) 4-(6-(3-(cyclopentyloxy)-4methoxyphenyl)pyrazin-2-yl)-1,2-oxaborolan-2-ol; (S) 4-(6-(3-(cyclopentyloxy)-4methoxyphenyl)pyrazin-2-yl)-1,2-oxaborolan-2-ol; (R) 4-(6-(4-methoxy-3-propoxyphenyl)pyridin2-yl)-1,2-oxaborolan-2-ol; (S) 4-(6-(4-methoxy-3-propoxyphenyl)pyridin-2-yl)-1,2-oxaborolan-230 ol; 4-(3'-(cyclopentyloxy)-4'-methoxy-[1,T-biphenyl]-3-yl)-1,2-oxaborol-2(5H)-ol; (R) 4-(3'(cyclopentyloxy)-4'-methoxy-[1,1'-biphenyl]-3-yl)-1,2-oxaborolan-2-ol; (S) 4-(3'-(cyclopentyloxy)4'-methoxy-[1,1'-biphenyl]-3-yl)-1,2-oxaborolan-2-ol (R) 4-(6-(3-(cyclopentyloxy)-4methoxyphenyl)-5-fluoropyridin-2-yl)-1,2-oxaborolan-2-ol; (S) 4-(6-(3-(cyclopentyloxy)-4methoxyphenyl)-5-fluoropyridin-2-yl)-1,2-oxaborolan-2-ol; (R) 4-(2-(3-(cyclopentyloxy)-435 methoxyphenyl)-6-methoxypyrimidin-4-yl)-1,2-oxaborolan-2-ol; (S) 4-(2-(3-(cyclopentyloxy)-4methoxyphenyl)-6-methoxypyrimidin-4-yl)-1,2-oxaborolan-2-ol; (R) ethyl 2-(6-(2-hydroxy-1,2oxaborolan-4-yl)-2-(4-methoxy-3-propoxyphenyl)pyrimidin-4-yl)acetate; (S) ethyl 2-(6-(2hydroxy-1,2-oxaborolan-4-yl)-2-(4-methoxy-3-propoxyphenyl)pyrimidin-4-yl)acetate; (R) 2-(6-(220225
P hydroxy-1,2-oxaborolan-4-yl)-2-(4-methoxy-3-propoxyphenyl)pyrimidin-4-yl)acetic acid; (S) 2-(6(2-hydroxy-1,2-oxaborolan-4-yl)-2-(4-methoxy-3-propoxyphenyl)pyrimidin-4-yl)acetic acid; (R) 4(5-fluoro-6-(4-methoxy-3-propoxyphenyl)pyridin-2-yl)-1,2-oxaborolan-2-ol; (S) 4-(5-fluoro-6-(4methoxy-3-propoxyphenyl)pyridin-2-yl)-1,2-oxaborolan-2-ol; (R) 4-(6-(4-methoxy-35 propoxyphenyl)pyridazin-4-yl)-1,2-oxaborolan-2-ol; (S) 4-(6-(4-methoxy-3propoxyphenyl)pyridazin-4-yl)-1,2-oxaborolan-2-ol; (R) 4-(4-(difluoromethyl)-5-(3-ethoxy-4methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; (S) 4-(4-(difluoromethyl)-5-(3-ethoxy-4methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; (R) 4-(5-(5-ethoxy-2-fluoro-4-methoxyphenyl)4-methylpyridin-3-yl)-1,2-oxaborolan-2-ol; (S) 4-(5-(5-ethoxy-2-fluoro-4-methoxyphenyl)-410 methylpyridin-3-yl)-1,2-oxaborolan-2-ol; (R) 4-(5-(3-ethoxy-4-(methylthio)phenyl)pyridin-3-yl)1,2-oxaborolan-2-ol; (S) 4-(5-(3-ethoxy-4-(methylthio)phenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; (R) 4-(5-(3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; (S) 4-(5-(3-propoxyphenyl)pyridin3-yl)-1,2-oxaborolan-2-ol; (R) 4-(5-(4-methoxy-3-propoxyphenyl)-1,2,4-thiadiazol-3-yl)-1,2oxaborolan-2-ol; (S) 4-(5-(4-methoxy-3-propoxyphenyl)-1,2,4-thiadiazol-3-yl)-1,2-oxaborolan-215 ol; (R) 4-(5-(3-(cyclopentyloxy)-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; (S) 4-(5-(3(cyclopentyloxy)-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; (R) 4-(2'-fluoro-4',5'dimethoxy-[1,1'-biphenyl]-3-yl)-1,2-oxaborolan-2-ol; (S) 4-(2'-fluoro-4',5'-dimethoxy-[1,1'biphenyl]-3-yl)-1,2-oxaborolan-2-ol; (R) 2-ethoxy-6-(6-(2-hydroxy-1,2-oxaborolan-4-yl)pyridin-2yl)-3-methoxybenzonitrile; (S) 2-ethoxy-6-(6-(2-hydroxy-1,2-oxaborolan-4-yl)pyridin-2-yl)-320 methoxybenzonitrile; (R) 4-(3-(5,6-dimethoxypyridin-2-yl)phenyl)-1,2-oxaborolan-2-ol; (S) 4-(3(5,6-dimethoxypyridin-2-yl)phenyl)-1,2-oxaborolan-2-ol; (R) 6-(5-(2-hydroxy-1,2-oxaborolan-4yl)pyridin-3-yl)-2,3-dimethoxybenzonitrile; (S) 6-(5-(2-hydroxy-1,2-oxaborolan-4-yl)pyridin-3-yl)2,3-dimethoxybenzonitrile; (R) 4-(2-(2-fluoro-4-methoxy-5-propoxyphenyl)-6(hydroxymethyl)pyrimidin-4-yl)-1,2-oxaborolan-2-ol; (S) 4-(2-(2-fluoro-4-methoxy-525 propoxyphenyl)-6-(hydroxymethyl)pyrimidin-4-yl)-1,2-oxaborolan-2-ol; 4-(3-(5-methoxy-6propoxypyridin-2-yl)phenyl)-1,2-oxaborol-2(5H)-ol; (R) 4-(3-(5-methoxy-6-propoxypyridin-2yl)phenyl)-1,2-oxaborolan-2-ol; (S) 4-(3-(5-methoxy-6-propoxypyridin-2-yl)phenyl)-1,2oxaborolan-2-ol; (R) 4-(3',4',5-trimethoxy-[1,r-biphenyl]-3-yl)-1,2-oxaborolan-2-ol; (S) 4-(3',4',5trimethoxy-[1,1 '-biphenyl]-3-yl)-1,2-oxaborolan-2-ol; (R) 4-(6-(4-methoxy-3-propoxyphenyl)-430 methylpyridin-2-yl)-1,2-oxaborolan-2-ol; (S) 4-(6-(4-methoxy-3-propoxyphenyl)-4-methylpyridin2-yl)-1,2-oxaborolan-2-ol; (R) 4-(2-(3,4-dimethoxyphenyl)thiazol-4-yl)-1,2-oxaborolan-2-ol; (S) 4(2-(3,4-dimethoxyphenyl)thiazol-4-yl)-1,2-oxaborolan-2-ol; (R) 4-(3-(5,6-dimethoxypyridin-3yl)phenyl)-1,2-oxaborolan-2-ol; (S) 4-(3-(5,6-dimethoxypyridin-3-yl)phenyl)-1,2-oxaborolan-2-ol; (R) 4-(6-(2-fluoro-3,4-dimethoxyphenyl)pyridin-2-yl)-1,2-oxaborolan-2-ol; (S) 4-(6-(2-fluoro-3,435 dimethoxyphenyl)pyridin-2-yl)-1,2-oxaborolan-2-ol; (R) 4-(5-(3-ethoxy-2,6-difluoro-4methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; (S) 4-(5-(3-ethoxy-2,6-difluoro-4methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; (R) 4-(3'-(cyclopropylmethoxy)-4'-methoxy[1,1'-biphenyl]-3-yl)-1,2-oxaborolan-2-ol; (S) 4-(3'-(cyclopropylmethoxy)-4'-methoxy-[1,r biphenyl]-3-yl)-1,2-oxaborolan-2-ol; (R) 4-(3'-ethoxy-2'-fluoro-4'-methoxy-[1,1'-biphenyl]-3-yl)1,2-oxaborolan-2-ol; (S) 4-(3'-ethoxy-2'-fluoro-4'-methoxy-[1,1'-biphenyl]-3-yl)-1,2-oxaborolan-2ol; (R) 4-(5-(2,4-dimethoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; (S) 4-(5-(2,4dimethoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; (R) 4-(5-(4-methoxy-3((tetrahydro-2H-thiopyran-4-yl)oxy)phenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; (S) 4-(5-(4-methoxy3-((tetrahydro-2H-thiopyran-4-yl)oxy)phenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; (R) 4-(5-(3ethoxy-4-methoxyphenyl)-6-ethylpyridin-3-yl)-1,2-oxaborolan-2-ol; (S) 4-(5-(3-ethoxy-4methoxyphenyl)-6-ethylpyridin-3-yl)-1,2-oxaborolan-2-ol; (R) 4-(3'-ethoxy-4'-(methylthio)-[1,1 'biphenyl]-3-yl)-1,2-oxaborolan-2-ol; (S) 4-(3'-ethoxy-4'-(methylthio)-[1,1'-biphenyl]-3-yl)-1,2oxaborolan-2-ol; (R) 4-(5-(3-chloro-5-ethoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; (S) 4-(5-(3-chloro-5-ethoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; (R) 4-(3-(4,5dimethoxypyridin-2-yl)phenyl)-1,2-oxaborolan-2-ol; (S) 4-(3-(4,5-dimethoxypyridin-2-yl)phenyl)1,2-oxaborolan-2-ol; (R) 4-(4-(3-(cyclopentyloxy)-4-methoxyphenyl)-6-methoxypyrimidin-2-yl)1,2-oxaborolan-2-ol; (S) 4-(4-(3-(cyclopentyloxy)-4-methoxyphenyl)-6-methoxypyrimidin-2-yl)1,2-oxaborolan-2-ol; (R) 3'-(2-hydroxy-1,2-oxaborolan-4-yl)-3,4-dimethoxy-[1,1 '-biphenyl]-2carbonitrile; (S) 3'-(2-hydroxy-1,2-oxaborolan-4-yl)-3,4-dimethoxy-[1,1 '-biphenyl]-2-carbonitrile; (R) 4-(5-methoxy-4-propoxy-[2,3'-bipyridin]-5'-yl)-1,2-oxaborolan-2-ol; (S) 4-(5-methoxy-4propoxy-[2,3'-bipyridin]-5'-yl)-1,2-oxaborolan-2-ol; (R) 4-(2-(hydroxymethyl)-6-(4-methoxy-3propoxyphenyl)pyridin-4-yl)-1,2-oxaborolan-2-ol; (S) 4-(2-(hydroxymethyl)-6-(4-methoxy-3propoxyphenyl)pyridin-4-yl)-1,2-oxaborolan-2-ol; (R) 4-(5-(3-cyclopropoxy-4-methoxyphenyl)1,2,4-thiadiazol-3-yl)-1,2-oxaborolan-2-ol; (S) 4-(5-(3-cyclopropoxy-4-methoxyphenyl)-1,2,4thiadiazol-3-yl)-1,2-oxaborolan-2-ol; (R) 4-(4'-ethoxy-3'-methoxy-[1,1'-biphenyl]-3-yl)-1,2oxaborolan-2-ol; (S) 4-(4'-ethoxy-3'-methoxy-[1,1'-biphenyl]-3-yl)-1,2-oxaborolan-2-ol; (R) 4-(3'isobutoxy-4'-methoxy-[1,1'-biphenyl]-3-yl)-1,2-oxaborolan-2-ol; (S) 4-(3'-isobutoxy-4'-methoxy[1,1'-biphenyl]-3-yl)-1,2-oxaborolan-2-ol; (R) 4-(3'-cyclobutoxy-4’-methoxy-[1,1 '-biphenyl]-3-yl)1,2-oxaborolan-2-ol: (S) 4-(3'-cyclobutoxy-4'-methoxy-[1,1 '-biphenyl]-3-yI)-1,2-oxaborolan-2-ol; (R) 4-(2-(3-ethoxy-4-methoxyphenyl)-6-methoxypyrimidin-4-yl)-1,2-oxaborolan-2-ol; (S) 4-(2-(3ethoxy-4-methoxyphenyl)-6-methoxypyrimidin-4-yl)-1,2-oxaborolan-2-ol; (R) 4-(5-(4-ethoxy-3methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; (S) 4-(5-(4-ethoxy-3-methoxyphenyl)pyridin-3yl)-1,2-oxaborolan-2-ol; (R) 3-ethoxy-3'-(2-hydroxy-1,2-oxaborolan-4-yl)-4-methoxy-[1,1'biphenyl]-2-carbonitriIe; (S) 3-ethoxy-3'-(2-hydroxy-1,2-oxaborolan-4-yl)-4-methoxy-[1,1'biphenyl]-2-carbonitrile; (R) 4-(6-(2-hydroxyethoxy)-2-(4-methoxy-3-propoxyphenyl)pyrimidin-4yl)-1,2-oxaborolan-2-ol; (S) 4-(6-(2-hydrOxyethoxy)-2-(4-methoxy-3-propoxyphenyl)pyrimidin-4yl)-1,2-oxaborolan-2-ol; (R) 4-(6-(3,4-dimethoxyphenyl)pyridin-2-yl)-1,2-oxaborolan-2-ol; (S) 4(6-(3,4-dimethoxyphenyl)pyridin-2-yl)-1,2-oxaborolan-2-ol; (R) 4-(4-(hydroxymethyl)-6-(4methoxy-3-propoxyphenyl)pyrimidin-2-yl)-1,2-oxaborolan-2-ol; (S) 4-(4-(hydroxymethyl)-6-(4methoxy-3-propoxyphenyl)pyrimidin-2-yl)-1,2-oxaborolan-2-ol; (R) 4-(6-(3-ethoxy-2-fluoro-4methoxyphenyl)pyridin-2-yl)-1,2-oxaborolan-2-ol; (S) 4-(6-(3-ethoxy-2-fluoro-4 methoxyphenyl)pyridin-2-yl)-1,2-oxaborolan-2-ol; (R) 4-(1-(4-methoxy-3-propoxyphenyl)-1Hpyrazol-3-yl)-1,2-oxaborolan-2-ol; (S) 4-(1-(4-methoxy-3-propoxyphenyl)-1H-pyrazol-3-yl)-1,2oxaborolan-2-ol; (R) 4-(5-(3-methoxy-4-(methylthio)phenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; (S) 4-(5-(3-methoxy-4-(methylthio)phenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; (R) 4-(6-(3-ethoxy-4(methylthio)phenyl)pyridin-2-yl)-1,2-oxaborolan-2-ol; (S) 4-(6-(3-ethoxy-4(methylthio)phenyl)pyridin-2-yl)-1,2-oxaborolan-2-ol; (R) 4-(5-(3-ethoxy-4-methoxyphenyl)-4,6dimethylpyridin-3-yl)-1,2-oxaborolan-2-ol; (S) 4-(5-(3-ethoxy-4-methoxyphenyl)-4,6dimethylpyridin-3-yl)-1,2-oxaborolan-2-ol; (R) 4-(3'-methoxy-4'-(methylthio)-[1,1'-biphenyl]-3-yl)1,2-oxaborolan-2-ol; (S) 4-(3'-methoxy-4'-(methylthio)-[1,1'-biphenyl]-3-yl)-1,2-oxaborolan-2-ol; (R) 4-(3',4'-dimethoxy-5-methyl-[1,1 '-biphenyl]-3-yl)-1,2-oxaborolan-2-ol; (S) 4-(3',4'-dimethoxy5-methyl-[1,1 biphenyl]-3-yI)-1,2-oxaborolan-2-ol; (R) 4-(2'-fluoro-3',4'-dimethoxy-[1,1 ’-biphenyl]3-yl)-1,2-oxaborolan-2-ol; (S) 4-(2'-fluoro-3',4'-dimethoxy-[1,1'-biphenyl]-3-yl)-1,2-oxaborolan-2ol; (R) 4-(2-(3-(cyclopentyloxy)-4-methoxyphenyl)pyridin-4-yl)-1,2-oxaborolan-2-ol; (S) 4-(2-(3(cyclopentyloxy)-4-methoxyphenyl)pyridin-4-yl)-1,2-oxaborolan-2-ol; (R) 4-(2-(4-methoxy-3propoxyphenyl)pyrimidin-4-yl)-1,2-oxaborolan-2-ol; (S) 4-(2-(4-methoxy-3propoxyphenyl)pyrimidin-4-yl)-1,2-oxaborolan-2-ol; (R) 4-(6-(2-fluoro-4-methoxy-3propoxyphenyl)pyridin-2-yl)-1,2-oxaborolan-2-ol; (S) 4-(6-(2-fluoro-4-methoxy-3propoxyphenyl)pyridin-2-yl)-1,2-oxaborolan-2-ol; (R) 4-(6-(2-fluoro-4-methoxy-3propoxyphenyl)pyrazin-2-yl)-1,2-oxaborolan-2-ol; (S) 4-(6-(2-fluoro-4-methoxy-3propoxyphenyl)pyrazin-2-yl)-1,2-oxaborolan-2-ol; (R) 4-(5-(4-ethoxy-2-fluoro-3methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; (S) 4-(5-(4-ethoxy-2-fluoro-3methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; (R) 4-(6'-methoxy-2-methyl-5'-propoxy-[3,3'bipyridin]-5-yl)-1,2-oxaborolan-2-ol; (S) 4-(6'-methoxy-2-methyl-5'-propoxy-[3,3'-bipyridin]-5-yl)1,2-oxaborolan-2-ol; (R) 4-(6-(3-ethoxy-4-methoxyphenyl)-4-(trifluoromethyl)pyridin-2-yl)-1,2oxaborolan-2-ol; (S) 4-(6-(3-ethoxy-4-methoxyphenyl)-4-(trifluoromethyl)pyridin-2-yl)-1,2oxaborolan-2-ol; (R) 4-(6-ethoxy-2-(3-ethoxy-4-methoxyphenyl)pyrimidin-4-yl)-1,2-oxaborolan-2ol; (S) 4-(6-ethoxy-2-(3-ethoxy-4-methoxyphenyl)pyrimidin-4-yl)-1,2-oxaborolan-2-ol; (R) 4-(6methoxy-2-(4-methoxy-3-propoxyphenyl)pyrimidin-4-yl)-1,2-oxaborolan-2-ol; (S) 4-(6-methoxy2-(4-methoxy-3-propoxyphenyl)pyrimidin-4-yl)-1,2-oxaborolan-2-ol; (R) 2-(cyclopentyloxy)-6-(6(2-hydroxy-1,2-oxaborolan-4-yl)pyridin-2-yl)-3-methoxybenzonitrile; (S) 2-(cyclopentyloxy)-6-(6(2-hydroxy-1,2-oxaborolan-4-yl)pyridin-2-yl)-3-methoxybenzonitrile; 4-(2-(3,4dimethoxyphenyl)pyridin-4-yl)-1,2-oxaborol-2(5H)-ol; 4-(5-(3-ethoxy-4-methoxyphenyl)pyridin-3yl)-1,2-oxaborol-2(5H)-ol; (R) 4-(3-fluoro-6-(4-methoxy-3-propoxyphenyl)pyridin-2-yl)-1,2oxaborolan-2-ol; (S) 4-(3-fluoro-6-(4-methoxy-3-propoxyphenyl)pyridin-2-yl)-1,2-oxaborolan-2-ol; (R) 4-(5-methoxy-2'-methyl-6-propoxy-[2,3'-bipyridin]-5'-yl)-1,2-oxaborolan-2-ol; (S) 4-(5methoxy-2'-methyl-6-propoxy-[2,3'-bipyridin]-5'-yl)-1,2-oxaborolan-2-ol; (R) 4-(3',4'-dimethoxy[1,1 '-biphenyl]-3-yl)-1,2-oxaborolan-2-ol; (S) 4-(3',4'-dimethoxy-[1,1 '-biphenyl]-3-yI)-1,2oxaborolan-2-ol; (R) 4-(6-(3-ethoxy-4-methoxyphenyl)pyridin-2-yl)-1,2-oxaborolan-2-ol; and (S) 4-(6-(3-ethoxy-4-methoxyphenyl)pyridin-2-yl)-1,2-oxaborolan-2-ol; or a pharmaceutically acceptable sait thereof.
In another embodiment, the présent invention provides a pharmaceutical composition comprising a compound of Formula (I), Formula (IA), Formula (IB), or Formula (IC), or a pharmaceutically acceptable sait thereof, and at least one pharmaceutically acceptable excipient, diluent, or carrier.
In another embodiment, the présent invention provides a method for treating or preventing an inflammatory disease in a human comprising administering to the human in need of such treatment a therapeutically effective amount of a compound of Formula (I), Formula (IA), Formula (IB), or Formula (IC), or a pharmaceutically acceptable sait thereof.
In another embodiment, the présent invention provides a method for treating or preventing an inflammatory disease in a human comprising topically administering to the human in need of such treatment a therapeutically effective amount of a compound of Formula (I), Formula (IA), Formula (IB), or Formula (IC), or a pharmaceutically acceptable sait thereof, in the form of a transdermal patch, an ointment, a lotion, a cream, or a gel.
In another embodiment, the présent invention provides a method for treating or preventing atopie dermatitis, hand dermatitis, contact dermatitis, allergie contact dermatitis, irritant contact dermatitis, neurodermatitis, perioral dermatitis, stasis dermatitis, dyshidrotic eczema, xerotic dermatitis, nummalar dermatitis, seborrheic dermatitis, eyelid dermatitis, diaper dermatitis, dermatomyositis, lichen planus, lichen sclerosis, alopecia areata, vitiligo, rosacea, epidermolysis bullosa, keratosis pilaris, pityriasis alba, pemphigus, vulvovaginitis, acné, chronic spontaneous urticaria, chronic idiopathic urticaria, chronic physical urticaria, vogt-koyanagiharada disease, sutton nevus/nevi, post inflammatory hypopigmentation, senile leukoderma, chemical/drug-induced leukoderma, cutaneous lupus erythematosus, discoid lupus, palmoplantar pustulosis, pemphigoid, sweet's syndrome, hidradenitis suppurativa, psoriasis, plaque psoriasis, pustular psoriasis, nail psoriasis, flexural psoriasis, guttate psoriasis, psoriatic arthritis, érythrodermie psoriasis, or inverse psoriasis in a human comprising administering to the human in need of such treatment a therapeutically effective amount of a compound of Formula (I), Formula (IA), Formula (IB), or Formula (IC), or a pharmaceutically acceptable sait thereof.
In another embodiment, the présent invention provides a method for treating or preventing atopie dermatitis, hand dermatitis, contact dermatitis, allergie contact dermatitis, irritant contact dermatitis, neurodermatitis, perioral dermatitis, stasis dermatitis, dyshidrotic eczema, xerotic dermatitis, nummalar dermatitis, seborrheic dermatitis, eyelid dermatitis, diaper dermatitis, dermatomyositis, lichen planus, lichen sclerosis, alopecia areata, vitiligo, rosacea, epidermolysis bullosa, keratosis pilaris, pityriasis alba, pemphigus, vulvovaginitis, acné, cutaneous lupus erythematosus, discoid lupus, palmoplantar pustulosis, pemphigoid, sweet's syndrome, hidradenitis suppurativa, psoriasis, plaque psoriasis, pustular psoriasis, nail psoriasis, flexural psoriasis, guttate psoriasis, psoriatic arthritis, érythrodermie psoriasis, or inverse psoriasis in a human comprising topically administering to the human in need of such treatment a therapeutically effective amount of a compound of Formula (I), Formula (IA), Formula (IB), or Formula (IC), or a pharmaceutically acceptable sait thereof, in the form of a transdermal patch, an ointment, a lotion, a cream, or a gel.
In another embodiment, the présent invention provides a method for treating or preventing arthritis, asthma, fibrosis, lupus, allergy, fibromyalgia, wound healing, or inflammation resulting from surgical complications in a human comprising administering to the human in need of such treatment a therapeutically effective amount of a compound of Formula (I), Formula (IA), Formula (IB), or Formula (IC), or a pharmaceutically acceptable sait thereof.
In another embodiment, the présent invention provides a method for treating or preventing arthritis, asthma, fibrosis, lupus, allergy, fibromyalgia, wound healing, or inflammation resulting from surgical complications in a human comprising topically administering to the human in need of such treatment a therapeutically effective amount of a compound of Formula (I), Formula (IA), Formula (IB), or Formula (IC), or a pharmaceutically acceptable sait thereof in the form of a transdermal patch, an ointment, a lotion, a cream, or a gel.
In another embodiment, the présent invention provides a method for treating or preventing inflammatory bowel disease, ulcerative colitis, or Crohn’s disease in a human comprising administering to the human in need of such treatment a therapeutically effective amount of a compound of Formula (I), Formula (IA), Formula (IB), or Formula (IC), or a pharmaceutically acceptable sait thereof.
In another embodiment, the présent invention provides the use of a compound of Formula (I), Formula (IA), Formula (IB), or Formula (IC), or a pharmaceutically acceptable sait thereof, in the manufacture of a médicament for treating an inflammatory disease in a human.
In another embodiment, the présent invention provides the use of a compound of Formula (I), Formula (IA), Formula (IB), or Formula (IC), or a pharmaceutically acceptable sait thereof, in the manufacture of a médicament for treating atopie dermatitis, hand dermatitis, contact dermatitis, allergie contact dermatitis, irritant contact dermatitis, neurodermatitis, perioral dermatitis, stasis dermatitis, dyshidrotic eczema, xerotic dermatitis, nummalar dermatitis, seborrheic dermatitis, eyelid dermatitis, diaper dermatitis, dermatomyositis, lichen planus, lichen sclerosis, alopecia areata, vitiligo, rosacea, epidermolysis bullosa, keratosis pilaris, pityriasis alba, pemphigus, vulvovaginitis, acné, chronic spontaneous urticaria, chronic idiopathic urticaria, chronic physical urticaria, vogt-koyanagi-harada disease, sutton nevus/nevi, post inflammatory hypopigmentation, senile leukoderma, chemical/drug-induced leukoderma, cutaneous lupus erythematosus, discoid lupus, palmoplantar pustulosis, pemphigoid, sweet's syndrome, hidradenitis suppurativa, psoriasis, plaque psoriasis, pustular psoriasis, nail psoriasis, flexural psoriasis, guttate psoriasis, psoriatic arthritis, érythrodermie psoriasis, or inverse psoriasis in a human.
P In another embodiment, the présent invention provides the use of a compound of
Formula (I), Formula (IA), Formula (IB), or Formula (IC), or a pharmaceutically acceptable sait thereof, in the manufacture of a médicament for treating arthritis, asthma, fibrosis, lupus, allergy, fibromyalgia, wound healing, or inflammation resulting from surgical complications in a human.
In another embodiment, the présent invention provides the use of a compound of
Formula (I), Formula (IA), Formula (IB), or Formula (IC), or a pharmaceutically acceptable sait thereof, in the manufacture of a médicament for treating inflammatory bowel disease, ulcerative colitis, or Crohn’s disease in a human.
In another embodiment, the présent invention provides crystalline (R)-4-(5-(3-ethoxy-410 methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol.
In another embodiment, the présent invention provides crystalline (R)-4-(5-(3-ethoxy-4methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol having an X-ray powder diffraction pattern comprising diffraction peaks 10.5 ± 0.2, 18.3 ± 0.2, and 24.9 ± 0.2 degrees two thêta.
In another embodiment, the présent invention provides crystalline (R)-4-(5-(3-ethoxy-415 methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol having an X-ray powder diffraction pattern comprising diffraction peaks 10.5 ± 0.2, 12.3 ± 0.2, 13.5 ± 0.2, 15.8 ± 0.2, 16.0 ± 0.2,18.3 ± 0.2, and 24.9 ± 0.2 degrees two thêta.
In another embodiment, the présent invention provides crystalline (R)-4-(5-(3-ethoxy-4methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol having an X-ray powder diffraction pattern comprising diffraction peaks 10.5 ± 0.2, 12.3 ± 0.2, 13.5 ± 0.2, 15.8 ± 0.2, 16.0 ± 0.2,18.3 ± 0.2, 21.5 ± 0.2, 22.9 ± 0.2, 24.4 ± 0.2, 24.9 ± 0.2, 25.4 ± 0.2, 26.5 ± 0.2, 27.8 ± 0.2, and 30.2 ± 0.2 degrees two thêta.
In another embodiment, the present invention provides crystalline (R)-4-(5-(3-ethoxy-4methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol having an X-ray powder diffraction pattern comprising 3 to 10 diffraction peaks listed in Table 7.
In another embodiment, the present invention provides crystalline (R)-4-(5-(3-ethoxy-4methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol having an X-ray powder diffraction pattern comprising the diffraction peaks listed in Table 7.
In another embodiment, the present invention provides crystalline (R)-4-(5-(3-ethoxy-430 methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol having an X-ray powder diffraction pattern as depicted in Figure 5.
In another embodiment, the present invention provides a pharmaceutical composition comprising crystalline (R)-4-(5-(3-ethoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol and at least one pharmaceutically acceptable excipient, diluent, or carrier.
In another embodiment, the present invention provides a method for treating or preventing an inflammatory disease in a human comprising administering to the human in need of such treatment a therapeutically effective amount of crystalline (R)-4-(5-(3-ethoxy-4methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol.
In another embodiment, the présent invention provides a method for treating or preventing atopie dermatitis, hand dermatitis, contact dermatitis, allergie contact dermatitis, irritant contact dermatitis, neurodermatitis, perioral dermatitis, stasis dermatitis, dyshidrotic eczema, xerotic dermatitis, nummalar dermatitis, seborrheic dermatitis, eyelid dermatitis, diaper dermatitis, dermatomyositis, lichen planus, lichen sclerosis, alopecia areata, vitiligo, rosacea, epidermolysis bullosa, keratosis pilaris, pityriasis alba, pemphigus, vulvovaginitis, acné, chronic spontaneous urticaria, chronic idiopathic urticaria, chronic physical urticaria, vogt-koyanagiharada disease, sutton nevus/nevi, post inflammatory hypopigmentation, senile leukoderma, chemical/drug-induced leukoderma, cutaneous lupus erythematosus, discoid lupus, palmoplantar pustulosis, pemphigoid, sweet's syndrome, hidradenitis suppurativa, psoriasis, plaque psoriasis, pustular psoriasis, nail psoriasis, flexural psoriasis, guttate psoriasis, psoriatic arthritis, érythrodermie psoriasis, or inverse psoriasis in a human comprising administering to the human in need of such treatment a therapeutically effective amount of crystalline (R)-4-(5(3-ethoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol.
In another embodiment, the présent invention provides a method for treating or preventing atopie dermatitis, hand dermatitis, contact dermatitis, allergie contact dermatitis, irritant contact dermatitis, neurodermatitis, perioral dermatitis, stasis dermatitis, dyshidrotic eczema, xerotic dermatitis, nummalar dermatitis, seborrheic dermatitis, eyelid dermatitis, diaper dermatitis, dermatomyositis, lichen planus, lichen sclerosis, alopecia areata, vitiligo, rosacea, epidermolysis bullosa, keratosis pilaris, pityriasis alba, pemphigus, vulvovaginitis, acné, chronic spontaneous urticaria, chronic idiopathic urticaria, chronic physical urticaria, vogt-koyanagiharada disease, sutton nevus/nevi, post inflammatory hypopigmentation, senile leukoderma, chemical/drug-induced leukoderma, cutaneous lupus erythematosus, discoid lupus, palmoplantar pustulosis, pemphigoid, sweet's syndrome, hidradenitis suppurativa, psoriasis, plaque psoriasis, pustular psoriasis, nail psoriasis, flexural psoriasis, guttate psoriasis, psoriatic arthritis, érythrodermie psoriasis, or inverse psoriasis in a human comprising topically administering to the human in need of such treatment a therapeutically effective amount of crystalline (R)-4-(5-(3-ethoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol in the form of a transdermal patch, an ointment, a lotion, a cream, or a gel.
In another embodiment, the présent invention provides a method for treating or preventing an arthritis, asthma, fibrosis, lupus, allergy, fibromyalgia, wound healing, or inflammation resulting from surgical complications in a human comprising administering to the human in need of such treatment a therapeutically effective amount of crystalline (R)-4-(5-(3ethoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol.
In another embodiment, the présent invention provides a method for treating or preventing an arthritis, asthma, fibrosis, lupus, allergy, fibromyalgia, wound healing, or inflammation resulting from surgical complications in a human comprising topically administering to the human in need of such treatment a therapeutically effective amount of crystalline (R)-4-(5-
(3-ethoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol in the form of a transdermal patch, an ointment, a lotion, a cream, or a gel. .
In another embodiment, the présent invention provides a method for treating or preventing inflammatory bowel disease, ulcerative colitis, or Crohn’s disease in a human comprising administering to the human in need of such treatment a therapeutically effective amount of crystalline (R)-4-(5-(3-ethoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol.
In another embodiment, the présent invention provides the use of crystalline (R)-4-(5-(3ethoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol in the manufacture of a médicament for treating an inflammatory disease in a human.
In another embodiment, the présent invention provides the use of crystalline (R)-4-(5-(3ethoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaboroIan-2-ol in the manufacture of a médicament for treating atopie dermatitis, hand dermatitis, contact dermatitis, allergie contact dermatitis, irritant contact dermatitis, neurodermatitis, perioral dermatitis, stasis dermatitis, dyshidrotic eczema, xerotic dermatitis, nummalar dermatitis, seborrheic dermatitis, eyelid dermatitis, diaper dermatitis, dermatomyositis, lichen planus, lichen sclerosis, alopecia areata, vitiligo, rosacea, epidermolysis bullosa, keratosis pilaris, pityriasis alba, pemphigus, vulvovaginitis, acné, chronic spontaneous urticaria, chronic idiopathic urticaria, chronic physical urticaria, vogt-koyanagiharada disease, sutton nevus/nevi, post inflammatory hypopigmentation, senile leukoderma, chemical/drug-induced leukoderma, cutaneous lupus erythematosus, discoid lupus, palmoplantar pustulosis, pemphigoid, sweet's syndrome, hidradenitis suppurativa, psoriasis, plaque psoriasis, pustular psoriasis, nail psoriasis, flexural psoriasis, guttate psoriasis, psoriatic arthritis, érythrodermie psoriasis, or inverse psoriasis in a human.
In another embodiment, the présent invention provides the use of crystalline (R)-4-(5-(3ethoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol in the manufacture of a médicament for treating arthritis, asthma, fibrosis, lupus, allergy, fibromyalgia, wound healing, or inflammation resulting from surgical complications in a human.
In another embodiment, the présent invention provides the use of crystalline (R)-4-(5-(3ethoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol in the manufacture of a médicament for treating inflammatory bowel disease, ulcerative colitis, or Crohn’s disease in a human.
In another embodiment, the présent invention provides crystalline (R)-4-(5-(4-methoxy-3propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol.
In another embodiment, the présent invention provides crystalline (R)-4-(5-(4-methoxy-3propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol having an X-ray powder diffraction pattern comprising diffraction peaks 11.0 ± 0.2, 22.9 ± 0.2, and 25.1 ± 0.2 degrees two thêta.
In another embodiment, the présent invention provides crystalline (R)-4-(5-(4-methoxy-3propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol having an X-ray powder diffraction pattern comprising diffraction peaks 11.0 ± 0.2, 11.4 ± 0.2, 18.8 ± 0.2, 22.9 ± 0.2, 25.1 ± 0.2, and 26.4 ± 0.2 degrees two thêta.
P In another embodiment, the présent invention provides crystalline (R)-4-(5-(4-methoxy-3propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol having an X-ray powder diffraction pattern comprising diffraction peaks 11.0 ± 0.2, 11.4 ± 0.2, 13.2 ± 0.2, 15.1 ± 0.2, 18.8 ± 0.2, 21.3 ± 0.2,
22.9 ± 0.2, 25.1 ± 0.2, and 26.4 ± 0.2 degrees two thêta.
In another embodiment, the présent invention provides crystalline (R)-4-(5-(4-methoxy-3propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol having an X-ray powder diffraction pattern comprising diffraction peaks 11.0 ± 0.2, 11.4 ± 0.2, 13.2 ± 0.2, 14.5 ± 0.2, 15.1 + 0.2, 15.6 ± 0.2, 15.9 ± 0.2, 17.7 ± 0.2,18.8 ± 0.2, 19.4 ± 0.2, 19.7 ± 0.2, 20.5 ± 0.2, 21.3 ± 0.2, and 22.9 ± 0.2, degrees two thêta.
In another embodiment, the présent invention provides crystalline (R)-4-(5-(4-methoxy-3propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol having an X-ray powder diffraction pattern comprising diffraction peaks 11.0 ± 0.2, 11.4 ± 0.2, 13.2 ± 0.2, 14.5 ± 0.2, 15.1 ± 0.2, 15.6 ± 0.2, 15.9 ± 0.2, 17.7 ± 0.2,18.8 ± 0.2, 19.4 ± 0.2, 19.7 ± 0.2, 20.5 ± 0.2, 21.3 ± 0.2, 22.9 ± 0.2, 25.1 ± 0.2, 25.9 ± 0.2, 26.4 ± 0.2, 27.5 ± 0.2, and 28.4 ± 0.2 degrees two thêta.
In another embodiment, the présent invention provides crystalline (R)-4-(5-(4-methoxy-3propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol having an X-ray powder diffraction pattern comprising 3 to 10 diffraction peaks listed in Table 8.
In another embodiment, the présent invention provides crystalline (R)-4-(5-(4-methoxy-3propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol having an X-ray powder diffraction pattern comprising the diffraction peaks listed in Table 8.
In another embodiment, the présent invention provides crystalline (R)-4-(5-(4-methoxy-3propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol having an X-ray powder diffraction pattern as depicted in Figure 6.
In another embodiment, the présent invention provides a pharmaceutical composition 25 comprising crystalline (R)-4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol and at least one pharmaceutically acceptable excipient, diluent, or carrier.
In another embodiment, the présent invention provides a method for treating or preventing an inflammatory disease in a human comprising administering to the human in need of such treatment a therapeutically effective amount of crystalline (R)-4-(5-(4-methoxy-330 propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol.
In another embodiment, the présent invention provides a method for treating or preventing atopie dermatitis, hand dermatitis, contact dermatitis, allergie contact dermatitis, irritant contact dermatitis, neurodermatitis, perioral dermatitis, stasis dermatitis, dyshidrotic eczema, xerotic dermatitis, nummalar dermatitis, seborrheic dermatitis, eyelid dermatitis, diaper 35 dermatitis, dermatomyositis, lichen planus, lichen sclerosis, alopecia areata, vitiligo, rosacea, epidermolysis bullosa, keratosis pilaris, pityriasis alba, pemphigus, vulvovaginitis, acné, chronic spontaneous urticaria, chronic idiopathic urticaria, chronic physical urticaria, vogt-koyanagiharada disease, sutton nevus/nevi, post inflammatory hypopigmentation, senile leukoderma, chemical/drug-induced leukoderma, cutaneous lupus erythematosus, discoid lupus, palmoplantar pustulosis, pemphigoid, sweet's syndrome, hidradenitis suppurativa, psoriasis, plaque psoriasis, pustular psoriasis, nail psoriasis, flexural psoriasis, guttate psoriasis, psoriatic arthritis, érythrodermie psoriasis, or inverse psoriasis in a human comprising administering to the human in need of such treatment a therapeutically effective amount of crystalline (R)-4-(5(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol.
In another embodiment, the présent invention provides a method for treating or preventing atopie dermatitis, hand dermatitis, contact dermatitis, allergie contact dermatitis, irritant contact dermatitis, neurodermatitis, perioral dermatitis, stasis dermatitis, dyshidrotic eczema, xerotic dermatitis, nummalar dermatitis, seborrheic dermatitis, eyelid dermatitis, diaper dermatitis, dermatomyositis, lichen planus, lichen sclerosis, alopecia areata, vitiligo, rosacea, epidermolysis bullosa, keratosis pilaris, pityriasis alba, pemphigus, vulvovaginitis, acné, chronic spontaneous urticaria, chronic idiopathic urticaria, chronic physical urticaria, vogt-koyanagiharada disease, sutton nevus/nevi, post inflammatory hypopigmentation, senile leukoderma, chemical/drug-induced leukoderma, cutaneous lupus erythematosus, discoid lupus, palmoplantar pustulosis, pemphigoid, sweet's syndrome, hidradenitis suppurativa, psoriasis, plaque psoriasis, pustular psoriasis, nail psoriasis, flexural psoriasis, guttate psoriasis, psoriatic arthritis, érythrodermie psoriasis, or inverse psoriasis in a human comprising topically administering to the human in need of such treatment a therapeutically effective amount of crystalline (R)-4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol in the form of a transdermal patch, an ointment, a lotion, a cream, or a gel.
In another embodiment, the présent invention provides a method for treating or preventing an arthritis, asthma, fibrosis, lupus, allergy, fibromyalgia, wound healing, or inflammation resulting from surgical complications in a human comprising administering to the human in need of such treatment a therapeutically effective amount of crystalline (R)-4-(5-(4methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol.
In another embodiment, the présent invention provides a method for treating or preventing an arthritis, asthma, fibrosis, lupus, allergy, fibromyalgia, wound healing, or inflammation resulting from surgical complications in a human comprising topically administering to the human in need of such treatment a therapeutically effective amount of crystalline (R)-4-(5(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaboroIan-2-ol in the form of a transdermal patch, an ointment, a lotion, a cream, or a gel.
In another embodiment, the présent invention provides a method for treating or preventing inflammatory bowel disease, ulcerative colitis, or Crohn’s disease in a human comprising administering to the human in need of such treatment a therapeutically effective amount of crystalline (R)-4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol.
In another embodiment, the présent invention provides the use of crystalline (R)-4-(5-(4methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol in the manufacture of a médicament for treating an inflammatory disease in a human.
In another embodiment, the présent invention provides the use of crystalline (R)-4-(5-(4methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol in the manufacture of a médicament for treating atopie dermatitis, hand dermatitis, contact dermatitis, allergie contact dermatitis, irritant contact dermatitis, neurodermatitis, perioral dermatitis, stasis dermatitis, dyshidrotic eczema, xerotic dermatitis, nummalar dermatitis, seborrheic dermatitis, eyelid dermatitis, diaper dermatitis, dermatomyositis, lichen planus, lichen sclerosis, alopecia areata, vitiligo, rosacea, epidermolysis bullosa, keratosis pilaris, pityriasis alba, pemphigus, vulvovaginitis, acné, chronic spontaneous urticaria, chronic idiopathic urticaria, chronic physical urticaria, vogt-koyanagiharada disease, sutton nevus/nevi, post inflammatory hypopigmentation, senile leukoderma, chemical/drug-induced leukoderma, cutaneous lupus erythematosus, discoid lupus, palmoplantar pustulosis, pemphigoid, sweet's syndrome, hidradenitis suppurativa, psoriasis, plaque psoriasis, pustular psoriasis, nail psoriasis, flexural psoriasis, guttate psoriasis, psoriatic arthritis, érythrodermie psoriasis, or inverse psoriasis in a human.
In another embodiment, the présent invention provides the use of crystalline (R)-4-(5-(4methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol in the manufacture of a médicament for treating arthritis, asthma, fibrosis, lupus, allergy, fibromyalgia, wound healing, or inflammation resulting from surgical complications in a human.
In another embodiment, the présent invention provides the use of crystalline (R)-4-(5-(4methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol in the manufacture of a médicament for treating inflammatory bowel disease, ulcerative colitis, or Crohn’s disease in a human.
In another embodiment, the présent invention provides crystalline (S)-4-(5-(4-methoxy-3propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol.
In another embodiment, the présent invention provides crystalline (S)-4-(5-(4-methoxy-3propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol having an X-ray powder diffraction pattern comprising diffraction peaks 18.7 ± 0.2, 22.8 ± 0.2, and 25.0 ± 0.2 degrees two thêta.
In another embodiment, the présent invention provides crystalline (S)-4-(5-(4-methoxy-3propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol having an X-ray powder diffraction pattern comprising diffraction peaks 11.0 ± 0.2, 11.4 ± 0.2, 13.2 ±0.2, 18.7 ± 0.2, 22.8 ± 0.2, and 25.0 ± 0.2, degrees two thêta.
In another embodiment, the présent invention provides crystalline (S)-4-(5-(4-methoxy-3propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol having an X-ray powder diffraction pattern comprising diffraction peaks 11.0 ± 0.2, 11.4 ± 0.2, 13.2 ± 0.2, 14.5 ± 0.2, 15.1 ± 0.2, 15.6 ± 0.2, 18.7 ± 0.2, 22.8 ± 0.2, and 25.0 ± 0.2, degrees two thêta.
In another embodiment, the présent invention provides crystalline (S)-4-(5-(4-methoxy-3propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol having an X-ray powder diffraction pattern comprising diffraction peaks 11.0 ± 0.2, 11.4 ± 0.2, 13.2 ± 0.2, 14.5 ± 0.2, 15.1 ± 0.2, 15.6 ± 0.2,
18.7 ± 0.2, 19.7 ± 0.2, 21.2 ± 0.2, 22.8 ± 0.2, 25.0 ± 0.2, and 26.4 ± 0.2 degrees two thêta.
In another embodiment, the present invention provides crystalline (S)-4-(5-(4-methoxy-3propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol having an X-ray powder diffraction pattern comprising diffraction peaks 11.0 ± 0.2, 11.4 ± 0.2, 13.2 ± 0.2, 14.5 ± 0.2, 15.1 ± 0.2, 15.6 ± 0.2, 18.7 ± 0.2, 19.4 ± 0.2, 19.7 ± 0.2, 20.5 ± 0.2, 21.2 ± 0.2, 22.8 ± 0.2, 25.0 ± 0.2, 26.4 ± 0.2, 27.4 ± 0.2, and 28.3 ± 0.2, degrees two thêta.
In another embodiment, the present invention provides crystalline (S)-4-(5-(4-methoxy-3propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol having an X-ray powder diffraction pattern comprising 3 to 10 diffraction peaks listed in Table 9.
In another embodiment, the present invention provides crystalline (S)-4-(5-(4-methoxy-3propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol having an X-ray powder diffraction pattern comprising the diffraction peaks listed in Table 9.
In another embodiment, the present invention provides crystalline (S)-4-(5-(4-methoxy-3propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol having an X-ray powder diffraction pattern as depicted in Figure 7.
In another embodiment, the present invention provides a pharmaceutical composition comprising crystalline (S)-4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol and at least one pharmaceutically acceptable excipient, diluent, or carrier.
In another embodiment, the present invention provides a method for treating or preventing an inflammatory disease in a human comprising administering to the human in need of such treatment a therapeutically effective amount of crystalline (S)-4-(5-(4-methoxy-3propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol.
In another embodiment, the present invention provides a method for treating or preventing atopie dermatitis, hand dermatitis, contact dermatitis, allergie contact dermatitis, irritant contact dermatitis, neurodermatitis, perioral dermatitis, stasis dermatitis, dyshidrotic eczema, xerotic dermatitis, nummalar dermatitis, seborrheic dermatitis, eyelid dermatitis, diaper dermatitis, dermatomyositis, lichen planus, lichen sclerosis, alopecia areata, vitiligo, rosacea, epidermolysis bullosa, keratosis pilaris, pityriasis alba, pemphigus, vulvovaginitis, acné, chronic spontaneous urticaria, chronic idiopathic urticaria, chronic physical urticaria, vogt-koyanagiharada disease, sutton nevus/nevi, post inflammatory hypopigmentation, senile leukoderma, chemical/drug-induced leukoderma, cutaneous lupus erythematosus, discoid lupus, palmoplantar pustulosis, pemphigoid, sweet's syndrome, hidradenitis suppurativa, psoriasis, plaque psoriasis, pustular psoriasis, nail psoriasis, flexural psoriasis, guttate psoriasis, psoriatic arthritis, érythrodermie psoriasis, or inverse psoriasis in a human comprising administering to the human in need of such treatment a therapeutically effective amount of crystalline (S)-4-(5(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol.
In another embodiment, the présent invention provides a method for treating or preventing atopie dermatitis, hand dermatitis, contact dermatitis, allergie contact dermatitis, irritant contact dermatitis, neurodermatitis, perioral dermatitis, stasis dermatitis, dyshidrotic eczema, xerotic dermatitis, nummalar dermatitis, seborrheic dermatitis, eyelid dermatitis, diaper dermatitis, dermatomyositis, lichen planus, lichen sclerosis, alopecia areata, vitiligo, rosacea, epidermolysis bullosa, keratosis pilaris, pityriasis alba, pemphigus, vulvovaginitis, acné, chronic spontaneous urticaria, chronic idiopathic urticaria, chronic physical urticaria, vogt-koyanagiharada disease, sutton nevus/nevi, post inflammatory hypopigmentation, senile leukoderma, chemical/drug-induced leukoderma, cutaneous lupus erythematosus, discoid lupus, palmoplantar pustulosis, pemphigoid, sweet's syndrome, hidradenitis suppurativa, psoriasis, plaque psoriasis, pustular psoriasis, nail psoriasis, flexural psoriasis, guttate psoriasis, psoriatic arthritis, érythrodermie psoriasis, or inverse psoriasis in a human comprising topically administering to the human in need of such treatment a therapeutically effective amount of crystalline (S)-4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol in the form of a transdermal patch, an ointment, a lotion, a cream, or a gel.
In another embodiment, the présent invention provides a method for treating or preventing an arthritis, asthma, fibrosis, lupus, allergy, fibromyalgia, wound healing, or inflammation resulting from surgical complications in a human comprising administering to the human in need of such treatment a therapeutically effective amount of crystalline (S)-4-(5-(4methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol.
In another embodiment, the présent invention provides a method for treating or preventing an arthritis, asthma, fibrosis, lupus, allergy, fibromyalgia, wound healing, or inflammation resulting from surgical complications in a human comprising topically administering to the human in need of such treatment a therapeutically effective amount of crystalline (S)-4-(5(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol in the form of a transdermal patch, an ointment, a lotion, a cream, or a gel.
In another embodiment, the présent invention provides a method for treating or preventing inflammatory bowel disease, ulcerative colitis, or Crohn’s disease in a human comprising administering to the human in need of such treatment a therapeutically effective amount of crystalline (S)-4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol.
In another embodiment, the présent invention provides the use of crystalline (S)-4-(5-(4methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol in the manufacture of a médicament for treating an inflammatory disease in a human.
In another embodiment, the présent invention provides the use of crystalline (S)-4-(5-(4methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol in the manufacture of a médicament for treating atopie dermatitis, hand dermatitis, contact dermatitis, allergie contact dermatitis, irritant contact dermatitis, neurodermatitis, perioral dermatitis, stasis dermatitis, dyshidrotic eczema, xerotic dermatitis, nummalar dermatitis, seborrheic dermatitis, eyelid dermatitis, diaper dermatitis, dermatomyositis, lichen planus, lichen sclerosis, alopecia areata, vitiligo, rosacea, epidermolysis bullosa, keratosis pilaris, pityriasis alba, pemphigus, vulvovaginitis, acné, chronic spontaneous urticaria, chronic idiopathic urticaria, chronic physical urticaria, vogt-koyanagiharada disease, sutton nevus/nevi, post inflammatory hypopigmentation, senile leukoderma, chemical/drug-induced leukoderma, cutaneous lupus erythematosus, discoid lupus, palmoplantar pustulosis, pemphigoid, sweet's syndrome, hidradenitis suppurativa, psoriasis, plaque psoriasis, pustular psoriasis, nail psoriasis, flexural psoriasis, guttate psoriasis, psoriatic arthritis, érythrodermie psoriasis, or inverse psoriasis in a human.
In another embodiment, the présent invention provides the use of crystalline (S)-4-(5-(4methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol in the manufacture of a médicament for treating arthritis, asthma, fibrosis, lupus, allergy, fibromyalgia, wound healing, or inflammation resulting from surgical complications in a human.
In another embodiment, the présent invention provides the use of crystalline (S)-4-(5-(4methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol in the manufacture of a médicament for treating inflammatory bowel disease, ulcerative colitis, or Crohn’s disease in a human.
In another embodiment, the présent invention provides crystalline (-) 4-(5-(2(difluoromethyl)-3-ethoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol.
In another embodiment, the présent invention provides crystalline (-) 4-(5-(2(difluoromethyl)-3-ethoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol having an X-ray powder diffraction pattern comprising diffraction peaks 12.8 ± 0.2, 20.4 ± 0.2, and 25.7 ± 0.2 degrees two thêta.
In another embodiment, the présent invention provides crystalline (-) 4-(5-(2(difluoromethyl)-3-ethoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol having an X-ray powder diffraction pattern comprising diffraction peaks 12.8 ± 0.2, 17.9 ± 0.2, 20.4 ± 0.2, 22.9 ± 0.2, 23.1 ± 0.2, and 25.7 ± 0.2 degrees two thêta.
In another embodiment, the présent invention provides crystalline (-) 4-(5-(2(difluoromethyl)-3-ethoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol having an X-ray powder diffraction pattern comprising diffraction peaks 8.9 ± 0.2, 12.0 ± 0.2, 12.3 ± 0.2,12.8 ± 0.2, 17.8 ± 0.2, 20.4 ± 0.2, 22.9 ± 0.2, 23.1 ± 0.2, and 25.7 ± 0.2 degrees two thêta.
In another embodiment, the présent invention provides crystalline (-) 4-(5-(2(difluoromethyl)-3-ethoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol having an X-ray powder diffraction pattern comprising diffraction peaks 8.9 ± 0.2, 12.0 ± 0.2, 12.3 ± 0.2,12.8 ± 0.2, 13.9 ± 0.2, 14.2 ± 0.2, 17.6 ± 0.2, 17.8 ± 0.2, 19.2 ± 0.2, 19.4 ± 0.2, 19.6 ± 0.2, and 20.4 ± 0.2 degrees two thêta.
In another embodiment, the présent invention provides crystalline (-) 4-(5-(2(difluoromethyl)-3-ethoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol having an X-ray powder diffraction pattern comprising diffraction peaks 8.9 ± 0.2, 12.0 ± 0.2, 12.3 ± 0.2,12.8 ±
0.2, 13.9 ± 0.2, 14.2 ± 0.2, 17.6 ± 0.2, 17.8 ± 0.2, 19.2 ± 0.2, 19.4 ± 0.2, 19.6 ± 0.2, 20.4 ± 0.2,
21.4 ± 0.2, 22.0 ± 0.2, 22.3 ± 0.2, 22.9 ± 0.2, 23.1 ± 0.2, and 25.7 ± 0.2 degrees two thêta.
In another embodiment, the présent invention provides crystalline (-) 4-(5-(2(difluoromethyl)-3-ethoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol having an X-ray powder diffraction pattern comprising 3 to 10 diffraction peaks listed in Table 10.
In another embodiment, the présent invention provides crystalline (-) 4-(5-(2(difluoromethyl)-3-ethoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol having an X-ray powder diffraction pattern comprising the diffraction peaks listed in Table 10.
In another embodiment, the présent invention provides crystalline (-) 4-(5-(2(difluoromethyl)-3-ethoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol having an X-ray powder diffraction pattern as depicted in Figure 8.
In another embodiment, the présent invention provides a pharmaceutical composition comprising crystalline (-) 4-(5-(2-(difluoromethyl)-3-ethoxy-4-methoxyphenyl)pyridin-3-yl)-1,2oxaborolan-2-ol and at least one pharmaceutically acceptable excipient, diluent, or carrier.
In another embodiment, the présent invention provides a method for treating or preventing an inflammatory disease in a human comprising administering to the human in need of such treatment a therapeutically effective amount of crystalline (-) 4-(5-(2-(difluoromethyl)-3ethoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol.
In another embodiment, the présent invention provides a method for treating or preventing atopie dermatitis, hand dermatitis, contact dermatitis, allergie contact dermatitis, irritant contact dermatitis, neurodermatitis, perioral dermatitis, stasis dermatitis, dyshidrotic eczema, xerotic dermatitis, nummalar dermatitis, seborrheic dermatitis, eyelid dermatitis, diaper dermatitis, dermatomyositis, lichen planus, lichen sclerosis, alopecia areata, vitiligo, rosacea, epidermolysis bullosa, keratosis pilaris, pityriasis alba, pemphigus, vulvovaginitis, acné, chronic spontaneous urticaria, chronic idiopathic urticaria, chronic physical urticaria, vogt-koyanagiharada disease, sutton nevus/nevi, post inflammatory hypopigmentation, senile leukoderma, chemical/drug-induced leukoderma, cutaneous lupus erythematosus, discoid lupus, palmoplantar pustulosis, pemphigoid, sweet's syndrome, hidradenitis suppurativa, psoriasis, plaque psoriasis, pustular psoriasis, nail psoriasis, flexural psoriasis, guttate psoriasis, psoriatic arthritis, érythrodermie psoriasis, or inverse psoriasis in a human comprising administering to the human in need of such treatment a therapeutically effective amount of crystalline (-) 4-(5-(2(difluoromethyl)-3-ethoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol.
In another embodiment, the présent invention provides a method for treating or preventing atopie dermatitis, hand dermatitis, contact dermatitis, allergie contact dermatitis, irritant contact dermatitis, neurodermatitis, perioral dermatitis, stasis dermatitis, dyshidrotic eczema, xerotic dermatitis, nummalar dermatitis, seborrheic dermatitis, eyelid dermatitis, diaper dermatitis, dermatomyositis, lichen planus, lichen sclerosis, alopecia areata, vitiligo, rosacea, epidermolysis bullosa, keratosis pilaris, pityriasis alba, pemphigus, vulvovaginitis, acné, chronic spontaneous urticaria, chronic idiopathic urticaria, chronic physical urticaria, vogt-koyanagiharada disease, sutton nevus/nevi, post inflammatory hypopigmentation, senile leukoderma, chemical/drug-induced leukoderma, cutaneous lupus erythematosus, discoid lupus, palmoplantar pustulosis, pemphigoid, sweet's syndrome, hidradenitis suppurativa, psoriasis, plaque psoriasis, pustular psoriasis, nail psoriasis, flexural psoriasis, guttate psoriasis, psoriatic arthritis, érythrodermie psoriasis, or inverse psoriasis in a human comprising topically administering to the human in need of such treatment a therapeutically effective amount of crystalline (-) 4-(5-(2-(difluoromethyl)-3-ethoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2ol in the form of a transdermal patch, an ointment, a lotion, a cream, or a gel.
In another embodiment, the présent invention provides a method for treating or preventing an arthritis, asthma, fibrosis, lupus, allergy, fibromyalgia, wound healing, or inflammation resulting from surgical complications in a human comprising administering to the human in need of such treatment a therapeutically effective amount of crystalline (-) 4-(5-(2(difluoromethyl)-3-ethoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol.
In another embodiment, the présent invention provides a method for treating or preventing an arthritis, asthma, fibrosis, lupus, allergy, fibromyalgia, wound healing, or inflammation resulting from surgical complications in a human comprising topically administering to the human in need of such treatment a therapeutically effective amount of crystalline (-) 4-(5(2-(difluoromethyl)-3-ethoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol in the form of a transdermal patch, an ointment, a lotion, a cream, or a gel.
In another embodiment, the présent invention provides a method for treating or preventing inflammatory bowel disease, ulcerative colitis, or Crohn’s disease in a human comprising administering to the human in need of such treatment a therapeutically effective amount of crystalline (-) 4-(5-(2-(difluoromethyl)-3-ethoxy-4-methoxyphenyl)pyridin-3-yl)-1,2oxaborolan-2-ol.
In another embodiment, the présent invention provides the use of crystalline (-) 4-(5-(2(difluoromethyl)-3-ethoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol in the manufacture of a médicament for treating an inflammatory disease in a human.
In another embodiment, the présent invention provides the use of crystalline (-) 4-(5-(2(difluoromethyl)-3-ethoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol in the manufacture of a médicament for treating atopie dermatitis, hand dermatitis, contact dermatitis, allergie contact dermatitis, irritant contact dermatitis, neurodermatitis, perioral dermatitis, stasis dermatitis, dyshidrotic eczema, xerotic dermatitis, nummalar dermatitis, seborrheic dermatitis, eyelid dermatitis, diaper dermatitis, dermatomyositis, lichen planus, lichen sclerosis, alopecia areata, vitiligo, rosacea, epidermolysis bullosa, keratosis pilaris, pityriasis alba, pemphigus, vulvovaginitis, acné, chronic spontaneous urticaria, chronic idiopathic urticaria, chronic physical urticaria, vogt-koyanagi-harada disease, sutton nevus/nevi, post inflammatory hypopigmentation, senile leukoderma, chemical/drug-induced leukoderma, cutaneous lupus erythematosus, discoid lupus, palmoplantar pustulosis, pemphigoid, sweet's syndrome, hidradenitis suppurativa, psoriasis, plaque psoriasis, pustular psoriasis, nail psoriasis, flexural psoriasis, guttate psoriasis, psoriatic arthritis, érythrodermie psoriasis, or inverse psoriasis in a human.
In another embodiment, the présent invention provides the use of crystalline (-) 4-(5-(2(difluoromethyl)-3-ethoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol in the manufacture of a médicament for treating arthritis, asthma, fibrosis, lupus, allergy, fibromyalgia, wound healing, or inflammation resulting from surgical complications in a human.
In another embodiment, the présent invention provides the use of crystalline (-) 4-(5-(2(difluoromethyl)-3-ethoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol in the manufacture of a médicament for treating inflammatory bowel disease, ulcerative colitis, or Crohn’s disease in a human.
In another embodiment, the présent invention provides crystalline (R) 4-(5-(3-ethoxy-4methoxyphenyl)-6-methylpyridin-3-yl)-1,2-oxaborolan-2-ol.
In another embodiment, the présent invention provides crystalline (R) 4-(5-(3-ethoxy-4methoxyphenyl)-6-methylpyridin-3-yl)-1,2-oxaborolan-2-ol having an X-ray powder diffraction pattern comprising diffraction peaks 21.1 ± 0.2, 22.7 ± 0.2, and 23.8 ± 0.2 degrees two thêta.
In another embodiment, the présent invention provides crystalline (R) 4-(5-(3-ethoxy-4methoxyphenyl)-6-methylpyridin-3-yl)-1,2-oxaborolan-2-ol having an X-ray powder diffraction pattern comprising diffraction peaks 10.9 ± 0.2, 11.3 ± 0.2, 19.3 ± 0.2, 21.1 ± 0.2, 22.7 ± 0.2, 23.8 ± 0.2, and 30.4 ± 0.2 degrees two thêta.
In another embodiment, the présent invention provides crystalline (R) 4-(5-(3-ethoxy-4methoxyphenyl)-6-methylpyridin-3-yl)-1,2-oxaborolan-2-ol having an X-ray powder diffraction pattern comprising diffraction peaks 10.9 ± 0.2, 11.3 ± 0.2, 17.0 ± 0.2, 17.3 ± 0.2, 19.3 ± 0.2, 21.1 ± 0.2, 22.7 ± 0.2, 23.8 ± 0.2, and 30.4 ± 0.2 degrees two thêta.
In another embodiment, the présent invention provides crystalline (R) 4-(5-(3-ethoxy-4methoxyphenyl)-6-methylpyridin-3-yl)-1,2-oxaborolan-2-ol having an X-ray powder diffraction pattern comprising diffraction peaks 10.9 ± 0.2, 11.3 ± 0.2, 17.0 ± 0.2, 17.3 ± 0.2, 19.0 ± 0.2, 19.3 ± 0.2, 21.1 ± 0.2, 22.7 ± 0.2, 23.8 ± 0.2, 25.4 ± 0.2, 26.5 ± 0.2, and 30.4 ± 0.2 degrees two thêta.
In another embodiment, the présent invention provides crystalline (R) 4-(5-(3-ethoxy-4methoxyphenyl)-6-methylpyridin-3-yl)-1,2-oxaborolan-2-ol having an X-ray powder diffraction pattern comprising 3 to 10 diffraction peaks listed in Table 11.
In another embodiment, the présent invention provides crystalline (R) 4-(5-(3-ethoxy-4methoxyphenyl)-6-methylpyridin-3-yl)-1,2-oxaborolan-2-ol having an X-ray powder diffraction pattern comprising the diffraction peaks listed in Table 11.
In another embodiment, the présent invention provides crystalline (R) 4-(5-(3-ethoxy-4methoxyphenyl)-6-methylpyridin-3-yl)-1,2-oxaborolan-2-ol having an X-ray powder diffraction pattern as depicted in Figure 9.
In another embodiment, the présent invention provides a pharmaceutical composition comprising crystalline (R) 4-(5-(3-ethoxy-4-methoxyphenyl)-6-methylpyridin-3-yl)-1,2oxaborolan-2-ol and at least one pharmaceutically acceptable excipient, diluent, or carrier.
In another embodiment, the présent invention provides a method for treating or preventing an inflammatory disease in a human comprising administering to the human in need of such treatment a therapeutically effective amount of crystalline (R) 4-(5-(3-ethoxy-4methoxyphenyl)-6-methylpyridin-3-yl)-1,2-oxaborolan-2-ol.
In another embodiment, the présent invention provides a method for treating or preventing atopie dermatitis, hand dermatitis, contact dermatitis, allergie contact dermatitis, irritant contact dermatitis, neurodermatitis, perioral dermatitis, stasis dermatitis, dyshidrotic eczema, xerotic dermatitis, nummalar dermatitis, seborrheic dermatitis, eyelid dermatitis, diaper dermatitis, dermatomyositis, lichen planus, lichen sclerosis, alopecia areata, vitiligo, rosacea, epidermolysis bullosa, keratosis pilaris, pityriasis alba, pemphigus, vulvovaginitis, acné, chronic spontaneous urticaria, chronic idiopathic urticaria, chronic physical urticaria, vogt-koyanagiharada disease, sutton nevus/nevi, post inflammatory hypopigmentation, senile leukoderma, chemical/drug-induced leukoderma, cutaneous lupus erythematosus, discoid lupus, palmoplantar pustulosis, pemphigoid, sweet's syndrome, hidradenitis suppurativa, psoriasis, plaque psoriasis, pustular psoriasis, nail psoriasis, flexural psoriasis, guttate psoriasis, psoriatic arthritis, érythrodermie psoriasis, or inverse psoriasis in a human comprising administering to the human in need of such treatment a therapeutically effective amount of crystalline (R) 4-(5(3-ethoxy-4-methoxyphenyl)-6-methylpyridin-3-yl)-1,2-oxaborolan-2-ol.
In another embodiment, the présent invention provides a method for treating or preventing atopie dermatitis, hand dermatitis, contact dermatitis, allergie contact dermatitis, irritant contact dermatitis, neurodermatitis, perioral dermatitis, stasis dermatitis, dyshidrotic eczema, xerotic dermatitis, nummalar dermatitis, seborrheic dermatitis, eyelid dermatitis, diaper dermatitis, dermatomyositis, lichen planus, lichen sclerosis, alopecia areata, vitiligo, rosacea, epidermolysis bullosa, keratosis pilaris, pityriasis alba, pemphigus, vulvovaginitis, acné, chronic spontaneous urticaria, chronic idiopathic urticaria, chronic physical urticaria, vogt-koyanagiharada disease, sutton nevus/nevi, post inflammatory hypopigmentation, senile leukoderma, chemical/drug-induced leukoderma, cutaneous lupus erythematosus, discoid lupus, palmoplantar pustulosis, pemphigoid, sweet's syndrome, hidradenitis suppurativa, psoriasis, plaque psoriasis, pustular psoriasis, nail psoriasis, flexural psoriasis, guttate psoriasis, psoriatic arthritis, érythrodermie psoriasis, or inverse psoriasis in a human comprising topically administering to the human in need of such treatment a therapeutically effective amount of crystalline (R) 4-(5-(3-ethoxy-4-methoxyphenyl)-6-methylpyridin-3-yl)-1,2-oxaborolan-2-ol in the form of a transdermal patch, an omtment, a lotion, a cream, or a gel.
In another embodiment, the present invention provides a method for treating or preventing an arthritis, asthma, fibrosis, lupus, allergy, fibromyalgia, wound healing, or inflammation resulting from surgical complications in a human comprising administering to the human in need of such treatment a therapeutically effective amount of crystalline (R) 4-(5-(3ethoxy-4-methoxyphenyl)-6-methylpyridin-3-yl)-1,2-oxaborolan-2-ol.
In another embodiment, the present invention provides a method for treating or preventing an arthritis, asthma, fibrosis, lupus, allergy, fibromyalgia, wound healing, or inflammation resulting from surgical complications in a human comprising topically administering to the human in need of such treatment a therapeutically effective amount of crystalline (R) 4-(5(3-ethoxy-4-methoxyphenyl)-6-methylpyridin-3-yl)-1,2-oxaborolan-2-ol in the form of a transdermal patch, an ointment, a lotion, a cream, or a gel.
In another embodiment, the present invention provides a method for treating or preventing inflammatory bowel disease, ulcerative colitis, or Crohn’s disease in a human comprising administering to the human in need of such treatment a therapeutically effective amount of crystalline (R) 4-(5-(3-ethoxy-4-methoxyphenyl)-6-methylpyridin-3-yl)-1,2-oxaborolan2-ol.
In another embodiment, the present invention provides the use of crystalline (R) 4-(5-(3ethoxy-4-methoxyphenyl)-6-methylpyridin-3-yl)-1,2-oxaborolan-2-ol in the manufacture of a médicament for treating an inflammatory disease in a human.
In another embodiment, the present invention provides the use of crystalline (R) 4-(5-(3ethoxy-4-methoxyphenyl)-6-methylpyridin-3-yl)-1,2-oxaborolan-2-ol in the manufacture of a médicament for treating atopie dermatitis, hand dermatitis, contact dermatitis, allergie contact dermatitis, irritant contact dermatitis, neurodermatitis, perioral dermatitis, stasis dermatitis, dyshidrotic eczema, xerotic dermatitis, nummalar dermatitis, seborrheic dermatitis, eyelid dermatitis, diaper dermatitis, dermatomyositis, lichen planus, lichen sclerosis, alopecia areata, vitiligo, rosacea, epidermolysis bullosa, keratosis pilaris, pityriasis alba, pemphigus, vulvovaginitis, acné, chronic spontaneous urticaria, chronic idiopathic urticaria, chronic physical urticaria, vogt-koyanagi-harada disease, sutton nevus/nevi, post inflammatory hypopigmentation, senile leukoderma, chemical/drug-induced leukoderma, cutaneous lupus erythematosus, discoid lupus, palmoplantar pustulosis, pemphigoid, sweet's syndrome, hidradenitis suppurativa, psoriasis, plaque psoriasis, pustular psoriasis, nail psoriasis, flexural psoriasis, guttate psoriasis, psoriatic arthritis, érythrodermie psoriasis, or inverse psoriasis in a human.
In another embodiment, the present invention provides the use of crystalline (R) 4-(5-(3ethoxy-4-methoxyphenyl)-6-methylpyridin-3-yl)-1,2-oxaborolan-2-ol in the manufacture of a médicament for treating arthritis, asthma, fibrosis, lupus, allergy, fibromyalgia, wound healing, or inflammation resulting from surgical complications in a human.
In another embodiment, the présent invention provides the use of crystalline (R) 4-(5-(3ethoxy-4-methoxyphenyl)-6-methylpyridin-3-yl)-1,2-oxaborolan-2-ol in the manufacture of a médicament for treating inflammatory bowel disease, ulcerative colitis, or Crohn’s disease in a human.
In another embodiment, the présent invention provides pharmaceutical combinations for topical administration comprising a compound of Formula (I), Formula (IA), Formula (IB), or Formula (IC), or a pharmaceutically acceptable sait thereof, in combination with another pharmaceutical agent for the treatment ofthe diseases, conditions and/or disorders described herein. Suitable pharmaceutical agents that may be used in combination with the compounds of the présent invention for topical administration include, but are not limited to: a second compound of Formula (I), Formula (IA), Formula (IB), or Formula (IC); a PDE4 isoenzyme inhibitor including, but not limited to, crisaborole, ampremilast, roflumilast, rolipram and piclamilast; a corticosteroid including, but not limited to, fluocinonide, desoximetasone, mometasone, triamcinolone, betamethasone, alclometasone, desonide, hydrocortisone and mapracorat; a calcineurin inhibitor including, but not limited to, tacrolimus, pimecrolimus and cyclosporine; a JAK inhibitor including, but not limited to, tofacitinib, ATI-502, SNA-152, SHR0302, JTE052, BMS-986165, filgotinib, baricitinib, upadacitinib, ruxolitinib, peficitinib, PF04965842, PF-06651600, PF-06700841, and PF06826647; an aryl hydrocarbon receptor agonist including, but not limited to, tapinarof; an IRAK4 inhibitor including, but not limited to, PF-06650833; a non-steroidal anti-inflammatory including, but not limited to, WBI-1001 and MRX-6; vitamin D analog such as calcipotriene; retinoic acid dérivatives including, but not limited to, alitretinoin; a liver X receptor (LXR) sélective agonist including, but not limited to, VTP-38543; a H4 receptor antagonists including, but not limited to, ZPL-389; a NKI receptor antagonists including, but not limited to, Aprepitant and Tradipitant; a CRTH2 receptor antagonists including, but not limited to, Fevipiprant and OC-459; a Chymase inhibitors including, but not limited to, SUN 13834; a GATA-3 inhibitors including, but not limited to, SB011 and GR-MD-02; and a ROR inverse agonists including, but not limited to, VTP-43742, ARN6039, TAK-828 and JTE-451; immunomodulators such as PF-06763809, and inhibitors of SYK, BTK, and ITK, including but not limited to, R-348, cerdulatinib, ibrutinib, entospletinib, tirabrutinib, and JTE-051.
In another embodiment, the présent invention provides pharmaceutical combinations for oral administration comprising a compound of Formula (I), Formula (IA), Formula (IB), or Formula (IC), or a pharmaceutically acceptable sait thereof, in combination with another pharmaceutical agent for the treatment ofthe diseases, conditions and/or disorders described herein. Suitable pharmaceutical agents that may be used in combination with the compounds of the présent invention for oral administration include, but are not limited to: oral retinoic acid dérivatives including, but not limited to, alitretinoin; oral liver X receptor (LXR) sélective agonists including, but not limited to, vTP-38543; oral H4 receptor antagonists including, but not limited to, ZPL-389; oral NKI receptor antagonists including, but not limited to, Aprepitant and Tradipitant; oral CRTH2 receptor antagonists including, but not limited to, Fevipiprant and OC459; oral Chymase inhibitors including, but not limited to, SUN 13834; oral GATA-3 inhibitors including, but not limited to, SB-011; oral ROR inverse agonists including, but not limited to, VTP-43742, ARN6039, TAK-828 and JTE-451; oral JAK inhibitors including, but not limited to, baricitinib, cerdulatinib, decernotinib, delgocitinib, fedratinib, filgotinib, gandotinib, ilginatinib, itacitinib, lestaurtinib, momelotinib, oclacitinib, pacritinib, peficitinib, ruxolitinib, tofacitinib, upadacitinib, ASN-002, AT9283, ATI-501, ATI-502, AZD1480, AZD4205, BMS-911543, BMS986165, INCB-52793, INCB-54707, PF-04965842, PF-06263276, PF-06651600, PF-06700841, PF-06826647, SHR-0302, SNA-125, orTD-1473; immunomodulators and inhibitors of SYK, BTK, and ITK, including but not limited to, fostamatinib, ibrutinib, mastinib, mivavotinib, entospletinib, sperbrutinib, tirabrutinib, fenebrutinib, TOP-1288, R-348, cerdulatinib, SKI-O-703, TAS-05567, CG-806, R-343, CG-103065, PRT-2607, GSK-143, VRT-750018, UR-67767, PRN1008, BMS-935177, PRN-473, ABBV-105, AS-550, M-7583, WXFL-10230486, LOU-064, AEG42766, HCI-1401, KBP-7536, ARQ-531, GNE-4997, and GNE-9822; and oral IRAK4 inhibitors including, but not limited to, PF-06650833 and BAY-1830839.
In another embodiment, the présent invention provides pharmaceutical combinations for injectable administration comprising a compound of Formula (I), Formula (IA), Formula (IB), or Formula (IC), or a pharmaceutically acceptable sait thereof, in combination with another pharmaceutical agent for the treatment ofthe diseases, conditions and/or disorders described herein. Suitable pharmaceutical agents that may be used in combination with the compounds of the présent invention for injectable administration include, but are not limited to: TNFa inhibitors including, but not limited to, infliximab, adalimumab, golimumab, certolizumab pegol; injectable anti-IL4, IL-12, IL-17, IL-22, IL-23, IL-31, IL-33, IgE treatments such as dupilumab, lebrikizumab, nemolizumab, tralokinumab, etanercept, adalimumab, infliximab, ustekinumab, secukinumab, OmaZumilab, and CIM-331.
Combination therapy includes administration ofthe two or more therapeutic agents concurrently or sequentially. The agents may be administered in any order. Altematively, the multiple therapeutic agents can be combined into a single composition that can be administered to the patient. For instance, a single pharmaceutical composition could comprise the compound or pharmaceutically acceptable sait, ester or prodrug thereof according to the Formulae (I), (IA), (IB), and (IC), another therapeutic agent or a pharmaceutically acceptable sait, ester or prodrug thereof, and at least one pharmaceutically acceptable excipient or carrier.
When used in the above or other treatments, a therapeutically effective amount of one of the compounds ofthe présent invention can be employed in pure form or, where such forms exist, in pharmaceutically acceptable sait, ester, amide, or prodrug form. Altematively, the compound can be administered as a pharmaceutical composition containing the compound of interest m combination with one or more pharmaceutically acceptable carriers. The phrase therapeutically effective amount ofthe compound ofthe présent invention means a sufficient amount ofthe compound to treat the diseases, conditions, or disorders indicated herein at a reasonable benefit/risk ratio applicable to any medical treatment. The spécifie therapeutically effective dose level for any particular patient will dépend upon a variety of factors including the disorder being treated and the severity ofthe disorder; activity ofthe spécifie compound employed; the spécifie composition employed; the âge, body weight, general health, sex and diet ofthe patient; the time of administration, route of administration, and rate of excrétion ofthe spécifie compound employed; the duration of the treatment; drugs used in combination or coincidental with the spécifie compound employed; and like factors well known in the medical arts.
Pharmaceutical Compositions or Formulations
In another embodiment, the présent invention provides pharmaceutical compositions, or formulations, comprising a therapeutically effective amount of a compound ofthe présent invention and a pharmaceutically acceptable excipient, diluent or carrier. The pharmaceutical compositions, or formulations, ofthis invention may be administered to humans and other mammals topically, orally, parenterally, intracisternally, intravaginally, intraperitoneally, bucally, as an oral spray, as a nasal spray, rectally as a suppository, or in the form of a liposome.
A typical pharmaceutical composition or formulation is prepared by mixing a compound ofthe présent invention and a carrier, diluent or excipient. Suitable carriers, diluents and excipients include materials such as carbohydrates, waxes, water soluble and/or swellable polymers, hydrophilic or hydrophobie materials, gelatin, oils, solvents, water, and the like. The particular carrier, diluent or excipient used will dépend upon the means and purpose for which the compound ofthe présent invention is being applied. Suitable aqueous solvents include water, éthanol, propylene glycol, polyethylene glycols (e.g., PEG400, PEG300), etc. and mixtures thereof. The formulations may also include one or more buffers, stabilizing agents, surfactants, wetting agents, lubricating agents, emulsifiers, suspending agents, preservatives, antioxidants, opaquing agents, glidants, processing aids, colorants, sweeteners, perfuming agents, flavoring agents and other known additives to provide an élégant présentation ofthe drug (i.e., a compound ofthe présent invention or pharmaceutical composition thereof) or aid in the manufacturing ofthe pharmaceutical product (i.e., for use in the preparing a médicament).
The formulations may be prepared using conventional dissolution and mixing procedures. For example, the bulk drug substance (i.e., compound of the présent invention or stabilized form ofthe compound (e.g., complex with a cyclodextrin dérivative or other known complexation agent)) is dissolved in a suitable solvent in the presence of one or more ofthe excipients described above. The dissolution rate of poorly water-soluble compounds may be enhanced by the use of a spray-dried dispersion, such as those described by Takeuchi, H., et al. in “Enhancement ofthe dissolution rate of a poorly water-soluble drug (tolbutamide) by a spray-drying solvent déposition method and disintegrants’ J. Pharm. Pharmacol., 39, 769-773 (1987); and EP0901786 B1 (US2002/009494), incorporated herein by reference. The compound of the présent invention is typically formulated into pharmaceutical dosage forms to provide an easily controllable dosage ofthe drug and to give the patient an élégant and easily handleable product.
The pharmaceutical composition, or formulation, for application may be packaged in a variety of ways depending upon the method used for administering the drug. Generally, an article for distribution includes a container having deposited therein the pharmaceutical formulation in an appropriate form. Suitable containers include materials such as bottles (plastic and glass), sachets, ampoules, plastic bags, métal cylinders, and the like. The container may also include a tamper-proof assemblage to prevent indiscreet access to the contents ofthe package. In addition, the container has deposited thereon a label that describes the contents of the container. The label may also include appropriate warnings.
The term pharmaceutically acceptable carrier refers to carrier medium that provides the appropriate delivery of an effective amount of a active agent as defined herein, does not interfère with the effectiveness ofthe biological activity ofthe active agent, and that is sufficiently non-toxic to the host or patient. Représentative carriers include water, oils, both vegetable and minerai, cream bases, lotion bases, ointment bases and the like. These bases include suspending agents, thickeners, pénétration enhancers, and the like. Additional information concerning carriers can be found in Remington: The Science and Practice of Pharmacy, 21st Ed., Lippincott, Williams & Wilkins (2005) which is incorporated herein by reference. Further examples of materials which can serve as pharmaceutically acceptable carriers are sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols; such a propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnésium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonie saline; Ringer's solution; ethyl alcohol, and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium lauryl sulfate and magnésium stéarate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be présent in the composition, according to the judgment ofthe formulator.
The term “pharmaceutically acceptable topical carrier refers to pharmaceutically acceptable carriers, as described herein above, suitable for topical application. An inactive liquid or cream vehicle capable of suspending or dissolving the active agent(s), and having the properties of being nontoxic and non-inflammatory when applied to the skin, nail, hair, claw or hoof is an example of a pharmaceutically-acceptable topical carrier. This term is specifîcally intended to encompass carrier matenals approved for use m topical cosmetics as well.
The term topical administration refers to the application of a pharmaceutical agent to the external surface ofthe skin, nail, hair, claw or hoof, such that the agent crosses the external surface ofthe skin, nail, hair, claw or hoof and enters the underlying tissues. Topical administration includes application of the composition to intact skin, nail, hair, claw or hoof, or to a broken, raw or open wound of skin, nail, hair, claw or hoof. Topical administration of a pharmaceutical agent can resuit in a limited distribution ofthe agent to the skin and surrounding tissues or, when the agent is removed from the treatment area by the bloodstream, can resuit in systemic distribution ofthe agent.
Dosage forms for topical or transdermal administration of a compound of this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. The active component is admixed under stérile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required. Compounds that are volatile in may require admixture with spécial formulating agents or with spécial packaging materials to assure proper dosage delivery. In addition, compounds ofthe présent invention that hâve poor human skin permeability may require one or more permeability enhancers whereas compounds rapidly absorbed through the skin may require formulation with absorption-retarding agents or barriers.
The ointments, pastes, creams, lotions, gels, powders, and solutions, for topical administration may contain, in addition to an active compound ofthe présent invention, pharmaceutically acceptable excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose dérivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc, zinc oxide, preservatives, antioxidants, fragrances, emulsifiers, dyes, inert fillers, anti-irritants, tackifiers, fragrances, opacifiers, antioxidants, gelling agents, stabilizers, surfactants, émollients, coloring agents, preservatives, buffering agents, perméation enhancers, or mixtures thereof. Topical excipients should not interfère with the effectiveness ofthe biological activity ofthe active agent and not be deleterious to the épithélial cells or their function.
The terms permeability enhancer, or “perméation enhancer,” relates to an increase in the permeability ofthe skin, nail, hair, claw or hoof to a drug, so as to increase the rate at which the drug permeates through the skin, nail, hair, claw or hoof. The enhanced perméation effected through the use of such enhancers can be observed, for example, by measuring the rate of diffusion ofthe drug through animal or human skin, nail, hair, claw or hoof using a diffusion cell apparatus. A diffusion cell is described by Merritt et al. Diffusion Apparatus for Skin Pénétration, J of Controlled Release, 1 (1984) pp. 161-162. The term perméation enhancer or pénétration enhancer intends an agent or a mixture of agents, which, alone or in combination, act to increase the permeability ofthe skin, nail, hair or hoof to a drug.
The term transdermal delivery refers to the diffusion of an agent across the barrier of the skm, nail, haïr, claw or hoof resulting from topical administration or other application of a composition. The stratum corneum acts as a barrier and few pharmaceutical agents are able to penetrate intact skin. In contrast, the epidermis and dermis are permeable to many solutés and absorption of drugs therefore occurs more readily through skin, nail, hair, claw or hoof that is abraded or otherwise stripped ofthe stratum corneum to expose the epidermis. Transdermal delivery includes injection or other delivery through any portion ofthe skin, nail, hair, claw or hoof or mucous membrane and absorption or perméation through the remaining portion. Absorption through intact skin, nail, hair, claw or hoof can be enhanced by placing the active agent in an appropriate pharmaceutically acceptable vehicle before application to the skin, nail, hair, claw or hoof. Passive topical administration may consist of applying the active agent directly to the treatment site in combination with émollients or pénétration enhancers. As used herein, transdermal delivery is intended to include delivery by perméation through or past the integument, i.e. skin, nail, hair, claw or hoof.
Powders and sprays can contain, in addition to the compounds of this invention, lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants such as chlorofluorohydrocarbons.
Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert pharmaceutically acceptable carrier such as sodium citrate or calcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and salicylic acid; b) binders such as carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia; c) humectants such as glycerol; d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; e) solution retarding agents such as paraffin; f) absorption accelerators such as quaternary ammonium compounds; g) wetting agents such as cetyl alcohol and glycerol monostearate; h) absorbents such as kaolin and bentonite clay; and i) lubricants such as talc, calcium stéarate, magnésium stéarate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.
Solid compositions of a similar type may also be employed as fillers in soft and hardfilled gelatin capsules using lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part ofthe intestinal tract in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes.
Liquid dosage forms for oral administration include pharmaceutically acceptable émulsions, microemulsions, solutions, suspensions, syrups and élixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
The term parenterally, as used herein, refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous, intraarticular injection and infusion. Pharmaceutical compositions of this invention for parentéral injection comprise pharmaceutically acceptable stérile aqueous or nonaqueous solutions, dispersions, suspensions or émulsions and stérile powders for reconstitution into stérile injectable solutions or dispersions. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, éthanol, polyols (propylene glycol, polyethylene glycol, glycerol, and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate. Proper fluidity may be maintained, for example, by the use of a coating such as lecithin, by the maintenance ofthe required particle size in the case of dispersions, and by the use of surfactants.
Injectable depot forms are made by forming microencapsulated matrices ofthe drug in biodégradable polymers such as polylactide-polyglycolide. Depending upon the ratio of drug to polymer and the nature ofthe particular polymer employed, the rate of drug release can be controlled. Examples of other biodégradable polymers include poly(orthoesters) and poly(anhydrides) Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissues.
The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter or by incorporating sterilizing agents in the form of stérile solid compositions which can be dissolved or dispersed in stérile water or other stérile injectable medium just prior to use.
Injectable préparations, for example, stérile injectable aqueous or oleaginous suspensions may be formulated using suitable dispersing or wetting agents and suspending agents. The stérile injectable préparation may also be a stérile injectable solution, suspension or émulsion in a nontoxic, parenterally acceptable diluent or solvent such as a solution in 1,3butanediol. Among the acceptable vehicles and solvents that may be employed are water,
Ringer's solution, U.S.P. and isotonie sodium chloride solution.
In addition, stérile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the préparation of injectables.
Pharmaceutical compositions, or formulations, for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient température but liquid at body température and therefore melt in the rectum or vaginal cavity and release the active compound.
Compounds ofthe présent invention may also be administered in the form of liposomes. Liposomes are generally derived from phospholipids or other lipid substances and are formed by mono- or multi-lamellar hydrated liquid crystals that are dispersed in an aqueous medium. Any non-toxic, physiologically acceptable and metabolizable lipid capable of forming liposomes may be used. The présent compositions in liposome form may contain, in addition to the compounds ofthe présent invention, stabilizers, preservatives, and the like. The preferred lipids are the natural and synthetic phospholipids and phosphatidylcholines (lecithins) used separateiy or together. Methods to form liposomes are known in the art. See, for example, Prescott, Ed., Methods in Cell Biology, Volume XIV, Academie Press, New York, N. Y., (1976), p 33 et seq.
Pharmaceutical compositions, or formulations, ofthe présent invention may also contain adjuvants such as preservative agents, wetting agents, emulsifying agents, and dispersing agents. Prévention ofthe action of microorganisms may be ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phénol, sorbic acid, and the like. It may also be désirable to include isotonie agents, for example, sugars, sodium chloride and the like. Proionged absorption ofthe injectable pharmaceutical form may be brought about by the use of agents delaying absorption, for example, aluminum monostearate and gelatin.
The pharmaceutical compositions, or formulations, ofthe invention may be suspensions. Suspensions, in addition to the active compounds, may contain suspending agents, as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, tragacanth, and mixtures thereof.
The pharmaceutical compositions also include solvatés and hydrates ofthe compounds of the présent invention. The term “solvaté” refers to a molecular complex of a compound represented by Formulae (I), (IA), (IB), and (IC), including pharmaceutically acceptable salts thereof, with one or more solvent molécules. Such solvent molécules are those commonly used in the pharmaceutical art, which are known to be innocuous to the récipient, e.g., water, éthanol, ethylene glycol, (S)-propylene glycol, (R)-propylene glycol, and the like, The term “hydrate” refers to the complex where the solvent molécule is water. The solvatés and/or hydrates preferably exist in crystalline form. Other solvents may be used as intermediate solvatés in the préparation of more désirable solvatés. Intermediate solvents include, but are not limited to, methanol, methyl t-butyl ether, ethyl acetate, methyl acetate, 1,4-butyne-diol, and the like.
Actual dosage levels of active ingrédients in the pharmaceutical compositions of this invention may be varied so as to obtain an amount ofthe active compound(s) that is effective to achieve the desired therapeutic response for a particular patient, compositions, and mode of administration. The selected dosage level will dépend upon the activity ofthe particular compound, the route of administration, the severity ofthe condition being treated, and the condition and prior medical history ofthe patient being treated. However, it is within the skiil of the art to start doses of the compound at levels lower than required for to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved.
The total daily dose ofthe compounds of this invention administered to a human or lower animal may range from about 0.000001 to about 10 mg/kg/day. For purposes of oral administration, more préférable doses can be in the range of from about 0.001 to about 1 mg/kg/day. For topical administration, more préférable doses can be in the range of 0.00001 mg/kg/day to about 5 mg/kg/day. If desired, the effective daily dose can be divided into multiple doses for purposes of administration, e.g. two to four separate doses per day.
Définitions
As used throughout this spécification and the appended claims, the following terms hâve the following meanings:
The term (C2-C6)alkenyl as used herein, means a straight or branched chain hydrocarbon containing from 2 to 6 carbons and containing at least one carbon-carbon double bond. Représentative examples of (C2-C6)alkenyl include, but are not limited to, ethenyl, 2-propenyl, 2-methyl-2-propenyl, 3-butenyl, 4-pentenyl, and 5-hexenyl.
The term (C2-C6)alkenyloxy as used herein, means a (C2-C6)alkenyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom.
The term (C2-Cs)alkenylthio as used herein, means a (C2-Cs)alkenyl group, as defined herein, appended to the parent molecular moiety through a sulfur atom.
The term (Ci-C6)alkoxy as used herein, means a (Ci-Ce)alkyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom. Représentative examples of (Ci-Ce)alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, 2-propoxy, butoxy, tertbutoxy, pentyloxy, and hexyloxy.
The term (Ci-C6)alkoxy-c/i-i3 as used herein, means a (Ci-C6)alkyl-di-i3, group, as defined herein, appended to the parent molecular moiety through an oxygen atom. Représentative examples of (Ci-C6)alkoxy-di-i3 include, but are not limited to, methoxy-d3, ethoxy-d5, propoxy-d7, 2-propoxy-d7, butoxy-d9, tert-butoxy-d9, pentyloxy-dn, and hexyloxy-di3.
The term (Ci-C6)alkoxy(Ci-C6)alkoxy as used herein, means a (CrCejalkoxy group, as defined herein, appended to the parent molecular moiety through another (Ci-C6)alkoxy group, as defined herein. Représentative examples of (Ci-Cs)alkoxy(Ci-Cs)alkoxy include, but are not limited to, tert-butoxymethoxy, 2-ethoxyethoxy, 2-methoxyethoxy, and methoxymethoxy.
The term (Ci-C6)alkoxy(Ci-C6)alkyl as used herein, means a (Ci-Cs)alkoxy group, as defined herein, appended to the parent molecular moiety through a (Ci-Ce)alkyl group, as defined herein. Représentative examples of (Ci-C6)alkoxy(Ci-C6)alkyl include, but are not limited to, tert-butoxymethyl, 2-ethoxyethyl, 2-methoxyethyl, and methoxymethyl.
The term (CvCejalkoxycarbonyl as used herein, means a (Ci-Ce)alkoxy group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein. Représentative examples of (Ci-Ce)alkoxycarbonyl include, but are not limited to, methoxycarbonyl, ethoxycarbonyl, and tert-butoxycarbonyl.
The term (Ci-Csjalkyl as used herein, means a straight or branched chain hydrocarbon containing from 1 to 3 carbon atoms. Représentative examples of (CrC3)alkyl include methyl, ethyl, n-propyl, and iso-propyl.
The term “(Ci-C3)alkyl-di-7” as used herein, means a straight or branced chain hydrocarbon containing from 1 to 3 carbon atoms wherein one to seven of the hydrogens hâve been exchanged for deuterium (2H or D). Représentative examples of (Ci-Csjalkyl-dw include methyl-d3, ethyl-d5, ethyl-2,2,2-d3, propyl-d7, and 2-propyl-c/7.
The term (Ci-C6)alkyl as used herein, means a straight or branched chain hydrocarbon containing from 1 to 6 carbon atoms. Représentative examples of (Ci-C6)alkyl include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyi, sec-butyl, iso-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, and n-hexyl.
The term “(Ci-C6)alkyl-di.i3” as used herein, means a straight or branced chain hydrocarbon containing from 1 to 6 carbon atoms wherein one to thirteen ofthe hydrogens hâve been exchanged for deuterium (2H or D). Représentative examples of (Ci-Ce)alkyl-di-i3 include, but are not limited to, methyl-ds, ethyl-ds, ethyl-2,2,2-ds, propyl-d7, 2-propyl-d7, butyl-dg, tert-butyl-dg, pentyl-dn, and hexyl-di3.
The term (Ci-C6)alkylcarbonyl as used herein, means a (Ci-C6)alkyl group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein. Représentative examples of (Ci-C6)alkylcarbonyl include, but are not limited to, acetyl, 1-oxopropyl, 2,2-dimethyl-1-oxopropyl, 1-oxobutyl, and 1-oxopentyl.
The term (Ci-Cejalkylthio as used herein, means a (Ci-Ce)alkyl group, as defined herein, appended to the parent molecular moiety through a sulfur atom. Représentative examples of (Ci-Cejalkylthio include, but are not limited to, methylthio, ethylthio, tert-butylthio, and hexylthio.
The term (Ci-C6)alkylthio(Ci-Cs)alkyl as used herein, means a (Ci-C6)alkylthio group, as defined herein, appended to the parent molecular moiety through a (Ci-Ce)alkyl group, as defined herein. Représentative examples of (Ci-C6)alkylthio(Ci-C6)alkyl include, but are not limited to, methylthiomethyl and 2-(ethylthio)ethyl.
The term (C2-C6)alkynyl as used herein, means a straight or branched chain hydrocarbon group containing from 2 to 6 carbon atoms and containing at least one carboncarbon triple bond. Représentative examples of (C2-C6)alkynyl include, but are not limited to, to acetylenyl, 1-propynyl, 2-propynyl, 3-butynyl, 2-pentynyl, and 1-butynyl.
The term (C2-C6)alkynyloxy as used herein, means a (C2-C6)alkynyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom.
The term (C2-C6)alkynylthio as used herein, means a (C2-C6)alkynyl group, as defined herein, appended to the parent molecular moiety through a sulfur atom.
The term aryl, as used herein, means a phenyl or naphthyl group.
The term aryl(Ci-C6)alkoxy as used herein, means an aryl group, as defined herein, appended to the parent molecular moiety through an (Ci-Cejalkoxy group, as defined herein.
The term aryl(Ci-C6)alkyl as used herein, means an aryl group, as defined herein, appended to the parent molecular moiety through an (C-i-CeJalkyl group, as defined herein. Représentative examples of aryl(Ci-C6)alkyl include, but are not limited to, benzyl, 2phenylethyl, 3-phenylpropyl, and 2-naphth-2-ylethyl.
The term aryl(Ci-C6)alkylthio as used herein, means an aryl(C-i-C6)alkyl group, as defined herein, appended to the parent molecular moiety through sulfur atom, as defined herein. Représentative examples of aryl(Ci-C6)alkylthio include, but are not limited to, benzylthio, phenylethylthio, 3-phenylpropylthio, and 2-naphth-2-ylethylthio.
The term aryloxy as used herein, means an aryl group, as defined herein, appended to the parent molecular moiety through an oxygen atom. Représentative examples of aryloxy include, but are not limited to, phenoxy and naphthalenyloxy.
The term arylthio as used herein, means an aryl group, as defined herein, appended to the parent molecular moiety through a sulfur atom. Représentative examples of arylthio include, but are not limited to, phenylthio and naphthalenylthio.
The term carbonyl as used herein, means a -C(O)- group.
The term carboxy as used herein, means a -C(O)OH group.
The term carboxy(Ci-C6)alkoxy as used herein, means a carboxy group, as defined herein, is attached to the parent molecular moiety through a (Ci-C6)alkoxy group, as defined herein.
The term carboxy(Ci-C6)alkyl as used herein, means a carboxy group, as defined herein, is attached to the parent molecular moiety through a (Ci-Ce)alkyl group, as defined herein.
The term cyano as used herein, means a -CN group.
The term (Cs-Csjcycloalkyl as used herein, means a saturated cyclic hydrocarbon group containing from 3 to 8 carbons, examples of (C3-Cs)cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
The term (Cs-CsjcycloalkylCCi-Cejalkoxy as used herein, means a (C3-C8)cycloalkyl group, as defined herein, appended to the parent molecular moiety through a (Ci-Ce)alkoxy group, as defined herein.
The term (C3-C8)cycloalkyl(Ci-C6)alkyl as used herein, means a (C3-C6)cycloalkyl group, as defined herein, appended to the parent molecular moiety through a (Ci-Cejalkyl group, as defined herein. Représentative examples of (C3-C8)cycloalkyl(Ci-C6)alkyl include, but are not limited to, cyclopropylmethyl, 2-cyclobutylethyl, cyclopentylmethyl, cyclohexylmethyl, and 4-cycloheptylbutyl.
The term (C3-C8)cycloalkyl(Ci-C6)alkylthio as used herein, means a (C3-C8)cycloalkyl(Ci-C6)alkyl group, as defined herein, appended to the parent molecular moiety through a sulfur atom.
The term (C3-C8)cycloalkyloxy as used herein, means (C3-C8)cycloalkyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom, as defined herein. Représentative examples of (C3-C8)cycloalkyloxy include, but are not limited to, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, cycloheptyloxy, and cyclooctyloxy.
The term (C3-C8)cycloalkylthio as used herein, means (C3-C8)cycloalkyl group, as defined herein, appended to the parent molecular moiety through a sulfur atom, as defined herein. Représentative examples of (C3-C8)cycloalkylthio include, but are not limited to, cyclopropylthio, cyclobutylthio, cyclopentylthio, cyclohexylthio, cycloheptylthio, and cyclooctylthio.
The term formyl as used herein, means a -C(O)H group. .
The term halo or halogen as used herein, means -Cl, -Br, -I or -F.
The term halo(Ci-C6)alkoxy as used herein, means at least one halogen, as defined herein, appended to the parent molecular moiety through a (Ci-Ce)alkoxy group, as defined herein. Représentative examples of halo(Ci-C6)alkoxy include, but are not limited to, chloromethoxy, 2-fluoroethoxy, trifluoromethoxy, and pentafluoroethoxy.
The term halo(Ci-C6)alkyl as used herein, means at least one halogen, as defined herein, appended to the parent molecular moiety through a (Ci-C6)alkyl group, as defined herein. Représentative examples of halo(Ci-C6)alkyl include, but are not limited to, chloromethyl, 2-fluoroethyl, trifluoromethyl, pentafluoroethyl, and 2-chloro-3-fluoropentyl.
The term halo(Ci-C6)alkylthio” as used herein, means a halo(Ci-C6)alkyl group, as defined herein, appended to the parent molecular moiety through a sulfur atom. Représentative examples of halo(Ci-C6)alkylthio include, but are not limited to, trifluoromethylthio.
The term (5-6 membered)heteroaryl, as used herein, means a 5 or 6 membered monocyclic heteroaryl. The 5 membered ring consists of two double bonds and one, two, three or four nitrogen atoms and/or optionally one oxygen or sulfur atom. The 6 membered ring consists of three double bonds and one, two, three or four nitrogen atoms. The 5 or 6 membered heteroaryl is connected to the parent molecular moiety through any carbon atom or any nitrogen atom contamed within the heteroaryl. Représentative examples of monocyclic heteroaryl include, but are not limited to, furyl, imidazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, oxazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrazolyl, pyrrolyl, tetrazolyl, thiadiazolyl, thiazolyl, thienyl, triazolyl, and triazinyl.
The term (5-6 membered)heteroaryl(Ci-C6)alkoxy as used herein, means a (5-6 membered)heteroaryl, as defined herein, appended to the parent molecular moiety through an (Ci-Cs)alkoxy group, as defined herein. Représentative examples of heteroaryl(Ci-C6)alkoxy include, but are not limited to, fur-3-ylmethoxy, 1H-imidazol-2-ylmethoxy, 1H-imidazol-4ylmethoxy, 1-(pyridin-4-yl)ethoxy, pyridin-3-ylmethoxy, 6-chloropyridin-3-ylmethoxy, pyridin-4ylmethoxy, (6-(trifluoromethyl)pyridin-3-yl)methoxy, (6-(cyano)pyridin-3-yl)methoxy, (2-(cyano)pyridin-4-yl)methoxy, (5-(cyano)pyridin-2-yl)methoxy, (2-(chloro)pyridin-4-yl)methoxy, pyrimidin-5-ylmethoxy, 2-(pyrimidin-2-yl)propoxy, thien-2-ylmethoxy, and thien-3-ylmethoxy.
The term (5-6 membered)heteroaryl(Ci-C6)alkyl as used herein, means a (5-6 membered)heteroaryl, as defined herein, appended to the parent molecular moiety through an (CrCejalkyl group, as defined herein. Représentative examples of heteroaryl(Ci-C6)alkyl include, but are not limited to, fur-3-ylmethyl, 1H-imidazol-2-ylmethyl, 1H-imidazol-4-ylmethyl, 1-(pyridin-4-yl)ethyl, pyridin-3-ylmethyl, 6-chloropyridin-3-ylmethyl, pyridin-4-ylmethyl, (6-(trifluoromethyl)pyridin-3-yl)methyl, (6-(cyano)pyridin-3-yl)methyl, (2-(cyano)pyridin-4yl)methyl, (5-(cyano)pyridin-2-yl)methyl, (2-(chloro)pyridin-4-yl)methyl, pyrimidin-5-ylmethyl, 2(pyrimidin-2-yl)propyl, thien-2-ylmethyl, and thien-3-ylmethyl.
The term (5-6 membered)heteroaryl(C-i-C6)alkylthio as used herein, means a (5-6 membered)heteroaryl(Ci-C6)alkyl group, as defined herein, appended to the parent molecular moiety through a sulfur atom. Représentative examples of heteroaryl(Ci-C6)alkylthio include, but are not limited to, fur-3-ylmethylthio, 1 H-imidazol-2-ylmethylthio, 1 H-imidazol-4-ylmethylthio, pyridin-3-ylmethylthio, 6-chloropyridin-3-ylmethylthio, pyridin-4-ylmethylthio, (6-(trifluoromethyl)pyridin-3-yl)methylthio, (6-(cyano)pyridin-3-yl)methylthio, (2-(cyano)pyridin-4yl)methylthio, (5-(cyano)pyridin-2-yl)methylthio, (2-(chloro)pyridin-4-yl)methylthio, pyrimidin-5ylmethylthio, 2-(pyrimidin-2-yl)propylthio, thien-2-ylmethylthio, and thien-3-ylmethylthio.
The term (5-6 membered)heteroaryloxy as used herein, means a (5-6 membered)heteroaryl, as defined herein, appended to the parent molecular moiety through an oxygen atom. Représentative examples of heteroaryloxy include, but are not limited to, fur-3yloxy, 1H-imidazol-2-yloxy, 1 H-imidazol-4-yloxy, pyridin-3-yloxy, 6-chloropyridin-3-yloxy, pyridin4-yloxy, (6-(trifluoromethyl)pyridin-3-yl) oxy, (6-(cyano)pyridin-3-yl) oxy, (2-(cyano)pyridin-4yl)oxy, (5-(cyano)pyridin-2-yl)oxy, (2-(chloro)pyridin-4-yl)oxy, pyrimidin-5-yloxy, pyrimidin-2yloxy, thien-2-yloxy, and thien-3-yloxy.
The term (5-6 membered)heteroarylthio as used herein, means a (5-6 membered)heteroaryl, as defined herein, appended to the parent molecular moiety through a sulfur atom. Représentative examples of heteroarylthio include, but are not limited to, pyridin-3ylthio and quinohn-3-ylthio.
The term (4-7 membered)heterocycle or heterocyclic as used herein, means a 4, 5, 6 or 7 membered ring containing at least one heteroatom independently selected from the group consisting of O, N, and S. The 4 membered ring contains 1 heteroatom selected from the group consisting of O, N and S. The 5 membered ring contains zéro or one double bond and one, two or three heteroatoms selected from the group consisting of O, N and S. The 6 or 7 membered ring contains zéro, one or two double bonds and one, two or three heteroatoms selected from the group consisting of O, N and S. The heterocycle is connected to the parent molecular moiety through any carbon atom or any nitrogen atom contained within the heterocycle. Représentative examples of heterocycle include, but are not limited to, azetidinyl, azepanyl, aziridinyl, diazepanyl, 1,3-dioxanyl, 1,3-dioxolanyl, 1,3-dithiolanyl, 1,3-dithianyl, imidazolinyl, imidazolidinyl, isothiazolinyl, isothiazolidinyl, isoxazolinyl, isoxazolidinyl, morpholinyl, oxadiazolinyl, oxadiazolidinyl, oxazolinyl, oxazolidinyl, piperazinyl, piperidinyl, pyranyl, pyrazolinyl, pyrazolidinyl, pyrrolinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, thiadiazolinyl, thiadiazolidinyl, thiazolinyl, thiazolidinyl, thiomorpholinyl, 1,1dioxidothiomorpholinyl (thiomorpholine sulfone), thiopyranyl, and trithianyl.
The term (4-7 membered)heterocycle(Ci-C6)alkoxy as used herein, means a (4-7 membered)heterocycle, as defined herein, appended to the parent molecular moiety through an (Ci-Ce)alkoxy group, as defined herein.
The term (4-7 membered)heterocycle(Ci-C6)alkyl as used herein, means a (4-7 membered)heterocycle, as defined herein, appended to the parent molecular moiety through an (Ci-C6)alkyl group, as defined herein.
The term (4-7 membered)heterocycle(Ci-C6)alkylthio as used herein, means a (4-7 membered)heterocycle(Ci-C6)alkyl group, as defined herein, appended to the parent molecular moiety through a sulfur atom.
The term (4-7 membered)heterocycleoxy as used herein, means a (4-7 membered)heterocycle, as defined herein, appended to the parent molecular moiety through an oxygen atom. Représentative examples of heteroaryloxy include, but are not limited to, pyridin3-yloxy and pyrimidin-2-yloxy.
The term (4-7 membered)heterocyclethio as used herein, means a (4-7 membered)heterocycle, as defined herein, appended to the parent molecular moiety through a sulfur atom. Représentative examples of heteroarylthio include, but are not limited to, pyridin-3ylthio and pyrimidin-2-ylthio.
The term hydroxy as used herein, means an -OH group.
The term hydroxy(Ci-Cs)alkoxy as used herein, means at least one hydroxy group, as defined herein, is appended to the parent molecular moiety through a (Ci-C6)alkoxy group, as defined herein. Représentative examples of hydroxy(Ci-C6)alkoxy include, but are not limited to, hydroxymethoxy, 2-hydroxyethoxy, 3-hydroxypropoxy, 2,3-dihydroxypentoxy, and 2-ethyl-4hydroxyheptoxy.
The term hydroxy(Ci-C6)alkyl as used herein, means at least one hydroxy group, as defined herein, is appended to the parent molecular moiety through a (Ci-Ce)alkyl group, as defined herein. Représentative examples of hydroxy(Ci-Ce)alkyl include, but are not limited to, hydroxymethyl, 2-hydroxyethyl, 3-hydroxypropyl, 2,3-dihydroxypentyl, and 2-ethyl-4hydroxyheptyl.
The term mercapto as used herein, means a -SH group.
The term nitro as used herein, means a -ΝΟ2 group.
The term thio(Ci-C6)alkyl as used herein, means a sulfur atom appended to the parent molecular moiety through a (Ci-C6)alkyl group, as defined herein. Représentative examples of thio(Ci-C6)alkyl include, but are not limited to, thiomethyl, 2-thioethyl, 3-thiopropyl, and 4-thiobutyl.
The term “-NRaRb” as used herein, means two groups, Ra and Rb appended to the parent molecular moiety through a nitrogen atom. Ra and Rb are each independently hydrogen, (Ci-C6)alkyl, or (Ci-C6)alkylcarbonyl. Représentative examples of-NRaRb include, but are not limited to, amino, methylamino, dimethylamino, acetylamino, and acetylmethylamino.
The term “NRARB(Ci-C6)alkoxy” as used herein, mean a NRaRb group attached to the parent molecular moiety through a (Ci-Ce)alkoxy group.
The term “NRARB(Ci-C6)alkyl” as used herein, mean a NRaRb group attached to the parent molecular moiety through a (Ci-C6)alkyl group.
The term (NRARB)carbonyl as used herein, means a NRaRb group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein. Représentative examples of (NRARejcarbonyl include, but are not limited to, aminocarbonyl, (methylamino)carbonyl, (dimethylamino)carbonyl, and (ethylmethylamino)carbonyl.
The term “-NRcRd” as used herein, means two groups, Rc and Rd appended to the parent molecular moiety through a nitrogen atom. Rc and RD are each independently hydrogen, (Ci-Ce)alkyl, or (Ci-C6)alkylcarbonyl. Représentative examples of-NRcRo include, but are not limited to, amino, methylamino, dimethylamino, acetylamino, and acetylmethylamino.
The term “NRcRD(Ci-C6)alkoxy” as used herein, mean a NRcRd group attached to the parent molecular moiety through a (Ci-Ce)alkoxy group.
The term “NRcRD(Ci-C6)alkyl” as used herein, mean a NRcRd group attached to the parent molecular moiety through a (Ci-Ce)alkyl group.
The term (NRcRojcarbonyl as used herein, means a NRcRd group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein.
The compounds ofthe présent invention may form boron-oxygen dative bonds following exposure to water, alcohols (ROH, R is alkyl), and diols (ROH, R is hydroxyalkyl) as depicted in
Scheme A.
Scheme A
When a boron atom is covalently bonded to an oxygen atom and datively bonded to a second oxygen atom, the dative bond and covalent bond can interconvert or form a résonance hybrid as exemplified by structures (1), (2), (3), and (4) in Scheme A. Compounds ofthe présent invention following exposure to water, alcohols, and diols may exist as neutral compounds, exemplified by compounds (1)-(4), or as negatively charged compounds depicted by compounds (5) and (6), wherein Ri, R2, R3, R4, Rs, Rs, R7, Rg, R10 and p are as defined in the Summary section herein. In addition to oxygen, boron may form dative bonds with sulfur and
F nitrogen. It is to be understood that the présent invention encompasses the compounds of Formula (I), Formula (IA), Formula (IB), and Formula (IC) that form dative bonds with oxygen, sulfur, and nitrogen including, but not limited to compounds (7)-(12). Suitable counter ions include, but are not limited to, lithium, sodium, potassium, ammonium, tétraméthylammonium, 5 tetraethylammonium, méthylammonium, dimethylammonium, trimethylammonium, triethylammonium, diethylammonium, ethylammonium, calcium, magnésium, and aluminum.
The compounds ofthe présent invention may form oxygen-linked dimers following exposure to water. Représentative dimers ofthe présent invention are shown in Scheme B wherein Ri, R2, Rs, R4, Rs, Rs, R7, Rg, R10, and p are as defined in the Summary section herein.
Scheme B
It is to be understood that the présent invention encompasses the oxygen-linked dimers of Formula (I), Formula (IA), Formula (IB) and Formula (IC) including, but not limited to, bis((R)3-hydroxy-2-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)propyl)diboronic acid and bis((S)-315 hydroxy-2-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)propyl)diboronic acid.
The compounds ofthe présent invention may also form acyclic and cyclic trimers with exposure to water. Représentative acyclic and cyclic trimers ofthe présent invention are shown in Scheme C wherein Ri, R2, R3, R4, Rs, Rs, R7, Rg, Rio and p are as defined in the Summary section herein.
It is to be understood that the present invention encompasses acyclic and cyclic trimers of Formula (I), Formula (IA), Formula (IB) and Formula (IC) including, but not limited to, the acyclic trimers (13) and (14) shown in Scheme C and the cyclic trimers (2R,2'R,2R)-3,3',3(1,3,5,2,4,6-trioxatriborinane-2,4,6-triyl)tris(2-(5-(4-methoxy-3-propoxyphenyl)pyridin-3yl)propan-1-ol) and (2S,2'S,2S)-3,3',3-(1,3,5,2,4,6-trioxatriborinane-2,4,6-triyl)tris(2-(5-(410 methoxy-3-propoxyphenyl)pyridin-3-yl)propan-1 -ol).
The present invention encompasses anhydrides of Formula (I), Formula (IA), Formula (IB) and Formula (IC) formed under dehydrating conditions. Représentative anhydrides ofthe présent invention are shown in Scheme D wherein Ri, R2, R3, R4, Rs, Re, R7, Rg, R10, and p are as defined in the Summary section herein.
Scheme D (Rio)p (Rw)p (^1θ)ρ
It is to be understood that the présent invention encompasses the anhydrides of Formula (I), Formula (IA), Formula (IB) and Formula (IC) including, but not limited to, 5,5'-((4S,4'S)oxybis(1,2-oxaborolane-2,4-diyl))bis(3-(4-methoxy-3-propoxyphenyl)pyridine) and 5,5'-((4R,4'R)oxybis(1,2-oxaborolane-2,4-diyl))bis(3-(4-methoxy-3-propoxyphenyl)pyridine).
The compounds ofthe présent invention may form poly- or multi-valent species assembled from a single species or from more than one species ofthe présent invention. The polymeric constructs can be “homopolymeric consisting ofthe same or related constructs, or “hetereropolymeric” consisting of multiple different constructs.
The présent invention encompasses compounds that can be formulated with excipients such that one or more excipients interact with the compounds ofthe présent invention to afford single, poly-, or multi-valent species, including, for example, species such as esters, dimers, trimers, tetramers and higher homologs. For example, compounds of Formula (I), Formula (IA), Formula (IB) and Formula (IC) may form boron-esters with propylene glycol or hexylene glycol under appropriate conditions. Représentative esters ofthe présent invention are shown in Scheme E wherein Rb R2, R3, R4, R5, Re, R7, Rg, R10, and p are as defined in the Summary section herein.
Scheme E
It is to be understood that the présent invention encompasses boron-esters of Formula (I), Formula (IA), Formula (IB) and Formula (IC) including, but not limited to, 1-hydroxypropan-2yl hydrogen ((R)-3-hydroxy-2-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)propyl)boronate, (S)1 -hydroxypropan-2-yl hydrogen ((R)-3-hydroxy-2-(5-(4-methoxy-3-propoxyphenyl)pyridin-310 yl)propyl)boronate, (R)-1-hydroxypropan-2-yl hydrogen ((R)-3-hydroxy-2-(5-(4-methoxy-3propoxyphenyl)pyridin-3-yl)propyl)boronate, 2-hydroxypropyl hydrogen ((R)-3-hydroxy-2-(5-(4methoxy-3-propoxyphenyl)pyridin-3-yl)propyl)boronate, (S)-2-hydroxypropyl hydrogen ((R)-3hydroxy-2-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)propyl)boronate, (R)-2-hydroxypropyl hydrogen ((R)-3-hydroxy-2-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)propyl)boronate, 415 hydroxy-2-methylpentan-2-yl hydrogen ((R)-3-hydroxy-2-(5-(4-methoxy-3propoxyphenyl)pyridin-3-yl)propyl)boronate, (S)-4-hydroxy-2-methylpentan-2-yl hydrogen ((R)-3hydroxy-2-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)propyl)boronate, (R)-4-hydroxy-2methylpentan-2-yl hydrogen ((R)-3-hydroxy-2-(5-(4-methoxy-3-propoxyphenyl)pyridin-3yl)propyl)boronate, 4-hydroxy-4-methylpentan-2-yl hydrogen ((R)-3-hydroxy-2-(5-(4-methoxy-320 propoxyphenyl)pyridin-3-yl)propyl)boronate, (S)-4-hydroxy-4-methylpentan-2-yl hydrogen ((R)-3hydroxy-2-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)propyl)boronate, (R)-4-hydroxy-4methylpentan-2-yl hydrogen ((R)-3-hydroxy-2-(5-(4-methoxy-3-propoxyphenyl)pyridin-3yl)propyl)boronate, 1-hydroxypropan-2-yl hydrogen ((S)-3-hydroxy-2-(5-(4-methoxy-3 propoxyphenyl)pyridin-3-yl)propyl)boronate, (S)-1-hydroxypropan-2-yl hydrogen ((S)-3-hydroxy2-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)propyl)boronate, (R)-1-hydroxypropan-2-yl hydrogen ((S)-3-hydroxy-2-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)propyl)boronate, 2hydroxypropyl hydrogen ((S)-3-hydroxy-2-(5-(4-methoxy-3-propoxyphenyl)pyridin-3yl)propyl)boronate, (S)-2-hydroxypropyl hydrogen ((S)-3-hydroxy-2-(5-(4-methoxy-3propoxyphenyl)pyridin-3-yl)propyl)boronate, (R)-2-hydroxypropyl hydrogen ((S)-3-hydroxy-2-(5(4-methoxy-3-propoxyphenyl)pyridin-3-yl)propyl)boronate, 4-hydroxy-2-methylpentan-2-yl hydrogen ((S)-3-hydroxy-2-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)propyl)boronate, (S)-4hydroxy-2-methylpentan-2-yl hydrogen ((S)-3-hydroxy-2-(5-(4-methoxy-3propoxyphenyl)pyridin-3-yl)propyl)boronate, (R)-4-hydroxy-2-methylpentan-2-yl hydrogen ((S)-3hydroxy-2-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)propyl)boronate, 4-hydroxy-4methylpentan-2-yl hydrogen ((S)-3-hydroxy-2-(5-(4-methoxy-3-propoxyphenyl)pyridin-3yl)propyl)boronate, (S)-4-hydroxy-4-methylpentan-2-yl hydrogen ((S)-3-hydroxy-2-(5-(4methoxy-3-propoxyphenyl)pyridin-3-yl)propyl)boronate, and (R)-4-hydroxy-4-methylpentan-2-yl hydrogen ((S)-3-hydroxy-2-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)propyl)boronate.
The présent invention also encompasses cyclic esters formed by interaction of compounds of Formula (I), Formula (IA), Formula (IB), and Formula (IC) with certain diols that include, but are not limited to, propylene glycol and hexylene glycol. Représentative cyclic esters are shown in Scheme F wherein Ri, R2, Rs, R4, Rs, Re, R7, R9, R10, and pare as defined in the Summary section herein.
Scheme F
It is to be understood that the présent invention encompasses cyclic boron-esters of Formula (I), Formula (IA), Formula (IB) and Formula (IC) including, but not limited to, (2R)-2-(5(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-3-(4-methyl-1,3,2-dioxaborolan-2-yl)propan-1-ol, (R)2-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-3-((S)-4-methyl-1,3,2-dioxaborolan-2-yl)propan1 -ol, (R)-2-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-3-((R)-4-methyl-1,3,2-dioxaborolan-2yl)propan-1-ol, (2R)-2-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-3-(4,4,6-trimethyl-1,3,2dioxaborinan-2-yl)propan-1-ol, (R)-2-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-3-((S)-4,4,6 trimethyl-1,3,2-dioxaborinan-2-yl)propan-1-ol, (R)-2-(5-(4-methoxy-3-propoxyphenyl)pyridin-3yl)-3-((R)-4,4,6-tnmethyl-1,3,2-dioxabonnan-2-yl)propan-1-ol, (2S)-2-(5-(4-methoxy-3propoxyphenyl)pyridin-3-yl)-3-(4-methyl-1,3,2-dioxaborolan-2-yl)propan-1-oI, (S)-2-(5-(4methoxy-3-propoxyphenyl)pyridin-3-yl)-3-((S)-4-methyl-1,3,2-dioxaborolan-2-yl)propan-1-ol, (S)2-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-3-((R)-4-methyl-1,3,2-dioxaborolan-2-yl)propan1-ol, (2S)-2-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-3-(4,4,6-trimethyl-1,3,2-dioxaborinan2-yl)propan-1-ol, (S)-2-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-3-((S)-4,4,6-trimethyl-1,3,2dioxaborinan-2-yl)propan-1-ol, and (S)-2-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-3-((R)4,4,6-trimethyl-1,3,2-dioxaborinan-2-yl)propan-1-ol.
The salts, esters, anhydrides, dimers, and trimers exemplified in Schemes A-F are prodrugs that can hydrolyze back to the parent compounds under aqueous conditions which include in vivo conditions reforming the oxaborole ring.
The compounds ofthe présent invention can be used in the form of pharmaceutically acceptable salts derived from inorganic or organic acids. By pharmaceutically acceptable sait is meant those salts which are, within the scope of Sound medical judgement, suitable for use in contact with the tissues of humans and animais without undue toxicity, irritation, allergie response and the like and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well-known in the art. For example, S. M. Berge et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66:1-19, herein incorporated by reference. The salts can be prepared in situ during the final isolation and purification ofthe compounds ofthe présent invention or separately by reacting a free base (basic nitrogen) with a suitable organic or inorganic acid. Représentative acid addition salts include, but are not limited to acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsufonate, digluconate, glycérophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethansulfonate (isethionate), lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, phosphate, glutamate, bicarbonate, p-toluenesulfonate and undecanoate. Also, the basic nitrogen-containing groups can be quaternized with such agents as lower alkyl halides such as methyl, ethyl, propyl, and butyl chlorides, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl and diamyl sulfates; long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides; arylalkyl halides like benzyl and phenethyl bromides and others. Water or oil-soluble or dispersible products are thereby obtained. Examples of acids which can be employed to form pharmaceutically acceptable acid addition salts include such inorganic acids as hydrochloric acid, hydrobromic acid, sulphuric acid and phosphoric acid and such organic acids as oxalic acid, maleic acid, succinic acid and citric acid.
Compounds ofthe present invention may exist as stereoisomers wherein, asymmetric or chiral centers are present. These stereoisomers are “R or “S depending on the configuration of substituents around the chiral carbon atom. The terms “R” and “S” used herein are configurations as defined in IUPAC 1974 Recommendations for Section E, Fundamental Stereochemistry, Pure Appl. Chem., 1976,45: 13-30. In particular, the stereochemistry at the point of attachment of Y and Z, as shown in Formulae (I), (IA), and (IB) may independently be either (R) or (S), unless specifically noted otherwise. The enantiomers ofthe present invention indicated by (R), (S), or * are substantially free ofthe other enantiomer. “Substantially free” means that the enantiomeric excess is greater than about 90%, preferably greater than about 95%, and more preferably greater than about 99%. Within the context of enantiomeric excess, the term “about” means ±1.0%. The symbol * désignâtes a chiral carbon atom as either (R) or (S) stereochemistry depending on the configuration of substituents around the chiral carbon atom. The present invention contemplâtes various stereoisomers and mixtures thereof that are specifically included within the scope of this invention. Stereoisomers include enantiomers and mixtures of enantiomers. Individual stereoisomers of compounds ofthe present invention may be prepared synthetically from commercially available starting materials which contain asymmetric or chiral centers or by préparation of racemic mixtures followed by resolution wellknown to those of ordinary skill in the art. These methods of resolution include, but are not limited to, (1) attachment of a chiral auxiliary to a mixture of enantiomers, séparation ofthe resulting mixture of diastereomers by recrystallization orchromatography and libération ofthe optically pure product from the auxiliary or (2) direct séparation ofthe mixture of optical enantiomers on chiral chromatographie columns.
Compounds ofthe present invention not designated (R), (S), or * may exist as racemates (i.e. 50% (R) and 50% (S)) or as a mixture of two enantiomers wherein one enantiomer is in excess. For example, enantiomeric mixtures may include the (R) enantiomer in 51 % and the (S) enantiomer in 49% or vice versa or any combination of (R) and (S) other than the racemic mixture of 50% (R) and 50% (S). The present invention includes racemates and enantiomeric mixtures ofthe compounds ofthe present invention.
Compounds ofthe present invention may exist in different stable conformational forms which may be separable. Torsional asymmetry due to restricted rotation about an asymmetric single bond, for example because of steric hindrance or ring strain, may permit séparation of different conformers. The compounds ofthe present invention further include each conformational isomer of compounds of Formulae (I), (IA), (IB), and (IC) and mixtures thereof.
Tautomers may exist in the compounds ofthe present invention and are specifically included within the scope ofthe present invention. The term tautomer, as used herein, means a proton shift from one atom of a molécule to another atom ofthe same molécule wherein two or more structurally distinct compounds are in equilibrium with each other. Compounds ofthe present invention may exist as tautomers. The present invention contemplâtes tautomers due to proton shifts from one atom to another atom ofthe same molécule generating two or more distinct compounds that are m equilibnum with each other.
The compounds ofthe présent invention may be isolated and used perse or in the form of their pharmaceutically acceptable salts. In accordance with the présent invention, compounds with multiple basic nitrogen atoms can form salts with varying number of équivalents (eq.) of acid. It will be understood by practitioners that ail such salts are within the scope ofthe présent invention.
Compounds ofthe présent invention may exist in more than one crystal form. Polymorphs of compounds of Formulae (I), (IA), (IB), and (IC) and salts thereof (including solvatés and hydrates) form part of this invention and may be prepared by crystallization of a compound ofthe présent invention under different conditions. For example, using different solvents or different solvent mixtures for recrystallization; crystallization at different températures; various modes of cooling, ranging from very fast to very slow cooling during crystallization. Polymorphs may also be obtained by heating or melting a compound ofthe présent invention followed by graduai or fast cooling. The presence of polymorphs may be determined by solid probe nuclear magnetic résonance (NMR) spectroscopy, infrared (IR) spectroscopy, differential scanning calorimetry, powder X-ray diffraction or such other techniques.
This invention also includes isotopically-labeled compounds, which are identical to those described by Formulae (I), (IA), (IB), and (IC), but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds ofthe invention include isotopes of hydrogen, carbon, nitrogen, oxygen, sulfur, chlorine, iodine, and fluorine, such as 2H, 3H, 13C, 14C, 15N, 18O, 17O, 35S, 36CI, 125l, 129l, 18F, and 19F respectively. Certain isotopically-labeled compounds ofthe présent invention, for example those into which radioactive isotopes such as 3H and 14C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated (i.e., 3H), and carbon-14 (i.e., 14C), isotopes are particularly preferred for their ease of préparation and detectability. Further, substitution with heavier isotopes such as deuterium (i.e., 2H), can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements and, hence, may be preferred in some circumstances. Isotopically labeled compounds ofthe présent invention can generally be prepared by carrying out the procedures disclosed in the schemes and/or in the Examples below, by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.
In particular, the présent invention includes deuterated compounds of Formula (I), (IA), (IB), and (IC). Any ofthe hydrogens contâined on the compounds ofthe présent invention may be exchanged for deuterium. Représentative examples of deuterated compounds ofthe présent invention include, but are not limited to, the compounds listed below wherein D is deuterium.
AH patents, patent applications, and literature references cited in the spécification are herein incorporated by reference in their entirety.
Compounds ofthe présent invention were named by Chemdraw Professional version
15.0 or 16.0 or were given names which appeared to be consistent with Chemdraw nomenclature.
The présent invention encompasses compounds of Formulae (I), (IA), (IB), and (IC) when prepared by synthetic processes or by metabolic processes. Préparation of the compounds ofthe invention by metabolic processes include those occurring in the human or animal body (in vivo) or processes occurring in vitro.
The présent invention also contemplâtes pharmaceutically active métabolites formed by in vivo biotransformation of compounds of Formulae (I), (IA), (IB), and (IC). The term pharmaceutically active métabolite, as used herein, refers to a compound formed by the in vivo biotransformation of compounds of Formulae (I), (IA), (IB), and (IC). A thorough discussion of biotransformation is provided in (Goodman and Gilman’s, The Pharmacological Basis of Therapeutics, seventh édition, MacMillan Publishing Company, New York, NY, (1985)).
Compounds ofthe présent invention may be synthesized by synthetic routes that include processes analogous to those well-known in the Chemical arts, particularly in light ofthe description contained herein. The starting materials are generally available from commercial sources or are readily prepared using methods well known to those skilled in the art (e.g., prepared by methods generally described in Louis F. Fieser and Mary Fieser, Reagents for Organic Synthesis, v. 1-19, Wiley, New York (1967-1999 ed.), or Beilsteins Handbuch der organischen Chemie, 4, Aufl. ed. Springer-Verlag, Berlin, including suppléments (also available via the Beilstein online database)).
For illustrative purposes, the reaction schemes depicted below provide potential routes for synthesizing the compounds ofthe présent invention as well as intermediates for preparing compounds ofthe présent invention. For a more detailed description ofthe individual réaction steps, see the Examples section below. Those skilled in the art will appreciate that other synthetic routes may be used to synthesize the inventive compounds. Although spécifie starting materials and reagents are depicted in the schemes and discussed below, other starting materials and reagents can be substituted to provide a variety of dérivatives and/or reaction conditions. In addition, many ofthe compounds prepared by the methods described below can be further modified in light of this disclosure using conventional chemistrv well known to those skilled m the art.
In the préparation of compounds ofthe présent invention protection of remote functionalities such as carboxylic acids, amines, and/or hydroxy groups of intermediates may be necessary. The need for such protection will vary depending on the nature ofthe remote functionality and the conditions ofthe préparation methods. Suitable amino-protecting groups (NH-PG) include acetyl, trifluoroacetyl, t-butoxycarbonyl (BOC), benzyloxycarbonyl (Cbz) and 9fluorenylmethyleneoxycarbonyl (Fmoc). Similarly, a “hydroxy-protecting group” refers to a substituent of a hydroxy group that blocks or protects the hydroxy functionality. Suitable hydroxyl-protecting groups (O-PG) include for example, allyl, acetyl, silyl, benzyl, paramethoxybenzyl, trityl, and the like. Carboxylic acid protecting groups include alkyl esters such as methy, ethyl, propyl, and tert-butyl. The need for such protection is readily determined by one skilled in the art. For a general description of protecting groups and their use, see T. W. Greene, Protective Groups in Organic Synthesis, John Wiley & Sons, New York, 1991.
The reactions are performed in a solvent appropriate to the reagents and materials employed and suitable for the transformations being effected. It will be understood by those skilled in the art of organic synthesis that the functionality présent on the molécule should be consistent with the transformations proposed. This will sometimes require a judgment to modify the order ofthe synthetic steps or to select one particular process scheme over another in order to obtain a desired compound ofthe invention.
It will also be recognized that another major considération in the planning of any synthetic route in this field is the judicious choice ofthe protecting group used for protection of the reactive functional groups présent in the compounds described in this invention. An authoritative account describing the many alternatives to the trained practitioner is Greene and Wuts (Protective Groups In Organic Synthesis, Wiley and Sons, 1999). Suitable protecting groups include, but are not limited to, tert-butoxycarbonyl (BOC), trimethylsilylethanesulfonamide (SES), benzyloxycarbonyl (CBZ) and benzyl (Bn) protecting groups. The BOC protecting group may be removed by treatment with an acid such as trifluoroacetic acid or concentrated hydrochîoric acid and the SES protecting group may be removed with a fluoride sait, such as césium fluoride or tetrabutylammonium fluoride. The CBZ and Bn protection groups may be removed by catalytic hydrogénation. Additional suitable protecting groups for hydroxy substituents include, but are not limited to, t-butyldimethylsilyl (TBDMS), tetra-hydropyranyl (THP), or isopropyl (i-Pr) protecting groups. The TBDMS and THP protecting groups may be removed by treatment with an acid such as acetic acid or hydrochîoric acid while the i-Pr protecting group may be removed by aluminum trichloride.
Isolation and purification ofthe compounds and intermediates described herein can be effected, if desired, by any suitable séparation or purification procedure such as, for example, filtration, extraction, crystallization, column chromatography, thin-layer chromatography, thick layer chromatography, préparative low, medium, or high-pressure liquid chromatography, or a combination of these procedures. Spécifie illustrations of suitable séparation and isolation procedures can be had by reference to the Examples herein below. However, other équivalent séparation or isolation procedures could also be used.
The compounds of the invention may be prepared by any method known in the art for the préparation of compounds of analogous structure. In particular, the compounds of the invention can be prepared by the procedures described by reference to the Schemes that follow, or by the spécifie methods described in the Examples, or by similar processes to either.
The skilled person will appreciate that the experimental conditions set forth in the schemes that follow are illustrative of suitable conditions for effecting the transformations shown, and that it may be necessary or désirable to vary the précisé conditions employed for the préparation of compounds of Formulae (I), (IA), (IB), and (IC). It will be further appreciated that it may be necessary or désirable to carry out the transformations in a different order from that described in the schemes, orto modify one or more ofthe transformations, to provide the desired compound ofthe invention.
The dérivatives of Formulae (I), (IA), (IB), and (IC) can be prepared by the procedures described in the general methods presented below or by routine modifications thereof. The présent invention also encompasses one or more of these processes for preparing the dérivatives of Formulae (I), (IA), (IB), and (IC), in addition to any novel intermediates used therein. The person skilled in the art will appreciate that the following reactions may be heated thermally or under microwave irradiation.
The routes below, including those mentioned in the Examples and Préparations, illustrate methods of synthesising compounds of Formulae (I), (IA), (IB), and (IC). The skilled person will appreciate that the compounds ofthe invention, and intermediates thereto, could be made by methods other than those specifîcally described herein, for example by adaptation of the methods described herein, for example by methods known in the art. Suitable guides to synthesis, functional group interconversions, use of protecting groups, etc., are for example: “Comprehensive Organic Transformations” by RC Larock, VCH Publishers Inc. (1989); Advanced Organic Chemistry” by J. March, Wiley Interscience (1985); “Designing Organic Synthesis” by S Warren, Wiley Interscience (1978); “Organic Synthesis - The Disconnection Approach” by S Warren, Wiley Interscience (1982); “Guidebookto Organic Synthesis” by RK Mackie and DM Smith, Longman (1982); “Protective Groups in Organic Synthesis” by TW Greene and PGM Wuts, John Wiley and Sons, Inc. (1999); and “Protecting Groups” by PJ Kocienski, Georg Thieme Verlag (1994); and any updated versions of said standard works.
In addition, the skilled person will appreciate that it may be necessary or désirable at any stage in the synthesis of compounds ofthe invention to protect one or more sensitive groups, so as to prevent undesirable side reactions. In particular, it may be necessary or désirable to protect alcohol, amino or carboxylic acid groups. The protecting groups used in the préparation ofthe compounds ofthe invention may be used in a conventional manner. See, for example, those described m Greene s Protective Groups in Organic Synthesis' by Theodora W Greene and Peter GM Wuts, fifth édition, (John Wiley and Sons, 2014), incorporated herein by reference, which also describes methods for the removal of such groups.
In the general synthetic methods below, unless otherwise specified, the substituents are as defined above with reference to the compounds of Formula (I) above. Where ratios of solvents are given, the ratios are by volume unless otherwise specified.
The compounds ofthe invention may be prepared by any method known in the art for the préparation of compounds of analogous structure. In particular, the compounds ofthe invention can be prepared by the procedures described by reference to the Schemes that follow, or by the spécifie methods described in the Examples, or by similar processes to either. The skilled person will appreciate that the experimental conditions set forth in the schemes that follow are illustrative of suitable conditions for effecting the transformations shown, and that it may be necessary or désirable to vary the précisé conditions employed for the préparation of compounds of Formula (I).
According to the first process, compounds of Formula (1D) (where Ri, R2, R3, R4, Rs, Re, R7, Rg, R10, and pare as defined in the Summary section herein and v = 0, 1,2, 3, 4, 5) may be prepared from compounds of Formula (II) and (III) as illustrated by Scheme 1.
Scheme 1 /Rl5 (R1o)p λχ (R10)pV
R9
In Scheme 1, compounds ofthe Formula (II), wherein R14 is a suitable protecting group (preferably TBS), are converted to a compound of Formula (III) wherein R15 is boronic acid (preferably) or 4,4,5,5-tetramethyl-l ,3,2-dioxaborolane (Bpin) by treatment with a suitable hydroborating source such as catecolborane or bis(pinacolato)diboron, in the presence of a suitable catalyst (bis(1,5-cyclooctadiene)di-p-methoxydiiridium(l) or (1.5cycloocatdiene)(methoxy)iridium(l) dimer) and ligand (ethylenebis(diphenylphosphine), in a suitable solvent such as DCE or THF at an appropriate température (15 °C to 70 °C). A skilled person also knows alternative methods for hydroboration of alkenes are achievable using alternative reagents, solvents and températures. A compound of Formula (III) is converted into a compound of Formula (1D) under aqueous acidic conditions, treating with a suitable acid (acetic or hydrochloric) at a suitable température. It is well understood by a skilled person that a compound ofthe Formula (III) is prepared and isolated as described above or prepared in situ without isolation in a sequential reaction strategy leading to a compound of Formula (1D). In the case of compounds of Formula (III) and (1 D) lead to the presence of a chiral center, it is well understood by a skilled person that the individual enantiomers can be obtained using a suitable séparation method such as HPLC or SFC chromatography to afford both the (+) and (-) enantiomers of compounds of Formula (III) and (1 D). It is well understood by a skilled person that an individual enantiomer of a compound of Formula (III) and (1 D) is prepared and isolated as described above or isolated using an alternative séparation technique such as HPLC or SFC using a suitable chiral stationary phase eluting with a suitable mobile phase as determined to be necessary to isolate the required enantiomers.
According to a second process, compounds of Formula (1E) or (1F) may be prepared from Formula (II) as illustrated in Scheme 2.
Scheme 2
In Scheme 2, compounds of Formula (1E) or (1F) may be prepared in a similar manner as in Scheme 1 using suitable chiral ligands such as (S,S)-[2-(4'-i-propyloxazolin-2yl)ferrocynyl]diphenylphosphine or (R,R)-[2-(4'-i-propyloxazolin-2yl)ferrocynyl]diphenylphosphine leading to chiral compounds of Formula (IV). A person of skill in the art knows that chiral hydroboration strategies can use alternative chiral ligands, catalysts, boron sources, solvents and température combinations. It is well understood by a skilled person that a compound ofthe Formula (IV) can be prepared and isolated as described above or prepared in situ without isolation in a sequential reaction strategy leading to a compound of Formula (1 E) or (1 F). A skilled person also knows that compounds of Formula (1 E) or (1 F) can be further enriched through crystallization techniques or chiral chromatography (HPLC or SFC) using a suitable chiral stationary phase eluting with a suitable mobile phase as determined to be necessary to isolate the required enantiomers.
According to a third process, compounds of Formula (1G) may be prepared from Formula (II) as illustrated in Scheme 3.
Scheme 3
In Scheme 3, compounds of Formula (II) are converted to compounds of Formula (V) when treated with a halogenating agent such as pyridinium tribromide, in a suitable solvent, such as DCM, at an appropriate température such as 0 °C. A skilled person also knows that alternative methods for specifically introducing a suitable halogen group such as Br are achievable using alternative reagents, solvents and températures. Compounds of Formula (VI) can be synthesized by this method or by the reaction of compounds of Formula (V) using DBU with a suitable solvent, such as DCM, at a suitable température, such as 25 °C. Compounds of Formula (VI) can be converted to compounds of Formula (VII) (where R15 = Bpin) using Miyaura borylation conditions. Typical boronate ester formation conditions comprise of Pd(dppf)Cl2-DCM and potassium acetate with bispinacolatoboron in 1,4-dioxane at a suitable température, such as 55 °C. A compound of Formula (VII) can be converted into a compound of Formula (1G) under aqueous acidic conditions, treating with a suitable acid (acetic or hydrochîoric) at a suitable température.
Compounds of Formula (II) may be prepared from compounds of Formulae (VIII), (IX), (X) and (XI) as illustrated by Scheme 4.
Scheme 4
vin ix x n
In Scheme 4, compounds of Formula (X), wherein R17 is chlore, bromo or iodo may be prepared from compounds of Formula (VIII) and (IX) using a suitable organometallic crosscoupling reaction such as Suzuki cross-coupling reaction preceded if necessary by a boronic acid or ester formation. Typical Suzuki cross-coupling conditions comprise of a palladium catalyst containing suitable phosphine ligands, in the presence of an inorganic base, in aqueous dioxane or methanol, at elevated températures either thermally or under microwave irradiation.
Preferred conditions comprise Pd(OAc)2, Pd(dppf)CI2 or Pd(PPh3)4 with either sodium, césium or potassium carbonate in aqueous dioxane or methanol at from room température to 120 °C. A skilled person knows that organometallic cross-coupling reaction strategies can be used involving alternative metals, catalysts, ligands, bases, solvents and température combinations. Typical boronic ester formation conditions comprise of Pd(dppf)CI2 and potassium acetate with bispinacolatodiboron with compounds of Formula (VIII), where Rw = chloro, bromo or iodo, in dioxane at reflux. Compounds of Formula (VIII) may also be obtained commercially or be synthesized by those skilled in the art according to the literature or by analogy with the methods described herein.
Compounds of Formula (II) may be prepared from compounds of Formula (X) and (XI), (where Ris = boronic acid or Bpin) through an organometallic cross-coupling reaction, similar to the ones previously described. A skilled person knows that alternative organometallic crosscoupling reaction strategies can also be used involving alternative metals, catalysts, ligands, bases, solvents and température combinations. Preferred Suzuki conditions comprise of Pd(dppf)CI2 with potassium carbonate and potassium acetate in aqueous dioxane from room température to 120 °C.
Alternatively, compounds of Formula (II) may be prepared from compounds of Formulae (VIII), (IX), (XI) and (XII), in a reverse sequence of that in Scheme 4, illustrated by Scheme 5.
Scheme 5 r2
Compounds of Formula (XII) may be prepared from compounds of Formula (XI) (where Ris = boronic acid or pinacol) and (IX) (where R17 is chloro, bromo or iodo) using an organometallic cross-coupling reaction as described in Scheme 4. Preferred conditions comprise of Pd(dppf)CI2 with potassium carbonate in aqueous dioxane from room température to 120 °C. Compounds of Formula (XI) may be synthesized by those skilled in the art according to the literature or by analogy with the methods described herein. Compounds of Formula (XII) may be converted to compounds of Formula (II) using a similar method as previously described in Scheme 4, a Suzuki cross-coupling reaction preceded if necessary by a boronic acid or ester formation. A skilled person knows that alternative organometallic cross-coupling reaction strategies can also be used involving alternative metals, catalysts, ligands, bases, solvents and température combinations.
According to a sixth process, compounds of Formula (1H) may be prepared from Formula (XIII) and (XIV) as illustrated in Scheme 6.
Compounds of Formula (1H), where A is carbon or nitrogen, may be prepared in an analogous manner as compounds of Formula (1D), (1E) or (1F) as described in Schemes 1-5. It 5 is well understood by a skilled person that the individual enantiomers can be obtained using a suitable séparation method such as HPLC or SFC chromatography to afford both the (+) and (-) enantiomers of compounds of Formula (XIV) and (1H). It is also well understood by a skilled person that an individual enantiomer of a compound of Formula (XIV) and (1 H) is prepared and isolated as described above or isolated using an alternative séparation technique such as HPLC 10 or SFC using a suitable chiral stationary phase eluting with a suitable mobile phase as determined to be necessary to isolate the required enantiomers. Additionally, compounds of Formula (1H) in which the central ring is replaced by a substituted 5-membered heterocycle (exemplified by Y, in Formula (1)) can also be synthesized in an analogous manner by one skilled in the art.
The compounds and processes ofthe présent invention will be better understood in connection with the following Examples which are intended as an illustration of and not a limitation upon the scope ofthe invention as defined in the appended claims.
Abbreviations which hâve been used in the descriptions ofthe schemes and the examples that follow are: Ac is acetyl; AcOH is acetic acid; Ac2O is acetic anhydride; Adam’s 20 catalyst is platinum (IV) oxide; Br2 is bromine; n-BuLi is n-butyl lithium; °C is degrees celcius; CDCh isdeutero-chloroform; CD3OD is deuteromethanol; CO2 is carbon dioxide; Cs2CO3 is césium carbonate; δ is Chemical shift; DAST is N,N-Diethylamino-S,S-difluorosulfinium tetrafluoroborate; DBU is 1,8-Diazabicyclo[5.4.0]undec-7-ene; DCE is 1,2-dichloroethane; DCM is dichloromethane or methylene chloride; DEA is diethylamine; DMAP is 425 dimethylaminopyridine; DMF is dimethylformamide; DMSO is dimethyl sulfoxide; DMSO-ch is deuterodimethylsulfoxide; Et2O is diethyl ether; EtOAc is ethyl acetate; EtOH is éthanol; EtsN is triethylamine; Fe is iron; g is gram; HCl is hydrochloric acid; HCO2H is formic acid; HMTA is hexamethylenetetramine; HPLC is high pressure liquid chromatography; H2 is hydrogen; H2O is water; h is hours; Hr is hour; Hz is hertz; IPA is isopropyl alcohol; IPAm: is isopropylamine;
[lr(COD)CI]2 is bis(1,5cyclooctadiene)diiridium(l) dichloride; [lr(COD)OMe]2 is (1.5cycloocatdiene)(methoxy)iridium(l) dimer; K2CO3 is potassium carbonate; K3PO4 is potassium phosphate tribasic; KBr is potassium bromide; KMnO4 is potassium permanganate; KOAc is poatssium acetate; L is liter; LCMS is liquid chromatography mass spectrometry; LDA is lithium diisopropylamide; LiHMDS is lithium bis(trimethylsilyl)amide; LiOH is lithium hydroxide monohydrate; LTMP is lithium tetramethylpiperidine; M is molar; m-CPBA is metachloroperoxybenzoic acid; MeCN is acetonitriie; MeOH is methanol; MeNH2 is methyl amine; mg is milligram; MgSO4 is magnésium sulphate; MHz is mega Hertz; min is minutes; mL is milliliter; mm is millimeter; mmol is millimole; mol is mole; MS m/z is mass spectrum peak;
MTBE is tert-butyl methyl ether; MsCI is mesyl chloride; NaBH4 is sodium borohydride; Na2COs is sodium carbonate; NaOH is sodium hydroxide; NaOMe is sodium methoxide; Na2SO4 is sodium sulphate; NBS is N-bromo succinimide; NH3 is ammonia; NH4CI is ammonium chloride; NH2OH-HCI is hydroxylamine hydrochloride; NH4OH is ammonium hydroxide; nM is nanomolar; PCI5 is phosphorus pentachloride; Pd/C is palladium on carbon; Pd(dppf)CI2 is [1,1 ’-
F monohydrate; LTMP is lithium tetramethylpiperidine; M is molar; m-CPBA is metachloroperoxybenzoic acid; MeCN is acetonitrile; MeOH is methanol; MeNH2 is methyl amine;
mg is milligram; MgSO4 is magnésium sulphate; MHz is mega Hertz; min is minutes; mL is milliliter, mm is millimeter; mmol is millimole; mol is mole; MS m/z is mass spectrum peak;
MTBE is tert-butyl methyl ether; MsCI is mesyl chloride; NaBH4 is sodium borohydride; Na2CO3 is sodium carbonate; NaOH is sodium hydroxide; NaOMe is sodium methoxide; Na2SO4 is sodium sulphate; NBS is N-bromo succinimide; NH3 is ammonia; NH4CI is ammonium chloride; NH2OH HCI is hydroxylamine hydrochloride; NH4OH is ammonium hydroxide; nM is nanomolar; PCI5 is phosphorus pentachloride; Pd/C is palladium on carbon; Pd(dppf)CI2 is [1,1’- bis(diphenylphosphino) ferrocene]dichloropalladium(ll); Pd(dppf)CI2 DCM is[1,1 bis(diphenylphosphino) ferrocene]dichloropalladium(ll), complex with dichloromethane; Pd(dppf)-tBu is [1 ,T-bis(di-t-butylphosphino) ferrocene]dichloropalladium(ll); Pd(OAc)2 is palladium acetate; PPh3 is triphenylphosphine; pet. ether is petroleum ether; pH is power of hydrogen; Pin2B2 is bis(pinacolato)diboron; PinBO-iPr is 2-isopropoxy-4,4,5,5-tetramethyl-1,3,2- dioxaborolane; psi is pounds per square inch; ppm is parts per million; POCI3 is phosphorus oxychloride; PrOH is 1-propanol; PtO2 is platinum (IV) oxide; rt is room température, RT is rétention time; SEM-CI is 2-(trimethylsilyl)ethoxymethyl chloride; SFC is supercritical fluid chromatography; TBS is ί-butyldimethylsilyl; TBS-CI is ί-butyldimethylsilyI chloride; tBu3P is tri-tbutylphosphine; TFA is trifluoroacetic acid; TFAA is trifluoroacetic anhydride; TiCI4 is titanium tetrachloride; TfO is trifluoromethanesulfonyl; Tf2O is trifluoromethanesulfonic anhydride; pTsOH is p-toluenesulfonic acid; Turbo Grignard is isopropylmagnesium chloride lithium chloride complex solution; Xantphos is 4,5-Bis(diphenylphosphino)-9,9-dimethylxanthene; XPhos-Pd-G2 is Chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1 '-biphenyl)[2-(2'-amino-1,1'biphenyl)]palladium(ll).
1H and 19F Nuclear magnetic résonance (NMR) spectra were in ail cases consistent with the proposed structures. Characteristic Chemical shifts (δ) are given in parts-per-million downfield from tetramethylsilane (for1 H-NMR) and upfield from trichloro-fluoro-methane (for 19F NMR) using conventional abbreviations for désignation of major peaks: e.g. s, singlet; d, doublet; t, triplet; q, quartet; dd, doublet of doublets; dt, doublet of triplets; td, triplet of doublets;
m, multiplet; br, broad. The following abbreviations hâve been used for common solvents: CDCI3, deuterochloroform; DMSO-d6, deuterodimethylsulphoxide; and CD3OD, deuteromethanol. Where appropriate, tautomers may be recorded within the NMR data; and some exchangeable protons may not be visible.
Mass spectra, MS (m/z), were recorded using either electrospray ionization (ESI) or atmospheric pressure Chemical ionization (APCI).
Where relevant and unless otherwise stated the m/z data provided are for isotopes 19F, 35CI, 79Br and 127l.
I Wherein préparative TLC or column chromatography (silica) has been used, one skilled in the art may choose any combination of appropriate solvents to purify the desired compound.
Specific rotations based on the équation [a] = (100 a)/(l c) are reported as unitless numbers where the concentration c is in g/100 mL and the path length I is in decimeters. The units ofthe specific rotation, (degmL)/g-dm) are implicit and are not included with the reported value.
The following are analytical and préparative chromatography methods used for the analysis and purification of compounds ofthe invention.
Préparative SFC Methods
Prep SFC Method A: Column: Chiralpak IC-H, 250 mm x 30 mm, 5μ; Mobile Phase - Isocratic conditions: CO2/EtOH, 60/40 (v/v); Flow rate: 65 mL/min
Prep SFC Method B: Column: Lux Amylose-1 250 mm x 30 mm, 5μ; Mobile Phase - Isocratic conditions: CO2/MeOH + 0.2% (7N ammonia in MeOH) 80/20 (v/v); Flow rate: 150 mL/min
Prep SFC Method C: Column: Chiralpak IC-H, 250 mm x 50 mm, 5μ; Mobile Phase - Isocratic conditions: CO2/IPA 85/15 (v/v); Flow rate: 250 mL/min
Prep SFC Method D: Column: Chiralcel OJ, 250 mm X 30 mm, 5μ; Mobile Phase - Isocratic conditions: CO2/IPA, 65/35 (v/v); Flow rate: 50 mL/min)
Prep SFC Method E: Column: Daicel Chiralpak AD, 250 mm X 30 mm, 5μ; Mobile Phase Isocratic conditions: CO2/EtOH (0.1% NH4OH), 60/40 (v/v); Flow rate: 50 mL/min
Prep SFC Method F: Column: Daicel Chiralpak IC, 250 mm x 30 mm, 5μ; Mobile Phase Isocratic conditions: CO2/EtOH (0.1% NH4OH), 60/40 (v/v); Flow rate: 200 mL/min)
Prep SFC Method G: Column: Daicel Chiralpak AD, 250 mm x 50 mm, 10 μ; Mobile Phase 30 Isocratic conditions: CO2/EtOH (0.1% NH4OH), 55/45 (v/v); Flow rate: 200 mL/min
Prep SFC Method H: Column: Chiralpak IC-H, 250 mm X 30 mm, 5μ; Mobile Phase - Isocratic conditions: CO2/EtOH (0.1% NH4OH), 75/25 (v/v); Flow rate: 200 mL/min
Prep SFC Method I: Column: Chiralpak IC, 250 mm x 30 mm, 10μ; Mobile Phase - Isocratic conditions: CO2/EtOH (0.1% NH4OH), 60/40 (v/v); Flow rate: 60.0 mL/min
Prep SFC Method J: Column: Chiralpak IC 250 mm x 30mm, 10u; Mobile Phase - Isocratic conditions: CO2/EtOH (0.1% NH4OH), 80/20 (v/v); Flow rate: 60 mL/min
Prep SFC Method K: Column: Chiralpak AD, 250 mm x 30 mm, 5μ; Mobile Phase - Isocratic conditions: CO2/MeOH (0.1% NH4OH), 75/25 (v/v); Flow rate: 50.0 mL/min
Prep SFC Method L: Column: Chiralpak AD, 250 mm x 30 mm, 10μ; Mobile Phase - Isocratic conditions: CO2/MeOH (0.1% NH4OH), 75/25 (v/v); Flow rate: 200.0 mL/min
Prep SFC Method M: Column: Chiralpak IC, 250 mm x 30 mm, 5μ; Mobile Phase - Isocratic conditions: CO2/EtOH (0.1% NH4OH), 55/45 (v/v); Flow rate: 50.0 mL/min
Prep SFC Method N: Column: Chiralpak IC, 250 mm x 30 mm, 5μ; Mobile Phase - Isocratic conditions: CO2/EtOH (0.1% NH4OH), 75/25 (v/v); Flow rate: 60.0 mL/min
Prep SFC Method O: Column: Daicel Chiralpak AD, 250 mm x 50 mm, 10μ; Mobile Phase Isocratic conditions: CO2/MeOH, 60/40 (v/v); Flow rate: 200 mL/min
Prep SFC Method P: Column: Chiralcel OJ-H, 250 mm x 30 mm, 5μ; Mobile Phase - Isocratic conditions: CO2/EtOH (0.1% NH4OH), 85/15 (v/v); Flow rate: 50 mL/min
Prep SFC Method Q: Column: Daicel Chiralpak AD, 250 mm x 30 mm, 5μ; Mobile Phase Isocratic conditions: CO2/IPA (0.1% NH4OH), 75/25 (v/v); Flow rate: 60 mL/min
Prep SFC Method R: Column: Chiral Technologies AD-H, 250 mm x 21 mm, 5μ; Mobile Phase Isocratic conditions: CO2/MeOH (0.2% NH4OH), 80/20 (v/v); Flow rate: 75 mL/min
Prep SFC Method S: Column: Princeton PPU, 250 mm x 30 mm, 5μ; Mobile Phase - Isocratic conditions: CO2/MeOH, 80/20 (v/v); Flow rate: 80 mL/min
Analytical SFC Methods
Analytical SFC Method A: Column: Chiralpak IC, 250 mm x 4.6 mm, 5μ; Mobile Phase A: CO2, Mobile Phase B: EtOH (0.05% isopropylamine); Gradient: A:B=65:35; Flow rate: 2.5 mL/min
Analytical SFC Method B: Column: Lux Amylose-1, 250 mm x4.6 mm, 5μ; Mobile Phase A: CO2, Mobile Phase B: MeOH (0.2% MeNH2); Gradient Elution (time, %A, %B): (0 min, 95%A, 5%B), (1.0 min, 95%A, 5%B), (9.0 min, 40%A, 60%B), (10 min, 95%A, 5%B); Flow rate: 3.0 mL/min
Analytical SFC Method C: Column: Chiralpak IC-3, 150 mm x4.6 mm, 3u; Mobile Phase A: CO2,
Mobile Phase B: IPA (0.05% DEA); Gradient Elution (time, %A, %B): (0 min, 95%A, 5%B), (5.5 min, 60%A, 40%B), (8.5 min, 60%A, 40%B), (10 min, 95%A, 5%B), Flow rate: 2.5 mL/min
Analytical SFC Method D: Column: Chiralpak AD-3, 150 mm x 4.6 mm, 3μ; Mobile Phase A: CO2, Mobile Phase B: EtOH (0.05% DEA); Gradient Elution (time, %A, %B): (0 min, 95%A, 5%B), (5.5 min, 60%A, 40%B), (8.5 min, 60%A, 40%B), (10 min, 95%A, 5%B), Flow rate: 2.5 mL/min
Analytical SFC Method E: Column: Chiralpak IC-3, 150 mm x 4.6 mm, 3μ; Mobile Phase A: CO2, Mobile Phase B: EtOH (0.05% DEA); Gradient Elution (time, %A, %B): (0 min, 95%A, 5%B), (5.5 min, 60%A, 40%B), (8.5 min, 60%A, 40%B), (10 min, 95%A, 5%B), Flow rate: 2.5 mL/min
Analytical SFC Method F: Column: Chiralpak AD-3, 50 mm x 3.0 mm, 3μ; Mobile Phase - Isocratic conditions: CO2/EtOH (0.05% DEA), 60/40 (v/v); Flow rate: 2.0 mL/min
Analytical SFC Method G: Column: Chiralpak AD-3, 150 mm x 4.6 mm, 3 μ ; Mobile phase A: CO2, Mobile Phase B: MeOH (0.05% DEA); Gradient Elution (time, %A, %B): (0 min, 95%A, 5%B), (5.0 min, 60%A, 40%B), (7.5 min, 60%A, 40%B), (10 min, 95%A, 5%B), Flow rate: 2.5 mL/min
Analytical SFC Method H: Column: Chiralcel OJ-3, 100 mm x 4.6 mm, 3μ; Mobile Phase A: CO2, Mobile Phase B: EtOH (0.05% DEA); Gradient Elution (time, %A, %B): (0 min, 95%A, 5%B), (5.0 min, 60%A, 40%B), (7.5 min, 60%A, 40%B), (8.5 min, 95%A, 5%B), Flow rate: 2.8 mL/min
Analytical SFC Method I: Column: Chiralpak IC-3, 150 mm x 4.6 mm, 3μ; Mobile Phase A: CO2, Mobile Phase B: EtOH; Gradient Elution (time, %A, %B): (0 min, 95%A, 5%B), (5.5 min, 60%A, 40%B), (8.5 min, 60%A, 40%B), (10 min, 95%A, 5%B), Flow rate: 2.5 mL/min
Analytical SFC Method J: Column: Chiralpak AD-3, 150 mm x 4.6 mm, 3μ; Mobile Phase A: CO2, Mobile Phase B: EtOH (0.05% DEA); Gradient Elution (time, %A, %B): (0 min, 95%A, 5%B), (5.0 min, 60%A, 40%B), (7.5 min, 60%A, 40%B), (10 min, 95%A, 5%B), Flow rate: 2.5 mL/min
Analytical SFC Method K: Column: Chiral Technologies AD-H, 100 mm x 4.6 mm, 3μ; Mobile Phase A: CO2, Mobile Phase B: MeOH (0.2% NH4OH); Gradient Elution (time, %A, %B): (5 min, 60%A, 40%B, [Flow rate: 1.5 mL/min
Analytical SFC Method L: Column: ChiralCel OJ-H, 150 mm x 4.6 mm, 5μ; Mobile Phase A: CO2, Mobile Phase B: EtOH (0.05% DEA); Gradient Elution (time, %A, %B): (0 min, 95%A, 5%B), (5.0 min, 60%A, 40%B), (8.5 min, 60%A, 40%B), (10 min, 95%A, 5%B), Flow rate: 2.5 mL/min
Analytical SFC Method M: Column: Chiral Tech IG, 250 mm x 4.6 mm, 5μ; Mobile Phase A: CO2,
Mobile Phase B: MeOH (0.2% 7N NH3 in MeOH); Gradient Elution (time, %A, %B): (0 min, 95%A,
5%B), (1.0 min, 95%A, 5%B), (9.0 min, 40%A, 60%B), (9.5 min, 40%A, 60%B), (10 min, 95%A,
5%B), Flow rate: 3.0 mL/min
Analytical SFC Method N: Column: Chiralcel OJ-H 250 mm x 4.6 mm, 5μ; Mobile Phase A: CO2, Mobile Phase B; IPA (0.05% IPAm), Gradient Elution: B in A from 10% to 40% in 10 minutes, Flow rate: 2.5 mL/min
Analytical SFC Method O: Column: ChiralPak AY-3 150 mm * 4.6 mm, 3 μ;
Mobile Phase: A: CO2, Mobile Phase B: Methanol (0.05% DEA); Gradient Elution: (time, %A, %B): (0 min, 95%A, 5%B), (5.5 min, 60%A, 40%B), (8.5 min, 60%A, 40%B) (10 min, 95%A, 5%B), Flow rate: 2.5 mL/min
Analytical SFC Method P: Column: Chiralcel OJ-3 100 mm χ 4.6 mm, 3 μ;
Mobile Phase: A: CO2, Mobile Phase B: Methanol (0.05% DEA); Gradient Elution: (time, %A, %B): (0 min, 95%A, 5%B), (5.5 min, 60%A, 40%B), (7.5 min, 60%A, 40%B) (10 min, 95%A, 5%B), Flow rate: 2.8 mL/min
Analytical SFC Method Q: Column: ChiralCel OD-3, 150 mm x 4.6 mm, 3μ; Mobile Phase A: CO2, Mobile Phase B: EtOH (0.05% DEA); Gradient Elution (time, %A, %B): (0 min, 95%A, 5%B), (5.0 min, 60%A, 40%B), (5.5 min, 95%A, 5%B), (7 min, 95%A, 5%B), Flow rate: 2.5 mL/min
Analytical SFC Method R: Column: Chiralpak AD-3, 100 mm x 4.6 mm, 3μ; Mobile Phase Isocratic conditions: CO2/EtOH (0.05% DEA), 60/40 (v/v); Flow rate: 2.08 mL/min
Analytical SFC Method S: Column: Chiral Technologies OJ-H, 100 mm x 4.6 mm, 5μ; Mobile Phase - Isocratic conditions: CO2/EtOH (0.2% ΝΗ4ΟΗ), 95/5 (v/v); Flow rate: 3.0 mL/min
Analytical SFC Method T: Column: Chiralpak IC, 100 mm x 4.6 mm, 3μ; Mobile Phase A: CO2, Mobile Phase B: EtOH (0.05% DEA); Gradient Elution (time, %A, %B): (0 min, 95%A, 5%B), (0.5 min, 95%A, 5%B) (4.5 min, 60%A, 40%B), (7.0 min, 60%A, 40%B), (9.5 min, 95%A, 5%B), Flow rate: 1.5 mL/min ) Analytical SFC Method U: Column: Lux Amylose-2, 100 mm x 4.6 mm, 5μ; Mobile Phase A: CO2,
Mobile Phase B: MeOH (0.2% NH4OH); Gradient Elution (time, %A, %B): (0 min, 70%A, 30%B), (5.0 min, 70%A, 30%B); Flow rate: 1.5 mL/min
Analytical SFC Method V: Column: Chiral Technologies AD-H, 100 mm x 4.6 mm, 5μ; Mobile Phase A: CO2, Mobile Phase B: MeOH (0.2% Ammonium hydroxide); Gradient Elution (time, %A, %B): (0 min, 85%A, 15%B) (10 min, 85%A, 15%B). Flow rate: 1.5 mL/min
Analytical SFC Method W: Column: Chiral Tech IG, 250 mm x 4.6 mm, 5μ; Mobile Phase A: CO2, 10 Mobile Phase B: EtOH; Gradient Elution (time, %A, %B): (0 min, 95%A, 5%B), (1.0 min, 95%A, 5%B), (9.0 min, 40%A, 60%B), (9.5 min, 40%A, 60%B), (10 min, 95%A, 5%B), Flow rate: 3.0 mL/min
Analytical SFC Method X: Column: ChiralPak AY, 150 mm x 4.6 mm, 3μ; Mobile Phase A: CO2, 15 Mobile Phase B: EtOH (0.05% DEA); Gradient Elution (time, %A, %B): (0 min, 95%A, 5%B), (5.0 min, 40%A, 60%B), (7.5 min, 40%A, 60%B), (10 min, 95%A, 5%B), Flow rate: 2.5 mL/min
Analytical SFC Method Y: Column: Chiral Tech OJ-H, 100 mm x 4.6 mm, 5μ; Mobile Phase A:
CO2, Mobile Phase B: MeOH (0.2% NH4OH); Gradient Elution (time, %A, %B): (0 min, 95%A, 20 5%B), (10 min, 95%A, 5%B), Flow rate: 1.5 mL/min
Analytical SFC Method Z: Column: Chiralcel OJ-3, 150 mm x 4.6 mm, 3μ; Mobile Phase A: CO2, Mobile Phase B: EtOH (0.05% DEA); Gradient Elution (time, %A, %B): (0 min, 95%A, 5%B), (5 min, 60%A, 40%B), (7.5 min, 60%A, 40%B), (10 min, 95%A, 5%B), Flow rate: 2.5 mL/min 25
Analytical SFC Method AA: Column: ChiralPak AD-3 100 mm χ 4.6 mm, 3 μ; Mobile Phase: A: CO2, Mobile Phase B: MeOH (0.05% DEA); Gradient Elution: (time, %A, %B): (0 min, 60%A, 40%B), Flow rate: 2.8 mL/min
Analytical SFC Method BA: Column: Chiralpak IC-3, 150 mm x 4.6 mm, 3μ; Mobile Phase A: CO2, Mobile Phase B: IPA (0.05% DEA); Gradient Elution (time, %A, %B): (0 min, 95%A, 5%B), (5 min, 60%A, 40%B), (7.5 min, 60%A, 40%B), (10 min, 95%A, 5%B), Flow rate: 2.5 mL/min
Analytical SFC Method CA: Column: Lux Cellulose 100 mm χ 4.6 mm, 5 μ; Mobile Phase: A: 35 CO2, Mobile Phase B: MeOH (0.2% NH4OH); Gradient Elution: (time, %A, %B): (0 min, 70%A, 30%B), (5 min, 70%A, 30%B), Flow rate: 1.5 mL/min ) Analytical SFC Method DA: Column: Lux Cellulose-2, 150 mm x4.6 mm, 5μ; Mobile Phase A:
CO2, Mobile Phase B: MeOH (0.05% DEA); Gradient Elution (time, %A, %B): (0 min, 95%A,
5%B), (5.0 min, 60%A, 40%B), (8.5 min, 60%A, 40%B), (10 min, 95%A, 5%B), Flow rate: 2.5 mL/min
Analytical SFC Method EA: Column: Chiralcel OJ-3, 150 mm x 4.6 mm, 3μ; Mobile Phase Isocratic conditions: CO2/EtOH (0.05% DEA), 60/40 (v/v); Flow rate: 2.5 mL/min
Analytical SFC Method FA: Column: ChiralPak AD-3, 250 mm x 4.6 mm, 5μ; Mobile Phase A: 10 CO2, Mobile Phase B: EtOH (0.05% IPAm); Gradient Elution (time, %A, %B): (0 min, 65%A, 35%B), Flow rate: 2.5 mL/mi
Analytical SFC Method GA: Column: Chiral Tech IC, 250 mm x 4.6 mm, 5μ; Mobile Phase A: CO2, Mobile Phase B: IPA (0.2% NH3 in MeOH); Gradient Elution (time, %A, %B): (0 min, 15 95%A, 5%B), (1 min, 95%A, 5%B), (9 min, 40%A, 60%B), (9.5 min, 40%A, 60%B), (10 min,
95%A, 5%B), Flow rate: 2.5 mL/min
Préparative HPLC Methods
Prep HPLC Method A: Column: Xtimate C18, 150 mm x 25 mm, 5μ; Mobile Phase A: water (0.05%
NH4OH v/v), Mobile Phase B MeCN; B%: 18%-58%, 12 min; Flow rate: 25 mL/min
Prep HPLC Method B: Column: Phenomenex XB-C18, 250 mm x 21.2 mm, 5μ; Mobile Phase A: water (0.1% HCO2H), Mobile Phase B: MeCN (0.1% HCO2H); Gradient Elution (time, %A, %B): (0 min, 95%A, 5%B), (1.5 min, 95%A, 5%B), (10.0 min, 0%A, 100%B), (11 min, 0%A, 100%B), (12.5 min, 95%A, 5%B); Flow rate: 27 mL/min
Prep HPLC Method C: Column: Waters Atlantis C18, 50 mm x 4.6 mm, 5μ; Mobile Phase A: water (0.05% TFA), Mobile Phase B: MeCN (0.05% TFA); Gradient Elution (time, %A, %B): (0 min, 95%A, 5%B), (4 min, 5%A, 95%B), (5 min, 5%A, 95%B); Flow rate: 2 mL/min
Prep HPLC Method D: Column: Xtimate C18,150 mm x 25 mm, 5μ; Mobile Phase A: water (0.05% ammonium hydroxide), Mobile Phase B: MeCN; B%: 25% to 65% in 12 min, Flow rate: 25 ml/min
Prep HPLC Method E: Column: Waters Xbridge, 150 mm x 25 mm, 5μ; Mobile Phase A: water (10mM NH4HCO3), Mobile Phase B: MeCN; B%: 20%-50%, 12 min
Prep HPLC Method F: Column: Phenomenex luna C18, 250 mm x 80 mm, 10μ; Mobile Phase A: water (0.1%TFA), Mobile Phase B: MeCN; B%: 1 %-25%, 20 min
Prep HPLC Method G: Column: Phenomenex Synergi Max-RP, 250 mm x 80 mm, 10μ; Mobile Phase A: water (0.1%TFA), Mobile Phase B: MeCN; B%: 10%-40%, 20 min
Prep HPLC Method H: Column: Boston Green ODS, 150 mm x 30 mm, 5μ; Mobile Phase A: water (0.225% HCO2H), Mobile Phase B: MeCN; B%: 5%-53%, 11 min, Flow rate: 25 mL/min
Prep HPLC Method I: Column: Agela Durashell C18, 150 mm x 25 mm, 5μ; Mobile Phase A: water (0.225% HCO2H), Mobile Phase B: MeCN; B%: 9%-39%, 12 min, flow rate: 25 mL/min
Prep HPLC Method J: Column: Phenomenex Gemini C18, 250 mm x 50 mm, 10μ; Mobile Phase A: water (0.05% ammonium hydroxide), Mobile Phase B: MeCN; B%: 5%-25%, 15 min, flow rate: 100 mL/min
Prep HPLC Method K: Column: Agela Durashell C18, 150 mm x 25 mm, 5μ; Mobile Phase A: water (0.225% HCO2H), Mobile Phase B: MeCN; B%: 0%-32%, 11 min, Flow rate 25 mL/min
F Prep HPLC Method L: Column: Xtimate C18,150 mm x 25 mm, 5μ; Mobile Phase A: water (0.05%
NH4OH v/v), Mobile Phase B: MeCN; B%: 15%-55%, 12 min, Flow rate: 25 mL/min
Prep HPLC Method M: Column: Agela Durashell 150 mm x 25 mm, 5μ; Mobile Phase A: water 5 (0.05% NH4OH v/v), Mobile Phase B: MeCN; B%: 30%-60%, 2.5 min, Flow rate: 25 mL/min
Prep HPLC Method N: Column: Phenomenex luna C18, 250 mm x 80 mm, 10μ; Mobile Phase A: water (0.1%TFA), Mobile Phase B: MeCN; B%: 25%-55%, 20 min, Flow rate: 25 mL/min
Prep HPLC Method O: Column: Agela Durashell, 150 mm x 25 mm, 5μ; Mobile Phase A: water (0.05% NH4OH v/v), Mobile Phase B: MeCN; B%: 25%-55%, 10 min, Flow rate: 25 mL/min
Prep HPLC Method P: Column: Agela Durashell, 150 mm x 25 mm, 5μ; Mobile Phase A: water (0.05% NH4OH v/v), Mobile Phase B: MeCN; B%: 30%-60%, 10 min, flow rate: 25 mL/min
Prep HPLC Method Q: Column: Agela Durashell, 150 mm x 25 mm, 5μ; Mobile Phase A: water (0.05% NH4OH v/v), Mobile Phase B: MeCN; B%: 23%-53%, 10 min, flow rate: 25 mL/min
Prep HPLC Method R: Column: Phenomenex Gemini C18, 250 mm x 50 mm, 10μ; Mobile Phase
A: Water (0.05% NH4OH v/v), Mobile Phase B: MeCN; Gradient Elution (time, %A, %B): (0 min, 20 90%A, 10%B), (15 min, 60%A, 40%B), (18 min, 0%A, 100%B), Flow rate: 110 mL/min)
Prep HPLC Method S: Column: Phenomenex Gemini C18, 250 mm x 50 mm, 10μ; Mobile Phase A: Water (0.05% NH4OH v/v), Mobile Phase B: MeCN; Gradient Elution (time, %A, %B): (0 min, 80%A, 20%B), (15 min, 60%A, 40%B), (18 min, 0%A, 100%B), Flow rate: 110 mL/min 25
Prep HPLC Method T: Column: Phenomenex Gemini C18, 250 mm x 50 mm, 10μ; Mobile Phase
A: Water (0.05% NH4OH v/v), Mobile Phase B: MeCN; B%: 20%-40%, 15 min, flow rate 110 ml/min
Prep HPLC Method U: Column: Phenomenex Gemini C18, 250 mm x 50 mm, 10μ; Mobile Phase A: Water (0.05% NH4OH v/v), Mobile Phase B: MeCN; Gradient Elution (time, %A, %B): (0 min, 75%A, 25%B), (15 min, 55%A, 45%B), (18 min, 0%A, 100%B), Flow rate: 110 mL/min
Prep HPLC Method V: Column: Phenomenex Synergi Max-RP, 150 mm x 50 mm, 10μ; Mobile 35 Phase A: Water (0.225% HCO2H), Mobile Phase B: MeCN; B%: 0%-30%, 25 min, flow rate 120 mL/min
Prep HPLC Method W: Column: Xtimate C18, 150 mm x 25 mm, 5μ; Mobile Phase A: Water (0.05% NH4OH v/v), Mobile Phase B: MeCN; B%: 17%-57%, 12 min, Flow rate: 25 mL/min
Prep HPLC Method X: Column: Agela Durashell C18, 150 mm x 30 mm, 5μ; Mobile Phase A: Water, Mobile Phase B: MeCN; Gradient Elution (time, %A, %B): (0 min, 82%A, 18%B), (10 min, 42%A, 58%B), (18 min, 0%A, 100%B), Flow rate: 25 mL/min
Prep HPLC Method Y: Column: Boston Green ODS, 150 mm x 30 mm, 5μ; Mobile Phase A: water (0.05% NH4OH v/v), Mobile Phase B: MeCN; B%: 45%-65%, 9 min, Flow rate 25 mL/min
Prep HPLC Method Z: Column: Phenomenex Gemini C18, 250 mm x 50 mm, 10μ; Mobile Phase A: Water (0.05% NH4OH v/v), Mobile Phase B: MeCN; Gradient Elution (time, %A, %B): (0 min, 80%A, 20%B), (15 min, 60%A, 40%B), (18 min, 0%A, 100%B), Flow rate: 110 mL/min
Prep HPLC Method AA: Column: Gemini C18, 15 mm x 21.2 mm, 5 μ; Mobile Phase A: water (0.1% HCO2H) Mobile Phase B: MeCN (0.1% HCO2H); B% 25% - 35%; 25 mL/min
Prep HPLC Method BA: Column: Agela Durashell C18, 150 mm x 30 mm, 5μ; Mobile Phase A: water (0.05% NH4OH v/v), Mobile Phase B: MeCN; B%: 20%-55%, 15 min, Flow rate: 25 mL/min
Prep HPLC Method CA: Column: Phenomenex Gemini C18, 250 mm x 50 mm, 10μ; Mobile Phase A: Water (0.05% NH4OH v/v), Mobile Phase B: MeCN; Gradient Elution (time, %A, %B): (0 min, 75%A, 25%B), (15 min, 55%A, 45%B), (18 min, 0%A, 100%B); Flow rate: 110 mL/min
Examples
Préparation 1: 3-(1-((tert-butyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl)propan-2-yl)-5-(3,4-dimethoxyphenyl)pyridine
To a solution of 3-(3-((tert-butyldimethylsilyl)oxy)-1-(4,4,5,5-tetramethyl-1,3,2dioxaborolan-2-yl)prop-1-en-2-yl)-5-(3,4-dimethoxyphenyl)pyridine (Préparation 2, 1.6 g, 3.13 mmol) in EtOAc (50 mL) was added Pd/C (0.5 g, 10% loading). The mixture was stirred under H2 (5 psig) at 20 °C for about 3 h. The mixture was filtered and concentrated to afford 3-(1((tert-butyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-2-yl)-5-(3,4dimethoxyphenyl)pyridine (1.2 g), which was used directly without further purification. 1H NMR (CDCI3,400 MHz): δ 8.69 (d, J=7.6 Hz, 1H), 8.48 (s, 1 H), 7.78 (s, 1H), 7.32 (s, 1H), 7.18 (d, J = 8.4 Hz, 1H), 7.12 (d, J = 1.6 Hz, 1H), 7.04-7.01 (m, 1H), 4.15-4.20 (m, 1H), 4.00 (d, J = 8.4
Hz, 6H), 3.75-3.79 (m, 1H), 2.10 (s, 12H), 1.31 (d, J = 11.2 Hz, 9H), 1.15 (d, J = 12.8 Hz, 1H),
0.88 (d, J = 8.8 Hz, 1H), 0.01-0.02 (m, 6H). LCMS m/z = 514 [MH]+.
Préparation 2: 3-(3-((tert-butyldimethylsilyl)oxy)-1 -(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2yl)prop-1-en-2-yl)-5-(3,4-dimethoxyphenyl)pyridine
A solution of 3-(1-bromo-3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-5-(3,4dimethoxyphenyl)pyridine (Préparation 37, 0.83 g, 1.79 mmol), Pd(dppf)Cl2-DCM (73 mg, 89 umol), KOAc (263 mg, 2.68 mmol) and Pin2B2 (CAS 73183-34-3, 681 mg, 2.68 mmol) in 1,4dioxane (10 mL) was heated to 55 °C under N2 for 12 h. The mixture was concentrated and the residue was purified by column chromatography (silica) and eluted with pet. ether/EtOAc (3:1) to afford 3-(3-((tert-butyldimethylsilyl)oxy)-1-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)prop-1en-2-yl)-5-(3,4-dimethoxyphenyl)pyridine (900 mg, 98%). 1H NMR (CDCh.400 MHz): δ 8.74 (s, 1H), 8.71 (s, 1H), 8.03 (s, 1H), 7.13-7.16 (m, 1H), 7.09 (s, 1H), 6.98 (d, J= 8.4 Hz, 1H), 5.90 (s, 1H), 4.97 (s, 2H), 3.96 (s, 3H), 3.94 (s, 3H). LCMS m/z = 512 [MH]+.
Préparation 3: 3-(1-((tert-butyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2yl)propan-2-yl)-5-(3-ethoxy-4-methoxyphenyl)pyridine
3-(1 -((tert-butyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-l ,3,2-dioxaborolan-2-yl)propan2-yl)-5-(3-ethoxy-4-methoxyphenyl)pyridine (3.8 g, 95%) was prepared in an analogous manner to Préparation 1 using 3-(1-bromo-3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-5-(3-ethoxy-4methoxyphenyl)pyridine (Préparation 4, 4.0 g, 7.6 mmol) which was used without further purification.
Préparation 4: 3-(3-((tert-butyldimethylsilyl)oxy)-1 -(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2yl)prop-1-en-2-yl)-5-(3-ethoxy-4-methoxyphenyl)pyridine
3-(3-((tert-butyldimethylsilyl)oxy)-1 -(4,4,5,5-tetramethyl-l ,3,2-dioxaborolan-2-yl)prop-1en-2-yl)-5-(3-ethoxy-4-methoxyphenyl)pyridine (7.5 g, 97%) was prepared in an analogous manner to Préparation 2 using 3-(1-bromo-3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-5-(35 ethoxy-4-methoxyphenyl)pyridine (Préparation 38, 7.0 g, 14.6 mmol). 1H NMR (CDCH, 400MHz): δ 8.69-8.73 (m, 2H), 8.03 (s, 1H), 7.14 (dd, J = 2.0, 8.4 Hz, 1H), 7.10 (s, 1H), 6.97 (d, J= 8.4 Hz, 1H), 5.90 (s, 1H), 4.97 (s, 2H), 4.18 (q, J = 7.2 Hz, 2H), 3.93 (s, 1H), 1.51 (t, J= 7.2 Hz, 3H), 1.33 (s, 12H), 0.83 (s, 9H), 0.08 (s, 6H).
Préparation 5: 3-(1-((tert-butyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2yl)propan-2-yl)-5-(4-methoxy-3-propoxyphenyl)pyridine
To a solution of 3-(3-((tert-butyldimethylsilyl)oxy)-1-(4,4,5,5-tetramethyl-l ,3,2dioxaborolan-2-yl)prop-1-en-2-yl)-5-(4-methoxy-3-propoxyphenyl)pyridine (Préparation 8, 4.00 g, 7.41 mmol) in EtOAc (100 mL) was added Pd/C (1.0 g, 10% loading) under N2. The mixture was stirred under H2 (14 psig) at about 25 °C for about 3 h. The mixture was filtered and concentrated to afford 3-(1-((tert-butyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-l ,3,2dioxaborolan-2-yl)propan-2-yl)-5-(4-methoxy-3-propoxyphenyl)pyridine (3.44 g, 86%), which was used without further purification.
Préparation 6: (R)-(3-((tert-butyldimethylsilyl)oxy)-2-(5-(4-methoxy-3-propoxyphenyl)pyridin-3yl)propyl)boronic acid
Method A:
To a mixture of 3-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-5-(4-methoxy-3propoxyphenyl)pyridine (Préparation 50, 50.00 g, 120.9 mmol), [lr(COD)CI]2 (CAS 12112-67-3,
2.03 g, 3.02 mmol) and (S,S)-[2-(4'-i-propyloxazolin-2-yl)ferrocynyl]diphenylphosphine (CAS
163169-29-7, 3.20 g, 6.65 mmol) was added anhydrous THF (403 mL). The mixture was stirred for about 15 min at about 20 °C under N2. The flask was chilled in an ice water bath until the solution température was about 0 °C. Catecholborane (181.48 mL, 181 mmol, 1.0 M in THF) was added dropwise over 1 h. Once the catecholborane was added the flask was removed from the cooling bath and stirred at about 20 °C for about 3 h. The mixture was quenched with a dropwise addition of methanol (25 mL) at about 0 °C (ice bath). The solution was removed from the ice bath and stirred about 30 min. The solution was concentrated to afford (R)-(3-((tertbutyldimethylsilyl)oxy)-2-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)propyl)boronic acid (88 g), which is used directly without further purification. LCMS m/z = 460 [MH]+.
Method B:
To a solution of Turbo Grignard (180 mL, 117 mmol, 1.3 M in THF) was added 1,4dioxane (19 mL) and stirred at about 20 °C for about 1 h. To the mixture was added slowly a solution of (R)-3-(1-((tert-butyldimethylsilyl)oxy)-3-iodopropan-2-yl)-5-(4-methoxy-3propoxyphenyl)pyridine (Préparation 42, 46.8 g, 86.5 mmol) in anhydrous THF (270 mL), which was stirred at about 20 °C for about 20 min. A solution of trimethyl borate (96.4 mL, 865 mmol) in THF (107 mL) was added drop wise and stirred at about 20 °C for about 30 min. The mixture was concentrated and partitioned between water (500 mL) and EtOAc (200 mL). The aqueous layer was extracted with EtOAc (3 x 100 mL). The combined EtOAc layers were washed with brine, dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography (silica) and eluted with heptanes/EtOAc (80:20 to 0:100) followed by EtOAc/MeOH (100:0 to 90:10) to afford (R)-(3-((tert-butyldimethylsilyl)oxy)-2-(5-(4-methoxy-3propoxyphenyl)pyridin-3-yl)propyl)boronic acid (29.0 g, 73%). 1H NMR (CD3OD, 400 MHz): δ 8.51 (d, J = 2.3 Hz, 1H), 8.30 (d, J= 2.0 Hz, 1H), 7.85 (br s, 1H), 7.14-7.17 (m, 2H), 7.03 (d, J = 7.8 Hz, 1 H), 4.00 (t, J = 6.6 Hz, 2H), 3.85 (s, 3H), 3.70-3.80 (m, 2H), 3.27 (br s, 2H), 3.07-3.14 (m, 1H), 1.76-1.85 (m, 2H), 1.10-1.33 (m, 2H), 1.03 (t, J= 7.81 Hz, 3H), 0.79 (s, 9H), -0.08 (d, J = 12.9 Hz, 6H). LCMS m/z = 460 [MH]+.
Préparation 7: (S)-(3-((tert-butyldimethylsilyl)oxy)-2-(5-(4-methoxy-3-propoxyphenyl)pyridin-3yl)propyl)boronic acid
OH
I
To a mixture of 3-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-5-(4-methoxy-3propoxyphenyl)pyndine (Préparation 50, 1.0 g, 2.42 mmol), [lr(COD)CI]2 (CAS 12112-67-3, 44.2 mg, 0.06 mmol) and (R,R)-[2-(4'-i-propyloxazolin-2-yl)ferrocynyl]diphenylphosphine (CAS 541540-70-9, 58.2 mg, 0.12 mmol) was added anhydrous THF (8.1 mL). The mixture was stirred at about 20 °C for about 10 min. The reaction was cooled to about 0 °C and catecholborane (6.04 mL, 6.04 mmol, 1.0 M in THF) was added dropwise. The reaction was warmed to about 20 °C and stirred for about 8 h. The reaction was cooled to about 5 °C and quenched with MeOH. The mixture was concentrated and purified by column chromatography (silica) and eluted with DCM/MeOH (100:0 to 90:10) to afford (S)-(3-((tertbutyldimethylsilyl)oxy)-2-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)propyl)boronic acid (889 mg, 80%). 1H NMR (CD3OD, 400 MHz): δ 8.51 (d, J = 2.3 Hz, 1 H), 8.30 (d, J = 2.0 Hz, 1 H), 7.85 (brs, 1H), 7.14-7.17 (m, 2H), 7.03 (d, J = 7.8 Hz, 1H), 4.00 (t, J= 6.6 Hz, 2 H), 3.85 (s, 3H), 3.70-3.80 (m, 2H), 3.27 (brs, 2H), 3.07-3.14 (m, 1H), 1.76-1.85 (m, 2H), 1.10-1.33 (m, 2H), 1.03 (t, J = 7.81 Hz, 3H), 0.79 (s, 9H), -0.08 (d, J= 12.9 Hz, 6H). LCMS m/z = 460 [MH]+.
Préparation 8: 3-(3-((tert-butyldimethylsilyl)oxy)-1-(4,4,5,5-tetramethyl-1,3,2dioxaborolan-2-yl)prop-1-en-2-yl)-5-(4-methoxy-3-propoxyphenyl)pyridine
3-(1-Bromo-3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-5-(4-methoxy-3propoxyphenyl)pyridine (Préparation 39, 5.60 g, 11.37 mmol), Pd(dppf)CI2 (415.98 mg, 568.50 umol), Pin2B2 (4.33 g, 17.06 mmol) and KOAc (2.23 g, 22.74 mmol) in dioxane (100 mL) was heated to about 60 °C under N2for about 16 h. The mixture was filtered and concentrated. The residue was purified by column chromatography (silica) and eluted with pet. ether/EtOAc (5:1) to afford 3-(3-((tert-butyldimethylsilyl)oxy)-1-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)prop-1en-2-yl)-5-(4-methoxy-3-propoxyphenyl)pyridine (6.10 g, 99%). 1H NMR (CDCI3, 400MHz): δ 8.70-8.73 (m, 2H), 8.03 (t, J = 2.0 Hz, 1H), 7.14 (dd, J = 2.0, 8.4 Hz, 1H), 7.10 (s, 1H), 6.97 (d, J = 8.4 Hz, 1 H), 5.90 (s, 1 H), 4.97 (s, 2H), 4.06 (t, J = 6.8 Hz, 2H), 3.93 (s, 1 H), 1.87-1.96 (m, 2H), 1.33 (s, 12H), 1.08 (t, J = 7.6 Hz, 3H), 0.83 (s, 9H), 0.07 (s, 6H).
Préparation 9: 3-(1-((tert-butyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl)propan-2-yl)-5-(3-isopropoxy-4-methoxyphenyl)pyridine
Bis(1,5-cyclooctadiene)di-p-methoxydiiridium(l) (CAS 12148-71-9, 96 mg, 0.15 mmol) and ethylenebis(diphenylphosphine) (CAS, 1663-45-2, 116 mg, 0.29 mmol) in anhydrous DCE (10 mL) were stirred for about 15 min under N2 at about 15 °C. 3-(3-((tert5 butyldimethylsilyl)oxy)prop-1-en-2-yl)-5-(3-isopropoxy-4-methoxyphenyl)pyridine (Préparation 51,600 mg, 1.45 mmol) was added to the mixture under N2 at about 15 °C. After stirring for about 5 min, 4,4,5,5-tetramethyl-l,3,2-dioxaborolane (CAS 25015-63-9, 913 mg, 7.13 mmol) was added at about 70 °C and stirred for an additional 15 min. The reaction was quenched with MeOH and concentrated. The residue was purified by column chromatography (silica) and eluted with pet. ether:EtOAc (100:0 to 85:15) to give afford 3-(1-((tert-butyldimethylsilyl)oxy)-3(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)propan-2-yl)-5-(3-isopropoxy-4methoxyphenyl)pyridine (750 mg, 96%). LCMS m/z = 542 [MH]+.
Préparation 10: 3-(1-((tert-butyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2yl)propan-2-yl)-5-(3-cyclopropoxy-4-methoxyphenyl)pyridine
3-(1-((tert-butyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-l, 3,2-dioxaborolan-2-yl)propan2-yl)-5-(3-cyclopropoxy-4-methoxyphenyl)pyridine (750 mg, 95%) was prepared in an analogous manner to Préparation 9 using 3-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-5-(3cyclopropoxy-4-methoxyphenyl)pyridine (Préparation 52, 600 mg, 1.46 mmol). LCMS m/z = 540
[MH]+.
Préparation 11: 3-(1-((tert-butyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2yl)propan-2-yl)-5-(3-(2-((tert-butyldimethylsilyl)oxy)ethoxy)-4-methoxyphenyl)pyridine
3-(1 -((tert-butyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-l, 3,2-dioxaborolan-2-yl)propan2-yl)-5-(3-(2-((tert-butyldimethylsilyl)oxy)ethoxy)-4-methoxyphenyl)pyridine (2.0 g, 81%) was prepared in an analogous manner to Préparation 9 using 3-(3-(2-((tertbutyldimethylsilyl)oxy)ethoxy)-4-methoxyphenyl)-5-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2yl)pyridine (Préparation 53, 2.0 g, 3.8 mmol). LCMS m/z = 658 [MH]+.
Préparation 12: 3-(1-((tert-butyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2yl)propan-2-yl)-5-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-4-methoxyphenyl)pyridine
3-(1-((tert-butyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)propan2-yl)-5-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-4-methoxyphenyl)pyridine (12.0 g, 97%) was prepared in an analogous manner to Préparation 9 using 3-(3-((tert-butyldimethylsilyl)oxy)prop1-en-2-yl)-5-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-4-methoxyphenyl)pyridine (Préparation 54, 10.0 g, 18.4 mmol). LCMS m/z = 671 [MH]+.
Préparation 13: 3-(1-((tert-butyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-l ,3,2-dioxaborolan-2yl)propan-2-yl)-5-(3-(2-fluoroethoxy)-4-methoxyphenyl)pyridine
3-(1-((tert-butyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-l ,3,2-dioxaborolan-2-yl)propan2-yl)-5-(3-(2-fluoroethoxy)-4-methoxyphenyl)pyridine (700 mg, 89%) was prepared in an analogous manner to Préparation 9 using 3-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-5-(320225 (2-fluoroethoxy)-4-methoxyphenyl)pyridine (Préparation 55, 600 mg, 1.4 mmol). LCMS m/z =
433 [MH] .
Préparation 14: tert-butyl(2-(3'-(3-fluoropropoxy)-4'-methoxy-[1,1'-biphenyl]-3-yl)-3-(4,4,5,5tetramethyl-1,3,2-dioxaborolan-2-yl)propoxy)dimethylsilane
tert-butyl(2-(3'-(3-fluoropropoxy)-4'-methoxy-[1,1'-biphenyl]-3-yl)-3-(4,4,5,5-tetramethyl1,3,2-dioxaborolan-2-yl)propoxy)dimethylsilane was prepared in an analogous manner to Préparation 9 using 3-(3-((tert-butyldimethylsilyl)oxy)prop-1 -en-2-yl)-5-(3-(3-fluoropropoxy)-4methoxyphenyl)pyridine (Préparation 56).
Préparation 15: 3-(1-((tert-butyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl)propan-2-yl)-5-(2-(difluoromethyl)-3-ethoxy-4-methoxyphenyl)pyridine
3-(1-((tert-butyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan2-yl)-5-(2-(difluoromethyl)-3-ethoxy-4-methoxyphenyl)pyridine (300 mg, 46%) was prepared in an analogous manner to Préparation 9 using 3-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-5(2-(difluoromethyl)-3-ethoxy-4-methoxyphenyl)pyridine (Préparation 57, 361 mg, 1.13 mmol). LCMS m/z = 578 [MH]+.
Préparation 16: 3-(1-((tert-butyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl)propan-2-yl)-5-(3-ethoxy-5-fluoro-4-methoxyphenyl)pyridine
3-(1-((tert-butyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan2-yl)-5-(3-ethoxy-5-fluoro-4-methoxyphenyl)pyridine (650 mg, 75%) was prepared in an analogous manner to Préparation 9 using 3-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-5-(3ethoxy-5-fluoro-4-methoxyphenyl)pyridine (Préparation 58, 660 mg, 1.58 mmol). LCMS m/z = 546 [MH]+.
Préparation 17: 3-(1-((tert-butyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl)propan-2-yl)-5-(3-chloro-5-ethoxy-4-methoxyphenyl)pyridine
3-(1-((tert-butyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan2-yl)-5-(3-chloro-5-ethoxy-4-methoxyphenyl)pyridine (800 mg, 77%) was prepared in an analogous manner to Préparation 9 using 3-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-5-(3chloro-5-ethoxy-4-methoxyphenyl)pyridine (Préparation 59, 800 mg, 1.8 mmol). LCMS m/z = 562 [MH]+.
Préparation 18: 3-(1-((tert-butyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl)propan-2-yl)-5-(5-ethoxy-2-fluoro-4-methoxyphenyl)pyridine
3-(1-((tert-butyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan2-yl)-5-(5-ethoxy-2-fluoro-4-methoxyphenyl)pyridine (2.0 g, 85%) was prepared in an analogous manner to Préparation 9 using 3-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-5-(5-ethoxy-2fluoro-4-methoxyphenyl)pyridine (Préparation 60, 1.80 g, 4.31 mmol). 1H NMR (CDCh, 400MHz): δ 8.56 (t, J = 1.7 Hz, 1 H), 8.44 (d, J = 2.0 Hz, 1 H), 7.71 (m, 1 H), 6.88 (d, J = 7.5 Hz, 1H), 6.73 (d, J = 11.5 Hz, 1H), 4.10 (q, J= 7.0 Hz, 2H), 3.90 (s, 3H), 3.68-3.75 (m, 2H), 3.073.14 (m, 1H), 1.47 (t, J= 7.0 Hz, 3H), 1.22-1.29 (m, 2H), 1.09 (d, J= 13.1 Hz, 12H), 0.81 (s, 9H), -0.06 (d, J = 6.5 Hz, 6H). LCMS m/z = 546 [MH]+.
Préparation 19: 3-(1-((tert-butyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2yl)propan-2-yl)-5-(2-chloro-5-ethoxy-4-methoxyphenyl)pyridine
3-(1-((tert-butyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-l, 3,2-dioxaborolan-2-yl)propan2-yl)-5-(2-chloro-5-ethoxy-4-methoxyphenyl)pyridine (2.05 g, 73%) was prepared in an analogous manner to Préparation 9 using 3-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-5-(2chloro-5-ethoxy-4-methoxyphenyl)pyridine (Préparation 61,2.17 g, 5.0 mmol). 1H NMR (CDCI3, 400MHz): δ 8.44 (m, 2H), 7.63 (t, J = 2.0 Hz, 1 H), 6.95 (s, 1 H), 6.77 (s, 1 H), 4.06 (q, J = 7.0 Hz, 2H), 3.89 (s, 3H), 3.64-3.74 (m, 2H), 3.06-3.13 (m, 1H), 1.45 (t, J = 7.0 Hz, 3H), 1.23-1.29 (m, 2H), 1.08 (d, J = 13.6 Hz, 12H), 0.79 (s, 9H), -0.08 (d, J= 6.8 Hz, 6H).
Préparation 20: 3-(1-((tert-butyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2yl)propan-2-yl)-5-(2-fluoro-4-methoxy-5-propoxyphenyl)pyridine
3-(1-((tert-butyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-l, 3,2-dioxaborolan-2-yl)propan2-yl)-5-(2-fluoro-4-methoxy-5-propoxyphenyl)pyridine (4.0 g, 86%) was prepared in an analogous manner to Préparation 9 using 3-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-5-(2fluoro-4-methoxy-5-propoxyphenyl)pyridine (Préparation 62, 6 g, 8.3 mmol). LCMS m/z = 560 [MH]+.
Préparation 21: 3-(1-((tert-butyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2yl)propan-2-yl)-5-(4-(difluoromethoxy)-3-propoxyphenyl)pyridine
3-(1-((tert-butyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan2-yl)-5-(4-(difluoromethoxy)-3-propoxyphenyl)pyridine (2.25 g, 88%) was prepared in an analogous manner to Préparation 9 using 3-(3-((tert-butyIdimethylsilyl)oxy)prop-1-en-2-yl)-5-(4(difluoromethoxy)-3-propoxyphenyl)pyridine (Préparation 63, 2.0 g, 4.5 mmol). 1H NMR (CDCh, 400MHz): δ 8.61 (d, J= 2.2 Hz, 1H), 8.57 (d, J= 2.1 Hz, 1H), 7.73 (t, J= 2.1 Hz, 1H), 7.24 (d, J = 8.0 Hz, 1H), 7.09-7.12 (m, 2H), 6.61 (t, J= 75.3 Hz, 1H), 4.05 (t, J= 6.5 Hz, 2H), 3.67-3.77 (m, 2H), 3.09-3.16 (m, 1H), 2.16 (s, 2H), 1.84-1.93 (2H), 1.06-1.11 (m, 15H), 0.81 (s, 9H), -0.07-0.05 (d, J = 5.8 Hz, 6H). LCMS m/z = 578 [MH]+.
Préparation 22: 5'-(1-((tert-butyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl)propan-2-yl)-3-fluoro-5-methoxy-6-propoxy-2,3'-bipyridine
5'-(1-((tert-butyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan2-yl)-3-fluoro-5-methoxy-6-propoxy-2,3'-bipyridine (4.02 g, quant.) was prepared in an analogous manner to Préparation 9 using 5'-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-3fluoro-5-methoxy-6-propoxy-2,3'-bipyridine (Préparation 64, 3.1 g, 7.17 mmol). 1H NMR (CDCh, 400MHz): δ 9.03 (s, 1H), 8.45 (d, J=2.3Hz, 1H), 8.13-8.15 (m, 1H), 6.95 (d, J= 11.3 Hz, 1H), 4.12 (t, J = 7.0 Hz, 2H), 3.92 (s, 3H), 3.68-3.76 (m, 2H), 3.09-3.16 (m, 1H), 1.85-1.94 (m, 2H), 1.22-1.29 (m, 2H), 1.10 (d, J = 11.5 Hz, 12H), 1.05 (t, J= 7.5 Hz, 3H), 0.81 (s, 9H), -0.07-0.06 (d, J = 7.5Hz, 6H). LCMS m/z = 561 [MH]+
Préparation 23: 5'-(1-((tert-butyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl)propan-2-yl)-6-methoxy-5-propoxy-3,3'-bipyridine
5'-(1-((tert-butyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan2-yl)-6-methoxy-5-propoxy-3,3'-bipyridine (2.55 g, 81%) was prepared in an analogous manner to Préparation 9 using 5'-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-6-methoxy-5-propoxy3,3'-bipyridine (Préparation 65, 2.4 g, 5.8 mmol). LCMS m/z = 543 [MH]+.
Préparation 24: 5-(1-((tert-butyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl)propan-2-yl)-3-(3-ethoxy-4-methoxyphenyl)-2-methylpyridine
5-(1-((tert-butyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan5 2-yl)-3-(3-ethoxy-4-methoxyphenyl)-2-methylpyridine (700 mg, 91%) was prepared in an analogous manner to Préparation 9 using 5-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-3-(3ethoxy-4-methoxyphenyl)-2-methylpyridine (Préparation 66, 590 mg, 1.43 mmol). LCMS m/z = 542 [MH]+.
Préparation 25: 4-(1-((tert-butyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-210 yl)propan-2-yl)-2-(4-methoxy-3-propoxyphenyl)-6-(trifluoromethyl)pyrimidine
4-(1-((tert-butyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan2-yl)-2-(4-methoxy-3-propoxyphenyl)-6-(trifluoromethyl)pyrimidine (0.94 g, 59%) was prepared in an analogous manner to Préparation 9 using 4-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)15 2-(4-methoxy-3-propoxyphenyl)-6-(trifluoromethyl)pyrimidine (Préparation 67, 1.27 g, 2.63 mmol). Ή NMR (CDCh, 400MHz): δ 8.17-8.19 (m, 1H), 8.10 (d, J = 2.1 Hz, 1H), 7.42 (s, 1H), 6.97 (d, J= 8.6 Hz, 1H), 4.12-4.16 (m, 2H), 3.95 (s, 3H), 3.79-3.89 (m, 2H), 3.31-3.37 (m, 1H), 1.90-1.99 (m, 2H), 1.23-1.29 (m, 2H), 1.13 (s, 6H), 1.10 (t, J= 7.5 Hz, 3H), 1.05 (s, 6H), 0.800.82 (s, 9H), -0.04 (t, J = 3.1 Hz, 3H), -0.08 (t, J = 3.1 Hz, 3H). LCMS m/z = 611 [MH]+
Préparation 26: 2-(1-((tert-butyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl)propan-2-yl)-6-(3-ethoxy-4-methoxyphenyl)pyrazine
2-(1-((tert-butyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-l ,3,2-dioxaborolan-2-yl)propan2-yl)-6-(3-ethoxy-4-methoxyphenyl)pyrazine (720 mg, 43%) was prepared in an analogous manner to Préparation 9 using 2-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-6-(3-ethoxy-45 methoxyphenyl)pyrazine (Préparation 68, 1.26 g, 3.1 mmol). LCMS m/z = 529 [MH]+.
Préparation 27: 2-(6-(1-borono-3-((tert-butyldimethylsilyl)oxy)propan-2-yl)-2-(4-methoxy-3propoxyphenyl)pyrimidin-4-yl)acetic acid
Ethyl 2-(6-(1 -((tert-butyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-l ,3,2-dioxaborolan-210 yl)propan-2-yl)-2-(4-methoxy-3-propoxyphenyl)pyrimidin-4-yl)acetate (Préparation 28, 758 mg, 1.21 mmol) was dissolved in MeCN (10 mL) and water (10 mL). To the solution was added LiOHH2O (101 mg, 2.41 mmol) in portions. The mixture was stirred at about 25 °C for about 1 h. The mixture was concentrated. The reaction mixture was used directly in the next step without further purification. LCMS m/z = 519 [MH]+.
Préparation 28: ethyl 2-(6-(1-((tert-butyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-l ,3,2dioxaborolan-2-yl)propan-2-yl)-2-(4-methoxy-3-propoxyphenyl)pyrimidin-4-yl)acetate
101
Ethyl 2-(6-(1-((tert-butyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-l ,3,2-dioxaborolan-2yl)propan-2-yl)-2-(4-methoxy-3-propoxyphenyl)pynmidin-4-yl)acetate (437 mg, 70%) was prepared in an analogous manner to Préparation 9 using ethyl 2-(6-(3-((tertbutyldimethylsilyl)oxy)prop-1-en-2-yl)-2-(4-methoxy-3-propoxyphenyl)pyrimidin-4-yl)acetate (Préparation 69, 500 mg, 0.99 mmol). LCMS m/z = 629 [MH]+.
Préparation 29: 4-(1 -((tert-butyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2yl)propan-2-yl)-6-(((tert-butyldimethylsilyl)oxy)methyl)-2-(4-methoxy-3-propoxyphenyl)pyrimidine
4-(1-((tert-butyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-l, 3,2-dioxaborolan-2-yl)propan2-yl)-6-(((tert-butyldimethylsilyl)oxy)methyl)-2-(4-methoxy-3-propoxyphenyl)pyrimidine (1.0 g, 58%) was prepared in an analogous manner to Préparation 9 using 4-(((tertbutyldimethylsilyl)oxy)methyl)-6-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-2-(4-methoxy-3propoxyphenyl)pyrimidine (Préparation 70, 1.4 g, 2.5 mmol). LCMS m/z = 687 [MH]+.
Préparation 30: methyl (Z)-2-(2'-cyano-4'-methoxy-3'-propoxy-[1,1'-biphenyl]-3-yl)-3-(4,4,5,5tetramethyl-1,3,2-dioxaborolan-2-yl)acrylate
A mixture of methyl (Z)-2-(2'-cyano-4'-methoxy-3'-propoxy-[1,1'-biphenyl]-3-yl)-3(((trifluoromethyl)sulfonyl)oxy)acrylate (Préparation 40, 15.00 g, 30.03 mmol), Pd(dppf)Cl2 (1.10 g, 1.50 mmol), Pin2B2 (11.44 g, 45.05 mmol) and KOAc (4.42 g, 45.05 mmol) in 1,4-dioxane (200 mL) was stirred at about 80 °C for about 2 h under N2. The mixture was filtered and concentrated. The residue was purified by column chromatography (silica) and eluted with pet. ether/EtOAc (5:1) to afford methyl (Z)-2-(2'-cyano-4'-methoxy-3'-propoxy-[1,T-biphenyl]-3-yl)-3(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)acrylate (13.6 g, 94%). 1H NMR (CDCI3, 400MHz):
102 δ 7.52 (s, 1Η), 7.49-7.47 (m, 1H), 7.42-7.40 (m, 2H), 7.14-7.11 (m, 2H), 6.30 (s, 1H), 4.18-4.14 (m, 2H), 3.89 (s, 3H), 3.83 (s, 3H), 1.90-1.81 (m, 2H), 1.25 (s, 12H), 1.06 (t, J= 3.6 Hz, 3H).
Préparation 31: 2-(4-((tert-butyldimethylsilyl)oxy)-1-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl)butan-2-yl)-6-(4-methoxy-3-propoxyphenyl)pyridine
2-(4-((tert-butyldimethylsilyl)oxy)-1-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butan-2yl)-6-(4-methoxy-3-propoxyphenyl)pyridine (140 mg, 12%) was prepared in an analogous manner to Préparation 9 using 2-(4-((tert-butyldimethylsilyl)oxy)but-1-en-2-yl)-6-(4-methoxy-3propoxyphenyl)pyridine (Préparation 71, 900 mg, 2.10 mmol). LCMS m/z = 556 [MH]+.
Préparation 32: (E)-3-(1-((tert-butyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan2-yl)but-2-en-2-yl)-5-(4-methoxy-3-propoxyphenyl)pyridine
A solution of 2,2,6,6-tetramethylpiperidine (CAS 768-66-1, 1.08 mL, 6.41 mmol) in THF (2.5 mL) was cooled to about 0 °C (ice bath) under N2. N-BuLi (2.56 mL, 6.41 mmol, 2.5 M in hexanes) was added dropwise to the solution and stirred for about 30 min at about 0 °C. A solution of 2,2'-(ethane-1,1-diyl)bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolane) (Préparation 149, 1810 mg, 6.41 mmol) in THF (2 mL) was added dropwise, which was stirred for about 5 min before cooling to about -78 °C. A solution of 2-((tert-butyldimethylsilyl)oxy)-1-(5-(4-methoxy-3propoxyphenyl)pyridin-3-yl)ethan-1-one (Préparation 75, 666 mg, 1.60 mmol) in THF (3.0 mL) added dropwise and stirred under N2 at about -78 °C for about 1 h. The reaction was placed in an ice bath and stirred for an additional hour. The reaction was quenched with water and diluted with EtOAc. The EtOAc was separated, washed with brine and dried over MgSO4. The solution was filtered and concentrated. The residue was purified by column chromatography (silica) and eluted with heptane/EtOAc (9:1) to afford (E)-3-(1-((tert-butyldimethylsilyl)oxy)-3-(4,4,5,5tetramethyl-1,3,2-dioxaborolan-2-yl)but-2-en-2-yl)-5-(4-methoxy-3-propoxyphenyl)pyridine (400 mg, 45%). LCMS m/z = 554 [MH]+.
103
Préparation 33: ethyl 2-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-2-methyl-3-(4,4,5,5tetramethyl-1,3,2-dioxaborolan-2-yl)propanoate
To a mixture of ethyl 2-(6-bromopyridin-2-yl)-2-methyl-3-(4,4,5,5-tetramethyl-l,3,2dioxaborolan-2-yl)propanoate (Préparation 110, 249 mg, 0.625 mmol) and 2-(4-methoxy-3propoxyphenyl)-4,4,5,5-tetramethyl-l ,3,2-dioxaborolane (Préparation 114, 357 mg, 1.22 mmol) in 1,4-dioxane (8.5 mL) was added a solution of K3PO4 in water (2.0 M, 0.625 mL, 1.25 mmol).
The mixture was degassed using N2 at about 20 °C for about 10 min. Bis(tri-tbutylphosphine)palladium(O) (CAS 53199-31-8, 16.0 mg, 0.03 mmol) was added and the mixture was allowed to stir at about 20 °C for 2 h. The mixture was diluted with EtOAc, dried over Na2SO4, filtered, and concentrated. The residue was purified by column chromatography (silica) and eluted with heptane/EtOAc (100:0 to 0:100) to afford ethyl 2-(5-(4-methoxy-315 propoxyphenyl)pyridin-3-yl)-2-methyl-3-(4,4,5,5-tetramethyl-l ,3,2-dioxaborolan-2-yl)propanoate (134 mg, 44%). 1H NMR (CDCI3, 400MHz,): δ 7.40-7.56 (m, 1H), 7.23-7.38 (m, 4H), 7.07-7.13 (m, 4H), 6.96 (d, J = 8.6 Hz, 2H), 5.33 (s, 1 H), 4.02-4.22 (m, 7H), 3.93 (s, 6H), 1.83-2.08 (m, 4H), 1.71 (s, 4H), 1.49-1.67 (m, 9H), 1.37 (s, 1H), 1.17-1.29 (m, 19H), 1.09 (t, J = 7 A Hz, 7H). LCMS m/z = 399 [MH]+.
Préparation 34: 5-(3-((tert-butyldimethylsilyl)oxy)-1 -(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2yl)butan-2-yl)-3-(4-methoxy-3-propoxyphenyl)pyridazine
5-(3-((tert-butyldimethylsilyl)oxy)-1-(4,4,5,5-tetramethyl-l ,3,2-dioxaborolan-2-yl)butan-2yl)-3-(4-methoxy-3-propoxyphenyl)pyridazine (160 mg, 41%) was prepared in an analogous manner to Préparation 9 using 5-(3-((tert-butyldimethylsilyl)oxy)but-1-en-2-yl)-3-(4-methoxy-3propoxyphenyl)pyridazine (Préparation 72, 300 mg, 0.7 mmol). LCMS m/z = 557 [MH]+.
104
Préparation 35: 3-(1-((tert-butyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl)propan-2-yl)-5-(3-ethoxy-4-methoxyphenyl)-4-methylpyridine
3-(1-((tert-butyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)prOpan2-yl)-5-(3-ethoxy-4-methoxyphenyl)-4-methylpyridine (0.28 g, 26%) was prepared in an analogous manner to Préparation 9 using 3-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-5-(3ethoxy-4-methoxyphenyl)-4-methylpyridine (Préparation 73, 0.8 g, 1.93 mmol). 1H NMR (CDCh, 400MHz): δ 8.36 (s, 1 H), 8.22 (s, 1 H), 6.92 (d, J = 8.3 Hz, 1 H), 6.75-6.78 (m, 1 H), 6.73 (d, J = 2.0 Hz, 1 H), 4.08 (q, J = 7.0 Hz, 2H), 3.91 (s, 3H), 3.74-3.78 (m, 1 H), 3.64-3.68 (m, 1 H), 3.383.46 (m, 1H), 2.29 (s, 3H), 1.45 (t, J = 7.0 Hz, 3H), 1.22-1.29 (m, 2H), 1.03-1.08 (m, 12H), 0.79 (s, 9H), -0.11-0.08 (m, 6H). LCMS m/z = 542 [MH]+
Préparation 36: 4-(1-((tert-butyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl)propan-2-yl)-2-(3-ethoxy-4-methoxyphenyl)thiazole
4-(1-((tert-butyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan2-yl)-2-(3-ethoxy-4-methoxyphenyl)thiazole (0.41 g, 39%) was prepared in an analogous manner to Préparation 9 using 4-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-2-(3-ethoxy-4methoxyphenyl)thiazole (Préparation 74, 0.8 g, 1.97 mmol). 1H NMR (CDCh, 400MHz): δ 7.53 (d, J = 2.0 Hz, 1 H), 7.46 (dd, J = 2.0, 8.5 Hz, 1 H), 6.91 (s, 1 H), 6.89 (d, J = 8.3 Hz, 1 H), 4.20 (q, J = 7.0 Hz, 2H), 3.88-3.92 (s, 4H), 3.77-3.81 (m, 1 H), 3.27-3.34 (m, 1 H), 1.51 (t, J = 7.0Hz, 3H), 1.27-1.30 (m, 2H), 1.15 (d, J = 13.6, 12 H), 0.85 (s, 9H), -0.03 (s, 6H). LCMS m/z = 534 [MH]+.
Préparation 37: 3-(1-bromo-3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-5-(3,4dimethoxyphenyl)pyridine
105
To a solution of 3-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-5-(3,4dimethoxyphenyl)pyridine (Préparation 48, 30.00 g, 77.81 mmol) in DCM (500 mL) was added pyridinium tribromide (CAS 39416-48-3, 24.9 g, 77.8 mmol) in portions at about 0 °C. The mixture was stirred at about 20 °C for about 1 h and poured into cold aqueous Na2SÜ3 (100 mL). The mixture was extracted with DCM (3 x 50 mL). The combined DCM extracts were washed with brine (50 mL), dried over Na2SO4 and concentrated. DBU (CAS 6674-22-2, 58.64 mL, 389.1 mmol) was added to the above mixture in DCM (500 mL) at about 20 °C. The mixture was stirred at about 20 °C for about 16 h and poured into aqueous NH4CI (500 mL). The mixture was extracted with DCM (3 x 200 mL). The combined DCM extracts were washed with brine (200 mL), dried over Na2SO4 and concentrated. The residue was purified by column chromatography (silica) and eluted with pet. ether/EtOAc (15:1) to afford 3-(1-bromo-3-((tertbutyldimethylsilyl)oxy)prop-1-en-2-yl)-5-(3,4-dimethoxyphenyl)pyridine (27.0 g, 75%). 1H NMR (CDCI3,400 MHz): δ 8.74 (d, J = 2.4 Hz, 1 H), 8.55 (d, J = 3.0 Hz, 1 H), 7.88 (t, J = 2.0 Hz, 1 H), 7.13-7.15 (m, 1H), 7.08 (d, J = 3.0 Hz, 1H), 6.97 (d, J= 7.2 Hz, 1H), 6.57 (s, 1H), 4.76 (s, 2H), 3.96 (s, 3H), 3.94 (s, 3H), 0.82 (s, 9H), 0.07 (s, 6H).
Préparation 38: 3-(1-bromo-3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-5-(3-ethoxy-4methoxyphenyl)pyridine
A mixture of 3-(1,2-dibromo-3-((tert-butyldimethylsilyl)oxy)propan-2-yl)-5-(3-ethoxy-4methoxyphenyl)pyridine (Préparation 47a, 11.0 g, 19.66 mmol) and DBU (CAS 6674-22-2, 5.99 g, 39.33 mmol, 5.93 mL) in DCM (150 mL) was stirred at about 25 °C for about 16 h. The mixture was washed with 1N HCl (300 mL), brine (300 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography (silica) and eluted with pet. ether/EtOAc (10:1) to afford 3-(1-bromo-3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-5-(3ethoxy-4-methoxyphenyl)pyridine (7.0 g, 74%). 1H NMR (CDCI3, 400MHz): δ 8.74 (d, J = 1.6 Hz, 1H), 8.55 (d, J = 1.6 Hz, 1H), 7.87 (s, 1H), 7.14 (dd, J= 1.6, 8.0 Hz, 1H), 7.09 (s, 1H), 6.98 (d, J = 8.0 Hz, 1H), 6.57 (s, 1H), 4.77 (s, 2H), 4.18 (q, J = 6.8 Hz, 2H), 3.94 (s, 3H), 1.51 (t, J = 6.8 Hz, 3H), 0.82 (s, 9H), 0.08 (s, 6H).
Préparation 39: 3-(1-bromo-3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-5-(4-methoxy-3propoxyphenyl)pyridine
106
To a mixture of 3-(1,2-ibromo-3-((tert-butyldimethylsilyl)oxy)propan-2-yl)-5-(4-methoxy-3propoxyphenyl)pyridine (Préparation 47b, 10.0 g, 17.44 mmol) in DCM (150 mL) was added
DBU (CAS 6674-22-2, 5.26 mL, 34.88 mmol), which was stirred at about 25 °C for about 16 h under N2. The mixture was washed with 1N HCl (400 mL), brine (400 mL), dried over Na2SO4 and concentrated. The residue was purified by column chromatography (silica) and eluted with pet. ether/EtOAc (10:1) to afford 3-(1-bromo-3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-5-(4methoxy-3-propoxyphenyl)pyridine (5.60 g, 65%). 1H NMR (CDCh, 400MHz): δ 8.74 (d, J= 2.0 Hz, 1H), 8.55 (d, J= 1.6 Hz, 1H), 7.87 (s, 1H), 7.13 (dd, J= 1.6, 8.4 Hz, 1H), 7.09 (s, 1H), 6.98 (d, J = 8.0 Hz, 1 H), 6.57 (s, 1 H), 4.77 (s, 2H), 4.06 (t, J = 6.8 Hz, 2H), 3.93 (s, 3H), 1.87-1.96 (m, 2H), 1.08 (t, J = 7.6 Hz, 3H), 0.82 (s, 9H), 0.08 (s, 6H).
Préparation 40: methyl 2-(2'-cyano-4'-methoxy-3'-propoxy-[1,1'-biphenyl]-3-yl)-3(((trifluoromethyl)sulfonyl)oxy)acrylate
To a solution of methyl 2-(2'-cyano-4'-methoxy-3'-propoxy-[1,1'-biphenyl]-3-yl)-315 hydroxyacrylate (Préparation 41, 14.5 g, 39.47 mmol) in toluene (500 mL) was added LiOH (11.59 g, 276.27 mmol) in water (30 mL). To the mixture was added Tf2O (CAS 358-23-8, 15.63 mL, 94.72 mmol) dropwise at about 0 °C. The mixture was stirred at about 0 °C for about 1 h. The reaction was quenched with water (500 mL) and extracted with EtOAc (2 x 500 mL). The combined EtOAc extracts were washed with brine (2 x 300 mL), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by column chromatography (silica) and eluted with pet. ether/EtOAc (15:1) to afford methyl 2-(2'-cyano-4'-methoxy-3'-propoxy-[1,Tbiphenyl]-3-yl)-3-(((trifluoromethyl)sulfonyl)oxy)acrylate (15.00 g, 74%). 1H NMR (CDCI3, 400MHz): δ 7.56-7.59 (m, 1H), 7.48-7.52 (m, 2H), 7.39-7.41 (m, 1H), 7.13-7.18 (m, 3H), 4.19 (t, J = 6.8 Hz, 2H), 3.93 (s, 3H), 3.91 (s, 3H), 1.83-1.92 (m, 2H), 1.09 (t, J = 7.6 Hz, 3H).
Préparation 41: methyl 2-(2'-cyano-4'-methoxy-3'-propoxy-[1,T-biphenyl]-3-yl)-3hydroxyacrylate
107
To a mixture of methyl 2-(2'-cyano-4'-methoxy-3'-propoxy-[1 ,T-biphenyl]-3-yl)acetate (Préparation 85, 12.0 g, 35.36 mmol) and ethyl formate (11.39 mL, 141.43 mmol) in DCM (150 mL) was added TiCU (13.41 g, 70.72 mmol, 7.62 mL) and Et3N (8.59 g, 84.86 mmol, 11.76 mL) slowly at about 0 °C. The mixture was stirred at about 20 °C for about 1 h. Water (150 mL) was added and the mixture was extracted with DCM (2 x 150 mL). The combined DCM extracts were washed with brine (150 mL), dried over Na2SO4 and concentrated to afford methyl 2-(2'cyano-4'-methoxy-3'-propoxy-[1,1'-biphenyl]-3-yl)-3-hydroxyacrylate (14.50 g), which was used directly without further purification. Ή NMR (CDCh, 400MHz): δ 12.09 (d, J = 12.4 Hz, 1H), 7.43-7.44 (m, 3H), 7.38-7.41 (m, 1H), 7.29-7.34 (m, 1H), 7.15 (s, 2H), 4.19 (t, J = 6.8 Hz, 2H), 3.92 (s, 3H), 3.85 (s, 3H), 1.84-1.93 (m, 2H), 1.07-1.11 (m, 3H).
Préparation 42: (R)-3-(1-((tert-butyldimethylsilyl)oxy)-3-iodopropan-2-yl)-5-(4-methoxy-3propoxyphenyl)pyridine
A mixture of (R)-3-((tert-butyldimethylsilyl)oxy)-2-(5-(4-methoxy-3-propoxyphenyl)pyridin3-yl)propyl methanesulfonate (Préparation 43, 45.5 g, 89.28 mmol) and lithium iodide (38.2 g, 286 mmol) in acetone (446 mL) was stirred at about 30 °C for 3 days. The reaction was heated to about 50 °C for about 45 min. The mixture was cooled to about 20 °C and concentrated to remove acetone. The residue was diluted with DCM and washed with water (2 x 100 mL). The DCM extract was dried over MgSO4, filtered and concentrated. The residue was triturated in heptanes/EtOAc (1:1, 100 mL) for about 45 min. The solid material was filtered and purified by column chromatography (silica) and eluted with heptanes/EtOAc (85:15 to 30:70) to afford (R)3-(1-((tert-butyldimethylsilyl)oxy)-3-iodopropan-2-yl)-5-(4-methoxy-3-propoxyphenyl)pyridine (41.2 g, 85%). 1H NMR (CDCh, 400 MHz): δ 8.71 (d, J = 2.3 Hz, 1 H), 8.43 (d, J = 2.0 Hz, 1 H), 7.71 (t, J = 2.0 Hz, 1H), 7.09-7.15 (m, 2H), 6.98 (d, J = 8.2 Hz, 1H), 4.06 (t, J= 7.0 Hz, 2H), 3.98-4.02 (m, 1H), 3.93 (s, 3H), 3.84-3.88 (m, 1H), 3.68-3.72 (m, 1H), 3.43-3.47 (m, 1H), 3.093.15 (m, 1H), 1.87-1.96 (m, 2H), 1.08 (t, J = 7.4 Hz, 3H), 0.89 (s, 9H), 0.05 (d, J= 7.4 Hz, 6H). LCMS m/z = 542 [MH]+.
Préparation 43: (R)-3-((tert-butyldimethylsilyl)oxy)-2-(5-(4-methoxy-3-propoxyphenyl)pyridin-3yl)propyl methanesulfonate
108
To an ice cold solution of (S)-3-((tert-butyldimethylsilyl)oxy)-2-(5-(4-methoxy-3propoxyphenyl)pyridin-3-yl)propan-1-ol (Préparation 44, 42.8 g, 99.2 mmol) in DCM (600 mL) was added Et3N (25.1 mL, 178 mmol) and stirred for about 30 min. MsCI (9.98 mL, 129 mmol) was added dropwise and allowed to warm and stir at about 20 °C overnight. The mixture was washed with water, dried over MgSO4, filtered, passed through a silica gel plug and concentrated to afford (R)-3-((tert-butyldimethylsilyl)oxy)-2-(5-(4-methoxy-3propoxyphenyl)pyridin-3-yl)propyl methanesulfonate (45.5 g), which was used in Préparation 42. LCMS m/z = 510 [MH]+.
Préparation 44: (S)-3-((tert-butyldimethylsilyl)oxy)-2-(5-(4-methoxy-3-propoxyphenyl)pyridin-3yl)propan-1-ol
To an ice cold solution of (S)-3-((tert-butyldimethylsilyl)oxy)-2-(5-(4-methoxy-3propoxyphenyl)pyridin-3-yl)propyl acetate (Préparation 45, 45.7 g, 96.5 mmol) in THF (400 mL) was added aqueous NaOH (154 mL, 1 N). The mixture was allowed to warm and stir at about 20 °C for 2 days. The organic phase was separated and concentrated. The residue was dissolved in DCM (300 mL). The aqueous layer was extracted with DCM. The combined DCM extracts were washed with water, brine, dried over Na2SO4, filtered and concentrated to afford (S)-3-((tert-butyldimethylsilyl)oxy)-2-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)propan-1-ol (42.8 g), which was used in Préparation 43. LCMS m/z = 432 [MH]+.
Préparation 45: (S)-3-((tert-butyldimethylsilyl)oxy)-2-(5-(4-methoxy-3-propoxyphenyl)pyridin-3yl)propyl acetate
To an ice cold solution of (R)-3-hydroxy-2-(5-(4-methoxy-3-propoxyphenyl)pyridin-3yl)propyl acetate (Préparation 46, 43.4 g, 121 mmol) in 2-MeTHF (1400 mL) was added DCM (800 mL), imidazole (41.1 g, 604 mmol) and TBS-CI (91.0 g, 604 mmol). The reaction mixture
109 was warmed to about 20 °C and stirred overnight. The mixture was filtered and the solids washed with EtOAc. The combined filtrâtes were washed with water, brine, dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography (silica) and eluted with heptanes/EtOAc (100:0 to 60:40) to afford (S)-3-((tert-butyldimethylsilyl)oxy)-2-(5-(4methoxy-3-propoxyphenyl)pyridin-3-yl)propyl acetate (48.3 g, 85%). 1H NMR (CDCh, 400 MHz): δ 8.70 (d, J = 2.0 Hz, 1 H), 8.45 (d, J = 2.3 Hz, 1 H), 7.74 (t, J = 2.3 Hz, 1 H), 7.08-7.14 (m, 2H), 6.98 (d, J= 8.2 Hz, 1H), 4.40-4.49 (m, 2H), 4.06 (t, J= 7.0 Hz, 2H), 3.86-3.95 (m, 5H), 3.173.23 (m, 1 H), 2.04 (s, 3H), 1.67-1.96 (m, 2H), 1.08 (t, J = 7.4 Hz, 3H), 0.87 (s, 9H), 0.01 (d, J = 2.3 Hz, 6H). LCMS m/z = 474 [MH]+.
Préparation 46: (R)-3-hydroxy-2-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)propyl acetate
To a mixture of 2-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)propane-1,3-diol (Préparation 82, 38.3 g, 121 mmol) in 2-MeTHF (1088 mL) was added immobilized Rhizomucor miehei lipase (1.53 g, Lipozyme® RM IM, Novozymes A/S, Denmark). The mixture was stirred at about 20 °C for about 5 min. Vinyl acetate (89.0 mL, 965 mmol) was added to the mixture followed by 2-MeTHF (100 mL). The mixture was stirred at about 20 °C for about 39 h. The mixture was filtered and the filter cake was washed with 2-MeTHF (50 mL). The combined filtrâtes were concentrated to afford (R)-3-hydroxy-2-(5-(4-methoxy-3-propoxyphenyl)pyridin-3yl)propyl acetate (36.0 g, 83%), which was used in Préparation 45. Préparation 47a: 3-(1,2-dibromo-3-((tert-butyldimethylsilyl)oxy)propan-2-yl)-5-(3-ethoxy-4methoxyphenyl)pyridine
To a mixture of 3-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-5-(3-ethoxy-4methoxyphenyl)pyridine (Préparation 49, 8.00 g, 20.02 mmol) in DCM (150 mL) was added pyridinium tribromide (CAS 39416-48-3, 7.68 g, 24.02 mmol) in one portion at about 0 °C under N2. The mixture was stirred at about 25 °C for about 3 h. The DCM mixture was washed with aqueous Na2SO3 (100 mL), brine (100 mL), dried over Na2SO4 and concentrated. The residue was purified by column chromatography (silica) and eluted with pet. ether/EtOAc (10:1) to afford 3-(1,2-dibromo-3-((tert-butyldimethylsilyl)oxy)propan-2-yl)-5-(3-ethoxy-4-methoxyphenyl)pyridine (11.00 g) which was used directly for the next step. 1H NMR (CDCh, 400MHz): δ 8.72-8.74 (m,
110
2H), 7.99 (t, J = 2.0 Hz, 1H), 7.14 (dd, J= 2.0, 8.4 Hz, 1H), 7.09 (d, J = 2.0 Hz, 1H), 7.00 (d, J = .0 Hz, 1H), 4.37-4.40 (m, 2H), 4.28 (d, J= 11.2 Hz, 1H), 4.21-4.26 (m, 3H), 3.93 (s, 3H), 1.52 (t, J = 7.2 Hz, 3H), 0.94 (s, 9H), 0.14 (d, J = 9.6 Hz, 6H).
Préparation 47b: 3-(1,2-dibromo-3-((tert-butyldimethylsilyl)oxy)propan-2-yl)-5-(4-methoxy-3propoxyphenyl)pyridine
To a mixture of 3-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-5-(4-methoxy-3propoxyphenyl)pyridine (Préparation 50, 7.00 g, 16.92 mmol) in DCM (150 mL) was added pyridinium tribromide (CAS 39416-48-3, 6.49 g, 20.30 mmol) in one portion at about 0 °C under N2. The mixture was stirred at about 25 °C for about 3 h. The DCM mixture was washed with aqueous Na2SO3 (100 mL), brine (100 mL), dried over Na2SO4 and concentrated. The residue was purified by column chromatography (silica) and eluted with pet. ether/EtOAc (10:1) to afford 3-(1,2-dibromo-3-((tert-butyldimethylsilyl)oxy)propan-2-yl)-5-(4-methoxy-3propoxyphenyl)pyridine (10.00 g), which was used directly for the next step. 1H NMR (CDCI3, 400MHz): δ 8.72-8.75 (m, 2H), 7.99 (t, J= 2.0 Hz, 1H), 7.14 (dd, J= 2.0, 8.0 Hz, 1H), 7.09 (d, J = 2.0 Hz, 1H), 7.00 (d, J= 8.4 Hz, 1H), 4.39 (d, J = 10.8 Hz, 2H), 4.28 (d, J = 10.8 Hz, 1H), 4.20 (d, J= 10.4 Hz, 1H), 4.07 (t, J= 6.8 Hz, 2H), 3.93 (s, 3H), 1.97-1.87 (m, 1H), 1.08 (t, J = 7.2 Hz, 3H), 0.93 (s, 9H), 0.14 (d, J = 9.6 Hz, 6H).
Préparation 48: 3-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-5-(3,4dimethoxyphenyl)pyridine
A mixture of 3-(3,4-dimethoxyphenyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl)pyridine (Préparation 91a, 2.0 g, 5.86 mmol), 2-bromoallyloxy-tert-butyl-dimethyl-silane (Préparation 227, 1.47 g, 5.86 mmol), Pd(dppf)CI2 DCM (239.34 mg, 293 umol), Na2CO3 (621.26 mg, 5.86 mmol) and KOAc (1.15 g, 11.72 mmol) in 1,4-dioxane (50 mL) and water (5 mL) were heated to about 90 °C for about 12 h. The mixture was filtered and the filtrate concentrated. The residue was purified by column chromatography (silica) and eluted with DCM/MeCN (5:1) to afford 3-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-5-(3,4dimethoxyphenyl)pyridine (2.10 g, 5.45 mmol, 93%). 1H NMR (CDCI3, 400 MHz): δ 8.72 (d, J =
111
2.0 Hz, 1H), 8.61 (d, J= 2.0 Hz, 1H), 7.85 (t, J= 2.0 Hz, 1H), 7.14-7.16 (m, 1H), 7.08 (d, J = 2.0
Hz, 1H), 6.99 (d, J= 8.4 Hz, 1H), 5.52 (d, J = 12.0 Hz, 2H), 4.56 (s, 2H), 3.97 (s, 3H), 3.95 (s,
3H), 0.93 (s, 9H), 0.12 (s, 6H).
Préparation 49: 3-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-5-(3-ethoxy-4methoxyphenyl)pyridine
A mixture of 3-bromo-5-(3-ethoxy-4-methoxyphenyl)pyridine (Préparation 92, 20 g, 64.9 mmol), tert-butyldimethyl((2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)allyl)oxy)silane (Préparation 146, 23.23 g, 77.88 mmol), Pd(dppf)CI2 (1.42 g, 1.95 mmol), K2CO3 (17.94 g, 129.8 mmol) and KOAc (9.55 g, 97.35 mmol) in 1,4-dioxane (300 mL) and water (10 mL) was degassed and heated to about 90 °C for about 16 h under N2. The mixture was filtered and concentrated. The residue was purified by column chromatography (silica) and eluted with pet. ether/EtOAc (3:1) to afford 3-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-5-(3-ethoxy-4methoxyphenyl)pyridine (18.0 g, 69%). 1H NMR (CDCI3, 400MHz): δ 8.71 (d, J = 2.0 Hz, 1H), 8.60 (d, J= 2.0 Hz, 1H), 7.84 (t, J = 2.0 Hz, 1H), 7.14 (dd, J= 2.0, 8.4 Hz, 1H), 7.09 (d, J = 2.4 Hz, 1H), 6.99 (d, J=8.0Hz, 1H), 5.54 (s, 1H), 5.50 (s, 1H),4.56 (s, 2H), 4.19 (q, J = 7.2 Hz, 2H), 3.94 (s, 3H), 1.52 (t, J= 7.2 Hz, 3H), 0.93 (s, 9H), 0.12 (s, 6H).
Préparation 50: 3-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-5-(4-methoxy-3propoxyphenyl)pyridine
A mixture of 3-bromo-5-(4-methoxy-3-propoxyphenyl)pyridine (Préparation 93a, 15.0 g, 46.55 mmol), tert-butyldimethyl((2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)allyl)oxy)silane (Préparation 146, 18.05 g, 60.51 mmol), Pd(dppf)CI2 (1.70 g, 2.33 mmol), K2CO3 (12.87 g, 93.10 mmol) and KOAc (6.85 g, 69.83 mmol) in 1,4-dioxane (250 mL) and water (5 mL) was degassed and heated to about 90 °C for about 16 h under N2. The mixture was filtered and concentrated. The residue was purified by column chromatography (silica) and eluted with pet. ether/EtOAc (3:1) to afford 3-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-5-(4-methoxy-3propoxyphenyl)pyridine (13.50 g, 70%). 1H NMR (CDCI3, 400MHz): δ 8.71 (d, J = 2.4 Hz, 1H), 8.60 (d, J= 2.0 Hz, 1H), 7.84 (t, J = 2.0 Hz, 1H), 7.13 (dd, J= 2.4, 8.4 Hz, 1H), 7.10 (d, J = 2.4 Hz, 1H), 6.99 (d, J= 8.4 Hz, 1H), 5.53 (d, J= 1.2 Hz, 1H), 5.50 (d, J= 1.2 Hz, 1H), 4.56 (s, 2H),
112
W 4.06 (t, J = 6.8 Hz, 2H), 3.93 (s, 3H), 1.87-1.96 (m, 2H), 1.08 (t, J = 7.2 Hz, 3H), 0.93 (s, 9H),
0.13 (s, 6H).
Préparation 51: 3-(3-((tert-butyldimethylsilyl)oxy)prop-1 -en-2-yl)-5-(3-isopropoxy-4 methoxyphenyl)pyridine
3-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-5-(3-isopropoxy-4methoxyphenyl)pyridine (1.1 g, 75%) was prepared in an analogous manner to Préparation 50 using 3-bromo-5-(3-isopropoxy-4-methoxyphenyl)pyridine (Préparation 94, 1.15 g, 3.6 mmol) at 10 about 90 °C for about 2 h. LCMS m/z = 414 [MH]+.
Préparation 52: 3-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-5-(3-cyclopropoxy-4methoxyphenyl)pyridine
3-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-5-(3-cyclopropoxy-4methoxyphenyl)pyridine (730 mg, 76%) was prepared in an analogous manner to Préparation 50 using 3-bromo-5-(3-cyclopropoxy-4-methoxyphenyl)pyridine (Préparation 95, 0.75 g, 2.34 mmol). Ή NMR (CDCh, 400 MHz): δ 8.74 (d, J = 2.0 Hz, 1H), 8.61 (d, J = 2.5 Hz, 1H), 7.85 (t, J = 2.3 Hz, 1H), 7.47 (d, J= 2.0 Hz, 1H), 7.14-7.22 (m, 1H), 6.98 (d, J= 8.5 Hz, 1H), 5.53 (dd, J =
1.3, 10.3 Hz, 2H), 4.50-4.62 (m, 2H), 3.92 (s, 3H), 3.84 (tt, J = 3.2, 6.1 Hz, 1H), 0.81-0.96 (m,
13H), 0.11-0.14 (m, 6H). LCMS m/z = 412 [MH]+.
Préparation 53: 3-(3-(2-((tert-butyldimethylsilyl)oxy)ethoxy)-4-methoxyphenyl)-5-(3-((tertbutyldimethylsilyl)oxy)prop-1-en-2-yl)pyridine
113
3-(3-(2-((tert-butyldimethylsilyl)oxy)ethoxy)-4-methoxyphenyl)-5-(3-((tertbutyldimethylsilyl)oxy)prop-1-en-2-yl)pyridine (6.7 g, 62%) was prepared in an analogous manner to Préparation 50 using 3-bromo-5-(3-(2-((tert-butyldimethylsilyl)oxy)ethoxy)-4methoxyphenyl)pyridine (Préparation 96, 9.3 g, 21 mmol). 1H NMR (CDCh, 400 MHz): δ 8.71 (d, J= 2.0 Hz, 1H), 8.60 (d, J = 2.0 Hz, 1H), 7.83 (t, J= 2.0 Hz, 1H), 7.13-7.18 (m, 2H), 6.96-7.01 (m, 1H), 5.52 (dd, J= 1.3, 10.3 Hz, 2H), 4.56 (s, 2H), 4.16-4.22 (m, 2H), 4.02-4.07 (m, 2H), 3.92 (s, 3H), 0.92-0.95 (m, 9H), 0.90 (s, 9H), 0.12 (s, 6H), 0.10 (s, 6H). LCMS m/z = 530 [MH]+.
Préparation 54: 3-(3-((tert-butyldimethylsilyl)oxy)prop-1 -en-2-yl)-5-(3-(3-((tertbutyldimethylsilyl)oxy)propoxy)-4-methoxyphenyl)pyridine
3-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-5-(3-(3-((tertbutyldimethylsilyl)oxy)propoxy)-4-methoxyphenyl)pyridine (12.9 g, 99%) was prepared in an analogous manner to Préparation 50 using 3-bromo-5-(3-(3-((tertbutyldimethylsilyl)oxy)propoxy)-4-methoxyphenyl)pyridine (Préparation 97, 10.8g, 23.8 mmol). Ή NMR (CDCh, 400 MHz): δ 8.71 (d, J= 2.5 Hz, 1H), 8.60 (d, J= 2.0 Hz, 1H), 7.83 (t, J= 2.2 Hz, 1H), 7.11-7.16 (m, 2H), 6.98 (d, J= 8.3 Hz, 1H), 5.49-5.54 (m, 2H), 4.56 (t, J = 1.5 Hz, 2H), 4.21 (t, J = 6.4 Hz, 2H), 3.92 (s, 3H), 3.85 (t, J = 5.9 Hz, 2H), 2.05-2.13 (m, 2H), 0.92-0.94 (m, 9H), 0.89 (s, 9H), 0.12 (s, 6H), 0.05 (s, 6H). LCMS m/z = 544 [MH]+.
Préparation 55: 3-(3-((tert-butyldimethylsilyl)oxy)prop-1 -en-2-yl)-5-(3-(2-fluoroethoxy)-4methoxyphenyl)pyridine
3-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-5-(3-(2-fluoroethoxy)-4methoxyphenyl)pyridine (1.6 g, 78%) was prepared in an analogous manner to Préparation 50 using 3-bromo-5-(3-(2-fluoroethoxy)-4-methoxyphenyl)pyridine (Préparation 98, 1.4 g, 4.7 mmol). Ή NMR (CDCI3,400 MHz): δ 8.92 (d, J = 2.5 Hz, 1 H), 8.70-8.73 (m, 1 H), 7.73 (t, J = 8. 6 Hz, 1 H), 6.84-6.90 (m, 1 H), 6.07 (d, J = 1.5 Hz, 1 H), 5.76 (d, J = 1.5 Hz, 1 H), 4.76 (t, J = 1.7 Hz, 2H), 4.06 (t, J = 6.9 Hz, 2H), 3.94 (s, 3H), 1.81-1.86 (m, 2H), 1.03-1.09 (m, 3H), 0.95 (s, 9H), 0.14 (s, 6H). LCMS m/z = 433 [MH]+.
114
Préparation 56: 3-(3-((tert-butyldimethylsilyl)oxy)prop-1 -en-2-yl)-5-(3-(3-fluoropropoxy)-4methoxyphenyl)pyridine
3-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-5-(3-(3-fluoropropoxy)-45 methoxyphenyl)pyridine was prepared in an analogous manner to Préparation 50 using 3bromo-5-(3-(3-fluoropropoxy)-4-methoxyphenyl)pyridine (Préparation 99).
Préparation 57: 3-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-5-(2-(difluoromethyl)-3-ethoxy4-methoxyphenyl)pyridine
A solution of 2-(5-(2-(difluoromethyl)-3-ethoxy-4-methoxyphenyl)pyridin-3-yl)prop-2-en-1ol (Préparation 76, 321 mg, 0.71 mmol) and imidazole (97.2mg, 1.43 mmol) in DCM (20 mL) was added TBS-CI (129 mg, 0.86 mmol) at about 0 °C. The reaction mixture was stirred at about 20 °C for about 15 h. Additional TBS-CI (129 mg, 0.86 mmol) was added and the reaction mixture was stirred at about 20 °C for about 20 h. The reaction mixture was concentrated and purified by column chromatography (silica) and eluted with pet. ether/EtOAc (100:0 to 60:40) to afford 3-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-5-(2-(difluoromethyl)-3-ethoxy-4methoxyphenyl)pyridine (361 mg, 75%). 1H NMR (CDCI3,400 MHz): δ 8.66 (d, J = 2.0 Hz, 1H),
8.51 (d, J=2.0Hz, 1H), 7.71 (t, J=2.3Hz, 1 H), 7.05-7.10 (m, 1 H), 6.78-7.03 (m, 2H), 5.51 (dd,
J = 1.5, 14.1 Hz, 2H), 4.55 (t, J = 1.5 Hz, 2H), 4.17 (q, J =7.0 Hz, 2H), 3.93 (s, 3H), 1.43 (t, J = 7.0 Hz, 3H), 0.88-0.94 (m, 9H), 0.09-0.13 (m, 6H). LCMS m/z = 450 [MH]+.
Préparation 58: 3-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-5-(3-ethoxy-5-fluoro-4methoxyphenyl)pyridine
115
P To a mixture of 3-bromo-5-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)pyridine (Préparation 86, 795 mg, 2.42 mmol), 2-(3-ethoxy-5-fluoro-4-methoxyphenyl)-4,4,5,5tetramethyl-1,3,2-dioxaborolane (Préparation 132, 652 mg, 2.2 mmol), Pd(dppf)Cl2 DCM and K2CO3 (760 mg, 5.5 mmol) was suspended in 1,4-dioxane (20 mL) and water (0.7 mL). The 5 mixture was degassed and heated to about 85 °C under N2 for about 9 h. The mixture was concentrated and MTBE (50 mL) was added, stirring for about 20 min. The mixture was filtered and the filtrate was concentrated. The residue was purified by column chromatography (silica) and eluted with pet. ether/EtOAc (100:0 to 80:20) to afford 3-(3-((tertbutyldimethylsilyl)oxy)prop-1-en-2-yl)-5-(3-ethoxy-5-fluoro-4-methoxyphenyl)pyridine (660 mg, 10 72%). Ή NMR (CDCI3, 400 MHz): δ 8.66 (dd, J = 2.2, 15.4 Hz, 2H), 7.82 (t, J = 2.0 Hz, 1H), .94 (dd, J = 2.2, 11.0 Hz, 1 H), 6.88 (t, J = 1.7 Hz, 1 H), 5.50-5.57 (m, 2H), 4.54-4.57 (m, 2H), 4.18 (q, J = 7.0 Hz, 2H), 3.98 (s, 3H), 1.50 (t, J= 7.1 Hz, 3H), 0.92 (s, 9H), 0.12 (s, 6H). LCMS m/z = 418 [MH]+.
Préparation 59: 3-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-5-(3-chloro-5-ethoxy-415 methoxyphenyl)pyridine
3-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-5-(3-chloro-5-ethoxy-4methoxyphenyl)pyridine (840 mg, 61%) was prepared in an analogous manner to Préparation 58 using 2-(3-chloro-5-ethoxy-4-methoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (Préparation 133, 1.0 g, 3.2 mmol). 1H NMR (CDCI3,400 MHz): δ 8.66 (dd, J = 2.2, 11.5 Hz, 2H), 7.83 (t, J= 2.2 Hz, 1H), 7.19 (d, J = 2.0 Hz, 1H), 6.99 (d, J= 2.0 Hz, 1H), 5.53 (dd, J= 1.5, 12.2 Hz, 2H), 4.52-4.63 (m, 2H), 4.17 (q, J = 7.2 Hz, 2H), 3.94 (s, 3H), 1.51 (t, J = 6.9 Hz, 3H), 0.90-0.97 (m, 9H), 0.08-0.15 (m, 6H).
Préparation 60: 3-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-5-(5-ethoxy-2-fluoro-425 methoxyphenyl)pyridine
3-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-5-(5-ethoxy-2-fluoro-4methoxyphenyl)pyridine (400 mg, 89%) was prepared in an analogous manner to Préparation 50 using 3-bromo-5-(5-ethoxy-2-fluoro-4-methoxyphenyl)pyridine (Préparation 101, 350 mg,
116
1.07 mmol). Ή NMR (CDCI3, 400MHz): δ 8.66 (t, J = 1.7 Hz, 1H), 8.62 (d, J = 2.2 Hz, 1H), 7.847.86 (m, 1 H), 6.91 (d, J = 7.3 Hz, 1 H), 6.75 (d, J = 11.7 Hz, 1 H), 5.50-5.53 (m, 2H), 4.56 (t, J =
1.3 Hz, 2H), 4.12 (q, J = 7.0 Hz, 2H), 3.92 (s, 3H), 1.48 (t, J= 7.0 Hz, 3H), 0.92 (s, 9H), 0.11 (s,
6H). LCMS m/z = 418 [MH]+.
Préparation 61: 3-(3-((tert-butyldimethylsilyl)oxy)prop-1 -en-2-yl)-5-(2-chloro-5-ethoxy-4methoxyphenyl)pyridine
3-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-5-(2-chloro-5-ethoxy-410 methoxyphenyl)pyridine (2.1 g, 48%) was prepared in an analogous manner to Préparation 58 using 2-(2-chloro-5-ethoxy-4-methoxyphenyl)-4,4,5,5-tetramethyl-l ,3,2-dioxaborolane (Préparation 135, 3.13 g, 10.0 mmol). LCMS m/z = 434 [MH]+.
Préparation 62: 3-(3-((tert-butyldimethylsilyl)oxy)prop-1 -en-2-yl)-5-(2-fluoro-4-methoxy-5propoxyphenyl)pyridine
3-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-5-(2-fluoro-4-methoxy-5propoxyphenyl)pyridine (5.0 g, 99%) was prepared in an analogous manner to Préparation 50 using 3-bromo-5-(2-fluoro-4-methoxy-5-propoxyphenyl)pyridine (Préparation 102, 7.0 g, 9.0 mmol). Ή NMR (CDCI3,400 MHz): δ 8.66 (s, 1 H), 8.62 (d, J = 2.0 Hz, 1 H), 7.85 (d, J = 1.5 Hz, 20 1 H), 6.92 (d, J = 7.3 Hz, 1 H), 6.76 (d, J = 11.7 Hz, 1 H), 5.52 (d, J = 9.8 Hz, 2H), 4.55 (s, 2H), .00 (t, J = 6.8 Hz, 2H), 3.91 (s, 3H), 1.84-1.93 (m, 2H), 1.06 (t, J = 7.3 Hz, 3H), 0.94 - 0.92 (m, 9H), 0.12 - 0.11 (m, 6H). LCMS m/z = 432 [MH]+.
Préparation 63: 3-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-5-(4-(difluoromethoxy)-3propoxyphenyl)pyridine
117
3-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-5-(4-(difluoromethoxy)-3propoxyphenyl)pyridine (2.1 g, 62%) was prepared in an analogous manner to Préparation 58 using 2-(4-(difluoromethoxy)-3-propoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (Préparation 142, 2.46 g, 7.5 mmol). Ή NMR (CDCh, 400MHz): δ 8.66-8.71 (m, 2H), 7.85 (d, J =2.1 Hz, 1 H), 7.27-7.29 (m, 1H), 7.12-7.14 (m, 2H) 6.63 (t, J = 75.3 Hz, 1H), 5.53 (d, J = 12.0
Hz, 2H), 4.56 (s, 2H), 4.07 (t, J = 6.4 Hz, 2H), 1.85-1.94 (m, 2H), 1.09 (t, J = 7.4 Hz, 3H), 0.92 (s, 9H), 0.12 (s, 6H). LCMS m/z = 450 [MH]+.
118
Préparation 64: 5'-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-3-fluoro-5-methoxy-6-propoxy2,3'-bipyndine
To a mixture of 5'-chloro-3-fluoro-5-methoxy-6-propoxy-2,3'-bipyridine (Préparation 103, 3.0 g, 10.11 mmol) and tert-butyldimethyl((2-(4,4,5,5-tetramethyl-l ,3,2-dioxaborolan-2yl)allyl)oxy)silane (Préparation 146, 12.1 g, 40.4 mmol) in 1,4-dioxane (300 mL) was added Xphos Pd G2 (CAS 1310584-14-5, 0.64 g, 0.81 mmol), Pd(dppf)-tBu (0.66 g, 1.01 mmol), K2CO3 (2.79 g, 20.2 mmol) and KOAc (0.50 g, 5.06 mmol). The mixture was degassed, heated to about 70 °C for about 16 h under N2. The mixture was diluted with EtOAc (50 mL), dried over MgSO4, filtered and concentrated. The residue was purified by column chromatography (silica) and eluted with pet. ether/EtOAc (100:0 to 85:15) to afford 5'-(3-((tertbutyldimethylsilyl)oxy)prop-1-en-2-yl)-3-fluoro-5-methoxy-6-propoxy-2,3'-bipyridine (3.1 g, 71%). 1H NMR (CDCh, 400MHz): δ 9.13-9.14 (m, 1H), 8.62 (d, J= 2.1 Hz, 1H), 8.28 (t, J= 2.1 Hz, 1H), 6.97 (d, J= 11.4 Hz, 1H), 5.51-5.54 (m, 2H), 4.57 (t, J = 1.5 Hz, 2H), 4.44 (t, J= 7.0 Hz, 2H), 3.93 (s, 3H), 1.86-1.95 (m, 2H), 1.06 (t, J= 7.5 Hz, 3H), 0.93 (s, 9H), 0.12 (s, 6H). LCMS m/z = 433 [MH]+
Préparation 65: 5'-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-6-methoxy-5-propoxy-3,3'bipyridine
5'-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-6-methoxy-5-propoxy-3,3'-bipyridine (4.85 g, 87%) was prepared in an analogous manner to Préparation 58 using 2-methoxy-3propoxy-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridine (Préparation 124, 3.95 g, 13.5 mmol). Ή NMR (CDCh, 400 MHz): δ 8.67 (dd, J =2.2, 16.9 Hz, 2H), 7.9 (d, J= 2.2 Hz, 1H), 7.83 (t, J = 2.2 Hz, 1 H), 7.23 (d, J = 2.0 Hz, 1 H), 5.47-5.60 (m, 2H), 4.56 (t, J = 1.3 Hz, 2H), 4.034.08 (m, 5H), 1.90-1.99 (m, 2H), 1.04-1.13 (m, 3H), 0.92 (s, 9H), 0.10-0.13 (m, 6H).
119
Préparation 66: 5-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-3-(3-ethoxy-4-methoxyphenyl)2-methylpyridme
3-Bromo-5-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-2-methylpyridine (Préparation 87, 1.28 g, 3.7 mmol) and 2-(3-ethoxy-4-methoxyphenyl)-4,4,5,5-tetramethyl-1,3,2dioxaborolane (Préparation 113, 1.25 g, 4.49 mmol), Pd(dppf)Cl2 (274 mg, 0.374 mmol) and K2CO3 (1.29 g, 9.35 mmol) was suspended in 1,4-dioxane (60 mL) and water (2 mL). The mixture was degassed and heated to about 80 °C under N2 for about 5 h. The mixture was concentrated and to the residue was added MTBE (100 mL), which was stirred for about 20 min. The mixture was filtered and the filter cake was washed with MTBE (50 mL). The combined filtrâtes were dried and concentrated. The residue was purified column chromatography (silica) and eluted with pet. ether/EtOAc (100:0 to 85:15) to afford 5-(3-((tertbutyldimethylsilyl)oxy)prop-1-en-2-yl)-3-(3-ethoxy-4-methoxyphenyl)-2-methylpyridine (640 mg, 41 %). Ή NMR (CDCh, 400 MHz): δ 8.54 (d, J = 2.5 Hz, 1 H), 7.54 (d, J = 2.0 Hz, 1 H), 6.94-6.97 (m, 1H), 6.85-6.88 (m, 1H), 6.83-6.84 (m, 1H), 5.48 (d, J= 1.5 Hz, 1H), 5.43-5.45 (m, 1H), 4.52 (t, J= 1.5 Hz, 2H), 4.12 (q, J= 7.0 Hz, 2H), 3.93 (s, 3H), 2.51 (s, 3H), 1.49 (t, J= 7.0 Hz, 3H), 0.90-0.93 (m, 9H), 0.09-0.11 (m, 6H). LCMS m/z = 414 [MH]+.
Préparation 67: 4-(3-((tert-butyldimethylsilyl)oxy)prop-1 -en-2-yl)-2-(4-methoxy-3propoxyphenyl)-6-(trifluoromethyl)pyrimidine
To a mixture of 4-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-2-chloro-6(trifluoromethyl)pyrimidine (Préparation 90, 1.33 g, 3.77 mmol) in 1,4-dioxane (40 mL) was added 2-(4-methoxy-3-propoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (Préparation 114, 1.32 g, 4.52 mmol), K3PO4(3.01 g, 11.3 mmol) and Pd(dppf)CI2 (0.41 g, 0.57 mmol). The mixture was degassed and heated to about 90 °C for about 5 h under N2. The mixture was concentrated and the residue was purified by column chromatography (silica) and eluted with pet. ether:EtOAc (100:0 to 90:10) to afford 4-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-2-(4methoxy-3-propoxyphenyl)-6-(trifluoromethyl)pyrimidine (1.27 g, 70%). 1H NMR (CDCh, 400MHz): δ 8.13-8.16 (m, 1H), 8.07 (d, J = 2.0 Hz, 1H), 7.61 (s, 1H), 6.99 (d, J= 8.6 Hz, 1H),
120 φ 6.31 (d, J = 1.1 Hz, 1H), 5.95 (d, J = 1.0 Hz, 1H), 4.65 (t, J= 1.6 Hz, 2H), 4.13 (t, J= 6.9 Hz, 2H), 3.96 (s, 3H), 1.90-1.99 (m, 2H), 1.10 (t, J = 7.5 Hz, 3H), 0.97 (s, 9H), 0.13 (s, 6H). LCMS m/z = 483 [MH]+
Préparation 68: 2-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-6-(3-ethoxy-45 methoxyphenyl)pyrazine
2-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-6-(3-ethoxy-4-methoxyphenyl)pyrazine (1.26 g, 65%) was prepared in an analogous manner to Préparation 50 using 2-bromo-6-(3ethoxy-4-methoxyphenyl)pyrazine (Préparation 104, 1.5 g, 4.9 mmol). 1H NMR (CDCh, 400
MHz): δ 8.77-8.90 (m, 1H), 8.68 (s, 1H), 7.69 (d, J = 2.0 Hz, 1H), 7.60 (dd, J = 2.1, 8.44 Hz,
H), 6.99 (d, J = 8.3 Hz, 1 H), 6.07 (q, J = 1.4 Hz, 1 H), 5.77 (q, J = 1.9 Hz, 1 H), 4.80 (t, J = 1.7 Hz, 2H), 4.23 (q, J= 7.0 Hz, 2H), 3.96 (s, 3H), 1.53 (t, J = 7.0 Hz, 3H), 0.90-0.98 (m, 9H), 0.130.18 (m, 6H). LCMS m/z = 401 [MH]+.
Préparation 69: ethyl 2-(6-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-2-(4-methoxy-315 propoxyphenyi)pyrimidin-4-yl)acetate
Ethyl 2-(6-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-2-(4-methoxy-3propoxyphenyl)pyrimidin-4-yl)acetate (5.6 g, 82%) was prepared in an analogous manner to Préparation 50 using ethyl 2-(6-chloro-2-(4-methoxy-3-propoxyphenyl)pyrimidin-4-yl)acetate (Préparation 105, 5 g, 13.7 mmol). ’H NMR (CD3OD, 400 MHz): δ 8.05 (dd, J = 2.1, 8.4 Hz, 1 H), 8.01-8.03 (m, 1H), 7.46 (s, 1H), 7.05 (d, J= 8.6 Hz, 1H), 6.24 (d, J = 1.2 Hz, 1H), 5.81 (d, J = 1.5 Hz, 1 H), 4.81 (t, J = 1.6 Hz, 2H), 4.21 (q, J = 7.1 Hz, 2H), 4.05 (t, J = 6.6 Hz, 2H), 3.91 (s, 3H), 3.88 (s, 2H), 1.80-1.92 (m, 2H), 1.26-1.31 (m, 3H), 1.08 (t, J = 7.5 Hz, 3H), 0.95 (s, 9H), 0.13-0.16 (m, 6H). LCMS m/z = 501 [MH]+.
121
Préparation 70: 4-(((tert-butyldimethylsilyl)oxy)methyl)-6-(3-((tert-butyldimethylsilyl)oxy)prop-1en-2-yl)-2-(4-methoxy-3-propoxyphenyl)pyrimidine
4-(((tert-butyldimethylsilyl)oxy)methyl)-6-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-25 (4-methoxy-3-propoxyphenyl)pyrimidine (1 g, 77%) was prepared in an analogous manner to
Préparation 58 using 4-(((tert-butyldimethylsilyl)oxy)methyl)-6-(3-((tertbutyldimethylsilyl)oxy)prop-1-en-2-yl)-2-chloropyrimidine (Préparation 89, 2.0 g, 5.2 mmol) and 2-(4-methoxy-3-propoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (Préparation 114, 0.817 g, 2.8 mmol) at about 90 °C and substituting K3PO4 (1.55 g, 5.80 mmol) for K2CO3. 1H 10 NMR (CDCh, 400 MHz): δ 8.02-8.08 (m, 2H), 7.52 (s, 1H), 6.94-6.99 (m, 1H), 6.20 (d, J= 1.5
Hz, 1H), 5.84 (d, J= 1.5 Hz, 1H), 4.80-4.86 (m, 4H), 4.09-4.15 (m, 2H), 3.93-3.96 (m, 3H), 1.911.98 (m, 2H), 1.09 (t, J= 7.5 Hz, 3H), 1.00 (s, 9H), 0.97 (s, 9H), 0.17 (s, 6H), 0.15 (s, 6H).
LCMS m/z = 559 [MH]+.
Préparation 71: 2-(4-((tert-butyldimethylsilyl)oxy)but-1-en-2-yl)-6-(4-methoxy-315 propoxyphenyl)pyridine
2-(4-((tert-butyldimethylsilyl)oxy)but-1-en-2-yl)-6-(4-methoxy-3-propoxyphenyl)pyridine (900 mg, 68%) was prepared in an analogous manner to Préparation 50 using 2-bromo-6-(4methoxy-3-propoxyphenyl)pyridine (Préparation 93b, 1000 mg, 3.10 mmol) and tert20 butyldimethyl((3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)but-3-en-1-yl)oxy)silane (Préparation 148, 969 mg, 3.10 mmol). LCMS m/z = 428 [MH]+.
Préparation 72: 5-(3-((tert-butyldimethylsilyl)oxy)but-1-en-2-yl)-3-(4-methoxy-3propoxyphenyl)pyridazine
122
5-(3-((tert-butyldimethylsilyl)oxy)but-1-en-2-yl)-3-(4-methoxy-3-propoxyphenyl)pyridazine (3.0 g, 89%) was prepared in an analogous manner to Préparation 50 using 5-chloro-3-(4methoxy-3-propoxyphenyl)pyridazine (Préparation 107, 2.2 g, 7.9 mmol) and tert5 butyldimethyl((3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)but-3-en-2-yl)oxy)silane (Préparation 147, 4.9 g, 15.8 mmol). 1H NMR (CDCh, 400 MHz): δ 9.14 (d, J = 2.0 Hz, 1H), 7.91 (d, J = 2.0 Hz, 1H), 7.86 (d, J= 2.0 Hz, 1H), 7.53 (dd, J= 2.0, 8.3 Hz, 1H), 7.00 (d, J = 8.3 Hz, 1 H), 5.58 (s, 1 H), 5.53 (s, 1 H), 4.08-4.18 (m, 3H), 3.95 (s, 3H), 1.86-1.99 (m, 2H), 1.29 (d, J = 6.9 Hz, 3H), 1.08 (t, J = 7.3 Hz, 3H), 0.93 (s, 9H), 0.12 (d, J = 19.6 Hz, 6H). LCMS m/z = 429
[MH]+.
Préparation 73: 3-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-5-(3-ethoxy-4-methoxyphenyl)4-methylpyridine
3-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-5-(3-ethoxy-4-methoxyphenyl)-4- methylpyridine (0.8 g, 77%) was prepared in an analogous manner to Préparation 50 using 3bromo-5-(3-ethoxy-4-methoxyphenyl)-4-methylpyridine (Préparation 108, 0.81 g, 3.28 mmol) and tert-butyldimethyl((2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)allyl)oxy)silane (Préparation 146, 0.98 g, 3.28 mmol). 1H NMR (CDCh, 400MHz): δ 8.35 (s, 1H), 8.26 (s, 1H), 6.95 (d, J = 8.2 Hz, 1H), 6.83-6.86 (m, 1H), 6.78 (d, J = 2.0 Hz, 1H), 5.61-5.63 (m 1H), 5.10-
5.12 (m, 1H), 4.31-4.32 (m, 2H), 4.12 (q, J= 7.0 Hz, 2H), 3.93 (s, 3H), 2.21 (s, 3H), 1.48 (t, J =
7.0 Hz, 3H), 0.91 (s, 9H), 0.08 (s, 6H). LCMS m/z = 414 [MH]+.
Préparation 74: 4-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-2-(3-ethoxy-4methoxyphenyl)thiazole
4-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-2-(3-ethoxy-4-methoxyphenyl)thiazole was prepared (0.8 g, 91%) in an analogous manner to Préparation 50 using 4-bromo-2-(325
123 ethoxy-4-methoxyphenyl)thiazole (Préparation 109, 0.68 g, 2.16 mmol) and tertbutyldimethyl((2-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)allyl)oxy)silane (Préparation 146, 0.84 g, 2.81 mmol). Ή NMR (CDCh, 400MHz): δ 7.57 (d, J = 2.3Hz, 1H), 7.58 (dd, J = 2.3, 8.3Hz, 1H), 7.17 (s, 1H), 6.91 (d, J = 8.3Hz, 1H), 6.07-6.08 (m, 1H), 5.50-5.52 (m, 1H), 4.604.61 (m, 1H), 4.22 (q, J = 7.0Hz, 2H), 3.93 (s, 3H), 1.52 (t, J = 7.0Hz, 3H), 0.99 (s, 1H), 0.95 (s, 9H), 0.13 (s, 6H). LCMS m/z = 406 [MH]+.
Préparation 75: 2-((tert-butyldimethylsilyl)oxy)-1-(6-(4-methoxy-3-propoxyphenyl)pyridin-2yl)ethan-1-one
To a mixture of 1-(6-bromopyridin-2-yl)-2-((tert-butyldimethylsilyl)oxy)ethan-1-one (Préparation 88, 1270 mg, 4.36 mmol), K2CO3 (1000 mg, 7.27 mmol), KOAc (357 mg, 3.63 mmol), Pd(dppf)CI2 DCM (151 mg, 0.182 mmol) and a solution of 2-(4-methoxy-3propoxyphenyl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane (Préparation 114, 1200 mg, 3.633 mmol) in 1,4-dioxane (24 mL) was added water (2.4 mL). The mixture was degassed and heated to about 90 °C for about 16 h under N2. The reaction was filtered through a pad of MgSO4 and silica gel, washing with DCM and EtOAc. The filtrate was concentrated and the residue was purified by column chromatography (silica) and eluted with heptane/EtOAc (100:0 to 95:5) to afford 2-((tert-butyldimethylsilyl)oxy)-1-(6-(4-methoxy-3-propoxyphenyl)pyridin-2yl)ethan-1-one (1.21 g, 80%). Ή NMR (CDCh, 400 MHz): δ 7.84-7.93 (m, 3H), 7.72 (d, J= 2.0 Hz, 1H), 7.58 (dd, J = 2.0, 8.6 Hz, 1H), 7.00 (d, J = 8.6 Hz, 1H), 5.42 (s, 2H), 4.12 (t, J= 6.8 Hz, 2H), 3.95 (s, 3H), 1.90-2.00 (m, 2H), 1.10 (t, J = 7.4 Hz, 3H), 1.00 (s, 9H), 0.16-0.20 (m, 6H). LCMS m/z = 416 [MH]+.
Préparation 76: 2-(5-(2-(difluoromethyl)-3-ethoxy-4-methoxyphenyl)pyridin-3-yl)prop-2-en-1-ol
2-(5-(2-(difluoromethyl)-3-ethoxy-4-methoxyphenyl)pyridin-3-yl)prop-2-en-1-ol (321 mg, 61%) was prepared in an analogous manner to Préparation 50 using 3-bromo-5-(2(difluoromethyl)-3-ethoxy-4-methoxyphenyl)pyridine (Préparation 100, 558 mg, 1.56 mmol) at about 100 °C for about 15 h. Ή NMR (CDCh, 400 MHz): δ 8.70 (d, J = 2.0 Hz, 1H), 8.52 (d, J = 2.0 Hz, 1H), 7.76-7.79 (m, 1H), 7.07 (d, J= 8.6 Hz, 1H), 7.01 (d, J= 8.6 Hz, 1H), 6.96 (t, J =
124 • 54.4 Hz, 1H), 5.60(s, 1H), 5.49 (s, 1H), 4.58 (s, 2H), 4.12-4.22 (m, 2H), 3.93 (s, 3H), 1.75 (br s,
H), 1.43 (t, J = 7.0 Hz, 3H,). LCMS m/z = 336 [MH]+.
125
Préparation 77: 3-(5-(iodomethyl)-2,2-dimethyl-1,3-dioxan-5-yl)-5-(4-methoxy-3propoxyphenyl)pyridine
To a solution of (5-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-2,2-dimethyl-1,3-dioxan5 5-yl)methyl methanesulfonate (Préparation 78, 140 mg, 0.30 mmol) in acetone (1.20 mL) was added lithium iodide (201 mg, 1.50 mmol). The solution was stirred at about 50 °C for about 16 h. The reaction was cooled to about 50 °C, diluted with EtOAc, washed with water, dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography (silica) and eluted with heptane/EtOAc (100:0 to 0:100) to afford 3-(5-(iodomethyl)-2,2-dimethyl-1,310 dioxan-5-yl)-5-(4-methoxy-3-propoxyphenyl)pyridine (138 mg, 92%). 1H NMR (CDCb, 400MHz): δ 8.74 (d, J = 2.0 Hz, 1H), 8.45 (d, J = 2.3 Hz, 1H), 7.66 (t, J= 2.0 Hz, 1H), 7.08-7.17 (m, 2H), 7.00 (d, J = 8.2 Hz, 1H), 4.25-4.37 (m, 2H), 4.14-4.23 (m, 2H), 4.07 (t, J= 6.8 Hz, 2H), 3.93 (s, 3H), 3.81 (s, 2H), 1.92 (qd, J = 7.2, 14.3 Hz, 2H), 1.49 (d, J= 18.3 Hz, 6H), 1.08 (t, J= Ί A Hz, 3H). LCMS m/z = 498 [MH]+.
Préparation 78: (5-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-2,2-dimethyl-1,3-dioxan-5yl)methyl methanesulfonate
To a mixture of (5-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-2,2-dimethyl-1,3-dioxan20 5-yl)methanol (Préparation 79, 128 mg, 0.33 mmol) in DCM (7.0 mL) was added Me3N (84 pL, 0.60 mmol), followed by MsCI (33 pL, 0.43 mmol). The solution was stirred at about 20 °C for about 3.5 h. The mixture was concentrated and the residue was purified by column chromatography (silica) and eluted with heptane/EtOAc (100:0 to 0:100) to afford (5-(5-(4methoxy-3-propoxyphenyl)pyridin-3-yl)-2,2-dimethyl-1,3-dioxan-5-yl)methyl methanesulfonate (144 mg, 94%). Ή NMR (CDCb, 400MHz): δ 8.75 (d, J = 2.0 Hz, 1H), 8.47 (d, J= 2.0 Hz, 1H),
7.72 (t, J= 2.1 Hz, 1H), 7.08-7.17 (m, 2H), 6.99 (d, J= 8.2 Hz, 1H), 4.78 (s, 2H), 4.20-4.28 (m, 2H), 4.03-4.18 (m, 4H), 3.93 (s, 3H), 2.92-3.01 (m, 3H), 1.87-1.96 (m, 2H), 1.51 (d, J = 4.3 Hz, 6H), 1.08 (t, J= ΊΑ Hz, 3H).
126
Préparation 79: (5-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-2,2-dimethyl-1,3-dioxan-5yl)methanol
To a solution of 2-(hydroxymethyl)-2-(5-(4-methoxy-3-propoxyphenyl)pyridin-35 yl)propane-1,3-diol (Préparation 80, 406 mg, 1.17 mmol) in DCM (12 mL) was added 2,2dimethoxypropane (0.43 mL, 3.51 mmol) and pTSOH (33 mg, 0.18 mmol). The solution was stirred at about 40 °C for about 24 h and about 20 °C for about 4 days. The solution wasconcentrated and the residue was purified by column chromatography (silica) and eluted with heptane/EtOAc (100:0 to 0:100 gradient) to afford (5-(5-(4-methoxy-310 propoxyphenyl)pyridin-3-yl)-2,2-dimethyl-1,3-dioxan-5-yl)methanol (129 mg, 28%). 1H NMR (CDCh, 400MHz): δ 8.71 (d, J= 2.3 Hz, 1H), 8.50 (d, J= 2.0 Hz, 1H), 7.75 (t, J = 2.1 Hz, 1H), 7.05-7.15 (m, 2H), 6.99 (d, J = 8.6 Hz, 1H), 4.19 (d, J= 5.5 Hz, 3H), 4.12-4.17 (m, 3H), 4.06 (t, J = 6.8 Hz, 2H), 3.93 (s, 3H), 1.91 (qd, J = 7.2, 14.4 Hz, 2H), 1.62-1.64 (m, 1H), 1.49 (d, J= 5.1 Hz, 6H), 1.08 (t, J= 7.4 Hz, 3H). LCMS m/z = 388 [MH]+.
Préparation 80: 2-(hydroxymethyl)-2-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)propane-1,3diol
To a solution of methyl 3-hydroxy-2-(hydroxymethyl)-2-(5-(4-methoxy-320 propoxyphenyl)pyridin-3-yl)propanoate (Préparation 81,250 mg, 0.67 mmol) in methanol (2.0 mL) was added LiBH4 (17.5 mg, 0.80 mmol). The solution was stirred at about 20 °C for about 21 h. The mixture was treated with saturated aqueous NH4CI and extracted with DCM. The DCM extracts were washed with brine, dried over Na2SO4, filtered and concentrated to afford 2(hydroxymethyl)-2-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)propane-1,3-diol (55 mg, 24%).
Ή NMR (CDCh, 400MHz): δ 8.49 (br s, 1 H), 8.28 (br s, 1 H), 7.90 (br s, 1 H), 6.83-7.00 (m, 2H), 6.77 (d, J = 8.6 Hz, 1 H), 4.78 (br s, 2H), 4.04 (br s, 5H), 3.74-3.99 (m, 6H), 1.74-1.91 (m, 2H), 1.26 (s, 1 H), 1.00 (t, J = 7.4 Hz, 3H). LCMS m/z = 348 [MH]+.
127
Préparation 81: methyl 3-hydroxy-2-(hydroxymethyl)-2-(5-(4-methoxy-3-propoxyphenyl)pyridin3-yl)propanoate
To a solution of methyl 2-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)acetate (Préparation 84, 65 g, 210 mmol) in DMSO (200 mL) was added paraformaldéhyde (6.81 g, 227 mmol), followed by DMSO (300 mL). NaOMe (2.23 g, 41.2 mmol) was added, followed by another 100 mL of DMSO. The mixture was stirred at about 20 °C for about 18 h. The mixture was diluted with water (1200 mL) and extracted with diethyl ether and EtOAc. The diethyl ether and EtOAc combined extracts were washed with water, brine, dried over MgSO4, filtered and concentrated. The residue was stirred with EtOH (200 mL) at about 65 °C until the residue was dissolved. The solution was cooled to about 20 °C with stirring for about 2 h. The mixture was cooled to about 0 °C (ice water bath) for an additionall h. The mixture was filtered, and the filter cake was washed with ice-cold EtOH. The combined EtOH filtrâtes were concentrated and the residue purified by column chromatography (silica) eluting with EtOAc/MeOH (95:5) to afford methyl 3-hydroxy-2-(hydroxymethyl)-2-(5-(4-methoxy-3propoxyphenyl)pyridin-3-yl)propanoate (5.46 g, 7%). 1H NMR (CDCb, 400MHz): δ 8.64 (d, J = 2.0 Hz, 1H), 8.40 (d, J = 2.0 Hz, 1H), 7.71 (t, J = 2.0 Hz, 1H), 7.25 (s, 1H), 6.98 -7.10 (m, 2H), 6.94 (t, J = 7.3 Hz, 1 H), 4.36 (d, J = 11.3 Hz, 2H), 4.24 (d, J = 11.3 Hz, 2H), 4.02 (t, J = 6.6 Hz, 2H), 3.90 (s, 3H), 3.79 (s, 3H), 2.03 (s, 1H), 1.78-1.97 (m, 2H), 1.05 (t, J= 7.4 Hz, 3H).
Préparation 82: 2-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)propane-1,3-diol
To an ice cold solution of methyl 3-hydroxy-2-(5-(4-methoxy-3-propoxyphenyl)pyridin-3yl)propanoate (Préparation 83, 26.4 g, 73.5 mmol) in MeOH (350 mL) was added LiBH4 (3.2 g, 147 mmol) in 3 portions. The mixture was stirred for about 1 h. The mixture was concentrated and diluted with DCM. The mixture was washed with 2N NaOH. The DCM layer was separated, dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography (silica) and eluted with DCM/MeOH (100:0 to 90:10) to afford 2-(5-(4-methoxy3-propoxyphenyl)pyridin-3-yl)propane-1,3-diol (20.3 g, 87%). 1H NMR (DMSO-de, 400 MHz): δ 8.68 (d, J = 2.3 Hz, 1H), 8.37 (d, J = 2.0 Hz, 1H), 7.84 (t, J= 2.3 Hz, 1H), 7.21-7.25 (m, 2H),
128
7.06 (d, J = 8.2 Hz, 1 H), 4.64 (t, J = 5.4 Hz, 2H), 4.03 (t, J = 6.6 Hz, 2H), 3.81 (s, 3H), 3.65-3.79 (m, 4H), 2.89-2.95 (m, 1H), 1.72-1.80 (m, 2H), 1.00 (t, J =7.4 Hz, 3H). LCMS m/z = 318 [MH]+.
Préparation 83: methyl 3-hydroxy-2-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)propanoate
A mixture of methyl 2-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)acetate (Préparation 84, 30.0 g, 95 mmol), paraformaldéhyde (3.14 g, 105 mmol) and NaOMe (1.03 g, 19.0 mmol) in anhydrous DMSO (317 mL) was stirred at about 20 °C for about 16 h. The mixture was diluted with water (1200 mL) and extracted with diethyl ether and EtOAc. The combined diethyl ether and EtOAc extracts were washed with water, brine, dried over MgSO4, filtered and concentrated. The residue was dissolved in hot EtOH (120 mL). The solution was cooled to about 20 °C with stirring. Further cooling, to about 0 °C (ice bath) affording a precipitate which was filtered to afford methyl 3-hydroxy-2-(5-(4-methoxy-3-propoxyphenyl)pyridin-3yl)propanoate (15.6 g). The filtrate was concentrated and purified by column chromatography (silica) to provide additional solid (10.8 g). The solids were combined to afford methyl 3-hydroxy2-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)propanoate (26.4 g, 78%). 1H NMR (CDCh, 400 MHz): δ 8.72 (d, J= 2.0 Hz, 1H), 8.45 (d, J= 2.3 Hz, 1H), 7.76 (t, J= 2.0 Hz, 1H), 7.07-7.12 (m, 2H), 6.97 (d, J= 8.6 Hz, 1 H),4.16-4.22 (m, 1H), 4.05 (t, J= 7.0 Hz, 2H), 3.91-3.99 (m, 5H), 3.76 (s, 3H), 2.66-2.70 (m, 1 H), 1.67-1.95 (m, 2H), 1.08 (t, J = 7.4 Hz, 3H). LCMS m/z = 346 [MH]+.
Préparation 84: methyl 2-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)acetate
A mixture of methyl 2-(5-bromopyridin-3-yl)acetate (55.5 g, 241.0 mmol), 2-(4-methoxy3-propoxyphenyl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane (Préparation 114, 84.7 g, 290 mmol) and anhydrous Na2CO3 (51.1 g, 482 mmol) in 1,4-dioxane (700 mL) and water (180 mL) was degassed and stirred at about 20 °C for about 20 min under N2. Pd(dppf)CI2 (9.85 g, 12.1 mmol) was added to the mixture, which was heated to about 85 °C for about 18 h under N2. The reaction was cooled to about 20 °C and concentrated. The residue was partitioned between water and EtOAc. The aqueous layer was extracted with EtOAc. The combined EtOAc extracts were washed with water, brine, dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography (silica) eluting with heptane/EtOAc (85:15 to 40:60) to afford
129 methyl 2-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)acetate (75.4 g, 88%). 1H NMR (CDCI3,
400MHz): δ 8.72 (d, J= 2.0 Hz, 1H), 8.46 (d, J= 2.0 Hz, 1H), 7.77 (t, J = 2.0 Hz, 1H), 7.13 (dd, J = 2.3, 8.6 Hz, 1 H), 7.09 (d, J = 2.3 Hz, 1 H), 6.98 (d, J = 8.6 Hz, 1 H), 4.06 (t, J = 6.8 Hz, 2H), 3.92 (s, 3H), 3.70 (s, 2H), 2.94 (s, 3H), 1.86-1.95 (m, 2H), 1.08 (t, J = 7.4 Hz, 3H). LCMS m/z = 316 [MH]+.
Préparation 85: methyl 2-(2'-cyano-4'-methoxy-3'-propoxy-[1,1'-biphenyl]-3-yl)acetate
To a solution of 6-bromo-3-methoxy-2-propoxybenzonitrile (Préparation 171, 10.0 g, 37.02 mmol), (3-(2-methoxy-2-oxoethyl)phenyl)boronic acid (7.18 g, 37.02 mmol), Pd(dppf)CI2 (1.35 g, 1.85 mmol), KOAc (3.63 g, 37.02 mmol) and Na2CO3 (7.85 g, 74.04 mmol) in 1,4dioxane (100 mL) and water (5 mL) was degassed and heated to about 90 °C for about 5 h under N2. The mixture was filtered and concentrated. The residue was purified by column chromatography (silica) and eluted with pet. ether/EtOAc (4:1) to afford methyl 2-(2'-cyano-4'methoxy-3'-propoxy-[1,1'-biphenyl]-3-yl)acetate (12.0 g, 96%). 1H NMR (CDCI3, 400MHz): δ 7.40-7.44 (m, 3H), 7.33 (d, J = 6.8 Hz, 1H), 7.15 (d, J = 8.8 Hz, 2H), 4.18 (t, J = 6.8 Hz, 2H), 3.92 (s, 3H), 3.71 (d, J= 5.6 Hz, 5H), 1.83-1.92 (m, 2H), 1.09 (t, J= 7.2 Hz, 3H).
Préparation 86: 3-bromo-5-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)pyridine
A mixture of tert-butyldimethyl((2-(4,4,5,5-tetramethyl-l ,3,2-dioxaborolan-2yl)allyl)oxy)silane (Préparation 146, 14.9 g, 50 mmol), 3,5-dibromopyridine (12.4 g, 52.5 mmol), Pd(dppf)CI2 (1.83 g, 2.5 mmol) and K2CO3 (20.7 g, 150 mmol) were suspended in 1,4-dioxane (300 mL) and water (20 mL). The mixture was degassed and heated to about 85 °C for about 5 h under N2. The mixture was removed from heat and allowed to stand over the weekend. The mixture was concentrated, MTBE (100 mL) was added and stirred for about 20 min. The mixture was filtered and the filter cake was washed with MTBE (50 mL). The combined MTBE filtrâtes were dried and concentrated. The residue was purified by column chromatography (silica) eluting with pet. ether/EtOAc (100:0 to 95:5) to afford 3-bromo-5-(3-((tertbutyldimethylsilyl)oxy)prop-1-en-2-yl)pyridine (8.5 g, 51.8%). 1H NMR (CDCI3, 400 MHz): δ 8.5520225
130
8.63 (m, 2H), 7.84-7.93 (m, 1H), 5.44-5.55 (m, 2H), 4.49 (t, J= 1.5 Hz, 2H), 0.91 (s, 9H), 0.10 (s, 6H). LCMS m/z = 329 [MH]+.
Préparation 87: 3-bromo-5-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-2-methylpyridine
Br. Æ./ ίγ 1
A mixture of tert-butyldimethyl((2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl)allyl)oxy)silane (Préparation 146, 4.2 g, 14.08 mmol), 3,5-dibromo-2-methylpyridine (3.71 g, 14.8 mmol), Pd(dppf)CI2 (1030 mg, 1.41 mmol) and K2CO3 (5.84 g, 42.2 mmol) were suspended in 1,4-dioxane (150 mL) and water (5 mL). The mixture was degassed and heated to about 80 °C for about 5 h under N2. The mixture was concentrated and MTBE (100 mL) was added, stirring for about 20 min. The mixture was filtered and the filter cake was washed with MTBE (50 mL). The combined MTBE filtrâtes were concentrated and the residue was purified by column chromatography (silica) eluting with pet. ether/EtOAc (100:0 to 95:5) to afford 3-bromo-5-(3((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-2-methylpyridine (930 mg, 19.3%). 1H NMR (CDCI3, 400 MHz): δ 8.46-8.53 (m, 1H), 7.86 (d, J= 2.0 Hz, 1H), 5.41-5.50 (m, 2H), 4.43-4.54 (m, 2H), 2.66 (s, 3H), 0.92 (s, 9H), 0.10 (s, 6H).
Préparation 88: 1-(6-bromopyridin-2-yl)-2-((tert-butyldimethylsilyl)oxy)ethan-1-one
A solution of 1-(6-bromopyridin-2-yl)-2-hydroxyethan-1-one (Préparation 237, 977 mg, 4.52 mmol) and DCM (30 mL) cooled to about 0 °C, was added imidazole (770 mg, 11.3 mmol) and TBS-CI (750 mg, 4.97 mmol). The mixture was stirred at about 0 °C for about 2.5 h. The reaction was quenched with water and the layers were separated. The DCM layer was washed with water and brine. The DCM layer was passed through through a pad of MgSO4 and silica gel. The filtrate was concentrated to afford 1-(6-bromopyridin-2-yl)-2-((tertbutyldimethylsilyl)oxy)ethan-1-one (1.35 g, 90%). 1H NMR (CDCI3, 400 MHz): δ 7.93-8.04 (m, 1H), 7.62-7.78 (m, 2H), 5.21 (s, 2H), 0.97 (s, 9H), 0.15 (s, 6H).
131
Préparation 89: 4-(((tert-butyldimethylsilyl)oxy)methyl)-6-(3-((tert-butyldimethylsilyl)oxy)prop-1en-2-yl)-2-chloropyrimidme
4-(((tert-butyldimethylsilyl)oxy)methyl)-6-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-2chloropyrimidine (0.9 g, 34%) was prepared in an analogous manner to Préparation 50 using 4(((tert-butyldimethylsilyl)oxy)methyl)-2,6-dichloropyrimidine (Préparation 230, 1.65 g, 5.5 mmol) and K3PO4 as base. Ή NMR (CDCh, 400 MHz): δ 7.63 (s, 1 H), 6.23 (d, J = 1.5 Hz, 1 H), 5.87 (d, J = 1.5 Hz, 1 H), 4.76 (d, J = 1.0 Hz, 2H), 4.62-4.66 (m, 2H), 0.97-0.99 (m, 9H), 0.94 (s, 9H), 0.12-0.16 (m, 12H). LCMS m/z = 429 [MH]+.
Préparation 90: 4-(3-((tert-butyldimethylsilyl)oxy)prop-1 -en-2-yl)-2-chloro-6(trifluoromethyl)pyrimidine
4-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-2-chloro-6-(trifluoromethyl)pyrimidine (1.33 g, 66%) was prepared in an analogous manner to Préparation 50 using 2,4-dichloro-6(trifluoromethyl)pyrimidine (CAS 16097-64-6, 1.24 g, 5.72 mmol) and substituting K3PO4 (4.57 g, 17.1 mmol) for K2CO3. Ή NMR (CDCh, 400MHz): δ 7.77 (s, 1H), 6.38-6.39 (m, 1H), 5.99-6.00 (m, 1H), 4.65 (t, J = 1.5Hz, 2H), 0.92-0.94 (m, 9H), 0.13 (s, 6H). LCMS m/z = 353 [MH]+.
Préparation 91a: 3-(3,4-dimethoxyphenyl)-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2yl)pyridine
A mixture of 3-bromo-5-(3,4-dimethoxyphenyl)pyridine (Préparation 91b, 12.20 g, 41.48 mmol), Pin2B2 (21.07 g, 82.96 mmol), KOAc (8.14 g, 82.96 mmol) and Pd(dppf)CI2 (607 mg, 830 umol) in 1,4-dioxane (500 mL) was degassed and stirred at about 110 °C for about 4 h under
132
N2. The mixture was concentrated and the residue was purified by column chromatography (silica) eluting with pet. ether/EtOAc (100:1 to 10:1) to afford 3-(3,4-dimethoxyphenyl)-5(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (6.00 g, 42%). 1H NMR (CDCh, 400 MHz):
8.97 (d, J = 2.3 Hz, 1H), 8.71 (d, J=1.0 Hz, 1H), 8.14 (s, 1H), 7.27 (s, 1 H), 7.22-7.26 (m, 1H),
7.06 (d, J= 8.3 Hz, 1H), 3.86 (s, 3H), 3.80 (s, 3H), 1.33 (s, 13H).
Préparation 91b: 3-bromo-5-(3,4-dimethoxyphenyl)pyridine
A mixture of 3,5-dibromopyridine (17.90 g, 75.56 mmol), (3,4-dimethoxyphenyl) boronic acid (CAS 122775-35-3, 12.50 g, 68.69 mmol), Na2CO3 (10.92 g, 103.0 mmol), KOAc (10.11 g, 103.03 mmol) and Pd(dppf)CI2 (1.01 g, 1.37 mmol) in 1,4-dioxane (20 mL) was degassed and stirred at about 90 °C for about 8 h under N2. The mixture was filtered and concentrated The residue was purified by column chromatography (silica) and eluted with pet. ether/EtOAc (20:1 to 1:1) to afford 3-bromo-5-(3,4-dimethoxyphenyl)pyridine (20.2 g, 59%). 1H NMR (DMSO-ch, 400 MHz): 5 8.88 (d, J = 1.8 Hz, 1 H), 8.61 (d, J = 1.8 Hz, 1 H), 8.35 (t, J = 2.0 Hz, 1 H), 7.28-7.35 (m, 2H), 7.05 (d, J=7.9 Hz, 1H), 3.85 (s, 3H), 3.79 (s, 3H). LCMS m/z = 294 [MH]+.
Préparation 92: 3-Bromo-5-(3-ethoxy-4-methoxyphenyl)pyridine
A mixture of 2-(3-ethoxy-4-methoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (Préparation 113, 20.0 g, 71.9 mmol), 3,5-dibromopyridine (34.07 g, 143.8 mmol), K2CO3 (19.87 g, 143.8 mmol), KOAc (10.58 g, 107.9 mmol) and Pd(dppf)CI2 (2.10 g, 2.88 mmol) in 1,4dioxane (600 mL) and water (10 mL) was degassed and heated to about 100 °C for about 5 h under N2. The mixture was filtered and concentrated. The residue was purified by column chromatography (silica) and eluted with pet. ether/EtOAc (5:1) to afford 3-bromo-5-(3-ethoxy-4methoxyphenyl)pyridine (20 g, 90%). 1H NMR (CDCh, 400MHz): 5 8.71 (s, 1H), 8.60 (s, 1H), 7.96 (s, 1H), 7.11 (dd, J = 2.0, 8.4 Hz, 1H), 7.05 (s, 1H), 6.97 (t, J = 4.0 Hz, 1H), 4.18 (q, J = 6.8 Hz, 2H), 3.92 (s, 3H), 1.49 (t, J = 6.8 Hz, 3H).
133 ‘ Préparation 93a: 3-bromo-5-(4-methoxy-3-propoxyphenyl)pyridine \ JL^L^^/Br ^ilT
LL
2-(4-Methoxy-3-propoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (Préparation 114, 28.00 g, 95.83 mmol), 3,5-dibromopyridine (45.40 g, 191.66 mmol), K2CO3 (19.87 g, 5 143.75 mmol), KOAc (14.11 g, 143.75 mmol) and Pd(dppf)CI2 (3.51 g, 4.79 mmol) in 1,4dioxane (600 mL) and water (10 mL) was degassed and heated to about 100 °C for about 5 h under N2. The mixture was filtered and concentrated. The residue was purified by column chromatography (silica) and eluted with pet. ether/EtOAc (5:1) to afford 3-bromo-5-(4-methoxy3-propoxyphenyl)pyridine (15.00 g, 49%). 1H NMR (CDCh, 400MHz): δ 8.72 (d, J = 2.0 Hz, 1H), 10 8.61 (d, J= 2.0 Hz, 1H), 7.97 (t, J= 2.0 Hz, 1H), 7.12 (dd, J= 2.0, 8.4 Hz, 1H), 7.06 (d, J= 2.4
Hz, 1 H), 6.98 (d, J = 8.4 Hz, 1 H), 4.06 (t, J = 6.8 Hz, 2H), 3.93 (s, 3H), 1.87-1.96 (m, 2H), 1.08 (t, J= 7.2 Hz, 3H).
Préparation 93b: 2-bromo-6-(4-methoxy-3-propoxyphenyl)pyridine
2-(4-Methoxy-3-propoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (Préparation
114, 10.6 g, 36.3 mmol), 2,6-dibromopyridine (9.0 g, 38.0 mmol), K3PO4 (16.1 g, 76.0 mmol) and Pd(dppf)CI2 (1.55 g, 1.90 mmol) in dioxane (6 mL) and water (1.5 mL) was degassed and heated to about 80 °C overnight. The mixture was diluted with brine (150 mL) and EtOAc (150 mL). The layers were separated and the EtOAc layer was washed with brine (75 mL), dried over 20 Na2SO4, filtered and concentrated. The residue was purified by column chromatography (silica) and eluted with heptane/EtOAc (100:0 to 3:1) to afford 2-bromo-6-(4-methoxy-3propoxyphenyl)pyridine (5.34 g, 44%). 1H NMR (CDCh, 400MHz): δ 7.81-8.72 (m, 2H), 7.517.57 (m, 2H), 7.35 (d, J = 7.4 Hz, 1H), 6.95 (d, J = 8.2 Hz, 1H), 4.11 (t, J= 6.6 Hz, 2H), 3.93 (s, 3H), 1.86-1.97 (m, 2H), 1.09 (t, J = 7.4 Hz, 3H).
Préparation 94: 3-bromo-5-(3-isopropoxy-4-methoxyphenyl)pyridine
3-bromo-5-(3-isopropoxy-4-methoxyphenyl)pyridine (1.15 g, 52%) was prepared in an analogous manner to Préparation 93a using 2-(3-isopropoxy-4-methoxyphenyl)-4,4,5,520225
134 tetramethvl-1,3,2-dioxaborolane (Préparation 115, 2 g, 6.8 mmol) at about 120 °C for about 2 h.
Ή NMR (CDCh, 400 MHz): δ 8.71 (d, J= 1.5 Hz, 1H), 8.61 (d, J = 2.5 Hz, 1H), 7.95-7.98 (m, 1H), 7.12-7.16 (m, 1H), 7.09 (d, J =2.5 Hz, 1H), 6.99 (d, J =8.5 Hz, 1H), 4.58-4.67 (m, 1H), 3.92 (s, 3H), 1.42 (d, J = 6.0 Hz, 6H). LCMS m/z = 323 [MH]+.
Préparation 95: 3-bromo-5-(3-cyclopropoxy-4-methoxyphenyl)pyridine
3-bromo-5-(3-cyclopropoxy-4-methoxyphenyl)pyridine (860 mg, 52%) was prepared in an analogous manner to Préparation 93a using 2-(3-cyclopropoxy-4-methoxyphenyl)-4,4,5,5tetramethyl-1,3,2-dioxaborolane (Préparation 117, 1.5 g, 5.2 mmol) at about 120 °C for about 2 h. 1H NMR (CDCh, 400 MHz): δ 8.74 (d, J = 2.0 Hz, 1H), 8.62 (d, J = 2.5 Hz, 1H), 7.99 (t, J = 2.2 Hz, 1H), 7.43 (d, J =2.0 Hz, 1H), 7.14 (dd, J = 2.5, 8.3 Hz, 1H), 6.97 (d, J= 8.3 Hz, 1H), 3.92 (s, 3H), 3.81-3.87 (m, 1H), 0.83-0.96 (m, 4H). LCMS m/z = 321 [MH]+.
Préparation 96: 3-bromo-5-(3-(2-((tert-butyldimethylsilyl)oxy)ethoxy)-4-methoxyphenyl)pyridine
3-bromo-5-(3-(2-((tert-butyldimethylsilyl)oxy)ethoxy)-4-methoxyphenyl)pyridine
3-bromo-5-(3-(2-((tert-butyldimethylsilyl)oxy)ethoxy)-4-methoxyphenyl)pyridine 3-bromo5-(3-(2-((tert-butyldimethylsilyl)oxy)ethoxy)-4-methoxyphenyl)pyridine (6.8 g, 32%) was prepared in an analogous manner to Préparation 93a using tert-butyl(2-(2-methoxy-5-(4,4,5,5tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)ethoxy)dimethylsilane (Préparation 120, 20 g, 49 mmol) at about 120 °C for about 3 h. 1H NMR (CDCh, 400 MHz): δ 8.69-8.78 (m, 1H), 8.61 (d, J= 2.2 Hz, 1H), 7.97 (t, J = 2.1 Hz, 1H), 7.13 (qd, J = 2.2, 4.4 Hz, 2H), 6.98 (d, J = 8.8 Hz, 1H), 4.16-4.23 (m, 2H), 4.02-4.09 (m, 2H), 3.92 (s, 3H), 0.88-0.93 (m, 9H), 0.10 (s, 6H). LCMS m/z = 439 [MH]+.
135
Préparation 97: 3-bromo-5-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-4methoxyphenyl)pyridine
3-bromo-5-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-4-methoxyphenyl)pyridine (12.4 g, 5 64%) was prepared in an analogous manner to Préparation 93a using tert-butyl(3-(2-methoxy-5(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)propoxy)dimethylsilane (Préparation 121, 18 g, 42.6 mmol). Ή NMR (CDCh, 400 MHz): δ 8.68 (d, J = 2.0 Hz, 1H), 8.58 (d, J= 2.5 Hz, 1H), 7.94-8.01 (m, 1H), 7.10 (dd, J = 2.5, 8.3 Hz, 1H), 7.07 (d, J = 2.0Hz, 1 H), 6.96 (d, J=8.3 Hz, 1H), 4.19 (t, J = 6.4 Hz, 2H), 3.90 (s, 3H), 3.80-3.86 (m, 2H), 2.03-2.11 (m, 2H), 0.85-0.90 (m, 9H), 0.04 (s, 6H). LCMS m/z = 454 [MH]+.
Préparation 98: 3-bromo-5-(3-(2-fluoroethoxy)-4-methoxyphenyl)pyridine
3-Bromo-5-(3-(2-fluoroethoxy)-4-methoxyphenyl)pyridine (1.8 g, 74%) was prepared in an analogous manner to Préparation 93a using 2-(3-(2-fluoroethoxy)-4-methoxyphenyl)-4,4,5,515 tetramethyl-1,3,2-dioxaborolane (Préparation 122, 2.2 g, 7.4 mmol) at about 120 °C for about 2 h. Ή NMR (CDCh, 400 MHz): δ 8.68-8.76 (m, 1H), 8.58-8.65 (m, 1H), 7.97 (t, J= 2.3 Hz, 1H), 7.18 (dd, J = 2.0, 8.5 Hz, 1H), 7.12 (d, J = 2.0 Hz, 1H), 7.00 (d, J= 8.5 Hz, 1H), 4.83-4.92 (m, 1 H), 4.72-4.81 (m, 1 H), 4.37-4.44 (m, 1 H), 4.25-4.36 (m, 1 H), 3.88-3.97 (m, 3H). LCMS m/z = 325 [MH]+.
Préparation 99: 3-bromo-5-(3-(3-fluoropropoxy)-4-methoxyphenyl)pyridine
3-Bromo-5-(3-(3-fluoropropoxy)-4-methoxyphenyl)pyridine was prepared in an analogous manner to Préparation 93a using 2-(3-(3-fluoropropoxy)-4-methoxyphenyl)-4,4,5,5tetramethyl-1,3,2-dioxaborolane (Prpeartion 123).
136
Préparation 100: 3-bromo-5-(2-(difluoromethyl)-3-ethoxy-4-methoxyphenyl)pyridine
3-Bromo-5-(2-(difluoromethyl)-3-ethoxy-4-methoxyphenyl)pyridine (1000 mg, 28%) was prepared in an analogous manner to Préparation 93a using 2-(2-(difluoromethyl)-3-ethoxy-45 methoxyphenyl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane (Préparation 127, 4.09g, 12.46 mmol) heated to about 100 °C for about 15 h. 1H NMR (400 MHz, CDCI3): δ 8.67 (d, J = 2.0 Hz, 1H), 8.52 (d, J = 1.5 Hz, 1H), 7.86 (t, J= 2.0 Hz, 1H), 6.84-7.13 (m, 4H), 4.17 (q, J = 7.4 Hz, 2H), 3.93 (s, 3H), 1.42 (t, J =7.0 Hz, 3H). LCMS m/z = 359 [MH]+.
Préparation 101: 3-bromo-5-(5-ethoxy-2-fluoro-4-methoxyphenyl)pyridine
3-Bromo-5-(5-ethoxy-2-fluoro-4-methoxyphenyl)pyridine (350 mg, 27%) was prepared as in an analogous manner to Préparation 93a using 2-(5-ethoxy-2-fluoro-4-methoxyphenyl)4,4,5,5-tetramethyl-l ,3,2-dioxaborolane (Préparation 134, 1.2 g, 4.05 mmol). 1H NMR (CDCh, 400MHz): δ 8.68 (t, J= 1.7 Hz, 1H), 8.63 (d, J= 2.1 Hz, 1H), 7.98-8.00 (m, 1H), 6.88 (d, J= 7.3 15 Hz, 1H), 6.75 (d, J= 11.7 Hz, 1H), 4.12 (q, J = 7.0 Hz, 2H), 3.92 (s, 3H), 1.49 (t, J= 7.0 Hz, 3H). LCMS m/z = 327 [MH]+.
Préparation 102: 3-bromo-5-(2-fluoro-4-methoxy-5-propoxyphenyl)pyridine
3-Bromo-5-(2-fluoro-4-methoxy-5-propoxyphenyl)pyridine (3.4 g, 31%) was prepared as 20 in an analogous manner to Préparation 93a using 2-(2-fluoro-4-methoxy-5-propoxyphenyl)4,4,5,5-tetramethyl-l,3,2-dioxaborolane (Préparation 138, 10 g, 32 mmol). 1H NMR (CDCI3, 400MHz): δ 8.68 (t, J = 1.5 Hz, 1 H), 8.63 (d, J = 2.4 Hz, 1 H), 7.99 (q, J = 2.0 Hz, 1 H), 6.88 (d, J = 7.8 Hz, 1H), 6.75 (d, J= 11.7 Hz, 1H), 4.00 (t, J= 6.8 Hz, 2H), 3.91 (s, 3H), 1.84-1.93 (m, 2H), 1.06 (t, J = 7.6 Hz, 3H). LCMS m/z = 339 [MH]+.
137
Préparation 103: 5'-chloro-3-fluoro-5-methoxy-6-propoxy-2,3'-bipyridine
5'-Chloro-3-fluoro-5-methoxy-6-propoxy-2,3'-bipyridine (3.11 g, 78%) was prepared in an analogous manner to Préparation 93a using 3-fluoro-2-iodo-5-methoxy-6-propoxypyridine (Préparation 220, 4.18 g, 13.44 mmol) and (5-chloropyridin-3-yl)boronic acid (2.11 g, 13.4 mmol) at about 90 °C for about 16 h. 1H NMR (CDCb, 400MHz): δ 9.13 (s, 1H), 8.53 (d, J = 2.5 Hz, 1H), 8.27 (t, J= 2.1 Hz, 1H), 6.97 (d, J= 11.5 Hz, 1H), 4.43 (t, J = 6.9 Hz, 2H), 3.93 (s, 3H), 1.86-1.95 (m, 2H), 1.07 (t, J = 7.5 Hz, 3H). LCMS m/z = 328 [MH]+.
Préparation 104: 2-bromo-6-(3-ethoxy-4-methoxyphenyl)pyrazine
2-Bromo-6-(3-ethoxy-4-methoxyphenyl)pyrazine (2.9 g, 52%) was prepared in an analogous manner to Préparation 93a using 2-(3-ethoxy-2-fluoro-4-methoxyphenyl)-4,4,5,5tetramethyl-1,3,2-dioxaborolane (Préparation 113, 5 g, 18 mmol) and 2,6-dibromopyrazine (6.4 g, 27 mmol) at about 110 °C for about 16 h. 1H NMR (CDCb, 400MHz): δ 8.86-8.92 (m, 1H),
8.53 (s, 1H), 7.61 (d, J= 2.0 Hz, 1H), 7.57 (dd, J= 2.2, 8.3 Hz, 1H), 6.98 (d, J= 8.3 Hz, 1H),
4.23 (q, J = 6.9 Hz, 2H), 3.95 (s, 3H), 1.53 (t, J = 7.0 Hz, 3H). LCMS m/z = 309 [MH]+.
Préparation 105: ethyl 2-(6-chloro-2-(4-methoxy-3-propoxyphenyl)pyrimidin-4-yl)acetate
POCb(253 mL, 2716 mmol) was added to ethyl 2-(2-(4-methoxy-3-propoxyphenyl)-620 oxo-1,6-dihydropyrimidin-4-yl)acetate (Préparation 106, 42.98 g, 124.08 mmol), followed by pyridine hydrochloride (14.3 g, 124 mmol) at about 25 °C. The resulting mixture was heated to about 80 °C for about 0.5 h. The mixture was diluted with EtOAc (200 mL) and added into water dropwise. The EtOAc layer was treated with NaHCO3. The EtOAc layer was washed with brine,
138 f dried with Na2SO4, filtered and concentrated. The residue was purified by column chromatography on a reversed-phase column eluting with MeCN/water (0:100 to 100:0) to afford ethyl 2-(6-chloro-2-(4-methoxy-3-propoxyphenyl)pyrimidin-4-yl)acetate (22.07 g, 49%). 1H
NMR (CDCh, 400MHz): δ 8.08 (dd, J = 2.1, 8.4 Hz, 1H), 7.98 (d, J= 2.0 Hz, 1H), 7.20 (s, 1H),
6.95 (d, J = 8.6 Hz, 1 H), 4.24 (q, J = 7.2 Hz, 2H), 4.11 (t, J = 6.9 Hz, 2H), 3.95 (s, 3H), 3.85 (s,
2H), 1.89-1.96 (m, 2H), 1.31 (t, J = 7.2 Hz, 3H), 1.09 (t, J = 7.5 Hz, 3H). LCMS m/z = 365 [MH]+.
Préparation 106: ethyl 2-(2-(4-methoxy-3-propoxyphenyl)-6-oxo-1,6-dihydropyrimidin-4yl)acetate
A mixture of 4-methoxy-3-propoxybenzimidamide (Préparation 233, 25.3 g, 121 mmol),
NaHCO3(12.2 mg, 146 mmol) and diethyl 1,3-acetonedicarboxylate (CAS 105-50-0, 29.4 g, 146 mmol) in EtOH (500 mL) was stirred at about 100 °C for about 24 h. The mixture was filtered, and the filter cake was washed with MTBE (200 mL), MeOH (100 mL) and DCM (50 mL) to afford ethyl 2-(2-(4-methoxy-3-propoxyphenyl)-6-oxo-1,6-dihydropyrimidin-4-yl)acetate (34.34 g,
82%). Ή NMR (CDCh, 400MHz): δ 12.44 (br s, 1H), 7.73-7.86 (m, 2H), 6.99 (d, J= 8.3 Hz, 1H),
6.33 (s, 1H), 4.23 (q, J= 7.3 Hz, 2H), 4.16 (t, J= 6.9 Hz, 2H), 3.96 (s, 3H), 3.66 (s, 2H), 1.921.97 (m, 2H), 1.30 (t, J = 7.2 Hz, 3H), 1.10 (t, J= 7.5 Hz, 3H). LCMS m/z = 346 [MH]+.
Préparation 107: 5-chloro-3-(4-methoxy-3-propoxyphenyl)pyridazine
5-chloro-3-(4-methoxy-3-propoxyphenyl)pyridazine (2.9 g, 52%) was prepared in an analogous manner to Préparation 93a using 2-(4-methoxy-3-propoxyphenyl)-4,4,5,5tetramethyl-1,3,2-dioxaborolane (Préparation 114, 4.3 g, 14.7 mmol) and 3,5-dichloropyridazine (2.3 g, 15.5 mmol). Ή NMR (CDCh, 400 MHz): δ 9.08 (d, J = 2.5 Hz, 1H), 7.84 (d, J = 2.5 Hz, 2H), 7.51 (dd, J = 2.2, 8.6 Hz, 1H), 7.00 (d, J = 8.3 Hz, 1H), 4.12 (t, J = 6.9 Hz, 2H), 3.95 (s,
3H), 1.92-1.97 (m, 2H), 1.08 (t, J = 7.3 Hz, 3H). LCMS m/z = 278 [MH]+.
139
Préparation 108: 3-bromo-5-(3-ethoxy-4-methoxyphenyl)-4-methylpyridine
3-bromo-5-(3-ethoxy-4-methoxyphenyl)-4-methylpyridine (0.82 g, 35%) was prepared in an analogous manner to Préparation 93a using 2-(3-ethoxy-4-methoxyphenyl)-4,4,5,5tetramethyl-1,3,2-dioxaborolane (Préparation 113, 2.0 g, 7.19 mmol) and 3,5-dibromo-4methylpyridine (2.71 g, 10.8 mmol) at about 120 °C for about 2 h. 1H NMR (CDCh, 400MHz): δ 8.61 (s, 1H), 8.32 (s, 1H), 6.94 (d, J = 8.0 Hz, 1H), 6.81-6.83 (m, 1H), 6.78 (d, J = 2.3 Hz, 1H), 4.10 (q, J = 7.0 Hz, 2H), 3.92 (s, 3H), 2.34 (s, 3H), 1.47 (t, J = 7.0 Hz, 3H). LCMS m/z = 323 [MH]+.
Préparation 109: 4-bromo-2-(3-ethoxy-4-methoxyphenyl)thiazole
To a mixture of Pd(OAc)2 (CAS 3375-31-3, 40.4 mg, 0.18 mmol) and Xantphos (CAS 161265-03-8, 208.0 mg, 0.36 mmol), stirring for about 10 min., was added 2-(3-ethoxy-4methoxyphenyl)-4,4,5,5-tetramethyl-l ,3,2-dioxaborolane (Préparation 113, 1.0 g, 3.60 mmol), 2,4-dibromothiazole (0.83 g, 3.42 mmol) and K3PO4 (2.44 g, 11.5 mmol). The combined mixture was degassedand heated to about 60 °C for about 16 h. The mixture was concentrated and the residue was purified by column chromatography (silica) eluting with pet. ether:EtOAc (100:0 to 85:15) to afford 4-bromo-2-(3-ethoxy-4-methoxyphenyl)thiazole (0.68 g, 60%). 1H NMR (CDCh, 400MHz): δ 7.51 (d, J = 2.3 Hz, 1H), 7.45 (dd, J= 2.3, 8.3 Hz, 1H), 7.14 (s, 1H), 6.90 (d, J = 8.3 Hz, 1H), 4.20 (q, J = 7.0 Hz, 2H), 3.93 (s, 3H), 1.51 (t, J= 7.0 Hz, 3H). LCMS m/z = 315 [MH]+.
Préparation 110: ethyl 2-(6-bromopyridin-2-yl)-2-methyl-3-(4,4,5,5-tetramethyl-l ,3,2dioxaborolan-2-yl)propanoate
To a mixture of sodium iodide (1.05 g, 6.98 mmol) and acetone (1.50 mL) was added 2(chloromethyl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane (187 mg, 1.06 mmol) and was stirred at about 20 °C for about 30 min. The mixture was filtered through a pad of Celite® and the filtrate
140 concentrated. The residue was dissolved and concentrated with anhydrous THF (3x5 mL). The residue was dissolved in THF (6.0 mL) and added to a cold suspension of NaH (60% dispersion in minerai oil, 349 mg, 8.73 mmol) and ethyl 2-(6-bromopyridin-2-yl)propanoate (Préparation 111,1.502 g, 5.819 mmol) in THF (13.0 mL), which had been degassed under N2. The combined mixture was stirred at about 20 °C for about 18 h. The mixture was treated with saturated aqueous NH4CI and extracted with EtOAc. The combined EtOAc extracts were washed with brine, dried over Na2SO4, filtered and concentrated. The residue was dissolved in DMSO (5 mL) and was purified by préparative HPLC (Biotage C18 RP column, 60 g) eluting with MeCN (0.1% NH4CO2H)/water (0:100 to 100:0) to afford ethyl 2-(6-bromopyridin-2-yl)-2methyl-3-(4,4,5,5-tetramethyl-l ,3,2-dioxaborolan-2-yl)propanoate (339 mg, 14%). 1H NMR (CDCh, 500MHz): δ 7.44-7.48 (m, 1H), 7.31 (m, 1H), 7.25-7.29 (m, 2H), 4.15 (q, J= 7.1 Hz, 2H), 1.67-1.70 (m, 3H), 1.54 (s, 2H), 1.23-1.25 (m, 7H), 1.20 (d, J= 3.9 Hz, 13H). LCMS m/z = 399 [MH]+.
Préparation 111: ethyl 2-(6-bromopyridin-2-yl)propanoate
To a solution of ethyl 2-(6-bromopyridin-2-yl)acetate (Préparation 112, 5.72 g, 23.4 mmol) in THF (117 mL) cooled to about -78 °C was added a solution of LiHMDS in THF (1.0 M, 29.3 mL, 29.3 mmol). The solution was stirred for about 1 h and iodomethane (3.33 g, 23.4 mmol, 1.46 mL) was added dropwise. The reaction was allowed to warm to about 20 °C over about 19 h. The reaction mixture was diluted with EtOAc. The mixture was washed with saturated aqueous NH4CI, brine, dried over MgSO4 and Na2SO4, filtered and concentrated. The residue was purified by column chromatography (silica) and eluted with heptanes/EtOAc (100:0 to 80:20) to afford ethyl 2-(6-bromopyridin-2-yl)acetate (5.06 g, 84%). 1H NMR (CDCh, 400MHz,): δ 7.50-7.57 (m, 1H), 7.39 (d, J= 7.8 Hz, 1H), 7.26-7.31 (m, 1H), 4.19 (q, J= 7.0 Hz, 2H), 3.93 (q, J = 7.0 Hz, 1 H), 1.57 (d, J = 7A Hz, 3H), 1.25 (t, J = 7.0 Hz, 3H). LCMS m/z = 259 [MH]+.
Préparation 112: ethyl 2-(6-bromopyridin-2-yl)acetate
To a solution of 2-bromo-6-methylpyridine (CAS 5315-25-3, 10.2 g, 59.1 mmol) in THF (62 mL) was cooled to about -78 °C under N2 was added a solution of LDA in THF (2.0 M, 59 mL, 118 mmol) slowly while stirring. The solution was stirred at about -78 °C for about 30 min. To the mixture was added diethyl carbonate (8.6 mL, 70.9 mmol) at about -78 °C. The mixture
141 was allowed to warm to about 20 °C over overnight. The reaction was cooled to about 0 °C and diluted with saturated aqueous NH4CI solution. The aqueous layer was extracted with DCM and the combined DCM extracts were washed with water, brine, dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography (silica) and eluted with heptanes/EtOAc (100:0 to 60:40) to afford ethyl 2-(6-bromopyridin-2-yl)acetate (7.7 g, 53%). 1H NMR (CDCI3i 400MHz,): δ 7.55 (t, J = 7.8 Hz, 1 H), 7.42 (d, J = 8.2 Hz, 1 H), 7.28-7.34 (m, 1 H), 4.21 (q, J = 7.2 Hz, 2H), 3.85 (s, 2H), 1.26-1.34 (m, 3H). LCMS m/z = 245 [MH]+.
Préparation 113: 2-(3-ethoxy-4-methoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
A mixture of 4-bromo-2-ethoxy-1-methoxybenzene (Préparation 150, 48.0 g, 207.7 mmol), Pd(dppf)CI2 (4.56 g, 6.23 mmol), Pin2B2 (58.0 g, 228.5 mmol) and KOAc (40.8 g, 415.4 mmol) in 1,4-dioxane (500 mL) was degassed and heated to about 90 °C for about 16 h under N2. The mixture was filtered and concentrated. The residue was purified by column chromatography (silica) and eluted with pet. ether/EtOAc (10:1) to afford 2-(3-ethoxy-4methoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (50.0 g, 86%). 1H NMR (CDCI3, 400MHz): δ 7.41 (d, J = 8.0 Hz, 1H), 7.30 (s, 1H), 6.89 (d, J = 8.0 Hz, 1H), 4.16 (q, J =7.2 Hz, 2H), 3.90 (s, 3H), 1.47 (t, J= 7.2 Hz, 3H), 1.34 (s, 12H).
Préparation 114: 2-(4-methoxy-3-propoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
A mixture of 4-bromo-1-methoxy-2-propoxybenzene (Préparation 151,43.00 g, 175.43 mmol), KOAc (34.43 g, 350.86 mmol), Pin2B2 (49.00 g, 192.97 mmol) and Pd(dppf)CI2 DCM (4.30 g, 5.26 mmol) in 1,4-dioxane (500 mL) was degassed and stirred at about 80 °C for about 16 h. The solid was removed by filtration and the filtrate was concentrated. The residue was purified by column chromatography (silica) and eluted with pet. ether/EtOAc (10:1) to afford 2(4-methoxy-3-propoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (51.0 g, 99%). 1H NMR (CDCI3,400 MHz): δ 7.40-7.42 (m, 1 H), 7.30 (d, J = 1.2 Hz, 1 H), 6.89 (d, J = 8.0 Hz, 1 H), 4.03 (t, J = 7.0 Hz, 2H), 3.89 (s, 3H), 1.84-1.93 (m, 2H), 1.34 (s, 12H), 1.05 (t, J = ΊΑ Hz, 3H).
The following compounds were prepared using the appropriate bromide and 4,4,4',4',5,5,5',5'octamethyl-2,2'-bi(1,3,2-dioxaborolane), following the procedure described in Préparation 114.
142
Préparation No. | Structure/Name | Source | Analytical Data |
115 | o>OB-°Z 0 n 2-(3-isopropoxy-4-methoxyphenyl)- 4,4,5,5-tetramethyl-l ,3,2- dioxaborolane | Préparation 152 | 1H NMR (CDCb, 400 MHz): δ 7.40-7.44 (m, 1H), 7.33 (d, J= 1.5 Hz, 1H), 6.87-6.91 (m, 1H), 4.62 (td, J = 6.1, 12.2 Hz, 1H), 3.88 (s, 3H), 1.36-1.39 (m, 6H), 1.34 (s, 12H). LCMS m/z = 293 [MH]+. |
116 | oXXb'0^ xJ °~7x 2-(3-isobutoxy-4-methoxyphenyl)- 4,4,5,5-tetramethyl-l ,3,2dioxaborolane | Préparation 153 | 1H NMR (CDCb, 400 MHz): δ 7.41 (dd, J = 1.2, 8.1 Hz, IH), 7.29 (d, J = 1.0 Hz, 1H), 6.89 (d, J = 7.8 Hz, 1H), 3.89 (s, 3H), 3.82 (d, J = 6.9 Hz, 2H), 2.16-2.23 (m, 1H), 1.331.37 (m, 12H), 1.05 (d, J = 6.4 Hz, 6H). LCMS m/z = 307 [MH]+. |
117 | oXX-%/ Λ 2-(3-cyclopropoxy-4- methoxyphenyl)-4,4,5,5-tetramethyl- 1,3,2-dioxaborolane | Préparation 154 | 1H NMR (CDCb, 400 MHz): δ 7.62 (d, J =1.0 Hz, 1H), 7.40-7.48 (m, 1H), 6.83-6.91 (m, 1H), 3.87 (s, 3H), 3.81-3.86 (m, 1H), 1.33-1.36 (m, 12H), 0.80-0.88 (m, 4H). LCMS m/z = 291 [MH]+. |
143
118 | o-O^B-o '—s 2-(4-methoxy-3- ((tetrahydrothiophen-3yl)oxy)phenyl)-4,4,5,5-tetramethyl1,3,2-dioxaborolane | Préparation 155 | 1H NMR (CDCh, 400 MHz): δ 7.43-7.51 (m, 1H), 7.37 (d, J= 1.5 Hz, 1H), 6.88-6.92 (m, 1H), 5.135.15 (m, 1H), 3.87 (s, 3H), 3.09-3.18 (m, 3H), 2.89-2.96 (m, 1H), 2.392.47 (m, 1H), 2.04-2.07 (m, 1H), 1.34 (s, 12H). LCMS m/z = 337 [MH]+. |
119 | ύ A 2-(4-methoxy-3-((tetra hyd ro-2 Hthiopyran-4-yl)oxy)phenyl)-4,4,5,5tetramethyl-1,3,2-dioxaborolane | Préparation 156 | 1H NMR (CDCh, 400 MHz): 6 7.41-7.48 (m, 1H), 7.32 (d, J= 1.5 Hz, 1H), 6.86-6.93 (m, 1H), 4.264.37 (m, 1H), 3.86 (s, 3H), 2.87-3.01 (m, 2H), 2.512.62 (m, 2H), 2.13-2.25 (m, 2H), 1.98-2.10 (m, 2H), 1.29-1.36 (m, 12H). |
120 | Ο—/ tert-butyl(2-(2-methoxy-5-(4,4,5,5tetramethyl-1,3,2-dioxaborolan-2yl)phenoxy)ethoxy)dimethylsilane | Préparation 157 | Ή NMR (CDCh, 400 MHz): δ 7.42 (dd, J= 1.5, 7.8 Hz, 1H), 7.34 (d, J = 1.5 Hz, 1H), 6.86-6.90 (m, 1H), 4.10-4.18 (m, 2H), 3.99-4.03 (m, 2H), 3.88 (s, 3H), 1.34 (s, 12H), 0.900.92 (m, 9H), 0.09-0.11 (m, 6H). LCMS m/z = 409 [MH]+. |
144
121 | >u. Y । ο-/ tert-butyl(3-(2-methoxy-5-(4,4,5,5tetramethyl-1,3,2-dioxaborolan-2yl)phenoxy)propoxy)dimethylsilane | Préparation 158 | XH NMR (CDCh, 400 MHz): δ 7.40-7.43 (m, 1H), 7.33 (d, J= 1.5 Hz, 1H), 6.86-6.89 (m, 1H), 4.18 (t, J = 6.6 Hz, 2H), 3.88 (s, 3H), 3.81-3.85 (m, 2H), 2.05-2.09 (m, 2H), 1.34 (s, 12H), 0.90 (s, 9H), 0.050.06 (m, 6H). LCMS m/z = 423 [MH]+. |
122 | o-/ 2-(3-(2-fluoroethoxy)-4methoxyphenyl)-4,4,5,5-tetramethyl1,3,2-dioxaborolane | Préparation 159 | Ή NMR (CDCh, 400 MHz): δ 7.46 (dd, J= 1.5, 7.8 Hz, 1H), 7.32 (d, J = 1.0 Hz, 1H), 6.89-6.93 (m, 1H), 4.83-4.88 (m, 1H), 4.71-4.75 (m, 1H), 4.344.38 (m, 1H), 4.27-4.31 (m, 1H), 3.90 (s, 3H), 1.34 (s, 12H). LCMS m/z = 297 [MH]+. |
123 | O-/ 2-(3-(3-fluoropropoxy)-4methoxyphenyl)-4,4,5,5-tetramethyl1,3,2-dioxaborolane | Préparation 160 | Ή NMR (CDCh, 400 MHz): δ 7.44 (dd, J = 1.5, 7.8 Hz, 1H), 7.33 (d, J = 1.5 Hz, 1H), 6.89 (d, J = 7.8 Hz, 1H), 4.74 (t, J = 5.9 Hz, 1H), 4.62 (t, J = 5.9 Hz, 1H), 4.20 (t, J = 6.4 Hz, 2H), 3.89 (s, 3H), 2.27-2.30 (m, 1H), 2.202.23 (m, 1H), 1.32-1.37 (m, 12H). LCMS m/z = 311 [MH]+. |
145
124 | N l /\ o-Z 2-methoxy-3-propoxy-5-(4,4,5,5tetramethyl-1,3,2-dioxaborolan-2yl)pyridine | Préparation 215 | 1H NMR (CDCh, 400 MHz): δ 8.12 (d, J= 1.5 Hz, 1H), 7.34 (d, J= 1.5 Hz, 1H), 4.03 (s, 3H), 3.98-4.02 (m, 2H), 1.851.94 (m, 2H), 1.35 (s, 12H), 1.05 (t, J = 7.5 Hz, 3H). LCMS m/z = 294 [MH]+. |
125 | CN O— 2,3-dimethoxy-6-(4,4,5,5tetramethyl-1,3,2-dioxaborolan-2yl)benzonitrile | Préparation 162 | 1H NMR (CDCh, 400 MHz): δ 7.57 (d, J= 8.4 Hz, 1H), 7.07 (d, J= 8.4 Hz, 1H), 4.00-3.96 (m, 3H), 3.93-3.89 (m, 3H), 1.37 (s, 12H). |
126 | F °~Tx 2-(3-ethoxy-2-fluoro-4- methoxyphenyl)-4,4,5,5-tetramethyl- 1,3,2-dioxaborolane | Préparation 170a | 1H NMR (CDCh, 400 MHz): δ 7.35-7.44 (m, 1H), 6.69 (dd, J= 0.9, 8.4 Hz, 1H), 4.07-4.16 (m, 2H), 3.88 (s, 3H), 1.33-1.40 (m, 15H). |
127 | Β-'θγ^ ' z\ A. o—z F F 2-(2-(difluoromethyl)-3-ethoxy-4methoxyphenyl)-4,4,5,5-tetramethyl1,3,2-dioxaborolane | Préparation 168 | Ή NMR (CDCh,400 MHz): δ 7.15-7.18 (m, 1H), 7.11 (s, 1H), 4.14 (q, J = 7.0 Hz, 2H), 3.96 (d, J= 1.3 Hz, 3H), 1.46 (t, J= 7.0 Hz, 3H), 1.34 (s, 12H). 19F NMR (CDCh, 376 MHz): δ -114.25 (brs, 1F). LCMS m/z = 296 [MH]+. |
146
128 | I ' F °-Z 2-(2-fluoro-4-methoxy-3- propoxyphenyl)-4,4,5,5-tetramethyl1,3,2-dioxaborolane | Préparation 170b | LCMS m/z = 311 [MH]+. |
129 | ί II θηχ N ί 3-methoxy-2-propoxy-6-(4,4,5,5tetramethyl-1,3,2-dioxaborolan-2yl)benzonitrile | Préparation 171 | Ή NMR (CDCb,400 MHz): δ 7.54 (d, J= 8.1 Hz, 1H), 7.05 (d, J= 8.3 Hz, 1H), 4.06-4.11 (m, 2H), 3.89 (s, 3H), 1.79-1.90 (m, 2H), 1.35-1.38 (m, 12H), 1.031.08 (m, 3H). LCMS m/z = 318 [MH]+. |
130 | /ό^Ρ'β·'0 ^ °\ o—2^ 2-(2,4-dimethoxy-3-propoxyphenyl)- 4,4,5,5-tetramethyl-l ,3,2dioxaborolane | Préparation 210 | 1H NMR (CDCb, 400 MHz): δ 7.42 (d, J =8.5 Hz, 1H), 6.69 (d, J= 8.3 Hz, 1H), 3.92-3.99 (m, 2H), 3.823.87 (m, 6H), 1.73-1.84 (m, 2H), 1.33-1.38 (m, 12H), 1.00-1.08 (m, 3H). LCMS m/z = 345 [M+Na]+. |
131 | οΑ'Β·χ CN 2-(cyclopentyloxy)-3-methoxy-6(4,4,5,5-tetramethyl-l ,3,2dioxaborolan-2-yl)benzonitrile | Préparation 207 | 1H NMR (CDCb,400 MHz): δ 7.52 (d, J= 8.3 Hz, 1H), 7.00-7.10 (m, 1H), 4.985.11 (m, 1H), 3.88 (s, 3H), 1.91-2.01 (m, 4H), 1.651.76 (m, 2H), 1.53-1.64 (m, 2H), 1.37 (s, 12H). LCMS m/z = 344 [MH]+. |
147
132 | F I ζ\ °--Ζ 2-(3-ethoxy-5-fluoro-4- methoxyphenyl)-4,4,5,5-tetramethyl- 1,3,2-dioxaborolane | Préparation 172 | 1H NMR (CDCh,400 MHz): δ 7.17 (dd, J= 1.0, 10.5 Hz, 1H), 7.11 (s, 1H), 4.14 (q, J = 7.0 Hz, 2H), 3.96 (d, J= 1.0 Hz, 3H), 1.56 (s, 6H), 1.46 (t, J= 7.0 Hz, 3H), 1.34 (s, 12H). LCMS m/z = 297 [MH]+. |
133 | Cl '0·^ l /\ o-Z 2-(3-chloro-5-ethoxy-4- methoxyphenyl)-4,4,5,5-tetramethyl1,3,2-dioxaborolane | Préparation 177 | 1H NMR (CDCh,400 MHz): δ 7.44 (d, J= 1.0 Hz, 1H), 7.22 (d, J= 1.0 Hz, 1H), 4.10-4.17 (m, 2H), 3.91 (s, 3H), 1.46 (t, J = 7.0 Hz, 3H), 1.34 (s, 12H). LCMS m/z = 312 [MH]+. |
134 | l Z\ °-Z 2-(5-ethoxy-2-fluoro-4- methoxyphenyl)-4,4,5,5-tetramethyl- 1,3,2-dioxaborolane | Préparation 182 | 1H NMR (CDCh, 400 MHz): δ 7.14 (d, J= 5.5 Hz, 1H), 6.59 (d, J = 10.0 Hz, 1H), 4.02-4.16 (m, 2H), 3.86 (s, 3H), 1.40-1.52 (m, 3H), 1.34 (s, 12H). LCMS m/z = 297 [MH]+. |
135 | I z\ o-Z 2-(2-chloro-5-ethoxy-4- methoxyphenyl)-4,4,5,5-tetramethyl- 1,3,2-dioxaborolane | Préparation 183 | Ή NMR (CDCh,400 MHz): δ 7.18 (s, 1H), 6.86 (s, 1H), 4.12 (q, J= 7.0 Hz, 2H), 3.87 (s, 3H), 1.46 (t, J = 7.0 Hz, 3H), 1.36 (s, 12H). LCMS m/z = 312 [MH]+. |
148
136 | '''θ^Υ-B··0 I /\ o-Z 2-(5-ethoxy-4-methoxy-2- methylphenyl)-4,4,5,5-tetramethyl1,3,2-dioxaborolane | Préparation 187 | 1H NMR (CDCh,400 MHz): δ 7.28 (s, 1H), 6.69 (s, 1H), 4.13 (q, J = 6.9 Hz, 2H), 3.88 (s, 3H), 2.50 (s, 3H), 1.46 (t, J= 7.1 Hz, 3H), 1.33 (s, 12H). LCMS m/z = 292 [MH]+. |
137 | F B θΥ- I । /\ F °< 2-(3-ethoxy-2,6-difluoro-4methoxyphenyl)-4,4,5,5-tetramethyl1,3,2-dioxaborolane | Préparation 193 | Ή NMR (CDCh,400 MHz): δ 6.34-6.48 (m, 1H), 4.04 (q, J= 7.0 Hz, 2H), 3.85 (s, 3H), 1.32-1.42 (m, 15H). LCMS m/z = 315 [MH]+. |
138 | o-/ 2-(2-fluoro-4-methoxy-5- propoxyphenyl)-4,4,5,5-tetramethyl- 1,3,2-dioxaborolane | Préparation 188 | Ή NMR (CDCh, 400MHz): δ 7.15 (d, J= 5.9 Hz, 1H), 6.59 (d, J= 10.8 Hz, 1H), 3.98 (t, J = 6.8 Hz, 2H), 3.87 (s, 3H), 1.81-1.90 (m, 2H), 1.25-1.30 (m, 12H), 1.05 (t, J = 7.6 Hz, 3H). |
139 | ο·'ΟΒο l /\ ο—Z 2-(4-ethoxy-3-methoxyphenyl)4,4,5,5-tetramethyl-1,3,2dioxaborolane | Préparation 198 | Ή NMR (CDCh,400 MHz): δ 7.41 (dd, J= 1.2, 8.1 Hz, 1H), 7.29 (d, J= 1.5 Hz, 1H), 6.88 (d, J = 8.3 Hz, 1H), 4.14 (q, J = 7.0 Hz, 2H), 3.92 (s, 3H), 1.48 (t, J = 6.9 Hz, 3H), 1.34-1.36 (m, 12H). LCMS m/z = 279 [MH]+. |
149
140 | o'^Qb·0 I । z\ F ° K 2-(4-ethoxy-2-fluoro-3- methoxyphenyl)-4,4,5,5-tetramethyl1,3,2-dioxaborolane | Préparation 199 | 1H NMR (CDCh,400 MHz): δ 7.37 (dd, J= 6.4, 8.3 Hz, 1H), 6.64-6.73 (m, 1H), 4.07-4.18 (m, 2H), 3.90 (d, J= 1.0 Hz, 3H), 1.46 (t, J = 6.9 Hz, 3H), 1.35 (s, 12H). LCMS m/z = 297 [MH]+. |
141 | o-Z 2-(3,4-diethoxyphenyl)-4,4,5,5tetramethyl-1,3,2-dioxaborolane | Préparation 197 | 1H NMR (400 MHz, CDCh) δ 7.39 (dd, J= 1.2, 8.1 Hz, 1H), 7.30 (d, J = 1.0 Hz, 1H), 6.88 (d, J = 8.3 Hz, 1H), 4.08-4.17 (m, 4H), 1.41-1.49 (m, 6H), 1.33 (s, 12H). LCMS m/z = 293 [MH]+. |
142 | F^F ' z\ O—Z 2-(4-(difluoromethoxy)-3propoxyphenyl)-4,4,5,5-tetramethyl1,3,2-dioxaborolane | Préparation 223 | 1H NMR (CDCh,400 MHz): δ 7.40 (d, J = 1.2 Hz, 1H), 7.38 (s, 1H), 7.15 (dd, J = 0.7, 7.6 Hz, 1H), 6.41-6.82 (m, 1H), 4.04 (t, J= 6.5 Hz, 2H), 1.80-1.91 (m, 2H), 1.33-1.37 (m, 12H), 1.06 (t, J= 7.3 Hz, 3H). |
143 | B-0 - I z\ 0—/ 2-(3-methoxy-4-(methylthio)phenyl)4,4,5,5-tetramethyl-l ,3,2dioxaborolane | Préparation 203 | Ή NMR (CDCh. 400 MHz): δ 7.43 (dd, J= 1.1, 7.7 Hz, 1H), 7.22 (s, 1H), 7.13 (d, J = 7.8 Hz, 1H), 3.95 (s, 3H), 2.45 (s, 3H), 1.35 (s, 12H). LCMS m/z = 281 [MH]+. |
150
144 | I /\ o-Z 2-(3-ethoxy-4-(methylthio)phenyl)- 4,4,5,5-tetramethyl-1,3,2dioxaborolane | Préparation 204 | 1H NMR (MeOD-ch, 400 MHz): δ 7.34 (dd, J = 0.7, 7.6 Hz, 1H), 7.19 (s, 1H), 7.12-7.16 (m, 1H), 4.10 (q, J = 7.1 Hz, 2H), 2.39 (d, J = 1.0 Hz, 3H), 1.39-1.44 (m, 3H), 1.34 (s, 12H). LCMS m/z = 295 [MH]+. |
145 | o/OB·0. o % 2-(3-(cyclopentyloxy)-4(methylthio)phenyl)-4,4,5,5tetramethyl-1,3,2-dioxaborolane | Préparation 205 | Ή NMR (CDCh. 400 MHz): δ 7.39 (dd, J= 1.0, 7.8 Hz, 1H), 7.22 (s, 1H), 7.067.11 (m, 1H), 4.94-4.98 (m, 1H), 2.41 (s, 3H), 1.821.96 (m, 6H), 1.61-1.67 (m, 2H), 1.32-1.37 (m, 12H). LCMS m/z = 335 [MH]+. |
Préparation 146: tert-butyldimethyl((2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl)allyl)oxy)silane
Method A:
Five reactions were carried out in parallel. A mixture of ((2-bromoallyl)oxy)(tertbutyl)dimethylsilane (Préparation 227, 300 g, 1.19 mol), KOAc (234 g, 2.39 mol), 4,4,4',4,,5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (333 g, 1.31 mol) and Pd(PPh3)2Ch (16.7 g, 0.023 mol) in 1,4-dioxane (1.5 L) was degassed and stirred at about 80 °C for about 16
h. The solids were removed by filtration and the filtrate was concentrated. The residue was purified by column chromatography (silica) and eluted with pet. ether/EtOAc (1:0) to afford tertbutyldimethyl((2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)allyl)oxy)silane (520 g, 30%). GC (Column: Agilent J&W HP-5MS 30M x 0.25 mm ID x 0.25 um film thickness; injector temp. 250 °C; split ratio 100:1 ; ion source temp 230 °C; interface temp. 250 °C; Column temp. 50 °C 1 min to 100 °C @ 30 °C/min to 250 °C @ 10 °C/min.; run time 17.67 min.; Flow rate 1.5 mL/min; RT = 11.67 min. 1H NMR (CDCh, 400MHz): δ 5.97 (d, J = 1.3 Hz, 1H), 5.88 (td, J = 1.8, 3.9 Hz, 1H), 4.29 (t, J= 2.0 Hz, 2H), 1.21-1.30 (m, 12H), 0.93 (s, 9H), 0.07 (s, 6H).
151
Method B:
To a mixture of tert-butyldimethyl(prop-2-yn-1-yloxy)silane (250 mg, 1.47 mmol), sodium t-butoxide (21.2mg, 0.220mmol), copper (I) chloride (14.5 mg, 0.10 mmol) and 4,4,4',4',5,5,5',5'octamethyl-2,2'-bi(1,3,2-dioxaborolane) (410 mg, 1.61 mmol) under N2 was added dropwise a solution of tBu3P (1.0M solution in toluene, 0.176 mL, 0.12 mmol) in anhydrous toluene (2.5 mL). MeOH (94 mg, 2.94 mmol) was added to the mixture dropwise and the mixture was stirred at about 20 °C overnight. The reaction was quenched with MeOH (20 mL) and concentrated. The residue was purified by column chromatography (silica) and eluted with pet. ether/EtOAc (100:0 to 80:20) to afford tert-butyldimethyl((2-(4,4,5,5-tetramethyl-l ,3,2-dioxaborolan-2yl)allyl)oxy)silane (2.2 g, 50%). Ή NMR (CDCI3, 400MHz): δ 5.97 (br s, 1 H), 5.88 (d, J = 1.6 Hz, 1H), 4.29 (s, 2H), 1.25-1.33 (m, 12H), 0.93 (s, 9H), 0.08 (s, 6H).
Préparation 147: tert-butyldimethyl((3-(4,4,5,5-tetramethyl-l ,3,2-dioxaborolan-2-yl)but-3-en-2yl)oxy)silane
To a mixture of (but-3-yn-2-yloxy)(tert-butyl)dimethylsilane (CAS 193812-02-1, 10 g, 54.24 mmol), sodium t-butoxide (782 mg, 8.41 mmol), copper (I) chloride (537 mg, 5.42 mmol) and Pin2B2 (15.2 g, 59.7 mmol) in toluene (120 mL) under N2 was added a solution of tBu3P (13.2 g, 6.51 mmol) in anhydrous toluene (10 mL) drop-wise. MeOH (3.48g, 108 mmol) was added dropwise and the mixture was stirred at about 20 °C for about 16 h. The reaction was quenched with MeOH (10 mL) and concentrated. The residue was purified by column chromatography (silica) and eluted with pet. ether/EtOAc (100:0 to 97:3) to afford tertbutyldimethyl((3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)but-3-en-2-yl)oxy)silane (8.2g, 48.4%). Ή NMR (CDCh, 400 MHz): δ 5.88-6.02 (m, 1 H), 5.79 (dd, J = 1.5, 3.5 Hz, 1 H), 4.404.56 (m, 1H), 1.27 (d, J= 3.5 Hz, 12H), 1.24 (d, J= 6.5 Hz, 3H), 0.91 (s, 9H), 0.05 (d, J =5.5 Hz, 6H).
Préparation 148: tert-butyldimethyl((3-(4,4,5,5-tetramethyl-l ,3,2-dioxaborolan-2-yl)but-3-en-1yl)oxy)silane
B
I
O o'Si
152
A mixture of ((3-bromobut-3-en-1-yl)oxy)(tert-butyl)dimethylsilane (Préparation 229, 2.0 g, 7.54 mmol), Pin2B2 (2.87 g, 11.3 mmol) and KOAc (0.74g, 7.54mmol) was suspended in anhydrous 1,4-dioxane (10 mL). The mixture was degassed for about 10 min at about 18 °C under N2. Pd(PPh3)2Cl2 (106 mg, 0.15 mmol) was added and the mixture was heated to about 90 °C for 16 h. The reaction was cooled to about 20 °C and filtered. The filter cake was washed with 1,4-dioxane and the combined filtrâtes were concentrated. The residue was purified by column chromatography (silica) and eluted with heptane/EtOAc (100:0 to 80:20) to afford tertbutyldimethyl((3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)but-3-en-1-yl)oxy)silane (1.15 g, 49%). LCMS m/z = 313 [MH]+.
Préparation 149: 2,2'-(ethane-1,1 -diyl)bis(4,4,5,5-tetramethyl-l,3,2-dioxaborolane)
A mixture of 1,1-dibromoethane (14.9 g, 58.6 mmol), lithium methoxide (3.03 g, 79.8 mmol) and copper (I) iodide (5.07 g, 26.6 mmol) was suspended in DMF (150 mL) under N2. Additional lithium methoxide (5.0 g, 2.43 mL) in DMF (10 mL) was added to the mixture. The reaction mixture was warmed to about 40 °C and stirred for about 48 h under N2. The solution was cooled to to about 20 °C and extracted with heptane (3 x 300 mL). The heptane extracts were washed with water (100 mL), brine (100 mL) and passed through a pad of MgSO4 and silica gel. The pad was washed with DCM (100 mL). The combined filtrâtes were concentrated. The residue was purified by column chromatography (silica) and eluted with DCM to afford 2,2'(ethane-1,1-diyl)bis(4,4,5,5-tetramethyl-l,3,2-dioxaborolane (3.6 g, 48%). 1H NMR (CDCI3, 400 MHz): δ 1.23 (d, J = 3.1 Hz, 24H), 1.05 (d, J = 7.4 Hz, 3H), 0.72 (q, J = 7.0 Hz, 1H).
Préparation 150: 4-bromo-2-ethoxy-1-methoxybenzene
A mixture of 5-bromo-2-methoxyphenol (40.0 g, 197.0 mmol), iodoethane (23.6 mL, 295.5 mmol) and Cs2CO3 (96.3 g, 295.5 mmol) in DMF (350 mL) was stirred at about 25 °C for about 16 h. The mixture was filtered and water (500 mL) was added to the filtrate. The mixture was extracted with EtOAc (2 x 400 mL). The combined EtOAc extracts were washed with brine (100 mL), dried over Na2SO4 and concentrated. The residue was purified by column chromatography (silica) and eluted with pet. ether/EtOAc (10:1) to afford 4-bromo-2-ethoxy-1methoxybenzene (48.0 g), which was used directly in the next step. 1H NMR (CDCb, 400MHz):
153 δ 7.02 (dd, J = 2.4, 8.4 Hz, 1 H), 6.98 (d, J = 2.4 Hz, 1 H), 6.76-6.73 (m, 1 H), 4.08 (q, J = 7.2 Hz,
2H), 3.88 (s, 3H), 1.47 (t, J = 7.2 Hz, 3H).
Préparation 151: 4-bromo-1-methoxy-2-propoxybenzene
To a solution of 5-bromo-2-methoxyphenol (40.0 g, 197.0 mmol) and K2CO3 (54.5 g, 394 mmol) in DMF (200 mL) was added 1-iodopropane (28.9 mL, 295 mmol) in portions at about 20 °C. The mixture was stirred at about 20 °C for about 1 h. The mixture was poured into ice water (500 mL) and extracted with EtOAc (3 x 300 mL). The combined EtOAc extracts were washed with brine (200 mL), dried over Na2SO4 and concentrated. The residue was purified by column chromatography (silica) and eluted with pet. ether/EtOAc (40:1) to afford 4-bromo-1-methoxy-2propoxybenzene (43.0 g, crude). 1H NMR (CDCI3, 400 MHz): δ 7.27 (s, 1H), 6.99-7.03 (m, 1H), 6.74 (d, J = 8.4 Hz, 1 H), 3.96 (t, J = 6.8 Hz, 2H), 3.85 (s, 3H), 1.83-1.92 (m, 2H), 1.05 (t, J = 7.6 Hz, 3H).
Préparation 152: 4-bromo-2-isopropoxy-1-methoxybenzene
4-bromo-2-isopropoxy-1-methoxybenzene (16 g, 95%) was prepared in an analogous manner to Préparation 150 using 2-bromopropane (12.7 g, 103.4 mmol). 1H NMR (CDCI3, 400 MHz): δ 7.00-7.05 (m, 2H), 6.75 (d, J = 8.3 Hz, 1 H), 4.50-4.54 (m, 1 H), 3.83 (s, 3H), 1.35-1.40 (m, 6H). LCMS m/z = 245 [MH]+.
Préparation 153: 4-bromo-2-isobutoxy-1-methoxybenzene
To a solution of 5-bromo-2-methoxyphenol (25 g, 120 mmol), 2-methylpropan-1-ol (11.0 g, 148 mmol), PPh3 (48.4 g, 185 mmol) in anhydrous DCM (400 mL) at about 0 °C was added DIAD (37.3 g, 185 mmol) dropwise under N2. The mixture was stirred at about 0 °Cfor about 2 h. Additional DIAD (2.53 g, 12.5 mmol) and 2-methylpropan-1-ol (1.03 g, 13.9 mmol) were added and the mixture was stirred at about 10 °C for about 5 days then filtered. The filtrate was concentrated under reduced pressure. MTBE (500 mL) was added and the mixture was stirred at about 10 °C for about 20 min. A white precipitate was filtered. The filtrate was concentrated.
154
The residue was dissolved in water (200 mL) and extracted with MTBE (2 x 300 mL). The combined MTBE extracts were concentrated and the residue was purified by column chromatography (silica) and eluted with pet. ether/EtOAc (100:1 to 90:10) to afford 4-bromo-2isobutoxy-1-methoxybenzene (22 g, 69%). 1H NMR (CDCh, 400 MHz): δ 6.99-7.03 (m, 1H), 6.96-6.99 (m, 1H), 6.74 (d, J= 8.5 Hz, 1H), 3.84 (s, 3H), 3.75 (d, J = 7.0 Hz, 2H), 2.11-2.22 (m, 1H), 1.04 (d, J = 6.5 Hz, 6H).
Préparation 154: 4-bromo-2-cyclopropoxy-1-methoxybenzene
4-bromo-2-cyclopropoxy-1-methoxybenzene (6.15 g, 64%) was prepared in an analogous manner to Préparation 150 using bromocyclopropane (8.0 g, 39 mmol). 1H NMR (CDCh, 400 MHz): δ 7.36 (d, J = 2.5 Hz, 1 H), 7.05 (dd, J = 2.5, 8.5 Hz, 1 H), 6.74 (d, J = 8.5 Hz, 1H), 3.84 (s, 3H), 3.70-3.77 (m, 1H), 0.80-0.90 (m, 4H).
Préparation 155: 3-(5-bromo-2-methoxyphenoxy)tetrahydrothiophene
To a solution of 5-bromo-2-methoxyphenol (1.6 g, 7.88 mmol), tetrahydrothiophen-3-ol (0.903 g, 8.67 mmol), PPh3 (3.10 g, 11.8 mmol) in anhydrous DCM (20 mL) at about 0 °C was added DIAD (2.39 g, 11.8 mmol) dropwise under N2. The mixture was stirred at about 0 °C for about 2 h. The mixture was stirred for about 3 days. The mixture was filtered and the filtrate was concentrated. To the residue was added MTBE (50 mL) and stirred at about 10 °C for about 20 min. A white precipitate was filtered. The filtrate was concentrated again. The residue was dissolved in water (20 mL) and extracted with MTBE (2 x 30mL). The combined MTBE extracts were concentrated and the residue was purified by column chromatography (silica) and eluted with pet. ether/EtOAc (100:1 to 90:10) to afford 3-(5-bromo-2methoxyphenoxy)tetrahydrothiophene (2.0 g, 88%). 1H NMR (CDCh, 400 MHz): δ 7.05-7.11 (m, 2H), 6.74-6.79 (m, 1H), 5.06-5.09 (m, 1H), 3.82 (s, 3H), 3.04-3.15 (m, 3H), 2.93 (ddd, J = 3.7,
7.3, 10.5 Hz, 1H), 2.38-2.47 (m, 1H), 2.03-2.05 (m, 1H).
155
Préparation 156: 4-(5-bromo-2-methoxyphenoxy) tetrahydro-2H-thiopyran
4-(5-bromo-2-methoxyphenoxy) tetrahydro-2H-thiopyran (5.1 g, 68%) was prepared in an analogous manner to Préparation 155 using tetrahydro-2H-thiopyran-4-ol (3.2 g, 27.1 mmol). Ή NMR (CDCI3, 400 MHz): δ 7.03-7.08 (m, 1H), 7.01 (d, J= 2.5 Hz, 1H), 6.73-6.77 (m, 1H), 4.21-4.29 (m, 1H), 3.81-3.84 (m, 3H), 2.87-2.96 (m, 2H), 2.52-2.62 (m, 2H), 2.15-2.25 (m, 2H), 1.98-2.08 (m, 2H).
Préparation 157: (2-(5-bromo-2-methoxyphenoxy)ethoxy)(tert-butyl)dimethylsilane . 0..-C1 \ .Si O Br
X 1 (2-(5-bromo-2-methoxyphenoxy)ethoxy)(tert-butyl)dimethylsilane (60 g, 86%) was prepared in an analogous manner to Préparation 155 using 2-((tert-butyldimethylsilyl)oxy)ethan1-ol (34 g, 190 mmol). Ή NMR (CDCI3, 400 MHz): δ 7.07 (d, J= 2.2 Hz, 1H), 7.00-7.05 (m, 1H), 6.71-6.76 (m, 1H), 4.06-4.11 (m, 2H), 3.96-4.02 (m, 2H), 3.81-3.85 (m, 3H), 0.88-0.93 (m, 9H), 0.08-0.12 (m, 6H).
Préparation 158: (3-(5-bromo-2-methoxyphenoxy)propoxy)(tert-butyl)dimethylsilane
Ai, Xa (3-(5-bromo-2-methoxyphenoxy)propoxy)(tert-butyl)dimethylsilane (19.8 g, 86%) was prepared in an analogous manner to Préparation 155 using 3-((tertbutyldimethylsi!yl)oxy)propan-1-ol (Préparation 236, 12.5 g, 61.6 mmol). 1H NMR (CDCI3, 400 MHz): δ 6.99-7.03 (m, 2H), 6.71-6.75 (m, 1H), 4.08-4.13 (m, 2H), 3.83 (s, 3H), 3.81 (t, J= 5.9 Hz, 2H), 2.00-2.07 (m, 2H), 0.88-0.91 (m, 9H), 0.04-0.07 (m, 6H).
Préparation 159: 4-bromo-2-(2-fluoroethoxy)-1-methoxybenzene
156
4-bromo-2-(2-fluoroethoxy)-1-methoxybenzene (12 g, 98%) was prepared in an analogous manner to Préparation 155 using 2-fluoroethan-1-ol (3.79 g, 59 mmol). 1H NMR (CDCb, 400 MHz): δ 7.08 (dd, J = 2.5, 8.8 Hz, 1 H), 7.03 (d, J = 2.5 Hz, 1 H), 6.75-6.79 (m, 1 H), 4.82-4.87 (m, 1H), 4.71-4.74 (m, 1H), 4.27-4.31 (m, 1H), 4.20-4.24 (m, 1H), 3.86 (s, 3H).
Préparation 160: 4-bromo-2-(3-fluoropropoxy)-1-methoxybenzene
4-bromo-2-(3-fluoropropoxy)-1-methoxybenzene (10 g, 100%) was prepared in an analogous manner to Préparation 155 using 3-fluoropropan-1-ol (3.69 g, 47.3 mmol). 1H NMR (CDCb, 400 MHz): δ 7.03-7.07 (m, 1 H), 7.01-7.03 (m, 1 H), 6.75 (d, J = 8.3 Hz, 1 H), 4.72 (t, J = 5.6 Hz, 1H), 4.61 (t, J = 5.6 Hz, 1H), 4.13 (t, J = 6.1 Hz, 2H), 3.84 (s, 3H), 2.26-2.28 (m, 1H), 2.19-2.22 (m, 1H).
Préparation 161: 1-bromo-2-fluoro-3,4-dimethoxybenzene
F
A mixture of 1-fluoro-2,3-dimethoxybenzene (35.0 g, 224.1 mmol) and NBS (43.9 g, 246.6 mmol) in DCM (300 mL) was degassed and stirred at about 15 °C for about 12 h under N2. The reaction mixture was quenched with water (300 mL) and extracted with DCM (2 x 300 mL). The combined DCM extracts were washed with brine (2 x 100 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography (silica) and eluted with pet. ether/EtOAc (10:1) to afford 1-bromo-2-fluoro-3,4-dimethoxybenzene (35.0 g, 66%). Ή NMR (CDCb, 400MHz): δ 7.17-7.21 (m, 1H), 6.60-6.63 (m, 1H), 3.93 (s, 3H), 3.87 (s, 3H).
Préparation 162: 6-bromo-2,3-dimethoxybenzonitrile
To a solution of 6-bromo-2,3-dimethoxybenzaldehyde oxime (Préparation 163, 30.0 g, 115 mmol) in DCM (500 mL) was added TFAA (24.0 mL, 173 mmol) and Et3N (48.0 mL, 346.0
157
F mmol). The mixture was stirred at about 20 °C for about 2 h. The mixture was quenched with water (200 mL) at about 0 °C and extracted with DCM (300 mL). The combined DCM extracts were washed with brine, dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography (silica) and eluted with pet. ether/EtOAc (10:1 to 3:1) to afford 65 bromo-2,3-dimethoxybenzonitrile (25.0 g, 90%). 1H NMR (CDCb, 400MHz): δ 7.34-7.29 (m, 1H), 6.99 (d, J = 8.8 Hz, 1 H), 4.04-4.01 (m, 3H), 3.90-3.88 (m, 3H).
Préparation 163: 6-bromo-2,3-dimethoxybenzaldehyde oxime ^O^y^Br
Ή OH
To a solution of 6-bromo-2,3-dimethoxybenzaldehyde (Préparation 164, 15.0 g, 61.2 mmol) in EtOH (150 mL) was added NaHCO3 (7.7 g, 91.8 mmol) and NH2OH HCI (6.4 g, 91.8 mmol). The mixture was stirred at about 20 °C for about 2 h. The mixture was quenched by the addition of water (300 mL) at about 0 °C and extracted with EtOAc (200 mL). The EtOAc layer was washed with brine, dried over Na2SO4, filtered and concentrated to afford 6-bromo-2,3dimethoxybenzaldehyde oxime (15.0 g), which was used in Préparation 162. 1H NMR (CDCb,
400MHz): δ 7.27-7.34 (m, 1H), 6.99 (d, J= 9.2 Hz, 1H), 4.00-4.03 (m, 3H), 3.87-3.90 (m, 3H).
Préparation 164: 6-bromo-2,3-dimethoxybenzaldehyde
O'^T^Br । L
6-bromo-2,3-dimethoxybenzaldehyde (35.0 g, 82.5%) was prepared in an analogous manner to Préparation 172 using 6-bromo-2-hydroxy-3-methoxybenzaldehyde (Préparation 165, 20 40 g, 173.1 mmol) and iodomethane (36.8 g, 259.7 mmol). 1H NMR (CDCb, 400MHz): δ 10.35 (s, 1H), 7.33-7.37 (m, 1H), 6.97 (d, J= 8.8 Hz, 1H), 3.94 (s, 3H), 3.90 (s, 3H).
Préparation 165: 6-bromo-2-hydroxy-3-methoxybenzaldehyde
158
To a solution of 3-bromo-2-formyl-6-methoxyphenyl acetate (Préparation 166, 40.0 g,
146.5 mmol) in MeOH (400 mL) and water (50 mL) was added NaHCO3 (13.5 g, 161.1 mmol) and LiOH (12.3 g, 293.0 mmol). The mixture was stirred at about 20 °C for about 12 h. The reaction was adjusted to pH 5-6 and extracted with DCM. The DCM layer was concentrated to afford 6-bromo-2-hydroxy-3-methoxybenzaldehyde (40.0 g), which was used in Préparation 164. 1H NMR (CDCh, 400MHz): δ 12.21 (s, 1H), 10.22 (s, 1H), 7.03 (d, J= 8.4 Hz, 1H), 6.85 (d, J = 8.8 Hz, 1H), 3.81-3.85 (m, 3H).
Préparation 166: 3-bromo-2-formyl-6-methoxyphenyl acetate
To a solution of 2-formyl-6-methoxyphenyl acetate (Préparation 167, 50.0 g, 257.5 mmol) in water (500 mL) was added Br2 (53.5 g, 334.7 mmol) and KBr (46.0 g, 386.2 mmol). The mixture was stirred at about 20 °C for about 10 h. The precipitate was filtered, rinsed with ethyl acetate and recrystallized from EtOAc/pet. ether to afford 3-bromo-2-formyl-6methoxyphenyl acetate (40.0 g, 57%). Ή NMR (CDCh, 400MHz): δ 10.28 (s, 1H), 7.53 (d, J = 8.8 Hz, 1 H), 7.07 (d, J = 8.8 Hz, 1 H), 3.87 (s, 3H), 2.40 (s, 3H).
Préparation 167: 2-formyl-6-methoxyphenyl acetate
To a solution of 2-hydroxy-3-methoxybenzaldehyde (50.0 g, 328.6 mmol) in DCM (200 mL) was added Ac2O (33.5 g, 329 mmol), DMAP (4.0 g, 32.8 mmol) and Et3N (33.2 g, 329 mmol). The mixture was stirred at about 20 °C for about 2 h. The reaction mixture was quenched with saturated aqueous NH4CI (100 mL) and extracted with DCM (2 x 100 mL). The combined DCM extracts were washed with HCl (100 mL, 1 M), brine (300 mL), dried over Na2SO4, filtered and concentrated to afford 2-formyl-6-methoxyphenyl acetate (60.0 g, 94%). 1H NMR (CDCh, 400MHz): δ 10.12-10.17 (m, 1H), 7.46 (dd, J= 1.6, 7.8 Hz, 1H), 7.34 (t, J= 8.0 Hz, 1H), 7.22 (dd, J = 1.6, 8.2 Hz, 1H), 3.88 (s, 3H), 2.41 (s, 3H).
159
Préparation 168:1 -bromo-2-(difluoromethyl)-3-ethoxy-4-methoxybenzene
To a mixture of DAST (CAS 38078-09-0, 17.8 mL, 143.0 mmol) in DCM (100 mL) was added a solution of 6-bromo-2-ethoxy-3-methoxybenzaldehyde (Préparation 169, 4.64 g, 17.9 mmol) in DCM (20 mL) at about -20 °C. The reaction mixture was warmed to about 25 °C over 0.5 h and then at about 25 °C for about 15 h. The reaction was quenched with saturated aqueous NaHCO3 (200 mL) at about 0 °C and the mixture was extracted with DCM (2 x 100 mL). The combined DCM extracts were concentrated and the residue was purified by column chromatography (silica) and eluted with pet. ether/EtOAc (100:0 to 97:3) to afford 1-bromo-2(difluoromethyl)-3-ethoxy-4-methoxybenzene (4.77 g, 95%). 1H NMR (CDCI3, 400MHz): δ 7.31 (d, J= 8.8 Hz, 1H), 7.10 (t, J = 54.0 Hz, 1H), 6.87 (d, J= 8.8 Hz, 1H), 4.11 (q, J = 7.0 Hz, 2H), 3.87 (s, 3H), 1.40 (t, J = 7.0 Hz, 3H).
Préparation 169: 6-bromo-2-ethoxy-3-methoxybenzaldehyde
To a mixture of 6-bromo-2-hydroxy-3-methoxybenzaldehyde (Préparation 165, 5 g, 21.64 mmol) and K2CO3 (5.98 g, 43.3 mmol) in MeCN (100 mL) was added iodoethane (16.9 g, 108 mmol). The mixture was warmed to 60 °C and stirred for 4 h, followed by heating to 100 °C for 19 h. The mixture was cooled to r.t and condensed under reduced pressure. The residue was purified by column chromatography (silica) and eluted with pet. ether:EtOAc (100:0 to 90:10) to afford 6-bromo-2-ethoxy-3-methoxybenzaldehyde (5.1 g, 92%) as a light yellow oil. 1H NMR (CDCh, 400MHz): δ 10.37 (s, 1H), 7.34 (d, J = 8.8 Hz, 1H), 6.96 (d, J = 8.8 Hz, 1H), 4.15 (q, J = 7.0 Hz, 2H), 3.88 (s, 3H), 1.40 (t, J = 7.0 Hz, 3H). Préparation 170a: 1-bromo-3-ethoxy-2-fluoro-4-methoxybenzene
1-bromo-3-ethoxy-2-fluoro-4-methoxybenzene (25 g, 58%) was prepared in an analogous manner to Préparation 155 using 3-bromo-2-fluoro-6-methoxyphenol (38 g, 170 mmol) and iodoethane (40.2 g, 258 mmol). 1H NMR (CDCh, 400MHz): δ 7.14-7.20 (m, 1H), 6.58-6.63 (m, 1H), 4.02 (t, J= 6.7 Hz, 2H), 3.86 (s, 3H), 1.75-1.80 (m, 2H), 1.03 (t, J = 7.5 Hz, 3H).
160
Préparation 170b: 1-bromo-2-fluoro-4-methoxy-3-propoxybenzene
F
1-bromo-2-fluoro-4-methoxy-3-propoxybenzene (10.2 g 57%) was prepared in an analogous manner to Préparation 155 using 3-bromo-2-fluoro-6-methoxyphenol (15 g, 68.2 mmol) and 1-bromopropane (10.8 g, 88.6 mmol). 1H NMR (CDCh, 400MHz): δ 7.14-7.20 (m, 1 H), 6.58-6.63 (m, 1 H), 4.02 (t, J = 6.7 Hz, 2H), 3.86 (s, 3H), 1.75-1.80 (m, 2H), 1.03 (t, J = 7.5 Hz, 3H).
Préparation 171: 6-bromo-3-methoxy-2-propoxybenzonitrile
II N
6-bromo-3-methoxy-2-propoxybenzonitrile (10.9 g 92%) was prepared in an analogous manner to Préparation 155 using 6-bromo-2-hydroxy-3-methoxybenzonitrile (10 g, 44 mmol) and 1-bromopropane (7 g, 57 mmol). 1H NMR (CDCh, 400MHz): δ 7.27-7.30 (m, 1H), 6.96 (d, J = 8.8 Hz, 1H), 4.15 (t, J= 6.6 Hz, 2H), 3.86 (s, 3H), 1.78-1.87 (m, 2H), 1.06 (t, J= 7.5 Hz, 3H). LCMS m/z = 270 [MH]+.
Préparation 172: 5-bromo-1-ethoxy-3-fluoro-2-methoxybenzene F
To a mixture of 5-bromo-3-fluoro-2-methoxyphenol (Préparation 173, 2.21 g, 10.0 mmol) and iodoethane (3.12 g, 20.0 mmol) dissolved in MeCN (30 mL) was added K2CO3 (2.07 g, 15 mmol). The mixture was warmed to about 50 °C and stirred for about 5 h. The mixture was cooled to about 20 °C and was filtered. The filtrate was concentrated and the residue was triturated with MTBE (20 mL) for about 20 min. The mixture was filtered and the filtrate was concentrated to afford 5-bromo-1-ethoxy-3-fluoro-2-methoxybenzene (1.85 g, 74%). 1H NMR (CDCh, 400MHz): δ 6.88-6.91 (m, 1 H), 6.82-6.83 (m, 1 H), 4.07 (q, J = 7.0 Hz, 2H), 3.90 (d, J = 0.7 Hz, 3H), 1.46 (t, J = 7.0 Hz, 3H).
161
Préparation 173: 5-bromo-3-fluoro-2-methoxyphenol
To a mixture 5-bromo-3-fluoro-2-methoxyphenyl formate (Préparation 174, 4.98 g, 20.0 mmol) in MeOH (30 mL) and water (30 mL) was added LiOH (1.68 g, 40.0 mmol) in portions. The mixture was stirred at about 25 °C for about 16 h. The mixture was concentrated. The resulting aqueous phase was diluted with water and NaHCOs was added until pH 8. The aqueous phase was washed with MTBE (2 x 30 mL) and the combine MTBE extracts were concentrated. The residue was purified by column chromatography (silica) and eluted with pet. ether/EtOAc (100:0 to 85:15) to afford 5-bromo-3-fluoro-2-methoxyphenol (2.4 g, 54% over 2 steps). 1H NMR (CDCh, 400MHz): δ 6.91-6.92 (m, 1H), 6.81-6.84 (m, 1H), 5.82 (s, 1H), 4.00 (d, J = 1.8 Hz, 3H).
Préparation 174: 5-bromo-3-fluoro-2-methoxyphenyl formate
F
To a mixture of 5-bromo-3-fluoro-2-methoxybenzaldehyde (Préparation 175, 3.50 g, 15.0 mmol) in DCM (50 mL) was added m-CPBA (4.85 g, 22.5 mmol). The resulting mixture was stirred at about 25 °C for about 16 h. The reaction was concentrated to afford 2-(5-bromo-3fluoro-2-methoxyphenyl)acetaldehyde (3.74 g), which was used in Préparation 173.
Préparation 175: 5-bromo-3-fluoro-2-methoxybenzaldehyde
To a mixture of 5-bromo-3-fluoro-2-hydroxybenzaldehyde (Préparation 176, 18.6 g, 85.0 mmol) in MeCN (150 mL) was added K2CO3 (17.6 g, 128.0 mmol) and iodomethane (24.1 g, 170.0 mmol). The mixture was warmed to about 50 °C for about 16 h. The reaction was filtered and the filtrate was concentrated. The residue was triturated in MTBE (50 mL) and the resulting solid was filtered to afford 5-bromo-3-fluoro-2-methoxybenzaldehyde (4.9 g, 25%). 1H NMR (CDCh, 400MHz): δ 10.33 (s, 1H), 7.73-7.74 (m, 1 H), 7.47-7.51 (m, 1 H), 4.10 (d, J = 3.0 Hz, 3H).
162
Préparation 176: 5-bromo-3-fluoro-2-hydroxybenzaldehyde
To a mixture of 4-bromo-2-fluorophenol (20.0 g, 104.7 mmol) dissolved in TFA (100 mL) was added HMTA (CAS 100-97-0, 29.4 g, 209.0 mmol) in portions. The mixture was heated at about 90 °C for about 16 h. The mixture was poured into water (800 mL) and a solid formed which was filtered. The cake was washed with water (2 x 150 mL) and dried to afford 5-bromo3-fluoro-2-hydroxybenzaldehyde (18.9 g, 82%). 1H NMR (CDCh, 400MHz): δ 10.90 (s, 1H), 9.88 (d, J = 2.0 Hz, 1 H), 7.49-7.53 (m, 2H).
Préparation 177: 5-bromo-1-chloro-3-ethoxy-2-methoxybenzene
Cl
5-bromo-1-chloro-3-ethoxy-2-methoxybenzene (1.25 g, 86%) was prepared in an analogous manner to Préparation 172 using 5-bromo-3-chloro-2-methoxyphenol (Préparation 178, 1.3 g, 5.47 mmol). Ή NMR (CDCh, 400MHz): δ 7.12 (d, J = 2.3 Hz, 1H), 6.93 (d, J = 2.3 Hz, 1H), 4.06 (q, J= 7.0 Hz, 2H), 3.86 (s, 3H), 1.46 (t, J= 7.0 Hz, 3H).
Préparation 178: 5-bromo-3-chloro-2-methoxyphenol
Cl
To a mixture of 5-bromo-3-chloro-2-methoxyphenyl formate (Préparation 179, 15.6 g, 58.76 mmol) in MeOH (100 mL) and water (100 mL) was added LiOH (4.93 g, 118.0 mmol) in portions. The mixture was stirred at about 25 °C for about 16 h. The mixture was concentrated and the resulting aqueous phase was diluted with aqueous NaHCO3 (50 mL). The solution was extracted with MTBE (2 x 30 mL) and the combined MTBE extracts were dried and concentrated. The residue was purified by column chromatography (silica) and eluted with pet. ether:EtOAc (100:0 to 90:10) to afford 5-bromo-3-chloro-2-methoxyphenol (1.3 g, 7% over 2 steps). Ή NMR (CDCh, 400MHz): δ 7.07 (d, J = 2.3 Hz, 1 H), 7.05 (d, J = 2.3 Hz, 1 H), 5.79 (s, 1H), 3.92 (s, 3H).
163
Préparation 179: 5-bromo-3-chloro-2-methoxyphenvl formate
Cl
To a mixture of 5-bromo-3-chloro-2-methoxybenzaldehyde (Préparation 180, 20.0 g, 80.16 mmol) in DCM (200 mL) was added m-CPBA (25.9 g, 120 mmol). The mixture was stirred at about 25 °C for about 16 h. The white solid was filtered and the filtrate was concentrated to afford 5-bromo-3-chloro-2-methoxyphenyl formate (15.0 g, 70%), which was used in Préparation 178. LCMS m/z = 266 [MH]+.
Préparation 180: 5-bromo-3-chloro-2-methoxybenzaldehyde
Cl
To a mixture of 5-bromo-3-chloro-2-hydroxybenzaldehyde (Préparation 181, 10 g, 42.5 mmol) dissolved in MeCN (150 mL) was added iodomethane (24.1 g, 170 mmol) and K2CO3 (11.7 g, 84.9 mmol). The mixture was warmed to about 50 °C and stirred for about 24 h. The mixture was cooled to about 20 °C, filtered. The filtrate was concentrated and the residue was triturated with MTBE (30 mL) for about 20 min. before filtering. The filtrate was concentrated and the residue was diluted with water (20 mL) and extracted with EtOAc (2 x 100 mL). The combined EtOAc extracts were concentrated to afford 5-bromo-3-chloro-2methoxybenzaldehyde (8.9 g, 84%), which was used in Préparation 179. 1H NMR (CDCh, 400MHz): δ 10.30 (s, 1H), 7.87 (d, J = 2.5 Hz, 1 H), 7.77 (d, J = 2.5 Hz, 1 H), 4.01 (s, 3H).
Préparation 181: 5-bromo-3-chloro-2-hydroxybenzaldehyde
Cl
To a mixture of 4-bromo-2-chlorophenol (20.0 g, 94.41 mmol) in TFA (150 mL) was added HMTA (CAS 100-97-0, 27.0 g, 193 mmol) in portions. The mixture was stirred at about 90 °C for about 16 h. The mixture was poured into water (800 mL) forming a precipitate. The precipitate was filtered, washed with water (2 x 150 mL) and dried to afford 5-bromo-3-chloro-2hydroxybenzaldehyde (22.7 g), which was used in Préparation 180. 1H NMR (CDCh, 400MHz): δ 11.40 (br s, 1 H), 9.86 (s, 1 H), 7.75 (d, J = 2.3Hz, 1 H), 7.63 (d, J = 2.3Hz, 1 H).
164
Préparation 182: 1-bromo-5-ethoxy-2-fluoro-4-methoxybenzene
1-bromo-5-ethoxy-2-fluoro-4-methoxybenzene (7.1 g, 90%) was prepared in an analogous manner to Préparation 172 using 5-bromo-4-fluoro-2-methoxyphenol (Préparation 192, 7.0 g, 32.0 mmol). 1H NMR (CDCb, 400MHz): δ 6.96-6.98 (m, 1H), 6.69-6.71 (m, 1H), 4.02-4.07 (m, 2H), 3.84 (s, 3H), 1.41-1.52 (m, 3H).
Préparation 183: 1-bromo-2-chloro-5-ethoxy-4-methoxybenzene
1-bromo-2-chloro-5-ethoxy-4-methoxybenzene (5.7 g, 98%) was prepared in an analogous manner to Préparation 172 using 5-bromo-4-chloro-2-methoxyphenol (Préparation 184, 5.2 g, 21.9 mmol). 1H NMR (CDCb, 400MHz): δ 7.05 (s, 1H), 6.94 (s, 1H), 4.06 (q, J= 7.0 Hz, 2H), 3.86 (s, 3H), 1.47 (t, J = 7.0 Hz, 3H).
Préparation 184: 5-bromo-4-chloro-2-methoxyphenol
To a mixture of 5-bromo-4-chloro-2-methoxyphenyl formate (Préparation 185, 3.2 g, 12.05 mmol) in MeOH (50 mL) and water (50 mL) was added NaOH (0.72 g, 18.1 mmol). The mixture was stirred at about 20 °C for about 1 h. The mixture was acidified using 1N HCl to pH 3. The mixture was concentrated and the remaining aqueous phase was extracted with EtOAc (3 x 100 mL). The combined EtOAc extracts were washed with brine (200 mL), dried with anhydrous Na2SO4, filtered and concentrated to afford 5-bromo-4-chloro-2-methoxyphenol (2.8 g, 98%). Ή NMR (CDCb, 400MHz): δ 7.16 (s, 1H), 6.93 (s, 1H), 5.58 (s, 1H), 3.28 (s, 3H).
Préparation 185: 5-bromo-4-chloro-2-methoxyphenyl formate
To a mixture of 5-bromo-4-chloro-2-methoxybenzaldehyde (Préparation 186, 12.2 g, 48.9 mmol) in DCM (300 mL) was added m-CPBA (21.1 g, 97.8 mmol). The mixture was stirred at about 18 °C for about 16 h. The mixture was partitioned between DCM (400 mL) and saturated sodium metabisulfite solution (200 mL). The separated DCM layer was washed with
165 water (400 mL), brine (400 mL), dried over MgSO4 and concentrated. The residue was purified by column chromatography (silica) and eluted with pet. ether/EtOAc (100:0 to 90:10) to afford 5bromo-4-chloro-2-methoxyphenyl formate (3.2 g, 25%). 1H NMR (CDCh, 400MHz): δ 8.22 (s, 1H), 7.36 (s, 1H), 7.09 (s, 1H), 3.85 (s, 3H).
Préparation 186: 5-bromo-4-chloro-2-methoxybenzaldehyde
To a mixture of 1-bromo-2-chloro-4-methoxybenzene (15.0 g, 67.73 mmol) in TFA (100 mL) was added HMTA (CAS 100-97-0, 14.2 g, 102 mmol) in portions. The mixture was stirred at about 80 °C for about 12 h. The mixture was poured into water (1000 mL) and stirred at about 20 °C for about 1 h, forming a precipitate. The precipitate was filtered, dissolved in EtOAc (200 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography (silica) and eluted with pet. ether/EtOAc (100:0 to 90:10) to afford 5-bromo-4chloro-2-methoxybenzaldehyde (6.7 g, 40%). 1H NMR (CDCh, 400MHz): δ 10.33 (s, 1H), 8.03 (s, 1H), 7.12 (s, 1H), 3,94 (s, 3H).
Préparation 187: 1-bromo-5-ethoxy-4-methoxy-2-methylbenzene
1-bromo-5-ethoxy-4-methoxy-2-methylbenzene (8.0 g, 99%) was prepared in an analogous manner to Préparation 172 using 5-bromo-2-methoxy-4-methylphenol (Préparation 189, 7.16 g, 33.0 mmol). Ή NMR (CDCh, 400MHz): δ 7.01 (s, 1H), 6.74 (s, 1H), 4.05 (q, J= 7.0 Hz, 2H), 3.85 (s, 3H), 2.33 (s, 3H) 1.46 (t, J = 7.0 Hz, 3H).
Préparation 188: 1-bromo-2-fluoro-4-methoxy-5-propoxybenzene
1-bromo-2-fluoro-4-methoxy-5-propoxybenzene (13.5 g, 95%) was prepared in an analogous manner to Préparation 172 using 5-bromo-4-fluoro-2-methoxyphenol (Préparation 192, 12 g, 109 mmol) and 1-iodopropane (18.5 g, 109 mmol). 1H NMR (CDCh, 400MHz): δ 6.98 (d, J = 6.8 Hz, 1 H), 6.70 (d, J = 9.8 Hz, 1 H), 3.93 (t, J = 6.8 Hz, 2H), 3.84 (s, 3H), 1.81-1.90 (m 2H), 1.04 (t, J= 7.6 Hz, 3H).
166
Préparation 189: 5-bromo-2-methoxy-4-methylphenol
To a mixture of 5-bromo-2-methoxy-4-methylphenyl formate (Préparation 190, 19.3 g, 78.58 mmol) in MeOH (100 mL) and water (100 mL) was added NaOH (4.72 g, 118.1 mmol). The mixture was stirred at about 20 °C for about 1 h. The mixture was acidified using 1N HCl to pH 3. The mixture was concentrated and the remaining aqueous phase was extracted with EtOAc (3 x 150 mL). The combined EtOAc extracts were dried, filtered and concentrated. The residue was purified by column chromatography (silica) and eluted with pet. ether/EtOAc (100:0 to 80:20) to afford 5-bromo-2-methoxy-4-methylphenol (10.25 g, 60% over 2 steps). 1H NMR (CDCh, 400MHz): δ 7.10 (s, 1H), 6.72 (s, 1H), 5.46 (br s, 1H), 3.87 (s, 3H), 2.33 (s, 3H).
Préparation 190: 5-bromo-2-methoxy-4-methylphenyl formate
To a mixture of 5-bromo-2-methoxy-4-methylbenzaldehyde (Préparation 191, 18.0 g, 78.58 mmol) in DCM (200 mL) was added m-CPBA (33.9 g, 157.0 mmol). The mixture was stirred at about 18 °C for about 16 h. The mixture was filtered and the filtrate was concentrated. The residue was washed with aqueous sodium metabisulfite solution (1N, 200 mL), aqueous Na2COs (1N, 100 mL) and water. The residue afforded 5-bromo-2-methoxy-4-methylphenyl formate (19.3 g), which was used in Préparation 189.
Préparation 191: 5-bromo-2-methoxy-4-methylbenzaldehyde
To a mixture of 1-bromo-4-methoxy-2-methyIbenzene (25.1 g, 125.0 mmol) in TFA (120 mL) was added HMTA (26.3 g, 188 mmol) in portions. The mixture was stirred at about 80 °C for about 12 h. The mixture was poured into water (500 mL) and stirred at about 20 °C for about 2 h, forming a precipitate. The precipitate was filtered, suspended in water at about 60 °C for about 20 min, cooled to about 20 °C and filtered. The precipitate was dissolved in EtOAc (300 mL), dried over Na2SO4, filtered and concentrated to afford 5-bromo-2-methoxy-4methylbenzaldehyde (18.0 g, 63%). 1H NMR (CDCh, 400MHz): δ 10.34 (s, 1H), 7.95 (s, 1H), 6.88 (s, 1H), 3.92 (s, 3H), 2.45 (s, 3H).
167
Préparation 192: 5-bromo-4-fluoro-2-methoxyphenol
To a solution of 4-fluoro-2-methoxyphenol (5 g, 40 mmol) and Fe powder (98.2 mg, 1.76 mmol) in DCM (230 mL) was added a solution of Br2 (6.18 g, 38.7 mmol) in DCM (20mL). The solution was stirred for about 16 h at about 20 °C. The mixture was washed with water (3 x 200 mL) and NaOH (1N). The DCM layer was dried (Na2SO4) and concentrated. The residue was purified by column chromatography (silica) and eluted with pet. ether/EtOAc (100:0 to 90:10) to afford 5-bromo-4-fluoro-2-methoxyphenol (6.0 g, 77%). Ή NMR (CDCh, 400MHz): δ 7.07 (d, J = 6.8 Hz, 1 H), 6.68 (d, J = 9.6 Hz, 1 H), 5.47 (s, 1 H), 3.87 (s, 3H).
Préparation 193: 2-ethoxy-1,5-difluoro-3-methoxybenzene
To a mixture of 2-ethoxy-3,5-difluorophenol (6.0 g, 34.45 mmol) and iodomethane (Préparation 194, 24.5 g, 172.0 mmol) in MeCN (100 mL) was added K2CO3 (9.52 g, 68.9 mmol). The mixture was warmed to about 60 °C and stirred for about 5 h. The mixture was cooled to about 20 °C, filtered and concentrated. The residue was dissolved in EtOAc (200 mL). The EtOAc layer was washed with water (80 mL), brine (50 mL), dried over MgSO4, filtered and concentrated to afford 2-ethoxy-1,5-difluoro-3-methoxybenzene (5.0 g, 77%), which was used in Préparation 137. 1H NMR (CDCh, 400MHz): δ 6.43-6.50 (m, 2H), 4.07 (q, J= 7.0 Hz, 2H), 3.85 (s, 3H), 1.36 (t, J= 7.0 Hz, 3H).
Préparation 194: 2-ethoxy-3,5-difluorophenol
F
To a mixture of 2-(2-ethoxy-3,5-difluorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (Préparation 195, 13.0 g, 45.76 mmol) in THF (100 mL) was added H2O2 (30%, 7.78 g, 68.6 mmol) and aqueous NaOH (1M, 48.0 mL, 48.0 mmol) at about 0 °C. The mixture was allowed to warm to about 25 °C for about 2 h. The mixture was acidified with 1N HCl to pH 5. Brine (100 mL) was added and the mixture was extracted with EtOAc (2 x 200 mL). The combined EtOAc extracts were dried over NaSO4, filtered and concentrated. The residue was purified by column chromatography (silica) and eluted with pet. ether/EtOAc (10:1) to afford 2-ethoxy-3,520225
168 difluorophenol (6.0 g, 75%). Ή NMR (CDCI3, 400MHz): δ 6.49-6.52 (m, 1H), 6.37-6.43 (m, 1H),
5.95 (d, J= 1.5 Hz, 1H), 4.18 (q, J = 7.0 Hz, 2H), 1.39 (t, J = 7.0 Hz, 3H).
Préparation 195: 2-(2-ethoxy-3,5-difluorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
F
A combined mixture of 1-bromo-2-ethoxy-3,5-difluorobenzene (Préparation 196, 11.0 g, 46.4 mmol), Pin2B2 (6.53 g, 51.0 mmol) Pd(dppf)CI2 (1.7 g, 2.32 mmol) and KOAc (9.11 g, 92.8 mmol) in anhydrous 1,4-dioxane (200 mL) was degassed, heated and stirred at about 80 °C for about 24 h under N2. The suspension was filtered and the filtrate was concentrated. The residue was purified by column chromatography (silica) and eluted with pet. ether/EtOAc (100:0 to 70:30) to afford 2-(2-ethoxy-3,5-difluorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (13.0 g, 99%). Ή NMR (CDCI3, 400MHz): δ 7.14-7.17 (m, 1H), 6.90-6.95 (m, 1H), 4.06 (q, J = 7.1Hz, 2H), 1.41 (t, J = 7.1Hz, 3H), 1.37 (s, 12H). LCMS m/z = 285 [MH]+.
Préparation 196: 1-bromo-2-ethoxy-3,5-difluorobenzene
To a mixture of 2-bromo-4,6-difluorophenol (10.0 g, 47.85 mmol) and iodoethane (14.9 g, 95.7 mmol) in MeCN (200 mL) was added K2CO3 (13.2 g, 95.7 mmol). The mixture was warmed to about 60 °C and stirred for about 16 h. The mixture was cooled to about 20 °C, filtered and the filtrate concentrated. The residue was dissolved in EtOAc (200 mL). The EtOAc layer was washed with water (80 mL), brine (50 mL), dried over MgSO4, filtered and concentrated to afford 1-bromo-2-ethoxy-3,5-difluorobenzene (11.0 g, 97%), which was used in Préparation 195. Ή NMR (CDCI3, 400MHz): δ 7.09-7.12 (m, 1H), 6.82-6.88 (m, 1H), 4.12 (q, J = 7.0 Hz, 2H), 1.43 (t, J = 7.0 Hz, 3H).
Préparation 197: 4-bromo-1,2-diethoxybenzene
169
4-bromo-1,2-diethoxybenzene (6.3 g, 97%) was prepared in an analogous manner to
Préparation 172 using 4-bromobenzene-1,2-diol (5.0 g, 26 mmol). 1H NMR (CDCI3, 400MHz): δ 6.96-7.01 (m, 2H), 6.71-6.76 (m, 1H), 4.06 (dq, J= 3.5, 7.0 Hz, 4H), 1.40-1.48 (m, 6H).
Préparation 198: 4-bromo-1-ethoxy-2-methoxybenzene
4-bromo-1-ethoxy-2-methoxybenzene (5.1 g, 98%) was prepared in an analogous manner to Préparation 172 using 4-bromo-2-methoxyphenol (4.57 g, 22.5 mmol). 1H NMR (CDCh, 400MHz): δ 6.99-7.03 (m, 1 H), 6.97-6.99 (m, 1 H), 6.74 (d, J = 8.8 Hz, 1 H), 4.07 (q, J = 6.9 Hz, 2H), 3.86 (s, 3H), 1.46 (t, J = 6.9 Hz, 3H). LCMS m/z = 231 [MH]+.
Préparation 199: 1-bromo-4-ethoxy-2-fluoro-3-methoxybenzene
1-bromo-4-ethoxy-2-fluoro-3-methoxybenzene was prepared as a yellow oil (6.3 g, 99%) in an analogous manner to Préparation 172 using 3-bromo-6-ethoxy-2-fluorophenol (Préparation 200, 6 g, 25.5 mmol) and iodomethane (10.9 g, 76.6 mmol). 1H NMR (CDCh, 400MHz): δ 7.13-7.19 (m, 1H), 6.60 (dd, J = 2.0, 9.3 Hz, 1H), 4.08 (q, J = 7.2 Hz, 2H), 3.93 (d, J = 1.0 Hz, 3H), 1.46 (t, J= 7.1 Hz, 3H).
Préparation 200: 3-bromo-6-ethoxy-2-fluorophenol
To a solution of 2-(3-bromo-6-ethoxy-2-fluorophenyl)-4,4,5,5-tetramethyl-1,3,2dioxaborolane (Préparation 201, 15.2 g, 44.1 mmol) in THF (150 mL) was added H2O2 (30%, 7.49 g, 66.1 mmol) and aqueous NaOH (1M, 46.3 mL, 46.3 mmol) at about 0 °C. The mixture was allowed to warm to about 25 °C for about 1.5 h. The mixture was acidified with 1N HCl to pH 5. Brine (150 mL) was added and the mixture was extracted with EtOAc (2 x 200 mL). The combined EtOAc extracts were dried over Na2S04, filtered and concentrated to afford 3-bromo20225
170
6-ethoxv-2-fluorophenol (10.0 g, 97%). 1H NMR (CDCh, 400MHz): δ 6.99 (dd, J = 7.0, 9.0 Hz,
H), 6.53-6.62 (m, 1 H), 4.07-4.20 (m, 3H), 1.46 (t, J = 7.0 Hz, 3H).
Préparation 201: 2-(3-bromo-6-ethoxy-2-fluorophenyl)-4,4,5,5-tetramethyl-l ,3,2-dioxaborolane
To a solution of 1-bromo-4-ethoxy-2-fluorobenzene (Préparation 202, 11.0 g, 50.2 mmol) in THF (250 mL) was added dropwise a solution of LDA (37.7 mL, 75.3 mmol, 2 M in THF) at about -78 °C. The solution was stirred at about -78 °C for about 1 h, PinBO-Pr (14.0 g, 75.3 mmol) was added dropwise. After stirring at about -78 °C for about 2 h, the solution was quenched with aqueous NH4CI (1 M, 100 mL) and extracted with MTBE (3 x 300 mL). The combined MTBE extracts were washed with brine (200 mL), dried over Na2SO4, and concentrated. The residue was purified by column chromatography (silica) and eluted with pet. ether/EtOAc (10:1) to afford 2-(3-bromo-6-ethoxy-2-fluorophenyl)-4,4,5,5-tetramethyl-l ,3,2dioxaborolane (15.2 g, 88%). Ή NMR (CDCh, 400MHz): δ 7.43 (t, J = 8.6 Hz, 1 H), 6.51 (d, J = 8.8 Hz, 1H), 3.99 (q, J= 6.9 Hz, 2H), 1.35-1.45 (m, 16H).
Préparation 202: 1-bromo-4-ethoxy-2-fluorobenzene
1-bromo-4-ethoxy-2-fluorobenzene (11 g, 96%) was prepared in an analogous manner to Préparation 172 using 4-bromo-2-methoxyphenol (10 g, 52 mmol). 1H NMR (CDCh, 400MHz): δ 7.33-7.45 (m, 1H), 6.69 (dd, J = 2.9, 10.8 Hz, 1H), 6.60 (ddd, J= 1.0, 2.9, 8.8 Hz, 1 H), 4.00 (q, J = 7.2 Hz, 2H), 1.42 (t, J = 6.9 Hz, 3H).
Préparation 203: (4-bromo-2-methoxyphenyl)(methyl)sulfane
To a solution of dimethyl disulfide (35 g, 371 mmol) and isopentyl nitrite (57.9 g, 495 mmol) in THF (600 mL) was added 4-bromo-2-methoxybenzenamine (50 g, 247.46 mmol)
171 slowly. The mixture was stirred at about 70 °C for about 3 h. The reaction mixture was concentrated. The residue was purified by column chromatography (silica) and eluted with pet.
ether/EtOAc (100:0 to 90:10) to afford (4-bromo-2-methoxyphenyl)(methyl)sulfane (50 g, 87%).
Ή NMR (CDCh, 400MHz): δ 7.07-7.12 (m, 1H), 6.99-7.03 (m, 1H), 6.96 (d, J = 2.0 Hz, 1H),
3.90 (s, 3H), 2.42 (s, 3H). LCMS m/z = 233.0 [MH]+.
Préparation 204: (4-bromo-2-ethoxyphenyl)(methyl)sulfane
(4-bromo-2-ethoxyphenyl)(methyl)sulfane (35.0 g, 83%) was prepared in an analogous manner to Préparation 172 using 5-bromo-2-(methylthio)phenol (Préparation 20, 16 g, 73 mmol). Ή NMR (CDCh, 400MHz): δ 7.05-7.09 (m, 1H), 6.97-7.01 (m, 1H), 6.94 (d, J= 2.0 Hz, 1H), 4.09 (q, J= 7.1 Hz, 2H), 2.41 (s, 3H), 1.47 (t, J= 7.0 Hz, 3H).
Préparation 205: (4-bromo-2-(cyclopentyloxy)phenyl)(methyl)sulfane
IA ά (4-bromo-2-(cyclopentyloxy)phenyl)(methyl)sulfane (6.0 g, 92%) was prepared in an analogous manner to Préparation 153 using 5-bromo-2-(methylthio)phenol (5 g, 22.8 mmol) and cyclopentanol (2.36 g, 27.4 mmol). 1H NMR (CDCh, 400MHz): δ 7.05 (dd, J = 2.0, 8.3 Hz, 1H), 6.93-6.98 (m, 2H), 4.80-4.84 (m, 1H), 2.38 (s, 3H), 1.79-1.95 (m, 6H), 1.60-1.68 (m, 2H).
Préparation 206: 5-bromo-2-(methylthio)phenol
To a solution of (4-bromo-2-methoxyphenyl)(methyl)sulfane (19.0 g, 81.5 mmol) in DCM (300 mL) at about -78 °C was added BBr3 (179 mL, 179 mmol, 1 M in DCM) dropwise under N2 atmosphère. The reaction mixture was allowed to warm to about 20 °C and stirred for about 2 h. The mixture was quenched with MeOH at about 0 °C and concentrated. The residue was purified by column chromatography (silica) and eluted with pet. ether/EtOAc (100:0 to 70:30) to
172 afford 5-bromo-2-(methylthio)phenol (16.3 g, 91%). jH NMR (CDCh, 400MHz): δ 7.35 (d, J = 8.3
Hz, 1H), 7.17 (d, J= 2.2 Hz, 1H), 7.03 (dd, J = 2.2, 8.3 Hz, 1H), 6.67 (br s, 1H), 2.32 (s, 3H).
Préparation 207: 6-bromo-2-(cyclopentyloxy)-3-methoxybenzonitrile
A mixture of 6-bromo-2-(cyclopentyloxy)-3-methoxybenzaldehyde oxime (Préparation 208, 7g, 22.3 mmol), TFAA (7.16 g, 33.45 mmol) and Et3N (6.76 g, 66.9 mmol) in DCM (100 mL) was stirred at about 20 °C for about 16 h. Water (200 mL) was added to the mixture and extracted with DCM (2 x 200 mL). The combined DCM extracts were washed with brine (200 mL), dried and concentrated. The residue was purified by column chromatography (silica) and eluted with pet. ether/EtOAc (10:1) to afford 6-bromo-2-(cyclopentyloxy)-3-methoxybenzonitrile (1.6 g, 24%). Ή NMR (CDCh, 400MHz): δ 7.26-7.30 (m, 1H), 6.96 (d, J= 8.8 Hz, 1H), 5.11-5.17 (m, 1H), 3.87 (s, 3H), 1.89-2.02 (m, 4H), 1.70-1.80 (m, 2H), 1.59-1.68 (m, 2H).
Préparation 208: 6-bromo-2-(cyclopentyloxy)-3-methoxybenzaldehyde oxime
To a solution of 6-bromo-2-(cyclopentyloxy)-3-methoxybenzaldehyde (Préparation 209, 6.8 g, 22.7 mmol) in EtOH (100 mL) was added NaHCO3 (3.8 g, 45.4 mmol) and NH2OHHCI (2.35 g, 34 mmol). The mixture was stirred at about 20 °C for about 2 h. The reaction mixture was concentrated to afford 6-bromo-2-(cyclopentyloxy)-3-methoxybenzaldehyde oxime (7 g), which was used in Préparation 207.
Préparation 209: 6-bromo-2-(cyclopentyloxy)-3-methoxybenzaldehyde
173
6-bromo-2-(cyclopentyloxy)-3-methoxybenzaldehyde (6.8 g, 90%) was prepared in an analogous manner to Préparation 172 using 6-bromo-2-hydroxy-3-methoxybenzaldehyde (Préparation 165, 6 g, 30 mmol) and bromocyclopentane (4.26 g, 28.6 mmol) at about 60 °C for about 3 h. Ή NMR (CDCb, 400MHz): δ 10.31-10.38 (m, 1H), 7.31 (d, J= 8.8 Hz, 1H), 6.94 (d, J = 8.8 Hz, 1 H), 4.95-5.01 (m, 1 H), 3.87 (s, 3H), 1.70-1.93 (m, 7H), 1.62 (d, J = 5.4 Hz, 2H). LCMS m/z = 323 [M+Na]+.
Préparation 210: 1-bromo-2,4-dimethoxy-3-propoxybenzene
1-bromo-2,4-dimethoxy-3-propoxybenzene (10 g, 85%) was prepared in an analogous manner to Préparation 172 using 3-bromo-2,6-dimethoxyphenol (Préparation 211, 10 g, 43 mmol) and 1-iodopropane (14.6 g, 86 mmol). 1H NMR (CDCb, 400MHz): δ 7.17-7.22 (m, 1H), 6.58 (d, J= 8.8 Hz, 1H), 3.95-3.99 (m, 2H), 3.90 (s, 3H), 3.84 (s, 3H), 1.73-1.85 (m, 2H), 1.011.07 (m, 4H). LCMS m/z = 276 [MH]+.
Préparation 211: 3-bromo-2,6-dimethoxyphenol
To a stirring solution of 2,6-dimethoxyphenol (1 g, 6.5 mmol) in CCI4 (35 mL) at about10 °C was added Br2 (1.04 g, 6.5 mmol) and stirred for about 2 h. The reaction mixture was diluted with CCI4 (20 mL), washed with water (3 x 60 mL) and the CCI4 layer was washed with brine, dried over Na2SO4 and concentrated. The residue was purified by column chromatography (silica) and eluted with pet. ether/EtOAc (100:0 to 80:20) to afford 3-bromo-2,6dimethoxyphenol (1.46 g, 97%). 1H NMR (CDCb, 400MHz): δ 7.02 (d, J = 8.8 Hz, 1H), 6.57 (d, J = 8.8 Hz, 1H), 5.66 (s, 1H), 3.93 (s, 3H), 3.89 (s, 3H).
Préparation 212: 6-iodo-3-methoxy-2-propoxypyridine
174
6-iodo-3-methoxy-2-propoxypyridine was (11 g, 95%) prepared in an analogous manner to Préparation 172 using 6-iodo-2-propoxypyridin-3-ol (Préparation 213, 11 g, 39 mmol) and 1iodomethane (57 g, 402 mmol) at about 15 °C for about 6 h. 1H NMR (CDCh, 400MHz): δ 7.24 (d, J = 8.0 Hz, 1 H), 6.91 (d, J = 8.0 Hz, 1 H), 4.25 (t, J = 6.8 Hz, 2H), 3.83 (s, 3H), 1.73-1.90 (m,
2H), 1.04 (t, J = 7.5 Hz, 3H). LCMS m/z = 293 [MH]+.
Préparation 213: 6-iodo-2-propoxypyridin-3-ol
Sodium propan-1-olate (21.8 g, 265 mmol) was added to 2-bromo-6-iodopyridin-3-ol (Préparation 214, 26.5 g, 88.4 mmol) in DMF (200 mL), and the reaction mixture was stirred for about 16 h at about 110 °C under N2. After cooling to about 20 °C, the reaction mixture was partitioned between brine (200 mL) and EtOAc (250 mL). The aqueous layer was extracted with EtOAc (200 mL). The combined EtOAc extracts were dried (Na2SO4) and concentrated. The residue was purified by column chromatography (silica) and eluted with pet. ether/EtOAc (100:0 to 80:20) to afford 6-iodo-2-propoxypyridin-3-ol (11.2 g, 45%). Ή NMR (CDCh, 400MHz): δ 7.17 (d, J = 8.0 Hz, 1 H), 6.81 (d, J = 8.0 Hz, 1 H), 5.47 (s, 1 H), 4.31 (dt, J = 0.9, 6.7 Hz, 2H), 1.741.86 (m, 2H), 0.98-1.05 (m, 3H).
Préparation 214: 2-bromo-6-iodopyridin-3-ol
To a solution of 2-bromo-3-hydroxy pyridine (20.0 g, 114.95 mmol) in water (250 mL) was added K2CO3 (31.8g, 230 mmol) and l2 (29.2 g, 115 mmol). The mixture was stirred at about 20 °C for about 5 h. The mixture was cooled to 0 °C and treated with concentrated HCl. The precipitate was filtered to afford 2-bromo-6-iodopyridin-3-ol (30 g, 87%). 1H NMR (DMSOds, 400 MHz): δ 11.10 (br s, 1H), 7.62 (d, J= 8.1 Hz, 1H), 7.03 (d, J = 8.3 Hz, 1H). LCMS m/z = 299 [MH]+.
Préparation 215: 5-bromo-2-methoxy-3-propoxypyridine
175
To a solution of 2-methoxy-3-propoxypyridine (Préparation 216, 5.68 g, 34 mmol) dissolved in DCM (60 mL) was added HOAc (2.04 g, 34mmol). To the mixture, NBS (6.35 g, 35.7 mmol) was added in portions while stirring. The mixture was stirred at about 12 °C for about 16 h. The mixture was concentrated. The residue was diluted with water (200 mL) and extracted with EtOAc (2 x 100 mL) The combined EtOAc extracts were dried and concentrated. The residue was purified by column chromatography (silica) and eluted with pet. ether/EtOAc (100:0 to 85:15) to afford a mixture of 6-bromo-2-methoxy-3-propoxypyridine and 5-bromo-2methoxy-3-propoxypyridine. The mixture was chilled to about -10 °C overnight. A precipitate formed which was separated from the oil by centrifugation (3x5 min @ 3000 rpm) to afford 5bromo-2-methoxy-3-propoxypyridine (3 g, 53%). 1H NMR (CDCb, 400MHz): δ 7.76 (d, J = 2.0 Hz, 1H), 7.13 (d, J= 2.0 Hz, 1H), 3.98 (s, 3H), 3.95 (t, J = 6.8 Hz, 2H), 1.85-1.94 (m, 2H), 1.05 (t, J = 7.5 Hz, 3H).
Préparation 216: 2-methoxy-3-propoxypyridine
2-methoxy-3-propoxypyridine (5.7 g, 85%) was prepared in an analogous manner to Préparation 172 using 2-methoxypyridin-3-ol (5 g, 40 mmol) and 1-iodopropane (13.6 g, 80 mmol). Ή NMR (CDCb, 400MHz): δ 7.73 (dd, J = 1.5, 4.9 Hz, 1 H), 7.05 (dd, J = 1.5, 7.82 Hz, 1H), 6.83 (dd, J= 5.0, 7.7 Hz, 1H), 4.02 (s, 3H), 3.97 (t, J= 6.9 Hz, 2H), 1.86-1.93 (m, 2H), 1.05 (t, J =7.5 Hz, 3H).
Préparation 217: 2-bromo-5-methoxy-4-propoxypyridine
To a solution of 2-bromo-4-iodo-5-methoxypyridine (Préparation 218, 4.0 g, 13 mmol) in DMF (30 mL) was added NaH (765 mg, 19.1 mmol, 60%) and 1-propanol (1.53 g, 25.5 mmol) in DMF (25 mL) at about 20 °C. The mixture was heated to about 60 °C for about 1 h. The solution was quenched with aqueous NH4CI (1 M, 30 mL) and extracted with EtOAc (3 x 100 mL). The combined EtOAc extracts were washed with brine (100 mL), dried over Na2SO4 and concentrated. The residue was purified by column chromatography (silica) and eluted with pet. ether/EtOAc (100:0 to 89:11) to afford 2-bromo-5-methoxy-4-propoxypyridine (2 g, 64%). 1H NMR (CDCb, 400MHz): δ 7.84 (s, 1 H), 6.91 (s, 1 H), 4.00 (t, J = 6.9 Hz, 2H), 3.90 (s, 3H), 1.831.92 (m, 2H), 1.05 (t, J = 7.3 Hz, 3H). LCMS m/z = 247.8 [MH]+.
176
Préparation 218: 2-bromo-4-iodo-5-methoxypyridine
Sodium hydride (1.27 g, 31.8 mmol, 60%) was suspended in MeOH (2.55 g, 79.5 mmol) and DMF (80 mL) at about 25 °C. The mixture was added to a solution of 2-bromo-5-fluoro-4iodopyridine (Préparation 219, 8 g, 26.50 mmol) in DMF (10 mL) at about 0 °C. The mixture was stirred at about 0 °C for about 1 h. The solution was quenched with aqueous NH4CI (1 M, 60 mL) and extracted with MBTE (3 x 200 mL). The combined MTBE extracts were washed with brine (100 mL), dried over Na2SO4, and concentrated. The residue was purified by column chromatography (silica) and eluted with pet. ether/EtOAc (100:0 to 90:10) to afford 2-bromo-4iodo-5-methoxypyridine (4 g, 48.1%). Ή NMR (CDCh, 400MHz): δ 7.88 (s, 1H), 7.85 (s, 1H), 3.97 (s, 3H).
Préparation 219: 2-bromo-5-fluoro-4-iodopyridine
A solution of 2-bromo-5-fluoropyridine (24.6 g, 140 mmol) in THF (300 mL) was cooled to about -78 °C. LDA (2 M in THF, 90.9 mL, 182 mmol) was added dropwise and the mixture was stirred for about 20 min. To the mixture was added a solution of iodine (49.7 g, 196 mmol) in THF (100 mL) dropwise. The reaction mixture was warmed to about 0 °C and stirred for about 30 min. The reaction was quenched with 10% aq. Na2S2O3 solution and was extracted with EtOAc (3 x 500 mL). The combined EtOAc extracts were washed with brine (500 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatograph (silica) and eluted with pet. ether/EtOAc (10:1) to afford 2-bromo-5-fluoro-4-iodopyridine (50 g, 67% purity). The material was further purified by préparative HPLC (Column: Phenomenex Synergi Max-RP 150 mm x 50 mm, 10 μ; Mobile Phase: [water (0.225% HCO2H)-ACN]; B%: 30%-60%, 25 min. Flow rate 120 mL/min.) to afford 2-bromo-5-fluoro-4-iodopyridine (16.8 g, 40%). Ή NMR (CDCh, 400MHz): δ 8.15 (s, 1H), 7.92 (s, 1H). LCMS m/z = 303 [MH]+.
Préparation 220: 3-fluoro-2-iodo-5-methoxy-6-propoxypyridine
177
To a solution of 5-fluoro-3-methoxy-2-propoxypyridine (Préparation 221, 2.80 g, 15.1 mmol) in EtOH (50 mL) was added Ag2SO4 (7.07 g, 22.7 mmol) and l2 (5.76 g, 22.7 mmol). The reaction mixture was stirred at about 10 °C for about 16 h. The mixture was and the solution was partitioned between EtOAc (3 x 100 mL) and water (100 mL). The EtOAc extracts were dried with Na2SO4, filtered and concentrated to afford 3-fluoro-2-iodo-5-methoxy-6propoxypyridine (4.38 g, 93%). Ή NMR (CDCh, 400 MHz): δ 7.58-7.74 (m, 1H), 4.30 (t, J = 6.7 Hz, 2H), 3.92 (s, 3H), 1.75-1.91 (m, 2H), 1.05 (t, J = 7.3 Hz, 3H). LCMS m/z = 311 [MH]+.
Préparation 221: 5-fluoro-3-methoxy-2-propoxypyridine
A mixture of tBuXPhos-Pd-G3 (CAS 14447963-75-8, 443 mg, 0.557 mmol), PrOH (803 mg, 13.4 mmol), 2-chloro-5-fluoro-3-methoxypyridine (Préparation 222, 1800 mg, 11.14 mmol) and Cs2CO3 (7260 mg, 22.3 mmol) was dissolved in PrOH (40 mL) under a N2. The mixture was heated at about 90 °C for about 16 h. The mixture was dried and concentrated. The residue was purified by by column chromatography (silica) and eluted with pet. ether/EtOAc (100:0 to 90:10) to afford 5-fluoro-3-methoxy-2-propoxypyridine (1280 mg, 77%). 1H NMR (CDCh, 400MHz): δ 7.57 (d, J = 2.5 Hz, 1 H), 6.87 (dd, J = 2.7, 9.3 Hz, 1 H), 4.31 (t, J = 7.0 Hz, 2H), 3.87 (s, 3H), 1.77-1.93 (m, 2H), 0.98-1.08 (m, 3H). LCMS m/z = 185 [MH]+.
Préparation 222: 2-chloro-5-fluoro-3-methoxypyridine
2-chloro-5-fluoro-3-methoxypyridine (1.8 g, 72%) was prepared in an analogous manner to Préparation 153 using 2-chloro-5-fluoropyridin-3-ol (2.3 g, 16 mmol) and methanol (5 g, 156 mmol). Ή NMR (CDCh, 400MHz): δ 7.89 (d, J = 2.70 Hz, 1 H), 7.00 (dd, J = 2.5, 9.1 Hz, 1 H), 3.93 (s, 3H).
Préparation 223: 4-bromo-1-(difluoromethoxy)-2-propoxybenzene
178
Powdered KOH (1.34 g, 23.8 mmol) was added to a stirring solution of 4-bromo-2propoxyphenol (Préparation 224, 5.5 g, 23.8 mmol) in NMP (150 mL) at about 15 °C under N2.
The mixture was heated at about 50 °C for about 45 min then cooled to about 15 C. Difluorochloromethane was bubbled through the reaction mixture (approximately 20 min) until saturation and the mixture was stirred for an additional 20 min. Potassium hydroxide (2.68 g in 3 mL of water) was added dropwise, maintaining the température below 33 °C. The mixture was stirred for an additional 40 min. Additional potassium hydroxide (1.34 g, in 3 mL of water) was added dropwise and the mixture was stirred for 1 h. N2 was bubbled through the reaction and water was added. The pH ofthe resulting mixture was adjusted to 8 by the addition of potassium hydroxide (aqueous) and the mixture was extracted using MTBE (2 x 100 mL). The combined MBTE extracts were washed with water (50 mL), brine (3 x 100 mL), dried over Na2SO4, filtered, and concentrated. The residue was purified by column chromatography (silica) and eluted with pet. ether/EtOAc (100:0 to 90:10) to afford 4-bromo-1-(difluoromethoxy)-2propoxybenzene (4.8 g, 72%). Ή NMR (CDCh, 400MHz): δ 7.09 (d, J= 1.3 Hz, 1H), 7.03-7.06 (m, 2H), 6.33-6.74 (m, 1 H), 3.93-4.01 (m, 2H), 1.80-1.92 (m, 2H), 1.06 (t, J = 7.4 Hz, 3H).
Préparation 224: 4-bromo-2-propoxyphenol
To a solution of 4-bromo-2-propoxyphenyl formate (Préparation 225, 10.9 g, 42 mmol) in MeOH (75 mL) and water (75 mL) was added NaOH (4200 mg, 105 mmol). The mixture was stirred at about 10 °C for about 1h. The mixture was allowed to stand overnight. The mixture was acidified by HCl (1N) to pH 3. The mixture was concentrated and filtered. The filter cake was washed with water (20 mL). The cake was dissolved in MTBE (200 mL) and EtOAc (50 mL). The combined MTBE and EtOAc extracts were dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography (silica) and eluted with pet. ether/EtOAc (100:0 to 75:25) to afford 4-bromo-2-propoxyphenol (6.11 g, 63%). 1H NMR (CDCh, 400MHz): δ 6.94-7.06 (m, 2H), 6.81 (d, J = 8.5 Hz, 1 H), 3.99 (t, J = 6.8 Hz, 2H), 1.791.95 (m, 2H), 1.06 (t, J = 7.5 Hz, 3H).
Préparation 225: 4-bromo-2-propoxyphenyl formate
179
To a solution of 4-bromo-2-propoxybenzaldehyde (Préparation 226, 10.2 g, 42 mmol) dissolved in DCM (150 mL) was added m-CPBA (18.1 g, 84 mmol). The mixture was stirred at about 18 °C for about 16 h, then allowed to stand over the weekend. The mixture was filtered and concentrated to afford 4-bromo-2-propoxyphenyl formate (10.9 g), which was used in
Préparation 224. LCMS m/z = 248 [MH]+.
180
Préparation 226: 4-bromo-2-propoxybenzaldehyde
4-bromo-2-propoxybenzaldehyde (11.5 g, 95%) was prepared in an analogous manner to Préparation 172 using 4-bromo-2-hydroxybenzaldehyde (10 g, 50 mmol) and 1-iodopropane (11 g, 65 mmol). Ή NMR (CDCI3, 400MHz): δ 10.45 (d, J= 0.7 Hz, 1H), 7.69 (d, J= 8.1 Hz, 1H), 7.11-7.22 (m, 2H), 4.04 (t, J = 6.5 Hz, 2H), 1.80-2.02 (m, 2H), 1.09 (t, J= 7.3 Hz, 3H).
Préparation 227: ((2-bromoallyl)oxy)(tert-butyl)dimethylsilane
Five reactions were carried out in parallel. To a solution of 2-bromoprop-2-en-1-ol (Préparation 60, 150 g, 1.10 mol) and imidazole (Préparation 228, 74.6 g, 0.985 mol) in DMF (900 mL) was added TBS-CI (140 g, 0.93 mol) in portions at about 30 °C. Then the mixture was stirred at about 35 °C for 1 h. The mixture was poured into water (5.0 L). The combined mixtures were extracted with MTBE (3 x 2.5 L). The organic layer was washed with brine (2.0 L), dried over Na2SO4 and concentrated to afford ((2-bromoallyl)oxy)(tert-butyl)dimethylsilane (1250 g, 92%). Ή NMR (CDCh, 400MHz): δ 5.96 (d, J= 1.8 Hz, 1H), 5.54 (d, J= 1.8 Hz, 1H), 4.22 (t, J= 1.5 Hz, 2H), 0.89-0.97 (m, 9H), 0.11 (s, 6H).
Préparation 228: 2-bromoprop-2-en-1-ol
Five reactions were carried out in parallel: To a solution of 2,3-dibromoprop-1-ene (300 g, 1.50 mol) in DMF (900 mL) was added KOAc (221 g, 2.25 mol) in portions with stirring at about 20 °C. The mixture was stirred at about 20 °C for about 12 h. A solution of LiOH (126 g, 3.01 mol) in MeOH (900 mL) and H2O (300 mL) was added dropwise to the above mixture with stirring at about 20 °C. The mixture was stirred at about 20 °C for about 1 h. The mixture was concentrated and poured into ice-water (2.0 L). The mixture was extracted with EtOAc (3x1.5 L). The EtOAc extracts were washed with brine (1.0 L), dried over Na2SO4 and concentrated to afford 2-bromoprop-2-en-1-ol (750 g, 72%). 1H NMR (CDCh, 400MHz): δ 5.87-6.02 (m, 1H), 5.45-5.62 (m, 1H), 4.17 (s, 2H), 3.70 (br s, 1H).
181
Préparation 229: ((3-bromobut-3-en-1 -yl)oxy)(tert-butyl)dimethylsilane
To a mixture of 3-bromobut-3-en-1-ol (CAS 76334-36-6, 10.0 g, 66.2 mmol) in anhydrous DCM (65 mL) was added imidazole (5.41 g, 79.5 mmol) and TBS-CI (9.98 g, 66.2 mmol). The mixture was stirred at about 18 °C for about 16 h. The reaction was poured into ice water and extracted with EtOAc (2 x 200 mL). The combined EtOAc extracts were washed with brine, dried over Na2SO4 and filtered. The filtrate was concentrated. The residue was purified by column chromatography (silica) and eluted with pet. ether to afford ((3-bromobut-3-en-1yl)oxy)(tert-butyl)dimethylsilane (16.0 g, 91%). Ή NMR (CDCh, 400MHz): δ 5.64 (s, 1H), 5.46 (d, J = 1.6 Hz, 1 H), 3.80 (t, J = 6.4 Hz, 2H), 2.63 (t, J = 6.2 Hz, 2H), 0.90 (s, 9H), -0.08 (s, 6H).
Préparation 230: 4-(((tert-butyldimethylsilyl)oxy)methyl)-2,6-dichloropyrimidine
Cl
To a solution of 2,6-dichloropyrimidin-4-yl)methanol (Préparation 231, 3.5 g, 19.55 mmol) and imidazole (1.6 g, 23.5 mmol) in DMF (60 mL) was added TBS-CI (3.24 g, 22.4 mol) in portions at about 0 °C. The mixture was stirred at about 0 °C for about 2 h. The mixture was poured into ice water (50 mL) and extracted with EtOAc (3 x 50 mL). The combined EtOAc extracts were washed with brine (2 x 30 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography (silica) and eluted with pet. ether/EtOAc (100:0 to 90:10) to afford 4-(((tert-butyldimethylsilyl)oxy)methyl)-2,6-dichloropyrimidine (3.1 g, 54%). 1H NMR (CDCh, 400MHz): δ 7.48-7.57 (m, 1H), 4.72-4.82 (m, 2H), 0.93-1.03 (m, 9H), 0.14 (s, 6H). LCMS m/z = 293 [MH]+.
Préparation 231: 2,6-dichloropyrimidin-4-yl)methanol
2,6-Dichloropyrimidine-4-carbonyl chloride (Préparation 232, 10 g, 47.3 mmol) was dissolved in a mixture of MeCN (60 mL) and THF (70 mL). The mixture was cooled to about -78 °C and treated with a solution of NaBH4 (3.58 g, 94.6 mmol) in DMF (30 mL) dropwise. The
182 mixture was stirred at about -78 °C for about 2 h and diluted with aqueous HCl solution (1 M,
10mL). The mixture was diluted with saturated aqueous NaHCO3 and extracted with EtOAc (2 x 100 mL). The combined EtOAc extracts were dried over MgSO4, filtered and concentrated to afford 2,6-dichloropyrimidin-4-yl)methanol (8 g, 95%), which was used in Préparation 230. 1H NMR (CDCI3, 400MHz): δ 7.51 (s, 1H), 4.78 (s, 2H).
Préparation 232: 2,6-dichloropyrimidine-4-carbonyl chloride
A solution of 2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic acid (50 g, 0.32 mol) and PCk (220 g, 1.06 mol) in POCh (250 mL) was heated to reflux (120 °C) for about 16 h. The resulting mixture was concentrated and distilled under reduced pressure (120 °C, 10 mm Hg) to afford 2,6-dichloropyrimidine-4-carbonyl chloride (21 g, 31%), which was used in Prepartion 231.
Préparation 233: 4-methoxy-3-propoxybenzimidamide
Ethyl 4-methoxy-3-propoxybenzimidate (Préparation 234, 37.6 g, 158.45 mmol) was dissolved in EtOH (226 mL). Ammonia in methanol (226 mL) was added to the reaction mixture. The reaction mixture was stirred at about 28 °C for about 24 h. After concentration, MTBE (150 mL) was poured into the residue, stirred for 1h, and filtered and concentrated to afford 4methoxy-3-propoxybenzimidamide (33.8 g, 100%). 1H NMR (CD3OD, 400 MHz): δ 7.46 (dd, J = 2.2, 8.6 Hz, 1H), 7.36 (d, J= 2.2 Hz, 1H), 7.14 (d, J = 8.6 Hz, 1H), 4.04 (t, J = 6.5 Hz, 2H), 3.93 (s, 3H), 1.81-1.90 (m, 2H), 1.07 (t, J = 7.6 Hz, 3H). LCMS m/z = 209 [MH]+.
Préparation 234: ethyl 4-methoxy-3-propoxybenzimidate
183
Acetvl chloride (69.0 g, 879 mmol) was added dropwise to a solution of 4-methoxy-3propoxybenzonitrile (Préparation 235, 21.0 g, 110 mmol) in dry EtOH (60.7 g, 1320 mmol), which was stirred at about 30 °C for about 12 h. The mixture was concentrated and to the residue was added MTBE (150 mL). The mixture was stirred for about 1 h and filtered to afford ethyl 4-methoxy-3-propoxybenzimidate (26.1 g, 100%). 1H NMR (CDCh, 400 MHz): δ 12.28 (br s, 1 H), 11.56 (br s, 1 H), 8.01 (d, J = 2.2 Hz, 1 H), 7.98 (dd, J = 2.2, 8.6 Hz, 1 H), 7.0 (d, J = 8.6 Hz, 1 H), 4.91 (q, J = 7.0 Hz, 2H), 4.21 (t, J = 6.6 Hz, 2H), 3.96 (s, 3H), 1.85-1.96 (m, 2H), 1.61 (t, J = 7.0 Hz, 2H), 1.08 (t, J = 7.5 Hz, 3H). LCMS m/z = 238 [MH]+.
Préparation 235: 4-methoxy-3-propoxybenzonitrile
4-methoxy-3-propoxybenzonitrile (32.10 g, 100%) was prepared in an analogous manner to Préparation 172 using 3-hydroxy-4-methoxybenzonitrile (25 g, 170 mmol) and 1iodopropane (57 g, 335 mmol). Ή NMR (CDCh, 400 MHz): δ 7.25-7.29 (m, 1 H), 7.08 (d, J = 2.0 Hz, 1H), 6.90 (d, J= 8.3 Hz, 1H), 3.99 (t, J = 6.9 Hz, 2H), 3.92 (s, 3H), 1.84-1.93 (m, 2H), 1.031.09 (m, 3H). LCMS m/z = 191 [MH]+.
Préparation 236: 3-((tert-butyldimethylsilyl)oxy)propan-1-ol HO^^O,s,/ 1 P
Propane-1,3-diol (20 g, 260 mmol), tert-butylchlorodimethylsilane (47.5 g, 315 mmol), Et3N (76.0 mL, 526 mmol) and DMAP (1.610 g, 13.1 mmol) were suspended in DCM (300 mL). The mixture was stirred at about 18 °C overnight. The reaction mixture was partitioned between DCM (3 x 300 mL) and water (300 mL). The combined DCM extracts were concentrated. The residue was purified by column chromatography (silica) and eluted with pet. ether/EtOAc (100:0 to 97:3) to afford 3-((tert-butyldimethylsilyl)oxy)propan-1-ol (50 g, 100%), which was used in Préparation 158.
184
Préparation 237: 1-(6-bromopyrïdin-2-yl)-2-hydroxyethan-1-one
Step 1: A solution of 1-(6-bromopyridin-2-yl)ethanone (CAS 49669-13-8, 5.0 g, 25.0 mmol) in AcOH (12 mL) was heated to about 70 °C. Bromine (1.4 mL, 27.5 mmol) was added dropwise over 30 min. The solution was stirred at about 70 °C for about 19 h. The solution was cooled EtOAc (50 mL) and hexanes (50 mL) were added. The precipitate was filtered and washed with heptane (2 x 50 mL). The combined filtrâtes were washed with brine (30 mL), dried over MgSO4, filtered, and concentrated to give a 2-bromo-1-(6-bromopyridin-2-yl)ethan-1-one (6.85 g), which was used directly in the next step.
Step 2: To a solution of 2-bromo-1-(6-bromopyridin-2-yl)ethanone (6.74 g) in DMF (30 mL) was added sodium nitrite (2.00 g). The solution was stirred at about 20 °C for about 22 h. The reaction was diluted with EtOAc (100 mL) and washed with water (100 mL). The water layers extracted with EtOAc. The combined EtOAc extracts were washed with brine (20 mL), dried with MgSO4, filtered and concentrated. The residue was purified by column chromatography (silica) and eluted with heptane/EtOAc (90:10 to 70:30) to afford 1-(6bromopyridin-2-yl)-2-hydroxyethan-1-one (977 mg), which was used in Préparation 88. 1H NMR (CDCh, 400 MHz): δ 7.99-8.11 (m, 1H), 7.68-7.83 (m, 2H), 5.08 (d, J = 5.1 Hz, 2H).
Example 1: 4-(5-(3,4-dimethoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol, enantiomer 1
4-(5-(3,4-dimethoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol (Example 32, 500 mg, 1.67 mmol) was further purified by préparative SFC (Prep SFC Method A) to afford 4-(5-(3,4dimethoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol, enantiomer 1 (233 mg, 46%). 1H NMR (DMSO-cfe, 400MHz): δ 8.72 (d, J = 2.8 Hz, 2H), 8.43 (d, J = 2.0 Hz, 1 H), 7.95 (t, J = 2.0 Hz, 1 H), 7.25-7.29 (m, 1 H), 7.06 (d, J = 8.4 Hz, 2H), 4.28 (t, J = 4.28 Hz, 1 H), 3.84-3.88 (m, 4H), 3.80 (s, 3H), 3.46-3.54 (m, 1H), 1.28-1.34 (m, 1H), 1.12-1.18 (m, 1H). LCMS m/z = 300 [MH]+; RT [Analytical SFC Method A] = 5.20 min.
185
Example 2: (S)-4-(5-(3-ethoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol
4-(5-(3-ethoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol (Example 33, 2.3 g, 7.3 mmol) was further purified by préparative SFC (Prep SFC Method B). The solids were recrystallized from EtOAc (442 mg in 2 mL) to afford 4-(5-(3-ethoxy-4-methoxyphenyl)pyridin-3yl)-1,2-oxaborolan-2-ol, enantiomer 1 (253 mg, 11%) as a crystalline solid. 1H NMR (DMSO-d6, 400MHz): δ 8.70 (d, J = 2.3 Hz, 1 H), 8.68 (s, 1 H), 8.42 (d, J = 1.6 Hz, 1 H), 7.92-7.94 (m, 1 H), 7.23-7.29 (m, 2H), 7.06 (d, J = 8.2 Hz, 1H), 4.28 (t, J = 8.2 Hz, 1H), 4.13 (q, J= 6.8 Hz, 2H), 3.86 (t, J = 9.0 Hz, 1H), 3.80 (s, 3H), 3.45-3.55 (m, 1H), 1.28-1.39 (m, 4H), 1.10-1.20 (m, 1H). LCMS m/z = 314 [MH]+; RT [Analytical SFC Method B] = 6.59 min. [α]2% +19.5 (c = 0.3, EtOH).
Example 3: (R)-4-(5-(3-ethoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol
Further elution ofthe préparative SFC column (Prep SFC Method B) described in Example 2 provided enantiomer 2 that was recrystallization from EtOAc to afford (R) 4-(5-(3ethoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol (610 mg, 27%) as a crystalline solid. Ή NMR (DMSO-c/6, 400MHz): δ 8.70 (d, J = 2.3 Hz, 1 H), 8.68 (s, 1 H), 8.42 (d, J = 1.6 Hz, 1 H), 7.92-7.94 (m, 1H), 7.23-7.29 (m, 2H), 7.06 (d, J= 8.2 Hz, 1H), 4.28 (t, J= 8.2 Hz, 1H), 4.13 (q, J = 6.8 Hz, 2H), 3.86 (t, J = 9.0 Hz, 1H), 3.80 (s, 3H), 3.45-3.55 (m, 1H), 1.28-1.39 (m, 4H), 1.ΙΟΙ .20 (m, 1H). LCMS m/z = 314 [MH]+; RT [Analytical SFC Method B] = 7.07 min. [a]2% -22.5 (c = 0.2, EtOH).
Example 4: (R)-4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol
Method A:
To a mixture of (R)-(3-((tert-butyldimethylsilyl)oxy)-2-(5-(4-methoxy-3propoxyphenyl)pyridin-3-yl)propyl)boronic acid (Préparation 6, 55 g, 120 mmol) in IPA (247 mL) was added 5 M hydrogen chloride in IPA (37 mL, 185 mmol) at about 20 °C. The mixture was
186
I stirred for about 3 h and concentrated. The residue was diluted with EtOAc (500 mL) and 1N
HCl (500 mL) was added. The layers were separated and the EtOAc layer was extracted with
0.5 N HCl (2 x 200 mL). The aqueous extracts were combined with the separated acidic aqueous layer and washed with EtOAc (3 x 250 mL). The combined acidic aqueous layers were treated with K3PO4 to pH 5-6. The mixture was extracted with EtOAc (1 x 500 mL, 2 x 200 mL). The combined EtOAc extracts were washed with brine, dried over Na2SO4, filtered and concentrated to afford (R)-4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol (34.5 g, 88%). This was further purified by préparative SFC (Prep SFC Method C) to afford 29 g as a crude product. The crude product was dissolved in methanol (250 mL) and water (50 mL) 10 and stirred at 20 °C for about 30 min before concentrating. The concentrated solution was partitioned between brine and EtOAc. The aqueous layer was separated and extracted with EtOAc. The EtOAc extracts were combined with the separate EtOAc layer and were washed with brine, dried over Na2SO4 and concentrated. The residue was dissolved in degassed EtOAc (200 mL) and degassed heptane (100 mL) was added slowly. Heptane was added until a precipitate was observed and and the resulting mixture was stirred overnight under N2. The solid was filtered to afford 8.08 g of product. The filtrate was concentrated and the residue dissolved in EtOAc (50 mL). Heptane (25 mL) was slowly added and the mixture stirred overnight open to air. The solid was filtered to afford a second batch (6.16 g). This was repeated a second time to afford 3.0 g. The filtrate was stirred overnight to afford additional batches (2.09 g and 3.1 g) respectively. The solid batches were combined to afford (R)-4-(5-(4methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol (22.3 g, 57%) as a crystalline solid. Ή NMR (DMSO-ds, 400MHz): δ 8.70 (d, J = 2.3 Hz, 1 H), 8.68 (s, 1 H), 8.42 (d, J = 2.0 Hz, 1 H), 7.93 (s, 1 H), 7.27 (d, J = 2.0 Hz, 1 H), 7.23-7.26 (m, 1 H), 7.06 (d, J = 8.2 Hz, 1 H), 4.28 (t, J = 8.2 Hz, 1H), 4.03 (t, J= 6.4 Hz, 2H), 3.86 (t, J = 9.0 Hz, 1H), 3.81 (s, 3H), 3.46-3.54 (m, 1H), 1.7125 1.80 (m, 2H), 1.28-1.35 (m, 1H), 1.15 (dd, J= 10.5, 16.4 Hz, 1H), 1.00 (t, J= ΊΑ Hz, 3H). LCMS m/z = 328 [MH]+; RT [Analytical SFC Method B] = 7.30 min. [a]20 D -23.7 (c = 0.9, EtOH). Elemental analysis calculated (%) for Ci8H22BNO4: C 66.08, H 6.78, N 4.28. Found: C 65.86, H 6.59, N 4.18.
Method B:
Step 1: To THF (18.0 mL) was added 3-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-5(4-methoxy-3-propoxyphenyl)pyridine (Préparation 50, 3.0 g, 7.25 mmol), [lr(COD)CI]2 (CAS 12112-67-3, 36.9 mg, 0.054 mmol) and (S)[(Sp)-2-(diphenylphosphino)ferrocenyl]-4isopropyloxazoline (CAS 163169-29-7, 52.4 mg, 0.109 mmol). Additional THF (6.0 mL) was added to the mixture which was warmed to about 50 °C for about 5 min. Catecholborane (10.9 mL, 1,0M in THF) was added to the mixture and stirred at about 50 °C for about 1 h. The mixture was cooled to about 20 °C and treated with HCl (12.2 M, 1.51 mL) over 1 min. The mixture was held at about 20 °C for about 1 h, afterwhich a precipitate had formed. The mixture
187 was cooled to about 10 °C and filtered. The filtered solid was washed with THF (6.0 mL) and dried overnight at 35°C under vacuum to afford (R)-4-(5-(4-methoxy-3-propoxyphenyl)pyndine3-yl)-1,2-oxaborolan-2-ol hydrochloride monohydrate (3.98 g, 91%) as a crystalline solid. 1H NMR (CD3OD, 400MHz): δ 8.98 (d, J = 1.5 Hz, 1 H), 8.75 (s, 1 H), 8.67 (d, J = 1.3 Hz, 1 H), 7.377.43 (m, 2H), 7.15 (d, J= 8.3 Hz, 1H), 4.09 (t, J = 6.5 Hz, 2H), 3.89-3.92 (m, 1H), 3.86-3.95 (m, 5H), 3.46 (brs, 1H), 1.85 (m, 2H), 1.31-1.42 (m, 2H), 1.08 (t, J =7.4 Hz, 3H). LCMS m/z = 328 [MH]+.
Step 2: To a solution of (R)-4-(5-(4-methoxy-3-propoxyphenyl)pyridine-3-yl)-1,2oxaborolan-2-ol hydrochloride monohydrate (2.0 g, 5.24 mmol) in water (60 mL) was added EtOAc (20 mL). To the stirred mixture was added NaOH (1N) dropwise to adjust the pH ofthe aqeous layer to 7-8. The mixture was stirred at about 20 °C for about 5 min. The layers were separated and the aqueous layer was extracted with EtOAc (2 x 10 mL). The combined EtOAc extracts were concentrated. The residue was dissolved in THF/MTBE (1:3, 22 mL) and stirred at about 20 °C overnight. The precipitate was filtered and dried under vacuum to afford (R)-4-(5-(4methoxy-3-propoxyphenyl)pyridine-3-yl)-1,2-oxaborolan-2-ol (1.17 g, 68%) as a crystalline solid. Ή NMR (DMSO-d6, 400MHz): δ 8.70 (d, J= 2.3 Hz, 1H), 8.68 (s, 1H), 8.42 (d, J= 2.0 Hz, 1H), 7.93 (s, 1H), 7.27 (d, J= 2.0 Hz, 1H), 7.23-7.26 (m, 1H), 7.06 (d, J= 8.2 Hz, 1H), 4.28 (t, J = 8.2 Hz, 1 H), 4.03 (t, J = 6.4 Hz, 2H), 3.86 (t, J = 9.0 Hz, 1 H), 3.81 (s, 3H), 3.46-3.54 (m, 1 H), 1.71 1.80 (m, 2H), 1.28-1.35 (m, 1H), 1.15 (dd, J = 10.5, 16.4 Hz, 1H), 1.00 (t, J= 7.4 Hz, 3H). LCMS m/z = 328 [MH]+.
Method C:
To a solution of (R)-(3-((tert-butyldimethylsilyl)oxy)-2-(5-(4-methoxy-3propoxyphenyl)pyridin-3-yl)propyl)boronic acid (Préparation 6, 29.0 g, 63.1 mmol) in THF (66 mL) was added aqueous HCl (84.2 mL, 252 mmol, 3.0 M) and stirred at 20 °C for about 1.5 h. The mixture was concentrated. The mixture was diluted with 1 M HCl and extracted with EtOAc (3 x 100 mL). The combined EtOAc extracts were washed with 1 M HCl (3 x 50 mL). The combined aqueous extracts were neutralized with K3PO4 to pH 7-8 and extracted with EtOAc (3 x 100 mL). The combined EtOAc extracts were dried over Na2SO4, filtered and concentrated to afford (R)-4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol (19.0 g, 92%). This was further purified by préparative SFC (Prep SFC Method C) to afford 18 g ofthe crude product. The crude product was dissolved in MeOH (100 mL) and water (50 mL). The mixture was partitioned between brine and EtOAc. The layers were separated and the aqueous layer was extracted with EtOAc. The combined EtOAc extracts were washed with brine, dried over Na2SO4 and concentrated to afford 15 g of product. The residue was dissolved in EtOAc (60 mL) and heptane (30 mL) was slowly added over about 3 h. The mixture was stirred at about 20 °C overnight. The precipitate was filtered and dried to afford (8.08 g). This process was repeated 2 more times to afford additional batches (2.01 g and 1.03 g), respectively. The three
188 batches were combined in heptane (100 mL), chilled to about -78 °C for about 10 min, filtered and dried to afford (R)-4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol (10.4 g, 51 %) as a crystalline solid. 1H NMR (DMSO-de, 400MHz): δ 8.70 (d, J = 2.3 Hz, 1 H), 8.68 (s, 1 H), 8.42 (d, J = 2.0 Hz, 1 H), 7.93 (s, 1 H), 7.27 (d, J = 2.0 Hz, 1 H), 7.23-7.26 (m, 1 H), 7.06 (d, J = 8.2 Hz, 1 H), 4.28 (t, J = 8.2 Hz, 1 H), 4.03 (t, J = 6.4 Hz, 2H), 3.86 (t, J = 9.0 Hz, 1 H), 3.81 (s, 3H), 3.46-3.54 (m, 1H), 1.71-1.80 (m, 2H), 1.28-1.35 (m, 1H), 1.15 (dd, J = 10.5, 16.4 Hz, 1H), 1.00 (t, J = 7 A Hz, 3H). LCMS m/z = 328 [MH]+.
Example 5: (S)-4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol
A mixture of 3-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-5-(4-methoxy-3propoxyphenyl)pyridine (Préparation 50, 30 g, 73 mmol), [lr(COD)CI]2 (CAS 12112-67-3, 1.22 g, 1.81 mmol), (R,R)-[2-(4'-i-propyloxazolin-2-yl)ferrocenyl]diphenylphosphine (CAS 541540-70-9, 1.75 g, 3.63 mmol) and THF (240 mL) was cooled in an ice bath for about 30 min. A solution of catecholborane (109 mL, 109 mmol, 1.0 M in THF) was added slowly over about 20 min, afterwhich the mixture was stirred at about 20 °C for about 3 h. The reaction was quenched with MeOH (30 mL). The mixture was concentrated and dried overnight. The residue was treated with 3 M aqueous HCI/THF (1:1, v/v) for about 2 h and washed with EtOAc. The aqueous layer was separated and neutralized to pH 7-8 and extracted with EtOAc. The EtOAc extract was dried over Na2SO4, filtered and concentrated. The residue was dissolved in THF/MTBE (1:1, 180 mL) and stirred with Biotage MP-TMT resin (28 g, Biotage P/N 801470) at about 20 °C, under N2, overnight. The mixture was filtered and the resin was washed with THF (2 x 50 mL). The combined THF/MTBE filtrâtes were concentrated to afford (S)-4-(5-(4-methoxy-3propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol (23.5 g, 71%). This was further purified via SFC purification (Prep SFC Method C) to afford 12 g of a crude product. The crude product was dissolved in MeOH (35 mL) and water (15 mL). The mixture was partitioned between brine and EtOAc. The layers were separated and the aqueous phase was extracted with EtOAC. The combined EtOAc extracts were dried over Na2SO4, filtered and concentrated. The residue was dissolved in EtOAc (30 mL) and heptane was added until just cloudy. The mixture was stirred overnight. The precipitate was filtered and dried to afford (S)-4-(5-(4-methoxy-3propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol (5.39 g, 45%) as a crystalline solid. 1H NMR (DMSO-de, 400MHz): δ 8.70 (d, J = 2.3 Hz, 1H), 8.68 (s, 1H), 8.42 (d, J= 2.0 Hz, 1H), 7.93 (s, 1H), 7.27 (d, J= 2.0 Hz, 1H), 7.23-7.26 (m, 1H), 7.06 (d, J= 8.2 Hz, 1H), 4.28 (t, J= 8.2 Hz, 1H), 4.03 (t, J = 6.4 Hz, 2H), 3.86 (t, J = 9.0 Hz, 1H), 3.81 (s, 3H), 3.46-3.54 (m, 1H), 1.71-1.80 (m, 2H), 1.28-1.35 (m, 1H), 1.15 (dd, J= 10.5, 16.4 Hz, 1H), 1.00 (t, J= 7 A Hz, 3H). LCMS m/z
189 = 328 [ΜΗΓ; RT [Analytical SFC Method B] = 6.35 min. [a]20 D +27.3 (c = 0.6, EtOH). Elemental analysis calculated (%) for C18H22BNO4: C 66.08, H 6.78, N 4.28. Found: C 66.01, H 6.52, N 4.15.
Example 6: 4-(5-(3-isopropoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol, enantiomer 1
4-(5-(3-isopropoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol (Example 35, 90 mg, 0.28 mmol) was further purified by préparative SFC (Prep SFC Method D) followed by preprative HPLC (Method A) to afford 4-(5-(3-isopropoxy-4-methoxyphenyl)pyridin-3-yl)-1,2oxaborolan-2-ol, enantiomer 1 (17 mg, 19%). 1H NMR (DMSO-d6, 400MHz): δ 8.72 (s, 1H), 8.69 (d, J = 2.0 Hz, 1 H), 8.42 (d, J = 2.0 Hz, 1 H), 7.92 (t, J = 2.0 Hz, 1 H), 7.29 - 7.24 (m, 2H), 7.07 (d, J = 8.0 Hz, 1 H), 4.68-4.74 (m, 1 H), 4.27 (t, J = 8.3 Hz, 1 H), 3.86 (t, J = 9.0 Hz, 1 H), 3.79 (s, 3H), 3.47-3.55 (m, 1H), 1.26-1.35 (m, 7H), 1.10-1.18 (m, 1H). LCMS m/z = 328 [MH]+. RT [Analytical SFC Method C] = 5.425 min.
Example 7: 4-(5-(3-cyclopropoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol, enantiomer 2
4-(5-(3-cyclopropoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol (Example 36, 5.0 g, 4.54 mmol) was further purified by préparative SFC (Prep SFC Method E) to afford 4-(5(3-(2-hydroxyethoxy)-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol, enantiomer 2 (205 mg, 41 %). 1H NMR (DMSO-ds, 400MHz): δ 8.69-8.72 (m, 2H), 8.44 (d, J = 2.0 Hz, 1 H), 7.91 (t, J = 2.0 Hz, 1 H), 7.53 (d, J = 2.0 Hz, 1 H), 7.28 (dd, J = 2.4, 8.3 Hz, 1 H), 7.07 (d, J = 8.8 Hz, 1 H), 4.25-4.31 (m, 1 H), 3.97-4.01 (m, 1 H), 3.86 (t, J = 8.8 Hz, 1 H), 3.78 (s, 3H), 3.46-3.57 (m, 1 H), 1.32 (dd, J= 8.1, 16.4 Hz, 1H), 1.14 (dd, J = 10.3, 16.1 Hz, 1H), 0.76-0.83 (m, 2H), 0.67-0.72 (m, 2H). LCMS m/z = 326 [MH]+. RT [Analytical SFC Method D] = 5.736 min.
190
Example 8: (-) 4-(5-(3-(2-hydroxyethoxy)-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol, enantiomer 1
4-(5-(3-(2-hydroxyethoxy)-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol (Example 37, 1.5 g, 4.56 mmol) was further purified by préparative SFC (Prep SFC Method F) to afford 4(5-(3-(2-hydroxyethoxy)-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol, enantiomer 1 (261 mg, 27%). Ή NMR (DMSO-c/s, 400MHz): δ 8.70-8.72 (m, 2H), 8.42 (d, J = 2.0 Hz, 1H), 7.94 (t, J = 2.2 Hz, 1H), 7.30 (d, J= 2.0 Hz, 1H), 7.26 (dd, J = 2.1,8.4 Hz, 1H), 7.07 (d, J= 8.6 Hz, 1H), 4.88 (t, J = 5.4 Hz, 1 H), 4.25-4.30 (m, 1 H), 4.09 (t, J = 5.0 Hz, 2H), 3.86 (t, J = 9.0 Hz, 1 H), 3.81 (s, 3H), 3.75 (q, J= 5.2 Hz, 2H), 3.46-3.53 (m, 1H), 1.28-1.34 (m, 1H), 1.15 (dd, J=10.5, 16.1 Hz, 1H). LCMS m/z = 348 [MH+H2O]+; RT [Analytical SFC Method D] = 3.357 min. [α]2%-25.9 (c = 0.1, EtOH).
Example 9: (-) 4-(5-(3-(3-hydroxypropoxy)-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol, enantiomer 2
4-(5-(3-(3-hydroxypropoxy)-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol (Example 38, 1.2 g, 7.28 mmol) was further purified by préparative SFC (Prep SFC Method G) to afford 4(5-(3-(3-hydroxypropoxy)-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol, enantiomer 2 (639 mg, 35%). Ή NMR (DMSO-c/6, 400MHz): δ 8.68-8.72 (m, 2H), 8.43 (d, J = 2.0 Hz, 1H), 7.94 (t, J = 2.0 Hz, 1 H), 7.29 (d, J = 2.0 Hz, 1 H), 7.23-7.27 (m, 1 H), 7.06 (d, J = 8.5 Hz, 1 H), 4.55 (t, J = 5.1 Hz, 1H), 4.27 (t, J= 8.3 Hz, 1H), 4.14 (t, J= 6.4 Hz, 2H), 3.86 (t, J = 9.0 Hz, 1H), 3.80 (s, 3H), 3.58 (q, J= 6.0 Hz, 2H), 3.44-3.55 (m, 1H), 1.86-1.92 (m, 2H), 1.27-1.35 (m, 1H), 1.11-1.19 (m, 1H). LCMS m/z = 344 [MH]+; RT [Analytical SFC Method F] = 1.060 min. [α]2% -19.5 (c = 0.02, EtOH).
Example 10: (-) 4-(5-(2-(difluoromethyl)-3-ethoxy-4-methoxyphenyl)pyridin-3-yl)-1,2oxaborolan-2-ol, enantiomer 1
191
4-(5-(2-(difluoromethyl)-3-ethoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol (Example 41, 800 mg, 2.20 mmol) was further purified by préparative SFC (Prep SFC Method H) to afford 4-(5-(2-(difluoromethyl)-3-ethoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol, 5 enantiomer 1 (308 mg, 39%). The material was recrystallized from EtOAc/ heptane (1:1, v/v) to afford a crystalline solid. Ή NMR (DMSO-ds, 400MHz): δ 8.69 (s, 1H), 8.48 (d, J = 2.0 Hz, 1H), 8.34 (d, J= 1.5 Hz, 1H), 7.61 (s, 1H), 7.31 (d, J= 8.8 Hz, 1H), 6.80-7.14 (m, 2H), 4.27 (t, J= 8.3 Hz, 1H), 4.08 (q, J= 6.8 Hz, 2H), 3.89 (s, 3H), 3.80 (t, J= 8.8 Hz, 1H), 3.45-3.54 (m, 1H), 1.251.38 (m, 4H), 1.00-1.12 (m, 1H). LCMS m/z = 364 [MH]+; RT [Analytical SFC Method E] = 3.640 10 min. [a]23 D-27.5 (c = 0.2, EtOH).
Example 11: (+) 4-(5-(2-(difluoromethyl)-3-ethoxy-4-methoxyphenyl)pyridin-3-yl)-1,2oxaborolan-2-ol, enantiomer 2
Further elution ofthe préparative SFC column (Prep SFC Method H) described in
Example 10 provided 4-(5-(2-(difluoromethyl)-3-ethoxy-4-methoxyphenyl)pyridin-3-yl)-1,2oxaborolan-2-ol, enantiomer 2 (259 mg, 32%). 1H NMR (DMSO-de, 400MHz): δ 8.69 (s, 1H), 8.48 (d, J= 2.0 Hz, 1H), 8.34 (d, J = 1.5 Hz, 1H), 7.61 (s, 1H), 7.31 (d, J = 8.8 Hz, 1H), 6.807.14 (m, 2H), 4.27 (t, J= 8.3 Hz, 1H), 4.08 (q, J = 6.8 Hz, 2H), 3.89 (s, 3H), 3.80 (t, J= 8.8 Hz,
1H), 3.45-3.54 (m, 1H), 1.25-1.38 (m, 4H), 1.00-1.12 (m, 1H). LCMS m/z = 364 [MH]+; RT
[Analytical SFC Method E] = 4.050 min. [o]23d+18.3 (c= 0.2, EtOH).
Example 12: 4-(5-(3-ethoxy-5-fluoro-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol, enantiomer 1
4-(5-(3-Ethoxy-5-fluoro-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol (Example 44, 60 mg, 0.18 mmol) was further purified by préparative SFC (Prep SFC Method I) to afford 4-(5(3-ethoxy-5-fluoro-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol, enantiomer 1 (18 mg,
192
30%). Ή NMR (DMSO-de, 400MHz): δ 8.75 (d, J = 2.0 Hz, 1 H), 8.71 (s, 1 H), 8.47 (d, 4 = 1.47
Hz, 1 H), 8.00 (s, 1 H), 7.27 (dd, J = 2.0, 11.7 Hz, 1 H), 7.20 (s, 1 H), 4.27 (t, J = 8.3 Hz, 1 H), 4.21 (q, J = 6.9 Hz, 2H), 3.82-3.90 (m, 3H), 3.45-3.56 (m, 2H), 1.39 (t, J = 6.9 Hz, 3H), 1.26-1.34 (m, 1H), 1.12-1.20 (m, 1H). LCMS m/z = 350 [MH+H2O]+; RT [Analytical SFC Method D] = 4.282 min.
Example 13: 4-(5-(3-chloro-5-ethoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol enantiomer 1
4-(5-(3-Chloro-5-ethoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol (Example 45, 150 mg, 0.43 mmol) was further purified by préparative SFC (Prep SFC Method J) to afford 4(5-(3-chloro-5-ethoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol, enantiomer 1 (411.3 mg, 37%). 1H NMR (DMSO-ds, 400MHz): δ 8.75 (d, J = 2.0 Hz, 1 H), 8.70 (s, 1 H), 8.48 (d, J = 2.0 Hz, 1H), 8.02 (t, 4 = 2.2 Hz, 1H), 7.42 (d, 4 = 2.0 Hz, 1H), 7.34 (d, 4 = 2.0 Hz, 1H), 4.18-4.30 (m, 3H), 3.83-3.91 (m, 1 H), 3.81 (s, 3H), 3.44-3.57 (m, 1 H), 1.39 (t, J = 6.9 Hz, 3H), 1.26-1.34 (m, 1H), 1.12-1.22 (m, 1H). LCMS m/z = 348 [MH]+; RT [Analytical SFC Method D] = 4.932 min.
Example 14: 4-(5-(5-ethoxy-2-fluoro-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol, enantiomer 2
4-(5-(5-ethoxy-2-fluoro-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol (Example 46, 385 mg, 1.16 mmol) was further purified by préparative SFC (Prep SFC Method K) to afford 4(5-(5-ethoxy-2-fluoro-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol, enantiomer 2 (122 mg, 32%). 1H NMR (DMSO-de, 400MHz): δ 8.72 (s, 1H), 8.58 (s, 1H), 8.46 (s, 1H), 7.83 (s, 1H), 7.09 (d, 4= 7.7 Hz, 1H), 7.03 (d, 4= 12.4 Hz, 1H), 4.28 (t, 4= 8.2 Hz, 1H), 4.07 (q, 4 = 7.0 Hz, 2H), 3.82-3.86 (m, 4H), 3.46-3.55 (m, 1H), 1.29-1.34 (m, 4H), 1.07-1.14 (m, 1H). LCMS m/z = 332 [MH]+; RT [Analytical SFC Method D] = 4.111 min.
Example 15: (-) 4-(5-(2-chloro-5-ethoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol, enantiomer 2
4-(5-(2-chloro-5-ethoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol (Example 47, 1.6 g, 4.60 mmol) was further purified by préparative SFC (Prep SFC Method L) to afford 4-(5(2-chloro-5-ethoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol, enantiomer 2 (550 mg,
34%). 1H NMR (DMSO-d6, 400MHz): δ 8.71 (s, 1 H), 8.48 (t, J = 2.0 Hz, 2H), 7.76 (t, J = 2.2 Hz,
1H), 7.15 (s, 1H), 7.01 (s, 1H), 4.26-4.30 (m, 1H), 4.06 (q, J = 7.0 Hz, 2H), 3.81-3.85 (m, 4H), 3.47-3.55 (m, 1H), 1.29-1.35 (m, 4H), 1.06-1.12 (m, 1H). LCMS m/z = 348 [MH]+; RT [Analytical SFC Method G] = 4.089 min. [a]2%-18.0 (c = 0.1, EtOH).
Example 16: (-) 4-(3-fluoro-5-methoxy-6-propoxy-[2,3'-bipyridin]-5'-yl)-1,2-oxaborolan-2-ol, enantiomer 1
4-(3-fluoro-5-methoxy-6-propoxy-[2,3'-bipyridin]-5'-yl)-1,2-oxaborolan-2-ol (Example 48, 770 mg, 2.22 mmol) was further purified by préparative SFC (Prep SFC Method M) to afford 415 (3-fluoro-5-methoxy-6-propoxy-[2,3'-bipyridin]-5'-yl)-1,2-oxaborolan-2-ol, enantiomer 1 (298 mg, 39%). Ή NMR (DMSO-de, 400MHz): δ 8.89 (s, 1 H), 8.73 (s, 1 H), 8.49 (d, J = 2.0 Hz, 1 H), 8.09 (s, 1H), 7.49 (d, J = 12.0 Hz, 1H), 4.28-4.33 (m, 3H), 3.87 (s, 3H), 3.82 (t, J = 8.7 Hz, 1H), 3.493.57 (m, 1H), 1.73-1.81 (m, 2H), 1.31-1.37 (m, 1H), 1.03-1.09 (m, 1H), 0.98 (t, J= 7.5 Hz, 3H). LCMS m/z = 347 [MH]+; RT [Analytical SFC Method D] = 4.347 min. [α]2%-12.1 (c = 0.1, EtOH).
Example 17: (-) 4-(5-(4-(difluoromethoxy)-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol, enantiomer 1
4-(5-(4-(difluoromethoxy)-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol (Example
50, 506 mg, 1.39 mmol) was further purified by préparative SFC (Prep SFC Method N) to afford
4-(5-(4-(difluoromethoxy)-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol, enantiomer 1 (165 mg, 33%). Ή NMR (DMSO-d6, 400MHz): δ 8.74 (d, J = 2.1Hz, 1H), 8.72 (s, 1H), 8.49 (d, J = 2.0Hz, 1 H), 8.00 (t, J = 2.0Hz, 1 H), 7.45 (d, J = 1,6Hz, 1 H), 7.28-7.31 (m, 2H), 7.09 (t, J =
194
J 74.5Hz, 1H), 4.28 (t, J= 8.3Hz, 1H), 4.12 (t, J = 6.4Hz, 2H), 3.87 (t, J = 9.1Hz, 1H), 3.47-3.56 (m, 1H), 1.73-1.82 (m, 2H), 1.29-1.35 (m, 1H), 1.12-1.19 (m, 1H), 1.01 (t, J = 7.5Hz, 3H). LCMS m/z = 381 [MH+H2O]+; RT [Analytical SFC Method E] = 3.402 min. [α]2%-21.2 (c = 0.1, EtOH).
Example 18: (-) 4-(6'-methoxy-5'-propoxy-[3,3'-bipyridin]-5-yl)-1,2-oxaborolan-2-ol, enantiomer 1
OH /°V% rB
II */ b
4-(6'-Methoxy-5'-propoxy-[3,3'-bipyridin]-5-yl)-1,2-oxaborolan-2-ol (Example 51, 1.1 g, 3.4 mmol) was further purified by préparative SFC (Prep SFC Method O) to afford 4-(6'10 methoxy-5'-propoxy-[3,3'-bipyridin]-5-yl)-1,2-oxaborolan-2-ol, enantiomer 1 (411 mg, 37%). 1H NMR (DMSO-ds, 400MHz): δ 8.76 (d, J = 2.2 Hz, 1 H), 8.72 (s, 1 H), 8.48 (d, J = 2.0 Hz, 1 H), 8.06 (d, J= 2.0 Hz, 1H), 8.01 (t, J= 2.2 Hz, 1H), 7.61 (d, J= 2.2 Hz, 1H), 4.26-4.31 (m, 1H), 4.08 (t, J = 6.6 Hz, 2H), 3.92 (s, 3H), 3.87 (t, J = 9.1 Hz, 1H), 3.48-3.56 (m, 1H), 1.73-1.82 (m, 2H), 1.28-1.35 (m, 1H), 1.13-1.21 (m, 1H), 1.00 (t, J= 7.5 Hz, 3H). LCMS m/z = 347
[MH+H2O]+; RT [Analytical SFC Method G] = 4.231 min. [α]2%-27.2 (c = 0.1, EtOH).
Example 19: (R)-4-(5-(3-ethoxy-4-methoxyphenyl)-6-methylpyridin-3-yl)-1,2-oxaborolan-2-ol, enantiomer 1
OH r-B IA JC /°
4-(5-(3-ethoxy-4-methoxyphenyl)-6-methylpyridin-3-yl)-1,2-oxaborolan-2-ol (Example 52,
171.7 mg, 0.53 mmol) was further purified by préparative SFC (Prep SFC Method P) to afford 4(5-(3-ethoxy-4-methoxyphenyl)-6-methylpyridin-3-yl)-1,2-oxaborolan-2-ol, enantiomer 1, (66 mg, 36%). The material was recrystallized from EtOAc/heptane to afford a crystalline solid. 1H NMR (DMSO-d6, 400MHz): δ 8.67 (s, 1 H), 8.33 (d, J = 2.0 Hz, 1 H), 7.47 (d, J = 2.0 Hz, 1 H), 7.03 (d, J = 8.3 Hz, 1H), 6.94 (d, J= 2.0 Hz, 1H), 6.88 (dd, J= 2.0, 7.8 Hz, 1H), 4.24 (t, J = 8.1 Hz, 1H),
4.04 (q, J= 6.9 Hz, 2H), 3.76-3.83 (m, 4H), 3.39-3.50 (m, 1H), 2.40 (s, 3H), 1.24-1.36 (m, 4H), 1.01-1.10 (m, 1H). LCMS m/z = 328 [MH]+; RT [Analytical SFC Method H] = 1.768 min. [α]2%20.0 (c = 0.4, EtOH).
Example 20: (S)-4-(5-(3-ethoxy-4-methoxyphenyl)-6-methylpyridin-3-yl)-1,2-oxaborolan-2-ol, enantiomer 2
195
OH /
B O
Further elution ofthe préparative SFC column (Prep SFC Method P) described in Example 19 provided 4-(5-(3-ethoxy-4-methoxyphenyl)-6-methylpyridin-3-yl)-1,2-oxaborolan-2ol, enantiomer 2, (69 mg, 40%). 1H NMR (DMSO-d6, 400MHz): δ 8.67 (s, 1H), 8.33 (d, J = 2.0 Hz, 1 H), 7.47 (d, J = 2.0 Hz, 1 H), 7.03 (d, J = 8.3 Hz, 1 H), 6.94 (d, J = 2.0 Hz, 1 H), 6.88 (dd, J = 2.0, 7.8 Hz, 1H), 4.24 (t, J= 8.1 Hz, 1H), 4.04 (q, J= 6.9 Hz, 2H), 3.76-3.83 (m, 4H), 3.39-3.50 (m, 1H), 2.40 (s, 3H), 1.24-1.36 (m, 4H), 1.01-1.10 (m, 1H). LCMS m/z = 328 [MH]+; RT [Analytical SFC Method H] = 2.168 min.
Example 21: 4-(5-(3-ethoxy-4-methoxyphenyl)-4-methylpyridin-3-yl)-1,2-oxaborolan-2-ol, enantiomer 1
4-(5-(3-ethoxy-4-methoxyphenyl)-4-methylpyridin-3-yl)-1,2-oxaborolan-2-ol (Example 53, 45 mg, 0.14 mmol) was further purified by préparative SFC (Prep SFC Method I) to afford 4-(5(3-ethoxy-4-methoxyphenyl)-4-methylpyridin-3-yl)-1,2-oxaborolan-2-ol, enantiomer 1 (12.5 mg, 28%). Ή NMR (DMSO-c/6, 400MHz): δ 8.71 (s, 1H), 8.43 (s, 1H), 8.21 (s, 1H), 7.04 (d, J = 8.0 Hz, 1H), 6.90 (d, J= 2.3 Hz, 1H), 6.82-6.85 (m, 1H), 4.24-4.28 (m, 1H), 4.03 (q, J= 7.0 Hz, 2H), 3.90-3.95 (m, 1H), 3.80 (s, 3H), 3.63-3.71 (m, 1H), 2.22 (s, 3H), 1.30-1.36 (m, 4H), 1.04-1.10 (m, 1H). LCMS m/z = 328 [MH]+; RT [Analytical SFC Method I] = 5.208 min.
Example 22: (-) 4-(2-(4-methoxy-3-propoxyphenyl)-6-methylpyrimidin-4-yl)-1,2-oxaborolan-2-ol, enantiomer 2
4-(2-(4-methoxy-3-propoxyphenyl)-6-methylpyrimidin-4-yl)-1,2-oxaborolan-2-ol (Example 54, 2.5 g, 7.28 mmol) was further purified by préparative SFC (Prep SFC Method Q) to afford 4(2-(4-methoxy-3-propoxyphenyl)-6-methylpyrimidin-4-yl)-1,2-oxaborolan-2-ol, enantiomer 2 (68 mg, 22%). 1H NMR (CD3OD, 400MHz): δ 8.03 (dd, J = 2.0, 8.6 Hz, 1 H), 8.00 (d, J = 2.0 Hz, 1 H), 7.07 (s, 1H), 7.05 (d, J= 8.3 Hz, 1H), 4.17 (br s, 1H), 4.07 (t, J= 6.5 Hz, 2H), 4.00 (br s, 1H),
196
3.91 (s, 2H), 3.41 (brs, 1H), 2.52 (s, 2H), 1.84-1.89 (m, 2H), 1.29-1.38 (m, 1H), 1.21-1.29 (m,
H), 1.09 (t, J = 7.3 Hz, 3H). LCMS m/z = 343 [MH]+; RT [Analytical SFC Method J] = 3.148 min. [α]2%-23.2 (c= 0.1, EtOH).
Example 23: (-) 4-(2-(4-methoxy-3-propoxyphenyl)-6-(trifluoromethyl)pyrimidin-4-yl)-1,2oxaborolan-2-ol, enantiomer 2
4-(2-(4-methoxy-3-propoxyphenyl)-6-(trifluoromethyl)pyrimidin-4-yl)-1,2-oxaborolan-2-ol (Example 55, 572 mg, 1.45 mmol) was further purified by préparative SFC (Prep SFC Method M) to afford 4-(2-(4-methoxy-3-propoxyphenyl)-6-(trifluoromethyl)pyrimidin-4-yl)-1,2-oxaborolan2-ol, enantiomer 2 (100 mg, 18%). 1H NMR (DMSO-d6, 400MHz): δ 8.72 (s, 1H), 8.03 (dd, J = 2.0, 8.6 Hz, 1H), 7.95 (d, J = 2.0 Hz, 1H), 7.77 (s, 1H), 7.13 (d, J= 8.6 Hz, 1H), 4.32 (dd, J = 7 A, 9.0 Hz, 1H), 3.98-4.09 (m, 3H), 3.86 (s, 3H), 3.73-3.82 (m, 1H), 1.73-1.84 (m, 1H), 1.311.41 (m, 1H), 1.18-1.26 (m, 2H), 1.01 (t, J = 7.4 Hz, 3H). LCMS m/z = 397 [MH]+; RT [Analytical SFC Method E] = 4.765 min. [a]20D-12.6 (c = 0.4, EtOH).
Example 24: 4-(6-(3-ethoxy-4-methoxyphenyl)pyrazin-2-yl)-1,2-oxaborolan-2-ol, enantiomer 2
4-(6-(3-Ethoxy-4-methoxyphenyl)pyrazin-2-yl)-1,2-oxaborolan-2-ol (Example 56, 20 mg, 0.06 mmol) was further purified by préparative SFC (Prep SFC Method R) to afford 4-(6-(3ethoxy-4-methoxyphenyl)pyrazin-2-yl)-1,2-oxaborolan-2-ol, enantiomer 2 (6.4 mg, 34%). LCMS m/z = 315 [MH]+. RT [Analytical SFC Method K] = 3.23 min.
Example 25: 4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborol-2(5H)-ol
A mixture of 3-(3-((tert-butyldimethylsilyl)oxy)-1-(4,4,5,5-tetramethyl-l ,3,2-dioxaborolan2-yl)prop-1-en-2-yl)-5-(4-methoxy-3-propoxyphenyl)pyridine (Préparation 8, 1.30 g, 2.41 mmol)
197 in AcOH (10 mL) and water (5 mL) was stirred at about 50 °C for about 1 h. The mixture was concentrated and EtOH (10 mL) was added. The mixture was stirred at about 0 °C for about 15 min and filtered. The solid was washed with water (15 mL) and dried to afford 4-(5-(4-methoxy3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborol-2(5H)-ol (560 mg, 68%). 1H NMR (DMSO-de, 400MHz): δ 8.86 (d, J= 2.0 Hz, 1H), 8.77 (s, 1H), 8.73 (d, J = 2.0 Hz, 1H), 8.14 (t, J =2.0 Hz, 1H), 7.31-7.34 (m, 2H), 7.08 (d, J= 8.0 Hz, 1H), 6.46 (s, 1H), 5.02 (s, 2H), 4.05 (t, J = 6.4 Hz, 2H), 3.82 (s, 3H), 1.72-1.81 (m, 2H), 1.01 (t, J = 7.6 Hz, 3H). LCMS m/z = 326 [MH]+.
Example 26: 4-(6-(4-methoxy-3-propoxyphenyl)pyridin-2-yl)-1,2-oxaborinan-2-ol
2-(4-((tert-butyldimethylsilyl)oxy)-1-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butan-2yl)-6-(4-methoxy-3-propoxyphenyl)pyridine (Préparation 31, 140 mg, 0.25 mmol) was dissolved in AcOH (4.3 mL) and water (0.2 mL) and stirred at about 20 °C for about 16 h. The mixture was concentrated and the residue was purified by preparative HPLC (Prep HPLC Method B) to afford 4-(6-(4-methoxy-3-propoxyphenyl)pyridin-2-yl)-1,2-oxaborinan-2-ol (60 mg, 70%). 1H NMR (DMSO-d6, 400MHz): δ 7.71-7.76 (m, 4H), 7.64-7.66 (m, 1H), 7.15-7.17 (m, 1H), 7.03 (d, J = 8.6Hz, 1H), 4.02 (t, J = 6.6Hz, 2H), 3.64-3.98 (m, 2H), 3.81 (m, 3H), 3.13-3.20 (m, 1H), 1.922.00 (m, 1H), 1.72-1.82 (m, 3H), 1.09 (d, J = 7.0Hz, 2H), 1.00 (t, J = 7.4Hz, 3H). LCMS m/z = 342 [MH]+.
Example 27: 4-(6-(4-methoxy-3-propoxyphenyl)pyridin-2-yl)-3-methyl-1,2-oxaborolan-2-ol
A mixture of 4-(6-(4-methoxy-3-propoxyphenyl)pyridin-2-yl)-3-methyl-1,2-oxaborol-2(5H)ol (Example 28, 50 mg, 0.15 mmol) and Adam’s catalyst (10.0 mg, 0.044 mmol) in EtOAc (1.5 mL) was hydrogenated at 20 psig at about 40 °C for about 2 h. The reaction was filtered through a Celite® pad and the filtrate was concentrated. The residue was purified by column chromatography (silica) and eluted with heptane/EtOAc (80:20 to 0:100) followed by DCM/MeOH (90:10) to afford 4-(6-(4-methoxy-3-propoxyphenyl)pyridin-2-yl)-3-methyl-1,2oxaborolan-2-ol (40 mg, 80%). 1H NMR (CDCh, 400 MHz): δ 7.73 (br s, 1H), 7.51-7.66 (m, 4H), 6.92-7.00 (m, 2H), 4.36 (d, J= 3.1 Hz, 2H), 4.12 (t, J= 6.8 Hz, 2H), 3.92 (s, 3H), 3.56 (br s, 1H), 1.87-1.96 (m, 2H), 1.70-1.80 (m, 1 H), 1.08 (t, J = 7.4 Hz, 3H), 0.80 (d, J = 7.0 Hz, 3H). LCMS m/z = 342 [MH]+.
198
199
Example 28: 4-(6-(4-methoxy-3-propoxyphenyl)pyridin-2-yl)-3-methyl-1,2-oxaborol-2(5H)-ol
4-(6-(4-methoxy-3-propoxyphenyl)pyridin-2-yl)-3-methyl-1,2-oxaborol-2(5H)-ol (105 mg, 46%) was prepared in an analogous manner to Example 25 using 3-(1 -((tertbutyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)but-2-en-2-yl)-5-(4methoxy-3-propoxyphenyl)pyridine (Préparation 32, 370 mg, 0.668 mmol). 1H NMR (DMSO-de, 400MHz): δ 8.71 (s, 1 H), 7.86-7.91 (m, 2H), 7.75 (d, J = 2.0 Hz, 1 H), 7.67 (dd, J = 2.0, 8.6 Hz, 1 H), 7.36-7.44 (m, 1 H), 7.07 (d, J = 8.6 Hz, 1 H), 4.95 (d, J = 2.0 Hz, 2H), 4.02 (t, J = 6.6 Hz, 2H), 3.82 (s, 3H), 2.15 (s, 3H), 1.71-1.85 (m, 2H), 1.01 (t, J= 7 A Hz, 3H). LCMS m/z = 340 [MH]+.
Example 29: 4-(6-(4-methoxy-3-propoxyphenyl)pyridin-2-yl)-4-methyl-1,2-oxaborolan-2-ol
To a solution of ethyl 2-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-2-methyl-3-(4,4,5,5tetramethyl-1,3,2-dioxaborolan-2-yl)propanoate (Préparation 33, 134 mg, 0.277 mmol) in THF (3.0 mL) at about 20 °C was added LiBH4 (6.0 mg, 0.28 mmol), followed by water (0.10 mL). The reaction mixture was stirred at about 20 °C for about 3 h. Another portion of LiBH4 (25 mg, 1.15 mmol) and water (0.2 mL) was added. The mixture was stirred at about 20 °C for about 5 min. Another portion of LiBH4 (25 mg, 1.15 mmol) and water (0.3 mL) was added and stirred at about 20 °C for about 10 min. The mixture was diluted with water and extracted with EtOAc. The EtOAc extract was washed with brine and dried over Na2SO4. The mixture was filtered, concentrated and dissolved in THF (3 mL) and water (1 mL).The solution was treated with excess L1BH4 at about 20 °C for about 3 h. The mixture was diluted with water and extracted with EtOAc. The EtOAc extract was washed with brine, dried over Na2SO4, filtered and concentrated. The residue was purified by préparative HPLC (Prep HPLC Method C) to afford 4(6-(4-methoxy-3-propoxyphenyl)pyridin-2-yl)-4-methyl-1,2-oxaborolan-2-ol (46.1 mg, 49%). 1H NMR (CD3OD, 500MHz): δ 7.80 (br s, 1H), 7.74 (d, J= 1.5 Hz, 1H), 7.67 (d, J= 8.1 Hz, 1H), 7.62 (m, 1H), 7.32 (d, J= 7.1 Hz, 1H), 7.07 (d, J= 8.3 Hz, 1H), 5.51 (s, 1H), 4.29 (d, J = 8.8 Hz, 1H), 4.07-4.16 (m, 3H), 3.92 (s, 3H), 3.47 (m, 1H), 3.19 (m, 1H), 1.88 (m, 2H), 1.55 (d, J= 16.1 Hz, 1H), 1.51 (s, 3H), 1.20 (d, J = 15.7 Hz, 1H), 1.10 (t, J = 7.3 Hz, 3H). LCMS m/z = 342 [MH]+.
200
Example 30: 4-(6-(4-methoxy-3-propoxyphenyl)pyridazin-4-yl)-5-methyl-1,2-oxaborolan-2-ol
A mixture of 5-(3-((tert-butyldimethylsilyl)oxy)-1 -(4,4,5,5-tetramethyl-l,3,2-dioxaborolan2-yl)butan-2-yl)-3-(4-methoxy-3-propoxyphenyl)pyridazine (Préparation 34, 160 mg, 0.29 mmol) in AcOH (6 mL) and water (1 mL) was stirred at about 70 °C for about 21 h. The mixture was concentrated, dissolved in MeCN (15 mL) and concentrated again. The mixture was purified by préparative HPLC (Prep HPLC Method D) to afford 4-(6-(4-methoxy-3-propoxyphenyl)pyridazin4-yl)-5-methyl-1,2-oxaborolan-2-ol (10.6 mg, 11%). Ή NMR (DMSO-d6, 400MHz): δ 9.12 (s, 1H), 9.05 (d, J = 2.0 Hz, 1H), 8.77 (s, 1H), 8.69 (s, 1H), 8.13 (s, 1H), 7.98 (s, 1 H), 7.68-7.81 (m, 3H), 7.07-7.16 (m, 2H), 4.64 (t, J = 6.5 Hz, 1H), 4.25-4.35 (m, 1H), 4.04 (t, J = 6.5 Hz, 3H), 3.84 (s, 5H), 3.64 (d, J= 9.0 Hz, 1H), 2.92-3.01 (m, 1H), 1.74-1.83 (m, 3H), 1.48 (dd, J= 10.0, 16.1 Hz, 1H), 1.24-1.39 (m, 2H), 1.17 (d, 4 = 6.0 Hz, 3H), 1.01 (t, 4 = 7.0 Hz, 6H), 0.77 (d, 4 = 7.0 Hz, 1H). LCMS m/z = 343 [MH]+.
Example 31: 4-(hydroxymethyl)-4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan2-ol
Turbo Grignard (0.5 mL, 1.3 M in THF) was stirred with anhydrous 1,4-dioxane (0.05 mL) at about 20 °C under N2 for about 30 min to afford a mixture which was used directly in the following procedure (Reagent A). To a solution of 3-(5-(iodomethyl)-2,2-dimethyl-1,3-dioxan-5yl)-5-(4-methoxy-3-propoxyphenyl)pyridine (Préparation 77, 120 mg, 0.25 mmol) in THF (0.50 mL) under N2 was added Reagent A. The mixture was stirred at about 20 °C for about 1 h. Trimethyl borate (0.33 mL, 2.98 mmol) was added and stirred at about 20 °C under N2 for about 1 h. The cooled mixture was treated with HCl in IPA (5.5 M, 0.45 mL, 2.48 mmol) for about 1 h. The mixture was diluted with 1 M HCl and washed with EtOAc. The EtOAc layer was extracted with 1 M HCl (2x5 mL). The combined aqueous extracts were neutralized to pH 6-7 with K3PO4. The aqueous extract was extracted with EtOAc (3x10 mL). The combined EtOAc extracts were dried over Na2SO4, filtered and concentrated. The residue was purified by préparative SFC (Prep SFC Method S) to afford 4-(hydroxymethyl)-4-(5-(4-methoxy-3propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol (38 mg, 43%). 1H NMR (DMSO-de, 400MHz): δ 8.69 (d, 4= 2.0 Hz, 1H), 8.63 (s, 1H), 8.37 (d, 4 = 2.0 Hz, 1H), 7.75 (m, 1H), 7.19 - 7.28 (m, 2H),
201
7.08 (d, J= 8.6 Hz, 1H), 4.99 (m, 1H), 4.39 (d, J = 9.0 Hz, 1H), 4.00 - 4.13 (m, 4H), 3.82 (s, 3H),
3.47 (brs, 2H), 1.77 (m, 2H), 1.28- 1.38 (m, 1H), 1.14-1.22 (m, 1 H), 0.96 - 1.08 (m, 3H). LCMS m/z = 358 [MH]+.
Example 32: 4-(5-(3,4-dimethoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol
A mixture of 3-(1-((tert-butyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan2-yl)propan-2-yl)-5-(3,4-dimethoxyphenyl)pyridine (Préparation 1, 1.0 g, 1.95 mmol) in AcOH (15 mL), THF (5 mL) and water (5 mL) was stirred at about 55 °C for about 6 h. The mixture was concentrated and the residue was purified by préparative HPLC (Prep HPLC Method E) to afford 4-(5-(3,4-dimethoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol (98 mg, 17%). 1H NMR (DMSO-d6, 400MHz): δ 8.72 (d, J = 2.8 Hz, 2H), 8.43 (d, J = 2.0 Hz, 1 H), 7.95 (t, J = 2.0 Hz, 1 H), 7.25-7.29 (m, 1 H), 7.06 (d, J = 8.4 Hz, 2H), 4.28 (t, J = 4.28 Hz, 1 H), 3.84-3.88 (m, 4H), 3.80 (s, 3H), 3.46-3.54 (m, 1H), 1.28-1.34 (m, 1H), 1.12-1.18 (m, 1H). LCMS m/z = 300 [MH]+
Example 33: 4-(5-(3-ethoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol
A mixture of 3-(1-((tert-butyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan2-yl)propan-2-yl)-5-(3-ethoxy-4-methoxyphenyl)pyridine (Préparation 3, 3.80 g, 7.20 mmol) in AcOH (60 mL) and water (10 mL) was stirred at about 50 °C for about 1 h. The mixture was concentrated and the residue was purified by préparative HPLC (Prep HPLC Method F) to afford 4-(5-(3-ethoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol (810 mg, 34%). 1H NMR (DMSO-de, 400MHz): δ 8.70 (d, J = 2.3 Hz, 1 H), 8.68 (s, 1 H), 8.42 (d, J = 1.6 Hz, 1 H), 7.92-7.94 (m, 1H), 7.23-7.29 (m, 2H), 7.06 (d, J = 8.2 Hz, 1H), 4.28 (t, J = 8.2 Hz, 1H), 4.13 (q, J = 6.8 Hz, 2H), 3.86 (t, J= 9.0 Hz, 1H), 3.80 (s, 3H), 3.45-3.55 (m, 1H), 1.28-1.39 (m, 4H), 1.1 ΟΙ.20 (m, 1H). LCMS m/z = 314 [MH]+.
Example 34: 4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol
202
A mixture of 3-(1-((tert-butyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan2-yl)propan-2-yl)-5-(4-methoxy-3-propoxyphenyl)pyridine (Préparation 5, 3.44 g, 6.35 mmol) in AcOH (60 mL) and water (10 mL) was stirred at about 50 °C for about 1 h. The mixture was concentrated and the residue was purified by préparative HPLC (Prep HPLC Method G) to afford 4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol (1.04 g, 49%). 1H NMR (DMSO-c/s, 400MHz): δ 8.70 (d, J = 2.3 Hz, 1 H), 8.68 (s, 1 H), 8.42 (d, J = 2.0 Hz, 1 H), 7.93 (s, 1 H), 7.27 (d, J = 2.0 Hz, 1 H), 7.23-7.26 (m, 1 H), 7.06 (d, J = 8.2 Hz, 1 H), 4.28 (t, J = 8.2 Hz, 1H), 4.03 (t, J= 6.4 Hz, 2H), 3.86 (t, J= 9.0 Hz, 1H), 3.81 (s, 3H), 3.46-3.54 (m, 1H), 1.7110 1.80 (m, 2H), 1.28-1.35 (m, 1H), 1.15 (dd, J= 10.5, 16.4 Hz, 1H), 1.00 (t, J = 7.4 Hz, 3H). LCMS m/z = 328 [MH]+.
Example 35: 4-(5-(3-isopropoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol
4-(5-(3-isopropoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol (103 mg, 43%) was prepared in an analogous manner to Example 33 using 3-(1-((tert-butyldimethylsilyl)oxy)-3(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-2-yl)-5-(3-isopropoxy-4methoxyphenyl)pyridine (Préparation 9, 400 mg, 0.74 mmol) and purified by préparative HPLC (Prep HPLC Method H). Ή NMR (DMSO-d6, 400MHz): δ 8.72 (s, 1H), 8.69 (d, J = 2.0 Hz, 1H),
8.42 (d, J = 2.0 Hz, 1 H), 7.92 (t, J = 2.0 Hz, 1 H), 7.29 - 7.24 (m, 2H), 7.07 (d, J = 8.0 Hz, 1 H),
4.68-4.74 (m, 1 H), 4.27 (t, J = 8.3 Hz, 1 H), 3.86 (t, J = 9.0 Hz, 1 H), 3.79 (s, 3H), 3.47-3.55 (m, 1H), 1.26-1.35 (m, 7H), 1.10-1.18 (m, 1 H). LCMS m/z = 328 [MH]+.
Example 36: 4-(5-(3-cyclopropoxy-4-methoxyphenyl)pyridin-3-yI)-1,2-oxaborolan-2-ol
4-(5-(3-cyclopropoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol (45 mg, 10 %) was prepared in an analogous manner to Example 33 using 3-(1-((tert-butyldimethylsilyl)oxy)-3(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-2-yl)-5-(3-cyclopropoxy-425
203 methoxyphenyl)pyridine (Préparation 10, 750 mg, 1.39 mmol) and purified by préparative HPLC (Prep HPLC Method I). Ή NMR (DMSO-d6, 400MHz): δ 8.69-8.72 (m, 2H), 8.44 (d, J = 2.0 Hz, 1 H), 7.91 (t, J = 2.0 Hz, 1 H), 7.53 (d, J = 2.0 Hz, 1 H), 7.28 (dd, J = 2.4, 8.3 Hz, 1 H), 7.07 (d, J = 8.8 Hz, 1 H), 4.25-4.31 (m, 1 H), 3.97-4.01 (m, 1 H), 3.86 (t, J = 8.8 Hz, 1 H), 3.78 (s, 3H), 3.463.57 (m, 1H), 1.32 (dd, J = 8.1, 16.4 Hz, 1H), 1.14 (dd, J = 10.3, 16.1 Hz, 1 H), 0.76-0.83 (m, 2H), 0.67-0.72 (m, 2H). LCMS m/z = 326 [MH]+.
Example 37: 4-(5-(3-(2-hydroxyethoxy)-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol
4-(5-(3-(2-hydroxyethoxy)-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol (1.5 g, 75%) was prepared in an analogous manner to Example 33 using 3-(1-((tertbutyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)propan-2-yl)-5-(3-(2-((tertbutyldimethylsilyl)oxy)ethoxy)-4-methoxyphenyl)pyridine (Préparation 11, 4.0 g, 6.1 mmol) and purified by préparative HPLC (Prep HPLC Method J). 1H NMR (DMSO-de, 400MHz): δ 8.70-8.72 (m, 2H), 8.42 (d, J = 2.0 Hz, 1 H), 7.94 (t, J = 2.2 Hz, 1 H), 7.30 (d, J = 2.0 Hz, 1 H), 7.26 (dd, J = 2.1, 8.4 Hz, 1 H), 7.07 (d, J = 8.6 Hz, 1 H), 4.88 (t, J = 5.4 Hz, 1 H), 4.25-4.30 (m, 1 H), 4.09 (t, J = 5.0 Hz, 2H), 3.86 (t, J = 9.0 Hz, 1 H), 3.81 (s, 3H), 3.75 (q, J = 5.2 Hz, 2H), 3.46-3.53 (m, 1 H), 1.28-1.34 (m, 1H), 1.15 (dd, 4=10.5, 16.1 Hz, 1H). LCMS m/z = 330 [MH]+.
Example 38: 4-(5-(3-(3-hydroxypropoxy)-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol
4-(5-(3-(3-hydroxypropoxy)-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol (2.5 g, 41%) was prepared in an analogous manner to Example 33 using 3-(1-((tertbutyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)propan-2-yl)-5-(3-(3-((tertbutyldimethylsilyl)oxy)propoxy)-4-methoxyphenyl)pyridine (Préparation 12, 12 g, 18.0 mmol) and purified by préparative HPLC (Prep HPLC Method K). 1H NMR (DMSO-de, 400MHz): δ 8.68-8.72 (m, 2H), 8.43 (d, J = 2.0 Hz, 1 H), 7.94 (t, J = 2.0 Hz, 1 H), 7.29 (d, J = 2.0 Hz, 1 H), 7.23-7.27 (m, 1H), 7.06 (d, J= 8.5 Hz, 1H), 4.55 (t, J= 5.1 Hz, 1H), 4.27 (t, J = 8.3 Hz, 1H), 4.14 (t, J = 6.4 Hz, 2H), 3.86 (t, J = 9.0 Hz, 1 H), 3.80 (s, 3H), 3.58 (q, J = 6.0 Hz, 2H), 3.44-3.55 (m, 1H), 1.86-1.92 (m, 2H), 1.27-1.35 (m, 1H), 1.11-1.19 (m, 1H). LCMS m/z = 344 [MH]+.
204
Example 39: 4-(5-(3-(2-fluoroethoxy)-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol
4-(5-(3-(2-fluoroethoxy)-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol (122 mg, 29%) was prepared in an analogous manner to Example 33 using 3-(1-((tert5 butyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-2-yl)-5-(3-(2fluoroethoxy)-4-methoxyphenyl)pyridine (Préparation 13, 700 mg, 1.28 mmol) and purified by préparative HPLC (Prep HPLC Method L). 1H NMR (DMSO-d6, 400MHz): δ 8.71-8.78 (m, 2H), 8.44 (d, J= 1.5 Hz, 1H), 7.96 (t, J = 2.0 Hz, 1H), 7.30-7.37 (m, 2H), 7.10 (d, 4= 8.0 Hz, 1H), 4.81-4.87 (m, 1 H), 4.70-4.75 (m, 1 H), 4.38-4.43 (m, 1 H), 4.30-4.34 (m, 1 H), 4.27 (d, J = 8.5 Hz, 10 1H), 3.87 (t, J= 9.0 Hz, 1H), 3.83 (s, 3H), 3.47-3.57 (m, 1H), 1.32 (dd, J= 8.3, 16.3 Hz, 1H),
1.10 -1.21 (m, 1H). LCMS m/z = 332 [MH]+.
Example 40: 4-(3'-(3-fluoropropoxy)-4'-methoxy-[1,1'-biphenyl]-3-yl)-1,2-oxaborolan-2-ol
4-(3'-(3-fluoropropoxy)-4'-methoxy-[1,1'-biphenyl]-3-yl)-1,2-oxaborolan-2-ol was prepared in an analogous manner Example 33 using tert-butyl(2-(3'-(3-fluoropropoxy)-4'-methoxy-[1,1'biphenyl]-3-yl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propoxy)dimethylsilane (Préparation 14). Ή NMR (DMSO-c/6, 400MHz): δ 7.50 (brs, 1H), 7.46 (d, J= 7.8 Hz, 1H), 7.35 (t, J = 7.8 Hz, 1H) 7.18-7.25 (m, 3H), 7.04 (d, J = 8.2 Hz, 1H), 4.69 (t, 4= 5.9 Hz, 1H), 4.57 (t, J = 5.9 Hz, 1H), 4.26 (t, 4= 7.8 Hz, 1H), 4.02-4.18 (m, 3H), 3.80 (s, 3H), 3.42-3.51 (m, 1H), 2.07-
2.19 (m, 2H), 1.22-1.32 (m, 1H), 1.05-1.12 (m, 1H). LCMS m/z = 345 [MH]+.
Example 41: 4-(5-(2-(difluoromethyl)-3-ethoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2ol
4-(5-(2-(difluoromethyl)-3-ethoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol was prepared (80 mg, 42%) in an analogous manner to Example 33 using 3-(1-((tertbutyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-2-yl)-5-(2(difluoromethyl)-3-ethoxy-4-methoxyphenyl)pyridine (Préparation 15, 300 mg, 0.519 mmol) and
205 purified by préparative HPLC (Prep HPLC Method M). 1H NMR (DMSO-d6, 400MHz): δ 8.69 (s,
H), 8.48 (d, J = 2.0 Hz, 1 H), 8.34 (d, J = 1.5 Hz, 1 H), 7.61 (s, 1 H), 7.31 (d, J = 8.8 Hz, 1 H), 6.80-7.14 (m, 2H), 4.27 (t, J = 8.3 Hz, 1 H), 4.08 (q, J = 6.8 Hz, 2H), 3.89 (s, 3H), 3.80 (t, J = 8.8 Hz, 1H), 3.45-3.54 (m, 1H), 1.25-1.38 (m, 4H), 1.00-1.12 (m, 1H). LCMS m/z = 364 [MH]+.
Example 42: 3'-(2-hydroxy-1,2-oxaborolan-4-yl)-4-methoxy-3-propoxy-[1,1'-biphenyl]-2carbonitrile
To a solution of 3'-(2-hydroxy-2,5-dihydro-1,2-oxaborol-4-yl)-4-methoxy-3-propoxy-[1,Tbiphenyl]-2-carbonitrile (Example 43, 500 mg, 1.43 mmol) in EtOAc (15 mL) was added PtO2 (16 mg, 72 umol) under N2. The mixture was stirred under H2 (15 psi) at about 0 °C for about 2 h. The mixture was filtered and concentrated. The residue was purified by préparative HPLC (Prep HPLC Method N) to afford 3'-(2-hydroxy-1,2-oxaborolan-4-yl)-4-methoxy-3-propoxy-[1,1'biphenyl]-2-carbonitrile (284 mg, 55%). 1H NMR (DMSO-de, 400MHz): δ 7.45 (d, J = 8.8 Hz, 2H), 7.41 (d, J = 7.2 Hz, 1 H), 7.34 (t, J = 7.2 Hz, 2H), 7.26 (d, J = 8.8 Hz, 1 H), 4.26 (t, J = 8.0 Hz, 1H), 4.12 (t, J= 6.0 Hz, 2H), 3.89 (s, 3H), 3.81 (t, J= 8.8 Hz, 1H), 3.43-3.52 (m, 1H), 1.691.78 (m, 2H), 1.29 (q, J= 8.0 Hz, 1H). 1.07-1.11 (m, 1H), 1.01 (t, J= 7.6 Hz, 3H). LCMS m/z = 352 [MH]+.
Example 43: 3'-(2-hydroxy-2,5-dihydro-1,2-oxaborol-4-yl)-4-methoxy-3-propoxy-[1,1'-biphenyl]2-carbonitrile
To a mixture of methyl 2-(2'-cyano-4'-methoxy-3'-propoxy-[1,1'-biphenyl]-3-yl)-3-(4,4,5,5tetramethyl-1,3,2-dioxaborolan-2-yl)acrylate (Préparation 30, 13.6 g, 28.5 mmol) in THF (150 mL) and MeOH (5 mL) was added NaBH4 (754 mg, 19.9 mmol) slowly at about 0 °C. The mixture was stirred at about 20 °C for about 1 h. Water (150 mL) was added and the mixture was extracted with EtOAc (2 x 150 mL). The combined EtOAc extracts were washed with brine (150 mL), dried with Na2SO4, filtered and concentrated. The residue was purified by column chromatography (silica) and eluted with pet. ether/EtOAc (10:1), then re-crystallized from EtOH (30 mL) at about 0 °C to afford 3'-(2-hydroxy-2,5-dihydro-1,2-oxaborol-4-yl)-4-methoxy-3propoxy-[1,1'-biphenyl]-2-carbonitrile (2.60 g, 26%). 1H NMR (DMSO-de, 400MHz): δ 8.71 (s,
206
H), 7.70 (s, 1 H), 7.64-7.65 (m, 1 H), 7.53 (d, J = 4.4 Hz, 2H), 7.48 (d, J = 8.4 Hz, 1 H), 7.33 (d, J = 8.4 Hz, 1H), 6.27 (s, 1H), 4.95 (s, 2H), 4.13 (t, J = 6.4 Hz, 2H), 3.91 (s, 3H), 1.69-1.77 (m, 2H), 1.02 (t, J= 7.2 Hz, 3H). LCMS m/z = 350 [MH]+.
207
Example 44: 4-(5-(3-ethoxy-5-fluoro-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol
4-(5-(3-ethoxy-5-fluoro-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol (90 mg, 25%) was prepared in an analogous manner to Example 33 using 3-(1-((tert-butyldimethylsilyl)oxy)-3(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)propan-2-yl)-5-(3-ethoxy-5-fluoro-4methoxyphenyl)pyridine (Préparation 16, 600 mg, 1.1 mmol) and purified by préparative HPLC (Prep HPLC Method O). 1H NMR (DMSO-d6, 400MHz): δ 8.75 (d, J= 2.0 Hz, 1H), 8.71 (s, 1H), 8.47 (d, J = 1.47 Hz, 1 H), 8.00 (s, 1 H), 7.27 (dd, J = 2.0, 11.7 Hz, 1 H), 7.20 (s, 1 H), 4.27 (t, J = 8.3 Hz, 1 H), 4.21 (q, J = 6.9 Hz, 2H), 3.82-3.90 (m, 3H), 3.45-3.56 (m, 2H), 1.39 (t, J = 6.9 Hz, 3H), 1.26-1.34 (m, 1H), 1.12-1.20 (m, 1H). LCMS m/z = 332 [MH]+.
Example 45: 4-(5-(3-chloro-5-ethoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol
4-(5-(3-chloro-5-ethoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol (150 mg, 30%) was prepared in an analogous manner to Example 33 using 3-(1-((tertbutyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-l ,3,2-dioxaborolan-2-yl)propan-2-yl)-5-(3-chloro-5ethoxy-4-methoxyphenyl)pyridine (Préparation 17, 800 mg, 1.42 mmol) and purified by préparative HPLC (Prep HPLC Method P). Ή NMR (DMSO-c/6, 400MHz): δ 8.75 (d, J = 2.0 Hz, 1 H), 8.70 (s, 1 H), 8.48 (d, J = 2.0 Hz, 1 H), 8.02 (t, J = 2.2 Hz, 1 H), 7.42 (d, J = 2.0 Hz, 1 H), 7.34 (d, J= 2.0 Hz, 1H), 4.18-4.30 (m, 3H), 3.83-3.91 (m, 1H), 3.81 (s, 3H), 3.44-3.57 (m, 1H), 1.39 (t, J = 6.9 Hz, 3H), 1.26-1.34 (m, 1H), 1.12-1.22 (m, 1H). LCMS m/z = 347 [MH]+.
Example 46: 4-(5-(5-ethoxy-2-fluoro-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol
4-(5-(5-ethoxy-2-fluoro-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol (385 mg,
32%) was prepared in an analogous manner to Example 33 using 3-(1-((tertbutyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)propan-2-yl)-5-(5-ethoxy-2fluoro-4-methoxyphenyl)pyridine (Préparation 18, 2.0 g, 3.67 mmol) and purified by préparative
208
HPLC (Prep HPLC Method Q). Ή NMR (DMSO-d6, 400MHz): δ 8.72 (s, 1H), 8.58 (s, 1H), 8.46 (s, 1H), 7.83 (s, 1H), 7.09 (d, J = 7.7 Hz, 1H), 7.03 (d, J= 12.4 Hz, 1H), 4.28 (t, J= 8.2 Hz, 1H),
4.07 (q, J= 7.0 Hz, 2H), 3.82-3.86 (m, 4H), 3.46-3.55 (m, 1H), 1.29-1.34 (m, 4H), 1.07-1.14 (m, 1 H). LCMS m/z = 332 [MH]+.
Example 47: 4-(5-(2-chloro-5-ethoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol
4-(5-(2-chloro-5-ethoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol (1.6 g, 65%) was prepared in an analogous manner to Example 33 using 3-(1-((tert-butyldimethylsilyl)oxy)-3(4,4,5,5-tetramethyl-l, 3,2-dioxaborolan-2-yl)propan-2-yl)-5-(2-chloro-5-ethoxy-4methoxyphenyl)pyridine (Préparation 19, 4.1 g, 7.30 mmol) and purified by préparative HPLC (Prep HPLC Method R). Ή NMR (DMSO-d6, 400MHz): δ 8.71 (s, 1H), 8.48 (t, J= 2.0 Hz, 2H), 7.76 (t, J= 2.2 Hz, 1H), 7.15 (s, 1H), 7.01 (s, 1H), 4.26-4.30 (m, 1H), 4.06 (q, J= 7.0 Hz, 2H), 3.81-3.85 (m, 4H), 3.47-3.55 (m, 1H), 1.29-1.35 (m, 4H), 1.06-1.12 (m, 1H). LCMS m/z = 348 [MH]+.
Example 48: 4-(3-fluoro-5-methoxy-6-propoxy-[2,3'-bipyridin]-5'-yl)-1,2-oxaborolan-2-ol
4-(3-fluoro-5-methoxy-6-propoxy-[2,3'-bipyridin]-5'-yl)-1,2-oxaborolan-2-ol (780 mg, 49%) was prepared in an analogous manner to Example 33 using 5'-(1 -((tertbutyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-l, 3,2-dioxaborolan-2-yl)propan-2-yl)-3-fluoro-5methoxy-6-propoxy-2,3'-bipyridine (Préparation 22, 4.02 g, 7.14 mmol) and purified by préparative HPLC (Prep HPLC Method S). Ή NMR (DMSO-de, 400MHz): δ 8.89 (s, 1H), 8.73 (s, 1H), 8.49 (d, J= 2.0 Hz, 1H), 8.09 (s, 1H), 7.49 (d, J = 12.0 Hz, 1H), 4.28-4.33 (m, 3H), 3.87 (s, 3H), 3.82 (t, J = 8.7 Hz, 1 H), 3.49-3.57 (m, 1 H), 1.73-1.81 (m, 2H), 1.31-1.37 (m, 1 H), 1.031.09 (m, 1 H), 0.98 (t, J = 7.5 Hz, 3H). LCMS m/z = 347 [MH]+.
Example 49: 4-(5-(2-fluoro-4-methoxy-5-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol
209
4-(5-(2-fluoro-4-methoxy-5-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol (1.2 g, 49%) was prepared in an analogous manner to Example 33 using 3-(1-((tert-butyldimethylsilyl)oxy)-3(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-2-yl)-5-(2-fluoro-4-methoxy-55 propoxyphenyl)pyridine (Préparation 20, 4.0 g, 7.1 mmol) and purified by préparative HPLC (Prep HPLC Method T). 1H NMR (DMSO-d6, 400MHz): δ 8.89 (s, 1H), 8.74 (s, 1H), 8.49 (d, J = 2.0 Hz, 1 H), 8.09 (s, 1 H), 7.47-7.53 (m, 1 H), 4.27-4.36 (m, 3H), 3.87 (s, 3H), 3.82 (t, J = 8.7 Hz, 1H), 3.50-3.56 (m, 1H), 1.75-1.80 (m, 2H), 1.34 (dd, J= 8.2, 16.3 Hz, 1H), 1.01-1.12 (m, 1H), 0.98 (t, J = 7.3 Hz, 3H). LCMS m/z = 347 [MH]+.
Example 50: 4-(5-(4-(difluoromethoxy)-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol
4-(5-(4-(difluoromethoxy)-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol (0.51 g, 31%) was prepared in an analogous manner to Example 33 using 3-(1 -((tert15 butyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-2-yl)-5-(4(difluoromethoxy)-3-propoxyphenyl)pyridine (Préparation 21,2.6 g, 4.50 mmol) and purified by préparative HPLC (Prep HPLC Method U). Ή NMR (DMSO-d6, 400MHz): δ 8.74 (d, J = 2.1Hz, 1 H), 8.72 (s, 1 H), 8.49 (d, J = 2.0Hz, 1 H), 8.00 (t, J = 2.0Hz, 1 H), 7.45 (d, J = 1,6Hz, 1 H), 7.287.31 (m, 2H), 7.09 (t, J = 74.5Hz, 1 H), 4.28 (t, J = 8.3Hz, 1 H), 4.12 (t, J = 6.4Hz, 2H), 3.87 (t, J =
9.1Hz, 1H), 3.47-3.56 (m, 1H), 1.73-1.82 (m, 2H), 1.29-1.35 (m, 1H), 1.12-1.19 (m, 1H), 1.01 (t,
J = 7.5Hz, 3H). LCMS m/z = 382 [MH+H2O]+.
Example 51: 4-(6'-methoxy-5'-propoxy-[3,3'-bipyridin]-5-yl)-1,2-oxaborolan-2-ol
OH
4-(6'-methoxy-5'-propoxy-[3,3'-bipyridin]-5-yl)-1,2-oxaborolan-2-ol was prepared (720 mg, 25%) in an analogous manner to Example 33 using 5'-(1-((tert-butyldimethylsilyl)oxy)-3(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-2-yl)-6-methoxy-5-propoxy-3,3'-bipyridine (Préparation 23, 1.034 g, 1.9 mmol) and purified by préparative HPLC (Prep HPLC Method V).
210
Ή NMR (DMSO-d6, 400ΜΗζ): δ 8.76 (d, J = 2.2 Hz, 1 H), 8.72 (s, 1 H), 8.48 (d, J = 2.0 Hz, 1 H),
8.06 (d, J = 2.0 Hz, 1 H), 8.01 (t, J = 2.2 Hz, 1 H), 7.61 (d, J = 2.2 Hz, 1 H), 4.26-4.31 (m, 1 H), 4.08 (t, J= 6.6 Hz, 2H), 3.92 (s, 3H), 3.87 (t, J= 9.1 Hz, 1H), 3.48-3.56 (m, 1H), 1.73-1.82 (m, 2H), 1.28-1.35 (m, 1H), 1.13-1.21 (m, 1H), 1.00 (t, J= 7.5 Hz, 3H). LCMS m/z = 329 [MH]+.
Example 52: 4-(5-(3-ethoxy-4-methoxyphenyl)-6-methylpyridin-3-yl)-1,2-oxaborolan-2-ol
4-(5-(3-ethoxy-4-methoxyphenyl)-6-methylpyridin-3-yl)-1,2-oxaborolan-2-ol (182 mg, 43%) was prepared in an analogous manner to Example 33 using 5-(1-((tertbutyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)propan-2-yI)-3-(3-ethoxy-4methoxyphenyl)-2-methylpyridine (Préparation 24, 700 mg, 1.29 mmol) and purified by préparative HPLC (Prep HPLC Method W). Ή NMR (DMSO-c/6, 400MHz): δ 8.67 (s, 1H), 8.33 (d, J = 2.0 Hz, 1 H), 7.47 (d, J = 2.0 Hz, 1 H), 7.03 (d, J = 8.3 Hz, 1 H), 6.94 (d, J = 2.0 Hz, 1 H), 6.88 (dd, 4= 2.0, 7.8 Hz, 1H), 4.24 (t, 4= 8.1 Hz, 1H), 4.04 (q, 4 = 6.9 Hz, 2H), 3.76-3.83 (m, 4H), 3.39-3.50 (m, 1H), 2.40 (s, 3H), 1.24-1.36 (m, 4H), 1.01-1.10 (m, 1H). LCMS m/z = 328 [MH]+.
Example 53: 4-(5-(3-ethoxy-4-methoxyphenyl)-4-methylpyridin-3-yl)-1,2-oxaborolan-2-ol
4-(5-(3-ethoxy-4-methoxyphenyl)-4-methylpyridin-3-yl)-1,2-oxaborolan-2-ol (0.06 g, 33%) was prepared in an analogous manner to Example 33 using 3-(1-((tert-butyldimethylsilyl)oxy)-3(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)propan-2-yl)-5-(3-ethoxy-4-methoxyphenyl)-4methylpyridine (Préparation 35, 0.28 g, 0.51 mmol) and purified by préparative HPLC (Prep HPLC Method X). 1H NMR (DMSO-c/e, 400MHz): δ 8.71 (s, 1H), 8.43 (s, 1H), 8.21 (s, 1H), 7.04 (d, J = 8.0 Hz, 1 H), 6.90 (d, J = 2.3 Hz, 1 H), 6.82-6.85 (m, 1 H), 4.24-4.28 (m, 1 H), 4.03 (q, J = 7.0 Hz, 2H), 3.90-3.95 (m, 1H), 3.80 (s, 3H), 3.63-3.71 (m, 1H), 2.22 (s, 3H), 1.30-1.36 (m, 4H), 1.04-1.10 (m, 1H). LCMS m/z = 328 [MH]+.
Example 54: 4-(2-(4-methoxy-3-propoxyphenyl)-6-methylpyrimidin-4-yl)-1,2-oxaborolan-2-ol
211
4-(2-(4-methoxy-3-propoxyphenyl)-6-methylpynmidin-4-yl)-1,2-oxaborolan-2-ol (314 mg, 95%) was prepared in an analogous manner to Example 33 using ethyl 2-(6-(1-((tertbutyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-2-yl)-2-(4-methoxy3-propoxyphenyl)pyrimidin-4-yl)acetate (Préparation 28, 500 mg, 0.96 mmol) and purified by préparative HPLC (Prep HPLC Method Y). Ή NMR (CD3OD, 400MHz): δ 8.03 (dd, J = 2.0, 8.6 Hz, 1H), 8.00 (d, J = 2.0 Hz, 1H), 7.07 (s, 1H), 7.05 (d, J= 8.3 Hz, 1H), 4.17 (br s, 1H), 4.07 (t, J = 6.5 Hz, 2H), 4.00 (br s, 1 H), 3.91 (s, 2H), 3.41 (br s, 1 H), 2.52 (s, 2H), 1.84-1.89 (m, 2H), 1.29-1.38 (m, 1 H), 1.21-1.29 (m, 1 H), 1.09 (t, J = 7.3 Hz, 3H). LCMS m/z = 343 [MH]+.
Example 55: 4-(2-(4-methoxy-3-propoxyphenyl)-6-(trifluoromethyl)pyrimidin-4-yl)-1,2oxaborolan-2-ol
4-(2-(4-methoxy-3-propoxyphenyl)-6-(trifluoromethyl)pyrimidin-4-yl)-1,2-oxaborolan-2-ol (582 mg, 36%) was prepared in an analogous manner to Example 33 using 4-( 1 -((tertbutyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-2-yl)-2-(4-methoxy3-propoxyphenyl)-6-(trifluoromethyl)pyrimidine (Préparation 25, 2.5 g, 4.09 mmol) and purified by préparative HPLC (Prep HPLC Method Z). Ή NMR (DMSO-de, 400MHz): δ 8.72 (s, 1H), 8.03 (dd, J= 2.0, 8.6 Hz, 1H), 7.95 (d, J= 2.0 Hz, 1H), 7.77 (s, 1H), 7.13 (d, J= 8.6 Hz, 1H), 4.32 (dd, J = 7.4, 9.0 Hz, 1 H), 3.98-4.09 (m, 3H), 3.86 (s, 3H), 3.73-3.82 (m, 1 H), 1.73-1.84 (m, 1H), 1.31-1.41 (m, 1H), 1.18-1.26 (m, 2H), 1.01 (t, J =7.4 Hz, 3H). LCMS m/z = 397 [MH]+.
Example 56: 4-(6-(3-ethoxy-4-methoxyphenyl)pyrazin-2-yl)-1,2-oxaborolan-2-ol
4-(6-(3-ethoxy-4-methoxyphenyl)pyrazin-2-yl)-1,2-oxaborolan-2-ol (30 mg, 7%) was prepared in an analogous manner to Example 33 using 2-(1-((tert-butyldimethylsilyl)oxy)-320225
212 (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-2-yl)-6-(3-ethoxy-4-methoxyphenyl)pyrazine (Préparation 26, 720 mg, 1.36 mmol) and purified by préparative HPLC (Prep HPLC Method AA). 1H NMR (DMSO-c/β, 400MHz): δ 9.06 (s, 1H), 8.67 (s, 1H), 8.44 (s, 1H), 8.37-8.50 (m, 1H), 7.65-7.79 (m, 2H), 7.08 (d, J= 8.8 Hz, 1H), 4.30 (t, J= 8.2 Hz, 1H), 4.12 (q, J= 6.9 Hz, 2H), 3.98 (dd, J= 6.5, 8.9 Hz, 1H), 3.83 (s, 3H), 3.66-3.70 (m, 1H), 1.37 (t, J= 7.0 Hz, 3H), 1.27-1.34 (m, 1H), 1.14-1.22 (m, 1H). LCMS m/z = 315 [MH]+.
Example 57: 4-(6-(hydroxymethyl)-2-(4-methoxy-3-propoxyphenyl)pyrimidin-4-yl)-1,2oxaborolan-2-ol
4-(6-(hydroxymethyl)-2-(4-methoxy-3-propoxyphenyl)pyrimidin-4-yl)-1,2-oxaborolan-2-ol (0.2 g, 38.4%) was prepared in an analogous manner to Example 33 using 4-(1-((tertbutyldimethylsilyl)oxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-2-yl)-6-(((tertbutyldimethylsilyl)oxy)methyl)-2-(4-methoxy-3-propoxyphenyl)pyrimidine (Préparation 29, 1.0 g, 1.5 mmol) and purified by préparative HPLC (Prep HPLC Method BA). 1H NMR (DMSO-c/e, 400MHz): δ 8.71 (s, 1 H), 8.00 (dd, J = 2.0, 8.0 Hz, 1 H), 7.96 (d, J = 2.0 Hz, 1 H), 7.52 (s, 1 H), 7.27-7.31 (m, 1 H), 7.06 (d, J = 8.5 Hz, 1 H), 5.60-5.66 (m, 1 H), 4.59 (d, J = 6.0 Hz, 2H), 4.31 (dd, J = 7.0, 9.0 Hz, 1 H), 3.96-4.04 (m, 2H), 3.83 (s, 3H), 3.57-3.65 (m, 1 H), 1.75-1.82 (m, 2H), 1.25-1.35 (m, 1H), 1.12-1.21 (m, 1H), 0.96-1.07 (m, 3H). LCMS m/z = 359 [MH]+.
Example 58: 4-(2-(3-ethoxy-4-methoxyphenyl)thiazol-4-yl)-1,2-oxaborolan-2-ol
4-(2-(3-ethoxy-4-methoxyphenyl)thiazol-4-yl)-1,2-oxaborolan-2-ol (0.31 g, 37%) was prepared in an analogous manner to Example 33 using 4-(1-((tert-butyldimethylsilyl)oxy)-3(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-2-yl)-2-(3-ethoxy-4-methoxyphenyl)thiazole (Préparation 36, 1.42 g, 2.66 mmol) and purified by préparative HPLC (Prep HPLC Method CA). Ή NMR (DMSO-c/β, 400MHz): δ 8.66 (br s, 1 H), 7.42-7.46 (m, 2H), 7.30 (s, 1 H), 7.05 (d, J = 8.3 Hz, 1 H), 4.24-4.28 (m, 1 H), 4.09 (q, J = 7.0 Hz, 2H), 3.90-3.95 (m, 1 H), 3.82 (s, 3H), 3.55-3.63 (m, 1H), 1.36 (t, J= 7.0 Hz, 3H), 1.25-1.31 (m, 1H), 1.11-1.18 (m, 1H). LCMS m/z = 320 [MH]+.
213
Example 59: (2R)-2-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-3-(4,4,6-trimethyl-1,3,2dioxaborinan-2-yl)propan-1-ol
To hexylene glycol (1.0 g, 8.46 mmol) was added (R)-4-(5-(4-methoxy-35 propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol (Example 4, 0.051 g, 0.16 mmol) at about 20 °C. The mixture was stirred until homogeneous to afford (2R)-2-(5-(4-methoxy-3propoxyphenyl)pyridin-3-yl)-3-(4,4,6-trimethyl-1,3,2-dioxaborinan-2-yl)propan-1-ol (5 wt% solution in hexylene glycol) as a mixture of diastereomers (1:1 ratio). 1H NMR (DMSO-de, 400MHz): δ 8.64 (d, J = 2.2 Hz, 1 H), 8.32 (d, J = 1.9 Hz, 1 H), 7.77 (t, J = 2.2 Hz, 1 H), 7.23 (s,
1H), 7.17-7.25 (m, 1H), 7.06 (d, J= 8.1 Hz, 1H), 4.61 (m, 1H), 4.02 (t, J= 6.6 Hz, 2H), 3.97-4.07 (m, 1H), 3.80 (s, 3H), 3.46-3.58 (m, 2H), 2.84-2.98 (m, 1H), 1.69-1.83 (m, 3H), 1.14 (m, 1H), 1.02-1.09 (m, 10H), 1.00 (t, J = 7.4 Hz, 3H), 0.83 (dd, J = 9.0, 15.0 Hz, 1 H). LCMS m/z = 428 [MH]+.
The following compounds, Example 60-, were prepared similarly using methods described above. Examples containing an asterisk (*), désignâtes a single enantiomer obtained through chiral purification methods. For those examples characterized by HPLC rétention time (RT), the analytical HPLC methods are described.
Example No. | Structure and Name | Analytical Data |
60 | OH T X Γ .b N ' 4-(5-methoxy-6-propoxy-[2,3'-bipyridin]5'-yl)-1,2-oxaborolan-2-ol | Ή NMR (DMSO-dg, 400 MHz): δ 9.04 (d, J = 2.0 Hz, 1 H), 8.71 (s, 1 H), 8.45 (d, J = 2.0 Hz, 1 H), 8.22 (t, J = 2.2 Hz, 1 H), 7.61 (d, J = 7.8 Hz, 1H), 7.37 (d, J = 8.3 Hz, 1 H), 4.36 (t, J = 6.6 Hz, 2H), 4.26-4.32 (m, 1H), 3.80-3.88 (m, 4H), 3.45-3.58 (m, 1 H), 1.75-1.84 (m, 2H), 1.33 (dd, J = 8.3, 16.1 Hz, 1H), 1.06- 1.17 (m, 1H), 1.00 (t, J = 7.3 Hz, 3H). LCMS m/z = 329 [MH]+. |
214
Example 61 | OH Γ II b 4-(5-methoxy-6-propoxy-[2,3'-bipyridin]- 5'-yl)-1,2-oxaborolan-2-ol, enantiomer 1 | 1H NMR (DMSO-d6,400 MHz): δ 9.04 (d, J = 2.0 Hz, 1 H), 8.71 (s, 1 H), 8.45 (d, J = 2.0 Hz, 1H), 8.22 (t, J = 2.2 Hz, 1H), 7.61 (d, J = 7.8 Hz, 1 H), 7.37 (d, J = 8.3 Hz, 1H), 4.36 (t, J = 6.6 Hz, 2H), 4.26-4.32 (m, 1H), 3.80-3.88 (m, 4H), 3.45-3.58 (m, 1 H), 1.75-1.84 (m, 2H), 1.33 (dd, J = 8.3, 16.1 Hz, 1H), 1.06- 1.17 (m, 1H), 1.00 (t, J = 7.3 Hz, 3H). LCMS m/z = 329 [MH]+. RT [Analytical SFC Method I] = 4.57 min. |
62 | OH r-B T 1 * Γ > 4-(5-methoxy-6-propoxy-[2,3'-bipyridin]5'-yl)-1,2-oxaborolan-2-ol, enantiomer 2 | Ή NMR (DMSO-d6,400 MHz): δ 9.04 (d, J = 2.0 Hz, 1 H), 8.71 (s, 1 H), 8.45 (d, J = 2.0 Hz, 1H), 8.22 (t, J = 2.2 Hz, 1H), 7.61 (d, J = 7.8 Hz, 1 H), 7.37 (d, J = 8.3 Hz, 1H), 4.36 (t, J = 6.6 Hz, 2H), 4.26-4.32 (m, 1H), 3.80-3.88 (m, 4H), 3.45-3.58 (m, 1 H), 1.75-1.84 (m, 2H), 1.33 (dd, J = 8.3, 16.1 Hz, 1H), 1.06- 1.17 (m, 1H), 1.00 (t, J = 7.3 Hz, 3H). LCMS m/z = 329 [MH]+. RT [Analytical SFC Method I] = 4.98 min. |
63 | OH r-B f JC X X z° 4-(3'-(2-fluoroethoxy)-4'-methoxy-[1,1 'biphenyl]-3-yl)-1,2-oxaborolan-2-ol | Ή NMR (DMSO-de, 400MHz): δ 7.51 (br s, 1 H), 7.46 (d, J = 7.8 Hz, 1 H), 7.35 (t, J = 7.8 Hz, 1H), 7.18-7.23 (m, 3H), 7.06 (d, J= 8.2 Hz, 1H), 4.81-4.83 (m, 1H), 4.694.71 (m, 1H), 4.36-4.38 (m, 1H), 4.244.30 (m, 2H), 3.79-3.83 (m, 4H), 3.423.51 (m, 1H), 1.26-1.32 (m, 1H), 1.051.12 (m, 1H). LCMS m/z = 331 [MH]+. |
215
64 | OH ....... ΌΗ 4-(4-(hydroxymethyl)-6-(4-methoxy-3propoxyphenyl)pyridin-2-yl)-1,2- oxaborolan-2-ol | Ή NMR (DMSO-c/β, 400MHz): δ 8.59 (br s, 1H), 7.69 (d, J = 2.0 Hz, 1H), 7.577.66 (m, 2H), 7.11 (s, 1H), 7.00-7.06 (m, 1H), 5.41 (brs, 1H), 4.56 (s, 2H), 4.28 (dd, J = 7.3, 8.78 Hz, 1H), 3.94-4.03 (m, 3H), 3.80 (s, 3H), 3.52-3.62 (m, 1H), 1.70-1.82 (m, 2H), 1.13-1.30 (m, 2H), 1.00 (t, J = 7.5 Hz, 3H). LCMS m/z = 376 [MH+H2O]+. |
65 | I OH V;i X (j 4-(6-(3-(cyclopentyloxy)-4methoxyphenyl)pyridin-2-yl)-1,2oxaborolan-2-ol | Ή NMR (DMSO-d6, 400MHz): δ 8.59 (s, 1H), 7.70-7.75 (m, 3H), 7.62 (dd, J = 2.0, 8.3 Hz, 1H), 7.10-7.20 (m, 1H), 7.03 (d, J = 8.6 Hz, 1 H), 4.90 (t, J = 5.9 Hz, 1 H), 4.29 (t, J = 8.2 Hz, 1H), 3.99 (dd, J = 7.0, 8.9 Hz, 1H), 3.79 (s, 3H), 3.56-3.63 (m, 1H), 1.87-2.04 (m, 2H), 1.68-1.81 (m, 4H), 1.59 (brs, 2H), 1.16-1.30 (m, 2H). LCMS m/z = 372 [MH+H2O]+. |
66 | I OH rx °^ί rB' \A„ÀXNr/b O ψ 4-(6-(3-(cyclopentyloxy)-4methoxyphenyl)pyridin-2-yl)-1,2oxaborolan-2-ol, enantiomer 1 | LCMS m/z = 354 [MH]+. RT [Analytical SFC Method V] = 3.60 min. |
67 | I OH /x vk zLL»X/“ (j 4-(6-(3-(cyclopentyloxy)-4methoxyphenyl)pyridin-2-yl)-1,2oxaborolan-2-ol, enantiomer 2 | LCMS m/z = 354 [M+H]+. RT [Analytical SFC Method V] = 3.93 min. |
216
68 | I OH A ΛΑ Α> 0 Tjz ΙΨ 4-(5-(4-methoxy-3-(thietan-3yloxy)phenyl)pyridin-3-yl)-1,2oxaborolan-2-ol | Ή NMR (DMSO-de, 400MHz): δ 8.72 (s, 1H), 8.70 (d, J = 2.0 Hz, 1H), 8.42 (d, J = 2.0 Hz, 1 H), 7.92 (t, J = 2.0 Hz, 1 H), 7.31 (dd, J = 2.3, 8.3 Hz, 1 H), 7.22 (d, J = 2.5 Hz, 1 H), 7.09 (d, J = 8.5 Hz, 1 H), 5.445.53 (m, 1 H), 4.27 (t, J = 8.3 Hz, 1 H), 3.86 (t, J = 9.0 Hz, 1H), 3.81 (s, 3H), 3.47 (dd, J = 3.8, 7.8 Hz, 5H), 1.31 (dd, J = 8.3, 16.3 Hz, 1H), 1.11 1.19 (m, 1H). LCMS m/z = 358 [MH]+. |
69 | OH T X F b 4-(5-(5-ethoxy-4-methoxy-2methylphenyl)pyridin-3-yl)-1,2oxaborolan-2-ol | 1H NMR (MeOD-dg, 400 MHz): δ 8.40 (d, J = 2.0 Hz, 1 H), 8.31 (d, J = 2.5 Hz, 1 H), 7.69 (t, J = 2.0 Hz, 1 H), 6.92 (s, 1 H), 6.80 (s, 1H), 4.06 (q, J = 6.9 Hz, 2H), 3.83-3.90 (m, 4H), 3.33-3.40 (m, 1H), 2.21 (s, 3H), 1.39 (t, J = 6.9 Hz, 3H), 1.16-1.33 (m, 2H) LCMS m/z = 328 [MH]+. |
70 | OH T X *Γ b 4-(5-(5-ethoxy-4-methoxy-2methylphenyl)pyridin-3-yl)-1,2- oxaborolan-2-ol, enantiomer 1 | 1H NMR (DMSO-d6, 400MHz): δ 8.69 (br s, 1 H), 8.31-8.49 (m, 2H), 7.66 (br s, 1 H), 6.91 (brs, 1H), 6.81 (brs, 1H), 4.27 (br s, 1H), 4.01 (d, J = 5.9 Hz, 2H), 3.733.90 (m, 4H), 3.49 (br s, 1H), 2.18 (br s, 3H), 1.30 (brs, 3H), 0.99-1.16 (m, 2H). LCMS m/z = 346 [MH+H2O]+. RT [Analytical SFC Method L] = 2.67 min. |
71 | OH X^ X T b TF 4-(5-(5-ethoxy-4-methoxy-2methylphenyl)pyridin-3-yl)-1,2- oxaborolan-2-ol, enantiomer 2 | Ή NMR (DMSO-de, 400MHz): δ 8.69 (br s, 1H), 8.31-8.49 (m, 2H), 7.66 (brs, 1H), 6.91 (brs, 1H), 6.81 (brs, 1H), 4.27 (br s, 1H), 4.01 (d, J = 5.9 Hz, 2H), 3.733.90 (m, 4H), 3.49 (br s, 1H), 2.18 (brs, 3H), 1.30 (brs, 3H), 0.99-1.16 (m, 2H). LCMS m/z = 327 [MH]+. RT [Analytical SFC Method L] = 2.91 min. |
217
72 | \ Π ,ΟΗ Λ~Β ' //Χ/Ο S-N 4-(5-(3-ethoxy-4-methoxyphenyl)-1,2,4- thiadiazol-3-yl)-1,2-oxaborolan-2-ol | 1H NMR (DMSO-d6, 400MHz): δ 7.58 (dd, J = 1.8, 8.4 Hz, 1H), 7.46 (d, J = 1.71 Hz, 1H), 7.12 (d, J = 8.6 Hz, 1H), 4.27-4.37 (m, 1H), 4.07-4.16 (m, 3H), 3.85 (s, 3H), 3.76-3.83 (m, 1H), 1.231.43 (m, 5H). LCMS m/z = 321.1 [MH]+. |
73 | OH -Vz A JL JJ / o ^° iCi N 4-(5-(3-ethoxy-2-fluoro-4methoxyphenyl)pyridin-3-yl)-1,2oxaborolan-2-ol | Ή NMR (DMSO-d6, 400MHz): δ 8.70 (s, 1H), 8.54 (s, 1H), 8.48 (d, J = 2.0 Hz, 1 H), 7.81 (d, J = 1.5 Hz, 1 H), 7.26 (t, J = 8.8 Hz, 1H), 7.01 (dd, J= 1.0, 8.8 Hz, 1H), 4.28 (t, J = 8.3 Hz, 1H), 4.06 (q, J = 7.3 Hz, 2H), 3.80-3.90 (m, 4H), 3.44-3.58 (m, 1H), 1.24-1.39 (m, 4H), 0.99-1.16 (m, 1H). LCMS m/z = 332 [MH]+. |
74 | OH N 4-(5-(3-ethoxy-2-fluoro-4methoxyphenyl)pyridin-3-yl)-1,2oxaborolan-2-ol, enantiomer 2 | Ή NMR (DMSO-de, 400MHz): δ 8.70 (s, 1H), 8.54 (s, 1H), 8.48 (d, J = 2.0 Hz, 1 H), 7.81 (d, J = 1.5 Hz, 1 H), 7.26 (t, J = 8.8 Hz, 1H), 7.01 (dd, J = 1.0, 8.8 Hz, 1H), 4.28 (t, J = 8.3 Hz, 1H), 4.06 (q, J = 7.3 Hz, 2H), 3.80-3.90 (m, 4H), 3.44-3.58 (m, 1H), 1.24-1.39 (m, 4H), 0.99-1.16 (m, 1H). LCMS m/z = 332 [MH]+. RT [Analytical SFC Method GA] = 6.58 min. |
75 | OH r-B jT JJ Γ b 4-(3'-isopropoxy-4’-methoxy-[1,1 biphenyl]-3-yl)-1,2-oxaborolan-2-ol | 1H NMR (DMSO-de, 400MHz): δ 7.48 (s, 1H), 7.43 (d, J = 7.6 Hz, 1H), 7.34 (t, J = 7.6 Hz, 1H), 7.14-7.24 (m, 3H), 7.00-7.06 (m, 1H), 4.61-4.71 (m, 1H), 4.22-4.29 (m, 1H), 3.77-3.85 (m, 3H), 3.37-3.53 (m, 1H), 1.22-1.31 (m, 7H), 0.99-1.12 (m, 3H). LCMS m/z = 327 [MH]+. |
218
76 | OH ΌΗ (-) 4-(6-(hydroxymethyl)-2-(4-methoxy- 3-propoxyphenyl)pyrimidin-4-yl)-1,2- oxaborolan-2-ol, enantiomer 1 | Ή NMR (DMSO-de, 400MHz): δ 8.71 (s, 1H), 8.00 (dd, J = 2.0, 8.0 Hz, 1H), 7.96 (d, J = 2.0 Hz, 1 H), 7.52 (s, 1 H), 7.277.31 (m, 1H), 7.06 (d, J= 8.5 Hz, 1H), 5.60-5.66 (m, 1 H), 4.59 (d, J = 6.0 Hz, 2H), 4.31 (dd, J = 7.0, 9.0 Hz, 1 H), 3.964.04 (m, 2H), 3.83 (s, 3H), 3.57-3.65 (m, 1H), 1.75-1.82 (m, 2H), 1.25-1.35 (m, 1H), 1.12-1.21 (m, 1H), 0.96-1.07 (m, 3H). LCMS m/z = 359 [MH]+. [α]2% -10.0 (c = 0.1, EtOH). |
77 | OH T jl Γ b 4-(3'-ethoxy-4'-methoxy-[1,1 '-bip heny I]3-yl)-1,2-oxaborolan-2-ol | 1H NMR (DMSO-c/β, 400MHz): δ 8.65 (s, 1H), 7.50 (s, 1H), 7.45 (d, J = 7.6 Hz, 1H), 7.34 (t, J = 7.7 Hz, 1H), 7.21 (d, J = 7.6 Hz, 1H), 7.18 (s, 1H), 7.16 (d, J = 1.71 Hz, 1H), 7.02 (d, J = 8.1 Hz, 1H), 4.26 (t, J = 8.3 Hz, 1H), 4.10 (q, J = 6.9 Hz, 2H), 3.77-3.84 (m, 4H), 3.42-3.49 (m, 1H), 1.35 (t, J = 7.0 Hz, 3H), 1.28 (dd, J = 8.2, 16.3 Hz, 1H), 1.08 (dd, J = 10.0, 16.4 Hz, 1H). LCMS m/z = 313 [MH]+. |
78 | I OH 4-(5-(4-methoxy-3- ((tetrahydrothiophen-3yl)oxy)phenyl)pyridin-3-yl)-1,2oxaborolan-2-ol | Ή NMR (DMSO-de, 400MHz): δ 8.73 (s, 1H), 8.70 (d, J = 2.0 Hz, 1H), 8.43 (d, J = 2.0 Hz, 1 H), 7.93 (t, J = 2.0 Hz, 1 H), 7.36 (d, J = 2.0 Hz, 1H), 7.30-7.34 (m, 1H), 7.10 (d, J = 8.0 Hz, 1H), 5.30 (brs, 1H), 4.27 (t, J = 8.3 Hz, 1 H), 3.86 (t, J = 9.0 Hz, 1H), 3.81 (s, 3H), 3.46-3.55 (m, 1H), 3.13 (dd, J = 4.8, 11.8 Hz, 1H), 2.85-3.00 (m, 3H), 2.27-2.34 (m, 1H), 1.90-2.00 (m, 1H), 1.31 (dd, J = 8.3, 16.3 Hz, 1H), 1.14 (dd, J = 10.3, 16.3 Hz, 1H). LCMS m/z = 372 [MH]+. |
219
4-(5-(4-methoxy-3((tetrahydrothiophen-3yl)oxy)phenyl)pyridin-3-yl)-1,2oxaborolan-2-ol, diastereomer 1
4-(5-(4-methoxy-3((tetrahydrothiophen-3yl)oxy)phenyl)pyridin-3-yl)-1,2oxaborolan-2-ol, diastereomer 2
4-(5-(2-fluoro-4-methoxy-3propoxyphenyl)pyridin-3-yl)-1,2oxaborolan-2-ol 1H NMR (DMSO-c/e, 400MHz): δ 8.73 (s, 1H), 8.70 (d, J = 2.0 Hz, 1H), 8.43 (d, J = 2.0 Hz, 1 H), 7.93 (t, J = 2.0 Hz, 1 H), 7.36 (d, J = 2.0 Hz, 1 H), 7.30-7.34 (m, 1 H), 7.10 (d, J = 8.0 Hz, 1H), 5.30 (br s, 1H), 4.27 (t, J = 8.3 Hz, 1 H), 3.86 (t, J = 9.0 Hz, 1H), 3.81 (s, 3H), 3.46-3.55 (m, 1H), 3.13 (dd, J = 4.8, 11.8 Hz, 1H), 2.85-3.00 (m, 3H), 2.27-2.34 (m, 1H), 1.90-2.00 (m, 1H), 1.31 (dd, J = 8.3, 16.3 Hz, 1H), 1.14 (dd, J = 10.3, 16.3 Hz, 1H). LCMS m/z = 372.3 [MH]+. RT [Analytical SFC Method EA] = 3.30 min.
Ή NMR (DMSO-d6, 400MHz): δ 8.73 (s, 1H), 8.70 (d, J = 2.0 Hz, 1H), 8.43 (d, J = 2.0 Hz, 1H), 7.93 (t, J = 2.0 Hz, 1H), 7.36 (d, J = 2.0 Hz, 1H), 7.30-7.34 (m, 1H), 7.10 (d, J = 8.0 Hz, 1H),5.30 (br s, 1H), 4.27 (t, J = 8.3 Hz, 1H), 3.86 (t, J = 9.0 Hz, 1H), 3.81 (s, 3H), 3.46-3.55 (m, 1H), 3.13 (dd, J = 4.8, 11.8 Hz, 1 H), 2.85-3.00 (m, 3H), 2.27-2.34 (m, 1H), 1.90-2.00 (m, 1H), 1.31 (dd, J = 8.3, 16.3 Hz, 1H), 1.14 (dd, J = 10.3, 16.3 Hz, 1H). LCMS m/z = 372.1 [MH]+. RT [Analytical SFC Method EA] = 4.18 min.
Ή NMR (DMSO-ds, 400MHz): δ 8.71 (s, 1H), 8.54 (t, J = 2.0 Hz, 1H), 8.48 (d, J = 2.0 Hz, 1 H), 7.82 (d, J = 1.5 Hz, 1 H), 7.26 (t, J = 8.7 Hz, 1 H), 7.01 (dd, J = 1.5, 8.8 Hz, 1H), 4.24-4.32 (m, 1H), 3.97 (t, J = 6.6 Hz, 2H), 3.87 (s, 3H), 3.80-3.86 (m, 1H), 3.44-3.57 (m, 1H), 1.63-1.72 (m, 2H), 1.31 (dd, J = 8.2, 16.3 Hz, 1H), 1.10 (dd, J = 10.3, 16.1 Hz, 1H), 0.98 (t, J = 7.3 Hz, 3H). LCMS m/z = 346 [MH]+.
220
4-(5-(2-fluoro-4-methoxy-3propoxyphenyl)pyridin-3-yl)-1,2oxaborolan-2-ol, enantiomer 2
4-(6-(1 -hydroxyethyl)-2-(4-methoxy-3propoxyphenyl)pyrimidin-4-yl)-1,2oxaborolan-2-ol, diastereomer 1
4-(5-(4-methoxy-3-propoxyphenyl)-4methylpyridin-3-yl)-1,2-oxaborolan-2-ol
Ή NMR (DMSO-de, 400MHz): δ 8.71 (s, 1 H), 8.54 (t, J = 2.0 Hz, 1 H), 8.48 (d, J = 2.0 Hz, 1 H), 7.82 (d, J = 1.5 Hz, 1 H), 7.26 (t, J = 8.7 Hz, 1 H), 7.01 (dd, J = 1.5, 8.8 Hz, 1H), 4.24-4.32 (m, 1H), 3.97 (t, J = 6.6 Hz, 2H), 3.87 (s, 3H), 3.80-3.86 (m, 1H), 3.44-3.57 (m, 1H), 1.63-1.72 (m, 2H), 1.31 (dd, J = 8.2, 16.3 Hz, 1H), 1.10 (dd, J = 10.3, 16.1 Hz, 1H), 0.98 (t, J = 7.3 Hz, 3H). LCMS m/z = 372 [MH]+. RT [Analytical SFC Method E] = 4.76 min. Ή NMR (DMSO-c/6, 400MHz): δ 8.68 (s, 1H), 8.00 (dd, J = 2.0, 8.3 Hz, 1H), 7.97 (d, J = 2.0 Hz, 1 H), 7.32 (s, 1 H), 7.07 (d, J = 8.3 Hz, 1 H), 5.57 (d, J = 4.9 Hz, 1 H), 4.65-4.75 (m, 1H), 4.30 (dd, J = 7.3, 9.3 Hz, 1H), 3.96-4.03 (m, 3H), 3.83 (s, 3H), 3.61 (s, 1H), 1.71-1.83 (m, 2H), 1.43 (d, J = 6.4 Hz, 3H), 1.27 (dd, J = 1.5, 8.3 Hz, 1H), 1.11-1.20 (m, 1H), 1.01 (t, J = 7.6 Hz, 3H). LCMS m/z = 391 [MH+H2O]+. RT [Analytical SFC Method E] = 4.07 min.
1H NMR (DMSO-c/6, 400MHz): δ 8.71 (s, 1H), 8.43 (s, 1H), 8.21 (s, 1H), 7.04 (d, J = 7.8 Hz, 1 H), 6.90 (d, J = 2.0 Hz, 1 H), 6.84 (dd, J = 2.0, 8.3 Hz, 1H), 4.26 (dd, J = 7.3, 8.8 Hz, 1H), 3.89-3.97 (m, 3H), 3.80 (s, 3H), 3.67 (t, J = 8.1 Hz, 1H), 2.21 (s, 3H), 1.68-1.77 (m, 2H), 1.33 (dd, J = 8.3, 16.1 Hz, 1 H), 1.08 (dd, J = 8.6, 16.4 Hz, 1H), 0.97 (t, J = 7.3 Hz, 3H). LCMS m/z = 342 [MH]+.
221
85 | OH °ΤΊ i rB' ο ΐιΊ ^NT (+) 4-(5-(4-methoxy-3-propoxyphenyl)4-methylpyridin-3-yl)-1,2-oxaborolan-2ol, enantiomer 1 | Ή NMR (DMSO-de, 400MHz): δ 8.71 (s, 1H), 8.43 (s, 1H), 8.21 (s, 1H), 7.04 (d, J = 7.8 Hz, 1 H), 6.90 (d, J = 2.0 Hz, 1 H), 6.84 (dd, J = 2.0, 8.3 Hz, 1H), 4.26 (dd, J = 7.3, 8.8 Hz, 1H), 3.89-3.97 (m, 3H), 3.80 (s, 3H), 3.67 (t, J = 8.1 Hz, 1H), 2.21 (s, 3H), 1.68-1.77 (m, 2H), 1.33 (dd, J = 8.3, 16.1 Hz, 1H), 1.08 (dd, J = 8.6, 16.4 Hz, 1 H), 0.97 (t, J = 7.3 Hz, 3H). LCMS m/z = 342 [MH]+. [α]2% +14.7 (c = 0.1, EtOH). | |
86 | I r 6-(6-(2-hydro yl)pyridin-2-y propoxybenz | OH . / X rB I 1J i XX i xy-1,2-oxaborolan-4)-3-methoxy-2- onitrile | Ή NMR (DMSO-de, 400MHz): δ 8.58 (s, 1H), 7.85 (t, J = 7.7 Hz, 1H), 7.60 (d, J = 7.8 Hz, 1 H), 7.56 - 7.52 (m, 1 H), 7.447.49 (m, 1 H), 7.32 (d, J = 7.6 Hz, 1 H), 4.24-4.31 (m, 1H), 4.06-4.14 (m, 3H), 3.91 (s, 3H), 3.60-3.68 (m, 1H), 1.701.79 (m, 2H), 1.20-1.37 (m, 2H), 1.02 (t, J = 7.5 Hz, 3H). LCMS m/z = 353 [MH]+. |
87 | I r 6-(6-(2-hydro yl)pyridin-2-y propoxybenz | OH . / X rB Π I XX J xy-1,2-oxaborolan-4- )-3-methoxy-2- onitrile, enantiomer 2 | 1H NMR (DMSO-d6, 400MHz): δ 8.58 (s, 1H), 7.85 (t, J = 7.7 Hz, 1H), 7.60 (d, J = 7.8 Hz, 1 H), 7.56 - 7.52 (m, 1 H), 7.447.49 (m, 1H), 7.32 (d, J = 7.6 Hz, 1H), 4.24-4.31 (m, 1H), 4.06-4.14 (m, 3H), 3.91 (s, 3H), 3.60-3.68 (m, 1H), 1./ΟΙ.79 (m, 2H), 1.20-1.37 (m, 2H), 1.02 (t, J = 7.5 Hz, 3H). LCMS m/z = 353.3 [MH]+. RT [Analytical SFC Method M] = 5.79 min. |
88 | OH °ΥΊ rB' l X X z° 4-(4'-methoxy-3’-propoxy-[1,1 biphenyl]-3-yl)-1,2-oxaborolan-2-ol | 1H NMR (DMSO-ds, 400 MHz): δ 8.66 (s, 1H), 7.44-7.49 (m, 2H), 7.35 (m, 1H), 7.16-7.22 (m, 3H), 7.02 (d, J = 8.0 Hz, 1 H), 4.26 (t, J = 8.0 Hz, 1 H), 4.01 (t, J = 6.8 Hz, 2H), 3.79-3.83 (m, 4H), 3.34-3.51 (m, 1H), 1.73-1.79 (m, 2H), 1.25-1.29 (m, |
222
1H), 1.07-1.11 (m, 1H), 0.99 (t, J = 7.6 Hz, 3H). LCMS m/z = 327 [MH]+. | ||
89 | OH II J o 4-(4'-methoxy-3'-propoxy-[1,1 biphenyl]-3-yl)-1,2-oxaborolan-2-ol, enantiomer 1 | 1H NMR (DMSO-de, 400 MHz): δ 8.66 (s, 1H), 7.44-7.49 (m, 2H), 7.35 (m, 1H), 7.16-7.22 (m, 3H), 7.02 (d, J = 8.0 Hz, 1 H), 4.26 (t, J = 8.0 Hz, 1 H), 4.01 (t, J = 6.8 Hz, 2H), 3.79-3.83 (m, 4H), 3.34-3.51 (m, 1H), 1.73-1.79 (m, 2H), 1.25-1.29 (m, 1H), 1.07-1.11 (m, 1H), 0.99 (t, J = 7.6 Hz, 3H). LCMS m/z = 327 [MH]+. RT [Analytical SFC Method N] = 3.76 min. |
90 | OH z°n ύ Il .1 * I o 4-(4'-methoxy-3'-propoxy-[1,1 biphenyl]-3-yl)-1,2-oxaborolan-2-ol, enantiomer 2 | 1H NMR (DMSO-ds, 400 MHz): δ 8.66 (s, 1 H), 7.44-7.49 (m, 2H), 7.35 (m, 1H), 7.16-7.22 (m, 3H), 7.02 (d, J = 8.0 Hz, 1 H), 4.26 (t, J = 8.0 Hz, 1 H), 4.01 (t, J = 6.8 Hz, 2H), 3.79-3.83 (m, 4H), 3.34-3.51 (m, 1H), 1.73-1.79 (m, 2H), 1.25-1.29 (m, 1H), 1.07-1.11 (m, 1H), 0.99 (t, J = 7.6 Hz, 3H). LCMS m/z = 327 [MH]+. RT [Analytical SFC Method N] = 3.97 min. |
91 | OH / F f b /H N ο—Z νχ/ Il / /=/ Xs J Æ° 4-(2-(5-ethoxy-2-fluoro-4- methoxyphenyl)thiazol-4-yl)-1,2- oxaborolan-2-ol | Ή NMR (DMSO-d6, 400MHz): δ 8.66 (s, 1H), 7.62 (d, J = 7.0 Hz, 1H), 7.41 (s, 1H), 7.05-7.10 (m, 1H), 4.26 (dd, J = 7.5, 8.5 Hz, 1H), 4.05 (q, J = 6.9 Hz, 2H), 3.93 (dd, J = 7.5, 9.0 Hz, 1H), 3.83 (s, 3H), 3.57-3.66 (m, 1 H), 1.34 (t, J = 7.0 Hz, 3H), 1.25-1.32 (m, 1H), 1.12-1.20 (m, 1H). LCMS m/z = 338 [MH]+. |
223
92 | F *[ B-OH o—\ w T / j>=/ x Æ° (-) 4-(2-(5-ethoxy-2-fluoro-4- methoxyphenyl)thiazol-4-yl)-1,2- oxaborolan-2-ol enantiomer 2 | Ή NMR (DMSO-de, 400MHz): δ 8.66 (s, 1 H), 7.62 (d, J = 7.0 Hz, 1 H), 7.41 (s, 1H), 7.05-7.10 (m, 1H), 4.26 (dd, J = 7.5, 8.5 Hz, 1 H), 4.05 (q, J = 6.9 Hz, 2H), 3.93 (dd, J = 7.5, 9.0 Hz, 1H), 3.83 (s, 3H), 3.57-3.66 (m, 1 H), 1.34 (t, J = 7.0 Hz, 3H), 1.25-1.32 (m, 1H), 1.12-1.20 (m, 1H). LCMS m/z = 338 [MH]+. RT [Analytical SFC Method O] = 4.13 min. [α]2% -37.9 (c= 0.1, EtOH). |
93 | I OH Z \ L if I o N 4-(3-(4-(cyclopentyloxy)-5methoxypyrimidin-2-yl)phenyl)-1,2oxaborolan-2-ol | Ή NMR (DMSO-de, 400MHz): δ 8.67 (br s, 1H), 8.30 (s, 1H), 8.18 (s, 1H), 8.108.15 (m, 1H), 7.39-7.45 (m, 1H), 7.347.38 (m, 1H), 5.56-5.63 (m, 1H), 4.264.32 (m, 1H), 3.89 (s, 3H), 3.80 (t, J = 8.6 Hz, 1H), 3.48-3.55 (m, 1H), 2.04-2.15 (m, 2H), 1.60-1.85 (m, 6H), 1.33 (dd, J = 8.3, 16.1 Hz, 1H), 0.99-1.08 (m, 1H). LCMS m/z = 355 [MH]+. |
94 | OH A L II I o '° iCl F^F N 4-(5-(3-ethoxy-4-methoxy-2(trifluoromethyl)phenyl)pyridin-3-yl)-1,2oxaborolan-2-ol | 1H NMR (DMSO-d6, 400MHz): δ 8.70 (d, J = 2.5 Hz, 1H), 8.48 (d, J = 2.0 Hz, 1H), 8.26-8.32 (m, 1H), 7.58 (d, J = 2.0 Hz, 1H), 7.37-7.43 (m, 1H), 7.05 (d, J = 9.0 Hz, 1 H), 4.19-4.34 (m, 1 H), 4.09 (td, J = 3.1, 9.9 Hz, 2H), 3.87-3.95 (m, 3H), 3.723.83 (m, 1H), 3.46-3.55 (m, 1H), 1.261.37 (m, 4H), 1.00-1.13 (m, 1H). LCMS m/z = 382 [MH]+. |
224
95 | OH .L II * 1 o F^F 4-(5-(3-ethoxy-4-methoxy-2- (trifluoromethyl)phenyl)pyridin-3-yl)-1,2oxaborolan-2-ol, enantiomer 1 | Ή NMR (DMSO-d6, 400MHz): δ 8.70 (d, J = 2.5 Hz, 1 H), 8.48 (d, J = 2.0 Hz, 1 H), 8.26-8.32 (m, 1H), 7.58 (d, J = 2.0 Hz, 1 H), 7.37-7.43 (m, 1 H), 7.05 (d, J = 9.0 Hz, 1H), 4.19-4.34 (m, 1H), 4.09 (td, J = 3.1, 9.9 Hz, 2H), 3.87-3.95 (m, 3H), 3.723.83 (m, 1H), 3.46-3.55 (m, 1H), 1.261.37 (m, 4H), 1.00-1.13 (m, 1H). LCMS m/z = 382 [MH]+. RT [Analytical SFC Method E] = 3.14 min. |
96 | OH ^°XX J 4-(5-(3,4-diethoxyphenyl)pyridin-3-yl)1,2-oxaborolan-2-ol | 1H NMR (DMSO-d6, 400MHz): δ 8.688.75 (m, 2H), 8.42 (d, J = 1.5 Hz, 1 H), 7.93 (s, 1 H), 7.27 (d, J = 2.0 Hz, 1 H), 7.23 (dd, J = 1.8, 8.3 Hz, 1 H), 7.04 (d, J = 8.5 Hz, 1H), 4.27 (t, J = 8.3 Hz, 1H), 4.13 (q, J = 6.9 Hz, 2H), 4.06 (q, J = 7.0 Hz, 2H), 3.86 (t, J = 8.8 Hz, 1H), 3.453.54 (m, 1H), 1.26-1.39 (m, 7H), 1.14 (dd, J = 10.5, 16.1 Hz, 1H). LCMS m/z = 328 [MH]+. |
97 | OH L II .J b ^KF 4-(5-(3,4-diethoxyphenyl)pyridin-3-yl)- 1,2-oxaborolan-2-ol, enantiomer 2 | Ή NMR (DMSO-c/6, 400MHz): δ 8.688.75 (m, 2H), 8.42 (d, J = 1.5 Hz, 1 H), 7.93 (s, 1 H), 7.27 (d, J = 2.0 Hz, 1 H), 7.23 (dd, J = 1.8, 8.3 Hz, 1 H), 7.04 (d, J = 8.5 Hz, 1H), 4.27 (t, J = 8.3 Hz, 1H), 4.13 (q, J = 6.9 Hz, 2H), 4.06 (q, J = 7.0 Hz, 2H), 3.86 (t, J = 8.8 Hz, 1H), 3.453.54 (m, 1H), 1.26-1.39 (m, 7H), 1.14 (dd, J = 10.5, 16.1 Hz, 1H). LCMS m/z = 345 [MH+H2O]+. RT [Analytical SFC Method D] = 5.73 min. |
225
98 | OH >G N 4-(5-(3,4-diethoxyphenyl)pyridin-3-yl)- 1,2-oxaborolan-2-ol, enantiomer 1 | Ή NMR (DMSO-de, 400MHz): δ 8.688.75 (m, 2H), 8.42 (d, J = 1.5 Hz, 1 H), 7.93 (s, 1 H), 7.27 (d, J = 2.0 Hz, 1 H), 7.23 (dd, J = 1.8, 8.3 Hz, 1 H), 7.04 (d, J = 8.5 Hz, 1H), 4.27 (t, J = 8.3 Hz, 1H), 4.13 (q, J = 6.9 Hz, 2H), 4.06 (q, J = 7.0 Hz, 2H), 3.86 (t, J = 8.8 Hz, 1 H), 3.453.54 (m, 1H), 1.26-1.39 (m, 7H), 1.14 (dd, J = 10.5, 16.1 Hz, 1H). LCMS m/z = 328 [MH]+. RT [Analytical SFC Method D] = 5.37 min. |
99 | I OH ΛΊ 3ΥΊ X \ A /L· A A o “ C 4-(5-(3-(cyclopentyloxy)-4(methylthio)phenyl)pyridin-3-yl)-1,2oxaborolan-2-ol | 1H NMR (DMSO-d6, 400MHz): δ 8.73 (s, 2H), 8.44-8.48 (m, 1H), 7.96 (s, 1H), 7.28-7.33 (m, 1H), 7.26 (s, 1H), 7.197.24 (m, 1H), 5.10 (t, J = 5.5 Hz, 1H), 4.28 (t, J = 8.3 Hz, 1H), 3.83-3.91 (m, 1H), 3.49-3.57 (m, 1H), 2.39 (s, 3H), 1.87-1.96 (m, 2H), 1.75 (d, J = 4.5 Hz, 4H), 1.56-1.66 (m, 2H), 1.32 (dd, J = 8.3, 16.3 Hz, 1H), 1.10-1.19 (m, 1H). LCMS m/z = 370 [MH]+. |
100 | I OH r-B ΑΊ A a * y ° 4-(5-(3-(cyclopentyloxy)-4(methylthio)phenyl)pyridin-3-yl)-1,2oxaborolan-2-ol enantiomer 1 | 1H NMR (DMSO-c/6, 400MHz): δ 8.73 (s, 2H), 8.44-8.48 (m, 1H), 7.96 (s, 1H), 7.28-7.33 (m, 1H), 7.26 (s, 1H), 7.197.24 (m, 1H), 5.10 (t, J = 5.5 Hz, 1H), 4.28 (t, J = 8.3 Hz, 1H), 3.83-3.91 (m, 1H), 3.49-3.57 (m, 1H), 2.39 (s, 3H), 1.87-1.96 (m, 2H), 1.75 (d, J = 4.5 Hz, 4H), 1.56-1.66 (m, 2H), 1.32 (dd, J = 8.3, 16.3 Hz, 1H), 1.10-1.19 (m, 1H). LCMS m/z = 388 [MH+H2O]+. RT [Analytical SFC Method P] = 3.83 min. |
226
101 | I OH γΑ \ JL * θ 4-(5-(3-(cyclopentyloxy)-4(methylthio)phenyl)pyridin-3-yl)-1,2oxaborolan-2-ol, enantiomer 2 | 1H NMR (DMSO-d6, 400MHz): δ 8.73 (s, 2H), 8.44-8.48 (m, 1H), 7.96 (s, 1H), 7.28-7.33 (m, 1H), 7.26 (s, 1H), 7.197.24 (m, 1H), 5.10 (t, J = 5.5 Hz, 1H), 4.28 (t, J = 8.3 Hz, 1H), 3.83-3.91 (m, 1H), 3.49-3.57 (m, 1H), 2.39 (s, 3H), 1.87-1.96 (m, 2H), 1.75 (d, J = 4.5 Hz, 4H), 1.56-1.66 (m, 2H), 1.32 (dd, J = 8.3, 16.3 Hz, 1H), 1.10-1.19 (m, 1H). LCMS m/z = 388 [MH+H2O]+. RT [Analytical SFC Method P] = 4.17 min. |
102 | OH /°y^ rB '°'ï Ό I 4-(2-(4-methoxy-3-propoxyphenyl)-6(methoxymethyl)pyrimidin-4-yl)-1,2oxaborolan-2-ol | 1H NMR (DMSO-ds, 400MHz): δ 8.69 (br s, 1H), 7.99 (dd, J = 1.9, 8.4 Hz, 1H), 7.95 (d, J = 1.8 Hz, 1 H), 7.22 (s, 1 H), 7.07 (d, J = 8.8 Hz, 1 H), 4.54 (s, 2H), 4.30 (dd, J = 7.5, 8.8 Hz, 1H), 3.96-4.03 (m, 3H), 3.83 (s, 3H), 3.58-3.65 (m, 1H), 3.43 (s, 3H), 1.73-1.81 (m, 2H), 1.241.34 (m, 1H), 1.12-1.21 (m, 1H), 0.961.06 (m, 3H). LCMS m/z = 391 [MH+H2O]+. |
103 | OH /°yx Γ-θ AJCnvA/O N 05® Ό I (-) 4-(2-(4-methoxy-3-propoxyphenyl)- 6-(methoxymethyl)pyrimidin-4-yl)-1,2- oxaborolan-2-ol, enantiomer 2 | 1H NMR (DMSO-d6, 400MHz): δ 8.69 (br s, 1 H), 7.99 (dd, J = 1.9, 8.4 Hz, 1 H), 7.95 (d, J = 1.8 Hz, 1 H), 7.22 (s, 1 H), 7.07 (d, J = 8.8 Hz, 1H), 4.54 (s, 2H), 4.30 (dd, J = 7.5, 8.8 Hz, 1 H), 3.96-4.03 (m, 3H), 3.83 (s, 3H), 3.58-3.65 (m, 1H), 3.43 (s, 3H), 1.73-1.81 (m, 2H), 1.241.34 (m, 1H), 1.12-1.21 (m, 1H), 0.961.06 (m, 3H). LCMS m/z = 391 [MH+H2O]+. RT [Analytical SFC Method Q] = 3.25 min. [α]2% -38.3 (c = 0.1, EtOH). |
227
104 | OH ^°X1 IT 4-(5-(4-ethoxy-3- propoxyphenyl)pyridin-3-yl)-1,2- oxaborolan-2-ol | 1H NMR (DMSO-c/β, 400MHz): δ 8.71 (s, 1 H), 8.70 (d, J = 1.5 Hz, 1 H), 8.42 (d, J = 1.5 Hz, 1 H), 7.93 (t, J = 2.0 Hz, 1 H), 7.28 (d, J = 2.0 Hz, 1H), 7.23 (dd, J = 2.0, 8.0 Hz, 1 H), 7.03-7.07 (m, 1 H), 4.27 (t, J = 8.3 Hz, 1H), 4.00-4.11 (m, 4H), 3.86 (t, J = 9.0 Hz, 1H), 3.45-3.55 (m, 1H), 1.701.80 (m, 3H), 1.27-1.37 (m, 3H), 1.ΙΟΙ.19 (m, 1H), 1.00 (t, J = 7.5 Hz, 3H). LCMS m/z = 342 [MH]+. |
105 | OH GG -G '^'ο'^ιΠι TT 4-(5-(4-ethoxy-3propoxyphenyl)pyridin-3-yl)-1,2oxaborolan-2-ol, enantiomer 2 | Ή NMR (DMSO-de, 400MHz): δ 8.71 (s, 1 H), 8.70 (d, J = 1.5 Hz, 1 H), 8.42 (d, J = 1.5 Hz, 1 H), 7.93 (t, J = 2.0 Hz, 1 H), 7.28 (d, J = 2.0 Hz, 1H), 7.23 (dd, J = 2.0, 8.0 Hz, 1H), 7.03-7.07 (m, 1H), 4.27 (t, J = 8.3 Hz, 1 H), 4.00-4.11 (m, 4H), 3.86 (t, J = 9.0 Hz, 1H), 3.45-3.55 (m, 1H), 1.701.80 (m, 3H), 1.27-1.37 (m, 3H), 1.ΙΟΙ.19 (m, 1H), 1.00 (t, J = 7.5 Hz, 3H). LCMS m/z = 342 [MH]+. RT [Analytical SFC Method R] = 3.48 min. |
106 | OH /ο-' / 4-(5-(4-ethoxy-3- propoxyphenyl)pyridin-3-yl)-1,2- oxaborolan-2-ol, enantiomer 1 | Ή NMR (DMSO-c/6, 400MHz): δ 8.71 (s, 1 H), 8.70 (d, J = 1.5 Hz, 1 H), 8.42 (d, J = 1.5 Hz, 1 H), 7.93 (t, J = 2.0 Hz, 1 H), 7.28 (d, J = 2.0 Hz, 1H), 7.23 (dd, J = 2.0, 8.0 Hz, 1 H), 7.03-7.07 (m, 1 H), 4.27 (t, J = 8.3 Hz, 1 H), 4.00-4.11 (m, 4H), 3.86 (t, J = 9.0 Hz, 1H), 3.45-3.55 (m, 1H), 1.701.80 (m, 3H), 1.27-1.37 (m, 3H), 1.ΙΟΙ.19 (m, 1H), 1.00 (t, J = 7.5 Hz, 3H). LCMS m/z = 342 [MH]+. RT [Analytical SFC Method R] = 2.25 min. |
228
107 | OH i jx /χ o χ°Ύυ N 4-(5-(2-fluoro-3,4- dimethoxyphenyl)pyridin-3-yl)-1,2oxaborolan-2-ol | Ή NMR (DMSO-d6, 400MHz): δ 8.72 (s, 1H), 8.56 (dd, J = 2.0, 8.8 Hz, 1H), 8.48 (d, J = 2.0 Hz, 1 H), 7.82 (s, 1 H), 7.257.29 (m, 1H), 7.02 (d, J= 8.8 Hz, 1H), 4.28 (t, J= 8.4 Hz, 1H), 3.81-3.87 (m, 7H), 3.41-3.55 (m, 1H), 1.29-1.35 (m, 1H), 1.06-1.13 (m, 1H). LCMS m/z = 318 [MH]+. |
108 | OH jf Ί *Γ b X°TU N 4-(5-(2-fluoro-3,4- dimethoxyphenyl)pyridin-3-yl)-1,2oxaborolan-2-ol, enantiomer 1 | LCMS m/z = 332 [MH+H2O]+. RT [Analytical SFC Method S] = 5.28 min. |
109 | OH r-B JT Ί b θΎΥ/ N 4-(5-(2-fluoro-3,4- dimethoxyphenyl)pyridin-3-yl)-1,2oxaborolan-2-ol, enantiomer 2 | LCMS m/z = 318 [MH]+. RT [Analytical SFC Method S] = 5.35 min. |
110 | OH /°^ rB II / b 4-(4'-methoxy-3'-(pentyloxy)-[1,1 biphenyl]-3-yl)-1,2-oxaborolan-2-ol | LCMS m/z = 355 [MH]+. |
229
111 | OH F K X X b (-) 4-(5-(2-fluoro-4-methoxy-5propoxyphenyl)pyridin-3-yl)-1,2- oxaborolan-2-ol, enantiomer 1 | 1H NMR (DMSO-de, 400MHz): δ 8.89 (s, 1 H), 8.74 (s, 1 H), 8.49 (d, J = 2.0 Hz, 1H), 8.09 (s, IH), 7.47-7.53 (m, 1H), 4.27-4.36 (m, 3H), 3.87 (s, 3H), 3.82 (t, J = 8.7 Hz, 1H), 3.50-3.56 (m, 1H), 1.751.80 (m, 2H), 1.34 (dd, J= 8.2, 16.3 Hz, 1H), 1.01-1.12 (m, 1H), 0.98 (t, J= 7.3 Hz, 3H). LCMS m/z = 346 [MH]+. [α]2%-17.7 (c = 0.15, EtOH). |
112 | OH Y X Co °fj'z 4-(5-(4-(methylthio)-3propoxyphenyl)pyridin-3-yl)-1,2oxaborolan-2-ol | 1H NMR (DMSO-de, 400MHz): δ 8.74 (d, J = 2.5 Hz, 1 H), 8.73 (s, 1 H), 8.46 (d, J = 2.0 Hz, 1 H), 7.98 (t, J = 2.0 Hz, 1 H), 7.30-7.34 (m, 1 H), 7.26 (d, J = 1.5 Hz, 1H), 7.22 (d, J = 8.0 Hz, 1H), 4.28 (t, J = 8.3 Hz, 1 H), 4.11 (t, J = 6.3 Hz, 2H), 3.87 (t, J = 9.0 Hz, 1 H), 3.46-3.57 (m, 1 H), 2.41 (s, 3H), 1.71-1.82 (m, 2H), 1.271.36 (m, 1H), 1.11-1.20 (m, 1H), 1.03 (t, J = 7.5 Hz, 3H). LCMS m/z = 344 [MH]+. |
113 | OH zsy\ rK II b 4-(5-(4-(methylthio)-3- propoxyphenyl)pyridin-3-yl)-1,2oxaborolan-2-ol, enantiomer 1 | 1H NMR (DMSO-d6, 400MHz): δ 8.74 (d, J = 2.5 Hz, 1 H), 8.73 (s, 1 H), 8.46 (d, J = 2.0 Hz, 1 H), 7.98 (t, J = 2.0 Hz, 1 H), 7.30-7.34 (m, 1 H), 7.26 (d, J = 1.5 Hz, 1 H), 7.22 (d, J = 8.0 Hz, 1 H), 4.28 (t, J = 8.3 Hz, 1 H), 4.11 (t, J = 6.3 Hz, 2H), 3.87 (t, J = 9.0 Hz, 1 H), 3.46-3.57 (m, 1 H), 2.41 (s, 3H), 1.71-1.82 (m, 2H), 1.271.36 (m, 1H), 1.11-1.20 (m, 1H), 1.03 (t, J = 7.5 Hz, 3H). LCMS m/z = 343 [MH]+. RT = 5.23 min. |
230
114 | OH •'θΎΑ H L II * I o ο ΓΧ'^ 4-(5-(4-(methylthio)-3- propoxyphenyl)pyridin-3-yl)-1,2- oxaborolan-2-ol, enantiomer 2 | Ή NMR (DMSO-d6, 400MHz): δ 8.74 (d, J = 2.5 Hz, 1H), 8.73 (s, 1H), 8.46 (d, J = 2.0 Hz, 1 H), 7.98 (t, J = 2.0 Hz, 1 H), 7.30-7.34 (m, 1 H), 7.26 (d, J = 1.5 Hz, 1 H), 7.22 (d, J = 8.0 Hz, 1 H), 4.28 (t, J = 8.3 Hz, 1H), 4.11 (t, J = 6.3 Hz, 2H), 3.87 (t, J = 9.0 Hz, 1H), 3.46-3.57 (m, 1H), 2.41 (s, 3H), 1.71-1.82 (m, 2H), 1.271.36 (m, 1H), 1.11-1.20 (m, 1H), 1.03 (t, J = 7.5 Hz, 3H). LCMS m/z = 343 [MH]+. RT = 5.63 min. |
115 | OH r® ΧΧ,νΥΑ 0^y 4-(6-(4-methoxy-3- propoxyphenyl)pyrazin-2-yl)-1,2oxaborolan-2-ol | Ή NMR (DMSO-de, 400MHz): δ 9.06 (s, 1 H), 8.67 (s, 1 H), 8.44 (s, 1 H), 7.73 (br s, 2H), 7.08 (d, J = 8.8 Hz, 1H), 4.30 (t, J = 8.2 Hz, 1H), 3.94-4.06 (m, 3H), 3.83 (s, 3H), 3.61-3.74 (m, 1H), 1.71-1.83 (m, 2H), 1.26-1.36 (m, 1H), 1.14-1.22 (m, 1H), 1.00 (t, J = 7.3 Hz, 3H). LCMS m/z = 329 [MH]+. |
116 | OH XX x$ 4-(2'-fluoro-4'-methoxy-3'-propoxy-[1,1 'biphenyl]-3-yl)-1,2-oxaborolan-2-ol | Ή NMR (DMSO-d6,400 MHz): δ 8.65 (s, 1H), 7.36-7.40 (m, 2H), 7.26-7.32 (m, 2H), 7.16 (t, J= 8.4 Hz, 1H), 6.97 (d, J = 8.8 Hz, 1H), 4.25 (t, J= 8.0 Hz, 1H), 3.96 (t, J = 4.2 Hz, 2H), 3.86 (s, 3H), 3.79 (t, J = 8.8 Hz, 1H), 3.34-3.49 (m, 1H), 1.651.71 (m, 2H), 1.26-1.28 (m, 1H), 1.021.08 (m, 1 H), 0.98 (t, J = 8.0 Hz, 3H). LCMS m/z = 343 [MH]’. |
231
117 | N II OH °Ί u L II 1 o 3'-(2-hydroxy-1,2-oxaborolan-4-yl)-4,5dimethoxy-[1,1 '-biphenyl]-3-carbonitrile | Ή NMR (DMSO-de, 400MHz): δ 7.47 (d, J = 8.8 Hz, 1 H), 7.44 (s, 1 H), 7.41 (d, J = 7.2 Hz, 1H), 7.32-7.37 (m, 2H), 7.29 (d, J = 8.6 Hz, 1H), 4.23-4.29 (m, 1H), 3.94 (s, 3H), 3.91 (s, 3H), 3.81 (t, J = 8.8 Hz, 1 H), 1.29 (dd, J = 8.4, 16.2 Hz, 1H), 1.08 (dd, J = 10.0, 16.2 Hz, 1H). LCMS m/z = 324 [MH]+. | |
118 | h I ^o^ 3-ethoxy-5 oxaborolar methoxybe | J । OH / -(5-(2-hydroxy-1,2i-4-yl)pyridin-3-yl)-2jnzonitrile | 1H NMR (DMSO-c/6, 400MHz): δ 7.47 (d, J = 8.8 Hz, 1 H), 7.44 (s, 1 H), 7.41 (d, J = 7.2 Hz, 1H), 7.32-7.37 (m, 2H), 7.29 (d, J = 8.6 Hz, 1H), 4.23-4.29 (m, 1H), 3.94 (s, 3H), 3.91 (s, 3H), 3.81 (t, J = 8.8 Hz, 1H), 1.29 (dd, J = 8.4, 16.2 Hz, 1H), 1.08 (dd, J= 10.0, 16.2 Hz, 1H). LCMS m/z = 339 [MH]+. |
119 | r 3-ethoxy-5 oxaborolar methoxybe | t 1 OH / -(5-(2-hydroxy-1,2- i-4-yl)pyridin-3-yl)-2- ïnzonitrile, enantiomer 1 | Ή NMR (DMSO-d6, 400MHz): δ 7.47 (d, J = 8.8 Hz, 1 H), 7.44 (s, 1 H), 7.41 (d, J = 7.2 Hz, 1H), 7.32-7.37 (m, 2H), 7.29 (d, J = 8.6 Hz, 1H), 4.23-4.29 (m, 1H), 3.94 (s, 3H), 3.91 (s, 3H), 3.81 (t, J = 8.8 Hz, 1 H), 1.29 (dd, J = 8.4, 16.2 Hz, 1H), 1.08 (dd, J = 10.0, 16.2 Hz, 1 H). LCMS m/z = 339.1 [MH]+. RT [Analytical SFC Method T] = 4.71 min. |
120 | OH T 1 JT b 4-(3-(6-ethoxy-5-methoxypyridin-2yl)phenyl)-1,2-oxaborol-2(5H)-ol | 1H NMR (DMSO-de, 400MHz): δ 8.68 (s, 1H), 8.13 (s, 1H), 8.02 (d, J = 7.6 Hz, 1 H), 7.60 (d, J = 8.4 Hz, 1 H), 7.54 (d, J = 7.6 Hz, 1 H), 7.48 (t, J = 7.6 Hz, 1 H), 7.35 (d, J = 8.0 Hz, 1 H), 6.27 (s, 1 H), 4.97 (s, 2H), 4.47 (q, J = 7.2 Hz, 2H), 3.83 (s, 3H), 1.39 (t, J = 6.8 Hz, 3H). LCMS m/z = 312 [MH]+. |
232
121 | OH rB X jl C b ^Ο^Ν^γ^^ 4-(3-(6-ethoxy-5-methoxypyridin-2yl)phenyl)-1,2-oxaborolan-2-ol | Ή NMR (DMS0-d6, 400MHz): δ 8.65 (s, 1 H), 7.88 (s, 1 H), 7.83 (d, J = 7.6 Hz, 1 H), 7.49 (d, J = 8.0 Hz, 1 H), 7.32-7.36 (m, 2H), 7.24 (d, J = 7.2 Hz, 1 H), 4.44 (q, J = 7.2 Hz, 2H), 4.27 (t, J = 8.0 Hz, 1 H), 3.82 (m, 4H), 3.43-3.51 (m, 1H) 1.38 (t, J = 6.8 Hz, 3H), 1.30 (q, J= 8.0 Hz, 1H), 1.03-1.10 (m, 1H). LCMS m/z = 314 [MH]+. |
122 | OH .O. d JL if / o ^ Ν^γγ^7 4-(3-(4,5-dimethoxypyrimidin-2yl)phenyl)-1,2-oxaborolan-2-ol | Ή NMR (DMSO-de, 400MHz): δ 8.67 (br s, 1H), 8.33 (s, 1H), 8.12-8.27 (m, 2H), 7.31-7.50 (m, 2H), 4.24-4.34 (m, 1H), 4.06 (s, 3H), 3.90 (s, 3H), 1.32 (br dd, J = 8.4, 16.2 Hz, 1H), 1.04 (brdd, J = 9.6, 16.1 Hz, 1H). LCMS m/z = 317 [MH]+. |
123 | OH L JJ 4 ,o ^ο^Ν^γγγ^^7 4-(3-(4,5-dimethoxypyrimidin-2yl)phenyl)-1,2-oxaborolan-2-ol, enantiomer 1 | RT [Analytical SFC Method U] = 1.64 min. |
124 | OH z°Y% TF F T (+) 4-(2-(4-methoxy-3-propoxyphenyl)- 6-(trifluoromethyl)pyrimidin-4-yl)-1,2- oxaborolan-2-ol, enantiomer 1 | 1H NMR (DMSO-de, 400MHz): δ 8.72 (s, 1 H), 8.03 (dd, J = 2.0, 8.6 Hz, 1 H), 7.95 (d, J = 2.0 Hz, 1H), 7.77 (s, 1H), 7.13 (d, J = 8.6 Hz, 1 H), 4.32 (dd, J = 7.4, 9.0 Hz, 1H), 3.98-4.09 (m, 3H), 3.86 (s, 3H), 3.73-3.82 (m, 1H), 1.73-1.84 (m, 1H), 1.31-1.41 (m, 1H), 1.18-1.26 (m, 2H), 1.01 (t, J= 7A Hz, 3H). LCMS m/z = 397 [MH+H2O]+. [a]20D + 19.4 (c = 0.1, EtOH). |
233
125 | I OH ΛΊ °ΥΊ A 4-(6-(3-(cyclopentyloxy)-4methoxyphenyl)pyrazin-2-yl)-1,2oxaborolan-2-ol | Ή NMR (DMSO-d6, 400MHz): δ 9.05 (s, 1H), 8.68 (s, 1H), 8.44 (s, 1H), 7.70-7.73 (m, 2H), 7.05-7.10 (m, 1H), 4.92 (t, J = 6.1 Hz, 1 H), 4.31 (dd, J = 7.3, 9.3 Hz, 1H), 3.99 (dd, J = 6.6, 9.0 Hz, 1H), 3.81 (s, 3H), 3.64-3.72 (m, 1 H), 1.94 (d, J = 6.4 Hz, 2H), 1.68-1.81 (m, 4H), 1.55-1.64 (m, 2H), 1.27-1.36 (m, 1H), 1.14-1.23 (m, 1H). LCMS m/z = 355 [MH]+. |
126 | I OH an °Ύ^ rB' <Y YJY« YY 4-(6-(3-(cyclopentyloxy)-4methoxyphenyl)pyrazin-2-yl)-1,2oxaborolan-2-oi, enantiomer 1 | Ή NMR (DMSO-c/β, 400MHz): δ 9.05 (s, 1H), 8.68 (s, 1H), 8.44 (s, 1H), 7.70-7.73 (m, 2H), 7.05-7.10 (m, 1H), 4.92 (t, J = 6.1 Hz, 1H), 4.31 (dd, J = 7.3, 9.3 Hz, 1H), 3.99 (dd, J = 6.6, 9.0 Hz, 1H), 3.81 (s, 3H), 3.64-3.72 (m, 1H), 1.94 (d, J = 6.4 Hz, 2H), 1.68-1.81 (m, 4H), 1.55-1.64 (m, 2H), 1.27-1.36 (m, 1H), 1.14-1.23 (m, 1H). LCMS m/z = 355 [MH]+. RT [Analytical SFC Method C] = 7.2 min. |
127 | OH /°^ γβ/ .. ΑΥ,^Υ Q 4-(6-(4-methoxy-3- propoxyphenyl)pyridin-2-yl)-1,2oxaborolan-2-ol | 1H NMR (DMSO-de, 400MHz): δ 8.59 (s, 1H), 7.70-7.76 (m, 3H), 7.64 (d, J = 8.3 Hz, 1H), 7.16 (dd, J = 2.8, 5.3 Hz, 1H), 7.04 (d, J = 8.3 Hz, 1 H), 4.29 (t, J = 8.1 Hz, 1H), 3.94-4.05 (m, 3H), 3.81 (s, 3H), 3.55-3.63 (m, 1H), 1.72-1.84 (m, 2H), 1.22-1.31 (m, 1H), 1.14-1.21 (m, 1H), 1.01 (t, J = 7.5 Hz, 3H). LCMS m/z = 346 [MH]+. |
128 | OH γβ/ , Υλ Y-1 (-) 4-(6-(4-methoxy-3- propoxyphenyl)pyridin-2-yl)-1,2- oxaborolan-2-ol, enantiomer 1 | Ή NMR (DMSO-c/β, 400MHz): δ 8.59 (s, 1H), 7.70-7.76 (m, 3H), 7.64 (d, J = 8.3 Hz, 1H), 7.16 (dd, J = 2.8, 5.3 Hz, 1H), 7.04 (d, J = 8.3 Hz, 1 H), 4.29 (t, J = 8.1 Hz, 1H), 3.94-4.05 (m, 3H), 3.81 (s, 3H), 3.55-3.63 (m, 1 H), 1.72-1.84 (m, 2H), 1.22-1.31 (m, 1H), 1.14-1.21 (m, 1H), 1.01 (t, J = 7.5 Hz, 3H). LCMS m/z = 328 [MH]+. [α]2%-39.5 (c = 3.8, EtOH). |
234
129 | I OH r-B X.X £ζθ °i/X' 4-(3'-(cyclopentyloxy)-4'-methoxy-[1,1 biphenyl]-3-yl)-1,2-oxaborol-2(5H)-ol | 1H NMR (DMSO-d6, 400MHz): δ 7.71 (s, 1H), 7.62 (d, J = 7.2 Hz, 1H), 7.51-7.53 (m, 1H), 7.44-7.48 (m, 1H), 7.21-7.24 (m, 2H), 7.04 (d, J = 8.0 Hz, 1 H), 6.27 (s, 1H), 4.94-4.98 (m, 3H), 3.79 (s, 3H), 1.87-1.94 (m, 2H), 1.74-1.78 (m, 4H), 1.54-1.62 (m, 2H). LCMS m/z = 351 [MH]+. |
130 | I OH /-Y r-B XX XL X £ z° 4-(3'-(cyclopentyloxy)-4'-methoxy-[1,1 'biphenyl]-3-yl)-1,2-oxaborolan-2-ol | Ή NMR (DMSO-de, 400MHz): δ 7.48 (s, 1H), 7.43 (d, J= 7.6 Hz, 1H), 7.35 (t, J = 7.6 Hz, 1 H), 7.21 (d, J = 7.6 Hz, 1 H), 7.15-7.17 (m, 2H), 7.02 (d, J= 8.8 Hz, 1H), 4.91-4.94 (m, 1H), 4.26 (t, J= 8.0 Hz, 1H), 3.81 (t, J = 8.8 Hz, 1H), 3.77 (s, 3H), 3.42-3.51 (m, 1H), 1.88-1.92 (m, 2H), 1.73-1.76 (m, 4H), 1.58 (m, 2H), 1.29 (q, J= 8.0 Hz, 1H), 1.05-1.11 (m, 1H). LCMS m/z = 353 [MH]+. |
131 | I OH VL AJVnVV5 Tl 4-(6-(3-(cyclopentyloxy)-4- methoxyphenyl)-5-fluoropyridin-2-yl)- 1,2-oxaborolan-2-ol | Ή NMR (DMSO-c/e, 400MHz): δ 8.61 (s, 1 H), 7.68 (dd, J = 8.3, 11.8 Hz, 1 H), 7.58 (s, 1H), 7.50-7.55 (m, 1H), 7.27 (dd, J = 3.3, 8.3 Hz, 1H), 7.07 (d, J = 8.5 Hz, 1H), 4.81-4.86 (m, 1H), 4.28 (dd, J = 7.5, 9.0 Hz, 1 H), 3.97 (dd, J = 7.3, 8.8 Hz, 1 H), 3.81 (s, 3H), 3.58-3.66 (m, 1H), 1.92 (d, J = 6.5 Hz, 2H), 1.68-1.80 (m, 4H), 1.59 (brs, 2H), 1.23-1.31 (m, 1H), 1.12-1.20 (m, 1H). LCMS m/z = 344 [MH]+. |
235
132 | I OH /-! °V> r® VL zULnJs/» cy 4-(2-(3-(cyclopentyloxy)-4- methoxyphenyl)-6-methoxypyrimidin-4yl)-1,2-oxaborolan-2-ol | 1H NMR (DMSO-d6, 400MHz): δ 8.66 (br s, 1H), 7.98 (d, J = 2.0 Hz, 1H), 7.96 (s, 1H), 7.05 (d, J = 8.5 Hz, 1H), 6.64 (s, 1H), 4.83-4.90 (m, 1H), 4.26 (dd, J = 7.5, 9.0 Hz, 1H), 3.92-4.01 (m, 4H), 3.81 (s, 3H), 3.50 (td, J = 7.3, 14.9 Hz, 1 H), 1.94 (d, J = 6.5 Hz, 2H), 1.68-1.82 (m, 4H), 1.59 (br s, 2H), 1.20-1.29 (m, 1 H), 1.091.18 (m, 1H). LCMS m/z = 385 [MH]+. |
133 | OH vB , AJx.+ V O ethyl 2-(6-(2-hydroxy-1,2-oxaborolan-4yl)-2-(4-methoxy-3propoxyphenyl)pyrimidin-4-yl)acetate | 1H NMR (DMSO-c/β, 400MHz): δ 8.69 (s, 1H), 7.98 (dd, J = 2.0, 8.3 Hz, 1H), 7.93 (d, J = 2.0 Hz, 1 H), 7.23 (s, 1 H), 7.07 (d, J = 8.6 Hz, 1H), 4.30 (dd, J = 7.5, 8.9 Hz, 1H), 4.14 (q, J = 7.1 Hz, 2H), 3.95-4.02 (m, 3H), 3.88 (s, 2H), 3.83 (s, 3H), 3.543.62 (m, 1H), 1.73-1.81 (m, 2H), 1.251.33 (m, 1H), 1.21 (t, J = 7.1 Hz, 3H), 1.12-1.19 (m, 1H), 1.00 (t, J = 7.3 Hz, 3H). LCMS m/z = 433 [MH+H2O]+. |
134 | OH rB XzX J / ,· /1' .-0 γ^ OH 2-(6-(2-hydroxy-1,2-oxaborolan-4-yl)-2(4-methoxy-3-propoxyphenyl)pyrimidin4-yl)acetic acid | Ή NMR (CD3OD, 400MHz): δ 8.05 (s, 2H), 7.18 (s, 1H), 7.03 (d, J = 8.6 Hz, 1H), 4.16-4.22 (m, 1H), 4.07 (t, J = 6.5 Hz, 2H), 3.96-4.02 (m, 1H), 3.90 (s, 3H), 3.70 (s, 2H), 3.40-3.46 (m, 1H), 1.811.90 (m, 2H), 1.15-1.31 (m, 2H), 1.08 (t, J = 7.3 Hz, 3H). LCMS m/z = 387 [MH]+. |
236
135 | OH r-B sAAnJj> ^JL jl 4-(5-fluoro-6-(4-methoxy-3propoxyphenyl)pyridin-2-yl)-1,2oxaborolan-2-ol | Ή NMR (DMSO-d6, 400MHz): δ 8.61 (s, 1 H), 7.68 (dd, J = 8.8, 11.7 Hz, 1 H), 7.58 (s, 1H), 7.53 (d, J = 8.8 Hz, 1H), 7.27 (dd, J = 3.4, 8.3 Hz, 1H), 7.08 (d, J = 8.3 Hz, 1 H), 4.27 (dd, J = 7.3, 8.8 Hz, 1 H), 3.92-4.01 (m, 3H), 3.82 (s, 3H), 3.583.65 (m, 1H), 1.71-1.80 (m, 2H), 1.231.31 (m, 1H), 1.11-1.19 (m, 1H), 0.99 (t, J = 7.3 Hz, 3H). LCMS m/z = 346 [MH]+. |
136 | OH T A X ° ^o^yV^ M 4-(6-(4-methoxy-3propoxyphenyl)pyridazin-4-yl)-1,2oxaborolan-2-ol, enantiomer 1 | LCMS m/z = 342.3 [MH]+. RT [Analytical SFC Method V] = 6.90 min. |
137 | OH r-B T A *X ζθ 4-(6-(4-methoxy-3propoxyphenyl)pyridazin-4-yl)-1,2oxaborolan-2-ol, enantiomer 2 | LCMS m/z = 342.3 [MH+H2O]+. RT [Analytical SFC Method V] = 7.90 min. |
138 | OH F^F A JL A JX/° Z''°^±Y N 4-(4-(difluoromethyl)-5-(3-ethoxy-4methoxyphenyl)pyridin-3-yl)-1,2oxaborolan-2-ol | LCMS m/z = 364.4 [MH]+. RT [Prep HPLC Method C] = 2.30 min. |
237
139 | OH χ Ί X JL/° 4-(4-(difluoromethyl)-5-(3-ethoxy-4methoxyphenyl)pyridin-3-yl)-1,2- oxaborolan-2-ol, enantiomer 1 | Ή NMR (CDCh, 400MHz): δ 8.72-8.92 (m, 1 H), 8.50 (br s, 1 H), 6.95-7.01 (m, 1H), 6.86 (dd, J = 2.3, 8.2 Hz, 1H), 6.516.83 (m, 2H), 4.48 (t, J = 8.2 Hz, 1H), 4.02-4.27 (m, 4H), 3.94 (s, 3H), 3.74 (s, 1H), 1.63 (dt, J = 8.6, 16.6 Hz, 2H), 1.49 (t, J = 7.0 Hz, 2H), 1.23-1.38 (m, 1 H). LCMS m/z = 364 [MH]+. RT [Analytical SFC Method W] = 3.95 min. |
140 | OH /O^^ F^F B' J χ X JL? 4-(4-(difluoromethyl)-5-(3-ethoxy-4methoxyphenyl)pyridin-3-yl)-1,2- oxaborolan-2-ol, enantiomer 2 | Ή NMR (CDCh, 400MHz): δ 8.72-8.92 (m, 1H), 8.50 (br s, 1H), 6.95-7.01 (m, 1H), 6.86 (dd, J = 2.3, 8.2 Hz, 1H), 6.516.83 (m, 2H), 4.48 (t, J = 8.2 Hz, 1H), 4.02-4.27 (m, 4H), 3.94 (s, 3H), 3.74 (s, 1H), 1.63 (dt, J = 8.6, 16.6 Hz, 2H), 1.49 (t, J = 7.0 Hz, 2H), 1.23-1.38 (m, 1 H). LCMS m/z = 364 [MH]+. RT [Analytical SFC Method W] = 3.95 min. |
141 | OH T X X J /0 4-(5-(5-ethoxy-2-fluoro-4- methoxyphenyl)-4-methylpyridin-3-yl)- 1,2-oxaborolan-2-ol | 1H NMR (CD3OD, 400MHz): δ 8.40 (s, 1H), 8.16 (s, 1H), 6.91 (d, J = 11.0 Hz, 1H), 6.82 (d, J = 7.0 Hz, 1H), 4.04 (q, J = 6.9 Hz, 3H), 3.89 (s, 4H), 3.64 (br s, 1H), 2.25 (d, J = 1.0 Hz, 3H), 1.39 (t, J = 7.0 Hz, 3H), 1.16-1.34 (m, 2H). LCMS m/z = 346 [MH]+. |
142 | OH Y X χ JL L° yj (-) 4-(5-(5-ethoxy-2-fluoro-4- methoxyphenyl)-4-methylpyridin-3-yl)- 1,2-oxaborolan-2-ol, enantiomer 2 | Ή NMR (DMSO-de, 400MHz): δ 8.72 (s, 1H), 8.48 (s, 1H), 8.22 (s, 1H), 7.02 (d, J = 11.5 Hz, 1 H), 6.86 (d, J = 7.5 Hz, 1 H), 4.26 (t, J = 8.3 Hz, 1H), 4.00 (q, J = 7.0 Hz, 2H), 3.93 (br s, 1H), 3.82 (s, 3H), 3.64-3.72 (m, 1H), 2.14 (s, 3H), 1.271.38 (m, 4H), 0.98-1.12 (m, 1H). LCMS m/z = 346 [MH]+. [α]2% -8.83 (c = 0.1, EtOH). |
238
143 | OH /OXZ\/F R ΧΎ i *ΧΧθ °^ΥΎ^ 4-(5-(5-ethoxy-2-fluoro-4- methoxyphenyl)-4-methylpyridin-3-yl)1,2-oxaborolan-2-ol, enantiomer 1 | 1H NMR (DMSO-d6, 400MHz): δ 8.72 (s, 1H), 8.48 (s, 1H), 8.22 (s, 1H), 7.02 (d, J = 11.5 Hz, 1 H), 6.86 (d, J = 7.5 Hz, 1 H), 4.26 (t, J = 8.3 Hz, 1 H), 4.00 (q, J = 7.0 Hz, 2H), 3.93 (br s, 1H), 3.82 (s, 3H), 3.64-3.72 (m, 1H), 2.14 (s, 3H), 1.271.38 (m, 4H), 0.98-1.12 (m, 1H). LCMS m/z = 346.2 [MH]+. RT [Analytical SFC Method X] = 3.52 min. |
144 | OH SY® H Il J / o ^hL 4-(5-(3-ethoxy-4- (methylthio)phenyl)pyridin-3-yl)-1,2oxaborolan-2-ol | Ή NMR (DMSO-de, 400MHz): δ 8.66 (s, 1H), 7.54 (s, 1H), 7.49 (d, J = 7.6 Hz, 1 H), 7.37 (t, J = 7.6 Hz, 1 H), 7.26 (br s, 1H), 7.18-7.25 (m, 2H), 7.18 (s, 1H), 4.26 (t, J = 8.2 Hz, 1H), 4.19 (q, J = 7.1 Hz, 2H), 3.81 (t, J = 8.9 Hz, 1H), 3.43-3.52 (m, 1 H), 2.40 (s, 3H), 1.36 (t, J = 7.0 Hz, 2H), 1.29 (dd, J = 8.2, 16.3 Hz, 1H), 1.09 (dd, J= 10.1, 16.3 Hz, 1H). LCMS m/z = 329 [MH]+. |
145 | OH ! X J Γ b 4-(5-(3-propoxyphenyl)pyridin-3-yl)-1,2oxaborolan-2-ol | Ή NMR (DMSO-de, 400MHz): δ 8.678.79 (m, 2H), 8.48 (d, J = 2.0 Hz, 1 H), 7.99 (s, 1H), 7.37-7.46 (m, 1H), 7.247.33 (m, 2H), 6.98 (d, J = 6.5 Hz, 1H), 4.28 (t, J = 8.3 Hz, 1H), 4.02 (t, J = 6.5 Hz, 2H), 3.87 (t, J = 9.0 Hz, 1H), 3.453.60 (m, 1H), 1.69-1.86 (m, 2H), 1.251.38 (m, 1H), 1.16 (dd, J = 10.5, 16.1 Hz, 1H), 1.01 (t, J = 7.5 Hz, 3H). LCMS m/z = 298 [MH]+. |
239
146 | OH JX jl * Γ b ' ° Α'Ύ (-) 4-(5-(3-propoxyphenyl)pyridin-3-yl)1,2-oxaborolan-2-ol, enantiomer 2 | Ή NMR (DMSO-cfe, 400MHz): δ 8.678.79 (m, 2H), 8.48 (d, J = 2.0 Hz, 1H), 7.99 (s, 1H), 7.37-7.46 (m, 1H), 7.247.33 (m, 2H), 6.98 (d, J = 6.5 Hz, 1H), 4.28 (t, J = 8.3 Hz, 1H), 4.02 (t, J = 6.5 Hz, 2H), 3.87 (t, J = 9.0 Hz, 1H), 3.453.60 (m, 1H), 1.69-1.86 (m, 2H), 1.251.38 (m, 1H), 1.16 (dd, J= 10.5, 16.1 Hz, 1H), 1.01 (t, J = 7.5 Hz, 3H). LCMS m/z = 298 [MH]+. [o]20d -25.7 (c = 0.1, EtOH). |
147 | Il I ,oh ' // V-O S~N 4-(5-(4-methoxy-3-propoxyphenyl)- 1,2,4-thiadiazol-3-yl)-1,2-oxaborolan-2ol | 1H NMR (DMSO-de, 400MHz): δ 8.70 (br s, 1 H), 7.56-7.64 (m, 1 H), 7.47 (d, J = 2.2 Hz, 1H), 7.12 (d, J = 8.3 Hz, 1H), 4.294.35 (m, 1H), 4.12 (dd, J = 6.7, 9.2 Hz, 1H), 4.01 (t, J = 6.5 Hz, 2H), 3.85 (s, 3H), 3.81 (t, J = 7.7 Hz, 1 H), 1.72-1.81 (m, 2H), 1.27-1.40 (m, 2H), 1.00 (t, J = 7.5 Hz, 3H). LCMS m/z = 335 [MH]+. |
148 | Il i ^oAAx^^s S~N (-) 4-(5-(4-methoxy-3-propoxyphenyl)1,2,4-thiadiazol-3-yl)-1,2-oxaborolan-2ol, enantiomer 2 | Ή NMR (DMSO-d6, 400MHz): δ 8.70 (br s, 1 H), 7.56-7.64 (m, 1 H), 7.47 (d, J = 2.2 Hz, 1H), 7.12 (d, J = 8.3 Hz, 1H), 4.294.35 (m, 1H), 4.12 (dd, J = 6.7, 9.2 Hz, 1H), 4.01 (t, J = 6.5 Hz, 2H), 3.85 (s, 3H), 3.81 (t, J = 7.7 Hz, 1 H), 1.72-1.81 (m, 2H), 1.27-1.40 (m, 2H), 1.00 (t, J = 7.5 Hz, 3H). LCMS m/z = 335 [MH]+. [α]2% -10.3 (c= 0.1, EtOH). |
149 | I OH /a °YN H < I II J / o 4-(5-(3-(cyclopentyloxy)-4- methoxyphenyl)pyridin-3-yl)-1,2- oxaborolan-2-ol | Ή NMR (DMSO-de, 400MHz): δ 8.658.74 (m, 2H), 8.43 (d, J = 1.7 Hz, 1 H), 7.91 (t, J = 2.0 Hz, 1H), 7.17-7.30 (m, 2H), 7.05 (d, J = 8.8 Hz, 1H), 4.96 (t, J = 5.7 Hz, 1 H), 4.27 (t, J = 8.3 Hz, 1 H), 3.86 (t, J = 9.0 Hz, 1 H), 3.79 (s, 3H), 3.413.59 (m, 1H), 1.90 (d, J = 6.4 Hz, 2H), 1.66-1.80 (m, 4H), 1.58 (br s, 2H), 1.29 (d, J = 8.3 Hz, 1H), 1.14 (dd, J = 10.4, 16.3 Hz, 1H). LCMS m/z = 354 [MH]+. |
240
150 | OH T X Y b 4-(2'-fluoro-4',5'-dimethoxy-[1,1 biphenyl]-3-yl)-1,2-oxaborolan-2-ol | Ή NMR (DMSO-c/e, 400 MHz): δ 8.66 (s, 1H), 7.33-7.44 (m, 3H), 7.26 (d, J= 6.4 Hz, 1H), 6.94-7.05 (m, 2H), 4.23-4.28 (m, 1H), 3.74-3.85 (m, 6H), 3.45-3.50 (m, 1H), 1.29 (dd, J= 16.0, 8.0 Hz, 1H), 1.05 (dd, J= 16.0, 10.0 Hz, 1H), 1.02-1.09 (m, 1H). LCMS m/z = 317 [MH]+. |
151 | OH rB N 2-ethoxy-6-(6-(2-hydroxy-1,2oxaborolan-4-yl)pyridin-2-yl)-3methoxybenzonitrile | Ή NMR (DMSO-de, 400MHz): δ 8.58 (s, 1 H), 7.85 (t, J = 7.7 Hz, 1 H), 7.60 (d, J = 7.6 Hz, 1H), 7.53-7.58 (m, 1H), 7.43-7.50 (m, 1 H), 7.33 (d, J = 7.8 Hz, 1 H), 4.254.31 (m, 1H), 4.20 (q, J = 7.1 Hz, 2H), 4.09 (t, J = 8.7 Hz, 1H), 3.91 (s, 3H), 3.60-3.68 (m, 1H), 1.21-1.38 (m, 5H). LCMS m/z = 339 [MH]+. |
152 | OH r-B X X Γ b 4-(3-(5,6-dimethoxypyridin-2-yl)phenyl)- 1,2-oxaborolan-2-ol | 1H NMR (DMSO-d6, 400 MHz): δ 8.66 (s, 1 H), 7.91 (s, 1 H), 7.85 (d, J = 8.0 Hz, 1H), 7.51 (d, J= 8.4 Hz, 1H), 7.38-7.33 (m, 2H), 7.24 (d, J = 7.6 Hz, 1 H), 4.27 (t, J= 8.0 Hz, 1H), 3.97 (s, 3H), 3.80-3.82 (m, 4H), 3.43-3.52 (m, 1H), 1.27-1.33 (m, 1H), 1.04-1.10 (m, 1H). LCMS m/z = 300 [MH]+. |
153 | OH n & χ°ΎΥϊ 1 1 N 6-(5-(2-hydroxy-1,2-oxaborolan-4- yl)pyridin-3-yl)-2,3dimethoxybenzonitrile | 1H NMR (DMSO-dg, 400MHz): δ 8.72 (s, 1H), 8.57 (d, J = 2.0 Hz, 1H), 8.55 (d, J = 1.7 Hz, 1 H), 7.93 (s, 1 H), 7.51 (d, J = 8.6 Hz, 1H), 7.38 (d, J = 8.6 Hz, 1H), 4.28 (t, J = 8.3 Hz, 1H), 3.95 (s, 3H), 3.92 (s, 3H), 3.84 (t, J = 9.0 Hz, 1H), 3.49-3.57 (m, 1H), 1.32 (dd, J = 8.2, 16.3 Hz, 1H), 1.12 (dd, J = 10.4, 16.3 Hz, 1H). LCMS m/z = 325 [MH]+. |
241
154 | OH /OyyF rE! XXX/NaXX y--/ ΌΗ (-) 4-(2-(2-fluoro-4-methoxy-5- propoxyphenyl)-6- (hydroxymethyl)pyrimidin-4-yl)-1,2- oxaborolan-2-ol, enantiomer 2 | 1H NMR (DMSO-d6, 400MHz): δ 8.66 (s, 1 H), 7.57 (d, J = 7.8 Hz, 1 H), 7.34 (s, 1H), 6.95 (d, J = 12.7 Hz, 1H), 5.62 (t, J = 5.6 Hz, 1 H), 4.57 (d, J = 5.9 Hz, 2H), 4.26-4.33 (m, 1 H), 4.00 (dd, J = 7.1, 9.0 Hz, 1H), 3.93 (t, J = 6.6 Hz, 2H), 3.84 (s, 3H), 3.58-3.66 (m, 1H), 1.69-1.78 (m, 2H), 1.25-1.34 (m, 1H), 1.12-1.21 (m, 1H), 0.98 (t, J = 7.3 Hz, 3H). LCMS m/z = 377 [MH]+. [o]20d -11.9 (c = 0.1, EtOH). |
155 | OH X X F b ^^O^ N 4-(3-(5-methoxy-6-propoxypyridin-2yl)phenyl)-1,2-oxaborol-2(5H)-ol | Ή NMR (DMSO-de, 400MHz): δ 8.68 (s, 1H), 8.13 (s, 1H), 8.01 (d, J = 7.2 Hz, 1 H), 7.60 (d, J = 8.0 Hz, 1 H), 7.54 (d, J = 8.0 Hz, 1H), 7.48 (t, J= 7.6 Hz, 1H), 7.36 (d, J = 8.0 Hz, 1 H), 6.26 (s, 1 H), 4.97 (s, 2H), 4.37 (t, J = 6.8 Hz, 2H), 3.83 (s, 3H), 1.80 (q, J = 6.8 Hz, 2H), 1.00 (t, J = 6.8 Hz, 3H). LCMS m/z = 326 [MH]+. |
156 | OH r-B X X F b n XX^^ 4-(3-(5-methoxy-6-propoxypyridin-2yl)phenyl)-1,2-oxaborolan-2-ol | Ή NMR (DMSO-ds, 400MHz): δ 8.68 (s, 1H), 8.13 (s, 1H), 8.01 (d, J= 7.2 Hz, 1 H), 7.60 (d, J = 8.0 Hz, 1 H), 7.54 (d, J = 8.0 Hz, 1 H), 7.48 (t, J = 7.6 Hz, 1 H), 7.36 (d, J = 8.0 Hz, 1 H), 6.26 (s, 1 H), 4.97 (s, 2H), 4.37 (t, J = 6.8 Hz, 2H), 3.83 (s, 3H), 1.80 (q, J = 6.8 Hz, 2H), 1.00 (t, J = 6.8 Hz, 3H). LCMS m/z = 328 [MH]+. |
157 | OH r-B X^ X F b °\ 4-(3',4',5-trimethoxy-[1,1 '-bi phe ny l]-3yl)-1,2-oxaborolan-2-ol | Ή NMR (DMSO-ds, 400MHz): δ 8.65 (s, 1H), 7.12-7.22 (m, 2H), 7.09 (s, 1H), 6.95-7.05 (m, 3H), 6.79 (s, 1H), 4.24 (t, J = 8.2 Hz, 1 H), 3.84 (s, 3H), 3.79 (d, J = 8.0 Hz, 7H), 3.40-3.50 (m, 1H), 1.19-1.33 (m, 1H), 1.08 (dd, J = 10.0, 16.1 Hz, 1H), 1.01-1.13 (m, 1H). LCMS m/z = 329 [MH]+. |
242
158 | OH 4-(6-(4-methoxy-3-propoxyphenyl)-4methylpyridin-2-yl)-1,2-oxaborolan-2-ol | Ή NMR (DMSO-d6, 400MHz): δ 8.58 (br s, 1H), 7.69 (d, J = 1.5 Hz, 1H), 7.63 (d, J = 8.3 Hz, 1H), 7.59 (s, 1H), 7.02 (d, J = 8.3 Hz, 1H), 6.99 (s, 1H), 4.26 (t, J = 8.1 Hz, 1H), 4.00 (t, J = 6.6 Hz, 2H), 3.96 (dd, J = 6.8, 8.8 Hz, 1 H), 3.80 (s, 3H), 3.49-3.57 (m, 1H), 2.34 (s, 3H), 1.721.80 (m, 2H), 1.20-1.28 (m, 1H), 1.131.20 (m, 1 H), 1.00 (t, J = 7.3 Hz, 3H). LCMS m/z = 342 [MH]+. |
159 | OH / rB / s-^ —o 4-(2-(3,4-dimethoxyphenyl)thiazol-4-yl)- 1,2-oxaborolan-2-ol | Ή NMR (DMSO-de, 400MHz): δ 8.64 (s, 1H), 7.42-7.48 (m, 2H), 7.31 (s, 1H), 7.05 (d, J = 8.1 Hz, 1H), 4.26 (dd, J = 7.7, 8.7 Hz, 1H), 3.93 (dd, J = 7.6, 8.8 Hz, 1H), 3.84 (s, 3H), 3.81 (s, 3H), 3.56-3.62 (m, 1H), 1.24-1.34 (m, 1H), 1.12-1.20 (m, 1H). LCMS m/z = 306 [MH]+. |
160 | OH / ,, * I 0 /fWr —o 4-(2-(3,4-dimethoxyphenyl)thiazol-4-yl)- 1,2-oxaborolan-2-ol, enantiomer 2 | LCMS m/z = 319.9 [MH]+. RT [Analytical SFC Method Y] = 5.76 min. |
161 | OH .O. /N. d 1 X Γ b 4-(3-(5,6-dimethoxypyridin-3-yl)phenyl)- 1,2-oxaborolan-2-ol | 1H NMR (DMSO-c/6, 400MHz): δ 7.98 (s, 1H), 7.55-7.57 (m, 1H), 7.50-7.52 (m, 2H), 7.39-7.41 (m, 1H), 7.28-7.37 (m, 1 H), 4.26 (t, J = 8.0 Hz, 1 H), 3.89 (s, 3H), 3.88 (s, 3H), 3.82 (t, J = 8.0 Hz, 1H), 3.32-3.79 (m, 1H), 1.28-1.32 (m, 1H), 1.03-1.14 (m, 1H). LCMS m/z = 300 [MH]+. |
243
162 | OH Τι rB' “TiJ 4-(6-(2-fluoro-3,4- dimethoxyphenyl)pyridin-2-yl)-1,2oxaborolan-2-ol | 1H NMR (DMSO-c/e, 400 MHz): δ 8.59 (s, 1H), 7.78 (t, J = 8.0 Hz, 1H), 7.67 (t, J = 8.8 Hz, 1H), 7.54-7.57 (m, 1H), 7.25 (d, J = 8.0 Hz, 1H), 7.02 (d, J = 9.2 Hz, 1H), 4.26-4.30 (m, 1H), 4.01-4.97 (m, 1H), 3.88 (s, 3H), 3.82 (s, 3H), 3.32-3.65 (m, 1H), 1.18-1.30 (m, 2H). LCMS m/z = 318 [MH]+. |
163 | OH T X Γ b N 4-(5-(3-ethoxy-2,6-difluoro-4methoxyphenyl)pyridin-3-yl)-1,2oxaborolan-2-ol | Ή NMR (DMSO-c/e, 400MHz): δ 8.71 (s, 1 H), 8.52 (d, J = 2.0 Hz, 1 H), 8.46 (s, 1H), 7.78 (s, 1H), 7.06 (d, J = 12.2 Hz, 1H), 4.28 (t, J = 8.3 Hz, 1H), 4.02 (q, J = 7.3 Hz, 2H), 3.88 (s, 3H), 3.81 (t, J = 8.8 Hz, 1H), 3.47-3.55 (m, 1H), 1.22-1.38 (m, 4H), 1.00-1.13 (m, 1H). LCMS m/z = 350 [MH]+. |
164 | OH z°yY u II *1 o Tu N (-) 4-(5-(3-ethoxy-2,6-difluoro-4methoxyphenyl)pyridin-3-yl)-1,2- oxaborolan-2-ol, enantiomer 1 | 1H NMR (DMSO-ds, 400MHz): δ 8.71 (s, 1H), 8.52 (d, J = 2.0 Hz, 1H), 8.46 (s, 1H), 7.78 (s, 1H), 7.06 (d, J = 12.2 Hz, 1 H), 4.28 (t, J = 8.3 Hz, 1 H), 4.02 (q, J = 7.3 Hz, 2H), 3.88 (s, 3H), 3.81 (t, J = 8.8 Hz, 1H), 3.47-3.55 (m, 1H), 1.22-1.38 (m, 4H), 1.00-1.13 (m, 1H). LCMS m/z = 318 [MH]+. [α]2% -20.6 (c = 0.22, EtOH). |
165 | OH jX X X b \T°^TCi 4-(3'-(cyclopropylmethoxy)-4'-methoxy[1,1'-biphenyl]-3-yl)-1,2-oxaborolan-2-ol |
244
166 | OH _ό (Ci 4-(3'-ethoxy-2'-fluoro-4'-methoxy-[1,1 biphenyl]-3-yl)-1,2-oxaborolan-2-ol | 1H NMR (DMSO-d6, 400MHz): δ 7.367.39 (m, 2H), 7.31-7.32 (m, 1H), 7.27 (d, J = 7.6 Hz, 1H), 7.15-7.19 (m, 1H), 6.96 (d, J = 8.8 Hz, 1H), 4.25 (t, J = 8.0 Hz, 1H), 4.05 (q, J = 7.2 Hz, 2H), 3.85 (s, 3H), 3.79 (t, J = 8.8 Hz, 1H), 3.41-3.50 (m, 1H), 1.26-1.32 (m, 4H), 1.02-1.08 (m, 1H). LCMS m/z = 331 [MH]+. |
167 | OH T X Xb /° M 4-(5-(2,4-dimethoxy-3propoxyphenyl)pyridin-3-yl)-1,2oxaborolan-2-ol | Ή NMR (DMSO-de, 400MHz): δ 8.70 (s, 1H), 8.47 (d, J = 2.0 Hz, 1H), 8.42 (d, J = 2.0 Hz, 1H), 7.73 (t, J = 2.1 Hz, 1H), 7.09 (d, J = 8.8 Hz, 1 H), 6.91 (d, J = 8.6 Hz, 1H), 4.25-4.32 (m, 1H), 3.90 (t, J = 6.5 Hz, 2H), 3.79-3.87 (m, 4H), 3.65 (s, 3H), 3.45-3.54 (m, 1H), 1.65-1.76 (m, 2H), 1.32 (dd, J = 8.2, 16.3 Hz, 1H), 1.03-1.12 (m, 1H), 0.99 (t, J = 7.5 Hz, 3H). LCMS m/z = 358 [MH]+. |
168 | OH Il Ί *1 b ^oVyv^ (-) 4-(5-(2,4-dimethoxy-3- propoxyphenyl)pyridin-3-yl)-1,2oxaborolan-2-ol, enantiomer 1 | Ή NMR (DMSO-c/e, 400MHz): δ 8.70 (s, 1 H), 8.47 (d, J = 2.0 Hz, 1 H), 8.42 (d, J = 2.0 Hz, 1H), 7.73 (t, J = 2.1 Hz, 1H), 7.09 (d, J = 8.8 Hz, 1H), 6.91 (d, J = 8.6 Hz, 1 H), 4.25-4.32 (m, 1 H), 3.90 (t, J = 6.5 Hz, 2H), 3.79-3.87 (m, 4H), 3.65 (s, 3H), 3.45-3.54 (m, 1H), 1.65-1.76 (m, 2H), 1.32 (dd, J = 8.2, 16.3 Hz, 1H), 1.03-1.12 (m, 1H), 0.99 (t, J = 7.5 Hz, 3H). LCMS m/z = 358 [MH]+. [o]20 D -18.8 (c = 0.1, EtOH). |
245
169 | I OH fl 1X r> 4-(5-(4-methoxy-3-((tetrahydro-2Hthiopyran-4-yl)oxy)phenyl)pyridin-3-yl)1,2-oxaborolan-2-ol | Ή NMR (DMSO-de,400 MHz): δ 8.69 (br s, 1 H), 8.42 (br s, 1 H), 7.90 (br s, 1 H), 7.34 (s, 1H), 7.30 (d, J = 8.3 Hz, 1H), 7.09 (d, J = 8.3 Hz, 1 H), 4.44-4.54 (m, 1H), 4.27 (t, J = 7.8 Hz, 1H), 3.74-3.89 (m, 4H), 3.45-3.56 (m, 1H), 2.75-2.85 (m, 2H), 2.56-2.66 (m, 2H), 2.13-2.18 (m, 2H), 1.76-1.88 (m, 2H), 1.27-1.37 (m, 1H), 1.14 (dd, J = 10.3, 16.1 Hz, 1H). LCMS m/z = 386 [MH]+. |
170 | I OH s/y θ' 11 IC ° Û 4-(5-(4-methoxy-3-((tetrahydro-2Hthiopyran-4-yl)oxy)phenyl)pyridin-3-yl)1,2-oxaborolan-2-ol, enantiomer 1 | Ή NMR (DMSO-de,400 MHz): δ 8.69 (br s, 1 H), 8.42 (br s, 1 H), 7.90 (br s, 1 H), 7.34 (s, 1H), 7.30 (d, J = 8.3 Hz, 1H), 7.09 (d, J = 8.3 Hz, 1 H), 4.44-4.54 (m, 1H), 4.27 (t, J = 7.8 Hz, 1H), 3.74-3.89 (m, 4H), 3.45-3.56 (m, 1H), 2.75-2.85 (m, 2H), 2.56-2.66 (m, 2H), 2.13-2.18 (m, 2H), 1.76-1.88 (m, 2H), 1.27-1.37 (m, 1H), 1.14 (dd, J = 10.3, 16.1 Hz, 1H). LCMS m/z = 386 [MH]+. RT [Analytical SFC Method Z] = 5.20 min. |
171 | OH T I Γ b 4-(5-(3-ethoxy-4-methoxyphenyl)-6- ethylpyridin-3-yl)-1,2-oxaborolan-2-ol | Ή NMR (DMSO-cy 400MHz): δ 8.65 (s, 1H), 8.39 (s, 1H), 7.43 (s, 1H), 7.02 (d, J = 8.0 Hz, 1H), 6.90 (s, 1H), 6.84 (d, J = 8.3 Hz, 1 H), 4.24 (t, J = 8.3 Hz, 1 H), 4.03 (q, J = 6.8 Hz, 2H), 3.75-3.84 (m, 4H), 3.39-3.52 (m, 1H), 2.69 (q, J = 7.4 Hz, 2H), 1.21-1.37 (m, 4H), 1.00-1.17 (m, 4H). LCMS m/z = 342 [MH]+. |
246
172 | OH ^b' A A A ζθ 4-(3'-ethoxy-4'-(methylthio)-[1,1 biphenyl]-3-yl)-1,2-oxaborolan-2-ol | Ή NMR (DMSO-cfe, 400MHz): δ 8.66 (s, 1 H), 7.54 (s, 1 H), 7.49 (d, J = 7.6 Hz, 1H), 7.37 (t, J = 7.6 Hz, 1H), 7.25 (d, J = 9.8 Hz, 2H), 7.17-7.22 (m, 2H), 4.26 (t, J = 8.2 Hz, 1H), 4.19 (q, J = 7.1 Hz, 2H), 3.81 (t, J = 8.9 Hz, 1H), 3.43-3.52 (m, 1 H), 2.40 (s, 3H), 1.36 (t, J = 7.0 Hz, 3H), 1.29 (dd, J = 8.2, 16.3 Hz, 1H), 1.09 (dd, J = 10.1, 16.3 Hz, 1H). LCMS m/z = 329 [MH]+. |
173 | Cl OH ^O^A A ΤΊ -Γ> tT 4-(5-(3-chloro-5-ethoxy-4methoxyphenyl)pyridin-3-yl)-1,2oxaborolan-2-ol, enantiomer 2 | 1H NMR (DMSO-c/6, 400MHz): δ 8.75 (d, J = 2.0 Hz, 1 H), 8.70 (s, 1 H), 8.48 (d, J = 2.0 Hz, 1 H), 8.02 (t, J = 2.2 Hz, 1 H), 7.42 (d, J = 2.0 Hz, 1 H), 7.34 (d, J = 2.0 Hz, 1H), 4.18-4.30 (m, 3H), 3.83-3.91 (m, 1H), 3.81 (s, 3H), 3.44-3.57 (m, 1H), 1.39 (t, J = 6.9 Hz, 3H), 1.26-1.34 (m, 1 H), 1.12-1.22 (m, 1H). LCMS m/z = 348 [MH]+. RT [Analytical SFC Method E] = 5.33 min |
174 | OH l A A z° 4-(3-(4,5-dimethoxypyridin-2-yl)phenyl)- 1,2-oxaborolan-2-ol | Ή NMR (DMSO-d6, 400MHz): δ 8.65 (s, 1H), 8.24 (s, 1H), 7.94 (s, 1H), 7.87 (d, J = 8.0 Hz, 1H), 7.51 (s, 1H), 7.38 (t, J = 7.6 Hz, 1 H), 7.29 (d, J = 7.2 Hz, 1 H), 4.27 (t, J = 8.4 Hz, 1H), 3.95 (s, 3H), 3.89 (s, 3H), 3.82 (t, J= 8.4 Hz, 1H), 3.44-3.53 (m, 1H), 1.30 (q, J= 8.0 Hz, 1H), 1.08 (q, J= 10.0 Hz, 1H). LCMS m/z = 300 [MH]+. |
247
175 | I OH Γ\ °ΥΊ A °\ 4-(4-(3-(cyclopentyloxy)-4- methoxyphenyl)-6-methoxypyrimidin-2yl)-1,2-oxaborolan-2-ol | 1H NMR (DMSO-de, 400MHz): δ 8.60 (s, 1H), 7.72-7.79 (m, 2H), 7.23 (s, 1H), 7.05 (d, J = 8.5 Hz, 1 H), 4.92 (br s, 1 H), 4.29 (t, J = 8.0 Hz, 1H), 4.10 (dd, J = 6.0, 8.5 Hz, 1H), 3.94 (s, 3H), 3.81 (s, 3H), 3.553.63 (m, 14.2 Hz, 1H), 1.93 (d, J = 5.5 Hz, 2H), 1.72 (br s, 4H), 1.58 (br s, 2H), 1.22-1.36 (m, 2H). LCMS m/z = 385 [MH]+. |
176 | I OH /-i °YN rB V+ ajYnyy °^YT °\ 4-(4-(3-(cyclopentyloxy)-4- methoxyphenyl)-6-methoxypyrimidin-2yl)-1,2-oxaborolan-2-ol, enantiomer 2 | Ή NMR (DMSO-c/θ, 400MHz): δ 8.60 (s, 1H), 7.72-7.79 (m, 2H), 7.23 (s, 1H), 7.05 (d, J = 8.5 Hz, 1H), 4.92 (br s, 1H), 4.29 (t, J = 8.0 Hz, 1H), 4.10 (dd, J = 6.0, 8.5 Hz, 1H), 3.94 (s, 3H), 3.81 (s, 3H), 3.553.63 (m, 14.2 Hz, 1 H), 1.93 (d, J = 5.5 Hz, 2H), 1.72 (br s, 4H), 1.58 (br s, 2H), 1.22-1.36 (m, 2H). LCMS m/z = 385 [MH]+. RT [Analytical SFC Method Z] = 2.79 min. |
177 | OH jT j] Γ b Il N 3'-(2-hydroxy-1,2-oxaborolan-4-yl)-3,4dimethoxy-[1,1 '-biphenyl]-2-carbonitrile | 1H NMR (DMSO-ds, 400MHz): δ 7.197.53 (m, 7H) 4.22-4.31 (m, 1H), 3.94 (s, 3H), 3.91 (s, 3H), 3.79-3.83 (t, J = 8.8 Hz, 1H), 3.42-3.53 (m, 1H), 1.26-1.32 (m, 1H), 1.04-1.11 (m, 1H). LCMS m/z = 322 [MH]+. |
178 | OH L Jf / o 4-(5-methoxy-4-propoxy-[2,3'-bipyridin]5'-yl)-1,2-oxaborolan-2-ol | Ή NMR (DMSO-c/θ, 400MHz): δ 8.89 (d, J = 2.0 Hz, 1H), 8.45 (d, J = 2.0 Hz, 1H), 8.24 (s, 1H), 8.20 (s, 1H), 7.47 (s, 1H), 4.18 (t, J = 6.4 Hz, 2H), 3.97 (s, 3H), 3.87 (br s, 1 H), 3.39 (br s, 1 H), 1.85-1.94 (m, 2H), 1.29 (d, J = 8.8 Hz, 2H), 1.10 (t, J = 7.6 Hz, 3H). LCMS m/z = 329 [MH]+. |
248
179 | OH γΒ L if *I o ''/©Ί' 7 N 4-(5-methoxy-4-propoxy-[2,3'-bipyridin]- 5'-yl)-1,2-oxaborolan-2-ol, enantiomer 1 | Ή NMR (DMSO-ds, 400MHz): δ 8.89 (d, J = 2.0 Hz, 1 H), 8.45 (d, J = 2.0 Hz, 1 H), 8.24 (s, 1H), 8.20 (s, 1H), 7.47 (s, 1H), 4.18 (t, J = 6.4 Hz, 2H), 3.97 (s, 3H), 3.87 (br s, 1 H), 3.39 (br s, 1 H), 1.85-1.94 (m, 2H), 1.29 (d, J = 8.8 Hz, 2H), 1.10 (t, J = 7.6 Hz, 3H). LCMS m/z = 329 [MH]+. RT [Analytical SFC Method G] = 4.36 min. |
180 | OH /°A jJ j] * Γ b A ΌΗ 4-(2-(hydroxymethyl)-6-(4-methoxy-3propoxyphenyl)pyridin-4-yl)-1,2oxaborolan-2-ol, enantiomer 1 | Ή NMR (DMSO-cfe, 400MHz): δ 8.73 (s, 1H), 7.61-7.67 (m, 3H), 7.26 (s, 1H), 7.03 (d, J = 8.3 Hz, 1H), 5.40 (t, J = 5.9 Hz, 1H), 4.58 (d, J = 5.4 Hz, 2H), 4.29 (t, J = 8.3 Hz, 1H), 4.00 (t, J = 6.6 Hz, 2H), 3.85 (t, J = 8.8 Hz, 1 H), 3.81 (s, 3H), 3.463.54 (m, 1H), 1.72-1.81 (m, 2H), 1.32 (dd, J = 8.3, 16.1 Hz, 1H), 1.09 (dd, J = 9.5, 16.4 Hz, 1H), 0.98-1.03 (m, 3H). LCMS m/z = 358 [MH]+. RT [Analytical SFC Method L] = 3.58 min. |
181 | Alll zoh L //A/O S-N (-) 4-(5-(3-cyclopropoxy-4- methoxyphenyl)-1,2,4-thiadiazol-3-yl)- 1,2-oxaborolan-2-ol, enantiomer 2 | Ή NMR (DMSO-de, 400MHz): δ 8.69 (s, 1 H), 7.78 (d, J = 2.2 Hz, 1 H), 7.60 (d, J = 8.3 Hz, 1H), 7.12 (d, J = 8.3 Hz, 1H), 4.32 (dd, J = 7.6, 9.0 Hz, 1 H), 4.12 (dd, J = 6.6, 9.0 Hz, 1 H), 3.97-3.99 (m, 1 H), 3.76-3.88 (m, 4H), 1.25-1.43 (m, 2H), 0.77-0.86 (m, 2H), 0.67-0.74 (m, 2H). LCMS m/z = 333 [MH]+. [a]2% -12.7 (c = 0.1, EtOH). |
182 | OH J. Il / b ''θ'^ιΟι 4-(4’-ethoxy-3'-methoxy-[1,1 ’-biphenyl]3-yl)-1,2-oxaborolan-2-ol | 1H NMR (DMSO-de, 400MHz): δ 7.50 (br s, 1 H), 7.46 (d, J = 7.8 Hz, 1 H), 7.35 (t, J = 7.8Hz, 1H), 7.14-7.22 (m, 3H), 7.01 (d, J = 8.2 Hz, 1 H), 4.26 (t, J = 7.8 Hz, 1 H), 4.04 (q, J = 7.0 Hz, 2H), 3.79-3.84 (m, 4H), 3.42-3.51 (m, 1H), 1.26-1.36 (m, 4H), 1.05-1.12 (m, 1H). LCMS m/z = 313 [MH]+. |
249
183 | OH L II I o 4-(3'-isobutoxy-4'-methoxy-[1,1 biphenyl]-3-yl)-1,2-oxaborolan-2-ol | Ή NMR (DMSO-ds, 400MHz): δ 7.447.56 (m, 2H), 7.32-7.39 (m, 1H), 7.157.24 (m, 3H), 7.00-7.04 (m, 1H), 4.15 (t, J= 10.5 Hz, 1H), 4.02-4.06 (m, 1H), 3.79-3.84 (m, 5H), 3.43-3.51 (m, 1H), 1.99-2.09 (m, 1H), 1.22-1.32 (m, 1H), 1.05-1.11 (m, 1H), 0.98-1.01 (m, 6H). LCMS m/z = 359 [MH+H2O]+. |
184 | I OH r-B jL J Y > 4-(3'-cyclobutoxy-4'-methoxy-[1,1 biphenyl]-3-yl)-1,2-oxaborolan-2-ol | Ή NMR (DMSO-de, 400MHz): δ 7.46 (s, 1H), 7.40-7.44 (m, 1H), 7.36 (d, J = 7.6 Hz, 1H), 7.21 (d, J = 7.3 Hz, 1H), 7.16 (dd, J = 2.1,8.4 Hz, 1 H), 6.99-7.05 (m, 2H), 4.75-4.83 (m, 1 H), 4.26 (t, J = 8.2 Hz, 1H), 3.78-3.84 (m, 4H), 3.41-3.54 (m, 1H), 2.39-2.47 (m, 2H), 2.02-2.14 (m, 2H), 1.74-1.84 (m, 1H), 1.59-1.71 (m, 1H), 1.29 (dd, J = 8.2, 16.3 Hz, 1H), 1.05-1.12 (m, 1H), 1.03 (d, J = 6.8 Hz, 1H). LCMS m/z = 339 [MH]+. |
185 | OH 4-(2-(3-ethoxy-4-methoxyphenyl)-6methoxypyrimidin-4-yl)-1,2-oxaborolan2-ol | 1H NMR (DMSO-d6, 400MHz): δ 8.67 (s, 1H), 7.99 (dd, J = 2.0, 8.5 Hz, 1H), 7.96 (d, J = 2.0 Hz, 1H), 7.06 (d, J = 8.5 Hz, 1H), 6.64 (s, 1H), 4.26 (dd, J = 7.3, 8.8 Hz, 1H), 4.10 (q, J = 6.9 Hz, 2H), 4.00 (s, 3H), 3.95 (dd, J = 6.0, 9.0 Hz, 1H), 3.83 (s, 3H), 3.48-3.54 (m, 1 H), 1.37 (t, J = 7.0 Hz, 3H), 1.21-1.27 (m, 1H), 1.11-1.18 (m, 1H). LCMS m/z = 345 [MH]+. |
186 | OH (-) 4-(2-(3-ethoxy-4-methoxyphenyl)-6methoxypyrimidin-4-yl)-1,2-oxaborolan2-ol, enantiomer 2 | 1H NMR (DMSO-d6, 400MHz): δ 8.67 (s, 1 H), 7.99 (dd, J = 2.0, 8.5 Hz, 1 H), 7.96 (d, J = 2.0 Hz, 1H), 7.06 (d, J = 8.5 Hz, 1H), 6.64 (s, 1H), 4.26 (dd, J = 7.3, 8.8 Hz, 1 H), 4.10 (q, J = 6.9 Hz, 2H), 4.00 (s, 3H), 3.95 (dd, J = 6.0, 9.0 Hz, 1H), 3.83 (s, 3H), 3.48-3.54 (m, 1 H), 1.37 (t, J = 7.0 Hz, 3H), 1.21-1.27 (m, 1H), 1.11-1.18 (m, 1H). LCMS m/z = 345 [MH]+. |
250
[o]20d -37.4 (c= 0.1, EtOH). | ||
187 | OH T 1 Γ b 4-(5-(4-ethoxy-3methoxyphenyl)pyridin-3-yl)-1,2oxaborolan-2-ol | Ή NMR (DMSO-de, 400MHz): δ 8.73 (s, 1H), 8.71 (d, J = 2.0 Hz, 1H), 8.42 (d, J = 2.0 Hz, 1H), 7.94 (t, J = 2.2 Hz, 1H), 7.28 (d, J = 2.0 Hz, 1H), 7.21-7.25 (m, 1H), 7.03-7.07 (m, 1H), 4.27 (t, J = 8.3 Hz, 1H), 4.05 (q, J = 7.2 Hz, 2H), 3.83-3.88 (m, 4H), 3.47-3.55 (m, 1H), 1.27-1.37 (m, 4H), 1.10-1.19 (m, 1H). LCMS m/z = 314 [MH]+. |
188 | OH Tl .. * Γ b 4-(5-(4-ethoxy-3- methoxyphenyl)pyridin-3-yl)-1,2- oxaborolan-2-ol, enantiomer 2 | 1H NMR (DMSO-ds, 400MHz): δ 8.73 (s, 1 H), 8.71 (d, J = 2.0 Hz, 1 H), 8.42 (d, J = 2.0 Hz, 1 H), 7.94 (t, J = 2.2 Hz, 1 H), 7.28 (d, J = 2.0 Hz, 1H), 7.21-7.25 (m, 1H), 7.03-7.07 (m, 1H), 4.27 (t, J = 8.3 Hz, 1H), 4.05 (q, J = 7.2 Hz, 2H), 3.83-3.88 (m, 4H), 3.47-3.55 (m, 1H), 1.27-1.37 (m, 4H), 1.10-1.19 (m, 1H). LCMS m/z = 314 [MH]+. RT [Analytical SFC Method AA] = 3.61 min. |
189 | OH i r-B j? ïi i χ θ 4-(5-(3-ethoxy-4-methoxyphenyl)-4methylpyridin-3-yl)-1,2-oxaborolan-2-ol, enantiomer 2 | 1H NMR (DMSO-de, 400MHz): δ 8.71 (s, 1H), 8.43 (s, 1H), 8.21 (s, 1H), 7.04 (d, J = 8.0 Hz, 1H), 6.90 (d, J = 2.3 Hz, 1H), 6.82-6.85 (m, 1H), 4.24-4.28 (m, 1H), 4.03 (q, J = 7.0 Hz, 2H), 3.90-3.95 (m, 1H), 3.80 (s, 3H), 3.63-3.71 (m, 1H), 2.22 (s, 3H), 1.30-1.36 (m, 4H), 1.04-1.10 (m, 1H). LCMS m/z = 328 [MH]+. RT [Analytical SFC Method E] = 5.71 min. |
190 | OH T T . rt 4-(5-(3-isopropoxy-4- methoxyphenyl)pyridin-3-yl)-1,2oxaborolan-2-ol, enantiomer 2 | 1H NMR (DMSO-de, 400MHz): δ 8.72 (s, 1 H), 8.69 (d, J = 2.0 Hz, 1 H), 8.42 (d, J = 2.0 Hz, 1 H), 7.92 (t, J = 2.0 Hz, 1 H), 7.29 - 7.24 (m, 2H), 7.07 (d, J = 8.0 Hz, 1 H), 4.68-4.74 (m, 1H), 4.27 (t, J = 8.3 Hz, 1H), 3.86 (t, J= 9.0 Hz, 1H), 3.79 (s, 3H), 3.47-3.55 (m, 1H), 1.26-1.35 (m, 7H), 1.10-1.18 (m, 1H). LCMS m/z = 328 |
251
[MH]+. RT [Analytical SFC Method BA] = 5.69 min. | |||
191 | /^o^ I r 3-ethoxy-3'-(2-l 4-yl)-4-methox\ carbonitrile | OH ! \ r-B I J iydroxy-1,2-oxaborolan- <-[1,1 '-biphenyl]-2- | 1H NMR (DMSO-de, 400MHz): δ 7.317.46 (m, 3H), 7.33-7.36 (m, 2H), 7.27 (d, J= 8.8 Hz, IH), 4.18-4.28 (m, 3H), 3.90 (s, 3H), 3.81 (t, J= 8.8 Hz, 1H), 3.453.52 (m, 1H), 1.26-1.34 (m, 4H), 1.081.11 (m, 1 H) . LCMS m/z = 338 [MH]+. |
192 | ^O^ I t 3-ethoxy-3'-(2-l 4-yl)-4-methox} carbonitrile, en | OH ία» I si iydroxy-1,2-oxaborolan- /-[1,1'-biphenyl]-2- antiomer 2 | RT [Analytical SFC Method CA] = 3.14 min. |
193 | OH z°W\ rt-B J? jl *Γ'ο 4-(5-(3-cyclopropoxy-4methoxyphenyl)pyridin-3-yl)-1,2oxaborolan-2-ol, enantiomer 1 | 1H NMR (DMSO-d6, 400MHz): δ 8.698.72 (m, 2H), 8.44 (d, J = 2.0 Hz, 1 H), 7.91 (t, J = 2.0 Hz, 1 H), 7.53 (d, J = 2.0 Hz, 1 H), 7.28 (dd, J = 2.4, 8.3 Hz, 1 H), 7.07 (d, J = 8.8 Hz, 1 H), 4.25-4.31 (m, 1H), 3.97-4.01 (m, 1H), 3.86 (t, J = 8.8 Hz, 1H), 3.78 (s, 3H), 3.46-3.57 (m, 1H), 1.32 (dd, J = 8.1, 16.4 Hz, 1H), 1.14 (dd, J = 10.3, 16.1 Hz, 1H), 0.76-0.83 (m, 2H), 0.67-0.72 (m, 2H). LCMS m/z = 326 [MH]+. RT [Analytical SFC Method D] = 5.38 min. | |
194 | OH / J b o^ t / )>=/ X Æ° (-) 4-(2-(3-ethoxy-4- methoxyphenyl)thiazol-4-yl)-1,2- oxaborolan-2-ol, enantiomer 1 | ’H NMR (DMSO-de, 400MHz): δ 8.66 (br s, 1H), 7.42-7.46 (m, 2H), 7.30 (s, 1H), 7.05 (d, J= 8.3 Hz, 1H), 4.24-4.28 (m, 1H), 4.09 (q, J= 7.0 Hz, 2H), 3.90-3.95 (m, 1H), 3.82 (s, 3H), 3.55-3.63 (m, 1H), 1.36 (t, J= 7.0 Hz, 3H), 1.25-1.31 (m, 1H), 1.11-1.18 (m, 1H). LCMS m/z = 320 |
252
[MH]+. RT [Analytical SFC Method DA] = 4.47 min. [a]20 D-17.4 (c= 0.1, EtOH). |
253
195
4-(6-(2-hydroxyethoxy)-2-(4-methoxy-3propoxyphenyl)pyrimidin-4-yl)-1,2oxaborolan-2-ol
196
(-) 4-(6-(2-hydroxyethoxy)-2-(4methoxy-3-propoxyphenyl)pyrimidin-4yl)-1,2-oxaborolan-2-ol, enantiomer 1
197
4-(6-(3,4-dimethoxyphenyl)pyridin-2-yl)1,2-oxaborolan-2-ol 1H NMR (DMSO-d6, 400MHz): δ 8.65 (s, 1 H), 7.97 (dd, J = 2.0, 8.3 Hz, 1 H), 7.93 (d, J = 1.7 Hz, 1H), 7.06 (d, J = 8.6 Hz, 1H), 6.64 (s, 1H), 4.89 (t, J = 5.4 Hz, 1H), 4.42-4.47 (m, 2H), 4.26 (dd, J = 7.3, 9.0 Hz, 1 H), 4.00 (t, J = 6.5 Hz, 2H), 3.95 (dd, J = 6.4, 9.0 Hz, 1H), 3.83 (s, 3H), 3.74-3.80 (m, 2H), 3.47-3.54 (m, 1H), 1.73-1.81 (m, 2H), 1.20-1.28 (m, 1H), 1.10-1.17 (m, 1H), 1.01 (t, J = 7.3 Hz, 3H). LCMS m/z = 406 [MH+H2O]+.
1H NMR (DMSO-c/6, 400MHz): δ 8.65 (s, 1H), 7.97 (dd, J = 2.0, 8.3 Hz, 1H), 7.93 (d, J = 1.7 Hz, 1H), 7.06 (d, J = 8.6 Hz, 1 H), 6.64 (s, 1 H), 4.89 (t, J = 5.4 Hz, 1 H), 4.42-4.47 (m, 2H), 4.26 (dd, J = 7.3, 9.0 Hz, 1H), 4.00 (t, J = 6.5 Hz, 2H), 3.95 (dd, J = 6.4, 9.0 Hz, 1H), 3.83 (s, 3H), 3.74-3.80 (m, 2H), 3.47-3.54 (m, 1H), 1.73-1.81 (m, 2H), 1.20-1.28 (m, 1H), 1.10-1.17 (m, 1H), 1.01 (t, J = 7.3 Hz, 3H). LCMS m/z = 406 [MH+H2O]+. [a]20D -38.9 (c = 0.1, EtOH).
Ή NMR (DMSO-de, 400 MHz): δ 8.59 (s, 1H), 7.73-7.75 (m, 3H), 7.64 (d, J= 8.4 Hz, 1H), 7.15-7.17 (m, 1H), 7.03 (d, J = 8.4 Hz, 1H), 4.27-4.31 (m, 1H), 3.95-3.99 (m, 1H), 3.84 (s, 3H), 3.80 (s, 3H), 3.573.60 (m, 1H), 1.15-1.29 (m, 2H) . LCMS m/z = 298 [MH]'.
254
198 | OH ΌΗ 4-(4-(hydroxymethyl)-6-(4-methoxy-3propoxyphenyl)pyrimidin-2-yl)-1,2oxaborolan-2-ol | Ή NMR (DMSO-ds,400 MHz): δ 8.71 (br s, 1H), 7.70-7.81 (m, 3H), 7.53 (d, J = 8.0 Hz, 1H), 7.07-7.14 (m, 1H), 5.71 (br s, 1H), 4.55 (d, J = 5.5 Hz, 2H), 4.29 (t, J = 8.3 Hz, 1H), 3.95-4.11 (m, 2H), 3.81-3.88 (m, 4H), 1.71-1.83 (m, 2H), 1.27 (d, J = 8.0 Hz, 1H), 0.96-1.05 (m, 4H). LCMS m/z = 359 [MH]+. |
199 | OH Ï U 4-(6-(3-ethoxy-2-fluoro-4methoxyphenyl)pyridin-2-yl)-1,2oxaborolan-2-ol | 1H NMR (DMSC-d6,400 MHz): δ 8.60 (br s, 1H), 7.75-7.82 (m, 1H), 7.67 (t, J = 8.8 Hz, 1 H), 7.55 (d, J = 6.4 Hz, 1 H), 7.25 (d, J = 7.6 Hz, 1H), 7.02 (d, J = 8.1 Hz, 1H), 4.25-4.32 (m, 1H), 4.06 (q, J = 7.0 Hz, 2H), 3.96-4.02 (m, 1H), 3.87 (s, 3H), 3.61 (td, J = 8.0, 15.8 Hz, 1H), 1.13-1.32 (m, 5H). LCMS m/z = 332 [MH]+. |
200 | OH \ AA 1 d 4-(1-(4-methoxy-3-propoxyphenyl)-1 Hpyrazol-3-yl)-1,2-oxaborolan-2-ol | Ή NMR (DMSO-ds, 400 MHz): δ 8.61 (s, 1 H), 8.30 (d, J = 2.0 Hz, 1 H), 7.33 (d, J = 2.5 Hz, 1H), 7.25 (dd, J = 2.5, 8.5 Hz, 1 H), 7.01 (d, J = 9.0 Hz, 1 H), 6.37 (d, J = 2.5 Hz, 1H), 4.18-4.25 (m, 1H), 3.98 (t, J = 6.5 Hz, 2H), 3.89 (t, J = 8.5 Hz, 1H), 3.78 (s, 3H), 3.44-3.52 (m, 1H), 1.711.80 (m, 2H), 1.27 (dd, J = 8.5, 16.1 Hz, 1H), 1.03-1.13 (m, 1H), 0.99 (t, J = 7.3 Hz, 3H). LCMS m/z = 317 [MH]+. |
201 | OH r-B IX. £ z° N 4-(5-(3-methoxy-4- (methylthio)phenyl)pyridin-3-yI)-1,2- oxaborolan-2-ol | Ή NMR (DMSO-d6,400 MHz): δ 8.60 (br s, 1 H), 7.75-7.82 (m, 1 H), 7.67 (t, J = 8.8 Hz, 1 H), 7.55 (d, J = 6.4 Hz, 1 H), 7.25 (d, J = 7.6 Hz, 1H), 7.02 (d, J = 8.1 Hz, 1H), 4.25-4.32 (m, 1H), 4.06 (q, J = 7.0 Hz, 2H), 3.96-4.02 (m, 1H), 3.87 (s, 2H), 3.57-3.65 (m, 1H), 1.13-1.33 (m, 5H). LCMS m/z = 316 [MH]+. |
255
202 | OH Tff u L II 1 o ΌΗ 4-(2-(hydroxymethyl)-6-(4-methoxy-3propoxyphenyl)pyridin-4-yl)-1,2- oxaborolan-2-ol | 1H NMR (DMSO-c/e,400 MHz): δ 8.74 (s, 1H), 7.61-7.69 (m, 3H), 7.26 (s, 1H), 7.03 (d, J = 8.3 Hz, 1 H), 5.40 (t, J = 5.6 Hz, 1H), 4.58 (d, J = 5.9 Hz, 2H), 4.29 (t, J = 8.3 Hz, 1 H), 4.00 (t, J = 6.4 Hz, 2H), 3.82-3.89 (m, 1H), 3.81 (s, 3H), 3.473.56 (m, 1H), 1.72-1.81 (m, 2H), 1.32 (dd, J = 8.3, 16.1 Hz, 1H), 1.09 (dd, J = 9.8, 16.6 Hz, 1H), 1.01 (t, J = 7.6 Hz, 3H). LCMS m/z = 358 [MH]+. |
203 | OH Λα H ij 4-(6-(3-ethoxy-4(methylthio)phenyl)pyridin-2-yl)-1,2- oxaborolan-2-ol | Ή NMR (DMSO-c/e, 400MHz): δ 8.61 (br s, 1H), 7.44-7.83 (m, 2H), 7.67-7.73 (m, 2H), 7.18-7.24 (m, 2H), 4.26-4.32 (m, 1H), 4.19 (q, J = 7.1 Hz, 2H), 3.97 (dd, J = 6.6, 8.8 Hz, 1H), 3.57-3.64 (m, 1H), 2.42 (s, 3H), 1.38 (t, J = 7.0 Hz, 3H), 1.22-1.31 (m, 1H), 1.14-1.22 (m, 1H). LCMS m/z = 330 [MH]+. |
204 | OH rB 4-(6-(3-ethoxy-4- (methylthio)phenyl)pyridin-2-yl)-1,2oxaborolan-2-ol, enantiomer 1 | RT [Analytical SFC Method Y] = 7.70 min. |
205 | OH i rB' Il d I J o (+) 4-(5-(3-ethoxy-4-methoxyphenyl)- 4,6-dimethylpyridin-3-yl)-1,2- oxaborolan-2-ol, enantiomer 1 | 1H NMR (DMSO-de,400 MHz): δ 8.70 (d, J = 2.0 Hz, 1 H), 8.31 (s, 1 H), 7.03 (d, J = 7.8 Hz, 1H), 6.72 (dd, J = 2.0, 3.9 Hz, 1H), 6.65 (ddd, J = 2.0, 4.2, 8.1 Hz, 1H), 4.22 (dd, J = 7.3, 8.8 Hz, 1H), 3.96-4.01 (m, 2H), 3.84-3.92 (m, 1H), 3.80 (s, 3H), 3.54-3.62 (m, 1H), 2.13 (s, 3H), 1.97 (s, 3H), 1.25-1.34 (m, 4H), 0.99-1.09 (m, 1H). LCMS m/z = 342 [MH]+. [α]2% +9.6 (c = 0.1, EtOH). |
256
206 | OH II 1 o “ Qf' 4-(3'-methoxy-4'-(methylthio)-[1,1 biphenyl]-3-yl)-1,2-oxaborolan-2-ol | Ή NMR (DMSO-d6,400 MHz): δ 8.65 (s, 1 H), 7.56 (s, 1 H), 7.51 (d, J = 7.8 Hz, 1H), 7.38 (t, J = 7.6 Hz, 1H), 7.26 (d, J = 8.1 Hz, 2H), 7.20 (d, J = 8.6 Hz, 2H), 4.26 (t, J = 8.2 Hz, 1H), 3.91 (s, 3H), 3.82 (t, J = 8.9 Hz, 1H), 3.44-3.52 (m, 1H), 2.41 (s, 3H), 1.29 (dd, J = 8.2, 16.3 Hz, 1H), 1.09 (dd, J= 10.3, 16.1 Hz, 1H). LCMS m/z = 315 [MH]+. |
207 | OH X X A /° 4-(3',4'-dimethoxy-5-methyl-[1,1 biphenyl]-3-yl)-1,2-oxaborolan-2-ol | 1H NMR (DMSO-ds, 400MHz): δ 8.64 (s, 1H), 7.27-7.30 (m, 2H), 7.14-7.18 (m, 2H), 6.99-7.02 (m, 2H), 4.22-4.26 (m, 1H), 3.78-3.84 (m, 7H), 3.37-3.46 (m, 1H), 2.34 (s, 3H), 1.24-1.30 (m, 1H), 1.04-1.11 (m, 1H). LCMS m/z 313 [MH]+. |
208 | OH /O^_F B' X X XJ° (+) 4-(3-fluoro-5-methoxy-6-propoxy- [2,3'-bipyridin]-5'-yl)-1,2-oxaborolan-2- ol, enantiomer 2 | 1H NMR (DMSO-d6, 400MHz): δ 8.89 (s, 1 H), 8.73 (s, 1 H), 8.49 (d, J = 2.0 Hz, 1H), 8.09 (s, 1H), 7.49 (d, J=12.0 Hz, 1H), 4.28-4.33 (m, 3H), 3.87 (s, 3H), 3.82 (t, J= 8.7 Hz, 1H), 3.49-3.57 (m, 1H), 1.73-1.81 (m, 2H), 1.31-1.37 (m, 1H), 1.03-1.09 (m, 1 H), 0.98 (t, J = 7.5 Hz, 3H). LCMS m/z = 347 [MH]+. [α]2% +20.4 (c = 0.1, EtOH). |
209 | OH /°y\ rA L Il / b Au 4-(2'-fluoro-3',4'-dimethoxy-[1,1'biphenyl]-3-yl)-1,2-oxaborolan-2-ol | Ή NMR (DMSO-d6,400 MHz): δ 8.66 (br s, 1H), 7.35-7.40 (m, 2H), 7.26-7.34 (m, 2H), 7.18 (t, J= 8.4 Hz, 1H), 6.95-7.00 (m, 1H), 4.22-4.28 (m, 1H), 3.86 (s, 3H), 3.77-3.84 (m, 4H), 3.41-3.52 (m, 1H), 1.29 (q, J= 8.0 Hz, 1H), 1.04 (q, 8.0 Hz, 1H). LCMS m/z = 317 [MH]+. |
257
210 | I OH XX X^ X x > 4-(2-(3-(cyclopentyloxy)-4methoxyphenyl)pyridin-4-yl)-1,2- oxaborolan-2-ol | Ή NMR (DMSO-cfe, 400MHz): δ 8.72 (s, 1H), 8.50 (d, J = 5.4 Hz, 1H), 7.77 (s, 1H), 7.66 (d, J = 2.0 Hz, 1H), 7.62 (dd, J = 2.2, 8.6 Hz, 1H), 7.18 (dd, J = 1.2, 5.1 Hz, 1 H), 7.03 (d, J = 8.3 Hz, 1 H), 4.874.94 (m, 1H), 4.24-4.31 (m, 1H), 3.84 (t, J = 9.0 Hz, 1H), 3.79 (s, 3H), 3.42-3.55 (m, 1H), 1.87-1.96 (m, 2H), 1.70-1.80 (m, 4H), 1.56-1.63 (m, 2H), 1.30 (dd, J = 8.3, 16.1 Hz, 1H), 1.10 (dd, J = 10.0, 16.4 Hz, 1H). LCMS m/z = 354 [MH]+. |
211 | I OH XX X. X *X ° 4-(2-(3-(cyclopentyloxy)-4methoxyphenyl)pyridin-4-yl)-1,2oxaborolan-2-ol, enantiomer 2 | Ή NMR (DMSO-cfe, 400MHz): δ 8.72 (s, 1H), 8.50 (d, J = 5.4 Hz, 1H), 7.77 (s, 1 H), 7.66 (d, J = 2.0 Hz, 1 H), 7.62 (dd, J = 2.2, 8.6 Hz, 1H), 7.18 (dd, J = 1.2, 5.1 Hz, 1 H), 7.03 (d, J = 8.3 Hz, 1 H), 4.874.94 (m, 1H), 4.24-4.31 (m, 1H), 3.84 (t, J = 9.0 Hz, 1H), 3.79 (s, 3H), 3.42-3.55 (m, 1H), 1.87-1.96 (m, 2H), 1.70-1.80 (m, 4H), 1.56-1.63 (m, 2H), 1.30 (dd, J = 8.3, 16.1 Hz, 1H), 1.10 (dd, J = 10.0, 16.4 Hz, 1H). LCMS m/z = 354 [MH]+. RT [Analytical SFC Method EA] = 4.27 min. |
212 | OH rB ' Ό 4-(2-(4-methoxy-3- propoxyphenyl)pyrimidin-4-yl)-1,2- oxaborolan-2-ol | Ή NMR (DMSO-dg.400 MHz): δ 8.71 (d, J = 5.1 Hz, 1H), 8.69 (s, 1H), 8.00 (dd, J = 1.8, 8.4 Hz, 1 H), 7.96 (d, J = 1.7 Hz, 1H), 7.26 (d, J = 4.9 Hz, 1H), 7.08 (d, J = 8.3 Hz, 1H), 4.30 (dd, J = 7.5, 8.9 Hz, 1H), 3.97-4.02 (m, 3H), 3.83 (s, 3H), 3.55-3.63 (m, 1H), 1.73-1.82 (m, 2H), 1.25-1.33 (m, 1H), 1.13-1.20 (m, 1H), 1.01 (t, J = 7.5 Hz, 3H). LCMS m/z = 329 [MH]+. |
258
213 | OH ο y f 4-(6-(2-fluoro-4-methoxy-3propoxyphenyl)pyridin-2-yl)-1,2oxaborolan-2-ol | Ή NMR (DMSO-de,400 MHz): δ 8.61 (s, 1H), 7.75-7.80 (m, 1H), 7.66 (t, J = 8.8 Hz, 1 H), 7.55 (dd, J = 1.8, 7.7 Hz, 1 H), 7.24 (d, J = 7.6 Hz, 1H), 6.99-7.04 (m, 1 H), 4.27 (dd, J = 7.8, 8.6 Hz, 1 H), 3.924.02 (m, 3H), 3.86 (s, 3H), 3.57-3.65 (m, 1H), 1.63-1.72 (m, 2H), 1.14-1.31 (m, 2H), 0.98 (t, J = 7.3 Hz, 3H). LCMS m/z = 346 [MH]+. |
214 | F OH d x° 4-(5-(3-ethoxy-5-fluoro-4methoxyphenyl)pyridin-3-yl)-1,2oxaborolan-2-ol, enantiomer 2 | 1H NMR (DMSO-d6, 400MHz): δ 8.75 (d, J = 2.0 Hz, 1 H), 8.71 (s, 1 H), 8.47 (d, J = 1.47 Hz, 1 H), 8.00 (s, 1 H), 7.27 (dd, J = 2.0, 11.7 Hz, 1 H), 7.20 (s, 1 H), 4.27 (t, J = 8.3 Hz, 1H), 4.21 (q, J= 6.9 Hz, 2H), 3.82-3.90 (m, 3H), 3.45-3.56 (m, 2H), 1.39 (t, J= 6.9 Hz, 3H), 1.26-1.34 (m, 1H), 1.12-1.20 (m, 1H). LCMS m/z = 349 [MH+H2O]+. RT [Analytical SFC Method D] = 4.59 min. |
215 | OH XX. ΧΧν®//° 0 jCj N 4-(6-(2-fluoro-4-methoxy-3propoxyphenyl)pyrazin-2-yl)-1,2- oxaborolan-2-ol | 1H NMR (DMSC-d6,400 MHz): δ 8.81 (d, J = 2.4 Hz, 1 H), 8.69 (s, 1 H), 8.53 (s, 1 H), 7.67 (t, J = 8.8 Hz, 1 H), 7.07 (d, J = 7.8 Hz, 1H), 4.31 (t, J = 8.3 Hz, 1H), 3.94-4.06 (m, 3H), 3.89 (s, 3H), 3.673.75 (m, 1H), 1.64-1.73 (m, 2H), 1.271.36 (m, 1H), 1.15-1.25 (m, 1H), 0.98 (t, J = 7.3 Hz, 3H). LCMS m/z = 347 [MH]+. |
216 | OH z°yy d 0 iïr N 4-(6-(2-fluoro-4-methoxy-3propoxyphenyl)pyrazin-2-yl)-1,2oxaborolan-2-ol, enantiomer 1 | Ή NMR (DMSO-c/s.400 MHz): δ 8.81 (d, J = 2.4 Hz, 1 H), 8.69 (s, 1 H), 8.53 (s, 1H), 7.67 (t, J = 8.8 Hz, 1H), 7.07 (d, J = 7.8 Hz, 1 H), 4.31 (t, J = 8.3 Hz, 1 H), 3.94-4.06 (m, 3H), 3.89 (s, 3H), 3.673.75 (m, 1H), 1.64-1.73 (m, 2H), 1.271.36 (m, 1H), 1.15-1.25 (m, 1H), 0.98 (t, J = 7.3 Hz, 3H). LCMS m/z = 347 [MH]+. RT [Analytical SFC Method C] = 4.40 min. |
259
217 | OH ^°X1 XB° AU N 4-(5-(4-ethoxy-2-fluoro-3methoxyphenyl)pyridin-3-yl)-1,2oxaborolan-2-ol | Ή NMR (DMSO-dg,400 MHz): δ 8.72 (s, 1 H), 8.54 (t, J = 2.0 Hz, 1 H), 8.48 (d, J = 2.5 Hz, 1 H), 7.82 (d, J = 1.5 Hz, 1 H), 7.24 (t, J = 8.8 Hz, 1H), 6.98-7.02 (m, 1H), 4.25-4.31 (m, 1H), 4.14 (q, J = 6.9 Hz, 2H), 3.81-3.87 (m, 4H), 3.46-3.56 (m, 1 H), 1.38 (t, J = 6.8 Hz, 3H), 1.32 (dd, J = 8.3, 16.3 Hz, 1H), 1.10 (dd, J = 10.0, 16.1 Hz, 1H). LCMS m/z = 332 [MH]+. |
218 | OH /<V A Y X Γ b ’° X/ N 4-(6'-methoxy-2-methyl-5'-propoxy- [3,3'-bipyridin]-5-yl)-1,2-oxaboroIan-2-ol | Ή NMR (DMSO-de, 400MHz): δ 8.69 (s, 1H), 8.37 (d, J = 2.0 Hz, 1H), 7.69 (m, 1H), 7.54-7.56 (m, 1H), 7.27-7.33 (m, 1H), 4.23-4.27 (m, 1H), 3.98-4.01 (m, 2H), 3.91 (s, 3H), 3.78-3.83 (m, 1H), 3.43-3.49 (m, 1H), 2.41 (s, 3H), 1.721.77 (m, 2H), 1.26-1.30 (m, 1H), 1.071.11 (m, 1H), 0.96-1.00 (m, 3H). LCMS m/z = 343 [MH]+. |
219 | OH II J b (-) 4-(6'-methoxy-2-methyl-5'-propoxy[3,3'-bipyridin]-5-yl)-1,2-oxaborolan-2ol, enantiomer 1 | 1H NMR (DMSO-d6, 400MHz): δ 8.69 (s, 1H), 8.37 (d, J = 2.0 Hz, 1H), 7.69 (m, 1H), 7.54-7.56 (m, 1H), 7.27-7.33 (m, 1H), 4.23-4.27 (m, 1H), 3.98-4.01 (m, 2H), 3.91 (s, 3H), 3.78-3.83 (m, 1H), 3.43-3.49 (m, 1H), 2.41 (s, 3H), 1.721.77 (m, 2H), 1.26-1.30 (m, 1H), 1.071.11 (m, 1H), 0.96-1.00 (m, 3H). LCMS m/z = 343 [MH]+. RT [Analytical SFC Method Z] = 2.28 min. [α]2% -16.2 (c = 0.1, EtOH). |
220 | OH Q F F F 4-(6-(3-ethoxy-4-methoxyphenyl)-4(trifluoromethyl)pyridin-2-yl)-1,2oxaborolan-2-ol | Ή NMR (MeOD-ds, 400MHz): δ 7.85 (s, 1 H), 7.76 (d, J = 2.0 Hz, 1 H), 7.67 (dd, J = 2.0, 8.3 Hz, 1H), 7.39 (s, 1H), 7.06 (d, J = 8.8 Hz, 1H), 4.17 (q, J = 7.2 Hz, 3H), 4.02 (br s, 1 H), 3.89 (s, 3H), 3.57 (br s, 1H), 1.45 (t, J = 7.1 Hz, 3H), 1.33-1.41 (m, 1H), 1.24-1.32 (m, 1H). LCMS m/z 382 [MH]+. |
260
221 | OH N II d * / o ° Tj 4-(5-(3,4-dimethoxyphenyl)pyridin-3-yl)- 1,2-oxaborolan-2-ol, enantiomer 2 | Ή NMR (DMSO-d6, 400MHz): δ 8.72 (d, J = 2.8 Hz, 2H), 8.43 (d, J = 2.0 Hz, 1 H), 7.95 (t, J = 2.0 Hz, 1H), 7.25-7.29 (m, 1 H), 7.06 (d, J = 8.4 Hz, 2H), 4.28 (t, J = 4.28 Hz, 1H), 3.84-3.88 (m, 4H), 3.80 (s, 3H), 3.46-3.54 (m, 1H), 1.28-1.34 (m, 1 H), 1.12-1.18 (m, 1H). LCMS m/z = 300 [MH]+. RT [Analytical SFC Method FA] = 6.04 min. |
222 | OH J AL· JJ5 °d 4-(6-ethoxy-2-(3-ethoxy-4methoxyphenyl)pyrimidin-4-yl)-1,2oxaborolan-2-ol | 1H NMR (DMSO-ds, 400MHz): δ 8.66 (s, 1H), 7.93-7.99 (m, 2H), 7.05 (d, J = 8.5 Hz, 1H), 6.59 (s, 1H), 4.47 (q, J = 6.9 Hz, 2H), 4.25 (t, J = 8.0 Hz, 1H), 4.09 (q, J = 6.9 Hz, 2H), 3.91-3.98 (m, 1H), 3.82 (s, 3H), 3.48 (br s, 1 H), 1.36 (t, J = 7.0 Hz, 6H), 1.19-1.28 (m, 1H), 1.09-1.18 (m, 1H). LCMS m/z [Analytical SFC Method FA] = 359 [MH]+. |
223 | OH °d 4-(6-ethoxy-2-(3-ethoxy-4methoxyphenyl)pyrimidin-4-yl)-1,2oxaborolan-2-ol, enantiomer 1 | Ή NMR (DMSO-d6, 400MHz): δ 8.66 (s, 1H), 7.93-7.99 (m, 2H), 7.05 (d, J = 8.5 Hz, 1 H), 6.59 (s, 1 H), 4.47 (q, J = 6.9 Hz, 2H), 4.25 (t, J = 8.0 Hz, 1H), 4.09 (q, J = 6.9 Hz, 2H), 3.91-3.98 (m, 1H), 3.82 (s, 3H), 3.48 (br s, 1 H), 1.36 (t, J = 7.0 Hz, 6H), 1.19-1.28 (m, 1H), 1.09-1.18 (m, 1H). LCMS m/z = 359 [MH]+. RT [Analytical SFC Method D] = 2.97 min. |
224 | OH AA^nAL·3 o y at 4-(6-methoxy-2-(4-methoxy-3propoxyphenyl)pyrimidin-4-yl)-1,2oxaborolan-2-ol | Ή NMR (DMSO-cfe, 400MHz): δ 8.69 (s, 1H), 7.98 (dd, J = 2.0, 8.5 Hz, 1H), 7.947.97 (m, 1H), 7.06 (d, J = 8.5 Hz, 1H), 6.63 (s, 1H), 4.26 (dd, J = 7.5, 9.0 Hz, 1H), 3.97-4.03 (m, 5H), 3.94 (dd, J = 6.0, 9.0 Hz, 1H), 3.82 (s, 3H), 3.50 (d, J = 8.0 Hz, 1H), 1.72-1.81 (m, 2H), 1.20-1.27 (m, 1H), 1.10-1.17 (m, 1H), 1.00 (t, J = 7.5 Hz, 3H). LCMS m/z = 359 [MH]+. |
261
225 | OH /° (-) 4-(6-methoxy-2-(4-methoxy-3propoxyphenyl)pyrimidin-4-yl)-1,2oxaborolan-2-ol, enantiomer 2 | 1H NMR (DMSO-c/6, 400MHz): δ 8.69 (s, 1 H), 7.98 (dd, J = 2.0, 8.5 Hz, 1 H), 7.947.97 (m, 1 H), 7.06 (d, J = 8.5 Hz, 1 H), 6.63 (s, 1H), 4.26 (dd, J = 7.5, 9.0 Hz, 1H), 3.97-4.03 (m, 5H), 3.94 (dd, J = 6.0, 9.0 Hz, 1H), 3.82 (s, 3H), 3.50 (d, J = 8.0 Hz, 1H), 1.72-1.81 (m, 2H), 1.20-1.27 (m, 1H), 1.10-1.17 (m, 1H), 1.00 (t, J = 7.5 Hz, 3H). LCMS m/z = 359 [MH]+. [α]2%-16.9 (c= 0.1, EtOH). |
226 | I OH /Y C* Yk YYnYY YYî ZJ Il + N 2-(cyclopentyloxy)-6-(6-(2-hydroxy-1,2oxaborolan-4-yl)pyridin-2-yl)-3methoxybenzonitrile | 1H NMR (DMSO-c/6, 400MHz): δ 8.57 (s, 1H), 7.81-7.88 (m, 1H), 7.59 (d, J = 7.8 Hz, 1H), 7.49-7.55 (m, 1H), 7.42-7.48 (m, 1 H), 7.32 (d, J = 7.6 Hz, 1 H), 5.11 (t, J = 5.1 Hz, 1H), 4.27 (t, J = 8.3 Hz, 1H), 4.08 (t, J = 8.7 Hz, 1H), 3.91 (s, 3H), 3.593.68 (m, 1H), 1.79-1.93 (m, 4H), 1.681.76 (m, 2H), 1.54-1.63 (m, 2H), 1.281.36 (m, 1H), 1.21-1.28 (m, 1H). LCMS m/z = 379 [MH]+. |
227 | OH rt-B JL jl JT b N^z 4-(2-(3,4-dimethoxyphenyl)pyridin-4-yl)- 1,2-oxaborol-2(5H)-ol | 1H NMR (DMSO-c/6, 400 MHz): δ = 8.85 (s, 1H), 8.65 (d, J= 5.2 Hz, 1H), 7.97 (s, 1H), 7.73-7.74 (m, 2H), 7.43 (d, J= 4.8 Hz, 1 H), 7.06 (d, J = 4.8 Hz, 1 H), 6.58 (s, 1 H), 5.00 (d, J = 1.6 Hz, 1 H), 3.86 (m, 3H), 3.82 (s, 3H). LCMS m/z = 298 [MH]+. |
228 | OH HO JL J. * 1 ζθ (+) 4-(5-(3-(2-hydroxyethoxy)-4methoxyphenyl)pyridin-3-yl)-1,2oxaborolan-2-ol, enantiomer 2 | 1H NMR (CD3OD, 400MHz): δ 8.60 (br s, 1 H), 8.37 (br s, 1 H), 7.93 (s, 1 H), 7.227.30 (m, 2H), 7.10 (d, J = 8.3 Hz, 1H), 4.16 (t, J = 4.6 Hz, 2H), 4.08 (br s, 1H), 3.83-3.95 (m, 6H), 3.34-3.42 (m, 1H), 1.25-1.39 (m, 2H). LCMS m/z = 330 [MH]+. [α]2% +31.9 (c = 0.1, EtOH). |
262
229 | OH z°xA cA x 1 jx o 4-(5-(3-ethoxy-4- methoxyphenyl)pyridin-3-yl)-1,2oxaborol-2(5H)-ol | Ή NMR (DMSO-c/6, 400MHz): δ 8.85 (d, J = 2.0 Hz, 1 H), 8.77 (s, 1 H), 8.73 (d, J = 2.0 Hz, 1H), 8.13 (s, 1H), 7.31-7.33 (m, 2H), 7.07 (d, J = 8.0 Hz, 1H), 6.45 (s, 1H), 5.01 (s, 2H), 4.14 (q, J = 6.8 Hz, 2H), 3.81 (s, 3H), 1.36 (q, J = 6.8 Hz, 3H). LCMS m/z = 312 [MH]+. |
230 | OH AJCnYJ5 ί J 4-(3-fluoro-6-(4-methoxy-3propoxyphenyl)pyridin-2-yl)-1,2oxaborolan-2-ol, enantiomer 1 | Ή NMR (DMSO-de, 400MHz): δ 8.64 (br s, 1 H), 7.84 (dd, J = 3.4, 8.8 Hz, 1 H), 7.67 (t, J = 4.6 Hz, 2H), 7.60 (dd, J = 1.5, 8.3 Hz, 1 H), 7.03 (d, J = 8.8 Hz, 1 H), 4.27 (t, J = 7.8 Hz, 1 H), 3.98-4.07 (m, 3H), 3.85 (d, J = 6.8 Hz, 1H), 3.81 (s, 3H), 1.72-1.80 (m, 2H), 1.22-1.27 (m, 2H), 1.00 (t, J = 7.3 Hz, 3H). LCMS m/z = 346 [MH]+. RT [Analytical SFC Method G] = 3.25 min. |
231 | OH X X X b o (-) 4-(5-methoxy-2'-methyl-6-propoxy[2,3'-bipyridin]-5'-yl)-1,2-oxaborolan-2ol, enantiomer 1 | 1H NMR (DMSO-d6, 400MHz): δ 8.67 (s, 1H), 8.34 (s, 1H), 7.65 (s, 1H), 7.37 (d, J = 8.1 Hz, 1H), 7.13 (d, J = 8.1 Hz, 1H), 4.21-4.28 (m, 3H), 3.76-3.85 (m, 4H), 3.41-3.50 (m, 1H), 2.52 (s, 3H), 1.701.78 (m, 2H), 1.29 (dd, J = 8.2, 16.3 Hz, 1H), 1.06 (dd, J = 10.0, 16.1 Hz, 1H), 0.95 (t, J = 7.5 Hz, 3H). LCMS m/z = 343 [MH]+. [a]2% -20.1 (c = 0.1, EtOH). |
232 | OH T X Γ b 4-(3',4'-dimethoxy-[1,1 '-biphenyl]-3-yl)1,2-oxaborolan-2-ol | Ή NMR (DMSO-de, 400MHz): δ 7.51 (s, 1 H), 7.45 (br d, J = 7.6 Hz, 1 H), 7.347.35 (m, 1H), 7.16-7.23 (m, 3H), 7.02 (d, J = 8.0 Hz, 1 H), 4.22-4.28 (m, 1 H), 3.84 (s, 3H), 3.81 (s, 1H), 3.79 (s, 3H), 3.423.51 (m, 1H), 1.25-1.31 (m, 1H), 1.051.12 (m, 1 H). LCMS m/z = 299 [MH]+. |
263
Example 233 | OH Λλ rB' 4-(6-(3-ethoxy-4- methoxyphenyl)pyridin-2-yl)-1,2oxaborolan-2-ol | 1H NMR (DMSO-c/6,400 MHz): δ 8.57 (s, 1 H), 7.61-7.70 (m, 3H), 7.59 (d, J = 2.0 Hz, 1H), 7.11-7.13 (m, 1H), 7.00 (d, J = 8.4 Hz, 1H), 4.23-4.28 (m, 1H), 4.07-4.09 (m, 2H), 3.92-3.96 (m, 1H), 3.78 (s, 3H), 3.56-3.58 (m, 1H), 1.33 (t, J= 7.0 Hz, 3H), 1.16-1.24 (m, 2H). LCMS m/z = 314 [MH]+. |
Single Crystal X-Ray Analysis of crystalline (R) 4-(5-(3-ethoxy-4-methoxyphenyl)pyridin-3-yl)1,2-oxaborolan-2-ol (Example 3)
The crystal structure of Example 3 was determined by single crystal X-ray diffraction analysis. The single crystal X-ray diffraction data collection was performed on a Bruker D8 Quest diffractometer at room température. Data collection consisted of oméga and phi scans. The structure was solved by intrinsic phasing using SHELX software suite in the Monoclinic class space group P2i. The structure was subsequently refined by the full-matrix least squares method. AH non-hydrogen atoms were found and refined using anisotropic displacement parameters. The hydrogen atoms located on oxygen were found from the Fourier différence map and refined with distances restrained. The remaining hydrogen atoms were placed in calculated positions and were allowed to ride on their carrier atoms. The final refinement included isotropie displacement parameters for ail hydrogen atoms. Analysis ofthe absolute structure using likelihood methods (Hooft 2008) was performed using PLATON (Spek 2010).
The Hooft parameter is reported as 0.02 with an Esd of 0.003 and the Parson’s parameter is reported as 0.02 with an Esd of 0.003. The final R-index was 4.5%. A final différence Fourier revealed no missing or misplaced électron density.
Figure 1 is the obtained X-ray structure (ORTEP drawing) of crystalline (R) 4-(5-(3ethoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol (Example 3). The crystal structure data is summarized in Table 3.
Table 3
Crystal data and structure refinement for Example 3
Empirical formula Formula weight | C17 H20 B N O4 313.15 | ||
25 | Température Wavelength Crystal system Space group | 296(2) K 1.54178 A Monoclinic P2i | |
Unit cell dimensions | a = 11.0798(5) A | a= 90°. | |
30 | Volume Z | b = 13.1083(6) A c= 11.2398(6) A 1610.77(13) A3 4 | β= 99.346(2)° γ = 90°. |
264
• | Density (calculated) | 1.291 Mg/m3 |
5 | Absorption coefficient F(000) Crystal size Thêta range for data collection | 0.738 mm'1 664 0.360x0.220x0.140 mm3 3.986 to 70.310° |
10 | Index ranges Reflections collected Independent reflections Completeness to thêta = 67.679° Absorption correction | -13<=h<=13, -16<=k<=15, -13<=l<=12 29459 6084 [R(int) = 0.0304] 99.9 % Empirical |
15 | Refinement method Data / restraints / parameters Goodness-of-fit on F2 Final R indices [l>2sigma(l)] R indices (ail data) | Full-matrix least-squares on F2 6084 /3/426 1.132 R1 = 0.0446, wR2 = 0.1005 R1 = 0.0452, wR2 = 0.1013 |
Absolute structure parameter Extinction coefficient Largest diff. peak and hole | 0.02(3) 0.125(4) 0.307 and -0.371 e.Â'3 |
Single Crystal X-Ray Analysis of crystalline (R) 4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)1,2-oxaborolan-2-ol (Example 4)
The crystal structure of Example 4 was determined by single crystal X-ray diffraction analysis. The single crystal X-ray diffraction data collection was performed on a Bruker D8 Venture diffractometer at -150 °C température. Data collection consisted of oméga and phi scans. The structure was solved by intrinsic phasing using SHELX software suite in the Monoclinic class space group P2i. The structure was subsequently refined by the full-matrix least squares method. Ail non-hydrogen atoms were found and refined using anisotropic displacement parameters. The hydrogen atoms located on oxygen were found from the Fourier différence map and refined with distances restrained. The remaining hydrogen atoms were placed in calculated positions and were allowed to ride on their carrier atoms. The final refinement included isotropie displacement parameters for ail hydrogen atoms. Analysis ofthe absolute structure using likelihood methods (Hooft 2008) was performed using PLATON (Spek 2010). The Hooft parameter is reported as 0.08 with an Esd of 0.003 and the Parson’s parameter is reported as 0.15 with an Esd of 0.002. The final R-index was 4.6%. A final différence Fourier revealed no missing or misplaced électron density.
Figure 2 is the obtained X-ray structure (ORTEP drawing) of crystalline (R) 4-(5-(4methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol (Example 4). The crystal structure data is summarized in Table 4.
265
Table 4
Crystal data and structure refinement for Example 4.
Empirical formula Formula weight Température Wavelength Crystal system Space group Unit cell dimensions
Volume
Z
Density (calculated)
Absorption coefficient
F(000)
Crystal size
Thêta range for data collection
Index ranges
Reflections collected Independent reflections Completeness to thêta = 67.679° Absorption correction Refinement method
Data / restraints / parameters
Goodness-of-fit on F3
Final R indices [l>2sigma(l)J R indices (ail data)
Absolute structure parameter Extinction coefficient
Largest diff. peak and hole
Cis H22 B N O4 327.17 123(2) K 1.54178 A Monoclinic
P2i a = 10.7077(14) A | a= 90°. |
b = 13.4140(17) A | β= 110.396(5)° |
c= 13.0151(16) A 1752.2(4) A3 | γ = 90°. |
4 |
1.240 Mg/m3
0.699 mrrH
696
0.240x0.160x0.120 mm3
3.623 to 72.240°
-12<=h<=13, -16<=k<=16, -16<=l<=16
63647
6737 [R(int) = 0.0312]
98.8 %
Empirical
Full-matrix least-squares on F3
6737 /3/443
1.044
R1 = 0.0457, wR2 = 0.1282
R1 = 0.0477, wR2 = 0.1311
0.08(3) n/a
0.279 and -0.203 e.Â'3
Single Crystal X-Ray Analysis of crystalline (S) 4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)1,2-oxaborolan-2-ol (Example 5)
The crystal structure of Example 5 was also determined by single crystal X-ray diffraction analysis. The single crystal X-ray diffraction data collection was performed on a Bruker D8 Quest diffractometer at room température. Data collection consisted of oméga and phi scans. The structure was solved by intrinsic phasing using SHELX software suite in the Monoclinic space group P2i. The structure was subsequently refined by the full-matrix least squares method. AH non-hydrogen atoms were found and refined using anisotropic displacement parameters. The hydrogen atoms located on oxygen were found from the Fourier différence map and refined with distances restrained. The remaining hydrogen atoms were placed in calculated positions and were allowed to ride on their carrier atoms. The final refinement included isotropie displacement parameters for ail hydrogen atoms. Analysis ofthe absolute structure using likelihood methods (Hooft 2008) was performed using PLATON (Spek 2010). The Hooft parameter is reported as 0.01 with an Esd of 0.007and the Parson’s
266 parameter is reported as 0.01 with an Esd of 0.006. The final R-index was 4.8%. A final différence Fourier revealed no missing or misplaced électron density.
Figure 3 is the obtained X-ray structure (ORTEP drawing) of crystalline (S) 4-(5-(4methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol (Example 5). The crystal structure data is summarized in Table 5.
Table 5.
Crystal data and structure refinement for Example 5
Empirical formula Formula weight Température Wavelength Crystal system Space group Unit cell dimensions
Volume
Z
Density (calculated)
Absorption coefficient
F(000)
Crystal size
Thêta range for data collection Index ranges
Reflections collected Independent reflections Completeness to thêta = 67.679° Absorption correction Refinement method
Data / restraints / parameters
Goodness-of-fit on F2
Final R indices [l>2sigma(l)] R indices (ail data)
Absolute structure parameter Extinction coefficient
Largest diff. peak and hole
Cis H22 B N O4 | |
327.17 296(2) K 1.54178 A Monoclinic P2i a = 10.6918(4) A | a= 90°. |
b = 13.4115(4) A | β= 110.311(2)° |
c = 13.0161(4) A | γ = 90°. |
1750.37(10) A3 4 |
1.242 Mg/m3
0.700 mm'1
696
0.260x0.220x0.140 mm3
3.621 to 70.234°
-12<=h<=13, -16<=k<=16, -15<=l<=15
16854
6536 [R(int) = 0.0328]
99.3 %
Empirical
Full-matrix least-squares on F2
6536 /3/446
1.065
R1 = 0.0478, wR2 = 0.1176
R1 = 0.0512, wR2 = 0.1220
0.01(7)
0.0385(19)
0.236 and -0.273 e.Â'3
267
I Single Crystal X-Ray Analysis of crystalline (R) 4-(5-(3-ethoxy-4-methoxyphenyl)-6methylpyridin-3-yl)-1,2-oxaborolan-2-ol (Example 19)
The crystal structure of Example 19 was also determined by single crystal X-ray diffraction analysis. The single crystal X-ray diffraction data collection was performed on a
Bruker D8 Quest diffractometer at room température. Data collection consisted of oméga and phi scans. The structure was solved by intrinsic phasing using SHELX software suite in the Monoclinic class space group P2!. The structure was subsequently refined by the full-matrix least squares method. Ail non-hydrogen atoms were found and refined using anisotropic displacement parameters. The hydrogen atoms located on oxygen were found from the Fourier différence map and refined with distances restrained. The remaining hydrogen atoms were placed in calculated positions and were allowed to ride on their carrier atoms. The final refinement included isotropie displacement parameters for ail hydrogen atoms. Analysis ofthe absolute structure using likelihood methods (Hooft 2008) was performed using PLATON (Spek 2010). The Hooft parameter is reported as 0.06 with an Esd of 0.004 and the Parson’s parameter is reported as 0.06 with an Esd of 0.003. The final R-index was 4.0%. A final différence Fourier revealed no missing or misplaced électron density.
Figure 4 is the obtained X-ray structure (ORTEP drawing) of crystalline (R) 4-(5-(3ethoxy-4-methoxyphenyl)-6-methylpyridin-3-yl)-1,2-oxaborolan-2-ol (Example 19). The crystal structure data is summarized in Table 6.
Table 6.
Crystal data and structure refinement for Example 19
Empirical formula Formula weight | C36 H44 B2 N2 Os 654.35 |
25 Température | 296(2) K |
Wavelength | 1.54178 A |
Crystal System | Monoclinic |
Space group | P2i |
Unit cell dimensions | a = 11.2655(18) A a= 90°. |
30 | b = 12.903(2) A β= 111.269(5)° C= 12.959(2) A γ = 90°. |
Volume | 1755.4(5) A3 |
Z | 2 |
Density (calculated) | 1.238 Mg/m3 |
35 Absorption coefficient | 0.698 mrrH |
F(000) | 696 |
Crystal size | 0.420x0.360x0.120 mm3 |
Thêta range for data collection | 3.660 to 72.747° |
Index ranges | -13<=h<=13, -15<=k<=15, -15<=l<=16 |
40 Reflections collected | 53020 |
Independent reflections | 6907 [R(int) = 0.0361] |
Completeness to thêta = 67.679° | 100.0 % |
Absorption correction | Empirical |
Refinement method | Full-matrix least-squares on F2 |
268 φ Data ! restraints / parameters Goodness-of-fit on F3 Final R indices [l>2sigma(l)] R indices (ail data)
Absolute structure parameter Extinction coefficient
Largest diff. peak and hole
6907 /3/446
1.055
R1 = 0.0396, wR2 = 0.1023
R1 = 0.0414, wR2 = 0.1043
0.06(4)
0.0261(13)
0.230 and -0.298 e.Â’3
X-Ray Powder Diffraction 10 The crystal structures of Examples 3, 4, 5, 10 and 19 were analyzed using X-ray powder ' diffraction (“PXRD”).
For Example 4, powder X-ray diffraction analysis was conducted using a Bruker AXS D8 ADVANCE diffractometer equipped with a Cu radiation source (K-α average). The system is equipped with a 2.5 axial Soller slits on the primary side. The secondary side utilizes 2.5 axial 15 Soller slits and motorized slits. Diffracted radiation was detected by a Lynx Eye XE detector.
The X-ray tube voltage and amperage were set to 40 kV and 40 mA respectively. Data was collected in the Theta-Theta goniometer at the Cu wavelength from 3.0 to 40.0 degrees 2-Theta using a step size of 0.037 degrees and a step time of 10 seconds per step. Samples were prepared by placing them in a low background holder (Bruker part number: C79298A3244B261) 20 and rotated during collection. Data were collected using Bruker DIFFRAC Plus software.
Analysis performed by EVA diffract plus software. The PXRD data file was not processed prior to peak searching. Using the peak search algorithm in the EVA software, peaks selected with a threshold value of 1 and a width of 0.3 were used to make preliminary peak assignments. To ensure validity, adjustments were manually made; the output of automated assignments was 25 visually checked and peak positions were adjusted to the peak maximum. Peaks with relative intensity of > 3% were generally chosen. The peaks which were not resolved or were consistent with noise were not selected. A typical error associated with the peak position from PXRD stated in USP up to +/- 0.2° 2-Theta (USP-941).
For Examples 3, 5, 10, and 19, powder X-ray diffraction analysis was conducted using a 30 Bruker AXS D4 Endeavor diffractometer equipped with a Cu radiation source (K-α average).
The System is equipped with a 2.5 axial Soller slits on the primary side. The secondary side utilizes 2.5 axial Soller slits and motorized slits. Diffracted radiation was detected by a Lynx Eye XE detector. The X-ray tube voltage and amperage were set to 40 kV and 40 mA respectively. Data was collected in the Theta-2Theta goniometer at the Cu wavelength from 3.0 to 43.0 35 degrees 2-Theta using a step size of 0.020 degrees and a step time of 3 seconds per step.
Samples were prepared by placing them in a low background holder and rotated during collection. Data were collected using Bruker DIFFRAC Plus software. Analysis performed by EVA diffract plus software. The PXRD data file was not processed prior to peak searching. Using the peak search algorithm in the EVA software, peaks selected with a threshold value of 1 and a width of 0.3 were used to make preliminary peak assignments. To
269
F ensure validity, adjustments were manually made; the output of automated assignments was visually checked and peak positions were adjusted to the peak maximum. Peaks with relative intensity of £ 3% were generally chosen. The peaks which were not resolved or were consistent with noise were not selected. A typical error associated with the peak position from PXRD stated in USP up to +/- 0.2° 2-Theta (USP-941).
As will be appreciated by the skilled crystallographer, the relative intensities ofthe various peaks reported in the Tables and Figures below may vary due to a number of factors such as orientation effects of crystals in the X-ray beam or the purity of the material being analyzed or the degree of crystallinity of the sample. The peak positions will remain substantially 10 as defined. The skilled crystallographer also will appreciate that measurements using a different wavelength will resuit in different shifts according to the Bragg équation -nÀ=2d sin Θ. Such further PXRD patterns ofthe crystalline materials ofthe présent invention and as such are within the scope ofthe présent information.
Figure 5 is the obtained powder X-ray diffraction pattern for crystalline (R)-4-(5-(315 ethoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol (Example 3) and Table 7 lists the PXRD peaks.
Table 7
270
30.2 | 10.2 |
32.1 | 3.2 |
33.5 | 5.3 |
33.8 | 3.0 |
34.5 | 4.4 |
37.7 | 4.7 |
40.5 | 6.4 |
41.3 | 3.5 |
Figure 6 is the obtained powder X-ray diffraction pattern for crystalline (R)-4-(5-(4methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol (Example 4) and Table 8 lists the PXRD peaks.
Table 8
Example 4 PXRD Data
Angle (2-Theta) Degrees | Rel. Intensity % |
11.0 | 94.9 |
11.4 | 64.8 |
13.2 | 43.1 |
14.5 | 27.3 |
15.1 | 39.3 |
15.6 | 23.1 |
15.9 | 9.4 |
17.7 | 10.0 |
18.8 | 81.8 |
19.4 | 13.0 |
19.7 | 49.3 |
20.5 | 12.4 |
21.3 | 45.1 |
22.0 | 8.5 |
22.9 | 100.0 |
23.8 | 5.7 |
24.5 | 6.0 |
25.1 | 71.8 |
25.6 | 4.6 |
25.9 | 20.5 |
26.4 | 36.0 |
27.5 | 17.1 |
28.4 | 8.9 |
28.8 | 4.9 |
30.4 | 3.6 |
Figure 7 is the obtained powder X-ray diffraction pattern for crystalline (S)-4-(5-(4methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol (Example 5) and Table 9 lists the
PXRD peaks.
271
Table 9
Example 5 PXRD Data
Angle (2-Theta) Degrees | Rel. Intensity % |
11.0 | 60.0 |
11.4 | 44.8 |
13.2 | 28.3 |
14.5 | 18.6 |
15.1 | 27.2 |
15.6 | 16.5 |
15.9 | 6.9 |
17.7 | 7.2 |
18.7 | 67.4 |
19.4 | 10.4 |
19.7 | 42.6 |
20.5 | 10.8 |
21.2 | 40.4 |
21.9 | 8.1 |
22.1 | 4.3 |
22.8 | 100.0 |
23.8 | 5.7 |
24.4 | 6.3 |
25.0 | 67.0 |
25.5 | 5.0 |
25.9 | 19.98 |
26.4 | 33.9 |
27.4 | 18.8 |
28.3 | 10.5 |
28.8 | 5.7 |
30.0 | 3.5 |
30.4 | 4.1 |
32.1 | 3.5 |
35.5 | 3.4 |
36.1 | 4.1 |
38.0 | 3.7 |
38.5 | 3.3 |
39.0 | 3.1 |
39.6 | 3.3 |
41.4 | 3.9 |
Figure 8 is the obtained powder X-ray diffraction pattern for crystalline (-) 4-(5-(25 (difluoromethyl)-3-ethoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol (Example 10) and Table 10 lists the PXRD peaks.
272
Table 10
Example 10 PXRD Data
Angle 2-Theta (Degrees) | Rel. Intensity % |
8.9 | 12.7 |
12.0 | 18.0 |
12.3 | 14.5 |
12.8 | 100.0 |
13.7 | 5.6 |
13.9 | 20.6 |
14.2 | 13.2 |
14.5 | 3.7 |
15.9 | 5.8 |
17.6 | 14.4 |
17.8 | 31.5 |
19.2 | 21.6 |
19.4 | 16.5 |
19.6 | 17.2 |
20.4 | 59.3 |
21.4 | 13.9 |
22.0 | 16.3 |
22.3 | 17.4 |
22.5 | 15.1 |
22.9 | 32.3 |
23.1 | 31.4 |
24.2 | 14.5 |
25.7 | 44.2 |
27.3 | 3.7 |
27.5 | 6.3 |
28.5 | 11.7 |
28.8 | 7.0 |
29.6 | 5.2 |
30.7 | 12.9 |
33.7 | 3.9 |
35.6 | 9.9 |
40.3 | 3.7 |
40.9 | 5.4 |
Figure 9 is the obtained powder X-ray diffraction pattern for crystalline (R)-4-(5-(35 ethoxy-4-methoxyphenyl)-6-methylpyridin-3-yl)-1,2-oxaborolan-2-ol (Example 19) and Table 11 lists the PXRD peaks.
273
Table 11
Example 19 PXRD Data
Angle 2-Theta (Degrees) | ReL Intensity % | ||
10.1 | 4.9 | ||
10.9 | 65.9 | ||
11.3 | 23.2 | ||
13.1 | 4.3 | ||
13.7 | 3.9 | ||
14.7 | 7.5 | ||
17.0 | 14.7 | ||
17.3 | 33.4 | ||
19.0 | 32.4 | ||
19.3 | 59.2 | ||
19.7 | 17.8 | ||
19.7 | 23.6 | ||
20.2 | 4.5 | ||
20.6 | 7.4 | ||
21.1 | 59.0 | ||
21.9 | 5.8 | ||
22.7 | 85.5 | ||
23.6 | 14.1 | ||
23.8 | 100.0 | ||
23.9 | 61.7 | ||
24.1 | 10.6 | ||
24.5 | 6.6 | ||
24.8 | 18.8 | ||
25.4 | 47.8 | ||
25.4 | 38.6 | ||
26.2 | 6.4 | ||
26.5 | 13.9 | ||
26.8 | 3.6 | ||
27.1 | 15.4 | ||
27.1 | 11.8 | ||
27.5 | 10.1 | ||
28.5 | 3.8 | ||
28.5 | 5.8 | ||
29.5 | 3.1 | ||
30.4 | 28.8 | ||
30.5 | 16.9 | ||
32.2 | 4.9 |
274
34.2 | 4.0 |
35.9 | 3.5 |
39.1 | 5.4 |
39.5 | 3.8 |
39.9 | 5.0 |
40.9 | 4.2 |
42.2 | 7.1 |
Formulation Examples
An embodiment of the present invention provides a topical pharmaceutical formulation comprising: (a) an active agent ofthe invention which treats an inflammatory related condition, 5 or a pharmaceutically acceptable sait, or a hydrate or a solvaté thereof, (b) from about 5% (w/w) to about 15% (w/w) solvent, and (c) an ointment base. In an embodiment, the present invention provides a topical pharmaceutical formulation comprising: (a) an active agent ofthe invention which treats an inflammatory related condition, or a pharmaceutically acceptable sait, or a hydrate or a solvaté thereof, (b) from about 5% (w/w) to about 15% (yj/w) solvent, and (c) petrolatum. In an embodiment, the present invention provides a topical pharmaceutical formulation comprising: (a) an active agent ofthe invention which treats an inflammatory related condition, or a pharmaceutically acceptable sait, or a hydrate or a solvaté thereof, (b) from about 5% (w/w) to about 15% (w/w) solvent, (c) ointment, (d) an antioxidant, (e) a stabilizer, (f) an emulsifying agent, and (g) a stiffening agent. In an embodiment, the present invention provides a topical pharmaceutical formulation comprising: (a) an active agent ofthe invention which treats an inflammatory related condition, or a pharmaceutically acceptable sait, or a hydrate or a solvaté thereof, (b) from about 5% (w/w) to about 15% (w/w) solvent, (c) ointment, (d) an antioxidant, (e) an emulsifying agent, and (f) a stiffening agent. In an embodiment, the present invention provides a topical pharmaceutical formulation comprising: (a) an active agent 20 ofthe invention which treats an inflammatory related condition, or a pharmaceutically acceptable sait, or a hydrate or a solvaté thereof, (b) from about 5% (w/w) to about 15% (w/w) solvent, (c) petrolatum, (d) an antioxidant, (e) an emulsifying agent, and (f) a stiffening agent. In an embodiment, the present invention provides a topical pharmaceutical formulation comprising: (a) an active agent ofthe invention which treats an inflammatory related condition, or a pharmaceutically acceptable sait, or a hydrate or a solvaté thereof, (b) from about 8% (w/w) to about 10% (w/w) propylene or hexylene glycol, (c) from about 75%(w/w) to about 80% (w/w) white petrolatum, (d) from about 8% (w/w) to about 10% of a glyceride blend, (e) from about 4% to about 6% paraffin, and (f) from about 0.05% to 0.5% butylated hydroxytoluene. In an embodiment, the present invention provides a topical pharmaceutical formulation comprising:
(a) an active agent ofthe invention which treats an inflammatory related condition, or a pharmaceutically acceptable sait, or a hydrate or a solvaté thereof, (b) from about 8% (w/w) to about 10% (w/w) hexylene glycol, (c) from about 75%(w/w) to about 80% (w/w) white
275 petrolatum, (d) from about 8% (w/w) to about 10% of a glyceride blend, (e) from about 4% to about 6% paraffin, and (f) from about 0.05% to 0.5% butylated hydroxytoluene.
In an embodiment, the présent invention provides a topical pharmaceutical formulation comprising an active agent wherein “active agent” is a compound ofthe présent invention or a pharmaceutically acceptable sait, hydrate or a solvaté thereof. In another embodiment, the active agent is (R)-4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol or a pharmaceutically acceptable sait, hydrate, or solvaté thereof. In another embodiment, the active agent is (S)-4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol or a pharmaceutically acceptable sait, hydrate, or solvaté thereof. In another embodiment, the active agent is (R)-4-(5-(3-ethoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol or a pharmaceutically acceptable sait, hydrate, or solvaté thereof. In another embodiment, the active agent is (R)-4-(5-(3-ethoxy-4-methoxyphenyl)-6-methylpyridin-3-yl)-1,2-oxaborolan-2-ol or a pharmaceutically acceptable sait, hydrate, or solvaté thereof. In another embodiment, the active agent is (-)-4-(5-(2-(difluoromethyl)-3-ethoxy-4-methoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol, or a pharmaceutically acceptable sait, hydrate, or solvaté thereof.
In another embodiment, the présent invention provides a topical pharmaceutical formulation comprising an active agent présent in a concentration of about 0.0001% to about 3.0% (w/w). In another embodiment, the active agent is présent in a concentration of about 0.001% to about 2.0% (w/w). In another embodiment, the active agent is présent in a concentration of about 0.01% to about 1.0% (w/w). In another embodiment, the active agent is présent in a concentration of about 0.05% to about 0.5% (w/w).
In another embodiment, the présent invention provides an active agent, or a sait, hydrate or solvaté thereof. In another embodiment, the présent invention provides a combination of an active agent and a second active agent wherein the second active agent is useful for the treatment of inflammatory disorders such as atopie dermatitis, eczema, psoriasis, arthritis, asthma, fibrosis, lupus, allergy, fibromyalgia, wound healing, and inflammation resulting from surgical complications. The combination may be comprised of an admixture or co-formulation of the two active ingrédients. Altematively, the combination may be packaged in a dispenser wherein one active agent is in one chamber and another active ingrédient is in a second chamber, but upon dispensing, the two active agents are simultaneously delivered together such that administration ofthe combination may occur in one application. Altematively, the active agents may individually be administered with the other active agent, wherein the second active agent may be administered either orally or topically.
In another embodiment, the présent invention provides an active agent described herein, or a sait, hydrate or solvaté thereof, in a topical formulation which comprises a solvent. In another embodiment, the solvent is an alkyl glycol or alkyl alcohol. In another embodiment, the solvent is an alkyl glycol. In another embodiment, the solvent is propylene glycol. In another embodiment, the solvent is hexylene glycol. In another embodiment, the solvent is butylène
276 glycol. In another embodiment, the solvent is présent in a concentration of about 5.0% (w/w) to about 15.0% (w/w). In another embodiment, the solvent is présent in a concentration of about 6.0% (w/w) to about 12.0% (w/w). In another embodiment, the solvent is présent in a concentration of about 7.0% (w/w) to about 11.0% (w/w). In another embodiment, the solvent is présent in a concentration of about 8.0% (w/w) to about 10.0% (w/w).
In another embodiment, the présent invention provides an active agent described herein, or a sait, hydrate or soivate thereof, in a topical formulation which comprises an ointment base. In another embodiment, the ointment base is white petrolatum. In another embodiment, the ointment base is minerai jelly, petroleum jelly, yellow petrolatum, yellow soft paraffin, yellow Petroleum jelly, white petrolatum jelly, or white soft paraffin. In another embodiment, the base is minerai oil, light minerai oil, paraffin, or lanolin alcohol. The amount of ointment base in the topical pharmaceutical formulation will be dépendent on the amounts ofthe other components. In another embodiment, the ointment base is présent in a quantum satis concentration. In another embodiment, the ointment base is présent in a concentration of from about 65% (w/w) to about 85% (w/w). In another embodiment, the base is présent in a concentration of from about 70% (w/w) to about 80% (w/w). In another embodiment, the base is présent in a concentration of from about 75% (w/w) to about 80% (w/w).
In another embodiment, the présent invention provides an active agent described herein, or a sait, hydrate or soivate thereof, in a topical formulation which further comprises an antioxidant. In another embodiment, the antioxidant is butylated hydroxytoluene, ascorbic acid, ascorbic palmitate, butylated hydroxyanisole, 2,4,5-trihydroxybutyrophenone, 4-hydroxymethyl2,6-di-tert-butyl phénol, erythorbic acid, gum guaiac, propyl gallate, thiodipropionic acid, dilauryl thiodipropionate, tert-butylhydroquinone, or tocopherol. In another embodiment, the antioxidant is butylated hydroxytoluene. In another embodiment, the antioxidant is présent in a concentration of about 0.01% (w/w) to about 1% (w/w). In another embodiment, the antioxidant is présent in a concentration of about 0.01% (w/w) to about 0.5% (w/w). In another embodiment, the antioxidant is présent in a concentration of about 0.05% (w/w) to about 0.5% (w/w). In another embodiment, the antioxidant is présent in a concentration of about 0.075% (w/w) to about 0.2% (w/w).
In another embodiment, the topical pharmaceutical formulation further comprises an emulsifying agent. In another embodiment, the emulsifying agent is a glyceride blend. In another embodiment, the emulsifying agent is a glyceride blend, wherein the glyceride blend comprises a monoglyceride and a diglyceride. In another embodiment, the emulsifying agent is a glyceride blend, wherein the glyceride blend comprises a monoglyceride, a diglyceride, and a triglycéride. In another embodiment, the emulsifying agent is a glyceride blend, wherein the glyceride blend comprises a monoglyceride and a diglyceride, and wherein from about 40% (w/w) to about 55% (w/w) ofthe glyceride blend is a monoglyceride. In another embodiment, the emulsifying agent is a glyceride blend, wherein the glyceride blend comprises a monoglyceride, a diglyceride, and
277 a triglycéride, and wherein from about 40% (w/w) to about 55% (w/w) ofthe glyceride blend is a monoglyceride. In another embodiment, the monoglyceride is selected from the group consisting of glyceryl monostearate, glyceryl monopalmitate, glyceryl monooleate, or combinations thereof. In another embodiment, the monoglyceride is a monoglyceryl ester of a long chain, saturated or unsaturated fatty acid. In an embodiment, the monoglyceride is an alpha-monoglyceride. In a preferred embodiment, the diglyceride is a diglyceryl ester of a long chain, saturated or unsaturated fatty acid. In another embodiment, the glyceride blend is présent in a concentration of about 3.0% (w/w) to about 10.0% (w/w). In another embodiment, the glyceride blend is présent in a concentration of about 5.0% (w/w) to about 10.0% (w/w). In another embodiment, the glyceride blend about 6.0% (w/w) to about 8.0% (w/w).
In another embodiment, the topical pharmaceutical formulation further comprises a stiffening agent. In another embodiment, the stiffening agent is a wax. In another embodiment, the stiffening agent is a wax and the wax is selected from the group consisting of beeswax, paraffin wax, and spermaceti wax. In another embodiment, the stiffening agent is paraffin wax. In another embodiment, the stiffening agent is présent in a concentration of about 3.0% (w/w) to about 7.0% (w/w). In a preferred embodiment, the stiffening agent is présent in a concentration of about 4.0% (w/w) to about 6.0% (w/w). In another embodiment, the stiffening agent is présent in a concentration of about 4.5% (w/w) to about 5.5% (w/w).
In another embodiment, the topical pharmaceutical formulation further comprises a stabilizer. In another embodiment, the stabilizer is ethylenediaminetetraacetic acid, or a pharmaceutically acceptable sait thereof. In another embodiment, the stabilizer is a pharmaceutically acceptable sait of ethylenediaminetetraacetic acid, and this sait is a sodium sait or a potassium sait or a calcium sait, or a combination thereof. In another embodiment, the stabilizer is présent in a concentration of about 0.000010% (w/w) to about 0.0450% (w/w).
The composition of topical formulations for compounds ofthe présent invention include excipients that provide at least one ofthe following functionalities: solvent; base; dispersing agent; emulsifying agent; stiffening agent; rheology modifying agent; stabilizing agent; and antioxidant. For example, suitable topical ointment formulations for Example 4 include, but are not limited to, the formulations listed in Tables 12, 13, 15 and 16. In addition to the ointment formulations listed in Tables 12 and 13, other topical formulations suitable for the compounds of the présent invention include, but are not limited to, creams, lotions, gels, solutions, suspensions, foams, and sprays.
278
Table 12
Quantity (% w/w) | ||||||
Example 4 | 0.001 - 1 | 0.001 - 1 | 0.001 - 1 | 0.001 - 1 | 0.001 - 1 | 0.001 - 1 |
Propylene glycol | 2 - 9 | MMM| | ||||
Hexylene glycol Transcutol | 2-9___ MM | feu A - 2 -V” | ||||
Diisopropyl adipate | 2 - 20 | |||||
PEG400 Propylene carbonate | — | 111¾¾ | 2 - 9 | 2 - 9 | ||
White petrolatum | qs | qs | qs | qs | qs | qs |
Mono- and diglycerides | 0-7 | 0-7 | 0-7 | 0-7 | 0-7 | 0-7 |
Span 60 | 0-2 | 0-2 | 0-2 | 0-2 | 0-2 | 0-2 |
Span 40 | 0-2 | 0-2 | 0-2 | 0-2 | 0-2 | 0-2 |
Phospholipid (lecithin) | 0-10 | 0-10 | 0- 10 | 0 - 10 | 0- 10 | 0 - 10 |
Butylated Hydroxytoluene | 0 - 0.1 | 0 - 0.1 | 0-0.1 | 0 - 0.1 | 0 - 0.1 | 0-0.1 |
Butylated Hydroxyanisole | 0-0.1 | 0 - 0.1 | 0-0.1 | 0-0.1 | 0-0.1 | 0-0.1 |
Paraffin Wax | 0-5 | 0-5 | 0-5 | 0-5 | 0-5 | 0-5 |
Total (%) | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 |
*qs or quantum satis means sufficient amount to make the total = 100%
Topical formulations prepared containing Example 4 that were tested for skin 5 permeability and maximum flux of Example 4 are listed in Table 13.
Table 13
Quantity (% w/w) | ||||
Example 4 | 1 | 0.1 | 0.01 | 0 |
White petrolatum, USP | 77.9 | 78.8 | 78.89 | 78.9 |
Mono- and diglycerides, NF | 7 | 7 | 7 | 7 |
Butylated Hydroxytoluene (BHT), NF/PhEur | 0.1 | 0.1 | 0.1 | 0.1 |
Paraffin Wax, NF | 5 | 5 | 5 | 5 |
Hexylene Glycol, NF/USP | 9 | 9 | 9 | 9 |
Total (%) | 100.0 | 100.0 | 100.0 | 100.0 |
ln-vitro skin perméation study or Franz cell assay was used to demonstrate the ability of 10 ofthe formulations in Table 13 to enable Example 4 perméation across stratum corneum barrier and mobility through epidermis and dermis by way of flux measurement. The formulations exhibited a concentration dépendent skin flux (Table 14) and may accommodate a broad range
279 of Example 4 concentrations, providing a range of thermodynamic driving forces for Example 4 to permeate skin. A higher driving force can be achieved via incorporation into the formulations of additional pénétration enhancers such as oleyl alcohol.
Table 14
Cumulative Amount Permeated and Maximum Flux of Example 4
Example 4 Formulations From Table 13 | N* | Mean, Cumulative Amount in 24 hours, (ng) | Std Error, Cumulative Amount in 24 hours (ng) | Mean, Max. Flux, (ng/cm2/hr) | Std Error, Max. Flux, (ng/cm2/hr) |
1% Example 4 | 15 | 3357.7 | 769.6 | 252.28 | 49.05 |
0.1% Example 4 | 15 | 1089.9 | 131.9 | 73.95 | 7.53 |
0.01% Example 4 | 15 | 233.0 | 23.5 | 20.14 | 1.75 |
0% Example 4 | 6 | 0 | 0 | 0 | 0 |
* Number of skin donor = 3; Replicate per donor = 5.
Table 15
Quantity (% w/w) | ||||
Example 4 | 0.001 - 1 | 0.001 - 1 | 0.001 - 1 | 0.001 - 1 |
Medium chain triglycérides* | 2-20 | |||
Crodamol GTCC | 2-20 | |||
Crodamol GMCC | 2 - 20 | |||
Triacetin | 2-10 | |||
White petrolatum | qs | qs | qs | qs |
Mono- and diglycerides | 0-7 | 0-7 | 0-7 | 0-7 |
Span 60 | 0 - 2 | 0-2 | 0-2 | 0-2 |
Span 40 | 0-2 | 0-2 | 0-2 | 0-2 |
Phospholipid (lecithin) | 0-10 | 0 - 10 | 0-10 | 0-10 |
Butylated Hydroxytoluene | 0-0.1 | 0-0.1 | 0-0.1 | 0 - 0.1 |
Butylated Hydroxyanisole | 0-0.1 | 0-0.1 | 0 - 0.1 | 0-0.1 |
Paraffin Wax | 0 - 5 | 0 - 5 | 0-5 | 0-5 |
Total (%) | 100.0 | 100.0 | 100.0 | 100.0 |
* Medium chain triglycérides contain two or three fatty acids having an aliphatic tail of 6-12 carbon atoms.
280
Table 16
Example 4 Topical Ointment Formulations
Component | milligrams/gram (mgs/g) | milligrams/gram (mgs/g) | milligrams/gram (mgs/g) |
Example 4 | 0.100 | 0.300 | 0.600 |
Hexylene Glycol | 90.000 | 90.000 | 90.000 |
White Petrolatum | 788.900 | 788.700 | 788.400 |
Mono- and Di-Glycerides | 70.000 | 70.000 | 70.000 |
Paraffin Wax | 50.000 | 50.000 | 50.000 |
Butylated Hydroxytoluene (BHT) | 1.000 | 1.000 | 1.000 |
Total | 1000.000 | 1000.000 | 1000.000 |
Biological Assays
PDE4 SPA Assay
Phosphodiesterase (PDE) activity is determined by measuring the effect of a test agent on the activity ofthe PDE4B enzyme in a scintillation proximity assay (SPA). At the time of assay, approximately 30 pL of PDE4B (aa 152-484, Uniprot ID Q07343) in 50 mM Tris pH 7.5, 10 1.3 mM MgCI2, 0.004% Brij 35 is added to a 384 well white clear bottom polystyrène plate (Corning) containing 1 pL of varying concentrations of test compound. After -10 minutes at room température (RT; ~21°C), the assay is initiated by the addition of 20 pL of a mixture of 3Hlabeled (adenosine 3', 5'-cyclic phosphate, ammonium sait, [2,8-3H]; Perkin Elmer) and unlabeled cAMP. The final assay conditions are approximately 81.6 pM PDE4B in 50 mM Tris 15 pH 7.5, 1.3 mM MgCI2, 0.004% Brij 35, 1 μΜ 3H-labeled/unlabeled cAMP (1425 dpm/pmol) and the indicated final concentration of test compound (approximately 10 μΜ to 9.5 pM by 4-fold dilution). The final concentration of DMSO in the assay is approximately 2.0%. After 30 minutes at RT, the assay is terminated by the addition of approximately 20 pL of an aqueous solution of PDE YSI SPA beads (8 mg/mL in water; Perkin Elmer). The beads are allowed to settle for at 20 least 2 hours and the plate is then counted on a MicroBeta2 (Perkin Elmer). The concentrations and resulting effect values for the tested compound are plotted and the concentration of compound required for 50% effect (IC50) is determined with a four-parameter logistic dose response équation (E-WorkBook, ID Business Solutions Ltd.) and shown in Table 17.
Cytokine Assays
Cytokine inhibitory activity is determined by measuring the effect of test agent on the release ofthe cytokines IL-4, IL-13 and IFNy from human peripheral blood mononuclear cells (PBMCs) stimulated with the T-cell mitogen phytohemagglutinin-L (PHA-L). At the time of assay, human PBMCs (Astarte Biologics) are removed from cryopreservation, thawed quickly at 30 37°C, diluted in assay medium (RPMI - Gibco 1640 medium, 10 % heat inactivated fêtai bovine
281
I sérum (HIFBS), 2 mM glutamine and 10 mM HEPES pH 7.4) and then centrifuged at 250 x g for minutes. The resulting cell pellet is re-suspended in assay medium to a concentration of approximateiy 5 x10s cells/mL and 50 pL of this cell suspension (approximateiy 250,000 cells) is added to each well of a 384-well cell culture microtiter plate (Perkin Elmer). Varying concentrations of test compound are then diluted in assay medium and added to the assay plate wells in a volume of 25 pL. After ~10 minutes at room température (~21°C) the cells are stimulated by the addition of 25 pL of PHA-L (14 pg/mL; Millipore) and the assay plate is placed in an incubator at 37°C in a humidified environment in 5% carbon dioxide. The final assay conditions are approximateiy 250,000 human PBMCs per well in assay medium containing 3.5 10 pg/mL PHA-L and the indicated final concentration of test compound (approximateiy 10 μΜ to .5 pM by 4-fold dilution). The final concentration of DMSO in the assay is approximateiy 0.25%. After 48 hours, the assay plate is removed from the incubator and centrifuged at 250 x g for 5 minutes. A portion ofthe resulting cell supematant is then used to détermine the amount of IL4, IL-13 and IFNy in each well. Cytokine measurements are made using human IL-4, IL-13 or
IFNy HTRF assay kits (CisBio) following the manufacturées assay protocol. The concentrations and resulting effect values for tested compounds are plotted and the concentration of compound required for 50% effect (IC50) is determined with a four-parameter logistic dose response équation (E-WorkBook, ID Business Solutions Ltd.) and shown in Table 17.
Table 17
Example number | PDE4B2 IC50 nM | IL13 IC50 nM | IL4 IC50 nM | IFNy IC50 nM |
1 | 3.16 | 284 | 14.34 | 2.98 |
2 | 0.67 | 1346 | 210.39 | 2.73 |
3 | 1.14 | 165 | 3.54 | 0.70 |
4 | 0.50 | 135 | 4.11 | 1.06 |
5 | 0.93 | 2394 | 36.33 | 4.04 |
6 | 1.05 | 283 | 17.58 | 0.72 |
7 | 0.97 | 289 | 7.76 | 0.71 |
8 | 2.42 | 25 | 0.76 | 1.20 |
9 | 1.26 | 265 | 3.63 | 1.87 |
10 | 6.92 | 438 | 2.39 | 1.62 |
11 | 33.49 | 10000 | 141.16 | 68.33 |
12 | 1.08 | 162 | 2.32 | 0.99 |
13 | 0.97 | 166 | 5.98 | 4.89 |
14 | 1.50 | 91 | 3.21 | 1.85 |
15 | 1.57 | 136 | 1.41 | 0.71 |
16 | 0.05 | 126 | 0.54 | 0.82 |
17 | 0.28 | 138 | 0.65 | 0.47 |
18 | 0.74 | 218 | 1.91 | 2.23 |
19 | 2.96 | 1482 | 2.56 | 1.68 |
20 | 26.91 | 8793 | 86.83 | 102.97 |
21 | 0.64 | 159 | 0.84 | 1.35 |
22 | 7.89 | 257 | 1.75 | 1.43 |
23 | 0.97 | 132 | 0.61 | 0.85 |
282
Example number | PDE4B2 IC50 nM | IL13 ICso nM | IL4 IC50 nM | IFNy IC50 nM |
24 | 0.99 | 163 | 2.24 | 1.33 |
25 | 2.40 | 2315 | 67.79 | 9.17 |
26 | 399.28 | 10000 | 1668.34 | 3302.07 |
27 | 73.39 | 10000 | 3786.25 | 208.88 |
28 | 10.85 | 8013 | 1036.85 | 200.54 |
29 | 10.47 | 3470 | 9.51 | 4.82 |
30 | 15.54 | 10000 | 70.71 | 11.61 |
31 | 4.20 | 5726 | 3.92 | 2.96 |
32 | 12.96 | 2249 | 64.00 | 8.47 |
33 | 1.25 | 181 | 39.82 | 1.44 |
34 | 0.52 | 309 | 14.34 | 1.39 |
35 | 1.17 | 230 | 6.98 | 1.55 |
36 | 0.98 | 476 | 5.25 | 1.27 |
37 | ||||
38 | ||||
39 | 1.63 | 182 | 13.78 | 1.82 |
40 | 0.37 | 175 | 29.25 | 1.28 |
41 | 6.85 | 397 | 6.20 | 1.87 |
42 | 0.35 | 205 | 90.39 | 1.55 |
43 | 8.23 | 10000 | 232.92 | 76.01 |
44 | 2.50 | 167 | 7.22 | 1.34 |
45 | 2.29 | 450 | 12.38 | 3.88 |
46 | 3.46 | 317 | 11.80 | 3.77 |
47 | 3.01 | 143 | 4.11 | 1.54 |
48 | 0.12 | 252 | 0.82 | 0.98 |
49 | 1.59 | 166 | 4.40 | 3.21 |
50 | 0.79 | 234 | 1.04 | 1.52 |
51 | 1.27 | 337 | 3.73 | 1.64 |
52 | 9.25 | 2607 | 14.59 | 5.74 |
53 | 1.41 | 115 | 4.87 | 0.60 |
54 | 7.77 | 1487 | 5.58 | 4.20 |
55 | 2.21 | 576 | 3.94 | 2.27 |
56 | 2.81 | 446 | 68.04 | 3.62 |
57 | 10.17 | 239 | 7.54 | 2.29 |
58 | 0.72 | 103 | 162.84 | 1.81 |
59 | ||||
60 | 0.34 | 308 | 2.04 | 0.53 |
61 | 0.53 | 499 | 0.73 | 2.12 |
62 | 0.28 | 2573 | 2.66 | 1.44 |
63 | 1.62 | 312 | 57.89 | 2.75 |
64 | 18.49 | 325 | 8.04 | 4.44 |
65 | 9.53 | 814 | 185.58 | 5.34 |
66 | 2.15 | 327 | 86.50 | 0.71 |
67 | 4.02 | 759 | 99.92 | 12.61 |
68 | 0.47 | 369 | 4.85 | 1.50 |
69 | 4.39 | 373 | 6.51 | 3.84 |
70 | 3.00 | 890 | 4.31 | 2.85 |
71 | 11.01 | 1908 | 42.00 | 18.84 |
72 | 0.85 | 375 | 102.82 | 6.21 |
73 | 2.19 | 384 | 49.87 | 1.66 |
74 | 3.04 | 768 | 10.91 | 2.71 |
75 | 4.52 | 395 | 125.12 | 5.98 |
283
Example number | PDE4B2 IC50 nM | IL13 IC50 nM | IL4 IC50 nM | IFNy IC50 nM |
76 | 10.00 | 403 | 5.75 | 2.17 |
77 | 2.40 | 415 | 40.81 | 2.61 |
78 | 0.55 | 416 | 19.09 | 1.35 |
79 | 1.38 | 748 | 13.33 | 0.82 |
80 | 1.34 | 2153 | 19.75 | 4.62 |
81 | 2.36 | 858 | 54.35 | 1.62 |
82 | 0.55 | 426 | 7.14 | 1.07 |
83 | 6.64 | 439 | 9.42 | 4.73 |
84 | 1.24 | 444 | 0.90 | 0.44 |
85 | 0.29 | 541 | 0.90 | 0.56 |
86 | 7.26 | 1334 | 104.66 | 5.00 |
87 | 5.03 | 444 | 19.12 | 3.02 |
88 | 2.64 | 609 | 63.68 | 6.14 |
89 | 1.21 | 449 | 26.43 | 3.50 |
90 | 4.33 | 2793 | 289.67 | 13.67 |
91 | 3.00 | 460 | 5.90 | 3.92 |
92 | 1.79 | 947 | 3.36 | 2.70 |
93 | 0.50 | 460 | 9.87 | 1.66 |
94 | 12.49 | 606 | 9.58 | 3.88 |
95 | 4.87 | 461 | 7.36 | 2.87 |
96 | 1.69 | 965 | 48.92 | 5.27 |
97 | 3.17 | 465 | 34.01 | 2.81 |
98 | 1.13 | 2800 | 219.37 | 2.67 |
99 | 1.37 | 957 | 44.33 | 9.42 |
100 | 1.68 | 472 | 32.73 | 4.32 |
101 | 2.70 | 2652 | 26.02 | 13.33 |
102 | 5.85 | 1236 | 2.07 | 3.01 |
103 | 1.43 | 487 | 0.83 | 0.76 |
104 | 3.58 | 750 | 29.41 | 5.46 |
105 | 3.20 | 490 | 14.20 | 5.46 |
106 | 1.83 | 2085 | 16.08 | 3.42 |
107 | 2.41 | 613 | 27.06 | 4.17 |
108 | 4.23 | 493 | 22.10 | 4.35 |
109 | 4.18 | 1270 | 22.69 | 6.24 |
110 | 0.61 | 496 | 48.41 | 5.10 |
111 | 0.97 | 496 | 3.01 | 2.95 |
112 | 1.41 | 588 | 79.88 | 8.10 |
113 | 1.38 | 497 | 36.10 | 3.81 |
114 | 3.00 | 2914 | 32.74 | 21.49 |
115 | 1.10 | 509 | 38.43 | 1.68 |
116 | 0.87 | 508 | 42.02 | 2.45 |
117 | 1.80 | 520 | 64.17 | 10.03 |
118 | 0.90 | 531 | 9.78 | 2.65 |
119 | 0.72 | 1188 | 5.74 | 7.34 |
120 | 1.11 | 2089 | 171.18 | 7.85 |
121 | 0.69 | 533 | 57.39 | 1.50 |
122 | 5.63 | 567 | 362.45 | 7.49 |
123 | 3.11 | 1635 | 34.10 | 3.58 |
124 | 2.20 | 1664 | 9.48 | 10.12 |
125 | 1.70 | 577 | 11.31 | 2.43 |
126 | 0.85 | 680 | 7.21 | 0.79 |
127 | 5.30 | 585 | 62.56 | 2.84 |
284
Example number | PDE4B2 IC50 nM | IL13 IC50 nM | IL4 IC50 nM | IFNy IC50 nM |
128 | 5.74 | 667 | 53.10 | 2.25 |
129 | 4.04 | 3337 | 34.48 | 24.60 |
130 | 1.60 | 587 | 120.36 | 3.21 |
131 | 8.10 | 591 | 11.55 | 5.70 |
132 | 2.63 | 604 | 12.95 | 2.42 |
133 | 1.91 | 628 | 1.37 | 1.92 |
134 | 7.46 | 1108 | 1.79 | 3.04 |
135 | 10.31 | 668 | 15.32 | 7.24 |
136 | 2.86 | 670 | 11.66 | 2.43 |
137 | 2.21 | 1087 | 37.16 | 2.52 |
138 | 2.04 | 988 | 1.08 | 0.90 |
139 | 0.25 | 788 | 0.78 | 0.40 |
140 | 2.70 | 3449 | 3.47 | 3.20 |
141 | 0.95 | 701 | 3.35 | 2.24 |
142 | 2.53 | 1035 | 4.50 | 2.04 |
143 | 2.71 | 1165 | 4.11 | 3.68 |
144 | 0.58 | 706 | 83.91 | 5.02 |
145 | 6.77 | 2239 | 103.33 | 52.07 |
146 | 1.21 | 757 | 24.35 | 23.83 |
147 | 0.44 | 1257 | 2.69 | 1.57 |
148 | 0.24 | 759 | 4.92 | 1.68 |
149 | 0.49 | 793 | 20.22 | 0.87 |
150 | 4.05 | 827 | 168.67 | 18.89 |
151 | 5.98 | 813 | 39.11 | 3.48 |
152 | 1.38 | 828 | 160.96 | 6.02 |
153 | 3.24 | 860 | 50.73 | 2.57 |
154 | 14.13 | 893 | 31.39 | 15.18 |
155 | 1.81 | 2602 | 292.55 | 5.64 |
156 | 0.82 | 901 | 127.25 | 1.56 |
157 | 2.96 | 906 | 189.65 | 5.62 |
158 | 12.04 | 929 | 59.12 | 10.23 |
159 | 15.08 | 931 | 467.60 | 25.05 |
160 | 10.09 | 2301 | 25.97 | 15.92 |
161 | 11.26 | 960 | 419.00 | 38.63 |
162 | 14.52 | 975 | 56.31 | 8.29 |
163 | 3.71 | 2512 | 31.09 | 14.15 |
164 | 5.58 | 986 | 41.11 | 7.87 |
165 | 2.11 | 990 | 127.75 | 3.25 |
166 | 0.97 | 1006 | 49.25 | 5.46 |
167 | 1.98 | 2786 | 1.37 | 1.13 |
168 | 0.88 | 1260 | 1.17 | 0.64 |
169 | 2.85 | 2017 | 32.95 | 5.84 |
170 | 3.78 | 1069 | 48.55 | 2.83 |
171 | 1.73 | 1351 | 2.43 | 3.22 |
172 | 1.76 | 1112 | 269.26 | 27.48 |
173 | 10.03 | 1132 | 77.06 | 30.17 |
174 | 8.57 | 1137 | 278.94 | 14.36 |
175 | 5.03 | 2307 | 14.32 | 4.35 |
176 | 5.51 | 1141 | 6.51 | 2.98 |
177 | 2.71 | 1225 | 154.73 | 8.49 |
178 | 2.02 | 1284 | 1.81 | 0.91 |
179 | 0.98 | 2730 | 0.72 | 0.74 |
285
Example number | PDE4B2 IC50 nM | IL13 IC50 nM | IL4 IC50 nM | IFNy IC50 nM |
180 | 3.01 | 1288 | 6.33 | 6.65 |
181 | 0.68 | 1299 | 2.23 | 3.17 |
182 | 5.14 | 1329 | 245.20 | 19.59 |
183 | 2.72 | 1367 | 102.50 | 6.40 |
184 | 0.80 | 1402 | 79.25 | 4.48 |
185 | 3.38 | 2984 | 5.75 | 1.30 |
186 | 4.43 | 1402 | 31.42 | 5.13 |
187 | 4.28 | 1420 | 41.13 | 8.84 |
188 | 12.46 | 1532 | 135.44 | 12.25 |
189 | 2.61 | 1457 | 7.72 | 1.46 |
190 | 1.43 | 1476 | 40.33 | 5.01 |
191 | 3.84 | 1502 | 175.98 | 4.42 |
192 | 2.15 | 1500 | 14.63 | 5.43 |
193 | 0.63 | 1529 | 73.11 | 2.16 |
194 | 3.63 | 1539 | 2.85 | 14.71 |
195 | 0.72 | 2190 | 0.36 | 0.33 |
196 | 0.34 | 1543 | 0.29 | 0.81 |
197 | 22.04 | 1575 | 106.85 | 12.18 |
198 | 14.28 | 1576 | 14.15 | 4.85 |
199 | 10.44 | 1586 | 90.38 | 4.55 |
200 | 12.88 | 1599 | 128.17 | 14.09 |
201 | 2.13 | 1661 | 105.21 | 9.51 |
202 | 4.29 | 1668 | 5.20 | 8.51 |
203 | 14.99 | 2185 | 176.06 | 114.15 |
204 | 6.07 | 1707 | 22.71 | 21.78 |
205 | 0.52 | 1772 | 1.06 | 1.09 |
206 | 2.65 | 1793 | 113.37 | 27.80 |
207 | 10.33 | 1802 | 389.57 | 53.50 |
208 | 0.22 | 1805 | 4.06 | 1.98 |
209 | 6.55 | 1819 | 308.43 | 21.72 |
210 | 1.92 | 2390 | 17.58 | 2.40 |
211 | 2.95 | 1839 | 27.81 | 1.83 |
212 | 2.27 | 1895 | 102.59 | 3.29 |
213 | 6.32 | 1980 | 80.86 | 3.36 |
214 | 4.92 | 1995 | 20.71 | 13.67 |
215 | 2.58 | 2052 | 62.71 | 2.18 |
216 | 4.05 | 2864 | 19.63 | 1.94 |
217 | 5.50 | 2067 | 20.53 | 10.33 |
218 | 1.45 | 2836 | 3.24 | 2.30 |
219 | 0.82 | 2130 | 4.10 | 1.67 |
220 | 3.29 | 2131 | 539.65 | 2.37 |
221 | 2.21 | 2426 | 47.35 | 9.35 |
222 | 1.14 | 2370 | 1.44 | 1.17 |
223 | 6.67 | 2689 | 30.93 | 22.52 |
224 | 2.17 | 2494 | 8.94 | 8.12 |
225 | 3.79 | 2376 | 21.22 | 4.36 |
226 | 8.72 | 2522 | 24.68 | 17.78 |
227 | 7.94 | 2541 | 285.17 | 9.16 |
228 | 6.32 | 2574 | 7.78 | 14.24 |
229 | 2.64 | 2733 | 194.76 | 2.90 |
230 | 17.09 | 2780 | 140.71 | 26.53 |
231 | 1.98 | 2954 | 1.25 | 1.72 |
286
• | Example number | PDE4B2 IC50 nM | IL13 IC50 nM | IL4 IC50 nM | IFNy IC50 nM |
232 | 4.65 | 583 | 197.03 | 17.92 | |
233 | 8.74 | 508 | 103.58 | 2.94 |
PDE4B is a major PDE4 isoform in neutrophils and in monocytes, and the PDE4B2 variant is a major subtype found in these cells associated with inflammation. Interferon gamma (IFNy), interleukin 4 (IL4), and interleukin 13 (IL13) are cytokines that are primarily produced by 5 T cells in addition to certain innate immune cell populations. Production of these cytokines has been associated with inflammatory skin diseases, such as atopie dermatitis and with other immune and inflammatory diseases. Inhibition of release of these inflammatory cytokines would modulate the inflammatory response.
It is understood that the foregoing detailed description and accompanying Examples are 10 merely illustrative and are not to be taken as limitations upon the scope ofthe invention, which is defined by the appended claims. Various changes and modifications to the disclosed embodiments will be apparent to those skilled in the art. Such changes and modifications, including without limitation those relating to the Chemical structures, substituents, dérivatives, intermediates, synthèses, formulations and/or methods of use of the invention, may be made 15 without departing from the spirit and scope thereof.
Powder X-Ray Diffraction analysis for crystalline (4-methoxy-3-propoxyphenyl)boronic acid, 3-bromo-5-(4-methoxy-3-propoxyphenyl)pyridine, and 3-(3-((tertbutyldimethylsilyl)oxy)prop-1-en-2-yl)-5-(4-methoxy-3-propoxyphenyl)pyridine.
Powder X-ray diffraction analysis was conducted using a Bruker AXS D8 Endeavor diffractometer equipped with a Cu radiation source (K-α average). The divergence slit was set at 15 mm continuous illumination. Diffracted radiation was detected by a PSD-Lynx Eye detector, with the detector PSD opening set at 2.99 degrees. The X-ray tube voltage and amperage were set to 40 kV and 40 mA respectively. Data was collected in the Theta-Theta goniometer at the
Cu wavelength from 3.0 to 40.0 degrees 2-Theta using a step size of 0.01 degrees and a step time of 1.0 second. The antiscatter screen was set to a fixed distance of 1.5 mm. Samples were rotated at 15 rotations /min during collection. Samples were prepared by placing them in a Silicon low background sample holder and rotated during collection. Data were collected using Bruker DIFFRAC Plus software and analysis was performed by EVA diffract plus software.
Data analysis was performed by EVA diffract plus software (version 4.2.1). The PXRD data file was not processed prior to peak searching. Using the peak search algorithm in the EVA software, peaks selected with a threshold value of 1 were used to make preliminary peak assignments. To ensure validity, adjustments were manually made; the output of automated assignments was visually checked and peak positions were adjusted to the peak maximum.
Peaks with relative intensity of > 3% were generally chosen. The peaks which were not resolved
287 or were consistent with noise were not selected. A typical error associated with the peak position of crystalline material, from PXRD, stated in USP, is up to +/- 0.2° 2-Theta (USP-941).
Table 18
PXRD peak list for (4-methoxy-3-propoxyphenyl)boronic acid.
H0 'oh
Angle 2-Theta ° | Relative Intensity % |
8.3 | 9.2 |
9.6 | 19.5 |
9.9 | 3.0 |
10.6 | 8.1 |
12.0 | 4.9 |
14.8 | 100.0 |
15.4 | 39.1 |
16.6 | 7.9 |
17.0 | 7.5 |
18.3 | 3.5 |
18.9 | 23.7 |
19.3 | 24.6 |
20.4 | 3.9 |
21.1 | 6.4 |
21.5 | 6.5 |
21.7 | 7.1 |
22.0 | 3.9 |
23.1 | 35.9 |
23.5 | 73.6 |
23.8 | 32.0 |
24.5 | 15.7 |
25.0 | 16.5 |
25.5 | 39.7 |
26.2 | 10.4 |
27.3 | 14.4 |
27.9 | 22.0 |
28.2 | 17.0 |
28.5 | 4.6 |
29.2 | 6.8 |
31.0 | 12.4 |
31.3 | 6.4 |
31.7 | 6.1 |
32.7 | 4.1 |
34.4 | 4.0 |
34.7 | 2.7 |
288
35.8 | 5.4 |
38.7 | 5.6 |
39.3 | 7.5 |
Table 19
PXRD peak list for 3-bromo-5-(4-methoxy-3-propoxyphenyl)pyridine.
Angle 2-Theta ° | Relative Intensity % |
5.5 | 100 |
11.0 | 5.1 |
16.4 | 4.4 |
21.2 | 6.6 |
22.1 | 78.7 |
25.2 | 11.1 |
25.3 | 10.7 |
26.1 | 11.6 |
26.2 | 6.8 |
27.7 | 22 |
30.0 | 16.0 |
30.1 | 7.1 |
30.9 | 15.9 |
33.3 | 14.2 |
33.4 | 7.1 |
39.1 39.2 | 7.7 3.8 |
Table 20
PXRD peak list for 3-(3-((tert-butyldimethylsilyl)oxy)prop-1-en-2-yl)-5-(4-methoxy-3propoxyphenyl)pyridine
Angle 2-Theta ° | Relative Intensity % |
5.5 | 34.3 |
7.7 | 43.6 |
9.4 | 8.6 |
11.0 | 19.7 |
13.4 | 100.0 |
15.3 | 32.2 |
15.6 | 2.6 |
16.3 | 95.0 |
289
18.1 | 20.9 |
18.8 | 92.4 |
20.5 | 7.9 |
21.0 | 3.4 |
21.8 | 6.2 |
22.0 | 17.5 |
22.5 | 4.1 |
23.0 | 38.0 |
23.3 | 5.5 |
23.6 | 38.0 |
23.7 | 77.7 |
23.9 | 4.6 |
24.8 | 2.9 |
25.5 | 35.5 |
26.8 | 16.5 |
27.1 | 3.4 |
27.5 | 3.0 |
28.4 | 6.7 |
28.5 | 7.9 |
31.1 | 4.9 |
31.3 | 9.1 |
31.6 | 2.8 |
32.0 | 5.2 |
32.8 | 5.1 |
33.2 | 3.4 |
33.9 | 8.7 |
34.0 | 11.6 |
34.1 | 10.3 |
35.2 | 4.3 |
290
or a pharmaceutically acceptable sait thereof, wherein
B is boron;
Ai and A2 are independently O or S;
Ri, R2, and Rs are independently H, deuterium, (C2-C6)alkenyl, (C2-C6)alkenyloxy, (C2-C6)alkenylthio, (Ci-Cejalkoxy, (Ci-C6)alkoxy-di-i3, (Ci-C6)alkoxy(Ci-C6)aIkoxy, (Ci-C6)alkoxy(Ci-C6)alkyl, (Ci-C6)alkoxycarbonyl, (Ci-Ce)alkyl, (Ci-Cejalkyl-di-is, (Ci-C6)alkylcarbonyl, (Ci-C6)alkylthio, (C2-C6)alkynyl, (C2-C6)alkynyloxy, (C2-C6)alkynylthio, aryl, aryl(Ci-C6)alkoxy, aryl(Ci-C6)alkyl, aryl(Ci-C6)alkylthio, aryloxy, arylthio, carboxy, carboxy(Ci-C6)alkoxy, carboxy(Ci-C6)alkyl, cyano, (C3-C8)cycloalkyl, (C3-C8)cycloalkyl(CiC6)alkoxy, (C3-C8)cycloalkyl(Ci-C6)alkyl, C3-C8)cycloalkyl(Ci-C6)alkylthio, (C3-C8)cycloalkyloxy, (C3-C8)cycloalkylthio, halogen, halo(Ci-C6)alkoxy, halo(Ci-C6)alkyl, halo(Ci-C6)alkylthio, (5-6 membered)heteroaryl, (5-6 membered)heteroaryl(Ci-C6)alkoxy, (5-6 membered)heteroaryl(Ci-C6)alkyl, (5-6 membered)heteroaryl(Ci-C6)alkylthio, (5-6 membered)heteroaryloxy, (5-6 membered)heteroarylthio, (4-7 membered)heterocycle containing at least one heteroatom independently selected from the group consisting of O, N, and S, (4-7 membered)heterocycle(Ci-C6)alkoxy, (4-7 membered)heterocycle(Ci-C6)alkyl, (4-7 membered)heterocycle(Ci-C6)alkylthio, (4-7 membered)heterocycleoxy, (4-7 membered)heterocyclethio, hydroxy, hydroxy(Ci-C6)alkoxy, hydroxy(Ci-C6)alkyI, mercapto, nitro, thio(Ci-C6)alkyl, -NRaRb, NRARB(Ci-C6)alkoxy, NRARB(Ci-C6)alkyl, or (NRARB)carbonyl;
Ra and Rb are independently hydrogen, (Ci-Cejalkyl, or (Ci-Cejalkylcarbonyl;
R3 and R4 are independently H, deuterium, (Ci-C3)alkyl, (Ci-C3)alkyl-di.7, (Ci-Cejalkyl, (Ci-C6)alkyl-c/i-i3, (C3-C8)cycloalkyl, halo(Ci-C6)alkyl, or hydroxy(Ci-C6)alkyl;
R6, R7, and Rg are independently, H, deuterium, (Ci-Cejalkoxy, (Ci-C6)alkoxy-di-i3, (Ci-C6)alkoxy(Ci-C6)alkoxy, (Ci-C6)alkoxy(Ci-C6)alkyl, (Ci-C6)alkoxycarbonyl, (Ci-C6)alkoxycarbonyl(Ci-C6)alkyl, (Ci-C3)alkyl, (Ci-C3)alkyl-c/i-7, (Ci-Cejalkyl, (Ci-C6)alkyl-di-i3, (Ci-C6)alkylcarbonyl, (Ci-C6)alkylthio, carboxy, carboxy(Ci-C6)alkoxy, carboxy(Ci-C6)alkyl, cyano, halogen, halo(Ci-C6)alkoxy, halo(Ci-C6)alkyl, hydroxy, hydroxy(Ci-C6)alkoxy,
291 hydroxy(Ci-C6)alkyl, mercapto, nitro, -NRcRd, NRcRD(Ci-C6)alkoxy, NRcRD(Ci-C6)alkyl, or (NRcRo)carbonyl;
Rc and Rd are independently hydrogen, (Ci-C8)alkyl, or (Ci-Cejalkylcarbonyl;
Rio at each occurrence is independently deuterium, (Ci-C6)alkoxy(Ci-C6)alkyl, (Ci-C3)alkyl, (Ci-C3)alkyl-di.7, (Ci-C6)alkyl, (Ci-C6)alkyl-di-i3, (Ci-C6)alkylthio(Ci-C6)alkyl, hydroxy(Ci-C6)alkyl, or thio(Ci-C6)alkyl; and p is 0, 1,2, 3, 4, or 5.
Claims (12)
1/12
FIG. 1
2/12
FIG. 2
C7
2. The compound of claim 1 of Formula (IA)
Formula (IA) or a pharmaceutically acceptable sait thereof, wherein B is boron;
Ai and A2 are independently O or S;
Ri, R2, and R5 are independently H, deuterium, (C2-C6)alkenyl, (C2-C6)alkenyloxy, (C2-C6)alkenylthio, (Ci-C6)alkoxy, (Ci-C6)alkoxy-c/i-i3, (Ci-C6)alkoxy(Ci-C6)alkoxy, (Ci-C6)alkoxy(Ci-C6)alky[, (Ci-C6)alkoxycarbonyl, (Ci-C6)alkyl, (Ci-C6)alkyl-di-i3, (Ci-C6)alkylcarbonyl, (Ci-C6)alkylthio, (C2-C6)alkynyl, (C2-C6)alkynyloxy, (C2-C6)alkynylthio, aryl, aryl(Ci-C6)alkoxy, aryl(Ci-C6)alkyl, aryl(Ci-C6)alkylthio, aryloxy, arylthio, carboxy, carboxy(Ci-C6)alkoxy, carboxy(CrCe)alkyl, cyano, (C3-C8)cycloalkyl, (C3-C8)cycloalkyl(CiC6)alkoxy, (C3-C8)cycloalkyl(Ci-C6)alkyl, C3-C8)cycloalkyl(Ci-C6)alkylthio, (C3-C8)cycloalkyloxy, (C3-C8)cycloalkylthio, halogen, halo(Ci-C6)alkoxy, halo(Ci-C6)alkyl, halo(Ci-C6)alkylthio, (5-6 membered)heteroaryl, (5-6 membered)heteroaryl(Ci-C6)alkoxy, (5-6 membered)heteroaryl(Ci-C6)alkyl, (5-6 membered)heteroaryl(Ci-C6)alkylthio, (5-6 membered)heteroaryloxy, (5-6 membered)heteroarylthio, (4-7 membered)heterocycle containing at least one heteroatom independently selected from the group consisting of O, N, and S, (4-7 membered)heterocycle(Ci-C6)alkoxy, (4-7 membered)heterocycle(Ci-C6)alkyl, (4-7 membered)heterocycle(Ci-C6)alkylthio, (4-7 membered)heterocycleoxy, (4-7 membered)heterocyclethio, hydroxy, hydroxy(Ci-Ce)alkoxy, hydroxy(Ci-C6)alkyl, mercapto, nitro, thio(Ci-C8)alkyl, -NRaRb, NRARB(Ci-C6)alkoxy, NRARB(Ci-C6)alkyl, or (NRARB)carbonyl;
292
Ra and Rb are independently hydrogen, (Ci-Ce)alkyl, or (Ci-Cejalkylcarbonyl;
R3 and R4 are independently H, deuterium, (Ci-Cs)alkyl, (Ci-C3)alkyl-di.7, (Ci-C6)alkyl, (Ci-C6)alkyl-di-i3, (Cs-Csjcycloalkyl, halo(Ci-C6)alkyl, or hydroxy(Ci-C6)alkyl;
Re, R7, and Rg are independently, H, deuterium, (Ci-Ce)alkoxy, (Ci-Ce)alkoxy-c/i-i3, (Ci-Ce)alkoxy(Ci-Ce)alkoxy, (Ci-C6)alkoxy(Ci-C6)alkyl, (Ci-C6)alkoxycarbonyl, (Ci-C6)alkoxycarbonyl(Ci-Ce)alkyl, (Ci-Cs)alkyl, (Ci-C3)alkyl-c/i-7, (Ci-Ce)alkyl, (Ci-Cejalkyl-cG-is, (Ci-Ce)alkylcarbonyl, (Ci-C6)alkylthio, carboxy, carboxy(Ci-C6)alkoxy, carboxy(Ci-Ce)alkyl, cyano, halogen, halo(Ci-C6)alkoxy, halo(Ci-C6)alkyl, hydroxy, hydroxy(Ci-C6)alkoxy, hydroxy(Ci-Ce)alkyl, mercapto, nitro, -NRcRd, NRcRD(Ci-Ce)alkoxy, NRcRD/Ci-Cejalkyl, or (NRcRo)carbonyl;
Rc and Rd are independently hydrogen, (Ci-Ce)alkyl, or (Ci-Cejalkylcarbonyi;
Rio at each occurrence is independently deuterium, (Ci-Ce)alkoxy(Ci-Ce)alkyl, (Ci-C3)alkyl, (Ci-C3)alkyl-di-7, (Ci-C6)alkyl, (Ci-C6)alkyl-di-i3, (Ci-C6)alkylthio(Ci-C6)alkyl, hydroxy(Ci-C6)alkyl, or thio(Ci-C6)alkyl; and p is 0, 1,2, 3, 4, or 5.
3/12
FIG. 3
3. The compound of claim 2, or a pharmaceutically acceptable sait thereof, wherein B is boron;
Ai and A2 are O;
Ri, R2, and R5 are independently H, cyano, halogen, or halo/Ci-Cejalkyl;
R3 and R4 are independently (Ci-C3)alkyl, (Ci-Cejalkyl, (Cs-Csjcycloalkyl, halo(Ci-C6)alkyl, or hydroxy(Ci-C6)alkyl;
R6, R7, and Rg are independently, H, (Ci-Ce)alkoxy, (Ci-Cejaikoxy/Ci-Cejalkyl, (Ci-C6)alkoxycarbonyl(Ci-C6)alkyl, (Ci-C3)alkyl, (Ci-Ce)alkyl, carboxy(Ci-C6)alkyl, halogen, halo(Ci-C6)alkyl, hydroxy(Ci-C6)alkoxy, or hydroxy(Ci-C6)alkyl;
Rio is (Ci-C6)alkyl or hydroxy(Ci-C6)alkyl; and p is 0 or 1.
4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40
2Theta
4/12
FIG. 4
4. The compound of claim 2, or a pharmaceutically acceptable sait thereof, wherein B is boron;
Ai and A2 are O;
Ri, R2, and R5 are H;
R3 and R4 are independently (Ci-C3)alkyl, (Ci-Cejalkyl, (Cs-Csjcycloalkyl, halo(Ci-C6)alkyl, or hydroxy(Ci-C6)alkyl;
293
R6, R?, and Rg are independently H or (Ci-C3)alkyl; Rio is methyl; and p is 0, 1, or 2.
5/12
FIG. 5
1oooooi
Counts
80000
60000
40000
20000
Ï0.........20.........30 .....40
2Theta (Coupled Two Theta/Theta) WL=1.54060
5. The compound of claim 2, or a pharmaceutically acceptable sait thereof, wherein B is boron;
Ai and A2 are O;
Ri, R2, and Rs are H;
Ra and R4 are independently (Ci-C3)alkyl;
R6, R?, and Rg are independently H or (Ci-C3)alkyl; and p is 0.
6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40
2Theta
6/12
FIG. 6
Counts
110001
100001
90001 80001
7000 î
6000 j 5000] 4000] 3000 i d
2000]
10001
0^
2Theta Scale
6. The compound of claim 1 of Formula (IB)
Formula (IB) or a pharmaceutically acceptable sait thereof, wherein
B is boron;
Ai and A2 are independently O or S;
Ri, R2, and Rs are independently H, deuterium, (C2-C6)alkenyl, (C2-C6)alkenyloxy, (C2-C6)alkenylthio, (Ci-C6)alkoxy, (Ci-C6)alkoxy-di-i3> (Ci-C6)alkoxy(Ci-C6)alkoxy, (Ci-C6)alkoxy(Ci-C6)alkyl, (Ci-C6)alkoxycarbonyl, (Ci-Ce)alkyl, (Ci-C6)alkyl-di-i3, (Ci-C6)alkylcarbonyl, (Ci-C6)alkylthio, (C2-C6)alkynyl, (C2-C6)alkynyloxy, (C2-C6)alkynylthio, aryl, aryl(Ci-C6)alkoxy, aryl(Ci-C6)alkyl, aryl(Ci-C6)alkylthio, aryloxy, arylthio, carboxy, carboxy(Ci-C6)alkoxy, carboxy(Ci-Ce)alkyl, cyano, (C3-C8)cycloalkyl, (C3-Cs)cycloalkyI(CiC6)alkoxy, (C3-C8)cycloalkyl(Ci-C6)alkyl, C3-C8)cycloalkyl(Ci-C6)alkylthio, (C3-C8)cycloalkyloxy, (Cs-Csjcycloalkylthio, halogen, halo(Ci-C6)alkoxy, halo(Ci-C8)alkyl, halo(Ci-C6)alkylthio, (5-6 membered)heteroaryl, (5-6 membered)heteroaryl(Ci-C6)alkoxy, (5-6 membered)heteroaryl(Ci-C6)alkyl, (5-6 membered)heteroaryl(Ci-C6)alkylthio, (5-6 membered)heteroaryloxy, (5-6 membered)heteroarylthio, (4-7 membered)heterocycle containing at least one heteroatom independently selected from the group consisting of O, N,
294 and S, (4-7 membered)heterocycle(Ci-C6)alkoxy, (4-7 membered)heterocycle(Ci-C6)alkyl, (4-7 membered)heterocycIe(Ci-C6)alkylthio, (4-7 membered)heterocycleoxy, (4-7 membered)heterocyclethio, hydroxy, hydroxy(Ci-Ce)alkoxy, hydroxy(Ci-Ce)alkyl, mercapto, nitro, thio(Ci-C6)alkyl, -NRaRb, NRARB(Ci-C6)alkoxy, NRARB(Ci-C6)alkyl, or (NRARB)carbonyl;
Ra and Rb are independently hydrogen, (Ci-Ce)alkyl, or (Ci-Ce)alkylcarbonyl;
Rs and R4 are independently H, deuterium, (Ci-Csjalkyl, (Ci-C3)alkyl-di.7, (Ci-Ce)alkyl, (Ci-C6)alkyl-di-i3, (C3-C8)cycloalkyl, halo(Ci-C6)alkyl, or hydroxy(Ci-C6)alkyl;
R6, R7, and R9 are independently, H, deuterium, (Ci-C8)alkoxy, (Ci-C8)alkoxy-c/i-i3, (Ci-C6)alkoxy(Ci-C6)alkoxy, (Ci-C6)alkoxy(Ci-C6)alkyl, (Ci-C6)alkoxycarbonyl, (Ci-C6)alkoxycarbonyl(Ci-C6)alkyl, (Ci-Cs)alkyl, (Ci-C3)alkyl-di-7, (Ci-Ce)alkyl, (Ci-Csjalkyl-di-is, (Ci-C6)alkylcarbonyl, (Ci-C6)alkylthio, carboxy, carboxy(Ci-C6)alkoxy, carboxy(Ci-C6)alkyl, cyano, halogen, halo(Ci-C6)alkoxy, halo(Ci-C6)alkyl, hydroxy, hydroxy(Ci-C6)alkoxy, hydroxy(Ci-Cs)alkyl, mercapto, nitro, -NRcRd, NRcRD(Ci-C6)alkoxy, NRcRD(Ci-C6)alkyl, or (NRcRo)carbonyl;
Rc and Rd are independently hydrogen, (Ci-Cs)alkyl, or (Ci-C8)alkylcarbonyl;
R10 at each occurrence is independently deuterium, (Ci-C6)alkoxy(Ci-C8)alkyl, (Ci-C3)alkyl, (Ci-C3)alkyl-c/i.7, (Ci-C6)alkyl, (Ci-C6)alkyl-di-i3, (Ci-C6)alkylthio(Ci-C6)alkyl, hydroxy(Ci-C6)alkyl, orthio(Ci-C6)alkyl; and p is 0, 1,2, 3, 4, or 5.
7/12
FIG. 7
Counts
2Theta (Coupled Two Theta/Theta) WL=1.54060
7. The compound of claim 6, or a pharmaceutically acceptable sait thereof, wherein
B is boron;
Ai and A2 are O;
Ri, R2, and R5 are independently H, cyano, halogen, or halo(Ci-C6)alkyl;
R3 and R4 are independently (Ci-Csjalkyl, (Ci-Cs)alkyl, (C3-C8)cycloalkyl, halo(Ci-Ce)alkyl, or hydroxy(Ci-Ce)alkyl;
R6, R7, and Rg are independently, H, (Ci-C8)alkoxy, (Ci-Ce)alkoxy(Ci-C6)alkyl, (Ci-C6)alkoxycarbonyl(Ci-C6)alkyl, (Ci-C3)alkyl, (Ci-Ce)alkyl, carboxy(Ci-C6)alkyl, halogen, halo(Ci-C6)alkyl, hydroxy(Ci-C6)alkoxy, or hydroxy(Ci-Ce)alkyl;
R10 is (Ci-Ce)alkyl or hydroxy(Ci-C8)alkyl; and p is 0 or 1.
8/12
FIG. 8
Counts
8. The compound of claim 6, or a pharmaceutically acceptable sait thereof, wherein B is boron;
295
Ai and A2 are O;
Ri, R2, and R5 are H;
Rs and R4 are independently (Ci-C3)alkyl, (Ci-Cs)alkyl, (C3-C8)cycloalkyl, halo(Ci-C6)alkyl, or hydroxy(Ci-Ce)alkyl;
R6, R7, and R9 are independently H or (Ci-Cs)alkyl;
R10 is methyl; and p is 0, 1, or 2.
9/12
Counts
150000;
120000;
90000^
60000'
30000;
FIG. 9
jujuJL-jL wuvU 10 .........20 .........30 .........40
2Theta (Coupled Two Theta/Theta) WL=1.54060
9. The compound of claim 6, or a pharmaceutically acceptable sait thereof, wherein
B is boron;
Ai and A2 are O;
Ri, R2, and R5 are H;
R3 and R4 are (Ci-C3)alkyl;
R6, R7j and R9 are independently H or (Ci-C3)alkyl; and p is 0.
10/12
FIG. 10
1200001
100000
Counts
80000 J
60000 ]
40000 '
20000 '
......................r......I...............................................p.....P................!.........p.....P'!....... ψ.ττ,Ί......................................................... !......... !.........,.........t.........,.........!
10. The compound of claim 1 that is (R)-4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2oxaborolan-2-ol or a pharmaceutically acceptable sait thereof.
11/12
FIG. 11
Counts
60000j
40000
200001
OA
AJ
11. The compound of claim 1 of structure
12. The compound of claim 1 that is Crystalline (R)-4-(5-(4-methoxy-3propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol.
13. The crystalline compound of claim 12 having an X-ray powder diffraction pattern comprising diffraction peaks 11.0 ± 0.2, 22.9 ± 0.2, and 25.1 ± 0.2 degrees two thêta.
14. The crystalline compound of claim 12 having an X-ray powder diffraction pattern comprising diffraction peaks 11.0 ± 0.2, 11.4 ± 0.2, 18.8 ± 0.2, 22.9 ± 0.2, 25.1 ± 0.2, and 26.4 ± 0.2 degrees two thêta.
296
15. The compound of claim 1 that is (S)-4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2oxaborolan-2-ol or a pharmaceutically acceptable sait thereof.
16. The compound of daim 1 of structure
17. The compound of claim 1 that is Crystalline (S)-4-(5-(4-methoxy-3- propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol.
10
18. The crystalline compound of claim 17 having an X-ray powder diffraction pattern comprising diffraction peaks 18.7 ± 0.2, 22.8 ± 0.2, and 25.0 ± 0.2 degrees two thêta.
19. The crystalline compound of claim 17 having an X-ray powder diffraction pattern comprising diffraction peaks 11.0 ± 0.2, 11.4 ± 0.2, 13.2 ± 0.2, 18.7 ± 0.2, 22.8 ± 0.2, and 25.0 ± 15 0.2, degrees two thêta.
ABSTRACT
The present invention relates to boron containing compounds of Formula (I)
X-Y-Z
Formula (I) that inhibit phosphodiesterase 4 (PDE4). The invention also encompasses pharmaceutical compositions containing these compounds and methods for treating diseases, conditions, or disorders ameliorated by inhibition of PDE4.
12/12
FIG. 12
Counts
2Theta
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62/741,868 | 2018-10-05 | ||
US62/889,599 | 2019-08-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA20225A true OA20225A (en) | 2022-03-18 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2019351960B2 (en) | Boron containing PDE4 inhibitors | |
JP6666263B2 (en) | A novel inhibitor of glutaminase | |
EP3191478B1 (en) | Compounds and compositions as raf kinase inhibitors | |
CA3175436A1 (en) | Biaryl derivatives as yap/taz-tead protein-protein interaction inhibitors | |
EA028194B1 (en) | Biaryl amide compounds as kinase inhibitors | |
SG181917A1 (en) | Isoindolinone inhibitors of phosphatidylinositol 3-kinase | |
EP3707136B1 (en) | Modulators of methyl modifying enzymes, compositions and uses thereof | |
AU2017280293B2 (en) | Mechanistic target of rapamycin signaling pathway inhibitors and therapeutic applications thereof | |
OA20225A (en) | Baron containing PDE4 inhibitors. | |
RU2793936C2 (en) | Boron-containing pde4 inhibitors | |
CA3218259A1 (en) | Small molecule modulators of glucocerebrosidase activity and uses thereof | |
CA3116141C (en) | Cycloalkane-1,3-diamine derivative | |
EA045319B1 (en) | BORON-CONTAINING PDE4 INHIBITORS | |
WO2021150918A1 (en) | 4,5,6,7-tetrahydrothieno[2,3-c]pyridine sumo inhibitors and uses thereof | |
WO2017218874A1 (en) | Hedgehog acyltransferase inhibitors and uses thereof |